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Foreword
The National Institute on Drug Abuse (NIDA) is pleased once again to
publish in its Research Monograph series the proceedings of the 49th
Annual Scientific Meeting of the Committee on Problems of Drug
Dependence, Inc. (CPDD). This meeting was held in Philadelphia,
Pennsylvania, in June 1987 and was cosponsored by the Research
Society on Alcoholism. Consequently, it was unusually well
attended, and the meeting resulted in the largest number of papers
and abstracts in the history of CPDD.
The CPDD is an independent organization of internationally
recognized experts in a variety of disciplines related to drug
addiction. They are interested in developing knowledge that will
reduce the destructive effects of abused drugs on the individual and
society. The CPDD maintains liaison with Government regulatory and
research agencies, with the pharmaceutical industry, with national
and international organizations interested in drug dependence and
abuse, and with those working on drug abuse problems in academic and
treatment settings. The Committee is unique in bringing together
annually at a single scientific meeting an outstanding group of
basic and clinical investigators working in the field of drug
dependence. This year, as usual, the monograph presents an
excellent collection of papers. It also contains progress reports
of the abuse liability testing program funded by NIDA.
The contents of this monograph comprise a "state-of-the-art" summary
of ongoing research into the biological, behavioral, and chemical
bases of drug abuse that should be valuable to readers with a wide
diversity of interests.
Khursheed Asghar, Ph.D.
Division of Preclinical Research
National Institute on Drug Abuse
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Initiatives at the National
Institute on Drug Abuse
C. Schuster
It is a pleasure and an honor to be here with you today. I
bring greetings from Dr. Macdonald in his dual role as
Administrator of the Alcohol, Drug Abuse, and Mental Health
Administration (ADAMHA), as well as Director of the White
House Drug Abuse Policy Office. Right now, he is working
closely with the First Lady on preparations for the
International Conference on Drug Abuse and Illicit
Trafficking, and I will be leaving from here to take part with
them in that meeting in Vienna.
My purpose in this presentation is to give you a brief status
report on drug abuse in general, NIDA's research efforts, and
other programmatic issues that NIDA is dealing with currently.
As you know, the prevalence rates for most illicit drug use
peaked in 1979-80 and have declined since then. Cocaine is
the exception to the overall pattern. Its use has shown a
small but significant increase over the same period of time.
It is important to note that, even with cocaine, the large
increase in usage occurred between 1977 and 1980, and the
subsequent rise in usage has been much slower.
Despite this overall slowing in the use of illicit drugs,
there has been unprecedented public interest and concern with
this subject in the past year. For example, in a survey
conducted by NIDA in August, 1986, fully 73 percent of a
random sample of 1,001 Americans age 18 and older said that
illegal drug use is "one of the most serious problems facing
the country." Twenty-five percent said that drug use is "an
important problem for the country." Only two percent did not
consider it an important problem.
I believe that this interest and concern stems from two
phenomena. First, there has been a great increase in both the
incidence and the visibility of cocaine-associated public
health problems. NIDA's data show alarming increases in
cocaine-related emergency room admissions, medical examiner
reports, and demand for treatment (Figure 1). Second, people
are becoming more and more aware that AIDS is spreading from
needle-sharing among intravenous drug users and, from them
through sexual contacts, to the general heterosexual
population.
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On the other hand, I won't hesitate to point out that "fame
and fortune" can be fleeting in Washington, D. C. I was told
only last week by a Congressional staff person that drug abuse
is last year's issue, and Congress is focussing more on the
emerging issue of homelessness. This illustrates a basic
problem we have in generating sustained interest in the
support of drug abuse research, prevention, and treatment.
It is up to us, who have long-term interest in the field of
drug abuse, to carry the message that drug abuse is not a
problem that can be solved and forgotten. Rather, just as we
consider heroin addiction to be a chronic disorder leaving
individuals subject to relapse, we must regard drug abuse as a
chronic disorder afflicting society, which is also vulnerable
to relapse. We all know that prevalence of drug abuse
waxes and wanes. In my opinion, this vacillation occurs
because of a waxing and waning of activities to control drug
abuse. When prevalence rates are driven down by societal
interventions, there is a relaxation of control measures and
the low-level endemic problem spreads. A parallel situation
can be seen when vaccinations reduce the rate of a particular
disease, everyone sighs with relief, people forget to have
their children vaccinated, and the disease rears its ugly head
again. When we succeed in reducing drug abuse, we turn our
attention to other concerns until the prevalence rates climb
back to a point at which society becomes concerned enough to
react. There is then a call for research to develop
prevention and treatment strategies to solve the problem.
I would like to believe that we can do better than that in the
future. But this will demand a steady attention to the
problem of drug abuse, even when it is at a level that is not
2
"bothering" the general public. Only when we understand the
complex biobehavioral processes responsible for addictions
will we be in a position to develop maximally effective
prevention and treatment interventions. Sustained support of
research and demonstration grants is essential if we are to
reach this goal.
Let me turn now to the current grant situation at NIDA. It
looks as though NIDA will have enough excellent grant
applications to permit a useful allocation of all available
research funds for FY87. As of April 1, which was a special
deadline for application, we had received more than 800 grant
proposals (Figure 2). This is an extraordinary increase, and
includes applications from previous grantees as well as
researchers who are new to the drug abuse field or, at least,
new to NIDA. Twenty-two center grant applications or
supplements were submitted, as opposed to the usual two or
three. Let me note that at this time, of course, we still
don't know how much of the $26 million authorized for research
will be used for multi-year funding or whether it all can be
allocated to new starts. But in any case, there is plenty of
material to review, and we are fortunate to have the
assistance of Dr. Louis Harris, who is coordinating the review
process.
I want to move on to mention some areas of special priority
for NIDA and, indeed, for ADAMHA. The first is prevention.
We are concerned with populations that are at high risk of
drug abuse, whether for genetic, environmental, or social
reasons. The new Office of Substance Abuse Prevention in
ADAMHA is offering demonstration grant money to address the
problems of certain high risk populations. NIDA is conducting
basic research to identify such populations and to develop and
evaluate interventions that will prevent addiction. In light
3
of the AIDS epidemic, special efforts are, aimed toward
prevention and early intervention in geographic areas in which
intravenous drug abuse is prevalent.
Treatment research is another area of great interest to NIDA.
I want to stress that-treatment research, in this context,
includes all pre-clinical research which will have relevance.
to the development. of, new treatment approaches. It is not
limited to purely clinical research.
extramural
NIDA's intramural and
programs are involved in a broad variety of
treatment, research projects. For example, the Addiction
Research Center, (ARC) is evaluating current treatments for
cocaine dependence. Treatment programs across the country are
utilizing a variety of behavioral and pharmacologic approaches,
for the treatment of cocaine addiction, but there is little,
hard evidence demonstrating their efficacy. Another focus of
NIDA is toward the development of new pharmacologic and
behavioral treatment modalities for all
dependence,.
forms of drug
but with special emphasis placed on cocaine.
Anti-depressants are showing promise in tests of their ability
to lessen cocaine cravings. Again because of AIDS; we are
also emphasizing the treatment of heroin addiction in an
attempt to enlarge our armamentarium of approaches
Buprenorphine has been demonstrated to block the reinforcing
effects of opiate in rhesus monkeys and humans in controlled
laboratory conditions. Studies at the ARC (and elsewhere) are
now investigating its usefulness in heroin addicts seeking
treatment. A spectrum of treatment methods should draw more
addicts into treatment. To paraphrase Dr. Beny Primm,
methadone and therapeutic communities are not enough--we need
a "shopping center" where addicts can find a variety of
approaches and can choose the ones with which they are most
comfortable.
In its research, NIDA also looks at the consequences of drug
abuse. Functional deficits related to drug abuse that have
been noted in the workplace are being explored and measured in
the laboratory. At the ARC, scientists are studying
drug-induced neuropathology through some important animal
experiments and with the aid of such modern techniques as PETT
scanning. A NIDA-funded Maternal and Child Health Survey has
brought forth some interesting information in regard to the
teratogenic effects of cocaine. .
Let me emphasize that these examples are only illustrative of
our research priorities. They are by no means exhaustive.
Now I want to mention some programmatic issues NIDA has faced
in the past year. There has been major development in two
areas, AIDS and Workplace Initiatives.
The Office of Workplace Initiatives was established within
NIDA in response to the President's call for, a drug-free
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American workplace. Its Director, Dr. Michael Walsh, will be
establishing programs to deal with urine drug testing,
employee assistance programs, and referrals for treatment
(access to the system). NIDA has developed general guidelines
for drug screening, as well as technical guidelines that the
Federal government will follow in testing its own employees.
In addition, the accreditation of laboratories that wish to
perform urine drug testing is being addressed. We are
determined to ensure that drug testing is performed accurately
if it is to be done at all.
NIDA's efforts against AIDS are coordinated in the Division of
Clinical Research (DCR), headed up by Dr. Roy Pickens.
However, many parts of the Institute are involved in various
anti-AIDS initiatives. Seroprevalence studies have been
conducted by ARC staff. Ethnographic studies of needle
sharing are the responsibility of the Division of Epidemiology
and Statistical Analysis. The Office of Research
Communications is handling the development of an educational
campaign that will utilize mass media techniques. Some
materials are now awaiting clearance. DCR expects to award
demonstration grants that will assist five cities in
organizing comprehensive outreach, intervention, and treatment
programs. Also, targetted grants will help other cities
through smaller but equally vital programs. In addition, a
contract will be awarded to coordinate data collection from
these programs and to provide some evaluation of their
effectiveness.
NIDA is currently analyzing policy issues that have relevance
to the AIDS epidemic. Among these are the scientific, legal,
and ethical questions surrounding mandatory treatment; the
utility and desirability of needle exchange programs; and the
question of how drug treatment capacity can best be increased
to meet the challenge posed by AIDS. These and other policy
concerns will be reviewed on an ongoing basis.
In summary, we have the public's attention and its interest
right now. How long this will continue is unpredictable.
AIDS will keep the public interest high, at least for the next
five years, but the problem of drug abuse is very broad and
very deep. We have a lot of work left to do.
And now I must close and literally run to join a party of 32
delegates who are leaving on Air Force 1 this afternoon to
attend the International Conference on Drug Abuse and Illicit
Trafficking. This is the first ministerial level meeting in
which both supply and demand reduction authorities will
convene for developing integrated international strategies for
decreasing the world-wide problem of drug abuse. I am very
sorry that this meeting precludes my being here to participate
in the remainder of this scientific meeting. Fortunately, the
proceedings of this meeting will be published, as in the past,
as a NIDA Monograph.
AUTHOR: Charles R. Schuster, Ph.D., Director
National Institute on Drug Abuse, Rockville, MD
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Presentation of Nathan B. Eddy
Memorial Award
W. Martin
I am very pleased to introduce the 1987 recipient of the Nathan B.
Eddy Award. It is a long overdue recognition of Dr. C. K.
Himmelsbach's contributions to drug dependence. I am pinch
hitting for Dr. Harris Isbell who very much wanted to attend this
meeting honoring his old friend and predecessor as Director of the
Addiction Research center. Dr. Isbell felt reluctant to make this
trip and regrets his absence.
Dr. Himmelsbach was Director of the Addiction Research Center from
1935 to 1944. Following his tenure at the Addiction Research
Center, he served at the National Institutes of Heal
Assistant Director of the Clinical Center. Following his
retirement from the Public Health Service, he became an Associate
Dean at George University School of Medicine and Dentistry.
There are few in this audience that have not been the beneficiary
of Dr. Himmelsbach's efforts and creative mind. Dr. Himmelsbach
was a Public Health Service physician who was especially
identified to become the Addiction Research Center's first
Director. In preparation for this responsibility, he spent a year
in the laboratory of Dr. Torald Sollmann where he worked on
problems of morphine tolerance and dependence in rats. He then
worked with Nathan B. Eddy at the University of Michigan where he
continued his pharmacologic studies prior to initiating his first
clinical studies of addiction at the Leavenworth penitentiary.
When the United States Public Health Service Hospital (NARCO)
opened in Lexington, Kentucky, in 1935, Dr. Himmelsbach continued
his studies at this facility. He developed the abstinence scoring
system and was the first to quantify the morphine abstinence
syndrome in man. This scoring system has not only served a number
of investigators as an insightful and practical method for
measuring the intensity of abstinence, but also was a model for
quantitatively studying withdrawal and precipitated abstinence.
When Harris Isbell employed bioassay techniques to analyze
suppression data, the great power of this instrument was fully
demonstrated. He also devised the suppression technigue for
classifying morphine-like drugs. Although receptor theory had
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not, in 1935, become a part of pharmacologists' and physician's
way of thinking about drug actions, the suppression technique was
one of the first clues that a number of opioids were acting
through a common mechanism. Dr. Himmelsbach compared the actions
of a number of morphine-like analgesics. He also evaluated the
effects of several popular treatments for the morphine abstinence
syndrome.
Dr. Himmelsbach was the first to carefully characterize the
duration of the morphine abstinence syndrome and recognize that it
took many months for this process to resolve. Dr. Himmelsbach's
homeostatic theory of tolerance and physical dependence, with the
dual action theory of Tatum, Seevers and Collins, were the first
attempts to provide a pharmacologic explanation of opioid
dependence. The hemostatic theory still attracts interest and is
a seminal theory. Dr. Himmelsbach's work has had a profound
influence on my work, as well as on many others in this room, and
I deem it a high honor to introduce the recipient of the Nathan B.
Eddy Award in 1987, Dr. Clifton K. Himmelsbach.
AUTHORS
Harris Isbell, M. D.
W. R. Martin, M. D.
AFFILIATION
Albert B. Chandler Medical Center, College of Medicine, Department
of Pharmacology, University of Kentucky, Lexington, Kentucky
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Clinical Studies of Morphine
Addiction: Nathan B. Eddy
Memorial Award Lecture
C. Himmelsbach
The last time I met with you was May, 1975, when I had the honor
of presenting "An Historical Review of Research on Drug
Addiction" at your Washington Meeting. Today, in this City of
Brotherly Love, you do me an even greater honor by making me the
recipient of the prestigious Nathan B. Eddy Award. I am truly
grateful.
During the period of my activity in this field, I had the
pleasure and benefit of a close association with Dr. Eddy. Our
friendship continued throughout the remainder of his life-time.
This gives added meaning to having his likeness on my new medal.
Also, it is highly significant that this event takes place in
Philadelphia for I was born here 80 years ago; my parents are
buried here; and my brother lives here. Although I have lived
elsewhere most of my life I am especially glad to be here today.
Dr. Way suggested that you might be interested in a summary of
my research with particular reference to:
quantification of the abstinence syndrome,
testing for addiction liability, and
the nature of physical dependence.
But first, I think it is important to emphasize that, except for
the work of Light and Torrance (done right here in Philadelphia),
clinical research on morphine addiction was a wide-open field
when I started. I enthusiastically undertook to do the things I
was trained to do and was fortunate to have the opportunity to
contribute some base for the far-reaching studies now being
conducted by investigators here present. We all know that
success in research, as in most things, is dependent in some
measure on luck. I had my share.
QUANTIFICATION OF THE MORPHINE ABSTINENCE SYNDROME
As a novice in this field, and in preparation for the opening of
the Lexington Hospital, I first needed to gain familiarity with
8
addiction in man. For this purpose I was assigned to the U.S.
Penitentiary Annex in Ft. Leavenworth, Kansas were addicts then
served their sentences for violations of the Harrison Narcotic
Act. I was given a 12 bed ward, staffed with a nurse and three
attendants, and a laboratory technician. My first experience was
with a "chain" of 10 actively ill addicts from New York City.
Since there were too many to cope with at one time, I gave them
enough morphine to keep them comfortable, and then observed the
events which took place following abrupt withdrawal of the drug
from one patient at a time. It soon became clear that this was a
quite uniform and predictable illness which ran its main course
in about 10 days. Also, it lent itself to equating clinical
judgement of its severity with the appearance of a pattern of
signs which we first expressed as Mild (+), Moderate (++),
Marked (+++), or Severe (++++). (Figure 1)
While this was an improvement over narrative descriptions, it
did not distinguish between fine gradations of severity. So,
adhering to Pythagoras' dictum that "numbers are the language of
nature," arbitrary numeric values were given to the component
signs. After several trials we settled on the system shown in
the next (Figure 2) which gave a closer approximation to clin-
ical judgement, was smoother than 1+, 2+, 3+ and 4+, and lent
itself to graphic portrayal of this illness. (Figure 3)
It soon became apparent that there was a clear relationship
between the intensity of the abstinence syndrome and dosage of
morphine. (Figure 4)
TESTING FOR ADDICTION LIABILITY
Your predecessor committee had embarked on a scientific search
for a non-addictive substitute for morphine. To this end, a
Chemistry Laboratory had been established at the University of
Virginia under Dr. Lyndon F. Small for the purpose of developing
a host of variations of the morphine molecule, and synthesizing
new potential analgesics. These were studied pharmacologically
by Dr. Eddy at the University of Michigan to learn of relation-
ships of pharmacological actions to chemical structure. Those
which showed analgesic promise were to be tested for addiction
liability in man. That was my job.
The substitution method for accomplishing this came about
fortuitously when I attempted to replicate in man the demon-
stration of cross-tolerance to several opiates in dogs by Downs
and Eddy. Various derivatives of morphine were substituted for
the parent drug in addicts who were receiving enough morphine to
prevent abstinence signs. Not only was cross-tolerance evident,
but when the substituted drug was withheld about one week later,
a full-blown abstinence syndrome appeared. (Figure 5) I seemed
to have grafted one dependence on another. This led to the view
that an agent which could support established dependence would
probably produce it de novo.
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Experience with many narcotics favored the validity of this
assumption. Moreover, it seemed to apply in degree as well as
kind. Thus, codeine ranked as weakly addictive, while Dilaudid
was powerfully so. But, unfortunately, it did not seem possible
to dissociate addiction liability and analgesic power. In fact,
the two seemed to go together. Crucial to the validity of the
substitution hypothesis was our trial of the then new synthetic
analgesic "Demerol". Much to the surprise (and disappointment)
of many, it tested positive and clinical experience has borne
out its addiction liability.
While the substitution method was valuable, it was slow and
cumbersome. In searching for a better way to detect addiction
liability, we based our approach on the information gained from
checking out many so-called "withdrawal treatments".
These, including tetrahydrocannabinol, had no detectable effects
on the abstinence syndrome, whereas morphine had a pronounced
effect. (Figure 6)
The morphine abstinence syndrome is so uniform and predictable,
especially for the first 48 hours, that it lends itself to
measuring the effects, if any, of a drug administered at the
30th hour. The effect of 10mg. morphine is shown in (Figure 7).
Neither normal saline nor thiamine had any effect when adminis-
tered at the 30th hour, whereas codeine, morphine, morphine with
prostigmin, morphine sulfuric ether, and demerol had significant
and measurable effects. (Figure 8) This, then, seems to offer a
quick and easy means for detecting addiction liability.
ON THE NATURE OF PHYSICAL DEPENDENCE
Another assigned task was to try to unravel the mystery of
physical dependence. What was it that made morphine seem to
become a biological requirement? What changes occurred as a
result of chronic use? Were there biological changes that
predisposed to relapse? Or was the strong tendency to recidivism
entirely psychological and environmental?
Early on, I was impressed with the resemblance of the morphine
abstinence syndrome to an intense and prolonged "tempest"
occurring in the sympathetic division of the autonomic nervous
system--perhaps even centered in the region of hypothalamus.
(Figure 9) This impression grew stronger with continued obser-
vations and led to a rather simplistic explanation of physical
dependence as a compensatory physiologic response to repetitive
disturbances in homeostasis caused by morphine. Thus, it seemed
possible that dependence could be an adaptive phenomenon result-
ing from periodic restoration of steady states upset by morphine.
(Figure 10)
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If one considers homeostasis to be achieved by balanced forces
that "act" and "counteract" as required to preserve phylogene-
tically established levels of "normality", then repeated pharma-
cologic interference could tend to substitute and thereby weaken
one and reciprocally strengthen the other--so that, in time, the
interfering agent would become a pseudobiologic substitute and
thus become a requirement for achieving a semblance of homeo-
stasis. Inevitably, as the drug is metabolized the need arises
for a new supply, and thus dependence manifests itself--or, in
the addict's parlance, the user has become "hooked".
To seek greater insight on chronic effects, I carried out
long-range follow-up observations and investigations directed at
a better understanding of the role of the autonomic nervous
system. As controls, we were fortunate to have access to mari-
juana users who had no history of taking opiates, and who were
serving sentences under identical living conditions.
It became apparent that physical recovery was a very slow
process with measurable effects of dependence still detectable
up to six months after withdrawal. Even more significant were
evidences of hyperactivity of the sympathetic division of the
autonomic nervous system persisting up to two years in prisoners
serving long sentences. Thus it would appear that recidivism may
be abetted, in part, by what seem to be indelible effects of
addiction on the nervous system.
At this point I wish to pay tribute to the many, many patients
who made these studies possible. Despite the fact that they were
incarcerated, they were volunteers in the strict sense of the
word. While our studies predated the Nuremberg Trials, the
guidelines they formulated for research on man were implicit in
our patient-physician relationship. We obtained simple consent.
(As to its being "informed", I am sure the patients knew much
more about narcotic drug effects than we did). Patients were
privileged to withdraw from the protocol at will, and we could
terminate or modify the protocol as indicated. To the best of my
knowledge none was harmed by the experience.
Unfortunately, however, we did not find a non-addictive substi-
tute for morphine. Nor, despite the beautifully orchestrated
rehabilitation program carried out at Lexington, were we able to
make a significant impact on the relapse rate. But, I do hope
that the basic studies summarized today have been helpful to
your attack on this frightful problem. I wish you success and
good luck!
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Is Inpatient Medical Alcohol Detox-
ification Justified: Results of
a Randomized, Controlled Study
M. Hayashida, A. Alterman, T. McLellan, S. Mann,
I. Maany and C. O’Brien
Inpatient medical detoxification continues to be the
commonest form of alcohol detoxification (Sausser, et
al., 1982). Yet, there is indication that detoxifi-
cation can be accomplished in most patients without
medication or medical personnel (Sparadeo, et al.,
1982; Annis, 1979), in a nonmedical, "social-setting"
(Sparadeo, et al., 1982; Annis, 1979) or on an
ambulatory, outpatient basis (Sausser, et al., 1982).
Because of its low cost (Sparadeo, et al., 1982),
outpatient alcohol detoxification could be an
attractive alternative if it can be shown to be
comparable in effectiveness. However, to our
knowledge, only one study has directly compared the
effectiveness of inpatient and outpatient alcohol
detoxification treatment. Unfortunately, the
investigator was unable to randomly assign patients to
the two treatments and the only outcome measure
obtained was subsequent involvement in rehabilitation
treatment (McGovern, 1983).
We now report results of a study comparing patients
assigned on a random basis to either inpatient or
outpatient medical detoxification treatment. The
results to be reported include comparative data on the
efficacy of detoxification in the two settings as well
as one month post-treatment outcome status of
patients.
METHODS
Subjects: The subjects were 90 male alcoholic veterans
recruited for the study from among 280 veterans
requesting detoxification at the Philadelphia VA
Medical Center's Alcoholism Treatment Unit from March
through September 1985. These veterans exhibited
sufficient evidence of alcohol withdrawal (AW), as
defined by DSM-III, to qualify for outpatient
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detoxification, but did not exhibit severe AW, or
serious medical or psychiatric symptomatology
requiring immediate hospitalization. All patients were
able to comprehend medication instructions and agreed
to participate in a randomized assignment study after
being informed of its details.
They did not differ significantly in sociodemographic
and alcohol-related characteristics from the typical
patient seeking detoxification at the Medical Center.
Determining Need for Detoxification: Patients
requesting detoxification were first screened by a
Central Intake worker who obtained general background
information and were then evaluated by a psychiatrist.
The physical examination, diagnosis of AW, a
breathanalysis, i.e. blood alcohol concentration
(BAC), and a modified version of the Selected Severity
Assessment (SSA), developed by Gross et al (1973) to
assess the severity of AW symptoms, were completed by
the psychiatrist.
Randomized Treatment Assignment Procedure: The
psychiatrist described the research to eligible
patients and obtained informed consent. An independent
research technician then randomized the patient to
either inpatient or outpatient treatment. Forty-nine
subjects were successfully randomized to the
outpatient detoxification and 41 were assigned to
inpatient treatment.
Following the randomized treatment assignment the
technician administered the Michigan Alcoholism
Screening Test (MAST), Severity of Alcohol Dependence
Questionnaire (SADQ), Beck Depression Inventory (BDI)
and the Symptom Checklist-90 (SCL-90), instruments
designed to measure severity of alcoholism and alcohol
dependence, depression and mood, respectively. The
Addiction Severity Index (ASI), which assesses the
patient's history and functioning with respect to
seven life areas- medical, alcohol, drug, employment,
legal, social and psychological- was administered on
the following day by a research technician. One month
post-discharge status was ascertained using the
abbreviated ASI designed for follow-up purposes. This
instrument was slightly modified to include more
detailed information on alcoholism treatment received
during the follow-up period. The follow-up interviews
were conducted by trained technicians who were blind
to patient status.
Detoxification Objectives:
The major objectives of detoxification treatment were
to:
1. effectively resolve the acute medical and
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psychiatric problems associated with AW, and prevent
the more severe symptoms of AW such as seizures or
delirium tremens from developing;
2. disrupt the patient's pattern of abusive
drinking; and
3. help the patient to become engaged in the
rehabilitation treatment seen as being necessary to
establish and maintain alcohol-free living.
Given these immediate objectives, a one month
post-treatment follow-up was determined to be the
procedure for evaluating the relative effectiveness of
the two treatments.
Detoxification Procedures:
Designated inpatients were admitted to the ward that
day or on the following morning, while outpatient
detoxification was initiated immediately following
intake processing at the Alcoholism Outpatient Unit.
While there are several variations in the procedures
for medical alcohol detoxification (Naranjo and
Sellers, 1986). the major components for patients with
mild to moderate degrees of AW symptoms are medication
with a benxodiazepine to treat the AW and the use of
thiamine and multivitamins to correct nutritional
deficits that are frequently present as a result of a
long period of poor dietary intake. The emergence of
more serious symptoms of AW such as seizures and
delirium tremens, for the most part, will be
effectively prevented by the benzodiazepine
administration alone. Discrete measures to correct
water and electrolyte imbalances are seldom necessary
for this type of patient population.
a. Outpatient detoxification (n=49)- Ambulatory
medical detoxification was provided by one of several
psychiatrists. The patient was initially evaluated for
medical, psychiatric, and social problems. The
psychiatrist then reviewed the fundamental aspects of
AW and the detoxification procedures with the patient.
The need to take medications as prescribed was
particularly emphasized.
The typical patient was started on 30mg of oxazepam to
be taken qid. and at bedtime on a p.r.n. basis (with
the exception of patients with a history of alcohol
withdrawal seizures in whom oxazepam was to be taken
qid. unless the patient was oversedated), supplemented
by multivitamins and thiamine. He was instructed to
return for daily evaluations (except weekends) where
the AW symptoms (SSA), and his physical and
psychiatric status were briefly re-evaluated.
Medication was tapered accordingly each day. Limited
counselling for social problems was also provided in
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some cases. However, the patient's need for long-term
rehabilitation treatment following detoxification was
consistently emphasized.
Criteria for Completion of Detoxification:
Successful completion of detoxification was defined in
terms of a marked reduction in AW, as measured by the
SSA and a negative breathanalysis for three or four
consecutive days, depending upon the SSA score; as
well as the reduction of the oxazepam dose to zero. A
maximum period of two weeks for completion was
imposed. The average duration of detoxification was
six calendar days (5.5 visits) for treatment
completers. Further details on patient response to
ambulatory detoxification are provided in another
paper (Alterman, et al., in press).
b. Inpatient detoxification (n=41)- The medical
detoxification method was similar to that of the
outpatient detoxification. In addition, to initiate
rehabilitation, the program also offered group
counselling, Alcoholics Anonymous meetings, discharge
planning, recreational and social therapy. Disulfiram
treatment may also be initiated prior to discharge in
some cases.
Mean duration of detoxification was 9.8 days, while
the total duration of hospitalization was 15.3 days.
The additional five days of hospitalization was
generally used for the initiation of rehabilitation,
additional medical treatment for diagnosed problems,
and for protective care pending the availability of a
longer term rehabilitation bed at one of the
residential programs. Thus, inpatient detoxification
treatment was much more intensive and extensive than
the outpatient treatment.
RESULTS
Characteristics of Patients at Intake. The character-
istics (demographic, alcohol-related, psychological)
of the patients assigned to outpatient and inpatient
treatment were compared by means of t-tests where the
data was continuous or chi square for categorical
data. The outpatients and inpatients did not differ
significantly with respect to the more standard
demographic characteristics (age, race, education,
marital status, etc.). The two groups also did not
differ in the severity of alcoholism (MAST), alcohol
dependence (SADQ), or AW (SSA) at intake. The
psychological status of the two groups, as reflected
by their scores on the Beck Depression Inventory and
the Symptom Checklist-90, was not found to differ. The
comparative status of outpatients and inpatients at
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intake was also not found to differ on the seven areas
of functioning assessed by the ASI (see Table 1). A
group difference was revealed on only one of the
individual items shown. That is, the inpatients
reported significantly more days intoxicated (24.97
vs. 22.81) in the month prior to treatment than the
outpatients (p < .05). In general, however, very few
group differences were found among the host of
variables assessed at intake. The data, therefore,
indicate that alcoholics randomly assigned to either
outpatient or inpatient detoxification did not differ
substantially at intake.
Completion of Detoxification: Sixty-nine percent
(34/49) of the outpatients completed detoxification as
contrasted with 90% (37/41) of the Inpatients. This
group difference in treatment completion rate achieved
statistical significance (X =5.57, 1 df, p=.018).
None of the study patients developed seizures or
delirium tremens and none are known to have died
during detoxification.
One Month Post-Treatment Outcome. Employing the ASI.
one month post-discharge information was obtained for
83.7% (41 of 49) of the outpatients and 92.7% (38 of
41) of the inpatients. The proportion of follow-up
evaluations completed did not differ for outpatient
and inpatient groups. Analyses of covariance were
employed to evaluate group differences at one month
follow-up (baseline as covariate), while paired
t-tests were employed to examine pre- to post-
treatment changes for each group. Group composite
scores in seven areas of functioning, along with
illustrative items in each of the areas. are described
in Table 1. These comparisons indicate that the two
groups differed significantly only in one area,
medical problems, with outpatients reporting
significantly more improvement in medical status than
inpatients (e.g., self-report of how many days a
medical problem was experienced; how troubled the
patient is by medical problems, etc.). Both groups
reported a considerable reduction in alcohol related
problems and improvement in psychological functioning.
For example, with respect to alcohol use, the
outpatient group reported a decrease from drinking an
average of 24 days a month prior to treatment to
almost three days for the one-month post-treatment
period, while the inpatients reported a decrease from
more than 25 days to less than one day. Similarly,
intoxication was reduced from 23 days a month to less
than two days for the outpatients and from 25 days a
month to less than one day a month for the inpatients.
Employment and legal status did not improve; indeed,
employment problems worsened to a nonsignificant
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degree for both groups. Drug use appeared to decline
for both groups, but only significantly so for the
outpatient group. Thus, patients receiving either
inpatient or outpatient detoxification did no appear
to differ significantly at the one month
post-treatment follow-up.
Alcoholism Treatment During FOLLOW-Up Period. The
quantity and form of alcoholism treatment, i.e.,
inpatient vs. outpatient detoxification or
rehabilitation, received by the two groups during the
follow-up period were not found to differ.
TABLE 1. ASI SCORES OF OUTPATIENTS AND INPATIENTS AT
INTAKE AND AT ONE MONTH POST-TREATMENT FOLLOWUP
a. The intake scores were used as the covariate in the
analyses of covariance.
b. Composite scores range from a minimum of 0.00 to a
maximum of 1.00.
c. Number of days in past thirty.
* Indicates change from baseline to follow-up (paired
t-test) of p<.05; ** indicates change of p<.01;
*** indicates change of p<.001.
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SUMMARY
The findings of this study revealed relatively few
short-term outcome differences for patients meeting
study criteria who were randomly assigned to either
outpatient or inpatient medical detoxification. Given
the higher costs of inpatient treatment, these
findings suggest that outpatient detoxification be
considered as a meaningful and cost-effective
treatment for persons with mild to moderate alcohol
withdrawal symptomatology.
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Concurrent Alcohol and Tobacco
Use by Women
N. Mello, J. Mendelson
INTRODUCTION
There is increasing evidence that drugs from several pharmacolo-
gical classes (alcohol, opiates and certain stimulants) influence
tobacco smoking (see Mello and Mendelson, 1986 for review). An
association between smoking and drinking was first observed in
studies of alcoholic men (Dreher and Fraser, 1967; Maletzky and
Klotter, 1974; Walton, 1972; Mello and Mendelson, 1972) and was
clearly demonstrated under clinical laboratory conditions
(Griffiths et al., 1976). Smoking behavior was measured over 6
hours when alcohol or a non-alcohol control solution was avail-
able. Alcoholic men could consume one drink every 30 minutes and
smoke their preferred brand of cigarettes. Access to alcohol
consistently induced an increase in cigarette smoking in compari-
son to placebo control sessions when no alcohol was available.
Measures of the number of cigarette puffs and butt weight indica-
ted that this effect was not due to smoking less of each cigarette
during drinking (Griffiths et al., 1976).
These findings in alcoholic men have been confirmed (Henningfield
et al., 1983, 1984) and extended to male social drinkers (Mello et
al., 1980a). When social drinkers were given unrestricted access
to alcohol over several days, there was a striking covariation
between alcohol consumption and cigarette smoking (Mello et al. ,
1980a). However, pretreatment with a single dose of alcohol did
not consistently influence smoking in social drinkers (Henning-
field et al., 1984), but in alcoholics, alcohol pretreatment was
associated with a significant increase in cigarette smoking
(Henningfield et al., 1983, 1984).
Most studies of drug effects on cigarette smoking have been
conducted with men. One goal of the current study was to extend
the analysis of the relationship between alcohol consumption and
cigarette smoking to women. Cigarette smoking appears to be
increasing among young women and it is estimated that about 28
percent of American women smoke daily (see Glynn and Cullen, 1985
for review). Despite evidence of the prevalence and adverse
medical consequences of cigarette smoking (Grits, 1980; A Report
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of the Surgeon General, 1980; Glynn and Cullen, 1985), there is
little objective information available on smoking patterns among
women or factors that may influence increases or decreases in to-
bacco use. This is the first report of daily measures of tobacco
smoking by women during 35 consecutive days residence on a clini-
cal research ward. Alcohol was available during 21 of the 35 days
and the covariation between drinking and smoking was examined.
METHODS
Subjects: Twenty-four adult female volunteers (26 ± 0.76 years
old) with a history of regular tobacco and alcohol use gave
informed consent for participation in studies to evaluate the
effects of alcohol and tobacco use on reproductive function in an
inpatient clinical research study. Volunteer subjects were
recruited through advertisements in local newspapers. Subjects
were fully informed about the nature an duration of each phase of
the study and were told that they could withdraw at any time.
Each woman was in good health as determined by clinical and
laboratory examinations. Urine screens for drug use and pregnancy
tests were performed prior to admission to the research ward and
all were negative. Subjects were studied in groups of two to four
and lived on a clinical research ward for 35 days.
Smoking and Drinking History: These women had smoked tobacco
cigarettes for an average of 10.96 years (±1.02). During the
month prior to admission to the study, these women reported
smoking an average of 18 cigarettes per day (±1.9). Seventeen
women reported that they had tried to stop smoking on at least one
occasion. These women had been social drinkers for an average of
6.79 (±0.65) years.
Tobacco and Alcohol Availability Conditions: Subjects were given
access to tobacco only for seven days; alcohol and tobacco were
concurrently available for 21 days; then only tobacco was avail-
able for an additional seven days. Tobacco cigarettes were freely
available upon request. Each woman was given her preferred brand
of cigarettes. The time of each tobacco cigarette request and the
number of tobacco cigarettes smoked each day were recorded.
Smoking dynamics (puff frequency, puff volume) were not measured.
Subjects also could choose their preferred type of beverage
alcohol. Gin, vodka, scotch, bourbon, beer or wine and mixers
were available. Distilled spirits (one 50 ml miniature), beer
(one 12 ounce 360 ml can) and table wine (12.5 ounces or 375 ml)
each cost the same number of purchase points. Subjects were
allowed to buy only one alcohol drink at a time and were not
allowed to share drinks. There was no limit on the number of
alcohol drinks that subjects could elect to purchase each day.
Alcohol and Money Acquisition Procedures: Operant techniques were
used to provide an objective and quantitative measure of perfor-
mance for two alternative reinforcers, alcohol and money.
Subjects could work for money at a simple operant task on an FR
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300 (FI 1 sec:S) schedule of reinforcement throughout the study.
During the period of alcohol availability, women chose whether to
work for alcohol or money each time they activated their operant
instrument. Points earned for alcohol and for money were not
interchangeable. Subjects had to work at the operant task for
about 30 minutes to buy one drink or to earn 50 cents upon
completion of the study. Additional details of the operant task,
operant manipulanda and computer programming circuitry have been
described previously (Mello and Mendelson, 1985; Mello et al. ,
1987).
Medical Status and Related Measures: Pulse, temperature and blood
pressure were measured every eight hours and subjects were weighed
every day. Daily medical rounds and periodic physical examina-
tions were complemented by weekly clinical laboratory studies.
Pregnancy tests were carried out every week.
RESULTS AND DISCUSSION
Smoking Patterns: The 24 women were classified as heavy, moderate
or occasional tobacco smokers on the basis of the actual number of
cigarettes smoked while on the clinical research ward. Seven
women who smoked 25 or more cigarettes per day (X = 32 ± 1.6) were
classified as heavy smokers. Eleven women who smoked 15 to 25
cigarettes per day (X = 21 ± 0.7) were classified as moderate
smokers. Six women who smoked-3 to 11 cigarettes per day (X = 8.4
± 1.2) were classified as occasional smokers. The average number
of cigarettes smoked by each group was significantly different by
ANOVA (P < .001).
Observed smoking patterns were similar to self-reports of tobacco
use before the study. Women classified as heavy smokers reported
smoking 25 (± 2.9) cigarettes per day during the month preceding
the study. These women had smoked for an average of 13.7 (± 1.06)
years. Women classified as moderate smokers reported smoking an
average of 20 (± 1.1) cigarettes per day during the month before
the study. These women had smoked for 9.9 (± 1.76) years. Women
classified as occasional smokers reported smoking an average of 6
(± 1.9) cigarettes per day during the month before the study and
had smoked for 9.7 (± 1.9) years.
Concurrent Use of Tobacco and Alcohol: Women who were heavy
smokers smoked significantly more during alcohol availability when
smoking was analyzed independent of alcohol consumption (P < .05).
Smoking increased by 5.5 ± 0.95 cigarettes per day over the
pre-alcohol baseline. Moreover, there was a striking concordance
between variations in alcohol intake and in cigarette smoking.
Correlational analysis revealed that smoking and drinking were
significantly related (r = .602; P < .01). The heavy smokers
also smoked significantly more after alcohol availability than
before drinking (P < .01) (34 ± 2.7 cigarettes per day). The
heavy smokers also smoked significantly more than the moderate and
occasional smokers during all phases of the study (P < .001).
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Moderate smokers smoked 2.8 (± 0.64) more cigarettes each day
during drinking than during baseline but this difference was not
significant. Occasional smokers also stroked 0.9 (± 1.62) more
cigarettes during drinking than during baseline, but this dif-
ference was not significant. Both moderate and occasional smokers
acquired an equivalent number of cigarettes before and after
alcohol availability. Variations in smoking and drinking were
significantly correlated in the occasional smokers (r = .671; P <
.001) but not in the moderate smokers.
Analysis of smoking as a function of alcohol intake also showed
that women who were heavy and moderate drinkers smoked signifi-
cantly more during alcohol availability than during the pre-alco-
ho1 baseline. Moreover, the alcohol-associated increases in
smoking by moderate and occasional drinkers persisted during the
post-alcohol period. During the pre-alcohol baseline period, five
heavy alcohol users smoked an average of 19 (± 3.4) tobacco ciga-
rettes each day. During alcohol availability, the heavy drinkers
drank an average of 7.8 (±.69) drinks per day and increased
smoking significantly by 6 (± 1.24) cigarettes per day (P < .01).
Illustrative data for two heavy drinkers who smoked an average of
one pack of cigarettes per day during the pre-alcohol baseline are
shown in Figure 1. These individual smoking and drinking data
show an alcohol dose dependent influence on tobacco smoking.
Subject 15 increased average tobacco smoking from 20 to 30
cigarettes per day when she drank an average of 10 (± 1.38) drinks
per day. As alcohol consumption declined to 8 (± .92) and 6
(± 1.18) drinks per day, tobacco smoking also decreased from 30 to
26, then 25 cigarettes per day. Subject 16 also increased tobacco
smoking from 21 to 30 cigarettes per day when she began to drink
over 6 drinks per day. Subject 16's alcohol intake remained at 6
drinks per day throughout the 21 day period and cigarette smoking
also remained stable at 31 (± 2.20) cigarettes per day.
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Ten moderate alcohol users smoked an average of 21 (± 2.5) tobacco
cigarettes per day during baseline. The moderate alcohol users
drank 3.85 (± .19) drinks per day and increased smoking signif-
icantly during alcohol availability (P < .05). The moderate
alcohol users also smoked significantly more during the post-alco-
hol period than during the pre-alcohol baseline (P < .05).
Nine occasional alcohol users smoked an average of 16 (± 2.6)
tobacco cigarettes per day during the pre-alcohol baseline. These
women drank 1.22 (± .21) drinks per day and increased smoking to
17 (± 2.9) cigarettes per day. As the study progressed, the
occasional alcohol users continued to smoke more cigarettes.
Distribution of Intervals Between Successive Cigarettes: The
alcohol-related increases in the number of cigarettes smoked each
day were also associated with significant changes in the overall
rate of cigarette smoking. Women requested more cigarettes at
intervals of 11 to 20 min during alcohol availability than during
the pre-alcohol condition when cigarettes were usually smoked at
intervals of 21 to 30 or 31 to 40 min. These pre-alcohol inter-
cigarette intervals are similar to previous observations in three
male heavy smokers when puff duration and inter-puff intervals
were controlled (26.11 ± 1.58 to 37.28 ± 2.43 min) (Griffiths et
al., 1982).
The shift in the distribution of inter-cigarette intervals during
drinking is comparable to that previously observed in men main-
tained on buprenorphine (Mello et al., 1985) and on heroin (Mello
et al., 1980b, 1985). This smoking pattern is consistent with the
timecourse of nicotine metabolism, since plasma nicotine levels
peak within 10 min and fall precipitously in about 20-30 min
(Armitage, 1978; Gritz, 1980; Jaffe and Jarvik, 1978). These
findings with alcohol extend our previous observations that in-
creased cigarette smoking during opioid drug use occurs primarily
at shorter inter-cigarette intervals rather than being distributed
equally across the range of intervals studied (Mello et al. ,
1980b, 1985).
These data in women confirm and extend previous reports of an
association between cigarette smoking and drinking by alcoholic
men (Griffiths et al., 1976; Henningfield et al., 1983; Mello and
Mendelson, 1972) and male social drinkers (Mello et al., 1980a).
Although all women smoked more during alcohol availability, the
magnitude of the increase was related to the relative smoking and
drinking level. Heavy smoking and heavy and moderate drinking
were associated with greater increases in smoking during drinking
than moderate and occasional smoking and/or occasional alcohol
use.
The mechanisms by which alcohol affects cigarette smoking are
unclear. Drugs from several pharmacologic classes including
opioid agonists and mixed agonist-antagonists and stimulants have
also been shown to be associated with increased cigarette smoking
(Mello et al., 1980b, 1985; Schuster et al., 1979; Mello and
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Mendelson, 1986). Consequently, it is difficult to postulate that
any specific pharmacological effect accounts for increased
cigarette smoking during intoxication.
There remain many complex and as yet unresolved questions concer-
ning the nature of the reinforcer in polydrug use and abuse. We
have suggested elsewhere that a stimulus self-administration
framework may be a useful way to think about polydrug use of
substances with conflicting or antithetical behavioral effects
(Mello, 1977, 1983). The reinforcer for drug use may be a change
in state, and the direction of that change may be less important
than the occurrence of the change itself (for review, see Mello,
1983; Mello and Mendelson, 1986). The reinforcing properties of
cigarette smoking and how these are influenced by simultaneous use
of other substances remains to be clarified.
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The Syndrome Concept of Alcohol
and Drug Dependence: Results of
the Secondary Analysis Project
T. Babor, N. Cooney, R. Hubbard, J. Jaffe, T. Kosten,
R. Lauerman, T. McLellan, H. Rankin, B. Rounsaville
and H. Skinner
INTRODUCTION
This report describes the accomplishments of a multi-center
collaborative project formulated within the context of the
ongoing WHO/ADAMHA program on Classification and Diagnosis.
The goal of this project has been to provide empirically-based
research findings relevant to the improvement of diagnostic
systems currently used for the classification of alcohol and
drug dependence syndromes. Of particular interest to this
investigation was the detailed examination of the drug
dependence syndrome (DDS) concept (Edwards et al.,1981), its
patterning in clinic samples of opiate and alcohol dependent
persons, its generalizability to diverse cultural settings, its
relation to certain antecedent and concurrent variables, and
its value as a predictor of treatment response. The goals of
the project have been accomplished by re-analysis of nine
existing data sets obtained from recent treatment evaluation
studies conducted in the U.S., England, Canada and France. In
view of the potential commonalities existing within these data
sets, collaborating investigators coordinated a series of
secondary analyses designed to provide a preliminary evaluation
of the WHO dependence model. The analyses examined:
1) commonalities in the internal consistency and factor
structure of dependence elements across substances (opiates and
alcohol) and across cultural groups; 2) the relative
independence of the hypothesized dependence syndrome from other
kinds of physical, social and psychological disability; 3) the
relation between severity of dependence and rapidity of relapse.
METHODS
Detailed description of the study samples and research
methodologies is provided in the published reports of the
collaborating investigations (Babor, Cooney and Lauennan 1987;
Bray et al.,1981; Kosten et al. in press; Woody et al., 1983;
Skinner 1986; Kosten et al.,1986). These studies evaluated
alcohol and/or drug dependent patients at admission to
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treatment and, in many cases, again at follow-up. Conducted by
senior investigators in Great Britain, France, the United
States, and Canada, these studies have produced data sets
representing more than 16,000 patients. The secondary analyses
of these data sets fall into three categories: a) internal
consistency reliability analyses of dependence syndrome items;
b) factor analyses of dependence syndrome measures; and
c) analysis of the predictive validity of syndrome elements.
RESULTS
Internal consistency analysis. A major assumption of the
dependence syndrome concept is that a common core of behaviors,
cognitions and physiological symptoms tends to co-vary in
frequency and intensity. The common syndrome elements include
narrowing of the substance use behavioral repertoire, increased
salience of substance-taking behavior, increased tolerance,
repeated withdrawal symptoms, subjective compulsion to use the
substance, use to relieve withdrawal, and increased liability
to readdiction. In order to test this hypothesis, internal
consistency reliability analyses were conducted on data from 15
samples of opiate users and alcoholics. The results of those
analyses are summarized in Table 1. Items consistent with the
WHO dependence model were selected from the scales indicated on
the table. Where data were available on females, these have
been considered separately to provide additional replications.
The samples are predominantly alcoholic patients and all items
analyzed pertain to the hypothetical elements of the alcohol or
drug dependence syndrome. The results indicate a high degree
of internal consistency reliability across relatively disparate
samples of alcoholics, opiate users and polydrug users as
indicated by the high Cronbach's alphas.
The above analyses of internal consistency strongly suggest
that the dependence syndrome items form cumulative,
unidimensional scales. As a further test of unidimensionality,
Kosten et al., (in press) attempted to form Guttman scales for
each type of drug from 10 items derived from the Structured
Clinical Interview for DSR-III-R (SCID). Most of the drugs
demonstrated good approximations of "perfectly" unidimensional
and cumulative scales. The coefficients were 0.85 or above for
all drugs. This indicates that within each type of drug,
higher scores are consistent with more severe dependence. The
items associated with a more severe syndrome differed across
the various drugs. For example, opiate users reporting
"withdrawal symptoms" almost always reported every other item
of the dependence syndrome, but users of other substances often
reported this item with few other dependence symptoms. At the
other extreme, opiate users often reported "using more opiates
than they intended" along with few or no other dependence
items. Other types of substance users usually reported this
item in conjunction with most other items in the syndrome.
Factor analyses. A second test of the syndrome hypothesis was
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to apply factor analysis to those data sets having an adequate
representation of items measuring both dependence elements and
problems related to alcohol or drug use. Factor analyses have
been conducted on three samples (Farmington, Tours, Toronto),
Table 1. Results of internal consistency reliability analyses.
Sex, Sample Size Number Type of Cron-
Instru- & Primary Diagnosis of Depend- bath's
Sample ment of Respondents Items ence Alpha
UConn LSXMOa 197 male alcoholics 14 alcohol .86
Farmington 64 female alcoholics 14 alcohol .81
MASTb 156 male alcoholics 5 alcohol .70
58 female alcoholics 5 alcohol .62
Saint HiltonC 53 male alcoholics 17 alcohol .88
Andrew's 44 female alcoholics 17 alcohol .86
England
Tours LSXMOa 177 male alcoholics 18 alcohol .89
France 36 female alcoholics 18 alcohol .90
Yale MASTb 413 male opiate users 5 alcohol .82
New Haven 130 female opiate users 5 alcohol .63
Yale SADSd 413 male opiate users 7 alcohol .78
New Haven 130 female opiate users 7 alcohol .76
SCIDe 41 mental patients 10 alcohol .91
42 polydrug users 10 sedatives .85
54% males, 46% females 10 hallucinogens .90
10 stimulants .91
aLast Six Months Drinking Questionnaire 10 cannabis .83
bMichigan Alcoholism Screening Test 10 cocaine .95
cHilton Drinking Questionnaire 10 opiates .98
dSchedule for Affective Disorders and Schizophrenia
eStructured Clinical Interview for DSM-III-R
providing good support for the statistical independence of
dependence symptoms and problem indicators. The results of
those analyses are described in papers by Babor, Lauerman and
Cooney (1987), Skinner and Goldberg (1986), and Kosten et al.,
(in press).
Predictive validity. Additional analyses tested the relative
predictive power of pre-treatment dependence in relation to a
variety of other intake variables in accounting for the
severity of dependence at post-discharge follow-up among those
patients who attempted to drink or use opiates.
One analysis tested the hypothesis that the greater the degree
of alcohol dependence prior to admission to treatment, the more
likely the syndrome is to be reinstated once drinking is
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initiated following a period of abstinence. The results,
summarized in Babor, Lauennan and Cooney (1987) showed that the
strongest and most consistent predictors of severity of
dependence at 12-month follow-up among males (N =150) are
measures reflecting recent and lifetime dependence history.
Although pre-treatment dependence was found to be a significant
predictor for females (N=47), the degree of social problems at
intake was a stronger correlate, and the lifetime dependence
symptom count from the DIS did not predict reinstatement in
females.
Another hypothesis derived from DDS theory concerns the role of
craving as a mediator of relapse. It has been suggested that
craving is a cognitive label applied to conditioned responses
precipitated by alcohol-related stimuli. If craving is a
consequence of an alcoholic's dependence history, then reports
of the frequency and intensity of craving should be greatest in
persons scoring higher on our dependence measures. In order to
test this hypothesis, we correlated the intake dependence
measures with two measures of craving at one-year follow-up.
In order to control for the confounding influence of concurrent
drinking on craving, we analyzed data only from patients who
remained abstinent from alcohol during the entire follow-up
period. The results indicate that the severity of recent
pre-treatment dependence predicts the intensity of
post-treatment craving in both males (r=.33, p < .05) and
females (r=.55, p < .05).
A final series of analyses was designed to test the
reinstatement hypothesis in samples of opiate users studied by
researchers at the University of Pennsylvania (UPenn, Woody et
al., 1983), Yale University (Kosten et al. 1986). and Research
Triangle Institute (RTI, Bray et al. 1981). The primary
dependent measures of interest to these analyses were the Drug
and Alcohol Composite scores from the Addiction Severity Index
(ASI; McLellan et al., 1981). These composites are computed
from questions about recent frequency of use, money spent on
drugs or alcohol, and number of days in last month bothered by
drug or alcohol problems, such as craving, withdrawal, or
impaired control. ASI composites representing alcohol and drug
severity at intake and six-month follow-up evaluation were
correlated within three study samples: UPenn males (N=94),
Yale males (N=71), Yale females (N=27). The results indicated
that drug severity at intake predicts drug severity at
follow-up only in the UPenn sample (r=.34, p < .01). The
relationship between intake and follow-up alcohol severity was
replicated in both male samples, however. Re-analysis of the
RTI data set, using two measures of reinstatement (rapidity of
return to daily use and any return to daily use) in a logistic
regression analysis, was based on patients not participating in
methadone maintenance programs who relapsed to opiate use
during the one-year follow-up period (N =208). The results
revealed few significant predictors of either measure of
reinstatement and no evidence that indicators of prior
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dependence, such as treatment history or number of drugs used,
predicted reinstatement.
DISCUSSION
A major assumption of the DDS concept is that the syndrome
elements tend to co-occur in frequency, intensity and
duration. Another assumption is that syndrome elements are
statistically as well as conceptually independent of
disabilities consequent to alcohol or drug use. The results of
the internal consistency reliability analysis conducted on
various item sets provided strong support for the syndrome
hypothesis. Cronbach's alphas were consistently high across
samples regardless of substance (opiates, alcohol). gender
(males, females) or cultural identification (English, American,
French). Kosten et al.'s, (in press) Guttman Scale analysis of
identical items rated across six substances provided additional
support for the unidimensionality of the syndrome elements.
Factor analysis of the alcohol dependence items in samples of
American and French alcoholics demonstrated statistical
independence from scales measuring alcohol-related problems.
Skinner's and Goldberg's (1986) factor analysis of the DAST
(Drug Abuse Screening Test) items provided a preliminary
replication of these findings in a sample of drug users. A
three-item factor, labeled dependence, was defined by items
measuring impaired control over drug intake, compulsion to use
the substance, and drug withdrawal symptoms. The findings are
consistent with those obtained from alcoholics, opiate addicts,
and polydrug users studied by Kosten et al., (in press) and
McLellan et al., (1981).
The analyses described in this paper also attempted to evaluate
the usefulness of DDS measures as predictors of dependence
severity following posttreatment use of either alcohol or
drugs. The results provide some support for the predictive
validity of alcohol dependence measures, not only in persons
whose primary diagnosis is alcoholism (UConn sample), but also
among opiate addicts (Yale and UPenn samples). While the
relatively high prevalence of alcohol abuse in the opiate
addict samples makes these groups a logical source to test the
generalizability of the findings obtained from the alcoholics,
it should be noted that the nature of the follow-up methodology
employed does not permit a clear statement about the extent to
which alcohol dependence was actually reinstated. These
correlations may merely reflect the continuation of heavy
drinking by the opiate addicts during the posttreatment period
without any significant period of alcohol abstinence during
treatment.
Although the ASI drug severity score was a significant
predictor of posttreatment dependence severity in the UPenn
sample, the correlations found in the other samples were not
significant. These mixed results could be influenced by a
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variety of extraneous factors that make the DDS reinstatement
hypothesis difficult to test in samples of opiate addicts. The
first difficulty is the measurement of dependence. In the
present analysis, we relied primarily on the drug severity
composite from the ASI, a measure that only approximates the
content of the drug dependence construct. Second, it was
difficult to control for the opportunity to reinstate
dependence, since this depends on such factors as initiating
opiate use following a period of abstinence. Many
drug-treatment subjects in these analyses never truly abstained
from opiates since they were actually enrolled in methadone
maintenance programs. Under these circumstances, it is
surprising that a significant relationship was observed in the
UPenn sample.
In conclusion, the DDS concept provides the basis for a
relatively unambiguous set of hypotheses about the conditions
under which alcoholics and opiate addicts re-acquire dependence
after a period of abstinence. Instead of conceiving relapse as
a symptom of some underlying personality problem, it focuses
attention on the patient's maladaptive habit patterns and the
environmental as well as interoceptive stimuli that precipitate
reinstatement of dependence. The present research suggests
that the DDS concept may have merit as a theory of drug and
alcohol dependence, but should be subjected to a more rigorous
program of research aimed at better operational measures and
more intensive hypothesis testing, especially in samples of
drug users.
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Placebo Challenge: Effects Follow-
ing Repeated Alcohol vs. Placebo
Administration
M. McCaul, J. Turkkan and M. Stitzer
When the physiological and subjective effects of a drug such as
ethanol are repeatedly paired with stimuli in the natural en-
vironment, drug-related conditioned responses may come to be eli-
cited by these previously neutral stimuli. Such conditioned re-
sponses are thought to play an important role in triggering crav-
ing and precipitating relapse to drug use following periods of
abstinence. While much of the objective evidence of conditioning
during repeated drug administrations has been obtained in animal
studies, there have been a number of demonstrations of the opera-
tion of conditioning in humans.
Some research with alcoholics has reported differences in heart
rate, skin conductance and subjective response measures when sub-
jects were given controlled exposure to the taste of alcoholic
versus nonalcoholic beverages in doses that were insufficient to
produce direct drug effects (Baker and Cannon, 1979; Cannon and
Baker, 1981; Kaplan et al, 1985); however, other studies have
failed to replicate these findings. In a recent study with so-
cial drinkers, Newlin (1985) obtained significant increases in
heart rate and decreases in skin conductance depending on sub-
jects' identification of near-beer as an alcoholic or non-
alcoholic beverage. He suggested that the sight, taste and smell
of beer alone were not sufficient as conditioned stimuli but
rather the "experiential feeling of intoxication" was necessary
for demonstration of conditioned responses.
The present study examined the effects of a placebo drink in al-
coholic subjects following repeated administration of alcohol or
placebo drinks in a laboratory environment. One group of sub-
jects received active alcohol during sessions 1 through 4 and
placebo on day 5; the second group received placebo throughout
sessions 1 through 5. We hypothesized that subjects receiving
placebo in an environment previously associated with alcohol
availability would exhibit conditioned responses as compared with
subjects in the placebo control group. Further, we predicted
that these conditioned responses would be opposite in direction
to responses obtained during the active drink sessions.
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METHODS
Subjects. Subjects in both groups were alcoholics who met the
following selection criteria: five or more years heavy alcohol
use, 10 or more drinks on 3 - 7 days per week, one or more de-
pendence symptoms such as tremors, morning drinking or blackouts,
and either prior treatment for alcohol abuse or alcohol-related
social, legal or employment problems. Twelve subjects were as-
signed to the active alcohol condition and twelve subjects were
assigned to the placebo condition. There were no differences in
demographic characteristics or in the number and type of alcohol-
related problems between the two groups.
Since subjects were current heavy drinkers at the time of study
enrollment, subjects were hospitalized for a minimum of three
days before their first experimental session and remained hospi-
talized throughout the research protocol. All subjects received
thorough medical and psychiatric screens and provided signed in-
formed consent prior to experimental assignment. Subjects were
paid for their participation.
Procedures. Subjects participated in five successive daily ses-
sions each of which consisted of two methodologically distinct
data collection periods. At the beginning of each session, sub-
jects received a variable number of randomized-block presenta-
tions of three types of stimulus trials. Stimulus trials in-
cluded taste, sight and smell of alcohol, pepper juice or water.
These data are not included in this paper.
At the conclusion of the daily stimulus trial series, subjects in
the alcohol condition received 1.7 g/kg ethanol on days 1 - 4 and
placebo on day 5. Subjects in the placebo condition received
placebo drinks across days 1 - 5. Orange juice was mixed with
the appropriate dose of alcohol to maintain a constant volume of
16 oz; all drinks were delivered in a thermos surrounded by
alcohol-soaked gauze. A mouth-piece filled with 0.2 ml alcohol
was attached to the straw in order to deliver an initial strong
taste of alcohol in both drink conditions (Mendelson et al,
1984). Subjects were instructed to consume the drink during a
5-minute period. The research assistant and subjects were blind
to experimental assignment.
Physiological measures were collected continuously throughout the
drink period and the subsequent 20-minute interval. Heart rate
was recorded as interbeat interval using chest EKG electrodes;
the signal was amplified using a Beckman polygraph. Skin tem-
perature was measured using a skin surface thermistor placed on
the middle finger of the nondominant hand. Skin conductance was
recorded using an Autogen 3000 from two finger-tip electrodes
placed on the nondominant hand. In addition, five self-report
analog questions were completed a total of four times at 5-minute
intervals post-ingestion. Analog items were displayed on a com-
puter screen and responded to using a joystick which advanced a
cursor on the screen. Analog items included: high, good ef-
41
fects, bad effects, like drink and craving.
Physiological measures were analyzed using repeated measures
analyses of covariance with baseline (l-minute pre-drink) as the
covariate. Self-report analog items were analyzed with repeated
measures analyses of variance. For both physiological and sub-
jective data, factors included group (alcohol vs. placebo), days
(separate analyses were conducted using data from all days and
using only day 1 vs. day 5 data) and minutes. Planned compari-
sons were conducted when significant effects of days or minutes
were observed.
RESULTS
Physiological Measures. As seen in Figure 1, heart rate remained
relatively stable throughout the 20-minute post-ingestion period
for both the alcohol and placebo groups on day 1. In contrast on
day 5, heart rate decreased following ingestion of the placebo
drink in subjects who had consistently received alcohol on days 1
- 4. For the placebo group, there was no change in heart rate
response during the post-ingestion period from day 1 to day 5.
Comparing heart rate on day 1 versus day 5, there was a signifi-
cant days X group interaction (p<.O5). Planned comparisons indi-
cated that on day 1, heart rate in the alcohol group was signifi-
cantly less than in the placebo group only during minute eleven
through fifteen post-ingestion (p<.05). Whereas on day 5 follow-
FIGURE 1. Mean heart rate following ingestion of alcohol or pla-
cebo over successive minutes post-ingestion. Subjects in the
alcohol group received 1.7 g/kg ethanol on day 1 ( ) and placebo
on day 5 ( ). Subjects in the placebo group received placebo
drinks on day 1 ( ) and day 5 ( ). Data were averaged over a
5-minute interval for 12 subjects per group.
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ing placebo administration, heart rate was significantly less in
the alcohol group than in the placebo group from minute 6 post-
ingestion to the end of the 20-minute measurement period (p<.01).
As shown in figure 2, skin conductance on day 1 was significantly
higher in the group receiving alcohol than in the placebo group
from minute 6 post-ingestion to the end of the 20-minute measure-
ment period (p<.O1). In contrast, on day 5 following placebo
administration in both groups, skin conductance was significantly
lower in the group previously receiving alcohol than in the group
receiving placebo throughout all five sessions. This difference
in skin conductance was significant from minute 11 post-ingestion
to the end of the measurement period (p<.O5). For skin conduc-
tance there was a significant group X days X minute interaction
(p<.0001).
There were no significant day 1 vs. day 5 effect on skin tempera-
ture; however, across all days, there was a significant group X
days X minute interaction (p<.O2). As shown in Figure 3, skin
temperature on day 1 showed little systematic change from base-
line following ingestion of alcohol or placebo over the 20-minute
measurement period. On days 2 - 4 following active alcohol, skin
temperature increased above day 1 alcohol levels and also above
placebo levels during the sessions. On day 5, skin temperature
FIGURE 2. Mean skin conductance following ingestion of alcohol
or placebo over successive minutes post-ingestion. Subjects in
the alcohol group received 1.7 g/kg ethanol on day 1 ( ) and pla-
cebo on day 5 ( ). Subjects in the placebo group received pla-
cebo drinks on day 1 ( ) and day 5 ( ). Data were averaged over
a 5-minute interval for 12 subjects per group.
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FIGURE 3. Mean skin temperature following ingestion of alcohol
or placebo over successive minutes post-ingestion. Subjects in
the alcohol group received 1.7 g/kg ethanol on days 1 - 4 and
placebo on day 5. Subjects in the placebo group received placebo
drinks over days 1 - 5. Data were averaged over a 5-minute in-
terval for 12 subjects per group.
showed a similar decrease across the 20-minute measurement period
for both groups. Post-hoc comparisons of skin temperature across
days revealed a significant difference between day 2 and day 5
(p<.05) and between day 3 and day 5 (p<.01) for the alcohol group
only; there were no significant differences in skin temperature
across days for placebo subjects.
Self-report Measures. Similar results were obtained for three
out of five self-report measures. Scores for high and good ef-
fects were higher in the alcohol group than in placebo group
across sessions 1 - 4. In contrast, on day 5 following placebo
administration, scores were similar for the two groups. Com-
paring day 1 versus day 5, there were significant group X days X
minute interactions for high (p<.03) and good effects (p<.007).
Finally, there was a significant days effect (p<.04) and a mar-
ginal group X days interaction (p<.08) for craving. As shown in
figure 4, craving was lower in the alcohol group than in the pla-
cebo group on day 1. Craving increased from day 1 to day 4 in
the alcohol group even though subjects were receiving a constant,
high dose of alcohol daily.
istration,
On day 5 following placebo admin-
craving scores for the alcohol group were elevated
above the placebo group. There were no systematic changes in
craving in the placebo group over days.
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FIGURE 4. Mean subject ratings of alcohol craving over days.
Subjects in the alcohol group received 1.7 g/kg ethanol on days 1
- 4 and placebo on day 5. Subjects in the placebo group received
placebo drinks over days 1 - 5. Each point is the average of 4
ratings made at 5-minute intervals post-ingestion, averaged over
12 subjects per group.
DISCUSSION
A placebo challenge resulted in different physiological and sub-
jective responses depending on whether alcoholic subjects had
received earlier repeated administrations of alcohol or placebo
in the laboratory. Specifically, following a placebo challenge,
heart rate and skin conductance were significantly lower in sub-
jects previously receiving alcohol than in subjects previously
receiving placebo. This effect on skin conductance was opposite
in direction to the significant increase in skin conductance fol-
lowing active alcohol administration on day 1. In addition,
craving scores following a placebo challenge were higher for sub-
jects previously receiving alcohol than for subjects previously
receiving placebo.
Results on all three measures for the alcohol group only are con-
sistent with Siegel's model of conditioned compensatory responses
to repeated drug administration (Siegel, 1980). According to
this model, repeated drug administration results in the develop-
ment of drug-opposite conditioned responses which then serve to
offset the direct actions of the drug. While the results of many
animal studies on drug conditioning and tolerance have supported
this model, the results from human research have been less con-
sistent. As mentioned earlier, a recent study by Newlin (1985)
has suggested that exposure to alcohol-related stimuli alone may
not be sufficient to elicit conditioned responses in humans,
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rather subjects must experience alcohol-like effects in order to
demonstrate compensatory responses. The present data further
suggest that subjects may exhibit conditioned responses when the
environment signals alcohol availability but not when the same
environment has been associated with the non-availability of
alcohol.
These findings are important both methodologically and clinical-
ly. In terms of experimental methods, conditioned responses may
be smaller and more variable using laboratory procedures which do
not explicitly include alcohol availability; to date, most of the
human research on alcohol conditioning has relied on the taste,
smell and/or sight of alcohol. In terms of clinical application,
the data support the importance of relapse prevention training in
treating alcoholic clients since they may not experience the full
impact of physiological and subjective responses to alcohol-
related cues until their return to environments in which alcohol
continues to be available.
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Interactions Between Social
Behavior and Smoked Marijuana
R. Foltin, M. Fischman and J. Brady
A previous report from this laboratory (Foltin et al., 1986)
described the effects of smoked marijuana on contingency-
controlled behavior under conditions that involved the
maintenance of a law probability private work performance by
access to a high probability work task. The results of that
study, as with earlier reports describing marijuana effects on
behavior maintained by monetary contingencies (Mendelson et
al., 1976; Miles et al., 1974), showed no significant change in
the required instrumental performances following drug
administration. Interactions between smoked marijuana and
contingency-controlled behavior were suggested however, by the
finding of a somewhat surprising decrease in the contingent
high probability work performance under active marijuana
conditions described by Foltin et al
report describes a study that extended the analysis of
., (1986). The present
interactions between marijuana and performace to behavioral
contingencies involving social and recreational activities.
Specifically, the effects of smoked active and placebo
marijuana cigarettes were compared in the presence and absence
of contingencies that required performance of law probability
individual behaviors to access high probability social
interactions.
METHOD
Subjects. Six healthy adult male volunteers ranging in age
from 21 to 35 participated in two long-term residential
experiments. All subjects were current marijuana users.
Subjects received extensive medical and psychiatric
examinations prior to research participation and signed consent
forms that provided a detailed explanation of the experimental
procedure.
Laboratory. The studies were conducted in a self-contained
human residents laboratory environment that has been
previously described in detail (Brady et al., 1975). The three
identical private rooms (2.6 x 3.4 x 2.4 m) are similar to
47
facilities, bed, desk, chair, and other furnishings. The
social living area (4.3 x 6.7 x 2.7 m) is equipped with tables,
chairs, sofa beds, and a complete kitchen facility. The
workshop (2.6 x 4.1 x 2.7 m) contains an exercise area and a
washer-dryer combination. A common bath serves the social
living area and the workshop. Access to the exterior walls of
the laboratory is provided by a corridor between the
residential chambers and the external building shell that
permits transfer of supplies and materials through two-way
storage facilities accessible from both sides.
One subject resided in each of the three private efficiency
apartments and all had access to group areas at programmed
times. All subjects remained within the residential laboratory
environment through out the duration of the study. A networked
computer system with terminals in each room provided all
contact between subjects and experimenters. Subjects were
monitored from and adjacent control room using a video and audio
monitoring system and a computerized behavioral observation
program (Bernstein & Livingston, 1982).
Standard Day. The day consisted of three sections: a private
work period, a performance test, and a period of social access.
Subjects were awakened at 09:00, ate breakfast and had a work
period from 10:00 to 15:00. During the work period, subjects
were required to remain in their private rooms and engage in
one of four performance tasks. Subjects were tested in a
performance battery from 15:30 to 16:30. During the remainder
of the day subjects either remained in their private rooms or
used the facilities in the social area. The day ended at
24.00.
Procedure. The design for the experiment is presented in Table
1. The protocol involved both baseline and contingency
periods, with placebo and active marijuana cigarette smoking
superimposed on each of these conditions. During baseline
conditions
Table 1
EXPERIMENTAL DESIGN
Day 1 2 3 4 5 6 7 8 9 10 11 12 1 3 14 15 16 17 1 8
Drug N S M J P B O M J P B O
Social BASE CONTGY BASE CONTGY BASE BASE
("BASE" - Table 1), subjects engaged in activities in the
absence of restrictions. Each behavioral activity was
monitored continuously via the computerized obsezvational
system and time spent in each activity was recorded for each
subject. The resultant time-based behavioral hierarchies
determined the contingency conditions ("CONTGY" in Table 1)
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during which subjects had to spend time doing the least
preferred activity. A contingency relationship was determined
for each subject using the response-probability procedure of
Premack (1965). This required that subjects engage in four
times the amount of their least preferred baseline activity
(the instrumental activity) in order to maintain baseline
levels of their most preferred activity (the contingent
activity). During contingency periods, lack of availability of
the contingent activity was indicated by illumination of a red
light in each subject's room and the social area. Time earned
for the contingent activity accumulated as time was spent
performing the instrumental activity. As long as there was
time and accumulated for the contingent activity, each subject
could use it as he chose. Time earned was carried over each
day for the entire contingency period. Subjects were not told
the duration of the contingency, and each afternoon they were
givenwritten instructions describing the contingency in effect
during the social periods. Social contingencies occurred on
days 5 through 7 under active marijuana conditions and on days
11 through 13 under placebo conditions.
Drug administration. Marijuana cigarettes with 0% (placebo)
and 1.84% delta-9-THC concentrations were provided by the
National Institute on Drug Abuse. Five puffs of each cigarette
were smoked using a uniform puff procedure. Subjects smoked
placebo or active marijuana cigarettes in their individual
rooms at 10:00 and l5:25 and together in the social area at
19:25 and 22:oo.
RESULTS
contingency periods.
Figure 1 shows the in-
gency periods for each of five subjects.
creases in time spent engaged in the instrumental activity
This analysis compares active marijuana administration (days 5-
7) and the effects of placebo administration (days 11-13) on
contingency controlled behavior. Data were analyzed relative
to the baseline period occurring prior to each contingency.
under baseline conditions subjects
spent between 1% and 32% of
the social access period
"reading", an activity done
individually in each sub-
ject's private room. This
activity functionedas the
instrumental activity under
contingency conditions for all
subjects. Under baseline con-
ditions, subjects spent between
41% and 76% of the social access
period engaged in activities in
the social area. Access to the
social area served as the con-
Figure 1. Mean percent change from baseline for
tingent activity during the
time spent in the instrumental activity following
placebo and marijuana administration during contin-
49
during the contingency periods as a percentage of non-
contingent baseline time for 5 of the 6 subjects. The sixth
subject's baseline time in the instrumental reading activity
was less than 2% of the social access period and a meaningful
contingency ratio would not be calculated. For all five of the
remaining subjects however, instrumental activity increases
ranged between 100% and 500% of baseline and 4 of the 5
subjects showed consistently greater increases in instrumental
activity under placebo than under active marijuana conditions.
Decreases in percent time spent in the contingent activity were
observed during contingency periods, but there were no
differences between the active marijuana and placebo conditions
in this regard.
DISCUSSION
The results of this experiment extend the analysis of
interactions between smoked marijuana and behavior to
contingency-controlled social behavior. Increases in an
instrumental performance maintained by access to social
activity Were smaller after active marijuana administration
than after placebo administration. Time spent in contingent
social interactions however, Was decreased to a similar extent
following both placebo and active marijuana administration.
These results contrast the earlier reported effects of smoked
active marijuana on behavior involving non-social assigned Work
tasks (Foltin et al., 1986). Under such private work
conditions, there were no differences in the effects of active
marijuana and placebo on increases in instrumental performance,
but decreases in contingent activity were greater following
active marijuana administration. Clearly, there are
interactions between smoked marijuana and behavior that may
vary with current contingencies and the functional properties
of the performances observed.
Several early clinical reports suggested that repeated
marijuana smoking may result in the loss of desire to work and
an "amotivational syndrome" (McGlothin & West, 1968; Smith,
1968). For the most part, experimental studies of marijuana
effects on operant performances maintained by monetary gain
have provided little support for such "amotivational" phenomena
(see review by Miles, 1975). The present findings however, do
indicate that operant performances maintained by access to a
preferred social activity may be, to some extent, attenuated
following active marijuana administration. The relationship
between the instrumental performance decrement following
marijuana administration observed in the present study and the
"amotivational syndrome" reported in clinical settings (e.g.,
Lantner, 1982; Voth, 1982) remains unclear. The results
described in this report however, may provide the basis for an
experimental analysis of the factors upon Which such clinical
observations are based, as well as three that account for the
wide variability in marijuana effects described in the research
literature.
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Nicotine Replacement Effects on
Post-Cessation Withdrawal
Symptoms and Weight Gain
M. Stitzer and J. Gross
Drug replacement therapy can be an effective tool in the treatment of
substance abusers. A commercial chewing gum product (Nicorette) is
available for the treatment of tobacco dependence that delivers nicotine
via buccal absorption with 2 mg of nicotine contained in each piece of
gum. Smokers are typically prescribed the gum just prior to cessation
and are advised to chew up to 15 pieces per day for 3 months after
quitting. Nicotine gum reduces the intensity of tobacco withdrawal
symptoms following smoking cessation (Hughes et al., 1984; Schneider
et al., 1984; West et al., 1984) and treatment evaluation studies have
generally found that prescription of the gum results in increased
cessation rates (Hughes and Miller, 1984). The rationale for 3-month
gum prescription is not clear, however, since withdrawal symptoms may
dissipate well before this time. Since the duration of post-cessation
withdrawal effects is presently unknown, the first purpose of the present
experiment was to study nicotine replacement effects on post-cessation
withdrawal over a longer (10-week) time course than has previously
been examined. Weight gain is a second common effect of smoking
cessation (Hall et al., 1986; Wack and Rodin, 1982). Nicotine appears to
exert a chronic suppressing effect on body weight that is released upon
cessation of smoking (Wack and Rodin, 1982). Thus, there is reason to
believe that post-cessation nicotine gum use might counteract the
anticipated increase in body weight . Presently available data are
inconclusive with regard to demonstrating that nicotine replacement can
influence post-cessation weight gain (Fagerstrom, 1987). The second
purpose of the present study was to examine post-cessation weight gain
in people who remained smoking abstinent for 10 weeks while chewing
under random assignment double-blind procedures a gum that
contained 0 mg (placebo) or 2 mg nicotine.
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METHODS
Subjects. Smokers were recruited from the community for a cessation
program involving random assignment to active or placebo nicotine gum.
One hundred twenty-seven attended an introductory meeting; 87 were
assigned to a gum condition; 40 successfully completed the 10-week
study. The 40 study completers were 55% female with a mean age of
42.7 years. They reported on average a 24 year smoking history and
were smoking on average 30 cigarettes a day with a mean nicotine
delivery of 0.8 mg nicotine. There was a significant between-group
difference on reported cigarettes per day (placebo mean = 33, active
mean = 25) but not on any objective measure of pre-cessation tobacco
smoke exposure including expired air carbon monoxide, salivary
cotinine or salivary thiocyanate.
Procedures. Research volunteers attended three pre-cessation smoking
clinic meetings generally held on a Thursday, the following Monday and
again on Thursday. They received a supply of their assigned gum under
double blind conditions at the last Thursday meeting with the quit date
set for the next Sunday. During the 10 week study, subjects reported to
the laboratory twice weekly for data collection and were also visited at
their homes for surprise breath sample collection, which provided an
additional abstinence check. Home visits were conducted on two
randomly selected days each week during the evening (7 - 10 pm) on
weekdays and during the daytime on weekends. During laboratory
visits, subjects were weighed, gave breath and saliva samples for
analysis, turned in unused gum, received a fresh gum supply and filled
out data questionnaires. A 15-item smoking withdrawal questionnaire
was used that included all the DSM III criteria for tobacco withdrawal as
well as some additional somatic complaints (Hughes and Hatsukami,
1986). Subjects rated the severity of each symptom on a 4-point scale
from none to extreme. Subjects also rated the intensity of their craving
for cigarettes on a four point scale from no cravings to severe cravings.
Study completion criteria. Subjects had to meet two requirements to
successfully complete the study, 1) remain smoking abstinent for 10
weeks and 2) chew at least 5 pieces of gum daily throughout the study.
Abstinence criteria were based on frequently collected expired breath
samples and on salivary thiocyanate levels collected during post-
cessation weeks 3, 6 and 9. Subjects were allowed up to 3 carbon
monoxide readings during the entire 10 weeks that were above 9 ppm.
A salivary thiocyanate level of 2500 umoles/liter was used as the cutoff
indicating abstinence. The vast majority of the study disqualifications
were because of smoking relapse; only 3 subjects were dropped
because of noncompliance with the gum regimen.
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Data Analysis. Measures were collected once weekly or summarized
over weekly intervals and analyzed in repeated measures analysis of
variance or covariance for effects of treatment group, post-cessation time
and group X time interaction. Baseline measures obtained two weeks
prior to cessation were used as the covariate where appropriate.
Measures analysed were: 1) gums used per day, 2) total withdrawal
scale score, 3) scores on 15 individual withdrawal scale items and 4)
body weight.
RESULTS
Gum use. Placebo gum study completers chewed an average of 5.7
pieces per day while active gum subjects chewed an average of 6.9
pieces per day; the difference was not statistically significant. However,
a significant group X time interaction was observed. Both groups
chewed an average of about 7 pieces per day during week 1. Active
gum subjects remained at this level of use throughout the study while
placebo subjects gradually decreased their use to an average of about 5
pieces per day (the required study minimum).
Withdrawal symptoms. Figure 1 shows average total withdrawal scores
for 20 active and 20 placebo gum subjects over 10 successive post-
cessation study weeks. It is clear that nicotine gum suppressed post-
cessation reports of withdrawal symptoms (group effect F (1,37) = 10.6, p
< .005). Both the time factor ( F (9,342) = 13.9, p < .001) and the group
X time interaction (F (9, 342) = 2.5, p < .03) were significant. Average
withdrawal scores for the active gum group decreased steadily from their
pre-cessation baseline levels while scores for the placebo gum group
increased immediately after cessation then declined.
Withdrawal item analysis. Two distinct time course patterns were
apparent among the individual withdrawal items. Scores on four items:
irritability, anxiety, impatience and difficulty concentrating, were lower in
the active than in the placebo gum group during the first 4 - 5 post-
cessation weeks but scores for the two groups had declined to a similar
stable level by post-cessation week 6 (significant group X time
interaction). In contrast, scores on five items: sweating, drowsiness,
restlessness, excessive hunger and increased eating and also scores on
the craving intensity question were significantly reduced in the active
gum group throughout the 10-week post-cessation period. Items
unaffected by nicotine gum condition were heart racing, dizziness,
tremor, headaches, bowel/stomach problems and sleep disturbance.
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Fig. 1. Withdrawal symptom total scores (mean ± sem) are shown during
baseline assessment (2-weeks prior to quitting) and over 10 post-
cessation weeks for active gum (open circles; N = 20) and placebo gum
(closed circles; N = 20) subjects. Subjects rated 15 items weekly on a
scale of 0 = none to 4 = severe. Item scores were summed to obtain a
total score.
Weight gain. Consistent with reports of less hunger and eating among
active gum subjects, the study provided strong evidence for a gum effect
on post-cessation weight gain (group effects F (1,37) = 10.6, p < .003).
By week 10 placebo gum subjects had gained an average of about 8
pounds, while active gum subjects gained only about 4 pounds on
average. These data suggest that using active gum resulted in a 50%
reduction in cessation-related weight gain. The study also provided
suggestive evidence of a nicotine dose-effect on weight gain. Active
gum subjects who chewed conservatively (low use: mean = 5.4 pieces
per day; N = 12) gained an average of 5 pounds while those who
chewed more enthusiastically (high use: mean = 9.2 pieces per day; N =
8) gained 1.5 pounds. Weight gain suppression was most readily
apparent at higher doses of active gum.
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DISCUSSION
This study replicated previous findings by showing that tobacco
withdrawal symptoms are suppressed during nicotine replacement
therapy and extended previous reports by examining symptom patterns
over a prolonged 10-week post-cessation period. Nicotine replacement
suppressed total withdrawal scores throughout the 10 week post-
cessation assessment, providing support for the typical 12 week duration
of suggested post-cessation gum use. The item analysis time course
data suggested, however, that many of the most disturbing symptoms of
withdrawal (i.e. irritability, anxiety) dissipate by post-cessation week 6,
after which nicotine replacement no longer exerts beneficial effects.
Effects of nicotine replacement beyond 5 weeks were seen on reports of
craving for cigarettes, excessive hunger and increased eating. The
clinical significance of reduced cigarette cravings is not clear since
relapse was not an outcome measure in this study. Further, our data are
discrepant with previous studies showing no nicotine gum effect on post-
cessation cigarette cravings or urges to smoke (West, 1984).
Consistent with subjective reports of reduced eating and hunger in active
gum subjects, the study also showed that nicotine replacement can
suppress the weight gain that is commonly seen after smoking cessation.
The failure of previous studies to support a nicotine weight suppression
hypothesis may be due to methodological weaknesses such as failure to
verify gum use or to take amount and duration of gum use into account.
The present study utilized sensitive methodologies to examine gum
effects on post-cessation weight gain including continuous verification of
both abstinence and gum use. The observation that weight gain was
suppressed to a greater extent in those who chewed more gum is
consistent with data presented by Fagerstrom (1987) and suggests a
dose-effect relationship. However, the finding must be replicated in a
study where dose is controlled rather than self-selected. Weight gain
suppression may have important clinical implications. Weight gain is
often cited as an undesirable effect of cessation and a reason for
resuming smoking. If smokers can be motivated to use nicotine gum
regularly in order to avoid weight gain, this could result in improved
withdrawal suppression and cessation success.
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Efficacy of Nicotine Gum in Gen-
eral Practice: One Year Follow-up
J. Hughes, S. Gust, R. Keenan, K. Skoog, R. Pickens,
D. Ramlet, M. Healy and S. Higgins
Smokers (n=315) seen at a family practice and who
wished to quit smoking were randomly assigned in a
double-blind manner to either nicotine or placebo gum.
Smokers received 10 minutes of physician advice, 10
minutes of nurse advice, 2 booklets, a 13 minute
slide/tape show and a 10 minute followup.
At 1 year followup, 15% of those who received nicotine
gum and 13% of those who recieved placebo gum were
nonsmokers: i.e., reported continuously not smoking,
had observers who verified this, had CO levels < 10
ppm, had SCN levels < 100 ng/ml and, if on placebo gum
or not chewing nicotine gum, had salivary cotinines of
< 10 ng/ml (p > .10). Similar results were obtained
when only dependent smokers were examined.
These negative results replicate those of the two
prior placebo-controlled trials conducted in medical
practices (British Thoracic Society, Br Med J,
286:595, 1983; Jamrozik et al, Br Med J, 289:794,
1981). We hypothesize more motivated subjects and
more intensive psychological therapy and followup are
necessary for nicotine gum to be more effective than
placebo gum.
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Effects of Secobarbital on Aggres-
sive and Non-Aggressive Responding
of Normal Male Subjects
D. Cherek, C. Sebastian and J. Steinberg
The self-administration of relatively large doses of secobarbital
has been associated with an increased incidence of human
aggressive behavior (e.g., Tinklenberg and Stillman, 1970;
Tinklenberg, et al., 1974; 1976). More recent clinical reports have
observed increased probabilities of human aggressive behavior
following barbiturate self-administration (Mayfield, 1983) and
during barbiturate withdrawal (Kramer, 1983). This experiment
assessed the effects of the acute administration of secobarbital
on human aggressive and non-aggressive responding in a laboratory
setting.
METHOD
Subjects
Twelve males have participated after giving their informed consent.
Subjects were recruited by advertisements soliciting
participation in behavioral research projects. The advertisements
and consent form did not refer to aggressive behavior, since we
did not want to imply that the research subjects must respond
aggressively to participate in the experiment or to earn monetary
payments.
All subjects were given a complete physical exam and structured
psychiatric exam prior to drug administration. To avoid problems
associated with drug usage, daily breath alcohol measures were
taken and urine samples were obtained for complete drug screen
analysis.
PROCEDURE
Subjects were told that they would be randomly paired with other
people participating in the research project at the same time, but
in different locations. The situation was described as one in
which they could influence the amount of money earned by these
other individuals by subtracting money from them. Subjects were
told that the people with whom they were paired could choose to
subtract money from them at any time during the experimental
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sessions. Subjects were also informed that money subtracted from
them would be added to the other person's earnings. However, money
they subtracted from the other people would not be added to their
earnings.
Five subjects participated in a time-course study and came into
the medical center once per week. These subjects participated in
five successive 30 minute sessions conducted from 8:00 AM to 1:00
PM. Sessions were begun 0.5, 1, 2, 3 and 4 hours after drug
administration. The other subjects were in the dose-response
studies and came into the medical center for daily 50 minute
sessions five days per week (Mon. through Friday).
Subjects were required to swallow two #00 gelatin capsules 60
minutes prior to the sessions. These capsules contained either
placebo or 50, 100 or 200 mg of secobarbital per 70 kg of body
weight. Successive doses were separated by at least 72 hours, and
were administered if preceding placebo session responding was
within variability ranges established prior to drug administration.
The response console contained two response manipulanda, response
button A and B. Pressing button A was maintained by a fixed-ratio
(FR) 100 schedule of point presentation. Each point delivery was
indicated by incrementation of a counter mounted directly
adjacent to button A and was equivalent to ten cents. Pressing
button B ostensibly delivered an aversive stimulus to another
person and was defined as aggressive. The completion of each
fixed-ratio (FR) 10 on button B resulted in the ostensible
subtraction of one point, i.e., ten cents, from the other person.
Aggressive responding was established by subtracting money from
the subjects, which was attributed to the other participants.
Point subtractions (provocations) were scheduled to occur at
random points throughout the session. In the absence of
aggressive responding, subjects were scheduled to receive 40
provocations (point subtractions) per session. In addition to
ostensibly subtracting a point from the other person, ten
responses on button B also initiated a provocation-free interval
(PFI) during which point subtractions were not presented. PFI
durations were either 125 or 500 seconds. Subjects were able to
initiate a PFI only following at least one point subtraction, i.e.,
an escape contingency. When the PFI elapsed, point subtractions
were again presented randomly.
Subjects completed the Profile of Mood States (POMS) questionnaire
and were evaluated for clinical signs of intoxication after each
session. Subjects also completed the BUss-Durkee Hostility
Inventory at the end of the study. Following their participation,
subjects completed a series of questionnaires to determine if the
subjects believed they were paired with other people and then they
were debriefed.
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RESULTS
The time-course study of the effects of secobarbital on
aggressive responding 0.5, 1, 2, 3 and 4 hours after drug
administration are shown in figure 1. Four of the five subjects
increased aggressive responding following the administration of
secobarbital. Increased aggressive responding was observed at 0.5,
1 and 2 hours after secobarbital administration. Subject S-209
had a large increase in aggressive responding at the lowest dose
(50 mg per 70 kg), and the higher doses either decreased
aggressive responding (100 mg per 70 kg) or completely eliminated
responding (200 mg per 70 kg). This subject previously
participated in a diazepam study, in which diazepam (10 mg per 70
kg) produced substantial decreases in aggressive responding.
Subject S-231 decreased aggressive, responding, particularly 1 hour
after the 200mg per 70 kg secobarbital dose. At the end of
participation, questionnaires indicated that this subject did not
FIGURE 1. The effects of placebo and three doses of secobarbital
(50, 100 and 200 mg per 70 kg of body weight) on aggressive
responding 0.5, 1, 2, 3 and 4 hours after drug administration.
Data points are expressed as percentage changes from the
preceding placebo sessions. All subjects were assigned to PFI
durations of 125 seconds.
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FIGURE 2. The effects of placebo and three doses of secobarbital
(50, 100 and 200 mg per 70 kg of body weight) on aggressive
responding. Data points are expressed as percentage changes from
the placebo session values set at zero. Drug data points
represent the man of three different sessions. Vertical lines at
all data points represent ± SEM. Subjects assigned to PFI
durations of 500 seconds are shown in the top half of the figure,
and those assigned to PFI durations of 125 seconds are shown in
the bottom half of the figure.
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FIGURE 3. The effects of placebo and three doses of secobarbital
(50, 100 and 200 mg per 70 kg of body weight) on non-aggressive
responding. Data points are expressed as percentage changes from
the placebo session values set at zero. Drug data points
represent the mean of three different sessions. Vertical lines at
all data points represent ± SEM. Subjects assigned to PFI
durations of 500 seconds are shown in the top half of the figure,
and those assigned to PFI durations of 125 seconds are shown in
the bottom half of the figure.
64
accept the cover story and felt that a machine was subtracting
his points rather than another person. All other subjects
indicated that they believed they were paired with other people.
It is interesting to note, that the one subject that indicated
he did not accept the cover story was the only subject that
decreased aggressive responding following secobarbital
administration. Non-aggressive responding was decreased following
secobarbital administration at the 100 and 200 mg per 70 kg doses,
Peak decreases were typically observed at 1 and 2 hours after drug
administration.
The effects of placebo and three doses of secobarbital (50, 100 and
200mg per 70 kg) on aggressive responding are shown in Figure 2,
for subjects participating in dose-response studies. All subjects
increased aggressive responding following secobarbital administra-
tion. TwO subjects had the largest increase in aggressive respond-
ing following the 50mg per 70kg dose, while three subjects had
maximal increases at 100mg, and two subjects had largest increases
at the highest secobarbital dose. A repeated measures ANOVA
analysis indicated that the effect of secobarbital dose was
significant (F=3.12, d.f.=3,18 p<.05).
The effects of placebo and three doses of secobarbital on
non-aggressive monetary reinforced responding are shown in Figure
3. All subjects decreased non-aggressive responding following
secobarbital administration. Decreases in non-aggressive
responding were dose-dependent, with the largest decreases
observed at the highest secobarbital dose. A repeated measures
ANOVA analysis indicated that the effect of secobarbital dose was
significant (F=7.64, d.f.=3,18 p<.001).
DISCUSSION
The acute administration of secobarbital increased aggressive
responding in normal male subjects in a laboratory setting. This
effect is similar to reports of violence associated with
secobarbital self-administration among young adolescent males.
The increased aggressive responding following secobarbital
administration appears to be specific, since simultaneously
occurring non-aggressive responding was decreased. Increased
aggressive responding following secobarbital administration was
the result of subjects engaging in more frequent aggressive
responding following provocation and occasionally initiating
aggressive responses in the immediate absence of provocation.
Alcohol was also observed to increase aggressive responding in
some subjects (Cherek et al., 1985), but the effects of
secobarbital produced consistent increases in aggressive
responding in all subjects.
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Hyperprolactinemia During Cocaine
Withdrawal
J. Mendelson, S. Teoh, U. Lange, N. Mello, R. Weiss
and A. Skupny
ABSTRACT
Plasma prolactin levels were determined for 8 patients (7 males
and 1 female) who reported an average of 3.7 years of cocaine
abuse. The mean prolactin level for these 8 patients 24 to 72
hours following admission to the hospital was 20.58 (S.E. ± 3.2)
ng/ml. Hyperprolactinemia ( > 20 ng/ml) was detected in 4
patients and 3 others had high borderline prolactin levels.
Only 1 patient had a normal prolactin value at the time of
admission to the hospital. The mean prolactin level obtained
prior to the patients' discharge from the hospital was 31.7
(S.E. ± 5.3) ng/ml. Five of the 8 patients had an increase in
prolactin levels between time of admission and discharge from
the hospital. The mean increment in plasma prolactin levels for
these 5 patients was 15.5 (S.E. ± 4.2) ng/ml ( P < .02). Two
patients who had significant hyperprolactinemia ( > 50 ng/ml) at
the time of discharge from the hospital reported
self-administering the highest cocaine dose (6-8 gm per week) of
the 8 patient cohort. Since cocaine blocks dopamine reuptake
and prolactin secretion is regulated, in part, by dopaminergic
inhibitory mechanisms, cocaine withdrawal may induce rebound
supersensitivity of prolactin secretion. Findings obtained in
this study suggest that cocaine-related derangements in
prolactin secretion may be a biologic marker of a protracted
cocaine abstinence syndrome.
INTRODUCTION
The cocaine epidemic in the United States during the past decade
has involved widespread use of the drug by both men and women
(Kozel and Adams 1986). Most women who abuse cocaine are of
childbearing age (Washton et al., 1985). Although cocaine self-
administration is purported to Initially enhance libidinal drive
(Siegel 1984), recent clinical studies indicate that chronic
cocaine abuse is associated with decreased libido and sexual
dysfunction (Washton et al., 1985). In males, impotence (Ashley
1975) and gynecomastia have been observed in regular cocaine
users, and these abnormalities have persisted for long periods
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following drug abstinence (Cocores et al., 1986). Women who
abuse cocaine have reported major derangements in menstrual
cycle function including galactorrhea (Cocores et al., 1986),
amenorrhea and infertility (Siegel 1982).
There are also recent reports that cocaine abuse may adversely
effect pregnancy. In 1985, Chasnoff and his associates reported
that "the number of cocaine-using pregnant women presenting to
the perinatal addiction project of Northwestern Memorial
Hospital has escalated dramatically in the past 2 years." These
investigators studied 23 infants who were born to cocaine-using
women and concluded that "cocaine exerts an influence on preg-
nancy outcome as well as neonatal behavior." Chasnoff and his
associates also stated that there is also the possibility that
cocaine exposed infants are "at risk for a higher rate of
congenital malformations and perinatal mortality." It therefore
appears that cocaine abuse, like alcohol, cannabis and opiate
abuse by pregnant women, significantly enhances risk for abnor-
malities of growth and development of the newborn.
The mechanisms by which cocaine adversely effects reproductive
function and fetal development are unknown and there have been
few systematic studies of endocrine function in cocaine abusers.
However, recent clinical reports suggest that cocaine abuse may
be associated with alterations in prolactin levels (Cocores et
al., 1986, Dackis and Gold 1985, Gawin and Kleber 1985). One
study (Gawin and Kleber 1985) reported a cocaine-related
decrease in plasma prolactin levels of men and women. However,
a second study (Dackis and Gold 1985) found that prolactin
levels were significantly greater in men who abused cocaine in
comparison to age-matched normal controls. A third study
(Cocores et al., 1986) reported hyperprolactinemia and sexual
dysfunction in 7 of 10 chronic cocaine abusers. The purpose of
this study was to determine plasma prolactin levels in men and
women admitted to the McLean Hospital for treatment of cocaine
abuse during early and protracted cocaine abstinence.
METHODS
Eight patients admitted to the Alcohol and Drug Abuse Treatment
Center of the McLean Hospital for treatment of cocaine abuse
participated in this study. All patients were Caucasian, 7 were
males, 1 was a female. Their mean age was 27.9 years (range
20-38 years). Patients reported a history of cocaine abuse
averaging 3.7 years (range 2-10 years). All patients self-
administered cocaine via the intranasal (snorting) route. The
amount of cocaine regularly self-administered ranged from 1 1/2
to 8 grams per week.
All patients reported withdrawal symptoms during the first 24 to
48 hours following admission to the hospital. These symptoms
included headache, backache, anxiety, insomnia, and persistent
craving for cocaine.
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A plasma sample for prolactin analysis was obtained 24 to 72
hours following admission after reports of withdrawal symptoms
had abated. At this time no patient had any intercurrent
medical disorder: physicial examinations including blood
pressure and cardiovascular function were normal and all routine
blood chemistry and hemogram studies were within normal ranges.
A second blood specimen was obtained for prolactin analysis
immediately prior to the patient's discharge from the hospital
(mean interval between samples was 22 days).
Prolactin concentrations were measured in duplicate plasma
samples using a double antibody radioimmunoassay procedure
similar to that described by Midgley (1966), with materials
provided by the National Hormone and Pituitary Program
(University of Maryland School of Medicine), supported by the
National Institute of Arthritis, Diabetes and Digestive and
Kidney Diseases (NIADDK).
The prolactin assay sensitivity is less than 3.1 nq/ml. Intra-
and interassay coefficients of variation were 6.8 and 14
percent, respectively.
RESULTS
Figure 1 shows plasma prolactin levels (ng/ml) for the 8
patients following admission to the hospital (sample 1) and
prior to discharge (sample 2). The mean prolactin value after
admission was 25.8 (± 3.2) ng/ml and mean prolactin value for
sample 2 was 31.7 (±5.3) ng/ml. Hyperprolactinemia ( > 20
ng/ml) was observed-in 4 patients (numbers 1, 3, 5, and 7) shortly
following admission to the hospital. Three other patients
(numbers 2, 6, 8) had high borderline prolactin levels. Only 1
patient (number 4) had a normal prolactin level at the time of
admission to the hospital.
Only 2 patients had normal prolactin levels ( < .20 ng/ml) at
the time of discharge from the hospital. Five of the 8 patients
(numbers 1, 2, 3, 4, 8) showed an increase in plasma prolactin
levels prior to discharge (sample 2). The mean increment in
plasma prolactin for these 5 patients was 15.5 (± 4.2) ng/ml)
and was statistically significantly different (P< .02) from
mean prolactin levels following admission to the hospital. Two
patients had a decrease in plasma prolactin levels (numbers
5, 7). However, 1 of these patients (number 7) continued to have
an elevation of prolactin levels (35 ng/ml) which was in the
hyperprolactinemic range. One patient (number 6) had a slight
decrease in borderline high plasma prolactin values.
Two patients (numbers 1 [female], and 3 [male]) who had abnormal
prolactin levels following admission to the hospital showed
significant hyperprolactinemia ( > 50 ng/ml) at the time of
discharge. It is of interest that these 2 patients reported
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self-administering the highest cocaine dose (6-8 grams per week)
of this 8 patient cohort.
DISCUSSION
These data are consistent with previous reports (Cocores et al. ,
1986, Dackis and Gold 1985). In 1985, Dackis and Gold reported
studies of serum prolactin levels in 18 male cocaine abusers and
20 normal age-matched male controls. Prolactin levels obtained
in studies with the cocaine abusing patients (35.4 ± 26.9 ng/ml)
were significantly greater than those of the control subjects
(7.0 ± 5.0 ng/ml).
findings as "consistent with either decreased functional
Dackis and Gold (1985), interpreted these
dopaminergic tone or activation by cocaine of serotinergic
transmission." Dackis and Gold (1985), studied cocaine abusers
during inpatient hospitalization, and thus their data were less
likely to be confounded by factors associated with studies
carried out with outpatient populations. Cocores and co-workers
(1986), also reported hyperprolactinemia in patients during
cocaine withdrawal.
However, these data are not consistent with reports of studies
with an outpatient population. Gawin and Kleber (1985),
measured plasma prolactin levels in 15 males and 6 females who
abused cocaine for an average of 3.4 years. Female plasma
prolactin levels were within the range of normal values for
adult women, but plasma prolactin levels were decreased in male
cocaine abusers when compared with healthy age-matched control
subjects. Although the mean plasma prolactin levels for male
cocaine abusers was 5.3 ng/ml, i.e. within the range of normal
prolactin levels for healthy adult males, 5 of the 14 males who
abused cocaine had abnormally low prolactin levels.
Gawin and Kleber (1985) interpreted these findings cautiously,
noting that "the methodological shortcomings of the research on
recently active drug users preclude firm conclusions being
reached." They pointed out that their patients exhibited marked
heterogeneity which included "differences in the purity of
cocaine obtained, chronicity of use, routes of administration,
self-report accuracy, sensitivity to cocaine effects, and
degrees of dependence. Other shortcomings of outpatient
clinical studies which are unrelated to cocaine abuse itself,
such as possible undetected use of other drugs or -medication,
differences in diurnal patterns, sleep habits, diet, or psycho-
social stressors and the possibility of preexisting endocrino-
pathy could have also effected the results." Because the
patients studied by Gawin and Kleber (1985) were recruited from
an outpatient clinic population, it was not possible to control
for many critical factors which effect prolactin secretion.
Our studies, as well as the studies of Dackis and Gold (1985)
and Cocores et al., (1986), indicate that chronic cocaine abuse
may lead to significant derangements in prolactin secretory
activity. Moreover, our findings suggest that chronic cocaine
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abuse may lead to prolonged derangements of anterior pituitary
function, even during protracted cocaine abstinence.
There is considerable evidence that cocaine may block dopamine
reuptake (Iversen 1966, Reichlin 1975, Ross and Renyi 1966,
Scheel-Kruger 1971, Taylor and Ho 1978, Trendelenburg and Graefe
1975, Whitby et al., 1960), and it is also known that dopaminer-
gic systems are important modulators of prolactin secretion
(Tuomisto and Mannisto 1985). Since prolactin secretion in
humans is under chronic dopaminergic inhibitory control, it may
be postulated that cocaine administration would suppress
prolactin levels. However, following cocaine withdrawal, it
would also be reasonable to postulate that rebound supersensiti-
vity of prolactin secretion would occur. The elevated prolactin
levels found in this study, as well as the elevation in prolac-
tin levels reported by Dackis and Gold (1985) and Cocores et al. ,
(1986), are consistent with this hypothesis. However, the
continued elevation in prolactin levels found in 5 of our 8
patients during protracted cocaine abstinence was surprising.
This observation suggests that a cocaine-related derangement in
dopaminergic regulatory systems may parallel a protracted
cocaine abstinence syndrome. Since a protracted cocaine
abstinence syndrome may be an important factor which effects
recrudescence of cocaine use, plasma prolactin levels may be a
useful biologic marker for determining relapse potential.
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FIGURE 1
Plasma prolactin levels (ng/ml) for 8 patients (s1 - s8)
shortly following admission to the hospital (sample 1) and
immediately prior to discharge (sample 2).
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Conditioned Craving and Arousal
in Cocaine Addiction:
A Preliminary Report
A. Childress, R. Ehrman, A. T. McLellan and C. O’Brien
INTRODUCTION
For several years our research group has studied the conditioned
responses associated with chronic opioid use, speculating that some
of these responses (particularly conditioned craving and withdrawal)
could lead to drug use and relapse in the abstinent patient (O’Brien et
al., 1977, Childress et al., 1984, 1985, 1986). The recent upsurge of
cocaine use among our patients has given us the opportunity to
study and to document the kinds of conditioned responses which may
occur in chronic cocaine abusers (Childress et al., 1987a).
A number of detoxified cocaine users in our clinic population report
experiencing intense arousal and cocaine craving when they encounter
‘reminders’ of their previous cocaine use: the sight of cocaine-using
friends or locations, the use of alcohol, the sight of white bread
crumbs on the carpet, even the sight of talcum powder while changing
a child’s diaper. Apparently, almost any stimulus that has been
repeatedly associated with getting and using cocaine can become a
cocaine ‘reminder’ (Siegel, 1984; Washton, 1986).
In our view, these cocaine ‘reminders’ are essentially classically
conditioned stimuli which have acquired their ‘reminder power’
through repeated pairings with cocaine’s pharmacologic effects
over the natural course of a patient’s drug use. By giving repeated
exposures to conditioned cocaine ‘reminders’ without cocaine, it
should be possible to reduce or to extinguish their ability to
trigger the conditioned responses (arousal, craving, etc.) which could
lead to drug use and relapse.
At our research center we have recently begun a large-scale study
attempting to understand and to treat the causes of relapse in
cocaine dependence. As one part of this program we are trying 1) to
characterize the kinds of responses patients may experience
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when they are exposed to cocaine ‘reminders’, 2) to measure these
responses, and 3) to reduce these responses through extinction
(repeated non-reinforced exposure).
METHODS
Subjects. The subjects of this initial report were 29 male
Veterans presenting to the Philadelphia Drug Dependence Treatment
Unit with a primary problem of cocaine dependence. The demographic
and clinical characteristics of this population have been more fully
described in a recent report (Childress, 1987b). Of these, the first 9
patients were pilots; the second group of 20 patients were
randomly-assigned participants in a large scale treatment-outcome
study investigating the potential benefits of adding extinction
(repeated exposure to cocaine ‘reminders’) and other interventions to
standard drug treatment.
General Procedures
Laboratory Measurement Sessions. Prior to extinction or other
treatments, all patients were tested for their initial responsivity to
cocaine-related stimuli in a 90-minute laboratory measurement
session. Both laboratory and extinction sessions have been described
in detail in recent publications (Childress et al., 1986, 1987b) and will
be summarized very briefly here. Both physiological and
subjective measures were obtained. Physiological measures
included peripheral skin temperature (TEMP), galvanic skin
resistance (GSR), a general arousal index, heart rate (HR), and
respiration (RESP). Subjective measures were obtained by asking
each abstinent patient to rate, on a 1 to 10 scale, the degree of
subjective cocaine high, craving, or ‘crash’ (withdrawal)
experienced under each set of stimulus conditions. The following
stimulus components were used: 1) Neutral Baseline, 2) Neutral
Videotape (a nature story), 3) Neutral Activity (video pong game), 4)
Drug Baseline, 5) Drug-related Videotape (buy-sell and cocaine
administration rituals), 6) Drug-related Activity (handling drug
paraphernalia and performing a simulated cocaine administration) and
7) Recovery Baseline. To control for order effects, approximately half
the patients experienced the stimuli in the order listed above
(‘Forward’ condition), while the remaining patients experienced the
Drug-related video/activity before the Neutral video/activity
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(‘Reverse’ condition).
Extinction Sessions. Patients assigned to extinction groups
received 15 hour-long sessions of repeated, non-reinforced exposure
to cocaine ‘reminders’. Each hour-long cocaine extinction session
contained 3-five minute audiotape segments, 3 five-minute
exposures to a cocaine-related videotape and 3 simulated cocaine
administration rituals. These drug-related stimuli were presented in
the sequence audio-video-activity, repeated 3 times per session.
For both laboratory and hospital ward extinction sessions, data
reported here derive from patient ratings of the overall intensity of
cocaine-like high, craving, and ‘crash’ (withdrawal) using a 1-10
scale for each rating. These items are part of the Within-Session
Rating Scale-Cocaine (1985), which was administered at the beginning
and again at the end of each extinction session.
RESULTS
In the interest of conserving space, the reader is referred to recent
reports (Childress et al., 1987a; 1987b) for detailed derivation of the
percentage baseline values (physiological measures) or difference
scores (subjective measures) used in the analyses below.
Pretreatment Laboratory Testing
Physiological Measures (n=17). Analyses first were completed for
GSR and TEMP, as these physiological variables have historically
best reflected the conditioned arousal associated with drug-related
stimuli. A three-way ANOVA revealed significant main effects of
Type (Drug vs. Neutral, p <. 003), Mode (Video vs. Activity,
p<.003), and Order of stimulus presentation (Forward vs. Reverse,
p<.003) on TEMP, with no significant interactions among these three
variables. Thus, as shown in Figure 1, skin temperature reductions
were significantly greater to Drug (cocaine)-related than to Neutral
stimuli; and were generally greater in response to activities than to
video stimuli. The Forward order of stimulus presentation (Neutral
stimuli first, Drug-related stimuli second) resulted in greater overall
temperature reductions, suggesting that patients are more aroused
during the Neutral stimuli when they are anticipating the
Drug-related stimuli, and that this general arousal sums with the
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drug-related arousal to produce a larger temperature response.
Figure 1. Skin temperature response in cocaine abusers (N = 17)
The average temperature reduction to cocaine-related stimuli
(including ‘non-responders’) was approximately 4 Fahrenheit degrees.
Among differential temperature ‘responders’, however, dramatic
reductions of 8 to 12 Fahrenheit degrees (in response to
cocaine-related stimuli) were not uncommon. The magnitude and
pattern of these temperature changes in response to cocaine-
related stimuli is similar to the changes which occur in response to
opioid-related stimuli, frequently reported by our laboratory
(Childress et al., 1985, 1986).
For the physiological variable of GSR (skin resistance), the
three-way ANOVA revealed a similar pattern of results: there was a
main effect of both stimulus Type (Neutral vs. Drug-related,
p<.001) and Mode (Video vs. Activity, P<.000). There was a
significant Type X Mode interaction effect (Pe<.01) : GSR values were
significantly different for Neutral vs. Drug-related Video stimuli,
but did not differ significantly between Neutral and Drug-related
Activities. There was no significant effect of Order (Reverse vs.
Forward) of stimulus presentation upon GSR (p>.15).
Subjective Responses (N=21) An overall ANOVA (with stimulus
condition as the repeated measure) was performed upon each of the
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subjective variables of self-rated high, craving, and withdrawal.
These overall analyses revealed a significant effect of stimulus
condition upon cocaine craving (p<0.0000), high (p<.01) and
withdrawal/'crash’ (p<.01).
Of these responses, craving was clearly the most prevalent,
reported two to three times as often as either high or withdrawal/
‘crash’ responses. Subsequent Bonferroni paired comparisons showed
that craving to both the Drug-related video and activity differed
significantly from craving to both the Neutral video and activity
(p<.01). Additional Bonferroni tests showed that reports of high
were significantly different for the Drug video vs. the Neutral task or
activity (p<.05), while reports of withdrawal//crash’ were
significantly different for the Drug activity vs. the Neutral video or
activity (p<.05).
Figure 2. Reduction in cocaine craving as a function of extinction .
Extinction Sessions
Subjective Responses. A one-way ANOVA with repeated measures
was performed for each of the subjective variables of craving,
high, and withdrawal/'crash‘, using sessions as the repeated
measure. These analyses revealed a significant effect of sessions
upon all three subjective variables: craving (p<0000), high (p<.0001),
and withdrawal ‘crash’ (p<.0000). Of these responses, craving was the
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most prevalent and persistent, reducing gradually over the course of
fifteen extinction sessions. Figure 2 (above) shows the reduction in
craving as a function of extinction trials. Reports of high and
‘crash’/withdrawal were less common, and were largely extinquished
by the sixth hour of extinction.
PRELIMINARY CLINICAL OUTCOME
A few early indicators of clinical outcome are available. Thus far, all
patients who entered the study have been retained throughout the two
week inpatient treatment phase and are generally compliant with the
intensive extinction regimen. Despite this regimen, physiological
arousal to cocaine ‘reminders’ was still evident (though reduced) at
the end of the inpatient stay for more than half the extinction
patients. Though craving to the extinction stimuli was virtually
eliminated, most patients have reported episodes of craving in
response to real-world cocaine ‘reminders’ during the two month
period following hospital discharge. Given the incomplete extinction
of physiological arousal and the incomplete generalization of
extinction for subjective craving, it is perhaps not surprising that
approximately two thirds of the patients have at least one episode of
cocaine use during the two month period following the inpatient
treatment phase.
SUMMARY
Though data collection is still in progress, several significant
findings are already apparent from our study of cocaine ‘reminders’:
1) In the laboratory, detoxified cocaine abusers show a differential
responsivity to drug-related cocaine ‘reminders’, responding with
strong signs of physiological arousal (peripheral skin
temperature reductions and decreases in skin resistance) and
subjective cocaine craving.
2) In extinction sessions, repeated, non-reinforced exposure to
cocaine ‘reminders’ led to a complete reduction in craving to
these stimuli by the fifteenth hour-long session. High and ‘crash’
responses were virtually eliminated by the sixth hour of extinction.
3) Physiological arousal to cocaine ‘reminders’ was often still in
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evidence even after fifteen hours of extinction.
4) Even after completing the current extinction protocol cocaine
abusers may crave--and use--cocaine when experiencing drug
‘reminders’ in the natural environment.
Clearly, detoxified cocaine abusers can experience conditioned
craving and arousal to cocaine ‘reminder’ stimuli. These responses
can be both intense and persistent, meaning that the abstinent
cocaine abuser may be vulnerable long after detoxification is
complete. Though the program of extinction described here is
effective in reducing craving to cocaine-related stimuli presented in
the context of the laboratory or clinic, this effect may not generalize
well to the natural environment. We are currently considering two
approaches to this problem: 1) One approach would attempt to
increase the generalization of extinction by the use of even more
realistic stimuli (e.g., the sight of real cocaine) and stimulus contexts
(e.g., in vivo repeated exposures). We have been reluctant to employ in
vivo exposures near ‘copping’ corners or shooting galleries because of
possible risk to both patients and clinical staff. Somewhat less
dangerous stimuli could involve the patient’s own home, or the use of
‘neighborhood’ videos taped from a moving car. 2) A second approach
would explore the effectiveness of other behavioral techniques in
countering conditioned craving and arousal. These techniques could
include the training of cognitive or behavioral alternatives in
response to cocaine ‘reminders’, encouraging the patient to actively
cope with the arousal triggered by these stimuli. This second
approach is clinically quite compatible with extinction and could
conceivably enhance its effectiveness: patients could practice these
coping techniques in response to the repeated, non-reinforced
presentation of cocaine ‘reminders’.
REFERENCES are available from the first author upon request.
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A Pilot Trial of Amantadine for
Ambulatory Withdrawal for Cocaine
Dependence
C. Morgan, T. Kosten, F. Gawin and H. Kleber
INTRODUCTION
Recent focus on neurochemical adaptation in chronic cocaine
abusers has increased interest in possible pharmacologic
intervention in this population. Dopaminergic autoreceptor
supersensitivity has been postulated to be the mechanism
underlying post-cocaine dysphoria or craving and contribute
to relapse. To deal with the early phase of cocaine with-
drawal, two medications acting on the dopaminergic system
have been proposed, bromocriptine and amantadine.
Bromocriptine, a direct agonist has been shown to be more
effective than placebo in reducing cocaine craving and other
signs of withdrawal in single dose studies. In a 10 day
double-blind comparison of amantadine and bromocripizine by
Tennant and Saghexian, both drugs were effective, however,
side effects of bromocriptine led to drop-outs.
This study examines the effect of amantadine on a) acute and
short-term craving, b) cocaine use, and c) compliance with out-
patient treatment.
SUBJECTS AND METHODS
Twelve patients aged 19 to 42 years old who had sought
treatment for cocaine abuse at the Yale Substance Treatment
Unit were included. All subjects met DSM-III criteria for
cocaine abuse, and had used cocaine within ten (10) days.
None were dependent by DSM-III criteria on other drugs or
alcohol or met criteria for other Axis I diagnosis.
Patients gave informed consent after being explained the
rationale for the use of amantadine for cocaine withdrawal, and
asked to participate in a 30 day drug trial. For the first
two days subjects entered a blinded cross-over, where they
received identical looking capsules of either placebo or
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active drug Day 1 and then switched to the other form on Day
2. From Day 3 to the completion of treatment subjects were
given prescriptions for amantadine hydrochloride 300 mgs
daily for each week of study. Patients continued to be seen
by their clinicians on a weekly basis and had weekly
ratings.
Subjects were asked to keep track of their daily craving on a
linear analog scale, and a narrative section and to report weekly
the number of grams of cocaine used. Random urine monitoring for
benzolyecognine was done during the drug trial period. On a
weekly basis patients were also asked whether the medication
affected their mood, energy level or sleep pattern. Side effects
were monitored including blurred vision, insomnia, dry mouth,
confusion, lightheadedness, anxiety, weakness, gastrointestinal
symptoms. Finally patients who used cocaine during the study
were asked to describe whether they perceived any change in the
effects of cocaine while taking amantadine.
RESULTS
The majority of patients remained in the study for 14 or more
days (10/12). Three remained for the entire length of the study.
Compared to baseline the mean craving scores decreased within 24
hours of starting amantadine. This was not statistically signi-
ficant. Furthermore, patients on placebo experienced a similar
decrease in craving over the same time period. (Figure 1). At
14 days mean craving scores had decreased to less than 50% of
baseline (p < 0.01). (Figure 2)
Cocaine use at endpoint was decreased in the majority of patients
(8/12) and two patients remained at their low level of baseline
use. One patient dropped out after 6 days on medication and
presumably resumed cocaine use and another increased to above
baseline use at the time he left the study.
Individual patients experienced fluctuations in craving while on
amantadine. In particular conditioned cues caused increased
craving which often led to cocaine use. Conditioned cues
included 1) anticipating and/or receiving paychecks, 2) telephone
or other contact with drug dealers or users, 3) social settings
where alcohol was used, 4) job tension and, 5) family arguments.
Five patients reported side effects attributable to amantadine
(dizziness, tinnitus, drymouth, insomnia). Reduction in dosage
from 300 to 200 mgs daily eliminated side effects in two patients
and allowed them to continue treatment. In the others, side
effects were time limited and did not adversely affect compliance
with treatment.
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None of the patients taking amantadine reported untoward effects
with continued cocaine use. No qualitative difference in
cocaine-induced euphoria was reported by any patient on amanta-
dine.
While the majority of patients remained in the study through the
14th day, there was a 50% drop-out between the 14th and 23rd day
(Figure 3). Two patients reported that the "medication didn't
work" during the second or third week and the craving scale of
one patient paralleled this. No explanation was obtained from
the other drop-outs.
FIGURE 1
FIGURE 2
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FIGURE 3
DISCUSSION
In our study amantadine appeared to be a safe and possibly
effective short term treatment for cocaine craving and
abuse. While the drug does not appear to have any immediate
anti-craving effect, patients who remained on amantadine
showed a decreasing trend in their cocaine use and craving.
The decrease was for placebo and active treatments of two
weeks in other pharmacotherapy trials, and double-blind
random assignment trials will be needed to assess amanta-
dine's clinical effect.
Patients in the Tennant and Sagherian study had all used cocaine
within 72 hours of entering. We did not adhere to a cut-off, but
eight of twelve patients had used cocaine within 72 hours. All
of the patients specifically sought treatment with medication or
were referred by their clinician for medication trial because
they failed to become abstinent on their own or while in standard
treatment at the clinic.
While we did not analyze urines for the presence of amantadine,
we found that patients accurately reported their cocaine use as
confirmed by benzolyecognine and had complied with other aspects
of treatment.
Chronic administration of central stimulants causes a protracted
anergic withdrawal syndrome in man and a corresponding subsen-
sitivity of the principal dopaminergic center, the nucleus accum-
bens, in animals. Tricyclic antidepressants have been shown to
reverse the supersensitivity in animals and ameliorate abstinence
symptoms in chronic cocaine abusers. The tricyclics suffer the
disadvantage of 2 - 4 week delay time before onset of action.
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While the exact mechanism of action of amantadine is not known,
the drug's action may be more rapid than tricyclic
antidepressants and may reduce early drop-outs.
Of note is that the majority of our patients remained in treat-
ment up through the third week of study. While this might make
amantadine ideal in combination with tricyclics, it raises the
question of whether on its own amantadine's effectiveness
decreases with time, since side effects cannot explain the
delayed drop-out. If amantadine acts presynaptically to release
dopamine, then residual dopamine would be required for the drug
to act. Long term amantadine administration could therefore
exacerbate an already dopamine depleted state created by chronic
cocaine use. The role of tyrosine, a norepineptrine and dopamine
precursor, was not examined in this study, but warrants further
consideration.
It is our view that amantadine may be effective in treating the
early phase of cocaine withdrawal. Well controlled clinical
trials are required before large scale use of the drug can be
recommended for the treatment of cocaine abuse.
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Behavioral and Neurochemical
Effects of Repeated or Continuous
Exposure to Cocaine
M. Kleven, W. Woolverton, C. Schuster and L. Seiden
The behavioral effects of cocaine (COC) were studied in rhesus monkeys using
a paradigm in which operant behavior was sampled for 1/2 hr every 6 hours and
COC was continuously infused via an iv catheter. COC (4-32 mg/kg/day) initially
caused reductions in the rate of responding for food and tolerance developed to
this effect. When the infusion of COC was terminated following a prolonged pe-
nod of exposure to the high dose (32 mg/kg/day), there was a marked sup-
pression of operant behavior, lasting as long as 72 hrs, as well as observable
changes in behavior (e.g. hyporesponsiveness). The long-term neurochemical
consequences of exposure were examined in rats with COC administered by
continuous iv infusion (100 mg/kg/day for 21 days). There were no significant
changes in the concentration of DA or 5-HT 2 weeks after continuous infusion.
These results suggest that prolonged exposure to COC does not produce
neurotoxicity like that observed with methamphetamine (MA) and am-
phetamine-like (AMPH-like) compounds.
The behavioral effects of single injections of psychomotor stimulants include lo-
comotor stimulation, reduction in food intake, and stereotypy. These effects are
thought to be mediated by enhanced catecholamine neurotransmission in the
brain (Lewander 1974; Wise 1984). In contrast, the behavioral and neurochemi-
cal effects of repeated or prolonged exposure to COC are not well known. With
the recent rapid increase in the use of COC, the effects of long-term exposure to
COC have become an important public health issue.
The consequences of repeated administration of a drug may include tolerance
or sensitization, dependence, and long-term changes in brain chemistry. Both
tolerance (Wood and Emmett-Oglesby 1986; Woolverton et al., 1978a,b) and
sensitization (e.g., Post et al., 1976) to the behavioral effects of COC have been
reported to develop upon repeated administration. The direction of the change
in sensitivity seems to depend upon such variables such as the conditions of
drug administration and the behavior being studied (Jones 1984). Whether pro-
longed exposure to COC results in dependence is more controversial. Although
COC has been thought not to produce physical dependence, recent research
with COC abusers has revealed a predictable sequence of signs and symptoms
(e.g., irritability, depression and anxiety) that occur following prolonged intake of
COC (Gawin and Kleber 1986).
The neurochemical consequences of repeated exposure to COC administration
have only recently been examined. The similarities in acute neurochemical ef-
fects of COC and AMPH-like compounds raise the possibility that repeated ex-
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posure to COC might produce long-term neurotoxic changes similar to those
produced by AMPH. These effects include, but are not limited to, reductions in
the concentrations of dopamine (DA) and serotonin (5-HT) in several brain re-
gions, and are probably the result of destruction of nerve terminals containing
these monoamines (Seiden 1985; Ricaurte et al., 1982;1984; Wagner et al.,
1983). It has recently been reported that repeated COC administration to rats
depleted striatal tyrosine hydroxylase activity 60 days after the last injection
(Trulson et al., 1986) suggesting that prolonged exposure to COC can produce
long-lasting damage to DA-containing neurons. More research is needed before
definitive statements can be made concerning the neurotoxicity of COC.
METHODS
Behavioral effects of continuous infusion of COC in rhesus monkeys.
Rhesus monkeys were fitted with stainless steel harnesses and spring arms for
restraint and catheter protection. They were housed in experimental chambers
containing 2 response levers with stimulus lights and a houselight. Water was
continuously available and food was restricted to that obtained during behav-
ioral sessions and supplementary feeding with monkey chow to maintain body
weight. The procedure was identical to one used previously to study the effects
of continuous infusions of PCP or THC (Beardsley et al., 1986; Slifer et al.,
1984). Every 6 hours (10 AM - 4 PM - 10 PM - 4 AM), the house light and lever
lights were illuminated for 30 min and responding on the right lever under a
fixed-ratio schedule (FR 50 or 100) resulted the delivery of 1 gram banana-fla-
vored food pellets. The FR was held at the maximum level at which typical FR
patterns of responding were observed and the monkeys maintained stable body
weights with food received during the sessions. Responding on both levers was
recorded between periods of food availability.
When behavior was stable, an intravenous catheter was implanted and a con-
tinuous i.v. infusion of saline was delivered by a syringe pump. When behavior
was again stable, a continuous infusion of COC was begun 2 hours before the
10 AM session on day 1. If COC disrupted behavior, the infusion was continued
for a minimum of 10 days, until behavior returned to baseline levels or a new
stable level of responding was achieved. If responding remained below base-
line levels for 3 consecutive days, the monkeys were given 2 small post-session
(10 AM and 4 PM) meals of monkey chow to maintain a consistent level of food-
intake. As tolerance developed, doses were increased by doubling to a maxi-
mum of 32 mg/kg/day. Saline was then substituted for COC and continued for at
least 30 days. The regimen was repeated at least once in each monkey.
Neurochemical effects of continuous administration of COC in rats.
Male Sprague-Dawley rats (Harlan, IN; 250-300g) were housed individually in
steel cages with food and water available ad lib. Room lights were on a 12
hour dark-light cycle (0700-1900) and temperature was maintained at 24 °C.
Rats (n=4) were anesthetized with pentobarbital (50 mg/kg, ip) and the external
jugular vein was catheterized using silicone tubing. Catheters were connected
to sc implanted alzet® osmotic pumps (2ML4; alza, Palo Alto, CA) containing
COC (0.58 mg/ml) resulting in a dose of approximately 100 mg/kg/day. The
wounds were closed with Michael clips and the rats were returned to their home
cages. A sham group (n=5) was implanted with sealed jugular catheters. After
21 days of continuous COC infusion, pumps were removed under pentobarbital
anesthesia. Two weeks later rats were sacrificed by decapitation and the brains
were dissected (Heffner et al., 1980). Tissues (30-100 mg) were stored in liquid
nitrogen until assayed for DA, DCPAC, HVA, 5-HT, and 5HIAA by HPLC-EC.
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RESULTS
The effects of the various infusion conditions on FR responding for food are
summarized as effects on total number of food pellets received over an entire 24
hr period. Although there were occasional irregularities in responding in indi-
vidual time periods, the effects of COC on responding are accurately reflected
by this measure. When saline was infused, 5018 received an average of
approximately 150-165 food pellets/day (fig. 1). Monkey 2039 received an av-
erage of
Figure 1. Effect of Continuous Infusion of Cocaine upon FR Operant Behavior in the
Rhesus Monkey. Doses of cocaine, shown above the data points, are expressed as
mg/kg/day. Each symbol represents the mean number of reinforces earned during 3
successive days comprised of 4 1/2 hr sessions (10 AM-4PM-10PM-4AM). The solid and
dashed horizontal lines represent the mean and 1 SD during saline infusion (N=6-9
days), respectively.
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184 pellets/day before the first cycle of COC but his baseline had shifted to an
average of 109 pellets/day when the second cycle was begun (fig. 2). Con-
sequently, it was necessary to supplement his food intake to 170 g/day during
the second exposure to COC.
Continuous infusion of 2 mg/kg/day COC in monkey 5018 (fig. 1) had little effect
on behavior. Higher doses of COC (4-32 mg/kg/day), however, reduced re-
sponding initially in both monkeys in a dose-related manner (fig.1 and fig. 2).
Observable effects of COC included stimulation of locomotor activity beginning
at 4 mg/kg/day. Stereotyped grooming and visual checking were seen at 16 and
32 mg/kg/day. The initial decrease in lever-pressing was followed by a gradual
Figure 2. Effect of Continuous Infusion of Cocaine upon FR Operant Behavior in the
Rhesus Monkey. See fig. 1 for details.
(usually 6-12 days) return to baseline levels of responding, indicative of the de-
velopment of tolerance. There was also evidence of the development of cumu-
lative tolerance to COC over repeated cycles. For instance, monkey 5018 (fig.
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1, panel A) 16 mg/kg initially suppressed responding for food, while more than 5
months later (panel B) the 16 mg/kg/day dose had minimal effects on behavior.
A similar effect was evident in monkey 2039 (fig. 2). Although observable effects
of COC were not quantified in this study, their intensity did not appear to change
with continuous infusion.
Figure 3. Effect of Withdrawal of Continuous Cocaine Infusion in Rhesus Monkeys. Re-
sponding during daily sessions (10AM-4PM-10PM-4AM) is shown for each day following
withdrawal of continuous infusion of cocaine (32 mg/kg/day). The SAL and COC data
points represent the means of the last 5 days of saline and cocaine, respectively.
90
After a period of exposure that varied between 65 and 79 days, 32 mg/kg/day
COC was replaced with saline. Decreases in response rate were usually seen
beginning in the first day and continued over the next 2-3 days (figs. 1, 2). A de-
tailed analysis of these disruptions is presented in fig. 3. Saline infusions began
at 8 A.M. and responding was usually normal for the 10 A.M. session. By the 4
P.M. session on day 1, responding was completely suppressed. In sessions in
which responding was not completely suppressed, monkeys usually responded
at normal rates for 2-3 food pellets and stopped responding for the remainder of
the session. During this period of time monkeys sat in a hunched posture, were
hyporesponsive and took offered food. Responding recovered to baseline levels
during the third or fourth day following the termination of COC infusion.
Table 1 shows the levels of monoamines and metabolites in rats treated with
continuous COC for 21 days at a dose of 100 mg/kg/day. No significant deple-
tions of 5-HT, DA or DOPAC were observed in any of the regions after continu-
ous administration. Continuous infusion of a higher dose of COC (200
mg/kg/day) was lethal within 4 days and could not be tested further.
TABLE 7. Effect of Continuous Infusion of Cocaine (100 mg/kg/day) for 21 Days on Re-
gional Levels of Monoamines and Metabolites.
amean±SE, µg/g wet weight; bND-not determined
DISCUSSION
Continuous infusion of COC had several behavioral effects in rhesus monkeys.
The rate of responding under the FR schedule was reduced by COC in a dose-
related manner, as has been reported previously with single injections
(MacPhail and Seiden 1975; Woolverton et a/., 1978a). In addition, locomotor
stimulation and, at the high doses (16 and 32 mg/kg/day), stereotyped behaviors
were observed. As the COC infusion was continued, there was no apparent
change in sensitivity to the directly observable effects of COC. However, toler-
ance developed to the effect of COC on FR responding as evidenced by a return
of response rate to baseline levels generally over 5 to 15 days. As COC dose
was increased, tolerance developed repeatedly until the monkeys were re-
sponding at baseline rates with a continuous infusion of 32 mg/kg/day. Partial
tolerance to COC has been reported previously using single injections but re-
quired 45-60 days to develop (Woolverton et al., 1978a,b). Tolerance has also
been reported to develop to the discriminative stimulus effects of COC when the
drug was administered twice daily for 7 days (Wood and Emmet-Oglesby 1986).
Thus, it seems that more frequent exposure to COC leads to more rapid and
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complete tolerance development. The findings of the present experiment extend
the conditions under which tolerance develops to COC.
An additional factor apparent in the present study is the development of what
might be termed a “cumulative” tolerance to COC. When the continuous infusion
regimen was repeated, tolerance developed more rapidly than it had previously.
Evidence for this fact can be seen particularly at the dose of 16 mg/kg/day in
figs. 1 and 2. In addition, in pilot studies designed to establish the parameters
used in the present experiment, doses of COC as low as 8 mg/kg/day com-
pletely suppressed behavior (data not shown) but had little or no effect later in
the same animals. Such an effect, if born out in further studies, has implications
for the dose escalation that may be necessary for COC dependence to develop.
When continuous infusions of 32 mg/kg COC were terminated, a consistent set
of signs and symptoms were observed that suggested a withdrawal syndrome
resulting from COC dependence. Operant behavior was disrupted to the point of
complete suppression. The monkeys became hyporesponsive, sat in a hunched
posture and locomotor activity was much reduced. The time course was similar
for all of these effects. They began to appear within 6 hours after termination of
the COC infusion, and recovery began to occur approximately 48 -72 hours after
termination of the infusion. This time course is similar to that reported by Gawin
and Kleber (1986) or the “crash” period in human COC abusers. Thus, it is
possible that this may represent a useful paradigm for the laboratory investiga-
tion of the effects of withdrawal from a binge of COC self-administration. It is in-
teresting to note in this context that rhesus monkeys given a choice between an
injection of COC (0.3 mg/kg/inj) or food pellets every 15 minutes 24 hours/day
continuously for 8 days self-administered up to approximately 28 mg/kg/day of
COC (Aigner and Balster 1978). Thus, the dose of 32 mg/kg/day used in the
present study is clearly in the range of doses self-administered by monkeys giv-
en the option to respond for an alternative reinforcer. Research is underway to
further assess the utility of this animal model for studying COC dependence.
It is important to establish the conditions under which COC dependence de-
velops. The present results. using a continuous infusion paradigm suggest that
both dose and duration of exposure are of critical importance. Such a conclu-
sion would be consistent with what is known about dependence upon other
psychoactive compounds. In pilot studies, signs or symptoms of withdrawal from
COC were not seen with infusion doses of less than 32 mg/kg/day. The most in-
tense behavioral disruptions (cycle 1, monkey 5018) followed the most pro-
longed period of continuous COC infusion and exposure to the high dose, thus
demonstrating withdrawal from COC. It seems to be necessary to gradually es-
calate to this high dose of COC by developing tolerance to the low doses first. In
pilot studies, monkeys that were infused directly with 16 mg/kg/day COC without
first becoming tolerant to a lower dose failed to become tolerant to 16
mg/kg/day. In this context, the “cumulative” tolerance alluded to previously be-
comes an important phenomenon. If it becomes increasingly easy to achieve the
prolonged exposure to a high dose of COC, the probability of dependence de-
veloping in a relatively brief period of time becomes more likely. Further re-
search is needed to establish the generality of this finding.
Continuous infusion of a high dose of COC (100 mg/kg/day) for 21 days failed
to alter DA and 5-HT. Roy et al., (1978) also found that acute doses of COC
failed to alter DA content in the caudate nucleus after repeated injections of
COC (30 mg/kg/day for 30 days). On the other hand, Taylor and Ho (1977) re-
ported that repeated administration of COC (10 mg/kg/day for 7 days) caused a
decrease in both 5-HT levels and tryptophan hydroxylase activity in the caudate
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and an increase in striatal DA and NE metabolism which lasted for 24 hrs. Since
previous investigators have examined neurochemical effects within 24 hrs of the
last injection of COC, it is impossible to determine whether these effects were
long-lasting. More recently, Trulson et al. (1986) reported that tyrosine hydroxy-
lase immunoreactivity in the straitum was reduced by repeated administration of
COC for up to 60 days after the last injection. Such an effect on tyrosine hydrox-
ylase is consistent with toxicity to catecholamine-containing neurons. The rea-
sons for the apparent discrepancy with the present results is unclear. It is possi-
ble, however, that tyrosine hydroxylase activity was reduced after the chronic
regimen but that steady-state levels of neurotransmitter were unchanged.
Our results with COC are in contrast to what has been found with AMPH-like
psychomotor stimulants. Both MA and d-AMPH deplete monoamines in at least
one of the brain regions examined here. Although the precise reason for this dif-
ference between COC and AMPH is unclear, there are several pharmacological
differences between the two compounds that may play a role. For instance, it
has been postulated that the production of endogenous neurotoxins plays a role
in the neurotoxicity produced by MA (Seiden and Vosmer 1984). It is possible
that such a neurotoxin is produced but that COC limits it’s own toxicity by
blocking the uptake of the neurotoxin into the relevant neurons. Additionally,
COC does not cause release of DA and may, therefore, be self-limiting with re-
gard to elevating synaptic concentrations of neurotransmitter, thereby reducing
production of neurotoxin. In this context, the lack of MAO inhibition by COC as
compared to AMPH may also limit the availability of endogenously produced
neurotoxin. Finally, it has been suggested that COC, like methylphenidate, acts
via a different neurotransmitter pool than AMPH, a pool that does not depend
upon recent synthesis (Scheel-Kruger 1977). The observations that -methyl-
tyrosine, which inhibits catecholamine synthesis, blocks the neurotoxicity of
AMPH (Wagner, et al., 1983) and that methylphenidate does not cause AMPH-
like neurotoxicity (Wagner et al., 1981) are consistent with this hypothesis.
In summary, continuous exposure to COC results in tolerance to its effects on FR
responding for food. When continuous infusions of COC were terminated after a
period of exposure during which the dose was escalated to 32 mg/kg/day, a re-
liable sequence of behavioral changes suggestive of a withdrawal syndrome
were evident. COC is thus similar to other psychoactive drugs in its ability to
produce what has been termed “behavioral dependence” (Schuster 1968). In
addition, high doses of COC did not produce the damage to monoamine con-
taining neurons in the brains of rats that has been seen with AMPH-like com-
pounds. It should be emphasized that the lack of AMPH-like neurotoxicity does
not preclude the existence of some other form of toxicity to the brain.
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Neurochemical Basis for Cocaine
and Methamphetamine Interactions
G. Hanson, L. Matsuda and J. Gibb
ABSTRACT
We have evaluated the responses of rat monoaminergic pathways to
combinations of cocaine and methamphetamine (METH) administra-
tions and found that these two commonly abused stimulants significantly
interact. A 7-day pretreatment with daily doses of cocaine enhanced the
neurochemical changes induced by multiple doses of METH in the
dopaminergic and serotonergic systems of the basal ganglia and frontal
cortex. When cocaine was administered concurrently, it attenuated or
blocked the serotonergic changes caused by multiple doses of METH,
but it did not interfere with the METH-mediated changes in the
dopaminergic system.
INTRODUCTION
The commonly abused stimulants, cocaine and amphetamines, are
frequently self-administered in toxic doses, resulting in profound CNS
effects. Many of the neurochemical changes which result from the
separate administration of high doses of each of these potent drugs
have been previously described. It is well documented that a significant
portion of the stimulant abuser population consists of polydrug users
who administer both drugs either alternately or even concurrently
(Cohen, 1975; Siegel, 1984); however, little information is available
concerning the interactions of these agents. Previous reports that
administrations of both stimulants influence the neurochemistry of
similar monoaminergic systems, associated with structures of the basal
ganglia and mesocortical areas (Pradhan et al., 1978; Pradhan, 1983;
Goeders and Smith, 1983; Morgan and Gibb, 1980; Schmidt et al.,
1985), suggest that significant interactions are likely to occur and could
influence toxic and pharmacological responses to these agents.
94
We have evaluated the responses of dopaminergic and serotonergic
pathways, associated with either the basal ganglia or mesocortical
structures, to combinations of cocaine and methamphetamine (METH)
and found that the METH-induced changes in related neurochemical
parameters are significantly altered by cocaine treatments.
MATERIALS AND METHODS
Drug treatments: Male Sprague-Dawley rats (200-250 gm) were
housed 5 per cage and maintained at 26° C with a 12-hr alternating
light-dark cycle. Both cocaine and METH were dissolved in 0.9% saline
and administered intraperitoneally and subcutaneously, respectively.
Doses are expressed in terms of the free base. Cocaine pretreatments
consisted of a daily dose (20 mg/kg) for 7 days administered prior to 3
doses (15 mg/kg/dose; 6 hr-intervals) of METH. Animals were sacrificed
18 hr following the final drug administration. Concurrent drug
treatments were administered by injecting 5 doses (6-hr intervals) of
cocaine (20 mg/kg) and METH (15 mg/kg) at approximately the same
time and sacrificing the animals 18 hr after treatment.
Assays: Following decapitation, the brains were immediately removed
and placed on ice. The neostriata and frontal cortical regions were
dissected bilaterally and stored at -70° C until assayed. One of the
paired striata or cortical regions from each rat was assayed for
tryptophan hydroxylase (TPH) and tyrosine hydroxylase (TH; striata
only) enzyme activities while the other was used in the quantitation of
the monoamines and their metabolites.
All steps in the preparation of enzymes were performed at 0-5° C.
Tissues were weighed and homogenized (1:3) in 50 mM HEPES buffer,
pH 7.4,  conta in ing 0.2% Tr i ton X-100 and 5 mM di th iothre i to l .
Homogenates were centrifuged at 27,000 x g for 15 minutes. Duplicate
7.5-µl aliquots of the supernatant fraction from each sample were
analyzed for TH activity by a tritium release assay (Nagatsu et al., 1964)
utilizing 3H-tyrosine as substrate. Similar aliquots were assayed for
TPH activity using a modified 14CO2-trapping procedure (Ichiyama et al.,
1970); details of the assay are described by Hotchkiss et al. (1979).
Tissue concentrations of dopamine (DA) and its primary metabolites,
3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA),
and 5-hydroxytryptamine (5HT) and its major metabolite, 5-hydroxy-
indoleacetic acid (5HIAA), were measured by high-performance liquid
chromatography (HPLC) with electrochemical detection. Tissues were
weighed and homogenized in 0.3-0.5 ml mobile phase buffer containing
0.15 M monochloroacetic acid, 2.0 mM disodium EDTA and 25 mg/l
1-octane sulfonic acid in 12.5% methanol at pH 2.9. After centrifugation
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at 40,000 x g for 15 min the supematant fractions were filtered through a
0.2-µm Microfilter system (Bioanalytic Systems, Inc., West Lafayette, IN).
Fifty-pi volumes were injected by a WISP automatic sample processor
(Millipore Co., Millford, MA) onto a 3-µm reverse phase Microsorb C18
column (Rainin Instrument Co., Woburn, MA). Samples were run on a
LC-154  l i qu id  ch roma tog raph  equ ipped  w i t h  a  mode l  LC-4B
amperometric detector (Bioanalytical Systems, Inc.). The detector
potential was set at +0.73 V. Monoamines and their metabolites were
quantitated by measurement of peak heights and comparison with those
of standards of known concentration prepared in mobile phase buffer.
RESULTS
Pretreatment with single daily doses of cocaine for 7 days had no
significant neurochemical effects alone, but did substantially increase
neurochemical responses by monoaminergic systems to multiple doses
of METH (figure 1). Specifically, cocaine pretreatment enhanced the
METH-induced decreases in striatal TPH activity (figure 1 A), striatal and
cortical concentrations of 5HT and 5HIAA (figures 1 B and C) and
striatal concentrations of DA and DOPAC (figure 1 D).
FIGURE 1. Effects of cocaine pretreatment on METH-induced changes
in (A) striatal TH and TPH activities, (B and C) concentrations of 5HT
and 5HIAA in striatum and frontal cortex, respectively, and (D) striatal
concentrations of DA, DOPAC and HVA. Each value represents 4-10
animals. * P < 0.02, * * P < 0.01 compared to respective controls; † P <
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0.05, †† P < 0.02 compared to corresponding METH-treated groups.
Control values for striatal tissue were: TH=3080, TPH=33.9 nmol/g/hr;
5HT=0.441, 5HIAA=0.349, DA=10.8, DOPAC=1.55, HVA=0.82 µg/g
tissue. Controls for cortical tissue were: 5HT=0.353, 5HIAA=0.212 µg/g
tissue.
Interactions between cocaine and METH also were observed when
multiple doses of these agents were administered concurrently (figure
2). Multiple doses of cocaine alone significantly decreased the activities
of  s t r ia ta l  TH and TPH ( f igure 2A).  The presence of  cocaine
substantially attenuated or blocked the effects of METH on striatal and
cortical TPH activities (figures 2A and B), as well as striatal and cortical
concentrations of 5HT and 5HIAA (figures 2C and D). In contrast,
concurrent cocaine treatment did not alter the effects of METH on striatal
TH activity (figure 2A) or striatal concentrations of DA, DOPAC or HVA.
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FIGURE 2. Effects of concurrently administered cocaine on METH-
induced changes in (A) striatal TH and TPH activities, (B) cortical TPH
activity, (C and D) concentrations of 5HT and 5HIAA in striatum and
frontal cortex, respectively, and (E) striatal concentrations of DA,
DOPAC and HVA. Each value represents 4-6 animals. * P < 0.02, * * P
< 0.005 compared to respective controls. † P < 0.01 compared to
corresponding METH-treated groups.
DISCUSSION
These findings demonstrate that there exists substantial potential for
interactions between cocaine and METH and the nature of such
interactions vary according to dosing protocols. Chronic administration
of cocaine has been shown to cause sensitization to itself in rats (Post
and Contel, 1983), dogs, monkeys (Tatum and Seevers, 1922) and
humans (Jones, 1984). Results from the present study suggest that
cross-sensitization between cocaine and METH also occurs. Thus,
cocaine pretreatment for a week enhanced the response of mono-
aminergic systems associated with the striatum and frontal cortex to
METH treatment. The mechanism for this cocaine-induced sensitization
is not presently apparent. However, our previous observations that
many of the METH-related effects are due to the actions of this drug on
DA-release (Schmidt et al., 1985) would suggest a dopaminergic basis
for the cocaine-induced sensitization to METH action.
The changes observed wi th METH ef fects,  when cocaine was
administered concurrently, were particularly interesting. Cocaine signi-
ficantly attenuated the striatal and cortical serotonergic effects caused
by mulitple doses of METH (figure 2A, B, C and D): a similar, but greater
blockade by cocaine also was observed following a single concurrent
administration of these two stimulants (data not shown). In contrast, the
presence of cocaine did not interfere with the effects of METH on
dopaminergic-related parameters in the striatum, such as TH activity
(figure 2A) and concentrations of DA, DOPAC and HVA (figure 2E). In
fact, subsequent experiments suggest that the presence of cocaine may
actually enhance such METH actions (data not shown). It has been
reported that uptake blockers for 5HT and DA, when coadministered
with METH, block the respective dopaminergic and serotonergic effects
of this agent (Schmidt and Gibb, 1985a and 1985b). Consequently, the
5HT-uptake blocking properties of cocaine (Taylor and Ho, 1978) likely
account for its effects on METH-mediated serotonergic changes.
Cocaine also has been characterized as a potent DA-uptake blocker
(Hadfield and Nugen, 1982; Groppetti et al., 1973), but the lack of
interference by cocaine on METH-mediated dopaminergic changes
suggests that the effect of cocaine on the DA uptake complex is different
from that of other dopaminergic uptake blockers.
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In summary, significant interactions occur between cocaine and METH
ranging from an apparent sensitization to METH effects by cocaine
pretreatment to a blockade of METH-induced 5HT changes caused by
concomitant cocaine administration. These interactions could have
clinical significance to polydrug users who abuse both drugs as well as
help to elucidate the mechanisms of action of these compounds.
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Chronic Cocaine Modifies Brain
Benzodiazepine Receptor Densities
K. McAllister, N. Goeders and S. Dworkin
INTRODUCTION
Investigations of both the direct and indirect neurobiological
effects of acute and chronic cocaine administration may lead to
a greater understanding of compulsive drug use and associated
behavioral pathologies. Since cocaine increases the availability
of catecholamines in the synapse by blocking reuptake into pre-
synaptic neurons, most attention has focused on its dopamine-
mediated reinforcing and stimulant properties (see Woods et al. ,
1987). For example, the administration of alpha-flupenthixol (a
dopamine receptor antagonist) attenuates intravenous cocaine self-
administration (Ettenberg et al., 1982), and depletion of dopamine
in the nucleus accumbens by 6-hydroxydopamine (6-OHDA) decreases
cocaine self-administration (Roberts et al., 1980) as well as
cocaine-induced hyperactivity (Kelly and Iversen, 1976).
Chronic treatment with psychomotor stimulants can result in long
lasting changes in catecholaminergic systems although there is some
confusion as to the exact nature of these effects (Post et al. ,
1987). Thus, daily injections of amphetamine have been reported
to either increase (Akiyama et al., 1982) or decrease (Hitzemann
et al., 1980 dopaminergic receptor binding in mesolimbic areas.
Increases in 3H-spiroperidol binding have also been reported in
frontal cortical areas (Akiyama et al., 1982) with decreases found
in the striatum following amphetamine treatment (Howlett and
Nahorski, 1979; Akiyama et al., 1982). Cocaine increases [3H]-
spiroperidol binding in the striatum (Taylor et al. 1979; Memo
et al. , 1982) but decreases the binding of sulpiride, a relatively
specific ligand for the D2 receptor (Goeders and Kuhar, 1987).
Sulpiride binding is increased in the nucleus accumbens (Goeders
and Kuhar, 1987).
Since changes in brain catecholamines may, in turn, result in
additional central nervous system alterations, it may be possible
for chronic cocaine administration to induce neurobiological
modifications indirectly through its effects on catecholamine
systems. There is evidence that catecholaminergic systems mediate
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changes in benzodiazepine (BZD) receptor densities. Depletion of
brain dopamine by intraventricular 6-OHDA decreases BZD receptor
densities in the cerebral cortex (Sabato et al., 1981) and cere-
bellum (Noble et al., 1981). Systemic pretreatment with bus-
pirone, a non-benzodiazepine anxiolytic which blocks dopamine
receptors (McMillen et al., 1983), increases [3H]flunitrazepam and
[3H]Ro 15-1788 labeling of BZD receptors in the cerebral cortex,
cerebellum and hippocampus in vivo (Oakley and Jones, 1983; Goeders
et al., 1986). Furthermore, chronic cocaine administration has
been reported to affect -aminobutyric acid (GABA) receptor binding
in the rat striatum (Gale et al., 1981). Therefore, cocaine-
induced alterations in catecholaminergic and non-catecholaminergic
neurotransmission may result in changes in BZD receptor popula-
tions.
A complex relationship between stimulants and BZD receptor ligands
has been implicated in behavioral studies. Systemic chlordiaze-
poxide injections significantly decrease the frequency of cocaine
self-infusions by rats (Goeders and Dworkin, 1987) in a fashion
similar to that seen with dopaminergic antagonists (Ettenberg et
al., 1982). These latter results were interpreted as a modifica-
tion in the reinforcing efficacy of cocaine. Therefore, BZD
receptors may be involved in the neurobiological events mediating
cocaine reinforcement. In addition, co-injections of cocaine and
chlordiazepoxide augment locomotor activity above that of the two
drugs alone (D'Mello and Stolerman, 1977). Chlordiazepoxide
pretreatment also enhances the stimulatory effect of chlordiaze-
poxide and amphetamine combinations (Sansone et al., 1986). Acute
administration of amphetamine has been demonstrated to potentiate
the anticonflict properties of chlordiazepoxide (Lerner et al. ,
1986) as does chronic administration of chlordiazepoxide-ampheta-
mine mixtures (Ford et al., 1979). Cocaine generalizes to the
anxiogenic agent, pentylenetetrazol, and this generalization is
antagonized by diazepam (Shearman and Lal, 1979). These data
suggest that cocaine may have anxiogenic properties that could be
influenced by drugs specific for the BZD receptor. Indeed,
clinical reports have described anxiety reactions that are treat-
able with diazepam following high doses or chronic cocaine (Gay,
1982).
Therefore, both neurobiological and behavioral data suggest a
complex interaction between stimulants and BZD's and the neural
substrates at which each act. The present study investigated the
effects of cocaine administration upon BZD receptors since data of
potential clinical relevance in the treatment of compulsive cocaine
use and associated behavioral pathologies may be revealed.
METHODS AND MATERIALS
Twelve adult male rats (90-120 days old) originally derived from
the Fischer 344 strain were injected with cocaine (20.0 mg/kg,
i.p.) or an equal volume of physiological saline (1.0 ml/kg, i.p.)
for fifteen days. On the fifteenth day, the rats were sacrificed
by decapitation twenty minutes post-injection, and the brains were
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removed and dissected over ice into cerebellum, cerebral cortex,
diencephalon, brain stem, hippocampus and striatum. The dissected
brain regions were frozen on dry-ice and stored at -70°C until
assay. Membranes were prepared by tissue homogenization (Polytron,
at setting P-10 for 15 seconds) and centrifugation (15000 rpm for
10 minutes) in 15 ml of ice-cold 50 mM Tris-HCl (pH 7.7) two times,
with the supernatant discarded. The final membrane pellet was
diluted to 1.7 mg/ml (approx. 150 ug protein/ml). The binding
assay consisted of incubating triplicate samples of tissue (1.0 ml)
at 4°C for 60 minutes with [3H]Ro 15-1788 (10-9M) and various
concentrations of "cold" Ro 15-1788 (5x10-10M to 10-6M) or buffer.
The reactions were terminated by filtration. Binding was deter-
mined by liquid scintillation spectrophotometry, and specific
binding was calculated as the difference between total and non-
specific binding. Protein content of the tissue samples was
assessed using the Lowry method (Lowry et al., 1951), and
Scatchard and Hill plots were estimated by computer-aided regres-
sion analysis (McPherson, 1983) resulting in the binding affinities
(Kd) and densities (Bmax) for the tissue for each animal. Indepen-
dent t-tests were used to compare differences in Bmax and Kd values
obtained from the treatment groups.
RESULTS
Daily injections of cocaine resulted in increases in activity
and stereotypy over the fifteen day period. Figure 1 shows the
changes in behavior rated for one-hour post-injection for rats
in a preliminary study, according to a modification of the index
provided by Ellinwood and Balster (1974). Over the first few days,
FIGURE 1. Behavioral effects of cocaine (20 mg/kg) over a fi
day treatment period. Values represent mean (±S.E.M.).
fteen
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increases in locomotor activity and rearing were recorded, but
later in the treatment period, head weaving was the predominant
activity observed. Although a detailed record of behavior was not
made in the present study, similar changes over the fifteen day
treatment were noted.
Chronic cocaine injections resulted in significant increases in BZD
receptors labeled with [3H]Ro 15-1788 in the striatum and cerebel-
lum, significant decreases in the frontal cortex and no significant
effects in the other brain regions (Table 1). These increases in
binding were not due to changed affinity of the receptor for the
ligand since the Kd in each area was not significantly different
(Table 1).
TABLE 1. Specific [3H]Ro 15-1788 binding to membrane homogenates
of various brain regions of saline- and cocaine- treated rats
Mean (±S.E.M.) Kd and Bmax values for each brain region from
animals injected with saline or cocaine (20 mg/kg, i.p.) for
fifteen days (N=6). *p<O.O5, independent t-tests.
DISCUSSION
The changes in behavior over the testing period were similar to
those described by Post and Contel (1983) and Ellinwood and Balster
(1974) after repeated cocaine or amphetamine administration and
reflect a behavioral sensitization which may be mediated by meso-
limbic dopaminergic pathways (Fog, 1972; Randrup and Munkvad, 1970;
Kelly, 1977). These behavioral data indicate that cocaine-induced
changes in BZD receptors parallel modifications in dopamine recep-
tors after similar stimulant administration (Akiyama et al., 1982;
Goeders and Kuhar, 1987).
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The changes in BZD receptors labelled with [3H]Ro 15-1788 were not
attributable to changes in the binding affinity of the receptors
since there were no significant differences in Kd values for tissue
derived from saline- and cocaine-treated animals. Therefore, the
differences in Bmax likely result from changes in the BZD receptor
densities in these brain regions. These preliminary data therefore
support the hypothesis that chronic cocaine administration can
modify BZD receptor populations. The mechanism mediating these
changes is currently under investigation in this laboratory.
While these data suggest that chronic cocaine administration
may affect BZD receptors, the significance of these changes is
unclear. Most interest in BZD receptors and endogenous ligands
has centered on physiological and behavioral responses to pro-
cedures predictive of "stress" and "anxiety". BZD agonists
increase punished responding (Geller and Seifter, 1962), condi-
tioned emotional responses (Millensen and Leslie, 1974), punished
drinking (Vogel et al., 1971) and rodent social interactions
suppressed by environmental novelty (File and Hyde, 1978). Forced
swimming (Medina et al., 1986) and conditioned emotional response
(Lane et al., 1982) result in significant changes in BZD receptor
densities in the cerebellar cortex and hippocampus. Whether or not
cocaine can affect emotionality or the behavioral responses to
stressful stimuli? these changes in BZD receptors open a new line
of investigation into the underlying neurobiology of the behavioral
effects of cocaine. Certainly, the changes seen in cocaine self-
administration after chlordiazepoxide treatment (Goeders and
Dworkin, 1987, and unpublished observations) suggest an important
link between the reinforcing efficacy of cocaine and BZD mecha-
nisms. Although further investigation is needed, these data
suggest a potential role for BZD therapy in compulsive cocaine use
and associated behavioral pathologies.
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Flurothyl Seizure Thresholds
Associated with Acute and Chronic
Chlordiazepoxide Dependence and
Withdrawal
N. Boisse, G. Samoriski and J. Guarino
Tolerance to the anticonvulsant actions of the benzodiazepines is
a well recognized clinical problem (cf. Frey et al., 1986). When
it develops clinically, the dose may be Increased to restore
response. However, such a strategy might further stimulate
tolerance and also promote physical dependence which is dose
dependent (Lukas and Griffiths, 1984). Indeed, functional
anticonvulsant tolerance and physical dependence might share a
common adaptational neuronal mechanism. Although tolerance might
not always be associated with physical dependence, physical
dependence is invariably associated with tolerance for most
dependence producing drugs. Benzodiazepine anticonvulsant
tolerance and physical dependence have not been studied together.
Chemoconvulsant testing provides a single dimension of CNS
exictabillty to quantitate Initial anticonvulsant efficacy,
chronic tolerance and proconvulsant changes during withdrawal.
Flurothyl, a rapidly reversible Inhalation convulsant, is
particularly suited for this purpose because it produces
sub-lethal seizures allowing repeated testing in the same animal.
The objectives of this study are: (1) to evaluate functional
anticonvulsant tolerance over a range of chronic benzodiazepine
dose levels known to produce progressive dependence based on
spontaneous withdrawal signs; (2) to evaluate seizure thresholds
when spontaneous withdrawal is maximal; (3) to probe for an
association between the magnitude of functional tolerance and
dependence based on the flurothyl threshold criterion and (4) to
determine If seizure thresholds are reduced for acute
(single-dose) dependence preciplated by Ro 15-1788 (Boisse et.
al., 1986, a,b).
METHODS
Male Sprague-Dawley rats (Charles River, Wilmington, MA), 325-425g
were pair housed under standard conditions for this study and
randomly assigned to treatments.
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Chronic Chlordiazepoxide Dose-Response Studies: Rats were treated
with chlordiazepoxide HCL intragastrically twice daily at 8:00
a.m. and 6:00 p.m. at a dose level of 2.5, 5, 20, 75 or 150 mg/kg.
Animals received chronically the same dose they received acutely.
Concentrations of drug were adjusted to a constant dosage volume
of 5 ml/kg. Concurrent controls received water.
Immediately before and four hours after the first (acute) or last
(chronic) dose, rats were tested for CNS depression according to
the TDP score criterion described below and 100 ul of whole blood
was collected and frozen until analyzed by high performance liquid
chromatography (HPLC). Thirty minutes later at t=4.5 hours, rats
were tested for flurothyl seizure threshold as described below.
Following the last chronic chlordiazepoxide dose, rats were tested
daily for overt signs of withdrawal until tested for flurothyl
seizure threshold when spontaneous withdrawal was near maximal
(based on historical time-course data).
Acute Chlordiazepoxide Dependence Study: Acute chlordiazepoxide
dependence was induced by a single intragastric dose of 450 mg/kg
p.o. Withdrawal was precipitated 76 hours later by Ro 15-1788 (25
mg/kg, i.p.). Flurothyl seizure threshold testing was begun 2
minutes after Ro 15-1788 injection.
Pretreatment controls received water; antagonist controls received
the acacia vehicle.
Flurothyl Seizure Threshold Testing: Seizure thresholds were
determined by administering flurothyl (bis-(2,2,2,trifluro-
ethyl)ether) utilizing an inhalation technique similar to Adler
(1975). Briefly, the rat is placed in a 4L closed chamber
equipped with a wire mesh basket on which a 2" x 2" gauze pad is
placed. Constant rate infusion (O.11ml/min) of a 10% or 25%
solution of flurothyl in 95% ethanol (v/v) was begun. The animal
is continuously observed and the time to the first myoclonic jerk
and clonic seizure (loss of posture) recorded. A minimum of 5
min. was allowed between animals so that the chamber air could
become free of flurothyl vapor and to change the gauze pad.
Based on the concentration of the HFE solution, specific gravity
of flurothyl (HFE) and the infusion rate, delivered dose was
calculated. The response threshold (MJ or CL) is dose of
flurothyl (mg) necessary to overcome the anticonvulsant action of
chlordiazepoxide. To allow for comparison between acute and
chronic for the dose-response study, net HFE scores were
determined by subtracting the control group mean from individual
test animal scores for the appropriate response and timepoint.
All seizure testing was done between 10 a.m. and 2 p.m. to
eliminate any diurnal influences that affect chemoconvulsant
susceptibility.
TDP Score Evaluation: CNS depression was evaluated based on five
different ladder and open-field tests to detect motor impairment.
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The sum tally of all grades of impairment for the 5 tests comprise
the total depression point (TDP) score. The maximum TDP is 15.
Detailed descriptions of this method have been published (Boisse
et al., 1986a).
WD Score Fvaluation: Whole animal observations of withdrawal
signs were made by two concurrent experienced raters who were
blind to the chronic treatment. Twenty different motor, autonomic
and behavioral signs were monitored by operationally defined
criteria that have been described (Ryan and Boisse, 1983; Bofsse
et al., 1986a). The WD score is the sum of all grades for all
signs recorded.
Quantitation of Benzodiazepine Blood Levels: Blood levels of drug
were monitored at the time of peak effect for the first and last
dose of the chronic dose-response study. Drugs were extracted
from blood using the Bond-Elut system. Chlordfazepoxide and its
active metabolites -- nor-chlordiazepoxide and demoxepam -- were
quantified based on an HPLC method developed in this lab (Boisse
and Rivkin, 1981).
RESULTS
Acute versus Chronic Dose-Response Study
(a) Dose-Defined Tolerance: All acute doses of chlordiazepoxfde
produced a significant elevation of HFE thresholds compared to
controls. The CL criterion curve was just above the parallel to
the MJ criterion curve for both acute and chronic doses. An
analysis of HFE thresholds in acute and chronic water controls
revealed no significant difference for either MJ or CL criteria.
Therefore, the evaluation of chronic anticonvulsant tolerance was
not confounded by sensitization or altered responsivfty to HFE.
Compared to the acute, the chronic dose-response curve was just
below the acute curve for both ML and CL with the exception of one
data point -- the 75 mg/kg dose and CL criterion. Dose-defined
anticonvulsant tolerance was statistically significant for MJ
criterion at the 75 and 150 mg/kg doses and for the CL criterion
only at 150 mg/kg.
Dose-response curves for CNS depression also reveal statistically
significant tolerance (reduced TDP scores) only at the 150 mg/kg
at the P<.05 level for one-tailed t-test.
(b) Functional (blood level-defined) Tolerance: To evaluate
functional tolerance as a function of blood levels of active drug,
scattergrams of seizure thresholds were plotted against the total
benzodiazepfne blood level, the chlordiazepoxfde level and the
nor-chlordfazepoxide level on a double log plot. Regression 1 fnes
were calculated by the method of least squares for the acute and
for all the chronic data and the slopes compared by t-test. The
results of these analyses were most reveal ing. For the acute drug
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exposures, blood levels are about 60% chlordfazepoxfde, 40%
nor-chlordfazepoxide and 0% demoxepam independent of dose. For
the chronic, blood levels were about 25% chlordiazepoxidet 70%
nor-chlordfazepoxide and 6% demoxepam again independent of dose.
Because of the qualitative difference in active drug/metabolite
profile, total benzodfazepine blood level plots provided the most
balanced indicator of drug load to relate acute vs. chronic
flurothyl scores. Maximal functional tolerance was estimated from
the maximum potency shift for total benzodfazepfne blood levels at
the highest chronic dose and was 3.9 for MJ and 2.6 for CL
criteria. The slopes of the acute vs. chronic regression lines
were also sfgnfffcantly different by t-test for MJ (P<.001) and CL
(P<.05) criteria.
Comparable plots of TDP scores versus total benzodiazepine blood
levels revealed a potency shift of 3.8 for maximal functional
tolerance. However, variability for the TDP score response was
considerably greater than for anticonvulsant activity and the
difference in slope between acute and chronic LDR regression lines
was not significant (P>.10).
(c) Flurothyl Seizure Thresholds in Withdrawal: An analysis of
HFE thresholds in chronic and withdrawal group controls revealed a
high significant (P<.001) test-test interaction. Seizure
thresholds in withdrawal were elevated about 60% for MJ and 80%
for CL criteria. Despite this profound confounding influence, the
flurothyl threshold for the CL criterion only was significantly
(P<.02) reduced (by 8.9%) for the 75 mg/kg dose (see Fig. 10).
This chlordiazepoxide dose was also the dose that was associated
with the most intense spontaneous withdrawal fmmedfately prior to
flurothyl testing.
Acute Dependence Study
RO 15-1788 produced a sfgnfffcant anticonvulsant effect in
controls. Despite this effect, seizure thresholds were
dramatically reduced by 22.9% for MJ and 20.6% for CL criteria in
the acutely dependent rats during precipitated withdrawal.
DISCUSSION
Like physical dependence, the results of this study demonstrate
that chronic benzodfazepine anticonvulsant tolerance is a dose and
blood-level dependent phenomenon. On the basis of chronic dose,
tolerance for the three criteria of MJ, CL and TDP was evident
only at the 150 mg/kg dose. At lower doses, tolerance developed
covertly and in a more graded fashion as demonstrated by
blood-level-response curve analysis. Functional tolerance was
evidenced by a non-parallel shift of the blood-level response
curve to a more shallow slope compared to acute suggesting a loss
of maximal efficacy. However, there was no apparent ceiling to
the acute or chronic, dose or blood level reponse curves so that
perhaps heroic escalations of dose would have restored the initial
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(acute) response maxima obtained. Chronic anticonvulsant
tolerance was not only dose-dependent but response dependent. It
developed maximally for the highest dose and for the MJ criterion.
Since the magnitude of maximal tolerance for TDP mirrored the
magnitude of maximal tolerance for the MJ anticonvulsant
criterion, the escalation of dose clinically to compensate for
tolerance might create a no-win situation in terms of patient
benefit coupled with an increased risk of physical dependence. It
is noteworthy that chronic anticonvulsant tolerance against
flurothyl was associated with physical dependence.
Flurothyl seizure testing during peak withdrawal from chronic
chlordfazepoxfde revealed a pro-convulsant change of 8.9% compared
to controls. However, considering the flurothyl test-test
interaction demonstrated in the water treated controls between the
second and third seizure tests conducted at either 3 or 6 day
intervals, an 8.9% proconvulsant action may represent only the tip
of the iceburg. Moreover, the apparent 60-80% anticonvulsant
effect of the test-test interaction could have neutralized a
proconvulsant action of equal magnitude but opposite direction.
Flurothyl test-test interaction would also explain the anomaly
that a single dose of chlordiazepoxfde seems to produce more
proconvulsant change in withdrawal than does 5 weeks of treatment
(70 doses). Clearly, spontaneous withdrawal and Ro 17-1788
precipitated withdrawal seizure threshold changes can not be
fairly compared until both have been studied in acute or chronic
dependence models.
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The Discriminative Stimulus
Properties of Midazolam in Pigeons
S. Evans and C. Johanson
The discriminative stimulus (DS) properties of benzodiazepines have been studied
extensively in rats (e.g., Colpaert et al., 1976; Shannon and Herling, 1983;
Garcha et al., 1985) and to a lesser extent in primates (e.g., Ator and Griffiths,
1983, 1986; Spealman, 1985) and pigeons (Jarbe and McMillan, 1983; de la Garza
et al., 1987). In general, drugs that do not bind to benzodiazepine-recognition
sites do not have DS effects similar to benzodiazepines. However, the
barbiturates, particularly pentobarbital, are exceptions in that there is cross-
substitution between benzodiazepines and barbiturates. For instance, in pigeons
trained to discriminate oxazepam (4.0 mg/kg) from saline, both benzodiazepines
and barbiturates substituted for oxazepam as DS (de la Garza et al., 1987). A
similar overlap between benzodiazepines and barbiturates has been demonstrated in
other experiments which have evaluated the DS properties of anxiolytics in other
species. For instance, pentobarbital substituted for the benzodiazepine in diazepam
or chlordiazepoxide trained rats (Shannon and Herling, 1983; Colpaert et al. ,
1976; Haug and Gotestam, 1982). Conversely, benzodiazepines have also been
reported to substitute for drug in pentobarbital trained rats (Young and Dewey,
1982). Similarly, in pigeons trained to discriminate pentobarbital from saline, both
pentobarbital and diazepam substituted (Herling et al., 1980). Furthermore, the
benzodiazepines diazepam and lorazepam substituted for pentobarbital in baboons
(Ator and Griffiths, 1983). Thus, barbiturates and benzodiazepines has been
shown to substitute for one another in various species.
Based on the ability of barbiturates and benzodiazepines to substitute for one
another one might conclude that these compounds have identical DS properties.
However the benzodiazepine antagonist Ro 15-1788 (Hunkeler et al., 1981)
antagonizes the DS effects of benzodiazepines but not those of barbiturates
(Herling and Shannon, 1982; Young and Dewey, 1982; Ator and Griffiths, 1983).
This suggests that even though in many instances barbiturates and benzodiazepines
share DS properties, these compounds may be differentiated from each other in
terms of their mechanism of action by using selective antagonists.
Recently, other benzodiazepines have been used as DS and asymmetrical
substitution between barbiturates and benzodiazepines has been demonstrated
(Ator and Griffiths, 1983, 1985). For instance, baboons or rats trained to
discriminate pentobarbital from saline respond on the drug lever when tested with
lorazepam. However, in animals trained to discriminate lorazepam from saline,
pentobarbital does not reliably substitute for lorazepam (Ator and Griffiths, 1983,
1985). Thus, lorazepam appears to be more selective as a DS than other
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benzodiazepines such as diazepam, oxazepam and chlordiazepoxide. Furthermore,
another benzodiazepine, midazolam, has been shown to function as a DS in both
rats (Garcha et al., 1985) and squirrel monkeys (Spealman, 1985) and it also
appears to be more selective. For example, in squirrel monkeys trained to
discriminate midazolam from saline, various sedative compounds including
pentobarbital, barbital and phenobarbital failed to substitute for midazolam
(Spealman, 1985).
The purpose of the present study was to determine if the DS properties of
midazolam are selective in pigeons to the same extent as lorazepam and midazolam,
which have been demonstrated to be selective benzodiazepines in other species.
This was accomplished by training pigeons to discriminate midazolam from saline
and testing various benzodiazepines as well as the barbiturates pentobarbital and
phenobarbital. In most cases, the nonbenzodiazepine anxiolytic CL 2 18, 872 has
been shown to produce DS effects similar to various benzodiazepines (de la Garza
et al., 1987; McElroy and Feldman, 1982; Spealman, 1985; Ator and Griffiths,
1986). In contrast, buspirone, another nonbenzodiazepine anxiolytic, has reliably
failed to share DS effects with benzodiazepines (Ator and Griffiths, 1986; Hendry
et al., 1983). Therefore both CL 218, 872 and buspirone were evaluated in this
study. Furthermore, to determine the pharmacological specificity of this
discrimination, compounds not expected to substitute for midazolam, such as
chlorpromazine, morphine, and mazindol were evaluated.
METHODS
Animals. The animals used in this study were five White Cameaux pigeons
maintained at 80% of their free-feeding weights and housed individually with
water and grit freely available. Purina Pigeon Checkers were provided after the
session to maintain stabel weights. The pigeons were trained to discriminate 1.0
(#2779) or 3.0 mg/kg (#1490, 1859, 3315 and 7227) midazolam IM from saline
and were experimentally naive at the beginning of the study.
Apparatus. The experiment was conducted in two ventilated custom-made operant
chambers, each equipped with two translucent response keys which were
transilluminated during the experimental session. Purina Pigeon Checkers were
made available from a food magazine which was illuminated during food delivery.
Training. The discrimination training procedure used has been described in detail
previously (de la Garza and Johanson, 1985). During each experimental session
each pigeon was injected intramuscularly with the training dose of midazolam (1.0
or 3.0 mg/kg) or saline in a 1 ml/kg volume 10 min before the session. Following
this pretreatment period, the experimental session began, signalled by the
illumination of both keys and the houselight. Thirty consecutive responses (fixed-
ratio 30; FR 30) on the injection appropriate key resulted in 3-sec access to food.
The left key was correct after midazolam for 3 pigeons. The right key was
designated correct after midazolam for the remaining pigeons. The opposite key
was designated correct following saline injections. The drug-key-reinforcer
relationship was maintained throughout the experiment. Responses on the
incorrect key reset the fixed-ratio requirement on the correct key. Each session
lasted until 50 reinforcers were delivered or until 30 minutes had elapsed,
whichever occurred first.
Training sessions continued until the percent of total responses on the correct key
was above 90% and the number of responses emitted on the incorrect key before
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the first reinforcer was delivered was less than 30 for seven consecutive sessions.
The injection preceding each session was selected from a pseudorandom sequence,
with the restriction that no condition would occur for three consecutive sessions.
Testing. In order to evaluate the DS properties of various benzodiazepines,
sedatives and anxiolytics these compounds were administered instead of
midazolam or saline during test sessions. Throughout a test session, 30
consecutive responses on either the midazolam-appropriate or saline-appropriate
key resulted in food delivery. In all other respects, test sessions were identical to
training sessions. Between test sessions, training sessions continued. The
training drug and saline under training conditions were administered in a double
alternation sequence with test sessions inserted every third session, i.e., saline,
midazolam, test, midazolam, saline, test, etc. If an animal failed to meet the
training criteria during a training session, further testing was postponed until the
animal met these criteria on at least two consecutive training sessions.
Initially a dose-response function for midazolam was established during test
sessions. Subsequently, the DS properties of various compounds were
determined in a similar manner. In general, each dose of a test compound was
tested once and three or four doses of each compound were tested in a mixed
order. The dose-response function for each compound was completed before
another compound was tested. Dose-response functions for each drug were
determined in at least three pigeons. After the completion of each dose-response
function, pigeons were given test sessions with either midazolam (1.0 or 3.0
mg/kg), saline, or the vehicle of the compound just tested.
Data analyses. A drug was considered to produce DS effects similar to those of
midazolam if at least 80% of the total responses during the test session were
emitted on the midazolam-appropriate key. The discrimination data are presented
as the percentage of total responses emitted on the midazolam key for individual
pigeons or as the percentage of animals tested at a particular dose that reached the
80% criterion. In addition, response rate (resp/sec) on the two keys was
determined for each session. A test compound was tested until a dose was given
that resulted in at least 80% of the responses on the midazolam-appropriate key or
until a dose was reached which reduced response rate to at least 50% of the rate for
midazolam.
Drugs. The following drugs used in this experiment were gifts: alprazolam and
triazolam (The Upjohn Co., Kalamazoo, MI), morphine sulfate (National Institute
on Drug Abuse), buspirone HCl (Mead Johnson Pharmaceutical Division,
Evansville, IL), CL 218, 872 (Lederle Laboratories, Wayne, NJ), diazepam,
mazindol, and nordiazepam (Committee on Problems of Drug Dependence, Inc.),
flurazepam HCl, midazolam maleate, and nitrazepam (Hoffman-La Roche, Inc.,
Nutley, NJ), and lorazepam (Wyeth Laboratories, Inc., Philadelphia, PA).
Chlorpromazine HCl (injectable), phenobarbital and sodium pentobarbital were
purchased commercially. With the exception of CL 218,872, all injections were
IM, usually in a volume of 1.0 ml/kg. When given orally, CL 218, 872 was
administered PO 60 min before the session. Phenobarbital was administered IM
90 min before the session. All other drugs were administered IM 10 minutes
before the session.
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RESULTS
Control performances. Sessions to criteria, determined from the fiit day when
both keys were availiable required between 15 and 32 sessions (mean = 25). After
the initial training phase, all five pigeons responded above 90% on the correct key
throughout most of the experiment. Throughout the course of this study test
sessions of saline and midazolam were conducted and the rate of responding
across the five pigeons ranged from 0.91 to 3.43 resp/sec following saline and
from 0.33 to 2.22 resp/sec following the training dose of midazolam. Midazolam
produced a dose-related increase in the percentage of responses emitted on the
midazolam-appropriate key in all five pigeons. At the lowest dose tested (0.3
mg/kg), less than 25% of responding occurred on the midazolam-appropriate key
in all five pigeons whereas at the training dose (1.0 or 3.0 mg/kg) more than 95%
of responding occurred on the midazolam-appropriate key. A higher dose (10
mg/kg) produced greater than 95% midazolam-appropriate responding in the 3
pigeons tested. Midazolam also produced a dose-related decrease in response ram.
Benzodiazepines. Alprazolam, diazepam, flurazepam, lorazepam, midazolam,
nitrazepam, nordiazepam, and triazolam produced midazolam-appropriate
responding in a dose-dependent manner in all pigeons tested. These results are
shown in Figure 1 as the percentage of animals distributing at least 80% of total
responses on the midazolam-appropriate key as a function of dose. At the highest
dose(s) tested, midazolam-appropriate responding was well above the 80%
criterion in each pigeon.
Figure 1. The percentage of midazolam-trained pigeons responding at least 80%
on the midazolam-appropriate key as a function of dose during substitution test
sessions. The points above midazolam (M) and vehicle (V) are the means of all
midazolam and vehicle test sessions, respectively obtained during the
determination of each dose-response function.
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There were differences in relative potency among these benzodiazepines in terms
of their ability to produce midazolam-appropriate responding. The lowest dose
which produced over 80% midazolam-appropriate responding in all pigeons was
0.1 mg/kg for triazolam, 1.0 mg/kg for alprazolam, diazepam and lorazepam, 3.0
mg/kg for midazolam, 10 mg/kg for flurazepam and nitrazepam, and 17 mg/kg for
nordiazepam, an acitve metabolite of diazepam.
them (data not shown).
pigeons in Figure 2. Phenobarbital produced greater than 80% midazolam-
appropriate responding at 30 mg/kg for two pigeons and at 56 mg/kg for a third
pigeon. However, phenobarbital failed to produce greater than 36% midazolam-
appropriate responding in another pigeon. In contrast, pentobarbital produced
greater than 80% midazolam-appropriate responding at 10 mg/kg in two pigeons
and failed to substitute for midazolam in the other three pigeons tested. When the
dose-response function for pentobarbital was redetermined in four pigeons,
nentobarbital failed to produce 80% midazolam-appropriate responding in any
Sedatives and nonbenzodiazepine anxiolytics. Two barbiturates, phenobarbital
and nentobarbital. were also tested. These results are shown for individual
Figure 2. Effects of phenobarbital and pentobarbital in pigeons trained to
discriminate 1.0 or 3.0 mg/kg midazolam from saline. The percent of midazolam-
appropriate responding is shown as a function of dose during substitution tests for
individual pigeons. The points above midazolam (M) and vehicle (V) are the
means of all midazolam and vehicle test sessions, respectively obtained during the
determination of each dose-response function.
In addition to testing benzodiazepines, other drugs used as anxiolytics were also
investigated. CL 218,872 was administered both IM with a 10 min pretreatment
time and PO with a 60 min pretreatment time (Figure 3). When CL 218,872 was
administered IM in three pigeons it failed to produce 80% midazolam-appropriate
responding in any pigeon tested. In one pigeon, 10 mg/kg CL 2 18,872 produced
a maximum of 76% midazolam-appropriate responding. However, midazolam-
appropriate responding never exceeded 50% in the other two pigeons.
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Subsequently, CL 218,872 was administered orally with a 60 min pretreatment in
four pigeons. CL 218,872 produced 80% midazolam-appropriat responding in
only one pigeon at 10 mg/kg In the other three pigeons CL 218,872 produced
greater than 50% midazolam-appropriate responding with a maximum of 76%
midazolam-appropriate responding at 30 mg/kg CL 218,872 in one pigeon.
Buspirone (0.3 - 10 mg/kg), another nonbenzodiazepine anxiolytic, failed to
produce midazolam-appropriate responding (less than 1%) up to doses that
suppressed responding in any pigeon tested (data not shown).
Figure 3. Effects of CL 218,872 administered IM and PO in pigeons trained to
discriminate 1.0 or 3.0 mg/kg midazolam from saline. Other details as described
for Figure 2.
Compounds from other pharmacological classes. Several compounds from
different pharmacological classes including anorectics, morphine, and an
antipsychotic were tested. The anorectic mazindol (0.01 to 3.0 mg/kg) and the
antipsychotic chlorpromazine (10 to 100 mg/kg) failed to produce responding on
the midazolam-appropriate key above 2% for any individual pigeon tested up to
doses that substantially decreased response rate. Morphine failed to produce any
midazolam-appropriate responding in three pigeons. However, in one pigeon, 3.0
mg/kg morphine produced 78% midazolam-appropriate responding but a higher
dose (10 mg/kg) only produced 18% midazolam-appropriate responding and
substantially reduced response rate.
DISCUSSION
The results of the present study demonstrate that midazolam is an effective DS in
the pigeon and that its DS effects are pharmacologically specific. The only
compounds that reliably substituted for midazolam, i.e., produced greater than
80% midazolam-appropriates responding in all pigeons tested, were other
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benzodiazepines. However, phenobarbital did substitute for midazolam in three of
four pigeons tested. In contrast, pentobarbital failed to consistently substitute for
midazolam. In previous studies CL 218,872 has been shown to substitute for
benzodiazepines including midazolam in squirrel monkeys (Spealman, 1985),
oxazepam in pigeons (de la Garzag et al., 1987) and lorazepam in baboons and rats
(Ator and Griffiths, 1986). The results from the present study conflict with
previous studies in that CL 218,872 did not reliably substitute for midazolam when
administered either IM or orally. However, similar findings were demonstrated in
lorazepam trained rats when CL 218, 872 was administered IP; lorazepam-
appropriate responding never exceeded 75% (Ator and Griffiths, 1986). In
contrast, the failure of buspirone to substitute for midazolam in the present study
confirms the results of other studies (Ator and Griffiths, 1986; Spealman, 1985).
In addition, drugs from other pharmacological classes failed to substitute for
midazolam.
In summary, the results of this study indicate that the DS properties of midazolam
are not based on properties common to many CNS depressants such as their
hypnotic, muscle relaxant, anticonvulsant and antianxiety properties. Similar
results have been demonstrated with lorazepam (Ator and Griffiths, 1986) and
midazolam trained animals (Spealman, 1985; Garcha et al., 1985). Therefore, the
results of this study are consistent in that the DS effects of midazolam are more
selective to benzodiazepines than other benzodiazepines such as diazepam. The
ability of midazolam to serve as a selective DS in the pigeon demonstrates the
reliability of using pigeons in drug discrimination procedures and thereby
providing species comparisons.
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Alcohol Effects on LH and FSH
in Recently Ovariectomized Female
Monkeys
N. Mello, J. Mendelson, M. Bree and A. Skupny
INTRODUCTION
Very little is known about the effects of alcohol on anterior
pituitary hormones in post-menopausal women or in ovariectomized
animal models and the available data are conflicting (see Gavaler
1986 for review). Clinical studies of chronic alcoholic post-
menopausal women during sobriety showed that pituitary responsi-
vity to synthetic LHRH stimulation did not differ significantly
from non-alcoholic controls (Hugues et al., 1978). A single
acute dose of alcohol also did not suppress LH in five normal
post-menopausal women (Mendelson et al., 1985). However, in the
ovariectomized rat, acute alcohol administration (3.0 g/kg I.G.)
significantly lowered LH levels and reduced LH pulse frequency
during the second hour after alcohol administration (Dees et al. ,
1985). Alcohol did not significantly alter FSH secretory pat-
terns, but prolactin levels were elevated during the first hour
after alcohol administration. When synthetic LHRH (25 ng i.v.)
was given 140 minutes after alcohol or saline administration, LH
increased significantly in both groups. These data were inter-
preted to suggest that the alcohol-induced suppression of basal
LH levels probably reflected a disruption in the pulsatile re-
lease of hypothalamic LHRH and that there may be separate hypo-
thalamic regulatory mechanisms for control of FSH and LH (Dees et
al., 1985; McCann et al., 1983).
In our previous studies of chronically ovariectomized female
rhesus monkeys, alcohol administration was followed by a nonsig-
nificant decrease in LH and no change in FSH over 120 minutes
(Mello et al., 1986a, 1987). Whereas, after synthetic LHRH
administration, a significant alcohol dose-dependent increase in
LH was observed (Mello et al., 1986a, 1987). FSH was also higher
after alcohol (3.5 g/kg) than sucrose control administration but
increases were not dose-dependent (Mello et al., 1986a).
In rhesus monkey, ovariectomy is followed by a rapid increase in
anterior pituitary hormone levels and a circhoral pattern of LH
activity (Atkinson et al., 1970; Dierschke et al ., 1970). An
initial elevation in LH following abrupt removal of ovarian
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steroid feedback eventually declines to a stable level between
100 - 200 ng/ml. It is not known if the relative sensitivity of
the hypothalamic-pituitary axis to alcohol's effects is different
in recently ovariectomized females and chronic castrates. The
primary goal of the present study was to examine the acute ef-
fects of alcohol (2.5 - 3.5 g/kg) on basal levels of LH and FSH
in recently ovariectomized female rhesus monkeys.
pulse frequency and amplitude were also analyzed.
METHODS
Subjects: Six bilaterally ovariectomized female rhesus monkeys
(6.2 ± 0.42 kg) were studied. Each monkey was first exposed to a
single dose of alcohol (2.5 g/kg) within 18 ± 2.1 days after
ovariectomy, and the last study was completed within 40 to 70
days following ovariectomy (X = 52 ± 4.4 days). Two monkeys were
alcohol naive and the others had a history of low dose alcohol
self-administration but had been alcohol free for 5 to 19 months
prior to these studies. Monkeys were maintained on ad lib food
and water: monkey chow was supplemented daily with fresh fruit,
vegetables and multiple vitamins. A 12-hour light-dark cycle
(7:OO a.m. to 7:00 p.m.) was in effect. Animal maintenance and
research was conducted in accordance with recomnendations by the
Committee on Care and Use of Laboratory Animals of the Institute
of Laboratory Animal Resources, National Research Council. The
facility is licensed by the Department of Agriculture. The
health of the monkeys was periodically monitored by a consultant
veterinarian from the New England Regional Primate Research
Center.
Sequence of Conditions: The acute effects of alcohol and sucrose
control solutions on basal levels of LH and FSH were evaluated in
the same subjects under identical conditions. Basal levels of LH
and FSH were measured for 180 minutes before alcohol or sucrose
was administered and for 360 minutes following alcohol or sucrose
administration. Integrated plasma samples were collected at 20
minute intervals throughout the study. Samples for blood alcohol
analysis were collected every 40 minutes beginning with the
second post-alcohol sample. Details of the integrated plasma
sample collection procedures (Bree et al., 1982) and the radio-
immunoassay procedures for LH and FSH analysis have been pub-
lished (Mello et al., 1986a). The LH assay sensitivity was 6.5
ng/ml. Intra- and interassay coefficients of variation were 5.4%
and 10.6% respectively. The FSH assay sensitivity was 1.3 ng/ml
and the intra- and interassay coefficients of variation were 6.4%
and 9.0% respectively. The plasma alcohol assay sensitivity was
16.2 mg/dl. Intra- and interassay coefficients of variation were
3.0% and 4.5% respectively.
Alcohol Administration: Alcohol (2.5, 3.0 and 3.5 g/kg) prepared
in a 25% solution was administered through a pediatric grade
nascgastric tube. Alcohol effects were compared-with a sucrose
control solution isocalorically equivalent to 2.5 g/kg of alco-
hol. Monkeys were fasted for 18 to 20 hours to ensure uniform
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absorption of alcohol. Alcohol and sucrose control solutions
were given in an irregular order in the following sequence: 2.5
g/kg alcohol, 3.5 g/kg alcohol, sucrose control and 3.0 g/kg
alcohol.
RESULTS
LH Levels after Alcohol/Sucrose: ANOVA showed a significant
effect of dose (P < .001) and of condition (pre vs post-alcohol
or sucrose) (P < .001) on LH. Basal LH averaged 270 ± 20 ng/ml
before sucrose control administration and decreased significantly
to an average of 216 ± 8 ng/ml over the next 6 hours of observa-
tion (P < .05). A one way ANOVA for repeated measures showed a
significant main effect (P < .04). There were no significant
differences between baseline LH levels prior to sucrose and
alcohol (samples 1-9).
Average LH levels also decreased significantly after administra-
tion of a moderate alcohol dose (2.5 g/kg) (P < .01). Baseline
LH levels averaged 363 ± 46 ng/ml and decreased by 26% to 269 ±
25 ng/ml after alcohol. LH levels were significantly lower than
baseline during both the ascending (samples 10-18) and the stable
phase (samples 19-27) of the blood alcohol curve. Blood alcohol
levels gradually increased to peak values 256 ± 16 mg/d1 within
200 minutes after nasogastric intubation of 2.5 g/kg of alcohol.
Administration of a higher alcohol dose (3.0 g/kg) resulted in a
significant (P < .01) suppression of LH. Basal LH levels aver-
aged 223 ± 14.6 ng/ml and decreased to 174 ± 6 ng/ml after alco-
hol administration. LH fell significantly within 80 minutes when
blood alcohol levels averaged 192 ± 14 mg/d1 and remained signi-
ficantly suppressed (P < .05, .01) for five hours. Peak blood
alcohol levels were 289 ± 34 mg/d1 within four hours after alco-
hol administration.
After the highest dose of alcohol studied (3.5 g/kg), blood
alcohol levels increased to above 300 mg/d1 within 160 minutes.
Peak blood alcohol levels were 327 ± 33 mg/dl at 3 hours 20
minutes after alcohol administration. LH levels decreased from a
baseline average of 229 ± 12 ng/ml to 202 ± 12 ng/ml but this
difference was not statistically significant.
FSH Levels after Alcohol/Sucrose: ANOVA showed a significant
main effect of dose (P < .001) and a significant effect of condi-
tion (pre- versus post-alcohol and sucrose) (P < .001) on FSH.
Basal FSH levels were equivalent before sucrose/alcohol admini-
stration and ranged between 79 ± 2.1 and 89 ± 3.4 ng/ml. One way
ANOVA for repeated measures showed that basal FSH levels did not
change significantly after sucrose control administration.
Alcohol consistently supressed FSH. After administration of 2.5
g/kg of alcohol, basal FSH 1evels decreased significantly (P <
.001). Dunnett's test showed that FSH fell significantly below
baseline levels (P < .01) when blood alcohol levels exceeded 200
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mg/dl and remained suppressed for 2 hours. After administration
of 3.0 g/kg alcohol, FSH also decreased significantly below
baseline (P < .001). FSH declined significantly within two hours
after alcohol administration when blood alcohol levels exceeded
200 mg/dl and remained suppressed for 80 minutes (P < .01). This
significant decrease in FSH occurred 40 minutes after suppression
of LB. FSH also decreased significantly after administration of
3.5 g/kg of alcohol (P < .001). FSH fell abruptly within 2 hours
after alcohol administration when blood alcohol levels averaged
266 ± 31 mg/dl. A decline in LH paralleled the initial signifi-
cant decline in FSH but FSH remained significantly below baseline
for 160 minutes
LH and FSH Pulse Frequency and Amplitude: Group average LH and
FSH pulse frequency per hour during the three hour pre-sucrose/
alcohol condition and the six hour post-sucrose/alcohol were
evaluated with a computer program based on the procedures of
Santen and Bardin (1973). A peak was defined as an increase of
20% or more over the immediately preceding nadir. During the
pre-alcohol conditions, LH pulse frequency averaged 0.61 to 0.77
pulses per hour. This is similar to LB pulse frequency measured
during the early luteal phase (0.8 pulses per hour) in normal
female monkeys (Ellinwood and Norman 1983). LH pulse frequency
decreased following the administration of both sucrose and alco-
hol. LA pulse frequency after alcohol ranged between 0.41 and
0.36 pulses per hour. LH pulse frequency after sucrose control
administration was 0.47 pulses per hour. This is similar to the
average LH pulse frequency measured during the early follicular
phase (0.49 per hour) by Van Vugt and co-workers (1984).
FSH pulse frequency prior to sucrose or alcohol administration
ranged between 0.386 and 0.50 pulses per hour. There were no
significant pre vs. post differences in FSH pulses per hour and
no orderly alcohol dose effects on FSH pulse frequency. We are
unaware of previous reports of FSH pulse frequencies in female
rhesus monkeys.
LH pulse amplitude also declined after administration of both
sucrose control solution and 2.5 and 3.0 g/kg of alcohol. But
after administration of 3.5 g/kg of alcohol, average LH pulse
height increased. There was no systematic pattern of changes in
FSH pulse amplitude across conditions.
DISCUSSION
LH after Alcohol/Sucrose: No consistent effects of alcohol on LH
secretory activity were observed in this group of recently ovar-
iectomized monkeys. Administration of 2.5 and 3.0 g/kg signifi-
cantly suppressed LH but the highest alcohol dose (3.5 g/kg) had
no significant effect on LH. Interpretation of these data is
further complicated by the fact that LH levels were also signifi-
cantly suppressed after sucrose control administration. Analysis
of LH pulse frequency and amplitude also indicated a decline in
LH pulses per hour after both sucrose and alcohol administration.
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Consequently, it is difficult to attribute data obtained to the
effects of alcohol per se.
The factors that accounted for a significant suppression of LH by
sucrose control administration are unclear. It is possible that
LH suppression may reflect the nonspecific stress associated with
the procedure. It is well established that both alcohol and
"stress" stimulate CRF (corticotropin-releasing-factor) and sub-
sequently ACTH release which may inhibit pituitary gonadotropin
secretion (Redi et al., 1986; Rivier et al., 1984, 1986). Ad-
ministration of an antagonist to CRF has been shown to reverse
the inhibitory effect of stress on pulsatile LH release in rats
(Rivier et al., 1986). Unfortunately, ACTH was not measured in
monkeys in the present study so there are no data available to
directly confirm or refute the non-specific stress hypothesis.
The lack of alcohol dose-related effects on LH are concordant
with previous observations in post-menopausal women (Mendelson et
al., 1985) and in long term ovariectomized monkeys where basal LH
and FSH levels were unchanged for the first 2 hours after alcohol
administration (Mello et al., 1986a, 1987). These data in women
and female rhesus monkeys are inconsistent with studies in ovar-
iectomized rats where a single dose of alcohol (3.0 g/kg I.G.)
suppressed basal levels of LH but not FSH (Dees et al., 1985).
Species differences as well as several differences in methodology
limit comparisons between the present study in female monkeys and
previous studies in rats (Dees et al., 1985).
FSH after Alcohol/Sucrose: Both group and individual data analy-
sis indicated that sucrose control administration had no effect
on FSH but alcohol significantly depressed FSH at all doses (P <
.05 - .001). However, no consistent alcohol dose-related effects
on FSH were observed. We have previously reported a differential
effect of alcohol on LH and FSH in normally cycling females
during the follicular phase of the menstrual cycle after synthe-
tic LHRH stimulation (Mello et al., 1986b). However, in long
term ovariectomized females, there was no differential effect of
alcohol on LHRN stimulated LH and FSH (Mello et al., 1986a).
LHRH stimulated FSH increased significantly under both control
and alcohol conditions and alcohol appeared to enhance LHRH
stimulated LH and FSH in comparison to control conditions (Mello
et al., 1986a, 1987). We interpreted the contrast between alco-
hol's effects on LHRH stimulated FSH in long term ovariectomized
females and in normally cycling female rhesus monkeys as evidence
of the importance of ovarian negative feedback on pituitary FSH
secretory cell activity (Mello 1986a and b). We argued that
since the ovarian peptide, inhibin, has been shown to suppress
FSH without affecting LH in several species under many conditions
(Channing et al., 1985; McCann et al., 1983) alcohol may have
enhanced the effects of inhibin in normally cycling females
(Mello et al., 1986a and b).
Alcohol's suppression of FSH but not LH in the recently ovariec-
tomized females described in this study obviously cannot be
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attributed to ovarian inhibin. It is not clear if these differ-
ences in alcohol effects on FSH between recently and chronically
ovariectomized monkeys reflect changes in the relative sensitivi-
ty of the hypothalamic-pituitary axis as a function of time after
ovariectomy or are more parsimoniously attributed to procedural
differences, i.e. measures of basal hormone levels in the present
study and LHRH stimulated gonadotropin patterns in our previous
report (Mello et al., 1986a). Our current data are consistent
with the hypothesis that there is a separate hypothalamic regula-
tory factor (FSH-RH) which controls FSH separately from LHRH
control of LH (McCann et al., 1983). These observations are also
consistent with previous reports that acute alcohol administra-
tion was associated with a significant decrease in FSH over time
in human females (Valimaki et al., 1983). Studies are now in
progress to compare the effects of alcohol on LH and FSH pulse
frequency in recently and chronically ovariectomized females and
to determine if the relative sensitivity of the hypothalamic-
pituitary axis to alcohol effects changes as a function of time
after ovariectomy.
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Adrenal Enkephalin Biosynthesis
Regulated by Glucocorticoid
C. Inturrisi, S. Franklin, J. Shapiro, S. Calvano and
B. Yoburn
Denervation of the rat adrenal results in a 10 to 20-fold
increase in enkephalin-containing EC peptides 4 days after
surgery. This denervation-induced rise in medullary EC peptides
is blocked by hypophysectomy (hypox) and partially reinstated by
dexamethasone or ACTH treatment. Culture of adrenal medullary
explants (glands) for 4 days in serum-free medium without
dexamethasone resulted in a 6-fold increase in EC peptides in
glands from hypox rats while the addition of dexamethasone (10-
5M) produced a 29 fold increase. These results indicate that a
loss of depolarizing stimuli produced by denervation in vivo or
explantation in vitro initiates a pretranslational event which
requires glucocorticoid for the full expression of EC peptide
biosynthesis.
INTRODUCTION
Although the physiological function of the adrenal EC peptides
is only now emerging, the EC peptides are co-released with the
catecholamines (CAs) (Livett et al., 1981) and may be involved
in mediating some forms of stress-induced analgesia (Lewis et
al., 1982). When depolarizing influences are removed from the
a renal medulla in vivo by surgical denervation or by
pharmacological denervation by the use of the ganglionic
blocking agent, chlorisondamine, there is a large increase in EC
peptide levels that reaches a peak at 4 days after treatment
(Fig. 1). Also, explanation of rat adrenal medulla in culture
for 4 days produces an increase similar to that seen following
denervation in vivo. Furthermore, inclusion of potassium ions
(Fig. 1) in  the culture medium prevents the culture-induced
increase in EC peptides, presumably by maintaining depolarizing
conditions (Bohn et al., 1983, Fleminger et al., 1984a,
Fleminger et al., 1984b, Inturrisi et al., 1987, LaGamma et al.,
1984, LaGamma et al.,
1987).
1985, Lewis et al., 1982, Yoburn et al.,
The major species of newly appearing EC peptide is
represented by the intact precursor proenkephalin (Fleminger et
al., 1984a, Fleminger et al., 1984b).
129
Because of the critical role played by the pituitary-adrenal
axis in stress, we have examined the influence of this system
and of glucocorticoid in the regulation of the rise in EC
peptides which occurs when the rat adrenal medulla is denervated
in vivo or placed in culture.
MATERIALS AND METHODS
Studies of glands in vitro were conducted in male Sprague-Dawley
rats nine days following hypophysectomy so that the adrenal
cortex would have atrophied and endogenous corticosterone
levels would be minimal. In some in vivo studies, nine days
following hypophysectomy, the left adrenal medulla was
denervated and the contralateral gland served as the intact,
unoperated control. In separate studies, rats were
hypophysectomized and 48 hrs later injected SC once per day with
1 mg/kg dexamethasone (N=6), 4 units adrenocorticotrophic
hormone (ACTH) (N=7) or 1 ml/kg vehicle (N=9) for eleven days.
On the eighth injection day, the left adrenal medulla was
denervated in all rats. Four days following denervation (13
days following hypophysectomy), rats were sacrificed and the
left and right medullae collected.
Rat adrenal medullary explants were cultered for 4 days in
RPMI-1640 (serum free medium) at 37° C in an atmosphere of 95%
air and 5% CO2 at nearly 100% relative humidity.
Each adrenal medulla was assayed for EC peptides as described
previously (Fleminger et al., 1984b). EC peptides were
determined by radioimmunoassay (RIA) before (Free) and after
(Total) treatment with trypsin and carboxype tidase B. The
enzymatic digestion was used to release [Met]enkephalin from
precursor peptides and allowed measurement of the Total
[Met]enkephalin content of the gland. The lower limit of
sensitivity for the EC peptide RIA is 5.6 pg and the interassay
coefficient of variation for 12 consecutive assay averaged 6.6%.
Corticosterone levels in serum and the glands were measured by
use of RIA (Keith et al., 1978). Average assay sensitivity was
12.5 ± 2 ng/ml and the mean interassay coefficient of variation
for 4 consecutive assays was 9.6%.
Data were analyzed by analysis of variance and t-tests. Post
hoc comparison were made with the one and two-tailed t-test
using the error term from the preceding analysis of variance.
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FIGURE 1. Surgical denervatfon, pharmacological denervatfon and
culture increase rat adrenal medullary EC peptides. Medullae
were collected 4 days after surgical denervation, treatment with
chlorfsondamfne (5 mg/kg) and atropine (2 mg/kg) sc, twice a day
for 4 days or explantation for 4 days in a medium of RPMI-1640
plus 10% horse serum, 5% fetal calf serum and dexamethasone
10-5M in the presence or absence of 55 mM KCl. *indicates
significantly different (p<.01) from control (untreated)
animals.
FIGURE 2. Hypophysectomy prevents the denervatfon-induced
increase in EC peptides ([Met]-enkephalin equivalents) in rat
adrenal medullae. *indicates significantly different (p<.01)
from Normal-Denervated value B. Serum cortfcosterone levels in
hypophysectomized (Hypox) and Normal rats. *indicates
sfgnfffcantly different (p<.001) from normals.
(From Yoburn et al., 1987.
Journals, Ltd.)
Copyright 1987, Pergamon
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FIGURE 3. Dexamethadone or ACTH restores the denervation-
induced increase in adrenal medullary EC peptides ([Met]-
Enkephalin equivalents) in hypophysectomized (Hypox) rats.
*indicates significantly different (p<.01) from intact value.
TABLE 1. Adrenal Medullary EC Peptides are Increased Maximally
by Culture for 4 Days in Serum Free Medium with Dexamethasone.
* significantly different from corresponding 0 day group (p<.01)
+ significantly different from corresponding 4 day group without
Dex (p<.O5)
RESULTS
Hypophysectomy completely blocked the denervation-induced increase
in EC peptides (Fig. 2A) and produced virtually a complete loss of
handling-stimulated corticosterone release (Fig. 2B).
Hypophysectomy had no effect on the low levels of EC peptides
present in the intact right gland (Fig. 2A). As shown in Fig. 3
we could partially reinstate the denervation-induced increase in
adrenal EC peptides in the hypophysectomized rat by treating with
ACTH or dexamethasone.
To more definitively examine the role of glucocorticoid, sham and
hypox glands were placed in serum free medium for 4 days and
compared with control glands obtained at the time of sacrifice. In
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the absence of dexamethasone, EC peptides increased significantly
in sham and hypox glands (Table 1). The average increase for all
experiments was 13 fold for sham and 6 fold for hypox glands.
However, the addition of dexamethasone 10-5M produced a much
greater increase in EC peptides in sham and hypox glands which
averaged, for all experiments, 24 fold for sham and 29 fold for
hypox glands. In serum free medium hypox glands show a
concentration dependent increase in EC peptides with the ED50 for
dexamethasone equal to 5.7 x 10-7M (Inturrisi et al., 1987).
The nonglucocorticoid steroids, progesterone, testosterone and
deoxycorticosterone did not alter EC peptide levels in hypox
glands (unpublished observations).
DISCUSSION
The present report demonstrates that glucocorticoid is responsible
for most of the dramatic increase in rat adrenal medullary EC
peptides that occurs when depolarizing stimuli are removed by
denervation or explantation. Hypophysectomy blocked the
denervation-induced increase by eliminating ACTH and indirectly
reducing corticosterone levels at the gland. Both ACTH, by
preserving adrenal cortical function, and dexamethasone, acting
directly on the gland, allowed expression in hypophysectomized
rats of the denervation-induced increase in EC peptides. However,
the doses of dexamethasone and ACTH chosen were apparently not
optimal for full restoration of the denervation effect in
hypophysectomized rats. Thus, taken together, these results show
that glucocorticoid but not ACTH is required for EC peptide
biosynthesis in the denervated rat adrenal.
The results obtained in culture support and extend the in vivo
observations. The stimulatory action of glucocorticoids on EC
peptides was not shared by steroids devoid of glucocorticoid
activity. When glands from sham rats are placed in glucocorticoid
free medium, EC peptide levels are significantly increased but
become dependent upon the addition of dexamethasone for full
expression. Glands from hypox rats were almost entirely dependent
upon dexamethasone for EC peptide biosynthesis (Table 1). Medullae
from sham rats contained higher levels (27 ng/gland) of
corticosterone while in isolated hypox medullae, the
corticosterone levels had decreased to less than 1% of sham glands
and were at the limits of sensitivity of the assay. Thus, in order
to completely separate the contribution of glucocorticoids, glands
from hypox animals must be employed.
In rat adrenal medullary explants, the increased levels of EC
peptides are dependent on protein synthesis and are preceded by
an increase in preproenkephalin mRNA (LaGamma et al., 1985). Thus
the effects of adrenal denervation or explantation on EC peptides
appear to be mediated at a genomic level. Glucocorticoids are known
to modulate the transcription of specific genes. In this regard a
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consensus DNA binding site for the glucocorticoid-receptor complex
on several responsive genes has been identified as the core
sequence 5' TGTC/TCT 3' (Hollenberg et al., 1985) and the rat
proenkephalin gene includes this core sequence (Rosen et al. ,
1984).
The physiological response of the adrenal medulla to stress
includes increases in both transsynaptic impulse activity and
glucocorticoid levels. The recognition that both of these factors
are capable of regulating EC peptides as well as catecholamines
adds significantly to our understanding of the complexity involved
in the physiological response to stress and may point the way to
new approaches to define the sites of action and potential
therapeutic utility of EC peptides.
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Neuroadaptation of Rats to Kappa
Agonists U-50,488 and Tifluadom
C. Murray and A. Cowan
INTRODUCTION
Analgesic pharmacologists have long been interested in the behavioral
disturbances that appear after abrupt withdrawal of opioids from chronically
dosed animals, or after challenging these animals with narcotic antagonists
such as  naloxone.  Agonists  a t  mu opioid receptors  have been used
extensively in this type of research. Agonists showing selectivity for kappa
opioid receptors have only recently become available for study. The current
view is that agents of the latter class (e.g., U-50,488) are not associated with a
morphine-like withdrawal syndrome, at least in mice and rats [Tang and
Collins, 1985; Cowan et al., 1986]. This belief has helped to reinforce the
concept of developing selective, nonbenzomorphan kappa agonists (e.g.,
spiradoline) as clinically useful analgesics.
The question arises, however, as to whether or not rodents demonstrate any
neuroadaptation in response to sustained administration of a kappa agonist
such as U-50,488H (U50; Upjohn) or (±)tifluadom (TIF; Kali-Chemie).
Second, if neuroadaptation occurs, to what extent can it be unveiled by
traditional approaches such as abrupt withdrawal or challenge with opioid
antagonists? Third, if such adaptation can be revealed, and is accepted as
evidence of physical dependence of the kappa type, does tolerance develop in
parallel? These issues are addressed in the present report
MATERIALS AND METHODS
Animals. Male Sprague Dawley albino rats (Zivic-Miller Laboratories, 200-275
g), male ICR mice (Temple University Skin and Cancer Hospital, 25-35 g), and
male Hartley guinea pigs (Charles River, 250-350 g) were used. They were
housed 5 per cage with food and water availablead libitum. A 12 hr light/
dark cycle was maintained (lights on at 7:00 a.m.; all experiments were carried
out during the light phase).
Chronic U50 administration. Method 1: Osmotic minipumps (model 2001,
Alzet) were implanted s.c. in rats, mice and guinea pigs. These pumps had a
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fill volume of 237 ± 14 (S.D.) µl and released U50 at a rate of 18 µg/hr.
Antagonists were given 4 d after implantation. Method 2: Eats were injected
s.c. with U50 at 8:30 a.m. and 8:30 p.m. over 5 d. On the fifth day, only the
morning inject ion was given.  ( In  the case of  the abrupt  withdrawal
experiment, this ninth injection was omitted.) Doses were: day 1 - 10 mg/kg;
day 2 - 20 mg/kg; days 3 to 5 - 40 mg/kg. A similar experiment was done in
which the doses were ten times lower. This procedure was also carried out
with (±)-TIF using doses of 3.5 and 0.35, 7 and 0.7, and 14 and 1.4 mg/kg, s.c.,
respectively. If antagonists were to be given, they were administered 4 h after
the last agonist injection. For both methods, on day 4 the animals were
acclimated to their plexiglass observation cages in a constant temperature
room (20 ± 1 °C) for 1 hr, then trained to have their weights and rectal
temperatures taken with a minimum of stress. On day 5, this procedure was
repeated (after the last agonist dose for method 2) before baseline readings and
antagonist injections.
Endpoints. (a) During abrupt withdrawal, the following behaviors (presumed
to be evidence of physical dependence) were counted for one 15 min and four
30 min observation periods starting at 10:00 a.m. on day 5: licking of the
mouth/tongue protrusions; chewing movements; gnawing of the bedding
and/or feces; repetitive sniffing of the bedding; yawning; coughing; rearing;
“wet dog’ shakes. (b) After antagonists change in rectal temperature from t=0
(just before antagonist injection) to t=60 min post-injection; weight loss over
same time span; “wet dog” shakes - counted for 30 min post-injection;
rearing - counted for 30 min post-injection; other behaviors as listed in
Tables 3-5; general behavior/affect - observed for 60 min post-injection,
checked periodically over the following 5 hr.
Abrupt withdrawal study. Ten rats were given the course of U50 injections
described above; in parallel, 10 rats were given saline injections. Behavioral
observations commenced at 8:30 a.m. of day 5, using the endpoints outlined
above.
Antagonist studies. (a) Osmotic minipumps. Five mice and 4 guinea pigs
were each implanted with minipumps containing U50; 4 days later they were
injected with buprenorphine (1 mg/kg, s.c., NIDA) and observed for signs of
abstinence. Rats (n=20 overall, n=5 per group) were similarly implanted and
on day 4 received buprenorphine (0.1, 1, and 10 mg/kg, s.c.) or naloxone (3
mg/kg, s.c., Endo). In parallel, 20 rats were sham operated and received the
same doses of buprenorphine; the fourth group was injected with saline as a
baseline control for the weight and temperature data. (b) Repeated injections.
Using the schedules detailed above, rats (n=4-10 per group) were injected with
U50, TIF, or saline over 5 days. On day 5, buprenorphine (high and low dose
U50/TIF regimens) or naloxone (high dose U50 regimen only) were injected
s.c. and the animals were observed for behavioral signs of abstinence;
temperature and weight changes were also recorded. The antagonist doses
were 1 mg/kg of buprenorphine and 3 mg/kg of naloxone, respectively.
Tolerance studies. U50 was administered to rats at 18 mg/kg, s.c. After 30
min, the animals were assessed for antinociception using the hypertonic
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saline (4% NaCl, i.p.) writhing test [Collier and Schneider, 1969). Only the
animals in which this dose of U50 was analgetic were selected. One group
(n=16) was implanted with minipumps containing U50 (see above); a second
control group (n=14) was sham-operated. Four days later the same dose of
U50 was evaluated in these 30 rats. This experiment was also carried out via
the course of U50 injections described above, save that an 18 mg/kg test dose
took the place of the first 10 mg/kg injection (n=10 each for U50 and parallel
vehicle injections). The 18 mg/kg dose for the test on day 5 was given 3 hr
after the last 40 mg/kg dose. We defined tolerance as the inability of the same
dose of U50 to produce analgesia in an animal after a chronic exposure to U50.
RESULTS AND DISCUSSION
The data summarized in Table 1 set the scene for the present range of
experiments .  Abrupt  withdrawal  f rom U50 in rats  t r iggered a  higher
incidence of dopaminergic/muscarinic behaviors than was seen with vehicle
control animals. This set of behaviors was not observed when U50 was
del ivered from minipumps and the rats  chal lenged with naloxone or
buprenorphine, an analgesic with kappa antagonist properties in vivo
[Richards and Sadée, 1985; D.E. Gmerek, personal communication]. Signs of
morphine-like abstinence were also absent in these rats (Table 2), as well as in
mice and guinea pigs receiving U50 from minipumps (data not shown).
Of great interest was our finding that dopaminergic/muscarinic behaviors
(oral stereotypies - gnawing, tongue protrusion, cage licking; Figure 2) were
precipitated by buprenorphine challenge in rats receiving injections of U50.
This  observat ion was unexpected s ince dogma would have i t  that  a
continuous supply of agonist to opioid receptors is more likely to provoke
neuroadaptation than twice-daily injections. Buprenorphine-induced oral
stereotypies were dependent on the doses of U50 and TIE (Tables 3 and 4), had
an onset of about 5 min, and lasted for more than 4 hr. As part of a syndrome,
these rats also demonstrated a high degree of general behavioral activation
(e.g., agitation, rearing) vs. controls. Similarly, naloxone precipitated
behavioral  changes in rats  receiving U50 by inject ion but  not  from
minipumps. In this case, increased yawning and writhing were noted (Table
5) whereas marked changes in temperature and weight did not occur.
Importantly, the behaviors mentioned in this paragraph were not observed
when buprenorphine (1 mg/kg), naloxone (3 mg/kg) or sufentanyl (1 µg/kg)
were given s.c. to rats 4 hr after a large standard dose of U50 (40 mg/kg, s.c.)
(data not shown). In general, the syndrome precipitated by antagonist
injection was more intense than that brought about via abrupt withdrawal.
Data from the tolerance study are presented in Figure 1. Tolerance clearly
develops to the antinociceptive action of U50 in the rat hypertonic saline test
when this kappa agonist is delivered s.c. from minipumps or via twice-daily
injections.
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TABLE 1. Summary of behavioral data from abrupt withdrawal study. Values
represent the mean ± S.E.M. number of episodes of the indicated behavior from the
five observation periods (see Methods for details). *pp<0.05, **p<0.01, Mann-Whitney
U test vs. saline controls (n=10 per group; vehicle control data not shown to conserve
space).
TABLE 2. Summary of precipitated abstinence data in rats given chronic U50 by
osmotic minipump and subsequently challenged with buprenorphine (B) or naloxone
(Nx). Data are mean values from indicated time or observation period after injection
of B or Nx. Doses [in square brackets] are in mg/kg, s.c. (n=5 per group; values in
parentheses are S.E.M.)
TABLE 3. Number of rats per group showing oral stereotypy (cage licking)
precipitated by buprenorphine (1 mg/kg, s.c.) after chronic dosing with U50 or saline.
High dose regimen was from 10 to 40 mg/kg (s.c.); low dose regimen was from 1 to 4
mg/kg (s.c.). See Methods for details. *p<0.025, Fisher’s exact test vs. saline control
animals.
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TABLE 4. Effects of buprenorphine [2 mg/kg, s.c.] in rats given chronic
tifluadom 13.5 to 14 mg/kg, s.c.] and chronic vehicle injections. Values
represent the mean ± S.E.M. rectal temperature change (AT), body weight (wt.)
change, or number of episodes of the indicated behavior during the listed
observation periods (times are post-antagonist injection; see Methods for
details). NS = not significant vs. vehicle controls, Student t test; *p<0.05,
**p<0.01, Mann-Whitney U test vs. vehicle controls (n = 20 per group).
TABLE 5. Effects of naloxone [3 mg/kg, s.c.] in rats given chronic U50 [10 to 40
mg/kg, s.c.] and chronic vehicle injections. Values represent the mean ±
S.E.M. number of episodes of the indicated behavior counted for 30 min post-
antagonist injection; see Methods for details). *p<0.05, * *p<0.01, Mann-
Whitney U test vs. vehicle controls (n = 9 for USO; n = 5 for vehicle).
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FIGURE 1. Results of tolerance experiments. Upper panel: Study in which U50 was
delivered via osmotic minipump (n=16 for U50; n=14 for sham operated). Lower panel:
Study in which U50 was given by repeated injections (n=10 per group). Analgesic test
was i.p. hypertonic saline writhing. *p<0.05 Fisher’s exact test vs. control group. See
Methods for details.
FIGURE 2. Examples of rats exhibiting oral stereotypies resulting from
injection of buprenorphine after chronic treatment with a kappa agonist. Left
panel constant gnawing of bedding/feces; right panel: persistent licking of
cage walls.
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SUMMARY
1. When U50 was given to rats over 5 d by twice-daily s.c. injection (but not
when delivered by osmotic minipump), buprenorphine and naloxone each
precipitated strong, qualitatively distinct, behavioral syndromes.
2. The same dose of buprenorphine provoked similar behaviors in rats
given chronic U50 and chronic TIF (analogous s.c. injection protocols),
suggestive of neuroadaptation to kappa agonists as a class. This adaptation
clearly contrasts with that to chronic mu agonists.
3 .  The buprenorphine-induced syndrome was character ized by oral
stereotypies which had an onset of about 5 min and a duration greater than 4
hr. The intensity was dependent on the dose of agonist injected.
4. The naloxone-induced syndrome was characterized by repetitive yawning
and writhing.
5. If oral stereotypy, yawning and writhing are considered to represent an
abstinence syndrome, then it will be necessary to use multiple or more
selective kappa antagonists to fully unveil kappa dependence in the rat.
6. The present data indicate a strong trend toward the parallel development
of tolerance in rats given a similar course of chronic U50 injections as those
tested for physical dependence.
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Precipitation of Spinally Mediated Withdrawal
Signs by lntrathecal Administration of
Naloxone and the Mu-Receptor Antagonist
CTP in Morphine-Dependent Mice
J. Shook, W. Kazmierski, V. Hruby and T. Burks
ABSTRACT
We evaluated the ability of naloxone and the mu receptor antag-
onist CTP ( ) to precipitate
withdrawal in morphine-dependent mice after intrathecal (i.t.)
administration. The withdrawal syndromes elicited by naloxone and
CTP given i.t. were compared to those of CTP or naloxone injected
intracerebroventricularly (i.c.v.). When given i.t. or i.c.v.,
naloxone produced the classical syndrome of events including
jumping, wet dog shakes, urination, defecation followed by
diarrhea, and weight loss. There was no significant difference in
the potency or efficacy of naloxone when it was given i.t. or
i.c.v. The profile of withdrawal effects produced by i.t. CTP
resembled that caused by i.c.v. CTP; both were different from that
of naloxone. The withdrawal signs seen following both i.t. or
i.c.v. CTP included wet dog shakes and defecation. Mice treated
with i.t. CTP lost significantly less body weight than those
treated with i.c.v. CTP. In addition, i.t. and i.c.v. CTP did
not stimulate jumping behaviors or diarrhea. In contrast, while
i.c.v. CTP resulted in increased incidence of urination, CTP given
i.t. did not. These finding indicate that naloxone given spinally
acts on mu receptors to precipitate wet dog shaking and defeca-
tion, but acts on other non-mu opioid receptors (i.e. delta and/or
kappa) to cause jumping, urination, diarrhea and weight loss. The
differential effects of CTP given i.c.v. or i.t. suggest that
supraspinal mu receptors are more involved in gastrointestinal and
urinary bladder function during dependence/withdrawal than their
spinal counterparts. This in turn implies that another non-mu,
spinal opioid receptor (i.e. delta or kappa) is a more important
regulator of visceral function in withdrawal than spinal mu recep-
tors. Both spinal and supraspinal mu receptor mechanisms may be
related to wet dog shake behaviors.
INTRODUCTION
We have previously reported that the cyclic octapeptide CTP
( ) displays selective
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mu receptor antagonist activity in radioligand binding assays
(Pelton et al., 1985; Gulya et al., 1986), in the guinea pig ileum
and mouse vas deferens bioassays (Shook et al., 1987a) and in
mouse analgesic and gastrointestinal transit time tests (Shook et
al., 1987b). CTP injected i.c.v. has also been shown to produce
a distinct profile of withdrawal effects in morphine-dependent
mice, which is different from that of naloxone given i.c.v. (Shook
et al., 1986). CTP given i.c.v. caused dose-related increases in
wet dog shakes, urination, defecation and weight loss which were
equal to, or greater in magnitude, than those caused by i.c.v.
naloxone (Shook et al., 1986). CTP given i.c.v. did not stimulate
withdrawal jumping or diarrhea, even at very high doses (Shook et
al., 1986). The differences in withdrawal signs elicited by
i.c.v. CTP and i.c.v. naloxone may be attributed to their dif-
ferences in receptor selectivity. Naloxone, which interacts with
all known opioid receptors, should precipitate withdrawal effects
associated with all receptor types rendered dependent by chronic
morphine treatment, whereas CTP should only precipitate withdrawal
effects associated with the mu receptor. Accordingly, wet dog
shakes, urination, defecation and weight loss are probably
mediated by supraspinal mu receptors, precipitated by i.c.v. CTP
while jumping and diarrhea may be mediated by other non-mu,
supraspinal opioid receptors (i.e. delta or kappa).
In the present study we evaluated the ability of spinally-
administered naloxone and CTP to precipitate withdrawal in
morphine-dependent mice. Naloxone and CTP given i.c.v. were
included as standards of reference. All observations were limited
to the first 15 min following injection ino order to avoid misin-
terpretation of data due to redistribution of drugs outside of the
spinal compartment.
METHODS
One 75 mg morphine-base (or placebo) pellet was implanted sub-
cutanously in male ICR mice (20-259) under ether anesthesia.
Following pellet implantation, mice were housed 3 per cage under
standard 12 h light, 12 h dark conditions, and received food and
water ad libitum. Experimentation started at 72 h following
pellet implantation. Each mouse was weighed, and injected i.t. or
i.c.v. with naloxone, CTP or distilled water (vehicle). Mice were
then observed for the 15 min period immediately following injec-
tion. The behavioral and physiological signs recorded were
jumping, wet dog shakes, urination, defecation and diarrhea. Body
weights were redetermined at 15 min following injection, and loss
of body weight was calculated as a percent of each animal's pre-
injection body weight.
CTP was synthesized as previously described (Pelton et al., 1986).
Naloxone was purchased from Sigma (St. Louis, Mo.). Morphine base
pellets were received from the National Institute on Drug Abuse
(Rockville, Md.).
144
Intrathecal (i.t.) injections were carried out according to the
methods of Hylden and Wilcox (1980) in a total volume of 5 ul.
Intracerebroventricular (i.c.v.) injections were made in a total
volume of 3.0 or 3.3 ul, according to the methods of Porreca et
al., (1984).
Statistical differences were determined by ANOVA and the t-test
for grouped data as described by Tallarida and Murray (1981).
RESULTS
Morphine pelleted mice injected i.t. with distilled water showed
mild weight loss (loss at 15 min was 1.6+.4%) and defecation
(71%). Those injected with i.c.v. distilled water also showed
weight loss (loss at 15 min was 1.6+.2%) and defecation (75%).
No jumping, wet dog shakes, urination or diarrhea were seen in
placebo or morphine pelleted mice injected with distilled water
given i.t. or i.c.v.
Naloxone given i.t. stimulated dose-related increases in jumping,
wet dog shakes, urination, defecation and diarrhea (Table 1) and
loss of body weight (Table 2). When injected i.c.v. at the same
doses, naloxone produced a pattern of withdrawal responses iden-
tical to that produced by i.t. naloxone (Table 1). The magnitude
of weight loss following i.t. naloxone was also similar to that
caused by the same doses of naloxone given i.c.v. (Table 2).
CTP administered i.t. resulted in dose-related increases in wet
dog shakes and the percent of mice to defecate, but did not stimu-
late jumping, nor did it increase the number of mice with diarrhea
or micturition (Table 1). Weight loss was not significantly
greater than control (i.t. distilled water) after i.t. CTP (Table
2). When given i.c.v., CTP produced the same profile of signs as
equal doses of i.t. CTP, with the exceptions of (1) i.c.v. CTP
increased the number of mice which urinated, and i.t. CTP did not
(Table 1), and (2) i.c.v. CTP resulted in a significant degree of
weight loss and i.t. CTP did not (Table 2).
For both naloxone and CTP, as the dose was increased, the time of
onset decreased, with the 10 ug doses producing almost immediate
effects. The 10 ug dose of CTP given subcutaneously (s.c) did not
precipitate any withdrawal signs. The same dose of naloxone given
s.c. did precipitate measureable withdrawal signs, but with
delayed onset of action (greater than 10 min).
DISCUSSION
These results demonstrate that spinally located opioid receptors
are affected by chronic morphine exposure, and contribute, at
least in part to the withdrawal syndrome evoked by administration
of an opioid antagonist. The similar response of morphine-
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Table 1. Comparison of the effects of intracerebroventricular and
intrathecal administration of naloxone or CTP in morphine-
dependent mice.
an=6/dose
bn=8/dose
Tabel 2. Comparison of the effects of intrathecal or intra-
cerebroventricular administration of naloxone or CTP on weight
loss of morphine-dependent mice at 15 minutes following injection.
an=6/dose
Bn=8/dose
*significant difference from control (p>O.O5)
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dependent mice to naloxone given i.c.v. or i.t., suggests that
spinal opioid receptors are affected by chronic morphine to about
the same degree as supraspinal opioid receptors. We cannot be
absolutely sure that spinal opioid receptors are solely respon-
sible for causing its effects because the highest dose (10 ug) of
naloxone tested was also active upon systemic administration. The
delayed onset of action following s.c. and immediate onset
following i.t. administration indicate that spinal receptors are
at least partially involved in mediating the effects of 10 ug i.t.
naloxone, as it is unlikely naloxone could redistribute outside
the spinal compartment in significant amounts immediately
following injection.
The differences in withdrawal signs produced by naloxone and CTP
are probably related to their differences in receptor selec-
tivities. Naloxone interacts with all known opioid receptors, and
CTP interacts only with the mu receptors. That naloxone (i.c.v.
or i.t.) produced an array of effects consistent with, but greater
than that caused by the mu-receptor antagonist CTP, suggests that
chronic morphine exposure results in changes in other opioid
receptors, in addition to the mu receptor. Based on the assump-
tion that CTP will precipitate only those signs associated with
the mu receptor, it appears that supraspinal mu receptors mediate
wet dog shaking behaviors, gastrointestinal motility (but not
secretion) and urinary bladder motility in morphine-dependent
mice. The loss of urine and fecal weight may be responsible for
the weight loss seen after i.c.v. administration of CTP. In
contrast, spinal mu receptors do not regulate urinary bladder
motility in morphine-dependent mice, but do influence gastroin-
testinal motility and wet dog shaking behaviors. These findings
imply that other non-mu, supraspinal opioid receptors mediate
jumping behaviors, gastrointestinal secretion, jumping, and uri-
nary bladder motility. Although the identity of the particular
non-mu opioid receptors that mediate these effects is not known,
they may be delta or kappa related functions. Interestingly,
supraspinal delta receptors have been proposed to exert intestinal
antisecretory actions (Shook et al., 1987c), and spinal delta
receptors have been shown to have an inhibitory influence on uri-
nary bladder motility (Dray et al., 1984). Through combination of
the effects produced by acute administration of highly selective
receptor antagonists with the effects caused by receptor selective
antagonists in morphine-dependent mice, we hope to identify
further the fucntions associated with each receptor.
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Effects of 5,7-Dihydroxytryptamine Lesions
of the Nucleus Accumbens in Rats Responding
on a Concurrent Schedule of Food, Water and
Intravenous Morphine Self-Administration
S. Dworkin, G. Guerin, C. Co, J. Smith and N. Goeders
ABSTRACT
The role of serotonergic innervations of the nucleus accumbens
in the processes maintaining intravenous self-administration
was assessed in rats responding on a concurrent schedule of
food, water and morphine presentations. Five rats were trained
on a concurrent fixed-ratio schedule of food and water
presentation. They were then implanted with intravenous
jugular catheters and bilateral injection guide cannulae into
the central medial nucleus accumbens, made physically dependent
on morphine and allowed to choose between intravenous morphine,
food and water deliveries. A three-lever choice procedure
provided almost continuous access to the three reinforcers.
Dose-effect curves were determined by the substitution of the
daily dose of morphine (3.3 mg/injection) with other doses
(0.83-13.2 mg/injection) or eliminating drug injections
(extinction) for 24 hour periods. The behavioral effects of 24
hour food extinction probes were also determined. The rats
subsequently received bilateral microinjections of either the
vehicle or 5,7-dihydroxytryptamine (5,7-DHT) into the nucleus
accumbens. Following the lesion, response independent
infusions of morphine were delivered for 24 hours at the
previous rate of self-injection. The animals were placed back
on the concurrent schedule and morphine dose-effect curves were
redetermined. The 5,7-DHT lesion resulted in a significant
dose-related decrease in morphine self-administration, and
little or no effect on responding maintained by food or water
presentations. Serotonergic innervations of the nucleus
accumbens appear to participate in the neuronal activity
mediating intravenous morphine self-administration.
INTRODUCTION
Innervations and projections of the nucleus accumbens are
involved in the neuronal activity modulating the control of
behavior by drugs of abuse. The role of these systems have
been assessed using standard drug self-administration
procedures. Lesions of dopaminergic inputs to the nucleus
149
accumbens decrease intravenous cocaine (Roberts et al., 1977;
Roberts et al., 1980), amphetamine (Lyness et al., 1979) and
increase morphine (Smith et al., 1985) self-administration.
Lesions of intrinsic neurons and afferents of the nucleus
accumbens decrease cocaine and heroin self-administration (Zito
et al., 1985). 5,7-Dihydroxytryptamine lesions of serotonergic
innervations of this brain region increase both amphetamine
(Lyness et al., 1980) and morphine self-administration (Smith et
al., 1987).
Evaluations of the behavioral effects of neurobiologic
manipulations require the use of multiple baselines to assess
the specificity of the observed changes (Dworkin and Smith,
1987). For example, 6-hydroxydopamine lesions of the nucleus
accumbens decreases the self-administration of cocaine but have
little or no effect on heroin self-administration in rats
trained to self-administer both drugs (Pettit et al., 1984).
The behavioral specificity of two neurotoxin lesions of the
nucleus accumbens has been determined using a procedure that
allows for the simultaneous assessment of the reinforcing
effects of food, water and morphine. 6-OHDA lesions have
little or no effect on responding maintained by a concurrent
schedule of food, water and intravenous morphine availability
(Dworkin et al., 1987b), while kainic acid lesions result in a
selective decrease in morphine self-administration (Dworkin et
a l., 1987a). This study evaluated the effects of 5,7-DHT
lesions on responding maintained by the concurrent schedule of
food, water and intravenous morphine.
METHODS
Five adult male inbred rats developed from the Fischer 344
strain, weighing between 275-325 g at the beginning of training
were used. Each rat was implanted with a chronic indwelling
jugular catheter and bilateral guide cannulae aimed into the
central medial nucleus accumbens. The rats were continuously
housed in standard operant conditioning chambers containing
three retractable levers, a stimulus light above each lever, a
tone source, a pellet dispenser, a water dipper and a motor
driven syringe pump. An additional light mounted above the
Plexiglas top of the chamber illuminated the chamber from
5:00 p.m. to 5:00 a.m., providing a reversed 12 hr light/dark
cycle. The training procedure used has been described in
greater detail (Dworkin et al., 1984). Briefly, the subjects
were trained to respond on three levers under a concurrent
chained schedule of reinforcement. The first response on any
lever resulted in the retraction of the other two. Nine
additional responses on the extended lever resulted in the
presentation of the chosen reinforcer. The rats were given 100
seconds to complete the nine responses after the initial
response on one of the three levers (limited hold or LH). In
addition, a 30 second time out followed the presentation of
each reinforcer or elapse of the limited hold. The subjects
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had continuous 24 hour exposure to the schedule contingencies.
During the food extinction probes food pellets were not
delivered, the 3.3 mg/infusion dose of morphine was available
and all other aspects of the schedule were unchanged.
Morphine sulfate was dissolved in a bacteriostatic 0.9% sodium
chloride solution. Dose-effect relationships were determined,
before and after lesions of the nucleus accumbens, by replacing
the daily dose of morphine available (3.3 mg/injection) with
other doses (0.83-13.2 mg/infusion) or eliminating drug
injections for 24 hours. At least two determinations for each
dose were made.
The rats were pretreated with desmethylimipramine (30 mg/kg,
i/p/) 30 min prior to being anesthetized with methohexital (1
mg/kg, i.v.). Forty-five minutes after the desmethylimipramine
treatment, 0.5 ul of either the vehicle (isotonic saline-0.02%
ascorbic acid) or 5,7-DHT (6 ug in isotonic saline-0.02%
ascorbic acid) was bilaterally injected into the central medial
nucleus accumbens over 7.5 min. The injection was made through
30-gauge injection cannulae extending 0.5 mm below the guide
cannulae. They were left in place an additional 10 min after
the neurotoxin injection.
RESULTS
Responding maintained by the schedule contingency was very
similar to those previously reported (Dworkin et al., 1984).
Increasing the dose of morphine available for
self-administration resulted in a dose-related decrease in
responding on the morphine lever and a modest dose-related
increase in responding on the water lever. Responding on the
food lever was not altered by changes in the morphine dose.
The major effect of food extinction was a large increase in
responding on the drug lever, while the most significant effect
of morphine extinction was to almost completely eliminate
responding on the water lever.
The effects of the vehicle lesion are displayed in Figure 1.
The vehicle lesion of the nucleus accumbens did not result in
any significant changes in the number of ratios completed on
the levers that resulted in food or drug delivery. The only
significant effect observed was a small increase in responding
on the water lever when the largest dose of morphine (13.2
mg/infusion) was available and a greater decrease in responding
on the water lever during morphine extinction sessions.
Figure 2 shows the effects of the 5,7-DHT lesion on responding
maintained by food, water and morphine. The neurotoxin
microninjection resulted in statistically significant decreases
in the self-administration of the two lowest doses of morphine
investigated.
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FIGURE 1. Dose-response curve for the number of fixed ratios
completed on the food (top, left panel), water (top, right
panel) and morphine lever (bottom panel). Symbols above
"F.EXT" and "M.EXT" indicate the effects of food and morphine
extinction probes, respectively. Points indicated by open
circles represent the values observed before the vehicle lesion
and the open triangles depict data collected following the
vehicle lesion. The points are means of at least two
determinations in two subjects. The vertical lines above the
circles indicate +I standard deviation and the vertical lines
below the triangles indicate -1 standard deviation.
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FIGURE 2. Dose-response curve for the number of fixed ratios
completed on the food (top, left panel), water (top, right
panel) and morphine lever (bottom panel). Symbols above
"F.EXT" and "M.EXT" indicate the effects of food and morphine
extinction probes, respectively. Points indicated by open
circles represent the values observed before the 5,7-DHT lesion
and the open triangles depict data collected following the
neurotoxin lesion. The points are means of at least two
determinations in three subjects. The vertical lines above the
circles indicate +1 standard deviation and the vertical lines
below the triangles indicate -1 standard deviation. The
neurotoxin lesion did not result in any significant changes in
responding on the food or water levers during any of the
conditions investigated. The "*" indicate points that are
statistically different (p < .05) for responding on the
morphine lever.
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Responding maintained by the largest dose of morphine however,
was not altered by the lesion. Furthermore, the neurotoxin
lesion did not result in any significant changes in responding
on the food or water levers during any of the conditions
investigated.
CONCLUSION
Serotonergic innervations of the nucleus accumbens are involved
in the reinforcing aspects of morphine. Lesions of these
neurons with 5,7-DHT decreased morphine self-administration.
The observation that larger doses of the drug can overcome the
effect suggests that the reinforcing efficacy of lower doses
has been reduced. The effect on drug intake is not the result
of non-specific changes in motor output since responding on the
food lever was not altered and responding on the water lever
was slightly increased. Thus, the decrease in responding
occurred only on the morphine lever. Lesions of the
serotonergic innervations of the nucleus accumbens selectively
attenuated the reinforcing efficacy of morphine.
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An Approach to the Paradoxes of
Experimental Opiate Dependence
J. Villarreal, L. Silazar, J. Herrera and S. Cruz
INTRODUCTION
Experimental  analysis .  of  ear ly opiate  dependence in the neuronal
p l e x u s  o f  t h e  g u i n e a  p i g  i l e u m  h a s  l e d  t o  a  f o r m a l  t h e o r y  o n  t h e
n a t u r e  o f  t h i s  t y p e  o f  d e p e n d e n c e  ( V i l l a r r e a l ,  e t  a l . ,  1 9 8 5 ,  1 9 8 6 ,
and 1987a). The new theory provides a formal definition of depend-
ence  wh ich  i s  ana ly t i c a l  and  quan t i t a t i ve . I n  t h e  p r e s e n t  p a p e r
we take up some of the outstanding paradoxes of experimental opiate
dependence as  these occur  in  different  organisms and preparat ions
with  the  purpose of  tes t ing whether  or  not  the  new theory throws
l ight  on these pharmacologic  phenomena for  which no reasonable
solutions were previously known. It will be seen that these paradoxes
of dependence can now begin to be understood as peculiar but never-
theless quite natural expressions of the basic mechanisms of abstin-
e n c e  a n d  d e p e n d e n c e  p r o p o s e d  i n  t h e  n e w  t h e o r y ,  a s  p a r t s  o f  a
single coherent whole. Space,  l imitat ions al low only a succint  pre-
sentat ion of  the paradoxical  phenomena and the reader  is  referred
to the paper of Villarreal and Castro (1979) for details.
THE NATURE OF OPIATE DEPENDENCE
The theory of  opiate  dependence derived from work on the isolated
ileum is based’ on the experimental features of the kinetic behavior
of  the abst inence response. The re  i s  c l ea r  ev idence  t ha t  op i a t e
abs t i nence  i s  med ia t ed  by  a  r a t e - coup led  r ecep to r  sy s t em. There
is also clear evidence that opiate dependence is a concretely defina-
ble hypertrophy of  the rate-coupled receptor  system which mediates
abstinence. A  ra t e -coup led  sys t em is  ope ra t iona l ly  de f ined  a s  a
system mediat ing responses tha t  a r e  i n f luenced  by  t empora l ly -de -
termined variables  such as  the rate  constants  of  the drug-receptor-
e f f ec to r  sy s t em a s  we l l  a s  t he  r a t e  o f  d rug  admin i s t r a t i on  o r  o f
i ts  disappearance from the medium. Responding is  of  course in-
f l uenced  by  t he  s imp le  pa s sage  o f  t ime  i na smuch  a s  r a t e - coup l ed
systems give responses which show fade from an early peak effect .
Basical ly,  rate-coupling is  taken to mean that  the relat ionship bet-
ween receptor occupation and the production of the primary pharma-
cologic stimulus is not fixed but changing, and that such relationship
depends on temporal  variables. We  l ea rned  t h i s  i dea  f rom Pa rdo
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and Magana (1959).
Before the development of the new model there was no mathematical
f r a m e  o f  r e f e r e n c e  o f  d r u g - r e c e p t o r  t h e o r y  t o  h e l p  u s  h a n d l e  t h e
r a t e - c o u p l e d  n a t u r e  o f  t h e  a b s t i n e n c e  r e s p o n s e  a n d  e v e n  l e s s  t h e
dynamics of  modes of  responding which gradual ly shif t  f rom rate-
coupled towards occupation-coupled behavior. D iag ram I  o f  f i gu re
1  p r e s e n t s  t h e  m o d e l  s y s t e m  p r o p o s e d  t o  m e d i a t e  t h e  a b s t i n e n c e
response precipitated by antagonists. It consists of receptor-effector
elements  which are  act ivated by the onset  of  binding of  antagonist
molecules. After  the onset  of  act ivat ion,  the drug-receptor-effector
complex becomes inact ivated at  a  rate  determined by i ts  own rate
constant of inactivation (kt). Such rate of inactivation is independent
of the rate of chemical association (k1) or dissociation (k2) between
drug and receptor . T h e  i n a c t i v a t e d  e f f e c t o r  m a y  r e m a i n  s o  f o r
a while  in a  s tate  of  refractoriness and regain susceptibil i ty for
a new activation with a rate constant k4.
A second component  of  the theory proposes that  opiate  dependence
cons i s t s  i n  a  g r adua l  p rog re s s ive  i nc r ea se  i n  t he  ha l f - l i f e  o f  t he
act ive s tates  of  the receptor-effector  elements  which mediate  abs-
tinence. This proposit ion is supported by experimental  evidence
a n d  b y  s t u d i e s  o f  m a t h e m a t i c a l  s i m u l a t i o n  o f  t h e  b e h a v i o r  o f  t h e
ra t e -coup led  r ecep to r  mode l  (V i l l a r r ea l  e t  a l., 1985 and 1986).
The increased halflife of effector activation is represented mathema-
tically by a reduced kt.
T H E  N A T U R E  O F  O P I A T E  A B S T I N E N C E  P R E C I P I T A T E D  B Y
ANTAGONISTS.
T h e r e  a r e  t w o  a s p e c t s  o f  t h e  r e s p o n s e  o f  a n t a g o n i s t - p r e c i p i t a t e d
abstinence which specially have to be considered. One is  i t s  in ten-
sity. The other  is  the qual i ty  of  drug act ion of  the opiate  antago-
nist, namely, whether its action is abstinence-producing or abstinence-
blocking or a  m i x t u r e  o f  t h e  t w o . The important  determinants
of  these aspects  of  drug act ion are  the ra te  constants  of  the drug-
r e c e p t o r - e f f e c t o r  s y s t e m  a n d  t h e  r a t e  o f  a c c e s s  o f  t h e  a n t a g o n i s t
to the receptor pool.
To  i l l u s t r a t e  t he  mode l  w i th  a  p l aus ib l e  phys io log ica l  equ iva l en t ,
a n  a b s t i n e n c e  s y n d r o m e  m i g h t be  conce ived  a s  t he  mac roscop ic
resul t  of  the temporal  summation of  exci tatory depolarizing micro-
events, e a c h  p r o d u c e d  b y  t h e  o n s e t  o f  b i n d i n g  o f  a n  a n t a g o n i s t
molecule to a  receptor . The microevents  take place in opiate-sen-
s i t ive  neurons a n d  c o m e t o  p r o d u c e  p r o p a g a t e d  n e u r o n a l  a c t i o n
p o t e n t i a l s  w h e n  t h e  m i c r o e v e n t s  o c c u r  a t  a  r a t e  s u f f i c i e n t l y  h i g h
to al low them to summate and therefore depolar ize the local  mem-
brane potent ia l  up to  the neuronal  threshold.  Early in  dependence,
the rate  of  microevent  product ion required to produce ful ly propa-
ga t ed  r e sponse s  i s  ve ry  h igh  because  t he  mic roeven t s  a r e  b r i e f .
Otherwise, i f  the rate  of  exci tatory microevent  production is  very
slow, as with a very slow infusion of an opiate antagonist, the micro-
events wil l  occur but  they wil l  do so only at  relat ively long inter-
vals. Under  these condi t ions, t h e  m i c r o e v e n t s  w i l l  n o t  s u m m a t e
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FIGURE 1. Two different kinetic mechanisms for opiate abstinence. Antagonist-
precipitated abstinence is proposed to operate as in I; antagonist molecules
can be free as "A" or bound to a receptor as "AR". Abstinence produced by
opiate withdrawal is proposed to operate as in II: opiate molecules can be
free as "O" or bound to a receptor as "CR". onmditian of phramacologic
activation of the receptor-effector element is indicated by Ract. The constant
kt expresses therate of decay of this active state. The abstin-
ence response is proportional to Ract. Dependence is denoted by a reduced
k t .
and consequently no propagated responses will be produced. Never-
theless,  the receptors  wil l  be chemical ly occupied by the antagonist
g i v e n  i n  t h e  s l o w  i n f u s i o n  a n d  t h u s  t h e  e f f e c t s  o f  a  s u b s e q u e n t
a b r u p t  a d m i n i s t r a t i o n  o f  t h e  s a m e  o r  a n y  o t h e r  a n t a g o n i s t  a c t i n g
on the same receptor will be blocked. In contrast, in well developed
d e p e n d e n c e  t h e  m i c r o e v e n t s  a r e  l o n g - l a s t i n g  a n d  s o  t h e  r a t e  o f
exc i t a to ry  mic roeven t  p roduc t ion  may  be  s lower  and  s t i l l  p roduce
macroscopic abst inence because the microevents  can easi ly  summate
and  r each  f i r i ng  t h r e sho ld  l eve l s  even  i f  t hey  occu r  a t  r e l a t i ve ly
long intervals.
THE NATURE OF OPIATE ABSTINENCE PRODUCED BY OPIATE
WITHDRAWAL.
Of course , a n  a b s t i n e n c e  s y n d r o m e  c a n  a l s o  b e  p r o d u c e d  b y  t h e
s imp le  w i thd rawa l  o f  an  op i a t e  wh ich  has  been  p rev ious ly  admi -
nis tered in  a  chronic  manner . W e  n o w  p r o p o s e  t h a t  t h i s  t y p e  o f
syndrome resul ts  f rom the operat ion of  a  mechanism analogous to
that  of  antagonist-precipi tated abst inence. However, the evidence
suggests  that  in  the abst inence responses produced by opiate  with-
drawal, t h e  e x c i t a t o r y  m i c r o e v e n t  m u s t  o r i g i n a t e  a t  t h e  m o m e n t
of termination of the bond between opiate molecules and their recep-
tors (see II of Fig. I). The underlying process of dependence, i.e.,
t h e  h y p e r t r o p h y  o f  t h e  a b s t i n e n c e  r e c e p t o r  s y s t e m ,  d e n o t e d  b y  a
reduced kt , i s  i n  i den t i ca l  cond i t i on  fo r  t he  two  d i f f e r en t  t ypes
o f  p r o c e d u r e  t h a t  c a u s e  a b s t i n e n c e  s y n d r o m e s . Yet, t he  k ine t i c
m e c h a n i s m s  o f  a c t i o n  o f  t h e  t w o  p r o c e d u r e s  a r e  v e r y  d i f f e r e n t
and,  therefore , the abst inence responses obtained wil l  be different .
I n  t h e  c a s e  o f  a b s t i n e n c e  p r o d u c e d  b y  o p i a t e  w i t h d r a w a l ,  t h e  k 2
of the opiate and its rate of disappearance from the medium assume
the same roles  that  in antagonist-precipi tated abst inence are played
by the k1 of the antagonist and by its rate of access to the receptor
pool. I t  m u s t  b e  n o t e d  t h a t  i n  o p i a t e  d e p e n d e n c e  f r e e  r e c e p t o r s
are not  pharmacological ly inert . T h e  R a c t  e l e m e n t s  h a v e  e f f e c t s
of  opposi te  s ign to  the neurodepressant  act ions of  the OR elements
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a n d  t h u s  t h e  R a c t  c o n s t i t u t e  a  s t r o n g  m e c h a n i s m  f o r  t o l e r a n c e .
THE SUBLIMINAL ABSTINENCE SYNDROME
The mechanism of  opiate  abst inence must  include a  threshold s tep,
wh ich  i s  l i ke ly  t o  be  t he  neu rona l  t h r e sho ld  fo r  fu l l y  p ropaga t ed
neuronal action potentials. F u r t h e r  o n  w e  w i l l  r e f e r  t o  c l e a r  c u t
instances of subliminal abstinence conditions which appear to confirm
this idea. Subliminal abstinence should be identified by the produc-
t ion of  abst inence-l ike responses to the presentat ion of  exci tatory
non-opiate non-antagonist stimuli applied at a time when the pharma-
cologic condit ion of  the organism is  bordering on abst inence. The
response wil l  be abst inence-l ike because only in opiate-dependent
n e u r o n s  w i t h  s u b l i m i n a l  a b s t i n e n c e  i s  t h e r e  a  c o i n c i d e n c e  o f  t h e
t w o  k i n d s  o f  e v e n t :  t h e  s u b l i m i n a l  n a r r o w i n g  o f  t h e  d i s t a n c e  t o
f ir ing threshold and the addi t ional  effect  of  the non-opiate  genera-
lized excitatory stimulus.
PARADOXES OF EXPERIMENTAL OPIATE DEPENDENCE
1.-  Instances  of  Dissociat ion Between the Degrees  of  Dependence
“Unmasked” by:  a)  Withdrawal  of  Opiate and b)  Administrat ion of
an Opiate Antagonist.
1 . 1 . -  D i s soc i a t i on  o f  t he  i n t ens i t i e s  o f  ab s t i nence  ob t a ined  w i th
the above two procedures in early dependence.
This dissociation was initially observed when the first major antago-
nist introduced, nalorphine, was  f i r s t  t e s t ed  i n  op i a t e -dependen t
organisms. Previously, when invest igators  used to evaluate experi-
mental ly-produced opiate  dependence by the intensi ty of  the abst in-
ence syndrome caused  by  w i thd rawa l  o f  op i a t e ,  t hey  we re  u sed
to the fact  that  i t  normally takes 3 to 4 weeks of  opiate  adminis-
t r a t i on  t o  be  ab l e  t o  s ee  a  r e a sonab ly  robus t  ab s t i nence  r e sponse
to the withdrawal  of  the dependence-producing agent . Nalorphine
was found to precipi tate  abst inence responses of  important  severi ty
a f t e r  o n l y  a  f e w  d a y s  o f  o p i a t e  t r e a t m e n t  o r  e v e n  a f t e r  i n f u s i o n s
o f  m o r p h i n e  l a s t i n g  o n l y  a  f e w  h o u r s  ( M a r t i n  a n d  E a d e s ,  1 9 6 1 ) .
There was debate  and controversy over  the issues raised by these
findings. Of  course , n o w  t h a t  w e  c o u n t  w i t h  t h e  w e l l  v a l i d a t e d
fact  of  early dependence, t he  o ld  con t rove r s i e s  do  no t  appea r  a s
strong. However, a formal account of the mechanism of the discre-
pancies observed between the abstinence responses obtained through
the two procedures  has  not  been advanced before . The reason for
the  d i f f e r ences  i s  l i ke ly  t o  be  t he  d i f f e r en t  k ine t i c  mechan i sm o f
a c t i o n  o f  t h e  t w o  p r o c e d u r e s . Because the rates  of  dissociat ion
o f  op i a t e  agon i s t s  f r om the i r  r e cep to r s  a r e  i n  gene ra l  ve ry  much
slower than the rates  of  associat ion of  opiate  antagonists ,  the rates
of production of excitatory microevents will be far slower for opiate
withdrawal than for antagonist administration. Hence,  the  durat ion
of  the abst inence exci ta tory microevents  must  be much longer  for
an abstinence response to be obtained with simple opiate withdrawal
than with the administration of an antagonist. Therefore, the theory
predicts that abstinence syndromes will be produced by opiate antago-
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nists much earlier in the process of dependence than such syndromes
will be produced by opiate withdrawal.
1 . 2 . -  D i s soc i a t i on  o f  t he  i n t ens i t i e s  o f  ab s t i nence  ob t a ined  w i th
the above two procedures in  organisms t reated with opiate  analogs
which produce low levels of dependence.
This  point  is  qui te  important  for  the assessment  of  the dependence
potent ia l  of  new drugs. The chronic  t reatment  with  drugs of  low
dependence liability, such as many of the agonist-antagonist analge-
sics ,  leads to  pharmacologic condit ions where terminat ion of  drug
treatment  cause only abst inence syndromes of  low intensi ty. How-
ever, i f  d u r i n g  t h e  p e r i o d  o f  c h r o n i c  t r e a t m e n t  w i t h  o n e  o f  t h e s e
analgesics a  high dose of  a  fast-act ing opiate antagonists  is  admi-
nistered, then more intense abstinence responses are obtained.
O n e  m i g h t  a s k  w h i c h  o f  t h e  t w o  f o r m s  o f  a s s e s s i n g  d e p e n d e n c e
potential  should be regarded as val id. Besides the pract ical  issues
here,  the scient i f ic  di lemma posed by the quest ion vanishes i f  one
applies  to the present  problem the same considerat ions of  sect ion
1.1 .  above.
2 . -  The  In t ens i t y  o f  Abs t i nence has  an  Uppe r  L imi t  o f  Seve r i t y
and Yet  the Supersensi t ivi ty to the Abst inence-Precipi tat ing Actions
o f  A n t a g o n i s t s  C o n t i n u e s  t o  G r o w  E v e n  A f t e r  S u c h  U p p e r  L i m i t
of Severity has been Reached.
The r iddle associated with this  paradox disappears  with the not ions
of dependence discussed in this paper. The maximum level  of  abs-
t i nence  s eve r i t y  i s  de t e rmined  by  t he  fu l l  a c t i va t i on  o f  t he  en t i r e
set  of  opiate-sensi t ive neurons which part ic ipate  in  abst inence.  The
sensi t izat ion to the abst inence-precipi tat ing act ions of  antagonists
i s  de t e rmined  by  t he  i nc r ea se s  i n  du ra t i on  o f  t he  ac t i ve  s t a t e s  o f
t he  r ecep to r - e f f ec to r elements. Therefore, t h e  s e n s i t i z a t i o n  t o
antagonists  may very wel l  cont inue to  grow much beyond the point
where maximum levels  of  abst inence severi ty can be just  obtained.
In  turn , t he  l im i t  o f  s ens i t i z a t i on  t o  an t agon i s t s  i s  g iven  by  t he
law of hyperbolas (Villarreal, et al., 1987a).
3 . -  The Paradox of  Control  Basel ines  with Non-Zero Dependence.
Many reports  in  the l i terature  contain instances where animals  or
expe r imen ta l  p r epa ra t i ons  neve r  p r ev ious ly  t r ea t ed  w i th  op i a t e s
r e s p o n d  w i t h  a b s t i n e n c e - l i k e  p h e n o m e n a  t o  t h e  a d m i n i s t r a t i o n  o f
l a rge  doses  o f  op i a t e  an t agon i s t s . T h e  n e w  t h e o r y  a l s o  h a n d l e s
t h i s  p r o b l e m  i n  a  c l e a n  f a s h i o n . The abst inence effector  system
is there to s tar t  with,  but  in  a  s tate  of  varying degrees of  atrophy.
The theory predicts  that  preparat ions with effectors  in  an incom-
pletely atrophied state wil l  give abst inence responses to very large
doses of  antagonists  administered at  high rates . I t  m u s t  b e  n o t e d
that  the non-zero dependence basel ines are commonly obtained in
v i t r o  w h e r e  h i g h  d o s e s  o f  a n t a g o n i s t s  a d m i n i s t e r e d  a t  h i g h  r a t e s
are easily given.
4.- The Paradox of Abstinence Responses Precipitated by Antagonists
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Weeks or  Months After  the Last  Administrat ion of  a  Dependence-
Producing Opiate.
Abst inence-l ike syndromes can be produced in monkeys or  rodents
by the adminis trat ion of  opiate  antagonists  when these agents  are
g i v e n  w e e k s  o r  m o n t h s  a f t e r  t e r m i n a t i o n  o f  a  c h r o n i c  p e r i o d  o f
o p i a t e  t r e a t m e n t . A t  t h e  t i m e  o f  t h e  p a r a d o x i c a l  p r e c i p i t a t i o n
of abst inence most  i f  not  al l  of  the opiate  administered long before
should have been eliminated from the organism. Then, if the opiate
is  gone,  how is  i t  that  an antagonis t  produces abst inence. These
organisms would be in  abst inence f o r  a s  l o n g  a s  d e p e n d e n c e  w a s
present  i f  abst inence was simply mediated by an occupation-coupled
receptor mechanism. It is more reasonable to consider all the evid-
ence in favor of  the idea that  abst inence is  mediated by a  rate-cou-
pled receptor  system and that  dependence is  a  hypertrophy of  such
system. The hypertrophy caused by the dependence-producing opiate
o f  t h e  p r e s e n t  p a r a d o x  m i g h t  t h e n  d e c a y  a t  s o m e  s l o w  r a t e  o f  i t s
own after termination of opiate. High rates of microevent production
can be achieved with high doses of antagonists administered rapidly
when the effector  hypertrophy produced by dependence has decayed
perhaps a great deal but has not disappeared altogether.
5.-  Paradoxes About the Abstinence-Precipi tat ing Actions of  Opiate
Antagonists.
On of  the most  interest ing features  of  these pharmacologic  act ions
is  that  specif ic  opiate antagonists  differ  in their  intr insic act ivi t ies
fo r  t he  p r ec ip i t a t i on  o f  ab s t i nence . T h e r e  i s  e v e n  e v i d e n c e ,  f o r
certain antagonists, o f  a n  o r d e r l y  v a r i a t i o n  o f  i n t r i n s i c  a c t i v i t y
w i t h i n  e a c h  c o m p o u n d  w h e n  t h e s e  a g e n t s  a r e  t e s t e d  a t  d i f f e r e n t
levels  of  opiate dependence. Such paradoxes of  opiate  antagonists
are impossible to explain in terms of  s imple occupation drug-recep-
tor  theory. The rate-coupled model  accounts  in  an uncomplicated
f a s h i o n  f o r  t h e  p a r a d o x e s  c o n c e r n i n g  t h e  i n t r i n s i c  a c t i v i t y  o f  t h e
abstinence-precipitating antagonists (Villarreal, et al., 1987b).
6.- The Subliminal Abstinence-Syndrome.
Vil larreal  and Castro (1979) review str inking cases  of  abst inence-
l ike responses obtained in  opiate-dependent  organisms through the
application o f  exc i t a to ry experimental interventions u n r e l a t e d  t o
t h e  r e m o v a l  o f  o p i a t e  f r o m  i t s  r e c e p t o r  s i t e  o f  a c t i o n . Collier
(1979)  and his  coworkers  have drawn at tent ion to  what  they have
designated the quasi-abstinence syndrome whereby certain non-opiate
e x c i t a t o r y  d r u g s  e n h a n c e the  abs t i nence -p rec ip i t a t i ng  e f f ec t s  o f
opiate  antagonists . T h e  g r o u p  o f  p h e n o m e n a  o f  q u a s i - a b s t i n e n c e
c o u l d  p e r h a p s  b e  r e g a r d e d  a s  a  p a r t  o f  t h e  s e t  o f  e f f e c t s  o f  t h e
subliminal abstinence syndrome.
Finally, there is  another  set  of  interact ions,  discussed by Vil larreal
(1981), which can be added to the set of conditions where subliminal
abst inence operates . I n  t h e  p r e s e n c e  o f  m i l d  d e p e n d e n c e ,  s t r o n g
a b s t i n e n c e  r e s p o n s e s  c a n  b e  o b t a i n e d  w i t h  a n t a g o n i s t s  i f  a n y  o f
the following is applied: ouabain, low extracellular calcium, electrical
stimulation. These interventions are directly membrane depolarizing
except low calcium which, nevertheless, augments the self-regenerat-
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ing effects of membrane depolarization.
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Development of A Computerized
System for Inventory of
Controlled Drug Substances
W. Schmidt, G. Alberici and L. Cook
A B S T R A C T
An automated drug inventory system was developed to facilitate
record keeping requirements for controlled drug substances. A
hand-held barcode scanner and a computer-accessible top-loading
electronic balance are used to identify and weigh samples each
time they are removed from or returned to the safe. A computer
compares the initial sample weight to its last recorded weight to
assure that no discrepancies occurred prior to sample use. Upon
return, the computer compares the difference in initial and return
tare weights to the stated amount of drug used to assure accuracy
of the written inventory record. Unreconciled errors are
immediately brought to the attention of the safe custodian.
During its first year of operation, 2791 sample out/sample return
transactions on 381 drug samples were tracked by the system. The
most common errors detected by the system include sample loss of
moisture (9), sample absorption of moisture (4), wrong sample used
(4), incorrect weight recorded (4), and sample used without log
entry (4). Importantly, all errors were immediately identified and
reconciled. At the end of each working day, a printout of all
daily transactions shows sample use, possible errors, and whether
all samples have been returned to the safe. A printout of the
total drug inventory is immediately available when called for.
This system provides enhanced vigilance and security, and has been
readily accepted by all investigators using controlled drug
substances in our laboratory.
INTRODUCTION
Drug Enforcement Agency (DEA) regulations require that
investigators maintain complete and accurate records for the
receipt and dispensing of controlled drug substances. In
practice, many investigators keep drug samples in a locked drawer
or safe and record drug usage on hand-written inventory sheets.
We have found that, even in the best laboratories, inadvertent
inventory errors arise when an investigator (a) forgets to record
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the use of a sample, (b) uses the wrong sample, (c) records the
sample usage on the wrong inventory page, (d) records incorrect
data due to a misplaced decimal point or an incorrect balance
reading, or (e) makes addition/subtraction errors in the log book.
This can lead to serious and time-consuming problems when
reconciling inventory records prior to the annual dump-weigh drug
audit. We have now developed an automated inventory system to
guard against these errors. This procedure supplements current
DEA-approved inventory methods.
METHODS
Cur system was implemented by connecting a computer-accessible top
loading balance (Mettler PE 1600) to our existing laboratory
computer system. A hand-held barcode scanner (DEC RT701) was
connected in-line with the computer terminal and individual
barcode labels were affixed to each of the 300+ samples in our
safe. A custom-written Fortran program was developed to operate
the system functions and provide a user-friendly step-through
guide for inventory transactions. In practice, each time a sample
is used, a technician enters his/her initials on the computer
keyboard, then uses the barcode scanner to identify the sample.
After the sample is placed on the balance, the computer compares
the sample tare weight to the last recorded reading to assure that
no discrepancy has occurred prior to sample use. The procedure is
repeated when the drug is returned to the safe, with the exception
that the computer then compares the difference of initial/return
tare weights to the stated amount of drug used (entered on the
keyboard). If the numbers agree within a programmed accuracy
level (± 0.02 gm), the technician completes the entry by adding
the experiment name and notebook page number. The computer
indicates an error condition whenever there is a discrepancy in
tare-weight readings. Errors that remain unreconciled after two
additional weighing opportunities are flagged and brought to the
immediate attention of the safe custodian. The sample is not
released for further use until the source of the error can be
identified and corrected. Each attempted inventory access is
recorded and printed at the end of the day. All data are recorded
in a permanent computer file for further reference and database
applications.
RESULTS AND DISCUSSION
During the first year of operation, 2791 sample out/sample return
transactions were recorded on the autanated drug inventory system.
Thirty-seven technicians and investigators are authorized to use
drug samples from the controlled drug inventory; 4 of these
are “safe custodians” who may unlock the narcotics safe. The
system currently tracks 381 individual samples, of which 20 most
frequently used samples account for 92% of all record entries.
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Errors detected and corrected by the system include:
Loss of weight -- sample loss of moisture 9
Gain of weight -- sample absorption of moisture 4
Wrong sample used 4
Incorrect weight recorded 4
Sample used without log entry 4
Loss of weight -- powder stuck to weighing paper 1
Total = 26 errors
Significant benefits derived from use of the system include:
- Enhanced vigilance and security
- Fast, accurate, easy to use system
- Computer-read bar code on each sample assures
sample accuracy
- Automated record keeping prevents addition/subtraction
errors; assures record accuracy
- System indicates "who" has the sample if not in safe;
simplifies “sample searching” time
- Printout of daily log entries indicates samples not
returned to safe at end of day
- Permanent computer log permits rapid searching of
sample data
- System is easily adapted to tracking both scheduled
and non-scheduled drugs
- System readily accepted by technicians and investigators
During our annual audit, all dump-weighed C-I and C-II drugs had
weights within specified accuracy levels. All 49 samples emptied
since the audit had expected zero balance levels on the written
drug inventory record; no unresolved inventory errors were found.
Twelve samples found to have slightly increased or decreased
weights during storage were of particular interest. Seasonal
variations in moisture content and/or slight volatilization of the
drug substance were identified as the likely sources of error.
Samples gaining 0.04 to 0.09 gm weight during the spring-summer
period included morphine sulfate, morphine pellets, and
phenobarbital sodium. Initial sample weights were between 15 and
82 grams. Samples loosing 0.03 to 0.07 gm weight during the fall-
winter period included codeine phosphate, phenobarbital sodium,
phencyclidine HCl, normeperidine HCl, amphetamine sulfate, and
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amphetamine HCl. A 14 gm sample of codeine base having an 0.50
gm loss of weight over a 5 month fall-winter period was verified
by the manufacturer to have an unstable hydrate (0-7% water
content); moisture analysis demonstrated that the sample decreased
from 5.36% to 0.2% moisture content during the storage period.
This loss of moisture more than accounts for the weight
discrepancy. Hexobarbital sodium and chloral hydrate were found to
be slightly volatile in their solid form; loss of weight could be
prevented by tightly sealing the sample bottles with parafilm.
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Assessment of Opiate Tolerance
and Dependence In Vitro
A. Rezvani and E. Way
ABSTRACT
Experiments were performed to induce opiate tolerance and phy-
sical dependence in vitro and assess the applicablility of the
procedures for studying the basic mechanisms in tolerance and
dependence development. It was established that tolerance and
physical dependence could be demonstrated in the excised guinea
pig ileum and mouse vas deferens by direct incubation with an
opiate agonist. The selectivity of the response to opiates was
determined by experiments demonstrating stereospecificity,
naloxone reversibility and cross-tolerance. The magnitude of
tolerance and physical dependence was found to be dose, time, and
agonist type-dependent. A standardized degree of tolerance and
dependence were induced by using a dose of agonist sufficient to
inhibit electrically stimulated contractions by 50% (IC50). In
the isolated guinea pig myenteric plexus of the longitudinal
muscle, incubation of the IC50 of an agonist at 37°C for one hour
produced a 2 to 5-fold tolerance as evidenced by the increase in
its IC50. The rank order of decreasing potency in developing
tolerance was morphine, normorphine and methadone. Physical
dependence on the opiate was established by a contractual re-
sponse to naloxone or a supersensitive response to electrical
stimulus after removal of the agonist by washing. The degree of
dependence developed was found to be proportional to that of
tolerance. Similar incubation experiments on the mouse vas
deferens with opioids also resulted in the development of toler-
ance and dependence. Although naloxone failed to evoke a contrac-
tual response, it enhanced dose-dependently the sensitivity of
the preparation to electrical stimulus. Based on these observ-
ations, we conclude that our data are in agreement with ther
hypothesis that opiate tolerance and physical dependence develop-
ment are related processes.
INTRODUCTION
To elucidate the mechanisms involved in opiate tolerance and
physical dependence studies have been generally performed on
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experimental animals receiving repeated or sustained administra-
tion of an agonist. However, due to the complexities of analyzing
multiple pharmacologic responses in the whole animal, attempts
have been made to develop in vitro models in which specific
effects related to tolerance and dependence can be assessed more
directly. The guinea pig ileum and mouse vas deferens are common-
ly used for studying acute opioid effects and more recently,
these preparations were found to be suitable also for assessing
opiate tolerance and dependence development. In the present
communication, we will review some of the latter work and present
additional data to demonstrate the applicability of the ilea and
vas for assessment of opiate tolerance and dependence.
1. Guinea pig ileum
Assessment of tolerance: Three decades ago, it was established
that opiates inhibit electrically induced contractions of the
excised guinea pig ileum (Paton, 1957). Later, Kosterlitz et al.,
(1968) showed that the action of opiates on the myenteric plexus
of the longitudinal muscle is dose-dependent, stereoselective and
naloxone reversible. Moreover, the rank order in potency of the
various opiate agonists to inhibit the ileum was found to be
similar to that with respect to antinociceptive activity in
animal models (Kosterlitz et al., 1968). Subsequently, attempts
were made to adapt the guinea pig ileum preparation for tolerance
studies.
The presence of tolerance in the myenteric plexus of the ileum
excised from guinea pigs implanted with morphine pellets was
described by Goldstein and Schulz (1973) and Schulz and Herz
(1976). Tolerance was also produced in vitro in this preparation
by incubating segments of the isolated-m from naive animals
with an agonist for 18-22 hours at 4°C (Hammond et al., 1976) and
at 22°C (Opmeer et al., 1978, Collier et al., 1981).
Since tolerance in the ileum can be detected even after a single
dose of morphine (Huidobro-Toro et al., 1978), we attempted to
simplify the technique for inducing tolerance in this prepara-
tion. Accordingly, a systematic study was initiated using strips
of longitudinal muscle attached to the myenteric plexus excised
from naive guinea pigs. Segments of the ileum were incubated with
an opiate agonist at 37°C at various concentrations and time
intervals.
The results indicated that a high degree of tolerance can be
induced under such conditions (Rezvani et al., 1983). Also, the
development of tolerance and dependence in vitro was found to be
agonist and time dependent. Morphine induced the highest degree
of tolerance followed in order by normorphine and methadone.
Incubation of the ileum with 2x IC50 of morphine induced a
22-fold tolerance. Under the same conditions, an 18 and 10 fold
tolerance to normorphine and methadone was developed respectively
(Rezvani et al., 1983).
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The validity of this simplified in vitro procedure for producing
tolerance was demonstrated by its compatibility with data obtain-
ed on intact animals with respect to stereospecificity, naloxone
reversibility and cross-tolerance. Moreover, development of
tolerance to morphine did not affect the responsitivity of the
ileum to norepinephrine or acetylcholine. In addition, the
tissues rendered tolerant to morphine also exhibited physical
dependence as evidenced by a contractual response to naloxone.
Finally, the utility of the procedure was further buttressed by
the observation that segments of the ileum rendered tolerant to
morphine, regained their sensitivity to morphine after pre-incub-
ation with low concentrations of dynorphin 1-13 (Rezvani and Way
1984). These results are compatible with those obtained earlier
by Tulunay et al., (1981) who found that dynorphin enhances the
antinociceptive effects of morphine in morphine-tolerant mice.
Thus, the results clearly establish that in vitro induction of
tolerance in the guinea pig ileum can be utilized for the assess-
ment of opiate tolerance.
Assessment of dependence: Ehrenpreis et al., (1972) demonstrated
that guinea pig ileum strips incubated for 10 minutes with
morphine exhibit a contractile response upon exposure to nalo-
xone. This finding was confirmed by Schulz and Herz (1976), who
also found that the intensity of the contraction was proportional
to the degree of tolerance. Collier et al., (1981) incubated
segments of ileum with morphine for 24 hours at 4°C and observed
that the response to naloxone was stereospecific and concentra-
tion dependent.
While developing the simple method of inducing opiate tolerance
in the guinea pig ileum, we confirmed that exposure of the
tissues to naloxone causes a contraction and that the magnitude
of the contractile response could be correlated with the degree
of tolerance developed to each agonist. We noted further that
upon application of an electrical stimulus to the dependent
tissue, a supersensitive response could be obtained, as evidenced
by an increase in twitch height (Rezvani et al 1983). These
observations prompted us to investigate whether the supersen-
sitive response could be utilized for the quantitative assessment
of physical dependence.
After the ileum from an untreated animal was excised and stimul-
ated electrically for 15 minutes, the twitch height to a given
stimulus was measured. Subsequently, the tissue was rendered
tolerant to and physically dependent on morphine to varying
degrees by incubating with varying concentrations of morphine for
two hours at 37°C. With 1x, 2x or 5x IC50 a 7, 10 and 15 fold
tolerance, respectively, was observed. The tolerant-dependent
tissue was then washed thoroughly at five minute intervals for
one hour with Ringer solution to remove the morphine, and its
sensitivity to the initial electrical stimulus was redetermined.
The ratio of the twitch height obtained after and before treat-
ment provided an index of the degree of physical dependence.
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Under the above conditions, a supersensitivity response to
morphine, but not to ethylketocyclazocine (EKC), could be
obtained. Furthermore, the effect was found to be stereospecific
as evidenced by the demonstration of a supersensitive response to
levorphanol but not to dextrophan after tolerance had developed.
Both the development of supersensitivity and tolerance could be
blocked by co-incubation of morphine with naloxone. A super-
sensitive effect was not elicitable with the kappa agonists,
dynorphin and EKC. Met-enkephalin was effective but
leu-enkephalin was not (Rezvani and Way 1983). The development of
supersensitivity presumably involved protein synthesis, since it
could be blocked with chloramphenicol as described previously in
vivo (Della Bella and Fugeni 1978, Rezvani and Way 1983).
2. Mouse vas deferens
Assessment of tolerance: Henderson et al., (1972) reported that
opiates inhibit adrenergic neuroaffector transmission in the
mouse excised vas deferens dose-dependently. Later, Schulz et
al., (1983) observed that the isolated vas deferens from mice
treated chronically with morphine showed a high degree of
tolerance. In a follow-up study, (Schulz and Wuster 1984) carried
out cross-tolerance studies with a delta agonist DADLE
(D-Ala-D-Leu enkephalin) and a mu agonist, sufentanil. The vas
infused with DADLE showed about an 800 fold tolerance, but those
treated similarly with sufentanil or EKC exhibited only a 5- and
2-fold increase, respectively. Recently, we attempted to
circumvent pellet or mini pump implantation in the whole animal
by inducing opiate tolerance dependence in vitro.
Mouse vas deferens were incubated with a mu or delta agonist in
vitro for 2 hours at 37°C. After incubation of the tissues with
10-6 morphine, a 4-fold tolerance could be obtained. Under the
same conditions, with 1xC50 of DADLE, a 6-fold tolerance develop-
ed. These studies are still in progress.
Assessment of dependence: Earlier experiments to demonstrate
physical dependence in the mouse vas deferens were unsuccessful.
In tissue tolerant to different opioid ligands, a contractile
response to naloxone could not be elicited. A plausible explan-
ation for the failure to elicit a naloxone contracture might be
due to the fact that transection of the nerve somata during
removal of the vas reduces its responsitivity (Schulz and Wuster
1984). However, North and Vitek (1980) were able to establish
that physical dependence might occur in this tissue and that
mouse vas deferens tolerant to normorphine display supersensiti-
vity to electrical stimulation after exposure to naloxone. This
phenomenon is analogous to the supersensitivity response of the
morphine-tolerant guinea pig ileum to electrical stimulation upon
exposure to naloxone. In order to investigate whether the
supersensitivity to electrical stimulation after development of
tolerance/dependence can be quantified in the mouse vas deferens,
we performed the following experiment.
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The vas deferens from a naive mouse was mounted in an organ bath
and incubated with 1x1C50 of DADLE for one hour after which the
tissue was subjected to electrical stimulation in the presence of
increasing concentrations of naloxone. The amplitude of the
twitch to a given electrical stimulus was found not only to
increase from 29 to 41mm, but was also shown to be proportional
to the concentration of naloxone added. Thus, these results
indicate that dependence on opiate can be induced in the mouse
vas deferens in vitro and the degree of dependence can be
quantified by determining the antagonist ED50 for evoking such a
phenomenon.
Based on the varying degrees of tolerance obtained with different
ligands, the low degree of cross-tolerance exhibited between the
ligands and the inability to detect dependence development with
any of the ligands, upon exposure of the tissue to naloxone,
Schulz and Wuster (1984), concluded that different processes were
involved in tolerance and dependence development.
These conclusions can be criticized on at least two grounds.
Firstly, since different responses were used to assess tolerance
and physical dependence, it is unfair to equate the sensitivity
of the measures for determining tolerance and physical
dependence. Secondly, although the authors used the most
selective ligands available for each receptor type, it should be
noted that at high concentrations, the ligands also have affinity
for other types of opioid receptors. For example, (EKC) has been
shown to bind to the mu and delta as well as to kappa sites.
Also, DADLE has been known to have considerable affinity for the
mu receptor. Considering that in the experiment by Schulz and
Wuster (1984), fairly high concentrations of the agonists were
present in both the in vivo and in vitro studies, the activation
of more than one receptor type cannot be excluded.
Our present experiments lead us to arrive at conclusions contrary
to those of Schulz and Wuster (1984). Our observations establish
that tolerance induced in the guinea pig ileum or the mouse vas
deferens by direct incubation with an agonist is accompanied by
the development of physical dependence. The fact that tolerant
tissue exhibited a supersensitive response to electrical stimu-
lation after removal of the agonist by washing, suggests that
opiate tolerance and dependence are related since both tolerance
and dependence were assessed by changes to electrical stimulation
involving a common neural pathway.
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Chronic Opioid Treatment of
Intractable, Non-Malignant Pain
F. Tennant, Jr., D. Robinson, A. Sagherian and R. Seecof
INTRODUCTION
Despite the merits of many new pain therapies the
various treatments may be individually or even
collectively insufficient to achieve adequate pain
control in some chronic pain patients who have
non-malignant conditions. Consequently, these
patients require continuous administration of
opioids. Little is known, however, about these
patients since they have not been systematically
studied. In 1979, due to demand in our geographic
area, we began accepting patients on a referral
basis who had severe, non-malignant pain and who
were already dependent upon the daily administration
of opioids for pain relief. Reported here are the
52 patients evaluated and treated by us in this
pilot program between 1979 and 1986.
PROCEDURES AND METHODS
All patients were referred by a physician, hospital,
or government agency. Requirements for acceptance
by us were that the referral source and patient
believed that chronic opioid administration was
essential for adequate pain relief and that all
other pain treatments acceptable to the patient had
been unsuccessfully attempted. Pain was classified
as either structural or non-structural. In the
former case, there was documented evidence of
permanent, irreversible destruction of a bodily
structure such as bone, nerve, or muscle.
Non-structural pain consisted of cases in which
damage to a bodily structure could not be
documented, such as headache or neuralgia.
In four cases of generalized pain of unknown cause,
special diagnostic studies including immunologic
tests and skin biopsies were done. A urine specimen
was analyzed for 50 drugs by thin layer
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chromatography to help determine what drugs the
patient was self-administering.10 Patients were
initially prescribed the opioids that they had
previously been taking. Enough opioids were
prescribed to maintain the patient between visits.
Each patient gave written, informed consent for
opioid maintenance and the consent clearly stated
that opioid dependence would likely be for a
life-time.
In an attempt to minimize the daily opioid dosage and
enhance pain relief, every patient received multiple
sequential trials of non-opioid analgesics and opioid
potentiators including non-steroidal,
anti-inflammatory agents, tricyclic antidepressents,
neuroleptics, antihistamines, and amino acids,
tryptophan, tyrosine, leucine, and phenylalanine.
Various physiotherapies were concomitantly given to
all patients with structural pain involving the
spine, joints, and/or extremities. Intralesional
corticoids were administered to all patients who
demonstrated trigger points of pain. Ancillary
medical conditions were treated by us in conjunction
with the referring physician.
Pain control was assessed by self-report on each
clinic visit and judged by the attending physician as
adequate, partially adequate, or inadequate. When
pain control was clinically judged anything but
adequate, attempts were made to increase the opioid
dosage, prescribe an ancillary pain medication or
potentiator, incorporate a non-drug therapy, or
switch opioid drugs, particularly to an opioid which
has a longer duration of action than the one being
taken. Plasma concentrations of the therapeutic
opioid were determined in 11 patients who complained
of inadequate pain relief. Blood sampling was done
one to two hours after the patient was observed to
administer their opioid. In patients who
demonstrated no detectable opioid in their plasma,
non-absorption from the gastrointestinal tract was
assumed, and a different opioid was prescribed. Five
patients experienced recurrent, acute exacerbations
of pain and who required frequent hospitalizations or
emergency room visits to obtain intramuscular
injections of opioid were taught to utilize
hydromorphone or morphine suppositories to prevent
this need.
CLINICAL CHARACTERISTICS OF PATIENTS
Patients ranged in age from 20 to 77 years with a
mean of 48.6 ± 14.6 S.D. They were about evenly
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divided between males and females. Only 11 (21.2%)
were gainfully employed. Duration of time they had
taken opioids for chronic pain prior to treatment by
us ranged from .75 to 40 years (mean 12.0 10.6
S.D.). The longest duration of 40 years was in a
man who first began chronic opioid administration
for a battle wound sustained in 1941 during World
War II, and which resulted in a loss of a leg.
Second longest duration was a 70 year old woman who
began hydromorphone injections in 1947 for
trigeminal neuralgia. In addition to the primary
cause of pain, patients also had numerous other
medical conditions and took various pharmacologic
agents. Four patients used their opioids by
injection because they either had a gastrectomy
and/or previously found that oral opioids had no
effect.
CAUSE OF PAIN
The etiology of pain in 48 (92.3%) patients was
obvious and well-known to the patient and referral
source. Four (4;7.7%) patients were referred with
pain of unknown cause. Opioids had been prescribed
due to intractable muscle, joint, and/or abdominal
pain. Forty two of the 52 (80.8%) patients
demonstrated structural abnormalities of tissue as
their primary source of pain. The most common
causes of pain were arthritis and post-trauma or
postsurgical destruction of tissue (Table One).
Trauma cases were caused by auto accidents, falls,
or gunshot wounds that resulted in crushed vertebrae
or destruction of other bony structures.
Post-surgical pain was primarily the result of
multiple back or limb operations or tissue
destruction and/or adhesions resulting from
abdominal surgery. Three (3;5.8%) patients had
surgery for removal of cancers. Other causes of
structural pain were varied and included some
relatively uncommon medical conditions such as
Gaucher's disease and porphyria. Ten (10;19.2%)
patients had non-structural pain including seven
(7;13.5%) with intractable headaches, two (2;3.8%)
with trigeminal neuralgia, and one (1;1.9%) with
Restless Legs Syndrome. Of the four patients with
pain of unknown origin, two proved to have
scleroderma, one had systemic lupus erythematosus,
and the other had gout.
OPIOIDS USED FOR TREATMENT
Four techniques were primarily utilized to control
pain. One was simply raising the dosage of the
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opioid which the patient was accustomed to taking.
A second was changing the patient to a longer-acting
opioid, usually methadone or oxycodone in place of
codeine, meperidine, or hydromorphone. Some
patients, however, complained that the longer acting
opioids were not as effective in relieving pain as
the short acting opioids. Other patients achieved
adequate pain relief when low dosages of methadone,
10 to 40 mg per day, were given concomitantly with
codeine or another short-acting opioid which likely
suppressed intermittent withdrawal symptoms.8 Five
patients experienced episodic acute exacerbations of
pain which were controlled by hydromorphone or
morphine suppositories. Patients would supplement
their regular daily dosage of opioid with the
suppositories in a manner to eliminate repeated
visits to an emergency room or hospital to obtain
additional opioids during acute exacerbations of
pain (Table Two).
Plasma concentrations of opioid were determined in
11 (21.2%) patients who complained of inadequate
pain relief. Four patients who had plasma codeine
determinations revealed two, who administered 600
and 960 mg per day respectively, with non-detectable
levels while the other two who administered about
300 to 500 mg per day showed 322 and 1160 ng/ml.
Five patients with methadone plasma determinations
showed one, who administered 100 mg per day, with a
non-detectable level while the other four consumed
40 to 160 mg per day showed concentrations ranging
from 108 to 1470 ng/ml. Plasma concentration in one
patient who administered 1000 mg of propoxyphene per
day was 376 ng/ml and in one patient who
administered about 80 mg per day of oxycodone was
600 ng/ml. Patients without detectable plasma
levels of opioid were assumed to have inadequate
absorption of the opioids and were switched to
another oral or injectable opioid which, in all
cases, adequately provided pain relief. Those
patients who had detectable plasma levels were
assumed to adequately absorb their opioid and were
clinically managed by raising their daily dosage of
opioid or adding other non-opioid therapies until
adequate pain relief was achieved.
OUTCOME OF TREATMENT
After necessary and systematic changes in opioid and
dosage were done as described above, 46 of the 52
(88.5%) patients were clinically judged by attending
physicians to achieve adequate pain control on most
days of the week according to the patient's
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self-report. Six (6;11.5%) were judged as partially
controlled. Once pain control was adequate, the
daily intake of opioids remained relatively constant
and seldom varied over 10 to 15% each day according
to reports by patient and family.
In the year prior to this report, the 32 patients
still in treatment were hospitalized only four times
and made eight emergency room visits. The most
common complications observed were constipation
(20;38.5%) and edema (12;23.1%) of the extremities.
The latter would temporarily remit with
administration of adrenal corticotropin (ACTH). One
patient with systemic lupus erythematosus and gout
who required 80 mg per day of oxycodone for pain
relief developed adrenal insufficiency which
required corticoid replacement.11,12
SUMMARY
There is a sub-group of patients with non-malignant
medical conditions who have severe, intractable pain
and who require chronic opioid administration for
adequate pain control. Reported here is a
systematic clinical evaluation of 52 such patients
who were referred after they had failed numerous,
non-opioid pain treatments. Major causes of pain
were irreversible degenerative and/or traumatic
injuries to the musculoskeletal system. A variety
of opioids in high daily dosages were required to
achieve adequate pain control in these patients.
Once pain relief was achieved, patients did not
-escalate their dosage, and they were able to
maintain pain relief for long time periods.
Although opioids produced dependence in all patients
and complications of constipation and edema in about
one third, high daily opioid dosage. treatment
appeared to be the only medical means to achieve
adequate pain control in these subjects. We
conclude that opioid maintenance should be utilized
as a last resort treatment in patients who fail
other pain treatments.
TABLE 1
Major Causes of Chronic Pain
in 52 Patients Treated with Opioids
Arthritis
Post-Trauma
Post-Surgical-Back
No. Patients %
16 (30.8%)
13 (25.0%)
11 (21.2%)
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Collagen Disease
Post-Surgical-Abdominal
Headaches
Post-Surgical-Cancer
Chronic Pancreatitis
Neuralgia/Neuropathy
Chronic Liver Disease
Gaucher's Disease
Porphyria
Restless Legs Syndrome
Renal Stones-Inoperable
Osteomyelitis
Endometriosis
Gout
16
8
7
3
3
2
2
1
1
1
1
1
1
1
Total* 81
(17.3%)
(15.4%)
(13.5%)
( 5.0%)
( 5.8%)
( 3.8%)
( 3.8%)
( 1.9%)
( 1.9%)
( 1.9%)
( 1.9%)
( 1.9%)
( 1.9%)
( 2.9%)
*Numbers add to more than 52 since some patients had
more than one major pain source
Table 2
Opioids Administered to 52
Chronic Pain Patients *
Opioid
No. Usual Dosage
Patients Per 24 Hrs(MGS)
Codeine+ 18(34.6%)
Methadone 14(26.9%)
Propoxyphene + 7(13.5%)
Hydromorphone**
Oxycodone+
7(13.5%)
5( 9.6%)
Meperidine 4(7.7%)
Morphine**
Hydrocodone+
3(5.8%)
1(1.9%)
240-1080
10-240
400-1200
8-120
15-80
200-2000
60
20
Total*
59
* Adds up to more than 52 since some patients used
more than one opioid.
+ These opioids were usually in formulations which
contained acetaminophen.
** Subjects used their opioids by suppository only
for acute exacerbations of pain.
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The Role of -Endorphin in
Respiratory Disorders in Man
W. Dewey, D. Morris, D. Brase and E. Myer
INTRODUCTION
It is well established that endogenous opioid peptides, such as
beta-endorphin and the enkephalins, as well as the more stable
analogs of the enkephalins. are capable of producing respiratory
depression in experimental animals when administered directly into
the brain (Florez et al., 1980; Moss and Scarpelli 1981; Sitsen et
al., 1982; Haddad et al., 1984). Specific sites of respiratory
depressant action by opioid peptides in the brain have also been
identified and include the nucleus tractus solitarius (Hassen et
al., 1982). the nucleus ambiguus (Hassen et al., 1984) and the an-
terior hypothalamus (Pfeiffer et al., 1983). The ability of nal-
oxone to antagonize the respiratory depressant effect of these
peptides, as well as the potency characteristics of various opi-
oids, strongly indicated a role of the mu type of opioid receptor
in mediating the respiratory depression observed in many of these
studies in animals.
The first indication that endogenous opioid peptides may be in-
volved in respiratory depression associated with certain patho-
logical states in humans was in a report by Brandt et al. (1980).
who found markedly elevated levels of met-enkephalin immunoreac-
tivity in the brain and cerebrospinal fluid (CSF) of a child with
necrotizing encephalomyelopathy. This stimulated a search for
increased levels of enkephalins in the brains from victims of the
sudden infant death syndrome (SIDS), a syndrome postulated to in-
volve abnormal regulation of ventilation (Shannon et al., 1977).
However, abnormal enkephalin levels were not found in the brains
of SIDS victims (Kuich and Franciosi 1983; Bergstrom et al. ,
1984). On the other hand, Orlowski et al. (1982) reported some
preliminary data suggesting that infants with apnea had elevated
levels of beta-endorphin immunoreactivity (B-EIR) in their CSF.
In addition, plasma levels of B-EIR were reported to be signifi-
cantly increased in infants with apnea of prematurity (Sankaran et
al., 1984). This finding has recently been confirmed by MacDonald
et al. (1986). These studies indicated the possibility that in-
creased levels of beta-endorphin (or other related opioid pep-
tides) may contribute to the respiratory depression or apnea as-
sociated with certain pathological conditions in infants.
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The objectives of the present study were to provide confirmatory
evidence for elevated levels of B-EIR in CSF from infants with
apnea, as well as from infants resuscitated from an apparent life-
threatening event (ATLE); to determine whether siblings of SIDS
victims had elevated levels of B-EIR in CSF: to determine whether
the measurement of plasma B-EIR could serve as a useful index for
elevated CSF levels of B-EIR in these patients: and finally. to
determine whether increased CSF levels of B-EIR occur in Rett's
syndrome, a neurological disorder in females involving respiratory
hyperventilation and depression (apnea), seizures, abnormal hand
movements and progressive mental deterioration. As part of an on-
going study, we are also assessing the value of treatment with the
orally active opioid antagonist naltrexone in children with apnea
and in some of the patients with Rett's syndrome who demonstrated
elevations in the CSF level of B-EIR.
METHODS
Subjects. Based upon medical history and clinical evaluation. the
subjects were assigned to one of the groups described below before
any samples were analyzed for beta-endorphin. Group A originally
consisted of 2 control subgroups. One was a group of infants ad-
mitted to the hospital with suspected apnea (4 subjects) or a his-
tory  of apnea of prematurity (1 subject), but the presence of ap-
nea was not confirmed by full clinical evaluation (see below).
The other subgroup consisted of patients admitted for various
other (nonapneic) reasons requiring lumbar puncture (LP) for diag-
nostic purposes. Results from the analysis of CSF B-EIR in these
two subgroups were combined. since there was no significant dif-
ference between the mean levels for both groups. Group B con-
sisted of infants with clinically confirmed apnea (see below).
The infants in Group C were siblings of SIDS victims, two of which
were identical twins of SIDS victims. Only two of the subjects in
this group showed a normal pneumocardiogram or polysomnogram dur-
ing clinical evaluation (see below). Group D consisted of four
subjects who had experienced an ALTE (sometimes referred to in the
literature as "near-miss" SIDS). requiring active resuscitation
(CPR). In one of these, the ALTE had occurred over a year earlier
and the CSF was tested because of continued problems with apnea.
Another subject in this group died within 24 hours of CSF sampling
without regaining consciousness. Group E consisted of patients
diagnosed as having Rett's syndrome.
Evaluation. The clinical evaluation of these subjects consisted
of a complete clinical examination and laboratory tests, including
differential blood count, electrolytes and other blood chemistry,
pneumocardiogram, electroencephalogram. and LP. Polysomnography,
upper gastroesophageal studies and computerized axial tomography
scans were performed when indicated.
Assay of beta-endorphin. A double-blind study was conducted, in
which all CSF and plasma samples were coded without identification
of the diagnosis, and the clinician was not informed of the re-
sults of the analyses until after he had assigned the patients to
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one of the groups noted above. The lumbar CSF was divided into
l-ml aliquots and frozen immediately. Heparinized blood samples
from some of the subjects in Groups A, B and C were obtained be-
tween noon and 2 p.m., just after performing the LP. The heparin-
ized blood was centrifuged immediately at 1500 x g for 10 min at
4" C. The resulting plasma was divided into 1-ml aliquots, acidi-
fied with 0.1 ml of 1 N HCl and frozen at -70° C until analysis.
After thawing, beta-endorphin was extracted from the plasma, using
Sep-Pak C-18 cartridges (Waters Associates, Milford, MA), as de-
scribed by Hong et al. (1983). The samples of CSF were not ex-
tracted, because the smaller amount of protein in CSF permits the
direct assay of beta-endorphin.
Following lyophylization in a vacuum desiccator, the frozen CSF
samples were reconstituted in 0.4 ml of 20 mM sodium phosphate
buffer, pH 7.5, and divided in half for duplicate determinations
of beta-endorphin with a radioimmunoassay kit (Immunonuclear
Corp., Stillwater, MN), which utilizes a rabbit anti-beta-endor-
phin serum. This anti-serum exhibits 100% cross-reactivity with
des-Tyr1- and N-acetyl-beta-endorphins, 50% cross-reactivity with
beta-lipotropin, but less than 0.1% cross-reactivity with met-
enkephalin. leu-enkephalin and dynorphin. After mixing 0.1 ml of
the anti-serum with the samples and standard amounts (2.5-1000 pg)
of beta-endorphin (Sigma Chemical Co.), the tubes were incubated
for 24 hours at 4° C. Following this incubation, 0.1 ml (5 pg) of
1z5I-beta-endorphin was added to each tube and incubated for
another 24 hr at 4° C. Bound and free beta-endorphin were sepa-
rated using a 2-hr incubation at 4° C with a goat anti-rabbit im-
munoglobulin precipitating reagent. After centrifugation, the
supernatant was carefully removed, and the pellets were counted
for 2 min in a gamma counter.
Statistics. Data were analyzed for significant differences with
computer programs for Dunnett's test and for linear regression
(Tallarida and Murray 1981).
RESULTS
CSF levels of beta-endorphin. The results of the analyses of the
CSF samples from each group for B-EIR are summarized in Figure 1.
CSF samples from the control group, Group A, had a mean (± S.E.)
of 31 ± 3 pg of B-EIR/ml of CSF, which is not significantly dif-
ferent from values in lumbar CSF from adults (Schlachter et al. ,
1983). All of the other groups showed significant elevations in
the concentration of B-EIR in CSF. With the exception of 3 of the
20 patients with Rett's syndrome, there was no overlap between the
values in CSF from any of the control patients and the individual
values from subjects in the other groups.
Comparison of plasma with CSF beta-endorphin levels. From some of
the patients in Groups A, B and C in this study, blood samples
were obtained after the LP procedure for the purpose of determin-
ing whether there was a positive correlation between the levels
of B-EIR in plasma and CSF (Fig. 2). This phase of the study
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FIGURE 1. B-EIR in CSF (mean ± SE) from A, 22 Control Infants: B,
10 Infants with Proven Apnea: C, 11 Infant Siblings of SIDS Vic-
tims: D, 4 Infants with History of ALTE; and Et 20 Patients with
Rett's Syndrome. *P<0.01, compared to Group A (Dunnett's test).
(i.e., the collection of blood samples) was not continued after
linear regression of the results from 11 of the control infants
in Group A and from 14 of the infants in Groups B and C indicated
the lack of a significant correlation between the levels of B-EIR
in plasma and CSF (correlation coefficient = -0.411, N = 25). The
individual groups also showed no significant correlation between
plasma and CSF concentrations of B-EIR.
FIGURE 2. CSF vs. Plasma Levels of B-EIR (pg/ml) in Control
Infants (open circles) and Infants from Groups B and C (closed
circles).
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Effects of naltrexone treatment. So far, 19 children with docu-
mented apnea of unknown etiology have been treated orally with
either naltrexone syrup or tablets (1 mg/kg/day). No side effects
of naltrexone treatment have been encountered, other than the pre-
cipitation of an opiate-like withdrawal syndrome (hyperactivity,
irritability, vomiting and abdominal cramps) within 90 min after
the first oral dose in one of the older children.
Of the 12 infants treated with naltrexone, only one had a recur-
rence of apnea, which coincided with insufficient medication or
stress associated with an automobile accident (in which the infant
was not injured). Two of the infants treated with naltrexone had
repeat LP's (8 mo and 1 yr later), and the B-EIR in their CSF re-
mained elevated.
The 7 older children in our study ranged from 2 to 8 years of age.
In addition to apnea, these children also had elevated levels of
B-EIR in their CSF (74 to 276 pg/ml). No further apnea was noted
during naltrexone therapy. The child with the highest CSF level
of B-EIR was a 6-year-old sibling of a SIDS victim and had a his-
tory of repeated hospitalization for ALTE's. The first dose of
naltrexone precipitated a withdrawal syndrome in this child. The
absence of apnea during one month of naltrexone treatment prompted
her parents to stop the medication, which was followed by recur-
rent apnea requiring CPR and reinitiation of naltrexone therapy.
Of the 8 patients with Rett's syndrome who have been treated with
naltrexone (1-2 mg/kg/day, p.o.). seizures were decreased in 3,
improvement of apnea was observed in 3, and improvements in aware-
ness, responsiveness and behavior were noted in 7 by independent
observers. Only one of these patients showed no improvement with
naltrexone therapy.
DISCUSSION
The results of the present study indicate that the respiratory de-
pression associated with certain pathological syndromes is accom-
panied by increased levels of B-EIR in the CSF. Our results from
patients with the infant apnea syndrome confirm the findings of a
preliminary report by Orlowski et al., (1982) and a more extensive
report which appeared while our study was in progress (Orlowski
1986). Sakaran et al. (1986) have also recently reported a signi-
ficant increase of B-EIR in the CSF of infants who had experienced
"near-miss" SIDS within 48 hr of CSF sampling. In addition, we
have found increased concentrations of B-EIR in CSF from all of
the siblings of SIDS victims and in CSF from most of our patients
with Rett's syndrome. Although the infant siblings of SIDS victims
were apparently healthy and had not had any apneic events wit-
nessed by their parents, most of them showed an abnormal pneumo-
cardiogram or polysomnogram.
Considering the possible role of endogenous opioid peptides in
respiratory function (McQueen 1983; Malcolm and Holaday 1985).
these findings indicate that elevated levels of beta-endorphin or
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related opioid peptides may contribute to the respiratory dys-
function observed in our subjects. This hypothesis is supported
by the improvement in respiratory status observed during naloxone
infusion (Orlowski 1986) or during therapy with oral naltrexone.
The beneficial effect of naltrexone therapy appears to be due to
the blockade of opioid receptors, because the patients we have
tested during therapy with naltrexone still showed elevated levels
of B-EIR in their CSF. Apparently, the levels can be elevated
enough to produce a typical opiate-like physical dependence, as
indicated by the precipitation of the abstinence syndrome with
naltrexone in one of our subjects.
Although it is not known how much of the beta-endorphin released
within the central nervous system reaches the CSF at the lumbar
level or what fraction of the B-EIR in the lumbar CSF is due to
authentic beta-endorphin or other pharmacologically active opioid
peptides. the improvement in respiratory function by naltrexone
and the precipitation of withdrawal in one patient indicate that
at least part of the elevations we observed are due to abnormal
increases in endogenous peptides with opioid activity. Therefore,
the measurement of B-EIR in lumbar CSF may be a useful marker for
deciding to initiate narcotic antagonist therapy or for investi-
gating the possible role of endogenous opioids in SIDS or respir-
atory disorders accompanying other pathological syndromes. It is
not known, for example, whether the increased B-EIR in CSF from
siblings of SIDS victims represents a genetic abnormality or is
due to environmental factors.
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The Acquired lmmunodeficiency
Syndrome: Do Drug Dependence and
Ethnicity Share a Common Pathway?
L. Brown, Jr., D. Murphy, and B. Primm
INTRODUCTION
Among the problems that continue to plague the drug
dependent, the acquired immunodeficiency syndrome
(AIDS) has retained a prominent position in the
attentions of the scientific and medical communities
as well as the lay public. Yet, despite significant
technological advances, prevention and health
education remain as the greatest prospects for
combating the epidemic of AIDS. Efforts directed at
known methods of disease acquisition and populations
with a disproportionately greater susceptibility may
serve as important foci of health prevention. To this
end, intravenous drug users and minority group members
present some interesting concerns and similarities.
As the second largest hierachical risk group, intra-
venous drug abusers (IVDAS) represent a significance
beyond their own numbers. Intravenous drug use has
been associated with 51% of female AIDS cases and 57%
of AIDS among pediatric patients (Centers for Disease
Control 1986). Furthermore, intravenous drug use is
to a large extent responsible for the prominence of
reported AIDS cases in the northeastern United States.
While blacks comprise 12% and Hispanics 6% of the
United States population (Vital Statistics 1980),
their proportion of the reported AIDS cases has been
25% and 14%, respectively (Centers for Disease Control
1986). The racial distribution by risk group also dif-
fers between whites and minority group members. AIDS
cases that could be traced to homosexual or bisexual
men or to the use of blood or blood products were more
likely to be white, while blacks and Hispanics predom-
inated in cases associated with heterosexual contacts,
with no identifiable mode of transmission or IV drug
abuse. Among women, the cumulative incidences for
blacks and Hispanics is 13.3 and 11.1 times
188
respectively, the incidence for whites. Of the pedia-
tric AIDS cases for which race/ethnicity information
was collected, 58% were black and 22% Hispanic.
A great number of factors might explain these find-
ings, yet investigations of this type are uncommon.
To further explore the relationship between ethnicity
and IV drug use in connection to the development of
AIDS, we present the preliminary findings of an exami-
nation of the prevalence of infection with the human
immunodeficiency virus (HIV) in association with vari-
ous patterns of drug use, sexual behavior, medical his-
tory and physical examination findings, and various
laboratory data.
MATERIALS and METHODS
The Addiction Research and Treatment Corporation, Inc.
IS a comprehensive drug treatment program with clinics
in the New York city boroughs of Brooklyn and Man-
hattan. Admission is predicated on the demonstration
of at least one year of opiate addiction. After
informed consent, medical and drug histories and phy-
sical examinations were performed by medical staff.
The study population was composed of 288 male and 124
female patients applying for admission or currently
enrolled in methadone maintenance between the period
of January 1, 1986 and March 1, 1986.
Routine laboratory evaluation included a complete
blood count (Technicon H 6000), serum electrolytes
(Technicon SMAC), liver function tests (Technicon
SMAC), and urinalysis (Ames Clinitek 200). Urine toxi-
cology screening was performed by enzyme immunoassay
(EMIT) and high performance thin layer chromatography
(HPTLC), while hepatitis B was performed by the method
of enzyme immunoassay (Abbott). Syphilis serology was
assessed by the rapid plasma reagin (RPR) method and
serum protein electrophoresis was performed by the mi-
crozone method. Sera were also tested in duplicate
for HIV antibody by enzyme-linked immunosorbant assay
(ELISA) and positives confirmed by Western Blot
(Biotech/Dupont) assay.
Statistical data analysis consisted of regression
analyses of conceptual domains of variables (see table
1) on seropositivity. Variables from each domain were
entered into the equation to determine the total vari-
ance for which each accounted. Additionally, the uni-
que variance accounted for by each of the five concep-
tual domains of variables was determined by assessing
the additional variance contributed in turn by each
particular domain, once the other four had been enter-
ed into the equations.
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TABLE 1 REGRESSION EQUATION PREDICTORS
Demographic Domain: Age, Sex, Ethnicity
Drug Use Domain: Duration of Drug Use
Type of Drugs
Most Often Route of
Administration
Sexual Behavior Domain: Preference, Frequency
Number of Partners
Medical History/Physical
Examination Domain: Diseases Associated
with Drug Abuse
Symptoms
Physical Findings
Laboratory Data: Albumin, Globulin
Gamma Globulin
White Blood Cell
Count
RESULTS
The age range of this group was 19 to 62 years with a
mean age of 34.4 ±0.35 (SEM) years. The ethnicity of
this group consisted of 49 percent black, 42 percent
Hispanic, and 9 percent white. The duration of drug
use ranged from one year to 38 years with a mean of
12.4 ± 0.33 (SEM) years. The overall prevalence for
HIV exposure was 54% with females (see table 2) being
slightly more likely than males to have been to be
seropositive. Blacks and Hispanics as a group were
one and one half times more likely to be positive in
this population.
TABLE 2 HIV ANTIBODY PREVALENCE
SEX
Male
Female
Positives
N No. (%) Odds Ratio
288 152 (53) 1
124 71 (57) 1.2
ETHNICITY
Whites 38 17 (45)
Blacks/Hispanics 374 207 (55) 1.53 (1.49-1.58)
From the regression analysis (see table 3), the do-
mains of drug use, medical history and physical
examination and laboratory data had a significant
total variance. In the drug use domain, this was
primarily attributable to those who claimed that the
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intravenous route was their most often route of
administration. In the medical history and physical
examination domain, this was largely accounted for by
the prevalence of generalized lymphadenopathy.
However, only the laboratory data domain had a
significant unique contribution to the explained total
variance reaching the 0.0001 level of significance.
TABLE 3 TOTAL AND UNIQUE VARIANCES CONTRIBUTED BY
DOMAIN OF VARIABLES TO HIV SEROPOSITIVITY
Domain of Total
Variables Variance
Unique
Variance
Demographic Domain
Drug Use Domain:
0.006 0.005
0.022 * 0.0008
Sexual Behavior
Domain:
Medical History/
Physical Examination
Domain:
0.002 0.007
0.04 ** 0.02
Laboratory Data: 0.16 *** 0.14 ***
* p<0.05 ** p<0.01
*** p<0.001
DISCUSSION
The acquired immunodeficiency syndrome has brought re-
newed attention to the consequences of drug depend-
ence. While significant advances have been made on
many fronts, the greatest capacity for intervention re-
mains in public education and information. The suc-
cess of prevention efforts is predicated on tailoring
approaches directed at target populations which are ei-
ther particularly susceptible or which serve as por-
tals for wider dissemination. For this reason, the
disproportionate greater occurrence of AIDS and HIV
infection among IVDA's and minority group members has
begun to stimulate discussion (Bakeman et al., 1986,
Centers for Disease Control 1986, Chaisson et al. ,
1987, Freidland et al., 1985, Ward et al., 1986, Weiss
et al., 1985). That IVDAs have a greater seropositivi-
ty rate than the general public is understandable; im-
munologic derangements in IVDAs are not uncommon. In
a previous study, we were able to demonstrate that
various patterns of drug abuse are associated with
greater immunologic aberrancies (Brown et al., 1986).
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The racial/ethnic distribution among AIDS cases pre-
sents a greater challenge to explain. The present
study also demonstrates a greater prevalence of HIV
infection among blacks and Hispanics as compared to
whites. However, when various groups of drug use pat-
terns, sexual behaviors, medical history and physical
examination findings, and laboratory findings were con-
trolled for in a systematic fashion, no demographic
variable could explain the distribution of HIV seropo-
sitivity in this population. To the contrary, only
specific laboratory data that may reflect underlying
immunological compromise was significantly associated
with exposure to the AIDS virus. Whether this associ-
ation between the laboratory data studied and HIV anti-
body prevalence reflects a greater susceptibility as
an antecedent to HIV exposure or the consequences fol-
lowing infection can not be explained by this study.
The disproportionate greater frequency of HIV infec-
tion among minorities may be in part explained by the
maldistribution of intravenous drug use in ethnic mi-
norities. This phenomenon of greater drug use may
merely be a reflection of poverty. Economics may also
determine various patterns of drug abuse. In this
sense, the drug dependent person may more likely
practice more risky, HIV exposing behaviors. There
may be other, as of yet not fully investigated,
cultural factors responsible for the ethnic/racial
distribution of AIDS and HIV infection.
There are two basic dividends of this study and subse-
quent discussion. Blacks and Hispanics are at dispro-
portionately greater risk of developing AIDS or other
forms of HIV infection. However, race/ethnicity, by
itself does not adequately explain this quite consis-
tent observation by many investigators. It is the pre-
valence in minority communities of underlying factors,
which affords this enhanced risk to HIV exposure and
its various sequelae. For blacks and Hispanics, as
has been demonstrated in the present investigation and
in many other epidemologic evaluations, much of the in-
creased risk can be attributed to intravenous drug
use.
Investigations which focus on evaluating racial/ethnic
differences in the distribution of underlying, HIV ex-
posing behaviors are in acute need. While basic
science and clinical research continue their brisk de-
velopment, ethnographic studies unlocking information
of cultural differences remain center stage in educa-
tion and prevention efforts. While the public health
implications are heightened for ethnic/racial minori-
ties, its significance for society as a whole is unde-
niable.
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Acute Opioid Physical Dependence
in Humans: Naloxone Dose Response
Effects
S. Heishman and M. Stitzer
The development of physical dependence is considered to be one
causative factor in the continued use and addictive abuse of opioid
drugs (Lindesmith 1980). Physical dependence is defined by the
appearance of a characteristic abstinence syndrome upon abrupt
cessation of a chronically administered opiate (Jasinski 1977). Acute
physical dependence (acute antagonist sensitivity) refers to the
withdrawal symptoms precipitated by the administration of an opioid
antagonist several hours following a single dose of an opioid agonist
(Martin and Eades 1961). This phenomenon is particularly interesting
given that the opioid abstinence syndrome has generally been thought
to develop only after prolonged exposure to opioid agonists.
Studies with both animals and humans have clearly demonstrated the
occurrence of acute opioid dependence. Research from the animal
laboratory has shown the development of withdrawal symptoms
following acute opioid administration with (Aceto et al., 1977) and
without (Grilly and Gowans 1986) antagonist challenge. The initial
demonstration of acute opioid physical dependence in humans came
from the work of Nutt and Jasinski (1974), who observed physiological
and subjective withdrawal symptoms precipitated by a methadone-
naloxone mixture one week after a single methadone exposure.
Consonant with animal studies (Martin and Eades 1964) antagonist
p rec ip i t a ted  w i thd rawa l  symptoms  have  been  repor ted  to  be
qualitatively similar to those observed in individuals experiencing
spontaneous withdrawal from chronic opioid dependence (Jones 1979;
Wikler et al., 1953).
Bickel et al., (1986) recently investigated the withdrawal symptoms
induced by naloxone 6 hours after single doses of morphine in
nondependent humans. Physiological, subjective, and observer rated
withdrawal signs were precipitated in a morphine dose related manner,
suggesting that the withdrawal response was specifically related to the
amount of morphine in the body. The purpose of the present study was
to further characterize the acute opioid abstinence syndrome by using a
similar paradigm to demonstrate a naloxone dose response function.
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METHOD
Subjects
Participants were six males (32-38 years of age) reporting a history of
prior opioid use of 5-24 years (mean=13.5) and average current opioid
use of 8 times per month. Four subjects reported previous participation
in methadone maintenance or detoxification programs; however, none
were currently seeking treatment. During the 5-week study, subjects
lived on an eight-bed inpatient research unit. In order to verify the
absence of current opioid dependence, subjects were observed for
withdrawal symptoms for 3-4 days on the research unit and received a
challenge naloxone injection prior to the start of the study. No
withdrawal symptoms were observed in any of the subjects.
Drugs
The constant morphine dose was either 18 mg/70 kg (N=3) or 30 mg/70
kg (N=3). Naloxone challenge doses were 0.1, 0.3, 1, 3, 10, and 30
mg/70 kg and were presented in  random order . Drugs were
administered under double blind conditions in a constant volume of 2 ml
i.m. in the right or left deltoid muscle.
Procedure
During their first week of participation, subjects were evaluated on two
test sessions: 1) placebo morphine followed 6 hours later by a 10 mg/70
kg naloxone challenge, and 2) 18 mg/70 kg morphine followed by 10
mg/70 kg naloxone. Three subjects who failed to report and exhibit
naloxone-precipitated withdrawal symptoms following 18 mg morphine
pretreatment were tested at 30 mg/70 kg morphine for the remainder of
the study. Subjects then participated in seven experimental sessions
conducted twice weekly, separated by at least 72 hours. On session
days, morphine injections were given at 9:00 am. Five and a half hours
af ter  the morphine in ject ion,  subjects were seated in a quiet
expe r imen ta l  room and  connec ted  to  phys io log i ca l  reco rd ing
equipment. While measurements were stabilizing for 15-20 minutes, a
baseline pupil photograph was taken, subjective forms completed, and
objective signs of withdrawal observed. Basel ine physiological
measures were then recorded for 10 minutes. Approximately 30
minutes after starting the session (6 hours postmorphine), subjects, who
were blind to drug, received an i.m. injection of naloxone or naloxone
placebo and were then monitored for 60 minutes. The measurement
battery of pupil photographs, subjective reports, and observer-rated
objective withdrawal signs was repeated at 5, 15, 30, 45, and 60
minutes postnaloxone.
Physiological measurements
Five physiological measures were recorded each minute throughout the
session: (1) systolic and diastolic blood pressure (mm Hg) determined
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osci l lometr ical ly  by a Sentron blood pressure monitor  wi th an
automatically inflating cuff, (2) mean arterial pressure measured during
blood pressure determination by the Sentron monitor, (3) heart rate
sampled during blood pressure measurement and converted to beats
per minute by the Sentron monitor, (4) respiration rate measured by a
chest  bel lows detect ing negat ive pressure changes which were
converted to breaths per minute, and (5) skin temperature measured by
a finger thermister. All signals were recorded by and stored on an Apple
lie microcomputer. Pupil photographs were taken in ambient room
lighting using a Polaroid camera with 3X magnification. Pupillary
diameter was measured in millimeters from the photographs using
calipers.
Subjective report measurements
At each measurement point during the test session, subjects completed
opioid symptom, withdrawal symptom, and drug effect questionnaires.
The opioid and withdrawal symptom forms each contained 15 items
describing typical opioid effects (eg., nodding, relaxed, talkative) and
withdrawal symptoms (eg., hot or cold feelings, watery eyes, abdominal
cramps). The drug effect questionnaire assessed six items: (1) drug
“high”, (2) any drug effect, (3) good drug effects, (4) bad drug effects, (5)
drug liking, and (6) withdrawal sickness. On all questionnaires, subjects
rated the extent to which they currently experienced each symptom or
effect on a lo-point scale from 0 (not at all) to 9 (most strongly). Items
were answered by using a joystick to move a pointer on the computer
screen to the desired position of a segmented line. A total score was
obtained for the withdrawal and opioid symptom questionnaires by
summing across the 15 items; each drug effect question was scored
separately.
Observer rated measurements
During the testing session, the experimenter, who was blind to dose and
continually present in the experimental room, observed and rated six
objective withdrawal signs on the same 10-point scale described above.
The following signs were observed: (1) tearing eyes was rated by gently
moving the subject’s lower eyelid up and down, (2) runny nose was
rated by listening for fluid sounds while the subject sniffed, (3)
perspiration was rated by the amount of wetness on the subject’s palm
and forehead, (4) gooseflesh was rated by observing the skin reaction
when the observer ran his finger lightly over the inside of the subject’s
forearm, (5) yawning was rated by observing occurrences during the
observation period, and (6) restlessness was rated by observing the
frequency of seat movements. A composite observer rating score was
obtained by summing the individual item scores.
Data analysis
Data were analyzed by three-way, repeated measures analysis of
covariance with morphine dose, naloxone dose, and time postnaloxone
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as the factors. The prenaloxone baseline score on each measure was
used as the covariate. For the continuously recorded physiological
measures, baseline scores were an average of the 10 minutes prior to
naloxone administration; postnaloxone data were summarized in 5-
minute blocks of time. Data from the 18 and 30 mg morphine doses
were combined for the present report because pupillary diameter was
the only measure which significantly differed between the morphine
doses.
RESULTS
Prenaloxone basel ine measures (not shown) revealed residual
morphine-induced miosis and respiratory depression; pupils were
constricted to about 3.0 mm and respirations averaged 15 breaths per
minute. As shown for selected measures in Figure 1, naloxone reversed
residual morphine effects and precipitated withdrawal symptoms in a
dose related manner. Naloxone significantly increased pupillary
diameter (p<.001) and respiration rate (p<.001) over naloxone placebo
levels. Heart  rate was increased (p<.001) and skin temperature
decreased (p<.05) by naloxone in a dose dependent manner; however,
blood pressure failed to show orderly dose related effects. Although not
statistically significant, trends in the data of subjective measures
suggested a reversal of residual morphine effects. Responses to the
“good drug effects”, “drug high”, and “drug liking” items from the drug
effect questionnaire were reversed at doses above 0.3 mg naloxone.
Additionally, naloxone precipitated subjective and objective signs of
opioid withdrawal. Naloxone produced s igni f icant  dose related
increases in subjective responses on the withdrawal questionnaire
(p<.001), “bad drug effects” item (p<.001), and “withdrawal sickness?
item (p<.01) from the drug effect questionnaire. Naloxone significantly
increased composite observer ratings of objective withdrawal symptoms
(p<.001); yawning (p<.01) and tearing eyes (p<.05) were the only
individual items showing a significant dose effect.
Time course data over the 60-minute session indicated complete
reversal of pupillary constriction by 5 minutes postnaloxone which
remained stable throughout the session. Maximum reversal  of
respiratory depression was evident by 10-15 minutes postnaloxone.
Subject ive reports and observer rat ings indicated that  onset  of
precipi tated withdrawal ef fects was equal ly rapid. W ithdrawal
questionnaire scores and composite observer ratings were clearly
elevated at 5 minutes with peak effect occurring at 5 or 15 minutes,
depending on dose. Responses on both measures gradually declined
to placebo levels within the session, except for the 30 mg naloxone
dose scores which remained elevated at 60 minutes postnaloxone.
DISCUSSION
This study documented the occurrence of antagonist precipitated
withdrawal symptoms in humans following single opioid exposures and
extended prior work by demonstrating naloxone dose response effects.
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FIGURE 7. Effects of naloxone dose on selected physioiogical (top panels), subjective-report
(middle panels), and observer-rated (bottom panels) measures. Pupillary diameter, subjective-
report, and observer-rated data for each naloxons dose are means of measurements taken
5, 15, 30,  45, and 60 minutes postnaloxone. Respiration data are means of 12 5-minute time
blocks. Data are adjusted for prenaloxone baseline values and show means of six subjects.
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Subjective responses on a withdrawal symptom questionnaire, on “bad
drug effects” and “withdrawal sickness” ratings, and composite observer
ratings of withdrawal were significantly increased by naloxone in a dose
dependent manner. Naloxone simultaneously produced significant
dose related increases in pupillary diameter and respiration rate,
indicating the reversal of residual morphine effects. These findings,
together with the work of Bickel et al., (1986) who reported morphine
dose related effects using a similar paradigm, suggest that precipitated
withdrawal is specifically related to the presence of opioid agonist and
antagonist in the body.
With the exception of respiration rate which showed a decrease at the
30 mg naloxone dose, physiological, subjective report, and observer
rated measures revealed an orderly dose related progression to the
highest naloxone dose. This suggests that the underlying mechanism of
acute antagonist sensitivity may be dependent upon the degree of
receptor occupancy by agonist drug which was not maximally reversed
by naloxone in this study. It would be interesting to test higher naloxone
doses to clarify the upper end of the dose response relationship for
withdrawal precipitation.
The reversal of residual morphine effects and onset of precipitated
w i t h d r a w a l  s y m p t o m s  o c c u r r e d  r a p i d l y  f o l l o w i n g  n a l o x o n e
admin is t ra t ion ;  e f fec ts  were  genera l l y  apparen t  by  5  m inu tes
postnaloxone. This is consistent with naloxone’s rapid onset in
reversing the effects of opioid overdose. The similar time course for
opioid reversal and withdrawal precipitation suggests that the two
processes share the same mechanism, displacement of opioid drug
from the receptor site.
Consonant with previous studies (Bickel et al., 1986; Jones 1979) the
reported and observed precipitated withdrawal symptoms were similar
to those reported by individuals experiencing spontaneous withdrawal
from chronic opioid dependence. Yawning was the most obvious
objective sign. This similarity suggests that the development of opioid
physical dependence is a continuous process beginning with the first
exposure to opiates. Because physical dependence can perpetuate
opioid use and abuse (Lindesmith 1980), examining the full range of its
developmental pattern is essential to a complete understanding of the
etiology of opioid abuse and the formation of effective treatment
approaches.
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Behavioral, Physiological and
Hormonal Effects of a Naloxone
Challenge Following Acute Morphine
Pretreatment in Humans
S. Higgins, K. Preston, E. Cone, J. Henningfield and J. Jaffe
The administration of an opioid antagonist (e.g.,
naloxone) following chronic treatment with an opioid
agonist (e.g., morphine) produces a withdrawal
syndrome. Less well defined is the phenomenon
referred to as "acute physical dependence" in which
the administration of an opioid antagonist shortly
after a single dose of an opioid agonist also
produces a withdrawal syndrome. Acute physical
dependence of the morphine type has been
characterized in several nonhuman species (e.g., rat,
monkey, dog) using a variety of unconditioned and
conditioned behavioral responses as well as
physiological and neuroendocrine measures (e.g.,
Eisenberg, 1982; Eisenberg & Sparber, 1979; Krystal &
Redmond, 1983; Martin & Eades, 1964; Smitts, 1974;
Sparber et al., 1978). Acute physical dependence
also has been demonstrated to occur in humans, but
has not been well characterized (Bickel et al., 1986;
Jones, 1980, Nutt & Jasinski, 1974). For example,
the only dependent measures reported to date are
composite ratings of opioid withdrawal and routine
physiological measures (e.g., respiration, pupil
size). Thus, it remains to be determined to what
extent acutely precipitated opioid withdrawal in
humans is similar to the more thoroughly studied
withdrawal syndrome observed following chronic
administration of opioid agonists. The present study
was conducted to further characterize in humans the
effects of a naloxone challenge following acute
treatment with varying morphine doses. The procedure
also obtained a more comprehensive evaluation of
acute physical dependence by including behavioral and
neuroendocrine measures in addition to the standard
signs and symptoms of opioid withdrawal.
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METHOD
Subjects
Six male postaddict volunteers who were current
sporadic users of illicit opiates participated in the
study. Subjects gave their informed written consent
to participate and resided on the residential research
unit of the Addiction Research Center (ARC) for the
duration of the study. To verify the absence of
physical dependence, subjects were required to provide
a drug-free urine specimen on the day of admission to
the ward. Further, all subjects were required to
reside on the ward, without opioid exposure, for 10
days prior to the start of the study. None of the
subjects exhibited signs or symptoms of withdrawal
during this 10-day pre-study period.
Drugs
During each experimental session, subjects received an
injection in the morning (A.M.) followed 6 hours later
by a second injection (P.M.). Subjects were exposed
once to each of the following dose conditions (A.M. &
P.M. drugs are listed first and second, respectively,
for each dose condition): (1) placebo, placebo: (2)
placebo, 10 mg naloxone; (3) 4 mg morphine, 10 mg
naloxone; (4) 8 mg morphine, 10 mg naloxone; (5) 16 mg
morphine, 10 mg naloxone, (6) 16 mg morphine, placebo.
Subjects always received dose-condition 1 first: the
remaining 5 dose conditions were scheduled according
to a latin square design. This design permitted days
1 and 2 to serve as vehicle control days. Dose
condition 6 permitted observation of the time-course
of morphine (16 mg) in the absence of a naloxone
challenge. Finally, dose conditions 3-5 permitted
assessment of naloxone precipitated opiate
withdrawal.
Procedure
Experimental sessions were conducted in two
components, A.M. and P.M., which are described below:
A.M. component: The subject was escorted to the
experimental room and an intravenous catheter was
inserted in his nonpreferred arm. Physiological
measures (respiration, heart rate, blood pressure,
skin and oral temperature, and pupil diameter) were
permitted to stabilize for 30 min, and thereafter were
assessed predrug and 15, 30, 45, 60, 90, and 120 min
postdrug. Subject ratings were recorded during the
same observation times as the physiological measures,
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except for ratings of "drug effect" which were
assessed only postdrug. The Digit Symbol Substitution
Task (DSST) was completed at predrug and 45 and 90 min
postdrug. Blood samples were drawn predrug and 15,
30, 60 and 120 min postdrug. Following the 120 min
postdrug observation, subjects returned to the ward
for 3.25 hrs before beginning the P.M. component.
P.M. component: Physiological measures were
stabilized for 30 min and then recorded predrug and
10, 30, 45, and 60 min postdrug. Subject ratings were
recorded at these same observation times, except
ratings of drug effect which were assessed only
postdrug. The DSST was recorded predrug and 10, 30
and 60 min postdrug. Blood samples were drawn predrug
and 15, 30, and 60 min postdrug.
Subject-Rated Measures
Subjects rated drug effects on 100 point visual line
analog scales marked at either end with "not at all"
and "exremely,n in both the A.M. and P.M. components.
Scales included "strength of drug effect," "good" drug
effects, "bad" drug effects, "drug liking," "high,"
and "sick." Other scales were also used to measure
possible symptoms of opiate agonist and opiate
withdrawal effects. The opiate withdrawal
questionnaire consisted of true/false questions drawn
from the ARC Inventory Weak Opiate Withdrawal Scale.
Prolactin and Cortisol Levels
Prolactin and cortisol levels were determined from
blood samples which were collected as described above.
Plasma samples were analyzed using standard
radioimmunoassay techniques.
Data Analysis
Effects in the A.M. and P.M. components were analyzed
separately. All measures except subject ratings of
drug effect were analyzed as changes from predrug
values.
RESULTS
Subject Ratings
A.M. component. Ratings in the A.M. component were
consistent with the characteristic acute effects of
opioid agonists in postaddict subjects. For example,
scores on the MBG scale (i.e., "euphoria") of the ARC
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Inventory and visual-analog ratings of drug "liking"
and "high" increased as an orderly function of
morphine dose (P <0.001).
P.M. component. In the P.M. component, subjects
reported symptoms characteristic of opiate withdrawal.
For example, the naloxone challenge increased scores
on the withdrawal questionnaire on days that subjects
werepretreated with 8 and 16 mg of morphine, and a
slight increase was observed following the 4 mg
morphine dose (P <0.02). Additionally, subject
ratings on several of the visual-analog scales
increased (e.g., sick, restlessness) as an orderly
function of morphine pretreatment dose (P <0.05).
Behavioral Measures
Neither speed nor accuracy measures on the DSST were
affected in the A.M. or P.M. components under any of
the dose conditions.
Physiological Measures
A.M. component. Consistent with the characteristic
effects of opioid agonists, pupil diameter and
respiration decreased in the A.M. component as a
function of increasing morphine dose (P <0.001).
No other physiological measures were affected during
this component.
P.M. component. The P.M. naloxone challenge reversed
the pupillary effects and also increased heart rate
following the 8 mg and 16 mg morphine pretreatment
doses (P <0.03).
Neuroendocrine Measures
A.M. component. The 8 and 16 mg morphine doses
increased prolactin levels in plasma, while the 4 mg
dose and placebo produced no effect and small
decreases, respectively (P <0.001). Cortisol levels
decreased across all of the dose conditions, but the
decreases observed after 16 mg of morphine were of
greater magnitude than those observed under the
control conditions (P <0.01).
P.M. component. Prolactin levels decreased in the
P.M. component as an orderly function of morphine
pretreatment dose (P <0.001). This effect was not
related to the naloxone challenge, however, since
similar decreases were observed when naloxone or
placebo followed the 16 mg morphine dose. Naloxone
increased cortisol levels following the three morphine
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pretreatment doses and also the placebo pretreatment
dose (P <0.003); however, the increase in cortisol
levels following the 8 mg morphine dose was of
greater magnitude than the increase observed
following the placebo pretreatment condition.
CONCLUSIONS
The present results further characterize the effects
of naloxone administration following a single dose of
morphine. These findings extend those of earlier
studies in which it has been demonstrated that this
procedure can produce signs and symptoms
qualitatively similar to those observed during abrupt
abstinence from a schedule of chronic opioid
administration. Specifically, increases in subject
ratings of discomfort and increases in pupil diameter
and heart rate were observed. Additionally, the
present study is the first to demonstrate in humans
that such a procedure produces elevated plasma
cortisol levels. The failure to find significant
effects on the behavioral measure (DSST) indicates
that, at the drug doses examined in the present
study, subjects remained capable of performing this
complex task despite feeling sick, etc.
In the A.M. component, subject ratings of drug
effect, physiological measures, and neuroendocrine
measures changed as an orderly function of morphine
dose. The withdrawal-like effects in the P.M.
component also were roughly dose dependent: effects
observed following 8 mg and 16 mg morphine
pretreatment were reliably greater than those
produced by the 4 mg dose. It is noteworthy,
however, that effects in the P.M. component following
the 8 mg pretreatment dose sometimes exceeded those
observed with the 16 mg dose. This overall
difference is largely attributable to data from one
subject who experienced unpleasant side effects
(e.g., vomitting) during the A.M. component from the
16 mg dose of morphine: those unpleasant effects were
reduced during the P.M. component by the naloxone
challenge. In contrast, the 8 mg pretreatment dose
did not induce such side effects and, when a naloxone
challenge followed, this subject reported an increase
in withdrawal symptoms. Overall, then, effects in
the A.M. and P.M. components generally were an
orderly function of morphine pretreatment dose, but
complex interactions were evidenced in the later
component depending on the degree of side effects
associated with the agonist dose.
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The present results extend the conditions under which
acute withdrawal from opioids has been studied in
humans. These results confirm earlier findings of a
high degree of concordance between the withdrawal
syndromes observed when an antagonist challenge is
administered following acute and chronic agonist
pretreatment. These findings suggest that the acute
physical dependence model holds promise as a
practical method for investigating factors that
influence the development and maintenance of physical
dependence. This procedure could lend itself to
studies in humans of issues not as readily testable
using conventional models of physical dependence.
For instance, it is plausible that similar tests
could be conducted in subjects without histories of
opioid abuse.
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Drug Discrimination in Human
Post-Addicts: Agonist/Antagonist
Opioids
K. Preston, G. Bigelow, W. Bickel and I. Liebson
The drug discrimination paradigm has been used
extensively in animals to study the stimulus properties
of the opioids. Our laboratory has developed an
experimental paradigm modeled after that used in the
animal laboratory to the study the discriminative
stimulus properties of the opioids in human opioid
abusers. This human drug discrimination paradigm
combines the advantages of laboratory drug discrimination
methods with those of traditional clinical psycho-
pharmacology methods. As with laboratory drug
discrimination methods, subjects receive explicit
behavioral training to discriminate standard training
drugs against which to compare test compounds or test
doses. As with clinical psychopharmacology methods,
subjects provide subjective reports concerning the drugs'
effects. We have previously reported the results of two
studies, one in which opioid-dependent volunteers were
trained to discriminate between the effects of saline,
hydromorphone, and naloxone (Preston et al., 1985) and a
second study in which non-dependent opioid abusers were
trained to discriminate between the effects of saline,
hydromorphone, and pentazocine (Bickel et al., 1986). In
each of these studies, subjects easily learned to
discriminate between the training drugs. Generalization
testing with various doses of the training drugs resulted
in dose-related increases in drug-appropriate responding
and in those subjective effect measures which had been
shown previously to be sensitive to the training drugs.
The present study was a follow-up to the second
study and was designed to assess the stimulus properties
of several opioid mixed agonist/antagonists. Post-addict
volunteers were trained in a three-way discrimination
between saline, hydromorphone, and pentazocine.
Generalization curves were then determined for various
doses of the active training drugs and three
agonist/antagonist opioids, butorphanol, nalbuphine, and
buprenorphine. Dependent variables included three
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different measures of discrimination, as well as more
traditional self-report and physiological measures.
METHODS
Subjects: The participants were six adult male post
-addicts who gave written informed consent and who were
paid for their participation. The subjects reported
prior narcotic addiction of 15 to 26 years duration.
Prior to their participation, subjects were found to be
in good health and without significant psychiatric
disturbance other than their drug abuse. Subjects
participated while residing on an eight-bed behavioral
pharmacology research ward.
Drugs: The training drugs were normal saline (4 ml),
hydromorphone 3 mg/70 kg, and pentazocine 45 mg/70 kg.
Dose-response generalization testing was conducted on the
two active training drugs, hydromorphone and pentazocine,
and butorphanol (0.75, 1.5, 3, 6 mg/70 kg), nalbuphine
(3, 6, 12, 24 mg/70 kg) and buprenorphine (0.11, 0.22,
0.45, 0.9 mg/70 kg). Commercially available preparations
of each drug, diluted to a constant volume of 4.0 ml,
were given intramuscularly under double-blind conditions
in two divided doses (2 ml in the right and left deltoid
muscle). Training drugs were identified to subjects only
by arbitrary letter codes. For each subject the drug
letter codes associated with each of the training drugs
were randomly determined, but remained unchanged
throughout the protocol
General Methods: The study proceeded in three phases,
with sessions conducted daily. Discrimination training
was conducted in sessions 1-6, during which the subject
received two sessions of exposure to each of the three
training drugs (saline, hydromorphone and pentazocine).
During these training exposures each drug was identified
to the subject by letter code prior to drug administra-
tion. The subject was instructed to attend carefully to
the drug effects and to try to discriminate precisely
among them; he was informed that in each session he would
earn money by correctly identifying the administered drug
by letter code. In sessions 7-12 acquisition of the
discrimination was tested by exposing the subject to the
training doses of each of the training drugs twice in
randomized block order to determine whether the subject
could correctly identify the training drug/doses by
letter code. During these and all subsequent exposures
to the training doses the subject received feedback about
the code of the administered training drug after the
session. This test-of-acquisition procedure was also
repeated among test sessions during the subsequent test-
ing phase to provide continued training and to insure
continued correct discrimination. Beginning with session
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13, a series of test sessions was conducted. Test ses-
sions were randomly interspersed with test-of-acquisition
sessions in which one of the training drugs/doses was
given. During this testing phase dose response curves
for each active training drug were determined in ran-
domized order, followed by dose-response curves for
butorphanol, nalbuphine, and buprenorphine. Following
each test session the subject did not receive feedback
about the correct drug identification but was informed
that it had been a test session and that the drug code
could not be revealed. Earnings in training and test-of-
acquisition sessions were calculated based on correct
identifications in each of the discrimination measures;
earnings on test days were not contingent on subject
responses but were based on the average amounts earned in
previous test-of-acquisition sessions.
Experimental Session: A microcomputer presented all
questionnaires in a prearranged and timed sequence. The
subject indicated his responses on manipulanda consisting
of a numeric pad and three telegraph keys. Daily ses-
sions began with the measurement of respiration, heart
rate, temperature, blood pressure and pupil diameter and
baseline self-report questionnaires. Drug was then given
by the nursing staff. During the initial training
sessions the subject was informed of the drug's identi-
fying letter code at the time of injection. The subject
remained under observation for 20 min, and then returned
to the experimental room to complete the post-drug
measures. Post-drug testing consisted of 4 repeating
cycles which began at 20 min intervals. Each cycle
contained assessments of subjective effects; drug
discrimination questions were presented twice, once in
the third cycle and again in the fourth cycle. At the
end of the session the staff again recorded physiological
measures. A sealed envelope was then opened, and the
staff informed the patient of the letter-code identity of
the administered drug or that the session had been a test
session, and the amount of his earnings.
Discrimination Measures: Drug discrimination data were
collected in three ways. In each procedure only correct
responses were converted to monetary reinforcement for
the subject. As one component of each assessment cycle
the subject made a discrete choice, naming by letter code
(A, B, or C) the drug he thought he had received. To
gain quantitative information concerning the degree of
stimulus similarity or concerning the subject's
confidence in his discrete choice, in a second component
the subject distributed 50 points between one or more of
the three drug choice alternatives depending upon how
certain he was of the identity of the administered drug.
In a third component the subject responded on a fixed
interval 1 sec schedule on computer keys designated with
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drug letter codes to earn points for 8.5 minutes. Points
could be earned for each of the three choice drugs by
pressing the key corresponding to that drug with a 10-sec
delay occurring whenever the subject switched keys.
Subject-Rated Measures: Questionnaires included: (1) 100-
point quantitative visual analog scales to indicate the
degree of drug effects, drug liking, "good" and "bad"
effects, subjective "high", and the similarity of the
drug effect to each of the training drugs on a scale from
"not at all" to "extremely"; (2) a 32-item adjective
rating questionnaire containing an opioid Agonist scale
(to detect traditional mu-receptor agonist effects), an
Antagonist scale (to detect opioid withdrawal effects),
and a scale composed of side-effects reported for the
mixed agonist-antagonist opioids (kappa/sigma receptor
agonists), and (3) a 49-item shortened form of the
Addiction Research Center Inventory (ARCI), which
contained the MBG ("euphoria"), LSD ("dysphoria") and
PCAG ("sedation") scales.
Data Analysis: The results of the discrimination train-
ing (discrimination of the training doses following two
exposures to each training drug) are reported as mean
percent correct identifications over the entire session
from sessions 7-12. The results of the subjective mea-
sures from the training and test-of-acquisition phase are
reported as the mean of scores from 4 exposures to each
drug in sessions 1-12. The data reported for the subjec-
tive effects are those collected at the end of the fourth
cycle, approximately 110 min post-injection. Results of
the generalization testing for discrimination measures
and subjective effect measures were analyzed as the mean
of scores for one exposure to each drug condition.
Repeated measures analyses of variance were conducted on
the training and test-of-acquisition phases and on the
dose response functions for each active drug. Effects
were considered statistically significant if p 0.05.
RESULTS AND DISCUSSION
The discrimination between the training drugs was readily
learned, and few errors were made in identifying the
training doses during test of acquisition sessions 7-12.
Saline and hydromorphone 3 mg were correctly identified
in 100% of these trials; pentazocine 45 mg was correctly
identified in 75% of trials. When errors occurred, they
typically occurred identically on all discrimination
measures. The effects on subjective effects measures
produced by the training drugs in sessions 1-12 were
similar to those previously reported. Hydromorphone and
pentazocine produced significant increases in the drug
effect, high, liking, and good effects quantitative
visual analog scales compared to saline. On the three
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adjective rating scales hydromorphone produced the
largest increase in Agonist scale scores while penta-
zocine produced the greatest increase in Antagonist scale
scores. The Mixed Agonist/antagonist scale scores were
increased approximately equally by hydromorphone and
pentazocine. On the ARCI pentazocine produced a signifi-
cant increase in LSD scale scores. No statistically
significant effects on any of the other ARCI scales were
found, though hydromorphone tended to increase MBG scale
scores. On the three visual analog scales which asked
subjects to rate "How much is this drug like . . . (each of
the training drugs)? each training drug was rated as
being very similar to itself, with very little similarity
to the other training drugs. Hydromorphone and
pentazocine produced a decrease in pupil diameter and an
increase in systolic blood pressure compared to saline.
During generalization testing similar results were found
on all three discrimination measures. Hydromorphone
produced dose-related increases in identifications as
hydromorphone and dose-related decreases in identifica-
tions as saline with the two lowest doses of hydro-
morphone being identified as pentazocine in approximately
50% of trials. On the visual analog scales measuring the
similarity of the test drug to each of the training drugs
hydromorphone produced dose-related increases in ratings
of similarity to hydromorphone 3 mg; however, even the 3
mg dose was rated as being only approximately half the
maximum scale of similarity to itself. This is in
contrast to the 100% hydromorphone-appropriate responses
on the operant discrimination measure at the 3 mg dose.
Hydromorphone produced significant increases in the
Agonist adjective rating scale, the drug effect, high,
liking, and good effects visual analog scales, and the
MBG scale of the ARCI. Pentazocine produced dose-related
increases in identifications as pentazocine and dose-
related decreases in identifications as saline. Pentazo-
tine produced very few identifications as hydromorphone.
On the visual analog scales measuring the similarity of
the test drug to each of the training drugs pentazocine
produced dose-related increases in ratings of similarity
to pentazocine 45 mg; however, as with hydromorhphone,
even the 45 mg training dose was rated as being only
approximately half the maximum scale of similarity to
itself. Pentazocine produced significant increases in
the drug effect, high, liking, and good effects visual
analog scales and in the LSD scale of the ARCI.
Butorphanol produced dose-related increases in identifica-
tions as pentazocine and dose-related decreases in identi-
fications as saline. On the visual analog scales
measuring the similarity of the test drug to each of the
training drugs butorphanol produced dose-related
increases in ratings of similarity to pentazocine 45 mg.
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Butorphanol tended to increase the Agonist adjective
rating scale and produced significant increases in the
Antagonist and Mixed Agonist/antagonist adjective rating
scales, the drug effect, high, and bad effects visual
analog scales and in the LSD scale of the ARCI. The
effects of nalbuphine did not clearly show it to be
similar to either pentazocine or hydromorphone. Nalbu-
phine 3 mg produced primarily pentazocine-appropriate
responses while 6 mg produced primarily hydromorphone-
appropriate responses. The two highest doses were iden-
tified approximately equally as hydromorphone and penta-
zocine. None of the doses were identified as being
saline. On the visual analog scales measuring the simi-
larity of the test drug to each of the training drugs
nalbuphine was rated as being not very similar to any of
the training drugs. On most of the subjective effect
measures nalbuphine produced relatively flat dose-
response functions and produced significant increases in
only two measures, the Antagonist adjective rating scale
and the drug effect visual analog scale. Buprenorphine
also was not clearly demonstrated to be similar to either
pentazocine or hydromorphone. The three highest doses
were identified equally as hydromorphone and pentazocine,
and only the lowest dose was ever identified as being
saline. On the visual analog scales measuring the simi-
larity of the test drug to each of the training drugs
buprenorphine was rated as being more similar to pentazo-
cine than to hydromorphone, particularly at the highest
dose. Buprenorphine tended to increase scores on all of
the adjective rating scales and produced significant
increases in the drug effect and good effects visual
analog scales and in the MBG and LSD scales of the ARCI.
In conclusion, the results of this study replicated an
earlier study (Bickel et al., 1986) showing that post-
addict volunteers could be trained to discriminate
reliably between the administration of saline, hydro-
morphone, and pentazocine in a study paradigm analogous
to that used in animal drug discrimination studies. Gen-
eralization testing with novel doses of the active train-
ing drugs produced dose related increases in drug appro-
priate identifications. Further, as found in previous
studies (Preston et al., 1985; Bickel et al., 1986) the
results indicated that there were no differences among
the three measures of drug discrimination used in this
study. The effects of the test compounds on the discri-
mination measures and subjective effects measures were
generally in concordance. Butorphanol produced a pattern
of changes in subjective effect measures which was simi-
lar to that produced by pentazocine and was clearly
identified as being like pentazocine in the discrimina-
tion measures. Nalbuphine had only moderate effects on
the subjective measures and, while clearly identified as
not being saline, was not strongly identified as hydro-
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morphone or pentazocine. Buprenorphine also did not
produce a pattern of subjective effects similar to
hydromorphone or pentazocine and was not clearly identi-
fied as being hydromorphone- or pentazocine-like. The
drug discrimination measures appear to provide an
additional useful tool with which to study the effects of
the opioid agonist/antagonists.
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Hormone Secretion in Methadone-
Dependent and Abstinent Patients
G. Woody, A. T. McLellan, C. O’Brien, H. Persky,
G. Stevens, I. Arndt and S. Carroff
INTRODUCTION
This paper presents results from a project that was designed to study the
relationship between hormones and dysphoric affects in methadone maintained and
detoxified opiate addicts. The data presented here represent the hormonal changes
observed; the affective changes will be reported elsewhere.
Acute administration of opiates has been observed to decrease serum testosterone
and LH levels (Mirin et. al., 1976), and to increase prolactin and inhibit secretion
of cortisol (Zis et. al., 1984). Chronic administration of opiates, as occurs during
methadone maintenance, has been reported to produce more variable effects.
Cushman and Kreek (1974) reported no significant differences in plasma
testosterone, prolactin, FSH and LH between normals and 8 selected stable male
methadone patients, though there was a tendency for those with lower plasma
methadone levels to have higher testosterone levels. Conversely, Mendelson et. al. ,
(1975) reported suppression of testosterone in addicts maintained on 80-150
mg. methadone/day while finding no differences from normals in patients
receiving 10-60 mg./day. Azizi et. al., (1973) found suppression of testosterone
but not LH in 22 male subjects addicted to heroin or methadone. Cushman et. al . ,
(1970) found that morning plasma corticosteroid levels were within the normal
range for methadone-treated heroin addicts; afternoon levels were high and
62.5% of the patients studied did not have a normal diurnal variation. Renault et.
al., (1972) also found both normal morning and afternoon cortisol levels in five
methadone-treated heroin addicts. In Renault’s study, methadone was
administered at noon, and close examination of the data suggests that the morning
plasma cortisol levels were higher than those found in the afternoon. These
somewhat inconsistent findings may relate to a number of factors such as dose, the
length of time on methadone, and the time at which plasma samples were taken in
relationship to the time of the last methadone dose.
Findings following detoxification from narcotics have been more consistent.
Eisenman et. al. (1960) found “tremendous increases” in both plasma and
urinary 17-OHCS immediately after withdrawal in two subjects who had become
experimentally addicted to morphine. It was not clear how long these levels
remained elevated. While studying testosterone levels in methadone maintained
opiate addicts, Mendelson and Mello (1975) found a return of the suppressed
levels observed during methadone maintenance to normal about one month after
detoxification.
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The study reported here attempts to expand upon the available data in this area,
and to clarify some of the discrepancies noted above, by examining the secretion
of testosterone, LH, cortisol and prolactin in independent samples of opioid addicts
during well-defined stages of maintenance, detoxification and abstinence, and at
multiple points in time.
METHODS
Subjects
Male heroin addicts between the ages of 19 and 35, meeting FDA requirements for
methadone maintenance and who were free of serious medical or psychiatric
disorders were recruited. Subjects who fit into a variety of categories relative to
their time on methadone were chosen, as seen in Table I. The methadone dose for
all subjects on maintenance was .9mg./kg. (+ or - 10 mg.) except the
pre-maintenance group (“off the street”) who were tested immediately upon
beginning maintenance treatment and before they had reached their final
maintenance dose.
OCCASION #
1 PRE-MAINTENANCE
(“Off-the-Street”)
2 EARLY MAINTENANCE
3 STABLE MAINTENANCE
4 LONG TERM MAINT
5 EARLY DETOXIFICATION
6 EARLY DRUG FREE
7 LONG TERM D.F.
8 CONTROLS
DESCRIPTION # SUBJECTS
New intakes on no more than 18
30mg methadone, for not longer
than 2 weeks.
Not on methadone longer than 27
2 weeks, after reaching a dose
of .9mg/kg body weight (+/- 10mg)
274-6 months on .9mg/kg body
weight (+/- 10mg)
On methadone 2 or more years, 10
at .9mg/kg +/-10mg.
Immediately post detoxification: 1 8
2-5 days after last methadone dose.
3 or more weeks post
detoxification.
9
No methadone or illicit drugs for 1 5
2 or more years.
Non-addicts matched for age, race, 16
sex and socioeconomic status.
TABLE 1
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All maintenance subjects were recruited from the drug treatment program at
the Philadelphia V.A. Medical Center. Controls were members of the hospital
staff who were drug-free and had a negative history for drug abuse. Long
term drug-free subjects were recruited from graduates of two nearby
therapeutic communities. Both the long term drug-free and control groups
were matched by age, race and other sociodemographic characteristics with
the maintenance groups. All the long term drug-free subjects had been
treated with methadone for at least six months during their addiction career.
The medical history, physical examination, SMA 6/12, urinalysis, and urine
drug screen were used to verify the absence of current drug use and other
serious medical or psychiatric disorders in all subjects tested. Contacts from
the therapeutic communities also served to verify the fact that the long term
drug-free subjects were legitimate members of that category. Subjects were
excluded if they were taking any medication other than methadone.
Procedure
Study subjects were admitted to the Philadelphia V.A. Medical Center inpatient
drug ward for testing. The procedures followed on all testing occasions were
identical except for methadone administration. Informed consent was obtained
from each subject prior to study, according to standard procedures.
Blood samples were obtained by means of a Sigmamotor microflow blood
withdrawal pump through an indwelling non-thrombogenic catheter. The
pump, which provides an integrated plasma sample, was set at 10 ml/hr. and
collecting tubes were changed at 30-minute intervals. All blood samples
were centrifuged immediately after completion of collection and the plasma
was separated and stored at -25 degrees centigrade until analyzed. Hormone
analyses were done by SmithKline laboratories.
Blood samples were collected every half hour over a 7 hour period (8:30
A.M.- 3:30 P.M.) for determination of plasma testosterone, LH, cortisol and
prolactin. Methadone patients were given their daily dose at 10 A.M.
Methadone patients had been in the ward for at least the prior 24 hours, thus
all had received at least two consecutive daily doses at 10 A.M., and were free
of illicit drugs. Controls and the long term drug-free subjects rested at home
overnight and entered the inpatient drug ward at 7:30 A.M. on the day of
testing.
RESULTS
Maintenance
The levels of the four hormones studied on each occasion are seen in Tables
1-4A (maintenance groups) and 1-4B (drug-free groups). All maintenance
subjects demonstrated suppression of cortisol, testosterone and LH, beginning
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one and one half hours following the daily oral dose. Prolactin levels rose
precipitously at about the same time. All hormone levels appeared to slowly
revert toward those observed in the normal subjects beginning approximately
three to four hours after the daily methadone dose, such that they approached
control levels by the end of the 24 hour methadone dosing cycle. However,
this return toward normal levels was not identical for all hormones on all
occasions. As seen in the tables, the levels of cortisol, testosterone and LH
appear to be suppressed less in the long-term maintenance patients (more
than 2 years on methadone) than in the “off the street” and early maintenance
groups. Similarly, the rise in prolactin levels appears to be greater in the
early maintenance patients than in the long-term group. These differences
between occasions suggest that partial, but not complete, tolerance to the
hormonal effects of methadone occurs.
Drug free
There was an immediate and marked rise in cortisol levels immediately after
detoxification with a return to normal in the long-term drug-free subjects.
This elevation in cortisol was present even 2-3 weeks following
detoxification, though to a lesser degree than at 2-5 days. Prolactin levels
returned to normal immediately after detoxification, however the long-term
drug-free patients had significantly higher levels of prolactin than any other
of the drug-free groups. There was an immediate rise in testosterone and LH
after detoxification. The levels observed on Occasion 5 (Early detoxification)
appear somewhat higher than controls, with a return to control levels by 2-3
weeks. This change is not substantial, however, the long-term drug-free
subjects had significantly higher LH and testosterone levels than the controls,
as they have with prolactin.
DISCUSSION
These data indicate that discrepancies in earlier data about the effect of
methadone on these hormones can be accounted for by taking into consideration
1) the time at which the hormone is measured relative to the daily methadone
dose and 2) the length of time that the person has been on methadone. For
example, all hormones more closely approach normal levels if measured
immediately before the daily dose, and if measured at this point one is more
likely to find that they do not differ from normals. However, significant
differences are usually observed if the same measurements are done three or
four hours after dosing. Differences in hormonal levels can also be masked,
or accentuated, by choosing subjects who have been on methadone for varying
periods of time. We do not have data on differences according to dose as we
attempted to hold dose constant on all occasions except #1 , but Mendelson et.
al., (1974) findings indicate that dose can also significantly effect the
results obtained.
The finding of elevated testosterone, LH and prolactin levels in the long term
drug-free subjects is interesting. We cannot be certain if this reflects a
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rebound from the suppression of these hormones while on methadone, or if it
is a function of the sample. Most heroin addicts do not achieve long term
abstinence, and thus these subjects may differ from the maintenance patients
in terms of motivation, social skills or other dimensions. On the surface this
group resembles all the others, including having been treated with methadone
for at least six months at some time in their lives. However they may be
significantly different from the others in some subtle and perhaps
difficult-to-measure ways.
Finally, it should be noted that we began this study in an attempt to explore
possible biological alterations in a group of patients with high levels of
psychiatric disturbance (Rounsaville et al., 1982). Our data confirms the
fact that methadone has potent endocrinologic effects, accentuating diurnal
secretion in some hormones while significantly altering the secretion of
others. The behavioral and physiologic implications of these alterations, and
their long-term sequelae, may be clinically significant.
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TABLE 1A. CORTISOL LEVELS BY TIME AND GROUP
TABLE 2A. PROLACTIN LEVELS BY TIME AND GROUP
TABLE 3A. TESTOSTERONE LEVELS BY TIME AND GROUP
TABLE 4A. LH LEVELS BY TIME AND GROUP
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TABLE 1B. CORTISOL LEVELS BY TIME AND GROUP
TABLE 2B. PROLACTIN LEVELS BY TIME AND GROUP
TABLE 3B. TESTOSTERONE LEVELS BY TIME AND GROUP
TABLE 4B. LH LEVELS BY TIME AND GROUP
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The Reduction of Intravenous Heroin
Use, Non-Opiate Abuse and Crime
During Methadone Maintenance
Treatment: Further Findings
J. Bali, E. Corty, H. Bond, C. Myers and A. Tommasello
ABSTRACT
As part of a three state study of the effectiveness of methadone
maintenance treatment, data from 617 addict patients were
obtained with respect to their lifetime and in-treatment
characteristics. The Addiction Severity Index (ASI) was employed
along with supplementary items on previous treatment and criminal
behavior.
It was found that there was a marked reduction in intravenous
heroin use after admission to treatment and a lesser reduction in
the use of non-opiate drugs. Significantly, the overall
incidence of drug abuse continued to decline with time in
treatment; thus, the long-stay cohort (more than 4.5 years) had
the lowest incidence of abuse while in treatment.
The reduction in criminality after admission to methadone
maintenance treatment was dramatic; all 14 types of crime
declined markedly - most over 80 percent. The reduction in
criminality was associated with time in treatment. Thus, mean
crime-days per year at risk decreased as follows: (1) during
addiction period when "on the street" = 306.8; (2) in treatment
.5 to 4.5 years = 24.0; (3) in treatment more #an 4.5 years =
18.0 crime days per year.
INTRODUCTION - RESEARCH ISSUES ADDRESSED
Contemporary research has established that there is a marked
reduction in heroin use and crime among addicts in the United
States after admission to methadone maintenance (MM) treatment.
This finding has far-reaching ramifications as it indicates that a
nationwide modality of treatment can successfully impact those
addicts whom it reaches. Thus, the fact that there is a notable
reduction in intravenous heroin use and criminal behavior among
the 72,000 out-patients currently in methadone maintenance
programs is significant.
Although there is general agreement that methadone maintenance
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treatment reduces both heroin use and crime, a number of further
research questions remain to be addressed:
1. To what extent does non-opiate abuse and alcohol abuse persist
(or increase) after admission to methadone clinics?
2. What amount and types of crime persist after
admission to methadone maintenance treatment? How
is such crime affected by long-term stay?
3. How soon after admission does heroin use fall off?
Does it cease with long-term treatment?
RESEARCH METHOD
The present study is part of a federally supported project
investigating the effectiveness of methadone maintenance programs.
New admissions and patients already in treatment at six MM
programs ware interviewed concerning addiction related
problems by 12 professional, extramural interviewers.
The interview schedule consisted of the Addiction
Severity Index and supplementary questions on treatment
experiences and criminal behavior.
SUBJECTS
Male patients who ware admitted to these six programs during an
eight week period in the fall of 1985 were eligible for
participation. In addition, at each of these programs a random
sample of male patients who had been in treatment for six months
or longer was drawn and interviewed during the same eight week
period (these patients were interviewed again in 1986).
PRETREATMENT CHARACTERISTICS OF 617 MALE HEROIN ADDICTS
The 617 male patients selected for study were in six methadone
maintenance programs in three cities: New York, Philadelphia and
Baltimore. The mean age of the 617 male patients at time of first
interview (in Late 1985) was 36.3 years. With respect to race and
minority group status, 51.2 percent of the patients were black,
40.7 percent white, 6.3 percent Hispanic and the remaining 1.8
percent were Orientals, American Indians and of other races.
Thus, 59.3 percent of the patients ware minority group members.
From their onset of opiate use as teenagers, almost all the
subjects used heroin for many years. Thus, their mean years of
heroin use was 11.1 years and this was supplemented by use of
other opiates as wall. In this latter regard, 30.5 percent were
regular users of other opiates and these had 8.0 mean years of
such use.
In addition to their history of opiate addiction, these patients
also abused an assortment of non-opiate drugs. The two most
common were marihuana and cocaine, each of which was regularly
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abused by over half of the addicts (72.9 & 59.7 percent
respectively). In both these cases, the drugs were consistently
used over several years (10.4 years for marihuana and 5.7 years
for cocaine).
Next in lifetime prevalence were "other sedatives" (34.0 percent),
amphetamines (24.5 percent) and barbiturates (24.1 percent).
These three classes of drugs here used for some 2.9 years to 5.4
years each. Hallucinogens and inhalants were the least frequently
abused drugs. Hallucinogens were regularly abused in the past by
17.7 percent of the addicts; inhalants by only 6.7 percent.
Use of alcohol to intoxication on a regular basis was quite common
within this addict population. Thus, 50.7 percent reported one or
more years of such abuse and the mean years of regular use to
intoxication for these was 8.4.
Most of the 617 male methadone maintenance patients had a
considerable history of prior treatments for drug abuse. Indeed,
94.3 percent reported such prior treatment and the mean number of
episodes was 4.0. With regard to prior methadone maintenance
treatment, 28.0 percent have never had methadone maintenance
treatment before; 29.3 percent have been in methadone treatment
once before; 31.0 had 2 or 3 prior treatments, 11.7 percent have
had 4 or more prior methadone treatments. In addition to prior
treatment for drug abuse, some 11.9 percent of these patients have
had prior treatment for alcohol abuse.
CRIMINAL HISTORY AND INCARCERATION
Most of the male methadone maintenance patients in the present
study have a long history of criminal behavior, arrests and
incarceration. Thus, the 617 males reported 4,681 prior arrests
at time of interview. (or a mean of 8.8 arrests per person for
the 532 who had been arrested). With respect to type of arrest,
the following percentage of the 532 males have been arrested for
these offenses:
1. Shoplifting - 36.5% 7. Assault - 28.6%
2. Parole violation - 34.8% 8. Arson - 2.1%
3. Forgery - 14.5% 9. Rape - 1.7%
4. Weapons offenses - 33.5% 10. Homicide - 6.2%
5. Burglary - 43.6% 11. Other non-drug offense - 14.3%
6. Robbery -27.1% 12. Drug business - 71.1%
In addition to arrests, the addict patients reported on their
usual day-today offenses prior to current treatment. These data
indicate the actual extent of criminality while arrests do not
since less than one percent of crime-days result in arrest. With
regard to day-to-day criminal behavior during their last addiction
period, they reported that they engaged in crime some six days a
week. That is, 54.3 percent reported daily crime, 22.4 percent
engaged in crime 1 to 6 times per week and 21.4 percent reported
no crime on a regular weekly basis.
226
As might be expected, the incarceration history of these addicts
is extensive. Prior to their present treatment, 65.6 percent of
the addicts had been incarcerated and their mean years behind bars
was 3.8 years. Significantly, 7.3 percent had 10 or more years of
incarceration before this treatment.
REDUCTION IN DRUG ABUSE AND CRIME DURING METHADONE MAINTENANCE
TREATMENT
The 617 addict patients who were interviewed in late 1985 at six
methadone maintenance programs ware a stratified representative
sample of the 2,394 patients in these clinics. Thus, there were
126 new admissions, 342 average stay patients and 149 long-term
patients.
The extent of drug abuse among these 617 male patients in
methadone maintenance treatment is tabulated in Table 1. As
expected, the extent of opiate use among the admission sample was
high, with 66.1 percent reporting heroin use in the past 30 days
and 14.5 percent reporting use of other opiates. Inasmuch as some
of those patients came from jail or other incarceration, this
sample was in transition from various stages of their addiction
status to stabilization on methadone. With respect to non-opiate
use, this sample - or at least a major portion of it - was
simultaneously involved in the abuse of these drugs. Thus, 58.0
percent abused cocaine, 48.8 percent used marihuana, 38.7 percent
used alcohol to intoxication and 31.5 percent used sedatives other
than barbiturates. In sum, these new admissions were
significantly involved in non-opiate drugs prior to or during
admission (Table 1).
Those patients who were in treatment for .5 to 4.5 years reported
markedly lower incidence of drug abuse. With respect to the use
of heroin, 23.4 percent reported continued use, but such use was
only for 6.3 days per month. Use of other opiates similarly
declined from 14.5 percent (of admission sample) to 8.3 percent of
the moderate-stay sample. For non-opiate drug use, there also was
a general decline in the percent who used these drugs. There was
not, however, an appreciable decline in marihuana use (48.8 vs.
47.0 percent) and the overall frequency of use per month for those
who did abuse non-opiate drugs did not change.
The long-term impact of methadone maintenance is evident in the
extent of drug abuse among those in treatment for more than 4.5
years. Among these patients, both opiate use and non-opiate use
has almost ceased (with the exception of cannabis and alcohol
abuse). Thus, 92.4 percent report no use of heroin and 96.6
percent report no use of other opiates. For non-opiate drugs, 95
percent or more report no use of barbiturates or amphetamines; 83
percent were not using cocaine. Somewhat higher rates persist for
marihuana use (37.9 percent) and alcohol use to intoxication (30.3
percent).
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REDUCTION IN CRIMINAL BEHAVIOR AFTER ADMISSION TO TREATMENT
In order to obtain baseline information on patients'
criminality prior to treatment, patients were asked to recount the
types and frequency of offenses committed during their last
addiction period.
A marked reduction in crime occurs after patients are integrated
into methadone maintenance treatment. This reduction in
criminality is evident with respect to all types of crime.
Indeed, the general uniformity of the rate of reduction of
criminality for 14 types of crime is striking. That is, the fact
that 10 of the 14 types of crime decline by 80 percent or more is
an unexpected finding; more variation and less decline were
anticipated.
The extent to which crime was reduced during treatment can be seen
from a comparison with the crime rates for the moderate length of
stay and long-term stay patients.
Mean Crime Days Per Year:
Pretreatment: When Addicted, (N=600) 306.8
Intreatment: Moderate Stay, N=345 24.0
Intreatment: Long-Term Stay, N=145 18.0
CONCURRENT REDUCTION IN HEROIN USE AND CRIME DURING TREATMENT
The concurrent reduction in heroin use and crime following
admission to methadone maintenance treatment is tabulated in Table
2. For the new admission sample, many of the addicts had already
given up heroin or crime or both by time of interview. But this
sample was in transition during the 30 day period of record, so
cautious interpretation of these findings is indicated.
Most of the addict patients had completely given up both heroin
use and crime after 6 or more months in treatment. Thus, 66
percent of the patients in the moderate stay sample reported no
use of heroin and no crime. Significantly, most of those who were
not complete successes (i.e., heroin days or crime-days in past
30) engaged in one or the other, but not both. But of the 23
percent who reported some heroin use, the mean days per month of
use was only 1.4. Comparable findings with respect to crime were
that 19 percent continued with some offenses, but again the mean
days were (comparatively) low - only 2 crime days per month.
By the time patients had been in treatment over 4.5 years, both
heroin use and crime had almost ceased! Thus, 83 percent of the
long-stay sample here complete successes; 13 percent reported
either some heroin use or crime, but only 4 percent reported both.
But again, the frequency of heroin use or crime was low -0.9 days
per month for those who used heroin and 1.5 days per month for
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those still involved in crime.
CONCLUSION
Investigation of the lifetime and current characteristics of 617
patients in methadone maintenance treatment reveals that there was
a marked reduction in both opiate and non-opiate drug abuse during
treatment. Concomitantly, there was a notable decline in criminal
behavior.
It was found that length of stay in treatment was significantly
related to this reduction in drug abuse and crime; heroin use and
crime continued to decrease after one or more years in treatment.
These findings support the efficacy of long-term methadone
maintenance treatment.
At the same time, a number of collateral issues still need to be
addressed. Are there model programs in terms of effectiveness?
For example, which combinations of the five major components
(methadone, counseling, urinalysis , medical and administration) of
methadone maintenance treatment are most effective? What is the
impact of treatment upon rehabilitation and psychiatric status?
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Table 1. Frequency of Opiate and Non-Opiate Drug Use in Past
30 Days For Three Treatment Cohorts: New Admissions,
Moderate Stay and Long-Term Methadone Maintenance Patients.
Chi square tests for each drug type used are significant at the .01 level,
except for cannabis which was not significant.
(missing data on 10 cases).
Table 2. The Reduction of Heroin Use and Crime By Time in Methadone Maintenance
Treatment For 617 Male Patients.
NOTE: Success was defined as no heroin use days or crime days in past 30 days.
The Chi square value for this table is 303.8 which is significant at the .01 level.
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A 2.5 Year Follow-Up of Abstinence
and Relapse to Cocaine Abuse in
Opioid Addicts
T. Kosten, B. Rounsaville and H. Kleber
ABSTRACT
During a 2.5 year follow-up of opioid addicts, we
examined psychosocial antecedents and consequences of
the onset and remission of cocaine abuse. Patients
whose cocaine use increased during follow-up had more
severe problems than either those whose use decreased
or those who never used cocaine. Furthermore, the
attainment of cocaine abstinence among abusers was
associated with improved psychosocial functioning,
while the onset of cocaine abuse was associated with
increased problem severity. Compared to drug-free and
detoxification alone treatments, methadone maintenance
may minimize legal complications of cocaine abuse, but
otherwise it did not significantly reduce psychosocial
morbidity from increasing cocaine abuse.
INTRODUCTION
Cocaine abuse has become a significant problem among
opioid addicts, with the rate more than tripling from
1974 to 1978 (1-3). In previous reports, we examined
the rate of cocaine abuse among methadone maintained
patients in 1978-80 and in 1983 (2.3). In 1978-80
cocaine abuse was very common among opioid addicts, but
methadone maintenance treatment appeared to be
associated with reduced cocaine use (2). However, in a
follow-up conducted in 1983, patients on methadone
maintenance were reporting more cocaine use than those
opioid addicts not in any active treatment (3). In the
present longitudinal analyses we have focused on
several dimensions of treatment outcome that go beyond
drug abuse among the cocaine abusing opioid addicts.
The central question is whether increased cocaine abuse
during the follow-up was associated with deterioration
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in other dimensions of these patients' functioning or
was cocaine use a more circumscribed problem for these
patients. Early studies emphasized the benign nature
of cocaine use, but more recent work has suggested that
cocaine abuse may have adverse consequences (4,5).
To facilitate the analysis of antecedents and
consequences of cocaine use, our 2.5 year follow-up
will be divided into 6 month blocks and the three six
months before, during and after the two index events
(abstinence or onset of use) will be compared. If
psychosocial problems "cause" cocaine abuse rather than
being consequences of this abuse, then these problems
should be severe for the six months preceding the onset
of use and significantly lower during the six months
preceding the attainment of abstinence. With the
opposite findings (e.g. problems follow onset of use
and precede attainment of abstinence), the conclusion
that cocaine abuse leads to these psychosocial problems
would be more likely. Finally, if attainment of
abstinence or onset of use are unrelated to
psychosocial problems, this will suggest that cocaine
abuse may be a more circumscribed problem without
widespread effects on psychosocial functioning.
M E T H O D S
Three hundred and sixty-one (361) opioid addicts from
the Substance Abuse Treatment Unit (SATU) of the
Connecticut Mental Health Center were targeted for
follow-up evaluation 2.5 years after the initial
evaluation (3). From this target sample 268 were
relocated and agreed to participate. The followed-up
subjects included 48% whites, 76% males, 27% currently
married, 47% unemployed. These subjects had a mean age
of 27.6 ± 4.8 years and had used opiates for 9.3 ± 4.2
years. Eight subjects were not included in these
analyses because of incomplete data on cocaine use.
Drug abuse and treatment participation were elicited
using forms based on the Client Oriented Data
Acquisition Program (CODAP). The frequency of heaviest
abuse during the previous 6 months for each of ten
classes of drugs was rated using these 7 point CODAP
scales. Outcome was assessed using the Addiction
Severity Index (ASI) at follow-up interview and 100
point scales assessing outcome during the five 6-month
blocks of this 2.5 year follow-up. These 100 point
scales covered criminal activity, social adjustment,
employment, physical disability, global outcome, and
opiate, cocaine and alcohol use.
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RESULTS
in the top panel of the Figure are shown the scores on
the six ASI scales for three cocaine use categories:
never used (None), decreased (Less) use, and increased
(More) use of cocaine during the follow-up. In
general, patients with increased cocaine abuse had more
severe problems in the areas of drug abuse, legal
problems, employment, and family/social problems.
Psychological and medical problems showed no
significant differences among cocaine use groups. A
two way analysis of variance (ANOVA) was also performed
for each outcome factor using treatment type
(methadone, drug free or detoxification alone) and
change in cocaine use as main effects. None of the
interaction terms across cocaine abuse and treatment
type were statistically significant. However, there
were three significant differences among the treatment
types. Significant differences occurred among the
treatment types for the drug abuse, family/social and
psychological problem areas. When covariance
adjustments were made using ASI scores at intake,
however, the three treatments significantly differed
only in legal problems with the methadone patients
showing the least legal problems on the ASI.
To assess the time period surrounding attainment of
abstinence and the onset of cocaine use, the 30 months
of the follow-up were divided into 6 month blocks. An
episode of abstinence was defined as 6 months with no
cocaine use. Fifty-two cocaine abusing patients
attained abstinence for at least 6 months during the
follow-up. Forty-four patients had the onset of
cocaine abuse during the follow-up, and 36 of them had
not been using cocaine when they initially applied for
treatment. The other 8 patients had been using cocaine
at entrance to treatment, but had then become abstinent
and relapsed to cocaine abuse after being abstinent for
at least 6 months.
The antecedents and consequences of starting and
stopping cocaine abuse were examined by comparing the
ratings made for the 6 months before (Pre), during
(During) and after (Post) the index events of starting
or stopping cocaine abuse. The middle panel of the
Figure shows the problem severity scores for the onset
of cocaine use. When patients began using cocaine
(During time block), they developed significantly more
severe problems with criminal activity, global
assessment of functioning, social adjustment with
family, and opioid use. These problems continued to be
severe for the subsequent six months (Post time block),
in spite of a drop in cocaine use severity for the Post
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Figure I
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6 month period. Three other areas (employment,
physical disability and alcohol use) showed no
significant differences between any two time periods.
The relationship of attaining cocaine abstinence to
clinical status is shown in the bottom panel of the
Figure. It shows that with cocaine abstinence (During
time block), problems of criminal activity, global
assessment, family social adjustment, and opioid use
all decreased significantly. Overall, problems in each
of these areas substantially decreased when the patient
became abstinent from cocaine and increased when he
relapsed to cocaine use.
DISCUSSION
During this 2.5 year follow-up of opioid addicts we
found that those who increased their frequency of
cocaine abuse (e.g. from monthly to weekly or from
weekly to daily cocaine use) had more severe problems
on a wide range of outcome dimensions. Psychosocial
problems were generally more severe among the cocaine
users whose use increased than among those whose use
decreased or who had never used cocaine. Furthermore,
social adjustment deteriorated substantially with the
onset of cocaine use and improved substantially with
attainment of abstinence, as shown by the 6 month
blocks analysis. In general, psychosocial
complications of cocaine abuse did not differ among the
three treatment types, although the risk of legal
problems appeared to be significantly less for cocaine
abusers in methadone maintenance. This may simply
reflect the more frequent illegal activities associated
with non-methadone patients' seeking of illicit opioids
along with cocaine.
Two factors may be important in leading abusers to
abstain or at least decrease their cocaine use -
medical problems and legal pressure. Medical problems
were significantly worse among those whose cocaine use
decreased rather than increased. This suggested that
medical complications of cocaine use such as hepatitis
or other infections for I.V. users may have contributed
to these patients decreasing their cocaine use. The
legal system may also apply external pressure on
cocaine abusers. This speculation about legal
pressures leading to reduced cocaine use is consistent
with the higher levels of criminal activity preceding
attainment of abstinence that we found and with patient
reports that their cocaine "runs" would often be
interrupted by an arrest and brief incarceration.
Since legal and medical problems may motivate cocaine
abusers to decrease their abuse, treatment programs
should be prepared to address these problem areas at
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admission to treatment. Early medical interventions in
treatment might include careful medical evaluations on
admission with appropriate laboratory studies. Early
legal interventions might include provision of legal
aid counseling to insure that addicts get treatment
rather than simply incarceration.
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Treating Cocaine Abusing
Methadone Maintenance Patients
with Desipramine
T. Kosten, F. Gawin and B. Schumann
ABSTRACT
Intravenous cocaine use in methadone patients has become a major
problem because of both the complications of cocaine use and the
potential spread of AIDS. During an eight week open trial we
found that desipamine reduced cocaine craving and use in eight
cocaine abusing methadone maintenance patients compared to eight
patients getting no medication except methadone.
INTRODUCTION
Cocaine abuse has increased over the last ten years becoming a
major problem within methadone maintenance programs (MMP) with
up to 40% of MMP patients reporting cocaine abuse (1-3). Because
about 80% of the cocaine abusers in our MMP use it intra-
venously, contracting and spreading acquired immunodeficiency
syndrome (AIDS) by IV cocaine use is also a risk. During a 2.5
year follow-up of opioid addicts that was completed in 1983, we
found that the high rate of cocaine use in our MMP had minimally
declined, despite extensive opioid oriented treatment (3).
Furthermore, severe (more than weekly) cocaine abuse appeared to
have increased. Thus, treatment interventions are needed not
only to reduce the morbidity associated with cocaine itself, but
also to reduce the spread of AILS and HIV infection among MMP
patients. Pilot work with desipramine by our group has demon-
strated substantial reductions in cocaine craving and use (4).
Thus, desipramine appeared to be a good candidate for further
study among cocaine abusing MMP patients.
METHODS
Sixteen methadone maintain& patients who had been abusing
cocaine for at least three months at a level of over 1.5 grams
per week were offered desipramine in addiction to weekly group
counseling in an educational cocaine group. Eight patients chose
to start on desipramine and eight decided to not use it. The
patients included six females, 12 whites and had a mean age of
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35.4 years (range = 29-47 years). The desipramine and unmedi-
cated groups did not significantly differ in any of these
characteristics. The despiramine group included four females,
six whites and had a man age of 33.4 (±2.5) years. The unmedi-
cated group included two females, six whites and had a mean age
of 37.5 (±5.5) years.
All patients were administered the medication daily under
supervision at the clinic to insure adequate doses were being
taken, and six of eight patients on desipramine had blood levels
after at least 10 days on a stable dose. The mean desipramine
dose was 141 mg daily (range = 75-200 mg) with a mean blood
level of 219 ( ±84 s.d.) ng/ml. All patients remained on a
stable dose of methadone with a man level of 58 mg daily (range
= 25-80 mg).
Patients' cocaine use and craving were recorded weekly for eight
weeks and then followed for about six months after first
starting treatment. Cocaine craving was assessed using a 20
point analog scale, and cocaine use was assessed by self-
reported number of grams. Because no administrative sanctions
were imposed for cocaine use during the first eight weeks in the
cocaine group, we felt that self-reports of use during his eight
week open trail were reliable, although cocaine use was also
monitored by random weekly urine toxicologies.
RESULTS
Weekly craving scores were calculated as percent of craving at
entrance into the trial (baseline). Both groups showed decreases
in craving for the initial eight weeks of the trial and at the
six month follow-up. Statistical analysis of the data for the
eight weeks using repeated measures ANOVA demonstrated a signi-
ficant time effect (F=9.4, P<0.01), showing that cocaine craving
significantly decreased over time for both groups. However,
neither the treatment main effect (F=1.2. P<0.3) nor interaction
effect (F=1.6, P<0.2) were significant. However, using a
response defined as a 50% or greater reduction in cocaine
craving, 25% of the unmedicated had this response at week eight
compared to 75% of the desipramine patients (Fishers exact test,
P=0.03). Thus, desipramine appeared to significantly reduce
cocaine craving relative to no medication. Similar analysis of
the endpoint or "follow-up" data yielded a significant dif-
ference in craving reduction (50% unmedicated vs 100% desipr-
amine, Fishers =0.04).
Reduction in cocaine use was consistent and sustained for the
desipramine group, but very uneven for the unmedicated patients.
A sudden drop in cocaine use at week four for the unmedicated
group may have reflected a threat of administration sanctions at
eight weeks, if cocaine use was not reduced. Urine results
support this dramatic reduction in use, but craving was not
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substantially reduced and cocaine use returned. The desipramine
group reported more extensive cocaine use (5.6 grams vs. 2.8
grams) for the with before starting in the cocaine abuse
treatment, but for the week before starting both groups were
equivalent (2.1 vs. 2.2 grams). Amount of cocaine use declined
significantly during treatment using a repeated measures ANOVA
(F=2.7, P<0.05). At week eight, desipramine patients were not
statistically significantly more often abstinent (25% vs. 63%-
desipramine, Fishers = 0.14), but the trend clearly suggested
that desipramhe decreased cocaine use among MMP patients. Urine
toxicologies were also obtained weekly on a random schedule.
These urine results also demonstrated an effect of desipramine
on cocaine use. The unmedicated group had an average of 1.04 ( +
0.87) cocaine positive urines, while the desipramine group had
an average of 0.22 ( + 0.22) cocaine urines (t =5.4, P<0.001).
DISCUSSION
Although preliminary findings from several trials have suggested
the efficacy of desipramine in cocaine abusers not in a MMP,
there are five major reasons why efficacy needs to be assessed
in a controlled trial with cocaine abusers in the special
situation of an MMP.
1. In this study, the difference in urines positive for cocaine
use was statistically significant, and cocaine craving
substantially and significantly decreased suggesting that
replication in a larger, zandomized trial is warranted. More-
over, because this study involved a small sample with no random
assignment of patients to treatment groups, its conclusions are
tentative.
2. The client characteristics of cocaine abusers in a MMP may be
different from "pure" cocaine abusers. In previous studies,
our group has shown that MMP cocaine abusers tend to be anti-
social and significantly more often black males (2,3). Other
disorders, including major affective and anxiety disorders, have
been more prevalent among the cocaine abusing opioid addicts
than among non-abusers (2,3). These findings imply that cocaine
abuse treatment, particularly within methadone programs, may
need to differ substantially from treatments for "pure" cocaine
abusers. The high rate of antisocial personality disorder
suggests that treatment needs to be structured with admini-
strative sanctions as part of treatment. The greater than
expected rates of affective and anxiety disorders suggest that
the use of antidepressant medications may be doubly indicated
for many cocaine abusing MMP patients. An important component of
future studies will be to examine whether these comorbid
psychiatric disorder have remained prevalent among cocaine
abusing MMP patients, and whether these comorbid disorders have
prognostic significance in cocaine abuse treatment.
239
3. The pattern and subjective effect of cocaine abuse may be
different in MMP populations. For example, abuse may be more
severe and escalate more quickly to larger amounts of use, and
it is more likely to be by the I.V. route of administration. The
"speedball" abuser may be quite different from other cocaine
abusers. Methadone may also potentiate the euphoric effects of
cocaine by limiting cocaine induced anxiety.
4. The interactions of desipramine with methadone maintenance
maybe important. In this preliminary study, a possible inter-
action appeared, since quite low doses of desipramine produced
adequate blood levels and side effects were tolerable. Other
drug interactions including interactions with cocaine may differ
between MMP patients and non-MMP cocaine abusers.
5. There have been no studies describing how to integrate
cocaine abuse treatment into the ongoing structure of a MMP.
Although patients who select methadone maintenance may be part-
icularly appropriate for pharmacological adjuncts to cocaine
abuse treatment, these medications need to be provided in a
psychotherapeutic context. We have developed an interpersonal
therapy approach to cocaine abuse, and future studies might
combine this type of therapy with pharmacotherapy for cocaine
abusers in an MMP. This psychotherapy focuses on interpersonal
cues for cocaine use.
In summary, cocaine abuse in MMPs is common, dangerous (parti-
cularly with in I.V. drug use), and not well treated using
current methods. In fact, current MMP methods may aggravate the
problem and persistence of cocaine abuse. To find new treatments
for it within MMPs,we have looked to pharmacological approaches
that we have developed with non-MMP patients. We have examined
desipramine as the most potentially useful and have found that
it reduces both cocaine craving and use. This initial pilot
trial indicates that a more expensive controlled clinical trial
with desipramine among MMP patients seems promising and worth-
while.
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Counselor Differences in Methadone
Treatment
A. T. McLellan, L. Luborsky, G. Woody and L. Goebl
This report results from an unusual occurrence within the
methadone maintenance program: the resignation of two experi-
enced counselors within one week. Both counselors had worked in
the program for a minimum of five years and neither counselor
was released for disciplinary reasons. One counselor had to
resign because of an accident; the other resigned because
illness in the family required relocation. Since both counselors
had caseloads of forty active patients; and since the resign-
ations occurred so abruptly and within such a short period of
time, the patients were essentially randomly assigned to other
counselors over the next three-day period.
ROLE OF COUNSELING
Because the clinic collects weekly record of urinalysis results,
prescriptions for psychotropic medications, methadone dose,
arrest and employment rates, it was possible to compare the
performance of each patient during the six months prior to his
transfer with the six months following reassignment to the new
counselor. We reasoned that this unusual situation would provide
a relatively pure test of the contribution of counseling without
the artificiality of an experimental setting and without the
influence of the multiple factors generally associated with
assignment or reassignment of patients in the normal clinical
situation.
ROLE OF THE COUNSELOR
There is a large and still growing literature devoted to
evaluating the effectiveness of different "types" of counselors.
In particular professional counselors (i.e. those with masters
level education) para-professional counselors (i.e. those with
less than a masters level education) and ex-addict counselors
(i.e. those with prior histories of substance abuse who may or
may not have a masters level education) have been compared in
more than fifty studies. These groups of counselors have been
compared on a variety of patient performance measures including
during and post-treatment drug use (Aiken et al., 1984a; 1984b),
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client retention (Brown & Brewster, 1973; Brown et al., 1985),
and overall client adjustment following treatment (Brown et al. ,
1985; LoSciuto et al., 1984). The clear finding from these
studies is that as a group, there are no significant differences
in the perfomance of patients assigned to these "types" of
counselors' and that "...paraprofessionals achieve clinical
outcomes equal to or significantly better than those obtained by
professionals" (Durlak, 1979, p. 80 emphasis added).
The finding of no significant group differences among these
"types" of counselor has led to the suggestion that there may be
no individual differences among counselors generally. In this
regard we felt the data from this study were similar to data
from our earlier study of two types of professional psycho-
therapy for opiate addicts (Woody et al., 1983; 1987). In that
study, we too found no significant group differences between two
conceptually and methodologically different therapies, each
practiced by trained therapists. However, subsequent examination
of data within each therapy group revealed major outcome
differences among individual therapists (Luborsky et al., 1982;
1985; 1986). Thus, in the work to be reported here, we had the
opportunity to make individual comparisons of counselors with
regard to the benefits they had provided to their methadone
maintained patients.
METHOD
Subjects - were 61 opiate-dependent, male veterans in methadone
maintenance treatment at the Philadelphia VA Medical Center.
These individuals were a subgroup patients who had been assigned
to the two counselors in that program who resigned unexpectedly
and abruptly within a week of each other in early 1985.
In order to standardize the patient sample and to provide
comparable and representative measurement periods, only patients
who had been in treatment at least six months prior to transfer
and who stayed in treatment six months following reassignment
were included for study. Four counselors received 12 or more
transferred patient (N's = 12, 16, 16, 17) and these caseloads
were considered adequate for study.
Patient Reassignment - As a result of the large number of
patients affected by the counselor resignations and the abrupt-
ness of the situation, the normal clinic policy of contacting
individual patients and counselors to develop mutually satis-
factory reassignment "matched" was not followed. Instead, the
senior clinical supervisor was forced to reassign the affected
patients in a rapid manner using essentially random assignment
procedures. Assignments were made within three days and were
based entirely upon the size of the remaining counselors'
caseloads.
As a test of the results of the reassignment procedure on
caseload mix we performed comparisons of the demographic and
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background characteristics of the patients who were assigned to
the four caseloads. Measures included age, race, number of prior
treatments, duration of time in the methadone treatment program,
years and months they had been assignment to the transferring
counselor, number of different counselors they had been assigned
previously, years of alcohol use, years of opiate, stimulant and
depressant drug use, number of criminal convictions, methadone
dose and prescription of an ancillary psychotropic medication
(e.g. for sleep, anxiety or depression problem). Finally, the
four caseloads were compared with regard to the proportion of
patients that were transferred from each of the two resigning
counselors.
All comparisons showed non-significant differences and the
greatest difference found was only p<.14. The results of these
comparisons as well as the nature and rapidity of the assignment
procedure convinced us that there were not explicit or overt
differences among the caseloads at the time of transfer and that
the reassignment procedure had produced essentially random
distributions to the four counselors.
Standard Program Measures - All patients in treatment at the
Philadelphia VA Drug Dependence Treatment Center are requires to
provide a supervised urine specimen weekly on a randomized
schedule. Also available are weekly records of each patient's
methadone dose and records of any ancillary psychotropic
mediations prescribing by the program physicians. In addition,
monthly reports indicated whether the patient had been employed
and/or arrested during the reporting month. Because all of these
measures have been standard program requirements it was possible
to compare them among counselors (See below), over the l2 months
of observation (six pre and six post-reassignment).
RESULTS
Five measures were considered in the evaluation of patient
performance for each counselor's caseload over the six month
periods prior to and following the transfer point: the per-
centage of the caseload that had been employed or arrested, the
proportion of patients with positive urine results, the propor-
tion that was prescribed ancillary psychotropic medications (eg.
for problems with sleep, anxiety or depression) and the average
methadone dose of the caseload.
PRE-TRANSFER DIFFERENCE
One way (between-counslor) repeated measures (across months)
analyses of variance were performed on all five of the perfor-
mance measures for the period prior to transfer. Results of
these analyses revealed no significant between-counselor
differences (p>.10), no differences across the six month pre-
transfer period (p>.10) and no counselor-by-months interactions
effect (p>.10) on any of the measures examined.
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Post-Transfer Differences
Given the general tendency for comparable and stable performance
measures in the caseloads prior to the transfer, we questioned
whether there were improvements after the transfer point and if
these improvements were different among counselors. We therefore
performed a treatment (counselor) by levels (pre to post
transfer), repeated measures (month) multiple analysis of
variance (MANOVA) on all of the five patient performance
measures. Results indicated significant differences between
levels (p<.01) and between (p<.03) and therefore permitted a
more detailed examination of the individual measures using two
way (counselor by transfer) repeated measures ANOVAs. The
results are discussed individually below for each measure.
Urinalysis (Fig. 1) - A urine was considered positive if results
showed any of the following: opiate, cocaine, amphetamine,
barbiturate, benzodiazepine; or if methadone was absent from the
specimen. As can be seen, there was a significant counselor-by-
transfer interaction in the analysis of variance (F=4.89,
df3,40, p<.01). Subsequent paired comparisons among the coun-
selors on the post-transfer urine results indicated that
counselor 3 differed significantly from all other counselors
(p<.05 or less) who did not differ from each other (p>.10).
FIGURE 1
POSITIVE URINES BEFORE AND AFTER COUNSELOR TRANSFER
Methadone Dose (Fig. 2) - Results of the analysis of variance
indicated a siqnificant effect of the transfer (F=8.16,dfl,-
40,p<.01) and for the interaction of counselor and transfer
(F=8.23,df3,40,p<.01). Subsequent paired comparisons among the
caseloads during the post-transfer period indicated that the
caseload of counselor 2 had a significantly lower average
methadone dosage than the other caseloads (p<.05), which did not
differ from each other (p<.10).
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FIGURE 2
METHADONE DOSE BEFORE AND AFTER COUNSELOR TRANSFER
Ancillary Psychotropic  Medications (Fig. 3) - Although there was
no general change in the proportion of patients receiving
medication across the transfer point (p>.10), there were
significant differences in the nature and amount of change among
the caseloads (Interaction F=3.71,df3,40,p<.05). For example,
counselor 3 showed a modest increase (p<.10)  in the proportion
of his/her patients receiving prescribed medication, while
counselor 2 actually showed a significant decrease (p<.05).
FIGURE 3
% ON MEDICATION BEFORE AND AFTER COUNSELOR TRANSFER
Employment (Fig. 4) - As in the case of the urine results there
was a significant overall improvement following transfer
(F=49.21,dfl,40,p<.01). Again, a comparison of the caseloads
revealed that the patients of counselor 3 had a significantly
lower employment rate (p<.05) than other caseloads, which 
did not differ from each other ( p>.10).
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FIGURE 4
% EMPLOYED BEFORE AND AFTER COUNSELOR TRANSFER
Arrests (No Figure) - The proportion of patients arrested at any
time was generally low (mean=3.7%) throughout the period of
study. Thus, neither the pre to post-transfer changes nor the
post-transfer differences among the counselors were statistical-
ly significantly (p<.10).
DISCUSSION
When the performance of the caseloads was examined during the
six month periods prior to and following the transfer point
across five objective measures of patient status (methadone
dose, urine screening, prescription of ancillary psychotropic
medications, employment, and arrest rates) there were marked and
consistent differences in outcome among the four counselors. One
counselor (#2) significantly reduced illicit drug use and
unemployment in the caseload while concurrently reducing the
average methadone dose and the proportion of patients prescribed
ancillary medications. In contrast, another counselor (#3)
showed worsened status in employment, drug use, and criminality
in the caseload while concurrently increasing the average
methadone dose and the proportion of patients prescribed
psychotropic medications. The remaining two counselors (#1, #4)
showed worsened status in employment,  drug use and arrest rates in
their caseloads while maintaining approximately the same average
dose of methadone and the same proportion of patients receiving
psychotropic medications.
It should be noted that we have seen differences of this nature
and magnitude among professional psychotherapists treating
randomly assigned caseloads of methadone-maintained opiate
addicts in another study (Luborsky et al., 1985; Woody et al. ,
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1983). In that study, one therapist showed an average improve-
ment rate of more than 100% across seven outcome measures in 14
randomly assigned patients. Another psychotherapist with
comparable training and experience showed an average change rate
of -4% across the same measures and a similar randomly assigned
subject population (See Woody et al., 1983 for details).
What accounts for Counselor Differences?
With regard to prior treatment experience however, there were
few differences among the four counselors with all of them
averaging more than eight years in the field. The possibility
that formal education differences were implicated is more
difficult to evaluate. Counselor 2 had a masters degree in
psychology and had received a state license to practice.
Counselor 3 was a recovering addict with a high school degree.
These differences alone suggest that formal education has a
profound effect. However, when the backgrounds of the other
counselors are considered, the conclusion is much less clear.
For example, one of the resigning counselors also had a masters
degree in psychology, while three of the other counselors (1,4
and one of the resigning counselors) had bachelors degrees in
psychology. Thus, as has been reported in a large number of
prior studies (See Durlak, 1979 for a review), the differences
seen among the caseloads of these counselors cannot easily be
attributed to educational differences.
As a mean of examining differences in the actual process of
counseling we turned to the patient charts to get some indic-
ation of the rehabilitation strategies of the individuals
involved in the present study. There were definite and consis-
tent differences in the written work among the counselors
studied. For example, with regard to the written notes of
counselors 1 and 4, the charted  information suggests that they
performed their counseling duties in a concerned and organized
manner. The charts from these counselors showed thorough and
accurate charting of all pertinent aspects of patient contact.
These two counselors had a clearly formulated plan of rehabilit-
ation that had been worked out through consultation with the
treatment team and the patient. Further, the notes from these
charts suggested that the initial plans were generally followed
and document& at all points during the rehabilitation process.
The majority of the patients in these two caseloads were seen
more than once per month, with many seen weekly. The day-to-day
problems of their patients were dealt with through referral to
program resources such as physicians, nurse, employment coun-
selor, letters to legal authorities and public assistance
agencies as well as encouragement, support and basic, sensible
advice.
In contrast, the information from the charts of counselor 3 and
the two counselors who resigned,  indicated far less organization
in the treatment plans and far less detail in the treatment
notes. There was little indication of consistency in enforcement
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of program rules (e.g., take-home regulations, loitering, etc.)
and very little documentation of the use of program resources
for their caseloads (e.g., employment counselor, nurse, etc.).
perhaps most striking was the general lack of documentation
surrounding changes in methadone dose and prescription of
ancillary medications. Finally, the indications were that the
patients in these caseloads were seen less frequently than the
patients of the other counselors (average slightly more than
once per month).
The data from the charts of counselor 2 indicated the same high
level of organization and consistency as was exhibited by
counselors 1 and 4. However, the nature of the notes during
rehabilitation process suggested a different content in the
sessions and in the counseling process. The approach indicated
in the notes of this counselor was one anticipating problems in
the patient and discussing strategies to deal with the anti-
cipated situations, thereby focussing the rehabilitation on the
development of new behaviors and new ways of thinking by the
patient. In this regard it should be noted that this individual
now has a private therapy practice.
A Comment Regarding Counseling and Counselors
The performance differences seen among these counselors are all
the more interesting in that there is now a large and widely
quoted body of controlled studies that have shown no significant
performance differences among groups of counselors divided on
the basis of formal education or past history of addiction (See
Durlak, 1079; Aiken et al., 1982 for reviews. This body of work
is important to the field of addiction rehabilitation in that
the distinction between "ex-addict" or "recovering" versus
"professional" counselors has generally represented significant
ideological differences in treatment strategies. Since this
group distinction has had such ideological significance the
finding of no group differences in performance has been seen by
some as justification for the hiring of predominantly "ex-
addict" or "recovering" counselors since these counselors can
generally be hired for less money than counselors with higher
levels of education and since "the literature shows that there
are no differences in performance". Still others have used these
findings as an indication that counseling is a generic commodity
of relatively little importance in the overall rehabilitation
process.
It therefore becomes extremely important to note that this well-
replicated finding (as well as the data presented here) means
only that addiction background and formal educational level, are
by themselves, not well related to therapeutic performance and
therefore are neither good nor sufficient criteria to use in
hiring a counselor. By illustration, the finding that there were
no performance differences between left and right handed
counselors would not be justification for hiring predominantly
left-handed counselors, "since there were no differences in
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performance". These findings explicitly do not mean that there
are no indications of therapeutic performance, or particularly,
that there are no individual distinctions among counselors. We
do not pretend to know the important pre-employment personal,
ideological and experiential qualities that are related to
therapeutic efficacy in counselors or therapists. At this point,
the data suggest that the initial performance of the counselor,
as judged by his treatment plans, written notes and the objec-
tive indications of improvement in his/her caseload, maybe the
best indication of future therapeutic efficacy.
In summary, given the presented data with all the noted cautions
and qualifiers, we feel two conclusions are possible. First,
counseling is an "active ingredient" in the rehabilitation of
drug-dependent patients even in a treatment modality where
medical, and pharmacological interventions are also prominent
Second, as seen in earlier studies of psychotherapists (Luborsky
et al., 1985; 1986), there are significant differences in
effectiveness among counselors. Some promote rapid and sustained
change in their caseloads and others actually detract from the
effectiveness of the other components of treatment. It will be
important in future studies to examine the personal and pro-
cedural qualities associated with effective counseling and
therapy and then to work to implement the findings as a means of
improving the general  efficacy of substance abuse treatment.
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Occurrence of Central Nervous
System Defects in Fetal Alcohol
Syndrome
W. Rosenfeld, R. Jhaveri, F. Concecion, M. Mohyuddin
and C. Laqui-Pili
Alcohol consumption during pregnancy has been documented to
cause multiorgan anomalies and developmental retardation. Ex-
periments in animals exposed to alcohol in early pregnancy
demonstrate a significant incidence of central nervous system
defects including absence of the corpus callosum. The frequency
of this and other CNS anomalies in neonates with FAS is unknown.
To determine the incidence of CNS anomalies in FAS we studied
all neonates admitted with the diagnosis of FAS admitted to our
nurseries by CT Scan or neurosonography.
Thirty-seven neonates (22 males, 15 females), with a mean
gestational age of 35 weeks (range 29-34 weeks) and mean birth
weight of 1680 gms (range 539-3345) were examined. Abnormalities
were detected in 7 patients. Four patients had evidence of
absence of corpus callosum, two had evidence of prominent
cortical atrophy, and another had mild ventricular dilation.
The 4 patients with absence of the corpus callosum had strong
phenotypic expressions of FAS.
The 19% incidence of detectable CNS anomalies in FAS suggests
that CT and/or neurosonogram should be considered in evaluation
of infants suspected of this syndrome. The correlation of these
findings with neurologic and developmental abnormalities will
need to be determined by long term followup studies.
Department of Pediatrics, Division of Newborn Medicine,
Interfaith Medical Center, SUNY/Health Science Center at
Brooklyn, 1545 Atlantic Avenue, Brooklyn, New York 11213.
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Prenatal Alcohol Exposure,
Cognitive and Motor Development
in the First Year
I. Smith, C. Coles, A. Falek, C. Rubin, K. Platzman
and J. Lancaster
The goals of this study were to determine: (1) whether
differences in the developmental outcomes of children prenatally
exposed to alcohol can be correlated with the amount of alcohol
consumed by the mother during pregnancy; (2) whether there are
specific areas of cognitive, motor and/or behavioral development
in the first year which are more vulnerable to the effects of
alcohol; (3) whether the pattern of observed deficits in affected
children varies with the duration (the length of exposure during
gestation) of maternal alcohol use.
The sample was selected from the population of women receiving
prenatal care at Grady Memorial Hospital, a large inner city
hospital in Atlanta, Georgia. Three groups of women were
recruited for study: (1) women who reported alcohol use
equivalent to one ounce or more of absolute alcohol per week
throughout pregnancy; (2) women who drank an equivalent amount,
but discontinued alcohol use in the second trimester of
pregnancy; (3) women who did not drink at all during pregnancy.
Follow up psychological testing was done on the infants of all
women participating in the study at six and twelve months of age
using the Bayley Scales of Infant Development.
The results of this study indicated that: (1) discontinuing
alcohol use during the second trimester of pregnancy was
associated with better developmental outcomes as measured by the
Bayley Scales of Infant Development; (2) behavioral differences
were not significant at six months, but children exposed to
alcohol throughout gestation performed significantly poorer than
the other two groups at twelve months; (3) cognitive and language
skills were more affected than motor development and social
skills as measured by the Kent State scoring system for the
Bayley; (4) a significant interaction was found between volume
and duration of prenatal exposure for scores on the social skills
subscale at one year.
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Children Exposed to Methadone
In-Utero: Cognitive Ability in
Preschool Years
K. Kaltenbach and L. Finnegan
The outcome of infants born to drug dependent women
maintained on methadone during pregnancy has been an
area of special concern. The consequences of such
exposure for the neonate and young infant have been
widely investigated. However, there have been few
studies to determine if preschool children exposed to
methadone in-utero have impaired cognitive
functioning. The purpose of this study was to
evaluate the cognitive function of preschool children
born to women maintained on methadone during
pregnancy. Forty-five children (27 methadone exposed
children (M) and 18 non-drug exposed comparison (C)
children) were evaluated with the McCarthy Scale of
Children's Abilities when the children were between 3
1/2 and 4 1/2 years of age. All children were
participants in a longitudinal study examining
developmental outcome from birth through 5 years of
age. The mean daily maternal methadone dose during
pregnancy was 38.42 mg and 92% of the children
required pharmacotherapy for neonatal abstinence.
Student t-tests revealed no difference between groups
on the McCarthy General Cognitive Index (GCI) or any
of the 6 subscales. Mean scores were: GCI(M) 106.51,
(C) 106.05; Verbal(M) 53.44; Perceptual (M) 55.51 (C)
53; Quantitative(M) 51.33, (C) 53.38; Memory (M)
49.51, (C) 52.27; and Motor (M) 52.29, (C) 50.44.
These results indicate that the general cognitive
ability of children in the pre-school years who have
been exposed to methadone in-utero is not impaired.
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A Retrospective Search for the Etiology of
Drug Abuse: A Background Comparison of a
Drug-Addicted Population of Women and a
Control Group of Non-Addicted Women
T. Hagan
INTRODUCTION
For many years, researchers labeled substance abuse etiology as
the consequence of an addictive personality. Researchers sought
to discover the characteristics and the variable that distinguished
addict and non-addict populations on a myriad of demographic and
personality variables. "Instead of discovering just one reliable
characteristic, they discovered at least eleven, none of which
accounts for the majority of variance between groups, but each of
which increases the probability of drug abuse to a certain extent."
(Bry 1983, p. 255-256).
Therefore, the "one variable quest" was replaced by a search for
"one" combination of the established variables that best explained
substance abuse. Nearly every study, utilizing well-designed,
multi-variate, and longitudinal analyses, produced a different set
of explanatory variables, all of which are related to substance
abuse in a statistically significant manner. However, not one ex-
plains more that a moderate amount of variance. While some common-
alities exist, there are also discrepancies. For example, some re-
searchers found relationships to parents among the important vari-
ables. Other studies measured the parental variable, but found it
unimportant (Bry 1983).
Bry et al., (1982) responded to the variations by using the "multiple
risk factors hypothesis." This is a notion that disparate findings
are due to the fact that substance abuse is a function of the "num-
ber" of etiological factors instead of a particular set of them.
"When this hypothesis was tested on a data set containing six of
the eleven most comonly supported etiological characteristics, the
results revealed a highly significant relationship between number
of these characteristics and the probability of current abuse."
(Bry 1983, p. 256)
Additionally, there was not one predominant combination of risk
factors. Among the 156 subjects who exhibited two to four risk
factors, twenty-four different combinations occurred. Not one of
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the combinations accounted for more than twenty percent of the
cases (Bry 1983).
This research project was designed in order to target and to examine
risk factors that are considered significant in the etiology of drug
abuse. The project is a retrospective search which investigates and
compares the backgrounds of a population of drug-addicted women and
a non-addicted population of women. Additionally, the study exam-
ines the "numbers" of responses, and the "similarities" in the re-
sponses of individual users to particular etiological variables.
SUBJECTS AND METHODOLOGY
Twenty-eight drug-addicted women were asked to participate in this
study, as they walked into the lobby of Family Center of the Thomas
Jefferson University Hospital, Philadelphia, Pennsylvania. This
occurred over a ten day, non-consecutive period. Family Center is
a comprehensive outpatient methadone maintenance treatment program
for drug and/or alcohol dependent women. The program recognizes
the special needs of the pregnant addict, and provides patients and
their children with medical, psychiatric, and social services.
Twenty-four addicted women agreed to the interviews. Nineteen of
the women were in the clinic to receive methadone for opiate addic-
tion, and five came in to receive counseling for cocaine abuse.
All five cocaine abusers were black. Eight of the opiate addicted
women were black and eleven were white. All twenty-four were re-
ceiving one or more of the following assistance programs: Welfare;
Medical Assistance; Women Infants and Children Services; and/or
Maternal Infant Care.
Eight of the women were pregnant. Additionally, eight had delivered
within the last year. Five of the women had delivered more than a
year ago and were still receiving methadone and counseling from
Family Center. Three subjects had special classifications. One
had just aborted, and two subjects had miscarried.
A control group not affiliated with Family Center, and without
drug or alcohol problems, was obtained in the following manner.
Thirty subjects were approached as they walked into the Thomas
Jefferson University Hospital Obstetrical and Gynecological Clinic
(JOGA) for treatment regarding pregnancy, gynecological services,
or family planning information. Additional requests for interviews
were made to several JOGA women who had just delivered and were in
the hospital. A total of twenty-two women agreed to be interviewed.
Of the twenty-two, two were not appropriate, as they did not pass
a screening questionnaire concerning drug and alcohol consumption
(Vaillant 1977).
The "control" failure criteria in this research project for the
screening questionnaire was more than five drinks per week and two
affirmative answers on any of the other questions. In the drug
use circumstance, "trying marijuana a few times" was passable if
the subject was not presently smoking, and as long as there were
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not two affirmative answers on the other questions. If other drugs
were used more than one time, the subject was considered to exhibit
high-risk behavior, and was deemed inappropriate,
Subsequently, twenty non-addicted women were interviewed. Sixteen
of those were black and four were white. Four of the subjects were
interviewed postpartum. Six women were pregnant when interviewed,
and six had delivered in the last year. The remaining four women
were using either the JOGA gynecological services or the family
planning services when interviewed. The controls met the same
governmental assistance criteria as the drug-addicted subjects.
All subjects were administered verbally (by the author) the follow-
ing questionnaires: 1) A Vaillant (1979) untitled questionnaire
which indicates alcoholism in a family member or a friend. This
questionnaire was modified in order to include drug use considera-
tion. If three affirmative answers were received, the subject was
regarded as having experienced alcohol and/or drug addiction in a
family member; 2) Moos' Family Environment Scale (Moos 1974);
and 3) A comprehensive social data questionnaire compiled from
the social data forms prescribed by Family Center and the Hospital
of the University of Pennsylvania. The drug-addicted women were
given an additional questionnaire involving their drug history.
The subjects were reminded before each appropriate questionnaire
that the answers should be given from a retrospective point of
view - "How it was when you were growing up - not how it is now."
The questionnaires were placed in the past tense where necessary.
The Family Environment Scale was of special interest in that the
language utilized was not always understandable to the subjects,
or certain words were interpreted differently than intended by the
FES. For example, the phrase which states, 'We rarely (hardly ever)
went to lectures, plays, or concerts." The answer invariably would
be the following (for blacks and whites): "Oh, yes we did, we went
to lots of rock concerts." Because that was the explicit interpre-
tation for those subjects, the answer was marked "false." This
meant that they "did go to lectures, plays, and concerts."
Several words from the FES had to be defined for the subjects:
"rarely," "spontaneous," "cultural," and "inflexible." The phrase
stating, "We believed there were just some things you had to take
on faith," had to be explained to twelve of the forty-four subjects.
The point of these idiosyncrasies should be noted by anyone who
does not administer the FES verbally.
The questionnaires sought variables which indicated either demo-
graphic information or the subject's perception of familial func-
tioning; activities in childhood or drinking and/or drug patterns
of family members. Analysis of the data consisted of determining
the means and the standard deviations of the user group and the
non-user group on all variables where applicable.
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The results for each independent variable on the Family Environ-
ment Scale were compared using a Student's t-test. All data was
measured for an "at or below" p = .05 level of significance. If
any factor neared that level, it will be reported. A Chi-square
was used for the mean age at first drug use by race.
The means of both groups were compared with the scores in Appen-
dix A of the FES Manual. A percentage was obtained from the mean
score. This percentage was compared with the FES "normal range"
expectation of 50% to 60%. Ranges will be reported where signifi-
cant.
Additional student's t-tests were utilized on a population consis-
ting of all drug-addicted and all non-drug-addicted subjects who
had experienced family or origin alcohol or drug abuse. The con-
trol population of drug-addicted and non-addicted subjects had
not been exposed to familial alcohol or drug abuse. Probabilities
were computed for each FES variable at or below the p = .05 level
of significance. Specific and significant trends between the
groups will be discussed.
RESULTS AND CONCLUSIONS
The mean age of the Family Center drug-addicted women was 30.6
years with a range of 23 to 41 years. The mean age of the non-
addicted controls was 25.1 years, with an age range of 18 to 29
years. The age mismatch is indicative of the populations of
Family Center and of JOGA. Where age difference is an issue, the
discrepancies will be discussed.
The racial composition of the Family Center women consisted of 54%
black and 46% white; the racial composition of the controls was
80% black and 20% white. The disproportionate number of blacks
in the control population disallows racial comparisons between
user and non-user groups on most variables. However, a comparison
was made between blacks and whites in the drug-addicted population
for the mean age at first drug use by race. While the Chi-square
probability was not significant (p = .10), the percentages between
the groups were significant. Seventy-three percent of the whites
used drugs initially between the ages of 12 and 16. This is in
contrast to 46% for the blacks. The mean age of the total user
group for initial drug use was 15.7 years.
Seventy-nine percent of the Family Center group in this study are
opiate addicted, and 21% are cocaine addicted. The drugs reported
by the subjects to be first used included marijuana, heroin, amphet-
amines, valium, alcohol, barbiturates, tuinal, percodin, dilaudid,
and quaaludes, in decreasing order. First drug use by 54% of the
women was marijuana. Thirty-three percent of that group used
marijuana in combination with one or more of the other drugs.
Twelve and one-half percent of the women commenced with heroin
only, and 8% with alcohol only.
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Sixty-seven percent of the Family Center group experienced alco-
holism of one or both parents. This is in contrast to 35% of the
controls. Of that 35%, presently 57% of the controls have a drug
and/or alcohol addicted sibling. Additionally, 8% of the Family
Center women had one drug-addicted parent. Another 8% had a sibling
at least one decade older with an alcohol abuse problem. Therefore,
83% of the drug-addicted women were from chemically dependent fam-
ilies.
Much has been said about the negative effects of single-parent
households on the functioning of children. However, in this study
an interesting dichotomy occurs. Sixty-five percent of the controls
were from single parent households, while only 38% of the Family
Center women lived with a single parent. Race may be a factor in
the results, particularly since 80% of the controls are black. The
high incidence of female-headed households in black lower socio-
economic groups is well researched. In the Family Center group,
the racial composition of those living in single-parent house-
holds is 56% black and 44% white. The results may be affected
by another factor as well. A study by Kumpfer and DeMarsh (in
press) found that although abusing families were significantly less
cohesive on both the FES and the Olson et al., FACES-II standardized
tests, the marital dyads were significantly more cohesive or en-
meshed than other randomly selected families. That particular kind
of enmeshment seems to support the status of chemically-dependent
families. Because 83% of the Family Center women come from them-
ically dependent families, the Kumpfer and DeMarsh research sug-
gests a possible explanation for the higher incidence of dual-
parent families in the drug-addicted women. An examination of the
controls who were from chemically-dependent families reveals that
28% were from dual-parented white families where addiction occurred
in one or both parents; 57% came from black female-headed house-
holds where addiction occurred in every female head; and 15% came
from female-headed black households where the addicted father had
left. In order to evaluate any significant links, the parental-
dyads would have to be administered the FES and the FACE-II tests.
As in most retrospective studies, the task would be enormous if not
impossible. It does suggest, however, that the examination of the
parental-dyads of adolescents who are in treatment would be valua-
ble.
The educational and work histories of the Family Center group and
the controls were notable. Over 50% of the drug-addicted women
left school before the end of 11th grade. This is in contrast to
25% of the controls. Fifty percent of the Family Center women and
40% of the controls named Math and/or Science as their favorite
subjects. Seventy-one percent of the addicted subjects and 80%
of the controls received some kind of vocational or educational
training beyond school, As indicative of drug-addicted individuals,
Family Center women do not have substantial work histories. Twenty-
one percent have not worked since 1978, only 42% worked at some time
in 1986-87, and 8% have never been employed. Eighty-five percent
of the controls have worked sometime in 1986-87.
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In this research project, the issue of mean number of pregnancies
between groups and the actual number of children is exacerbated by
age and by drug use as well. Results for Family Center women and
for the control women are as follows: Mean user gravida = 4.1;
Mean user para = 2.2; Mean control gravida = 2.5; Mean control
para = 1.6. Sixty percent of the controls had normal pregnancies
in contrast to 38% of the addicted women. Thirty-four percent of
the drug population had complications due to miscarriage and still-
birth, probably caused by drug use. Thirty-four percent of the
Family Center women and 25% of the controls had abortions.
Both groups were asked how they perceived their childhoods, and
they were asked to rate their feelings in the following way: "My
childhood was: 1 - very happy; 2 - happy; 3 - neither happy nor
unhappy; 4 - unhappy; 5 - very unhappy. Forty-five percent of
the controls perceived their childhoods as "very happy, while only
12.5% of Family Center women answered similarly. When the responses
to choices 3 through 5 were combined, 54% of the addicted subjects
fell into that combination. Only 15% of the controls rated their
childhoods in the same manner.
The groups were asked, "When you were growing up, did you wish you
were someone else?" With the exception of one subject, all of the
drug-addicted women answered "yes.' By contrast, 30% of the con-
trols answered affirmatively. The drug-addicted women were always
specific about who or what they wished to be. For example, five
black Family Center women had wished to be white, and one white
woman had wished to be black. These results are far and above the
usual and expected adolescent disgruntlement concerning identity.
Sexual and physical assaults are significant variables occurring
in the drug-addicted women. Sixty-seven percent had been sexually
assaulted (penetrated) in comparison to 15% of the controls. Of
the drug-addicted sexual assault victims, 75% were raped under the
age of 16 years, and the youngest had been 8 years. The same
number of youth rapes occurred in the white and in the black drug-
addicted women. Two of the addicted subjects were raped by more
than one person during one encounter. One woman had been raped
at the age of 13 years by three men, and another had been raped
by nine men at the age of 9 years. Twenty-five percent of the
drug-addicted women were raped by a father, brother, or grandfather.
Literature concerning enmeshment issues in families of drug addicts
is prevalent (Coleman 1980; Stanton and Todd 1982; Friesen 1983;
Davis and Klagsbrun 1977). Two of the processes involved in the
concept of differentiation are "age at initial leave taking" and
"circumstances surrounding returns." The mean age of initial
leaving for the addicted women was 19.2 years, and 19.3 years
for the controls. Sixty three percent of the drug-addicted women
returned home sometime after they left originally, as compared to
25% of the controls. Of those, 33% of the addicted women, and
20% of the controls have remained. While the "return factor" may
be an important variable in relation to drug abuse, one would
suspect that the frequency of returns may be a more significant
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variable to examine. (Not available from this data.) Finances may
be another complicating factor with the total population of this
study.
The Family Center women and the controls were administered the Moos
Family Environment Scale. None of the variables between the groups
was statistically significant at the .05 level. However, the vari-
ables "cohesion" and "expression" yielded p values of .07. When the
means of the control population are compared with means from samples
published in the FES manual, the control population falls within the
ranges specified as normal, with the exception of "expression." The
Family Center women did not score within the normal ranges on cohe-
sion, expression, conflict, or control. For example, when means
were converted to percentages (appendix A of the FES manual), the
addicted women scored 34% and the controls 61% on cohesion. The
normal range is considered to fall between 50% and 60%. On expres-
sion, the Family Center women scored 35% and the controls 47%.
While the controls did not score within the normal range, the scores
were in the correct direction. When comparing conflict, the Family
Center women scored 66% on conflict, contrasted by 55% for the con-
trols. This suggests that if both of the populations were increased
(even if the means remained the same), the level of significance
would be at or below the .05 level. In addition, using the FES,
all of the women in the user group and the non-user group who were
"children of chemically dependent families" were compared with the
user and non-user groups who were not from chemically dependent
families. The "children of chemically dependent families" scored
significantly lower on cohesion (p = <.05). There were no signifi-
cant differences on any other variables. Once again, the means
were in the correct directions, and the non-user scores fell within
the normal ranges.
DISCUSSION
Criticisms of retrospective studies range from "recall problems" to
discrepancies surrounding "circumstantial subjectivity." Undoubted-
ly, this study is influenced by such recollective problems. However,
in terms of drug abuse and etiological issues, the study does reveal
"high agreement factor percentages" among the users on a "number"
of variables. The drug-addicted women experienced the following
significantly similar background risk factors: chemical abuse with-
in the family of origin (83%); "early" (before 16 years) sexual
abuse (55%); lack of cohesion and expression in their families
(19 of the 24 users scored below the 50% normal range on cohesion,
14 of those women scored below 40%; 18 users scored below the nor-
mal range on expression, 14 of those scored below 40%); familial
conflict and control issues (18 users scored above 60% on conflict,
13 of those scored 70% or above; 14 scored above 60% on conflict);
unhappy childhoods ( over one half); and a lack of ego center (96%
wished they had been someone else). This project suggests that
this population of women is a rich source for research and for under-
standing the cultural and social implications associated with the
etiology of drug abuse.
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The Detection of Heroin, Cocaine
and Cannabinoid Metabolites in
the Stools of Infants of Drug
Dependent Mothers
E. Ostrea, Jr., D. Asensio, A. Naluz, E. Abel,
M. Subramanian and K. Simkowski
We have shown (Dev Pharm Ther 1:163, 1980) in morphine addicted
fetal monkeys that the tissue concentration of morphine was
highest in their intestines due to bile secretion or swallowed
fetal urine. To test the corollary hypothesis that the stools
from infants of drug dependent mothers (IDDM) will contain
the drugs which the fetus has been exposed to, in utero, we
collected stools (meconium) during the first 5 days from 10
IDDMs and 2 control infants and tested them for the metabolites
of heroin (morphine), cocaine (benzoylecgonine), and cannabis
(delta-9-tetrahydrocannabinol or THC), three commonly abused
drugs. In addition, we addicted a pregnant Sprague-Dawley
rat by the daily subcutaneous injections of morphine sulfate
(10-20 mgs/kg bid) from the 8th to the 21st day of gestation.
Soon after birth, the rat pups were sacrificed and their intes-
tines were collected for morphine analysis. The drug metabolites
were extracted in appropriate solvents and quantitated by radio-
immunoassay. The control stools were used for background correc-
tion. RESULTS: Four of the 10 IDDM stools contained morphine
(range = 0.24 - 22.7 µg/gm stool, mean = 5.42) and 3 had cocaine
metabolites (range = 0.24 - 0.67 µg/gm stool, mean = 0.42)
up to the 2nd day of sampling. Five of 5 stools tested contained
delta-9-THC (range = 0.023 - 1.082 µg/gm stool, mean = 0.37)
up to the 5th day sample. In the 9 rat pups, their intestinal
contents collectively contained 1.65 µg of morphine or 0.18
µg morphine per pup. SIGNIFICANCE: This study shows that
the stool (intestinal content) is a repository of the drugs
which the fetus has been exposed to in utero and their detection
may provide a unique insight into the drug exposure of the
fetus throughout gestation. Likewise, since the complete evacua-
tion of meconium occurs slowly, drug detection for diagnostic
purposes in infants, is feasible even in late sampling.
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Variable Apnea in Term/Preterm
Infants Born to Drug Dependent
Mothers: A Prospective Study
A. Spitzer, R. Nye, M. Simmons, W. Fox and L. Finnegan
Recent studies have suggested that infants born to mothers with drug
dependency may be at greater risk for infant apnea and/or SIDS. In
order to evaluate this relationship, 54 infants were prospectively
studied with thermistor-pneumocardiograms. Fifteen infants (28%)
were premature, while 39 (72%) were full-term. Mean B.W. was 2.75 ±
.65 S.D. kg, mean G.A. was 37.9 ± 3.3 wks. Seven of 15 premature
infants (47%) had abnormal studies (central apnea-2, obstructive
apnea-2, periodic breathing 10%-3), whereas, 7/39 term infants (18%)
had abnormal studies (obstructive apnea-2, periodic breathing 5%-4,
mixed apnea-1). Infants in nearly every case had mothers with multiple
drug addictions. These results contrasted to control groups, which
demonstrated a 70% incidence of abnormalities in 55 well premature
infants (p=NS) and a 2.9% incidence in 34 normal term infants (p .025).
Chi ld ren wi th  abnormal  s tud ies  were moni tored unt i l  normal
pneumocardiograms were attained. Infants were monitored for a mean
of 3.8 ± 1.2 S.D. mos. Three infants (21%) were treated with
methylxanthines also because of severity of apnea. No infant required
resuscitation during monitoring. One parent refused to comply with
monitoring as prescribed. These results suggest that maternal drug
dependency has little effect upon apnea incidence in premature infants,
but increases apnea frequency in term infants. Apnea requiring
resuscitation, however, appears to be infrequent in this population if
diagnosed early and treated with methylxanthines and/or home
monitoring.
A F F I L I A T I O N
Department of  Pediat r ics ,  Un ivers i ty  of  Pennsy lvan ia School  of
Medicine, and The Children’s Hospital of Phi ladelphia, and the
Department of Pediatr ics, Thomas Jefferson University Hospital,
Philadelphia, PA.
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Maternal Use of Cocaine,
Methadone, Heroin and Alcohol:
Comparison of Neonatal Effects
W. Rosenfeld, I. Zabaleta, S. Sahdev, R. Jhaverji, K. Vohra,
A. Gatmaitan and L. Conception
While the effects of maternal narcotic use during pregnancy have
been well defined, the effects of cocaine have not been as
clearly delineated. We prospectively evaluated 55 infants for
neonatal signs and symptoms associated with drug use during
pregnancy. Four groups were identified (cocaine alone, cocaine
and alcohol; cocaine and other drugs; and methadone and/or
heroin). Cocaine was the most commonly abused drug (87%), far
exceeding methadone abuse (42%, p = 0.00008). Need for treat-
ment (Lipsitz > 6), duration of treatment, elevation of BP and
thrombocytosis were significantly greater in methadone and/or
heroin users compared to cocaine alone or in combination.
Whether cocaine symptomatology is inherently less severe, or
whether drug abuse among mothers who use cocaine differs from
those who do not, remains to be elucidated.
Department of Pediatrics, Division of Newborn Medicine,
Interfaith Medical Center, SUNY/Health Science Center at
Brooklyn, 1545 Atlantic Avenue, Brooklyn, New York 11213.
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Cocaine Use During Pregnancy:
Adverse Perinatal Outcome
I. Chasnoff, S. MacGregor and G. Chisum
We report the neonatal outcome of 70 pregnancies complicated by
cocaine use. Forty-two of the women used alcohol or marijuana
in addition to the cocaine, and 45 women (65%) used cocaine
throughout the pregnancy. Drug-free pregnancies were matched
for age, parity, tobacco use and medical complications. Polydrug
(non-cocaine)-complicated pregnancies (N=70) were matched for
these same parameters plus marijuana and alcohol use. A compari-
son of fetal outcomes revealed:
The incidence of IUGR (birthweight Brenner’s 10th percentile
for gestational age) in the cocaine group was 19% (N=13) vs 4%
(N=3) in the polydrug and 3% (N=2) in the controls (P< .005).
Abruptio placentae occurred in 17% (N=12) of cocaine vs 1.4%
(N=1) each of polydrug and control patients (P< .005). Two of
the cocaine-exposed infants suffered perinatal cerebral infarc-
tions, and 3 additional cocaine-exposed infants had seizures in
the neonatal period. No control or polydrug infants suffered
these complications. Four cocaine and one polydrug infant were
positive for HIV antibody in the neonatal period. Maternal cocaine
use places the infant at increased risk for complications in the
neonatal period.
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The Use of Tricyclic Antidepres-
sants in Methadone Maintained
Pregnant Women and Infant Outcome
L. Green, S. Ehrlich and L. Finnegan
Over the past two decades there has been considerable controversy over the use
of tricyclic antidepressants in pregnancy. In the early 1970's the tricyclics
were suspected of being tetatogenic. A possible correlation was reported
between imipramine use during the first trimester of pregnancy and infants born
with reduction deformities of the upper limbs.(1) Subsequent epidemiological
reports on birth defects out of Atlanta and Los Angeles were unable to establish
any connection between tricyclics and birth defects and the general conclusion
was drawn that if tricyclics have teratogenic potential in humans it is of low
order at therapeutic doses.(2) When Greenberg, et. al., (1972) compared mater-
nal drug use during pregnancy in a congenital abnormality and no abnormality
group the use of tricyclics was similar in both sets of mothers.(3) Concur-
rently, in the early 70's, other neonatal effects were reported with tricyclic
use. Shearer, et al., (1972) associated the use of the tricyclic, nortriptylene
in pregnancy with urinary retention in the neonate.(4) There have been reports
of withdrawal symptoms in neonates born to mothers on imipramine and desipra-
mine.(5,6) Animal studies have suggested more subtle teratogenic effects.
Mason and Von Pellen (1978) reported increased adrenergic responses in the
uteroplacenta1 vasculature with prior administration of imipramine and
amitriptylene in the pregnant ewe.(7) Coyle and Singer (1974) reported impaired
maze performance in rats with in utero exposure to imipramine.(8) Coyle and
Singer (1975) reported behavioral unresponsiveness and an absence of the
characteristic histological changes associated with enriched rearing conditions
when rats were exposed to prenatal imipramine.(9) Simkins, et al., (1985)
looked at the progeny of rats treated maternally with doxepin and imipramine and
concluded that tricyclics produce subtle alterations in selective adrenergic
function. Simkins also looked at trimester differences and found third
trimester exposure with imipramine reduced birth weight and growth rate of
progeny and found that fir-stand second trimester cbxepin and third trimester
imipramine increased infant mortality.(1O)
Khaki, et al., (1971) found no teratogenic effects in rats exposed to in utero
doxepin hydrochloride even at doses 400 tines the recommended clinical doses(1).
The literature is also filled with reports and letters from physicians of cases
where tricyclic pregnancies produced offspring without harmful effects to the
fetus.(12,13,14,15,15,17) Conclusive proof is, however, lacking and the contro-
versy remains.
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This preliminary study was undertaken to examine the data from 1983 to 1996 of
infants born to mothers on methadone maintenance and whose clinical status
warranted the use of tricyclics during pregnancy.
Methods:
The patients were enrolled in Family Center, an out-patient voluntary program
under the auspices of Thomas Jefferson University Hospital designed to offer
extensive medical care and psychosocial services for the pregnant drug-addicted
woman and her infant. The dictum which has been adhered to at Family Center,
was to prescribe tricyclics only in the second and third trimester of pregnancy
and only if warranted by severe clinical depression.
To determine the outcome of infants born to mothers on tricyclic antidepres-
sants, a population for comparison was selected which consisted of two groups.
Group 1 consisted of 17 infants born to women on methadone maintenance who had
received imipramine (n=2) or doxepin (n=15) during various trimesters of their
pregnancies: first and second trimesters (n=1), first, second and third (n=1),
second and third (n=5) and third trimester only (n=1O). All patients in group 1
were diagnosed as clinically depressed and prescribed tricyclics in low doses
between 25 mg and 100 mg which were administered on a daily basis along with
methadone maintenance. Low doses of tricyclics were considered due to preg-
nancy, the potential synergistic interaction between tricyclics and methadone,
(18) and clinical results demonstrated at these doses. The two patients who
received tricyclics during the first trimester became pregnant while on the
medication. The group II patients consisted of 18 infants born to women ran-
domly selected from the same pool of Family Center patients on methadone
maintenance but not receiving tricyclics. The maternal variables compare
between the groups were: age, race, gravidity, parity, methadone dose, number
of prenatal visits and socioeconomic status. Illicit drug use information was
obtained by self report and by routine urine toxicology and compared between the
groups. The infant variables compared between groups here: gestational age,
birth weight, head circumference, intrauterine growth, one and five minute Apgar
scores, length of hospital stay and neonatal abstinence. A comparison analysis
was then applied to control for in utero benzodiazepine drug exposure as benzo-
diazepine use in pregnancy and methadone maintenance is of concern.(19,20,21,22)
Group comparisons were analyzed using a student t-test for differences between
nuerical mean measures or a chi-square (x2) analysis for the frequency data.
Statistical differences were measured at or below the p=.O5 level of signifi-
cance. Mean trimester differences between infant variables within the tricyclic
group were then compared by gross analysis. Any infant complications were noted
for comparison and evaluation.
Results:
A comparison of group I - tricyclic prescribed methadone maintained women and
group II - non-tricyclic methadone maintained woman revealed the following:
Maternal Demographic Characteristics (Table 1) - The ratio of Black to White
women was 7/10 in group 1 and 10/8 in group 2. The average ages were 30.4 years
and 29.8 years, respectively. The average number of prenatal visits was 5 in
group 1 and 6.1 in group 2. Mean gravidity values were 5.2 and 4.6 and mean
parity values were 2.9 and 1.8. This difference in parity was significant at
the p=.05 level. The average methadone doses were 47.5 milligrams and 46.9
milligrams, respectively.
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TABLE I
Demographic characteristics of 35 pregnant women
*Significant at the p=.05 level.
Drug Use During Pregnancy (Table 2) - The illicit drug use during pregnancy
revealed the use of illicit heroin, benzodiazepines, cocaine, other opiates2,
propoxyphene, glutethimide and alcohol in both groups. The illicit use of
barbiturates and amphetamines and the prescribed use of barbiturates and amphe-
tamines and the prescribed use of thioridazine were confined to the tricyclic
group only.
TABLE II
Maternal drug use during pregnancy
*Information obtained by self-report upon enrollment at Family Center Program
and by routine urine toxicology report.
***Codeine, hydromorphone, morphine, oxycodone or non-identified opiate.
Outcome of the Neonate (Table 3) - The between group comparisons of neonatal
outcome variables which included birthweight, head circumference and Apgars at
one minute were lowest in group 1. None of these differences were found to be
significant at the p=.05 level. Mean gestational age of group I infants was
37.3 weeks compared to 38.7 weeks for group II infants. This difference was
significant at the p=.05 level.
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TABLE III
Infant outcomes
*Significant at the p=.O5 level.
Benzodiazepine as a factor in outcome of the neonate (Table 4) - When the
banzodiazepines were controlled for and all subjects from the study here placed
into a benzodiazepine group I, and a non-benzodiazepine group II, there were no
significant differences between these groups for any of the infant parameters
compared.
TABLE IV
Factorization of benzodiazepine use and infant outcome
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Outcome of the neonate - Trimester differences (Table 5) - Infant outcome
variables were sub-divided for comparison between trimester tricyclic use. The
tricyclic group was sub-divided into four groups: First and second trimester
condaml and third trimester (group II), first, second, and third
trimester (group III) and third trimester only (group IV). The comparison
revealed that birth weight, gestational age, head circumference and Apgar scores
at land 5 minutes were lowest in group IV. These third trimester only mean
infant variables were lower than total tricyclic group averages. Small numbers
and differences in trimester distribution made data inappropriate for statis-
tical analysis.
TABLE V
Trimester Tricyclic Use and Infant Outcome
Outcome of the neonate - Infant Complications (see Table 6) - There were 5 cases
of infant replications and 1 SIDS death at age 1 month in group II. There were
8 cases of infant complications in group I. The complications in group I
appeared more extensive in nature than controls. Some of the group I complica-
tions were identified with early gestational age.
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TABLE VI
Infant Outcome - Infant Complications
Discussion
This study suggests that the infants of mothers of methadone maintenance who are
concurrently on low doses of tricyclic antidepressants are born somewhat earlier
than infants born to methadone maintenance mothers not prescribed tricyclics.
The findings of lower mean birth weight, smaller mean head circumuference, lower
mean Apgar scores and the increased severity of infant complications seen in the
tricyclic exposed infants were not significant but may be attributed to earlier
gestational age. Of additional interest is the finding that, than gross compari-
sons were made according to trimester prescribed, infants exposed during the
third trimester only were born earlier and smaller than infants exposed in any
other trimester combinations.
These results are presented, however, with some limitations. First the matching
of demographic maternal characteristics cannot eliminate any inherent diffe-
rences in the profiles of diagnosed and treated depressed patients as compared
to presumably non-depressed patients. Differences in gravidity were determined
attributable to the potential differences in patient profiles. Second, and
perhaps related to the first, are differences in illicit drug use in the two
groups. Although these differences were taken into account in the analysis,
illicit drug use remains a general limitation in studying this population.
Depression remains a problem in pregnant drug dependent women.(23) The tri-
cyclic, doxepin has been established as an effective treatment for the relief of
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depression and anxiety in patients on methadone maintenance.(24) Depression and
anxiety may represent a stress to an already high risk pregnancy. Within the
context of these considerations along with the findings drawn from the study,
little more can be provided than to support what has previously been suggested:
that tricyclics can only be prescribed to pregnant methadone maintenance
patients when the potential benefits outweigh the carefully considered risks.
In conclusion, this study found that infants born to methadone maintained women
exposed to in utero tricyclic antidepressants were born earlier than infants of
methaadone maintained women not exposed to tricyclics. It was also an observa-
tion that the more severe complications were seen in the tricyclic exposed
infants and were attributable to the earlier gestational age.
Future investigation should attempt to collectively study greater numbers of
infants born to women on tricyclics in both the drug addicted as well as the
general population before tricyclic use in pregnancy can be unequivocally
accepted or rejected.
Footnotes
1. Subject no. 18 of group I was eliminated when it was established that
tricyclic use began subsequent to a diagnosis of fetal abnormality.
2. Other opiates included codeine, hydromorphone, morphine, oxycodone or
non-identified opiate.
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Pediatric Surveillance of AIDS
Among Infants of I.V. Drug-Using
Mothers
D. Kaplan, R. Kletter and J. Ferrara
POPULATION STUDIED: Infants of I.V. drug using mothers
SAMPLE SIZE: Twenty seropositives, 20 controls
TIME FRAME: Three years
METHODOLOGY
Weekly for first month; monthly for next six months; bi-monthly
for following six months; quarterly for next 12 months. Complete
history and physical, anthropomorphic measurements, immunizations,
lab workups.
BASIC FINDINGS CONCERNING WOMEN AND/OR CHILDREN
Significant seropositivity rate in population of i.v. drug using
mothers and their infants. Study data to present time does not
indicate significant progression of disease up to two years of
life.
CURRENT OR FUTURE RESEARCH STRATEGY
Following the experience of New York/New Jersey, increased numbers
of infected children will require policy consideration for day
care, foster care and school attendance. As number of
seropositive women increase, potential for isolating predictive
variables among i.v. drug using women may help to identify mothers
and their infants at greatest risk for infection (e.g., chaotic
lifestyle, uncontrolled drug use, unsafe sex practices, criminal
involvement).
AUTHORS
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Maternal Drug Abuse During
Pregnancy and Pharmacotherapy
for Neonatal Abstinence Syndrome
L. Finnegan
Newborns exposed in-utero to psychoactive drugs
frequently undergo abstinence. This study evaluated:
1) the relationship between the type of maternal drug
use and the incidence of neonatal abstinence and 2)
which of 3 treatment drugs was most effective --
paregoric, phenobarbital, or diazepam. Abstinence was
assessed by a scoring system related to drug dose.
Successful treatment was considered when one drug
controlled abstinence. Of the 300 infants, 59% were
treated for abstinence and 41% required no treatment.
Maternal drug use consisted of opiates, non-opiates
and varying combinations of both. Infants exposed to
non-opiates in-utero were less likely to undergo
abstinence (36%) than those exposed to opiates (58%)
or both (70%). The mean number of days to control
symptoms of abstinence was 7.6 days, and duration of
treatment averaged 38.6 days. If maternal drug use
included opiates alone, paregoric was the drug most
successful in controlling abstinence (87% of infants).
In maternal non-opiate use, phenobarbital was most
effective (100%). In maternal opiate and non-opiate
use, paregoric was most effective (88%). Treating an
infant with diazepam indicated the need for a second
treatment drug in 70% of cases, regardless of maternal
drug use. These data suggest that: 1) effective
treatment for neonatal abstinence is related to the
type of maternal drug use, 2) there is a higher
incidence of abstinence in infants prenatally exposed
to opiates alone or in combination with non-opiates,
and 3) diazepam is generally ineffective for the
treatment of neonatal abstinence.
AFFILIATIONS
Department of Pediatrics, Jefferson Medical College of
Thomas Jefferson University, Philadelphia, PA 19107.
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Separation of Opioid Receptor Blockade from
Production of Functional Supersensitivity
B. Yoburn and C. lnturrisi
Chronic treatment with opioid antagonists increases brain opioid
receptors (upregulation) and enhances the potency of opioid
agonists (supersensitivity) such as morphine. In the present
study we have examined the role that blockade of the analgesic
action of the µ receptor ligand morphine and the 6 receptor
ligand [D-Ala2-D-Leu5]enkephalin (DADLE) plays in the production
of supersensitivity. Mice were implanted subcutaneously with a
high (7.5mg) or low (2.0mg) dose naltrexone (NTX) pellet or a
placebo pellet for 8 days. Mice were tested for blockade of
morphine (24mg/kg,sc) analgesia (tailflick) or DADLE
(4.4nmol/mouse, intracerbroventricularly) at 4hr and 8 days
following implantation of NTX. Whereas 95-100% of placebo-
implanted mice showed complete analgesia 30min following
morphine at both time points, both NTX doses blocked analgesia
at 4hrs (100% of mice blocked) and 8 days (95-100% blocked).
Similarly, DADLE (20min after administration) produced analgesia
in 75% of placebo-treated mice at 4hr and 8 days following
implantation, and both doses of NTX blocked DADLE analgesia at
both time points (100% blocked). If blockade of analgesia is a
sufficient condition to produce supersensitivity, then both NTX
doses should also be equi-effective in increasing morphine’s
analgesic potency. Three groups of mice were implanted with the
low or high dose of NTX, or placebo for 8 days; The pellets
were then removed and 24hr later mice were injected with
morphine (8mg/kg,sc) and assessed for analgesia. Consistent
with our previous studies, this dose of morphine produced
analgesia in 27.9% of placebo-treated mice. The same dose of
morphine produced significant supersensitivity (70.7% analgesic)
in high dose NTX-treated mice. The low dose NTX treatment did
not produce a significant increase in analgesia (45% analgesic)
compared to controls, and produced significantly less analgesia
than the high dose NTX group. These results indicate that
blockade of analgesia mediated by µ and receptors is not
sufficient to produce a full supersensitivity response and
raises the possibility that blockade requires only partial
receptor occupancy and supersensitivity full receptor occupancy.
Supported in part by NIDA grant # DA 04185.
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Colonic Opiate Receptors Change with Age:
Preliminary Data
J. Culpeper-Morgan, P. Holt and M. J. Kreek
Elderly patients require lower doses of opiates for analgesia
than do younger patients. We have reported that constipated
elderly individuals increase stool wet weight and volume in
response to oral and parenteral naloxone. Thus changes in the
central as well as enteric human endogenous opioid system
probably occur with age. We have started to measure the differ-
ences in the relative opiate subtype densities in the colons of
young (6 weeks) and elderly (30-33 months) male albino Hartley
strain guinea pig(GP)s. Crude membrane fractions of longi-
tudinal muscle with attached myenteric plexus were prepared and
suspended in 50mM Tris (pH 7.4 @ 25°C). Results of binding
assays using 3H-naloxone displaced with naloxone and "universal
agonist" etorphine, were analyzed by a least squares curve
fitting routine (FITCOMP, PROPHET system). The table lists the
relative nanomolar affinities (IC50) of each model, relative
densities (%Bmax), and the significance of the improvement of
fit of a L-site versus a 1-site model.
The 1-site model reveals an overall increase in affinity for
naloxone with age and no change in etorphine affinity. The
ability of FITCOMP to resolve the data from the elderly GPs into
2 sites of equal density whereas this is not possible with the
data from the young animals implies a change in receptor subtype
density with age. The increased affinity of mu preferring
naloxone suggests an increase of mu subtype density. Full
characterization of these differences requires analysis of
competition experiments with highly selective ligands.
AFFILIATION
The Rockefeller University and St. Lukes-Roosevelt Hospital,
Columbia University, N.Y., NY 10021 (Reference requests to MJK)
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U50,488H Differentially Blocks the Central
Anticonvulsant and Bladder Motility Effects
of Mu Agonists in the Rat
F. Porreca and F. Tortella
A number  of  laborator ies  have shown that  kappa agoni s t s
block some, but not all, of the pharmacological actions of classical
mu agonists (Wood, Drug Dev. Res., 4:429, 1984). We studied the
mu antagonist properties in v ivo of U50,488H, a selective kappa
agonist, using elevation of seizure threshold (ST) and suppression
of bladder moti l i ty (BM) as central mu-opioid endpoints. Anticon-
v u l s a n t  p r o p e r t i e s  o f  t h e  m u  a g o n i s t s  [ D - A l a 2 ,  N M e P h e 4 ,  G ly -
ol]enkephalin (DAGO) and etorphine (ETOR) were studied in male
S.D. rats by as latency to seizure onset (ST) induced by flurothyl.
Bladder effects of DAGO and ETOR were studied in female S.D.
r a t s  a s  t h e  d u r a t i o n  o f  i n h i b i t i o n o f  v o l u m e - i n i t i a t e d  B M .
Int racerebrovent r icu lar  ( i .c .v . )  DACO (1.13 ug)  or  ETOR (1 .0  ug)
increased ST to 534 ± 34 sec and 484 ± 29 sec, respectively, when
compared to control alues (357 ± 8 sec); U50,488H (10 ug, i .c.v.)
had no protective effect (357 ± 18 sec). L i kewise ,  i .c .v .  DAGO
(0.0075 ug) and ETOR (0.0018 ug) suppressed BM for 22.8 ± 1.7 min
and 21.9 ± 3.1 min, respectively; i .c.v. sal ine or U50,488H (10 - 60
ug) were-ineffective. Antagonist properties of U50,488H on the
central ly-init iated effects of DAGO and ETOR were determined for
both endpoints in rats pretreated with saline or the kappa agonist.
Although lacking agonist activity, prior U50,488H treatment (10 ug,
i . c . v . )  b l o c k e d  t h e  S T  e l e v a t i o n  b y  i . c . v .  E T O R  ( 4 1 9  ±  1 9  s e c ,
P<0.05) ,  but  not  that  by i .c .v .  DAGO (503 ±  22 sec) .  S imi lar ly ,
p r e t r e a t m e n t  w i t h  U 5 0 , 4 8 8 H  ( 1 0  u g ,  i . c . v . )  a n t a g o n i z e d  t h e
suppression of BM by i .c.v. ETOR (3.6 ± 2.4 min duration, P<0.01),
but  not  that  by i .c .v .  DAGO (23.3  ±  116 min durat ion) .  Thus ,  in
two endpoints of central opioid activity, U50,488H was found to
selectively antagonize the effects of ETOR, but not those of DAGO,
b o t h  a g o n i s t s  a t  m u  r e c e p t o r s . These f indings  suggest  the
existence of subpopulations of mu-opioid receptors ( isoreceptors)
that  are d i f ferent ia l ly  af fected by kappa agonis t s  and through
which, a diverse group of mu agonists may exert s imilar effects.
A F F I L I A T I O N
Department  of  Pharmacology,  Un ivers i ty  of  Ar i zona,  Tucson,  AZ
85724 & Neuropharmacology Branch, Walter Reed Army Institute of
Research, Washington, D.C. 20307
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Tolerance and Abstinence to Mu and Kappa
Receptor Stimulation of the Hypothalamo-
Pituitary-Adrenal Axis
D. lgnar and C. Kuhn
The hypothalamo-pituitary-adrenal axis is stimulated by ad-
ministration of mu and kappa opioid receptor agonists to rats as
evidenced by a rise in circulating ACTH and corticosterone (CS).
Following chronic administration, tolerance and withdrawal develop
within the HPA axis. The focus of the present work is to eluci-
date ttie role of mu and kappa opioid receptors in the adaptations
responsible for these phenomena. This is a novel approach to the
study of opiate tolerance and dependence since it is an in vivo
model in which both processes may be studied. Adult male Sprague-
Dawley rats were injected with increasing doses of morphine or the
kappa receptor agonist U50,488 twice daily for 5 days. Abstinence
and tolerance were assessed 12 and 36 hours, respectively, after
the cessation of treatment. The rats were decapitated and blood
was collected for measurement of CS by radioimmunoassay. Complete
tolerance to a 10 mg/kg challenge dose of morphine was observed
after 5 days of morphine treatment (20 mg/kg to 40 mg/kg). The
abstinence-induced stimulation of CS which peaks 10 to 14 hours
after morphine administration, is observed after 1 day of treatment,
before substantial tolerance develops. After the fifth day of
treatment, abstinence-induced CS secretion was maximal and could
be totally suppressed by 5 mg/kg morphine, a dose to which the
HPA axis is completely tolerant, No evidence of cross-tolerance
to U50,488 was observed, and this drug did not suppress morphine
abstinence-induced increases in CS secretion. Chronic treatment
with U50,488 (1 mg/kg to 5 mg/kg) resulted in approximately 70%
tolerance to a 1 mg/kg challenge dose of U50,488. Cross-tolerance
to 10 mg/kg morphine was not observed. Withdrawal from U50,488
was not associated with elevation of CS levels. These results
demonstrate that tolerance to opiate effects on the HPA axis
occurs at both mu and kappa receptors, In contrast, abstinence-
induced rises in CS secretion seem to be related only to the mu
receptor. The mechanism by which abstinence and tolerance to
morphine-induced rises of CS secretion develop may be dissociable,
as abstinence is observed before measurable tolerance occurs,
Tolerance might result from adaptations at hypothalamic sites
directly involved in regulation of CRF secretion. Abstinence
secretion of CS may be integrated at other neural centers which
are known to exhibit hyperactivity during opiate withdrawal.
AFFILIATION
Department of Pharmacology, Duke University Medical Center,
Durham, NC 27710
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Tolerance Develops to Naloxone-Induced LH
Secretion in Neonatal Female Rats
E. Field, M. Doron and C. Kuhn
Tonic endogenous opioid peptide (EOP) inhibition
of luteinizing hormone (LH) secretion is especially
strong in neonatal female rats. Acute or repeated
treatment with the opiate antagonist, naloxone (NAL),
is followed by an immediate marked rise in serum LH
and by a rebound suppression 6 hr later. These
findings suggest that a recent report of precocious
puberty following chronic NAL treatment of neonatal
female rats might be explained by the immediate LH
effects of repeated NAL exposure. The current study
tests the hypothesis that chronic NAL causes repeated
rises in LH associated with accelerated pubertal
development. NAL (2.5 mg/kg SC) or saline (SAL) was
administered every 6 hr from 1 to 10 days of age. At
10 days of age, pups were challenged with NAL 6 hr
after their last chronic injection. Blood samples
were obtained by decapitation 20 min later. Some
animals were tested for MOR-induced antinociception 6
hr following the last NAL injection. Other chronica-
lly treated pups were examined daily for vaginal
opening and subsequent vaginal cytology. Whereas in
NAL-naive animals NAL challenge produced a 5-fold
rise in LH, animals chronically exposed to NAL did
not demonstrate an LH rise in response to NAL.
Furthermore, LH levels in chronic NAL rats were at
basal, not suppressed, levels 6 hr post-NAL. These
results suggest that tolerance develops during
chronic neonatal NAL treatment to EOP blockade
involved in the immediate rise and the rebound
suppression of serum LH and might reflect endogenous
responses to chronic antagonist treatment, such as
EOP receptor up-regulation, changes in EOP neuron
activity, or adaptations of the entire hypothalamic-
pituitary-ovarian axis. Also, NAL did not block MOR-
induced antinociception 6 hr later. Finally, we
found no effect of chronic neonatal NAL treatment on
the timing of vaginal opening or the first diestrus,
in contrast to previously published reports.
AFFILIATION
Department of Pharmacology, Duke University Medical
Center, Durham, NC 27710
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Early Maturation of Mu and Kappa Opiate
Control of Hormone Secretion and Effects
of Perinatal Opiate Addiction
C. Kuhn, D. Ignar, L. Bero, S. Lurie and E. Field
The significant and specific role of each endogenous opioid
peptide on neuroendocrine function suggest that hormone secre-
tion could be altered markedly by perinatal opiate addiction. To
investigate this possibility, we first investigated the ontogeny
of mu, kappa and delta-specific endocrine responses in neonatal
rats. The effects of chronic treatment then were assessed by
evaluating the endocrine response to opiate challenge after
chronic administration.
High doses of exogenous (methadone, 2.5 mg/kg) or endogenous
(beta endorphin) opiates to 5 day old rat pups elicited en-
docrine response resembling those observed in adults: increases
in prolactin (PRL), growth hormone (GH), corticosterone (CS) and
suppression of thyroid stimulating hormone (TSH). Administration
of agonists with relative specificity for mu (low dose (5 mg/kg)
morphine, morphiceptin (0.5 ug i.c.v.) kappa (U50,488, 1 mg/kg
s.c.) dynorphin, 1 ug i.c.v.) or delta (D-pen2-pen5 enkephalin,
1 ug i.c.v.) receptors revealed that mu and kappa receptors
modulated PRL, TSH and CS secretion as early as postnatal day 5.
Furthermore, opiate receptor antagonists naloxone (0.1 mg/kg)
and the kappa antagonist MR2266 significantly elevated LH
secretion. Kappa receptor stimulation actually decreased GH
secretion, while delta and possibly mu receptor stimulation
increased GH secretion. These results demonstrate the presence
of multiple opiate controls of hormone secretion at an age at
which opiate-induced analgesia is still immature.
Although tolerance of opiate-induced CS secretion was not
observed after chronic U50,488 administration, chronic morphine
(5 to 25 mg/kg, bid. for 5 days) resulted in a marked decrease
of CS responses to subsequent morphine challenge, as well as an
abstinence-related rise 12 hours after the last dose. This
tolerance suggests that endocrine function might both be a
target of and a useful experimental system for studying peri-
natal opiate addiction.
Department of Pharmacology, Duke University Medical Center,
Durham, NC.
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A Comparison of the Modes of Interaction of
(+)- and -(-) Opiates at PCP Receptors
A. Newman, V. Bykov, R. Rothman and K. Rice
Stereospecific binding of [3H]PCP to central PCP binding
sites has been established and recent evidence, based on drug
discrimination studies, suggests that the (+)-stereoisomers of
some opiates share certain effects with PCP, and these effects
are not observed to the same degree with the (-)-stereoisomers.
The natural (-)-opiates have proven invaluable in elucidating µ
opioid receptors. The few (+)-opiates that have been examined
have been found to be inert at classical opioid receptors.
However, the lack of availability of a variety of unnatural
(+)-opiates has precluded extensive study of the pharmacology of
these compounds. The recently developed NIH Total Opiate
Synthesis has enabled the preparation of many previously
unavailable (+)-opiates, for study. Thus synthesis of
(+)-morphine, (+)-naloxone, and (+)-naltrexone has been
accomplished and these compounds, their natural
(-)-stereoisomers, as well as several available opiate
enantiomeric pairs were evaluated to determine their mode of
interaction at the rat brain PCP receptor, in vitro, using ligand
binding techniques. Two models were compared: a competitive
model, which assumes that the test drug competes directly with
the PCP binding site, and a noncompetitive model which assumes
that the test drug competes indirectly for the PCP binding site,
acting to decrease the Bmax. [
3H]TCP was used to radiolabel PCP
binding sites in rat brain. Most (+)-opiates demonstrated higher
binding affinity (lower Kd values) to the PCP receptors than
their (-)-stereoisomers. The competitive and noncompetitive
models of binding fit the data equally well for the enantiomeric
pairs of morphine, naloxone and naltrexone, whereas the data for
all other compounds tested fit the competitive model over the
noncompetitive model of binding. Subsequent behavioral testing
will determine whether these compounds are acting as PCP receptor
agonists or antagonists.
AFFILIATION
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(+) - N - Allylnormetazocine Binding Sites:
Characterization with In Vitro and In Vivo
Methods
D. Compton and B. Martin
The distinct patterns of pharmacological effects observed with various opioids has
led others to postulate the existence of multiple subpopulations of receptors, and to
classify the benzomorphan N-allylnormetazocine (NANM, or SKF 10,047) as the
prototypic agonist of the opioid receptor. Evidence suggests that NANM and
phencylidine (PCP) may produce similar effects via a common site of action.
Additionally, though comparison of the similarities between (+)- or (-)-NANM
and PCP in the production of pharmacological effects depends on the specific test
and the species used, in all cases (+)-, but not (-), NANM resembles PCP. The in
vi tro binding of both isomers of 3 H-NANM indicates that the isomers bind to
distinct sites, and also suggests that it is (+)-, not (-), NANM which is PCP-like.
However, the in vitro binding of both PCP and NANM is a function of the assay
conditions (buffer, ionic strength, ions present, etc.), yet the extent to which such
factors alter the binding of (+)-3H-NANM in vivo are unknown. By using in vivo
binding methods, the characteristics of saturability, regional distribution, and
selective displacement for (+)-3 H-NANM binding to mouse brain homogenates
h a s  b e e n  d e t e r m i n e d  a n d  c o m p a r e d  t o  i n  v i t r o  m e t h o d s .  T h e  i n  v i v o
(+)-3H-NANM saturation (0.1 mg/kg - 1 mg/kg) and displacement (5 µg/kg - 25
mg/kg unlabeled (+)-NANM) curves are monophasic (R=0.98). Therefore, if
(+)-NANM interacts with multiple sites, then the isomer must do so with identical
a f f i n i t i e s  u n d e r  i n  v i v o  c o n d i t i o n s .  I n  v i v o  ( + ) - 3 H - N A N M  b i n d i n g  ( 1 8 2
µCi/0.85 µg/kg) is inhibited by PCP (75% at 25 mg/kg), (+)-ketocyclazocine
(88% at 10 mg/kg), and haloperidol (86% at 10 mg/kg), and is inhibited by
naloxone (26% at 1 mg/kg) though not in a dose-responsive fashion, but is not
i n h i b i t e d  b y  ( - ) - N A N M  ( 5 0  µ g / k g ) o r  ( - ) - k e t o c y c l a z o c i n e  ( 1 0  m g / k g ) .
Additionally, the displacement of (+)- H-NANM from various brain areas (given
below) by these drugs is similar to that observed in whole brain. Lastly, the rank
order  of  the  d is t r ibu t ion  of  i n  v i v o  and  i n  v i t r o  (+ ) -3 H-NANM binding  i s
identical, with the exception of the cerebellum which contains the largest number
of  s i tes  in  the  i n  v i v o  assay .  A rank  order  of  h ighes t  to  lowes t  i n  v i t r o
(+)-3H-NANM binding is: medulla, midbrain, hypothalamus, cerebellum, cortex,
shiatum, and hippocampus. The (+)3 H-NANM site described in this report is
similar to the site(s) previously reported for in vitro (+)-3H-NANM binding and
refered to as a PCP site. This site may represent a “ receptor” of unknown
pharmacological significance, or the /PCP, haloperidol, or “high affinity”
receptor reported by others.
AUTHORS: D.R. Compton; B.R. Martin; Dept. Pharmacol./Toxicol.,
Med.Coll.Va./Va. Commonwealth Univ., Richmond, VA 23298. Supported by
NIDA Grants DA-02396, DA-00490, and DA-07027.
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Effects of Amfonelic Acid, A Dopamine Agon-
ist, and Morphine on Brain Stimulation Reward
S. lzenwasser and C. Kornetsky
Many drugs of abuse, including stimulants such as cocaine
and amphetamine, and opioids like morphine and heroin, will
lower the threshold at which rats will work to receive
electrical stimulation to the medial forebrain
bundle-lateral hypothalamus (MFB-LH). The underlying
mechanisms by which this occurs are not completely
understood, however there is considerable evidence
suggesting that dopamine plays a major role in mediating
was conducted to investigate the effects of amfonelic acid
the reinforcing effects of these drugs. The present study
a selective dopamine agonist alone and in combination with
morphine, on the threshold for rewarding brain-stimulation.
Bipolar stainless steel electrodes were stereotaxically
implanted into the MFB-LH of male F344 rats Charles River
Laboratories). The animals were then trained on a discrete
trial procedure to turn a wheel manipulandum in order to
receive electrical stimulation to this brain site. Reward
thresholds were determined using a modification of the
psychophysical method of limits. As in many previous
reports, morphine lowered the reward threshold. Amfonelic
acid as in a recent study (Knapp et al. Pharmacologist
28:150 1986) also caused threshold lowerings, and these
were of a greater magnitude than those seen with morphine.
When a low (ineffective) dose of amfonelic acid was
concomitantly with morphine the threshold
lowerings observed were larger than those seen with either
drug alone.
These findings suggest that amfonelic acid has abuse
potential and that its reinforcing effects may, in fact, be
even greater than those of the opioids. Further, these
results support the hypothesis that dopamine plays a
significant role in mediating brain-stimulation reward and
that there is an interaction between opioid and
dopaminergic system.
(Supported in part by NIDA grant DA 02326 and NIDA Research
Scientist Award K05 DA00099 to CK)
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Antidepressants in Mouse Narcotic
Dependence Tests
W. Schmidt and L. Cook
Amitriptyline, imipramine, and other antidepressants have gained
increasing acceptance in the treatment of chronic pain (S. Butler,
Adv Pain Res Ther 7: 173, 1984). Previous studies have shown that
selected antidepressants produce naloxone-reversible analgesia or
morphine cross-tolerance in the mice, suggesting an opioid-type
analgesic component to their action (M.C. De Felipe et al., Eur J
Pharmacol 125: 193, 1986). Antidepressants used in these tests
also produce motor incoordination which makes interpretation of
their effects less certain. Accordingly, we examined the activity
of sedating and non-sedating antidepressants in several analgesic
tolerance and dependence procedures commonly used to investigate
the action of narcotic drugs. Using inhibition of phenylquinone
writhing to measure analgesic activity, analgesic tolerance
studies show that nanifensine, a non-sedating antidepressant, is
fully cross-tolerant to morphine in morphine-tolerant mice.
Amitriptyline and trazodone showed a partial cross-tolerance to
morphine that might have been greater had the drugs not caused
strong sedation and motor impairment at higher test doses. We
observed a reduction in these overt behavioral signs in morphine-
tolerant mice, indicating side-effect cross-tolerance in addition
to analgesic cross-tolerance. In the Single Dose Suppression test
(partially-withdrawn morphine-dependent mice), nomifensine and
trazodone suppressed morphine withdrawal jumping but not autonomic
signs of withdrawal. Amitriptyline exacerbated withdrawal
jumping. Morphine suppressed all withdrawal signs. In a 72 hr
dependence induction test, mice treated with continuous infusions
of amitriptyline or trazodone showed a high incidence of
withdrawal jumping responses upon discontinuation of the minipump
infusion. However they had none of the characteristic autonomic
withdrawal signs shown in morphine-treated mice. Mice treated with
chronic infusions of chlorpromazine or haloperidol also showed
abrupt abstinence withdrawal jumping. Naloxone was ineffective in
precipitating withdrawal in non-withdrawn mice infused with
amitriptyline, trazodone, chlorpromazine, or haloperidol. These
results demonstrate that anti-depressants and other CNS-active
drugs produce some tolerance or dependence-related signs similar
to those of narcotic-related analgesics, but do not show all signs
characteristic of narcotic-like activity in mice. Therefore, some
commonly observed withdrawal signs are not restricted to the use
of typical opioid analgesics.
AFFILIATION
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Calorimetric Analysis of ICV Morphine
in the Rat
A. Zwil, T. Lynch, R. Martinez, E. Geller and M. Adler
Body temperature (Tb), 02 consumption (V02) and heat loss (Q) were continuously recorded in a
whole-body calorimeter maintained at 20°C before and after intracerebroventricular (ICV)
injection of 30 µg morphine sulfate (MS) in awake, unrestrained, young adult, male
Sprague-Dawley rats. MS was injected via a cannula chronically implanted in the right lateral
cerebral ventricle.
ICV MS produced a sustained hyperthermia in all 7 animals tested. Tb began to rise between
0.25 and 3.25 (µ±SE = 2.0±0.42) hours post-injection, peaked at 1.5 to 3°’C above baseline at
2.25 to 4.25 (µ±SE = 3.14±0.29) hours, and remained at or near that level until the end of the
recording session. In the longest session recorded, Tb was still elevated at 3 hours after onset of
hyperthermia. In five out the seven cases hyperthermia was accompanied by an increase in V02.
while an increase in Q did not begin until 30 to 60 minutes after onset of hyperthermia. The net
result of the changes in V02 and Q was that the Q/V02 ratio, an index of thermoregulatoty
activity, usually decreased simultaneously with the hyperthermia (due to the increased V02) and
returned to near baseline after the subsequent increase in Q. These results show that the
hyperthermia was caused by an increase in metabolic heat production, and that thermoregulatory
responses were subsequently activated in an attempt to stabilize Tb at a higher level. Four
animals injected with saline instead of MS showed no change in Tb, and only transient
fluctuations in Q and V02.
In previous work from this laboratory, low doses of MS injected subcutaneously (SC) produced
hyperthermia with a decrease in Q/V02, while high doses of MS produced hypothermia
accompanied by an initial increase and followed by a subsequent decrease in Q/V02.1 In the
current investigation, MS administered ICV produced effects upon Q and V02 similar to a
hyperthermic SC dose, indicating that the mechanism of action is the same for both routes.
These results are in accord with the hypothesis, advanced previously, that MS causes
hyperthermia by acting upon mu receptors in the brain, and hypothermia by activating kappa
receptors in the spinal cord or periphery.2 (Supported in part by grant #DA00376 from NIDA.)
1Lynch TJ et al. In: Harris LS (ed.) Problems of Drug Dependence, 1986. Proceedings of the
48th Annual Scientific Meeting. The Committee on Problems of Drug Dependence, Inc.
NIDA Monograph 54, pp.12-26, 1987.
2Geller EB. Rowan CH, and Adler MW. Pharmacol. Biochem. Behav. 24:1761-65, 1986.
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Tolerance to Fentanyl and Cross Tolerance to
Morphine in a Drug Discriminative Procedure
M. Emmett-Oglesby and A. Herz
This investigation tested the hypothesis that tolerance
would develop to the discriminative stimulus properties of
fentanyl upon discontinuation of discrimination training and
injection of fentanyl in doses larger than the training
dose. Rats were trained to discriminate fentanyl, 0.04
mg/kg, from saline using a two-lever choice procedure with
food as a reinforcer. Subsequently training was stopped,
and fentanyl, 0.08 mg/kg, was injected every 12 h for one
week. This procedure did not produce tolerance, nor did
tolerance occur when fentanyl, 0.16 mg/kg every 24 h, was
continued for an additional week. In contrast, a dose of
morphine (8.0 mg/kg) equated for efficacy to the 0.08 mg/kg
dose of fentanyl, produced both tolerance to the morphine
stimulus and cross-tolerance to the fentanyl stimulus after
three to four days of administration. In an additional
experiment, the time course for detection of fentanyl was
found to be significantly shorter than the time course for
the detection of morphine. Thus, these results, as well as
a previous report (Colpaert et al. Neuropharmacology. 17:
705-713, 1978) of failure to find tolerance to fentanyl, are
perhaps attributable to fentanyl's brief duration of action.
This hypothesis predicts that tolerance should be observed
if the frequency of administration of fentanyl were
increased. In a subsequent study, when 0.12 mg/kg of
fentanyl was administered every 6 h for 4 days, tolerance
to fentanyl and cross-tolerance to morphine was found. In
addition, sensitivity to fentanyl spontaneously reverted to
baseline within 4 days of terminating chronic fentanyl
administration. These data indicate that tolerance occurs
to fentanyl in the drug discrimination procedure, and they
suggest that pharmacokinetic factors may account for some
failures to find tolerance.
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Regression Analysis as a Measure of
Tolerance Development to Opioid-Induced
Disruption of Food-Maintained Responding
in Macaque Monkeys
S. Lukas, N. Mello, M. Bree and J. Mendelson
This study assessed the development of tolerance to opioid-induced disruption of
food-maintained responding using regression analysis techniques. Single daily
subcutaneous injections of buprenorphine (1.0 mg/kg), diprenorphine (1.0
mg/kg), or heroin (1 .0 mg/kg) were given over 25 consecutive days to examine
the degree and the rate of tolerance development to drug-induced suppression of
food-maintained responding. Similar techniques were applied during saline
substitution for an additional 15 days. One gram food pellets were available on a
second order schedule (FR 4 VR 16:S) during 1-hr sessions three times a day
(7:00 a.m., 11:00 a.m., and 3:00 p.m.). Daily drug and saline control injections
were given at 10:00 a.m. During the first three days of treatment all three drugs
produced marked suppression of food-maintained performance. Recovery from
buprenorphine- and diprenorphine-induced suppression of food-maintained
responding occurred within four and eight days, respectively. By the 25th day of
buprenorphine and diprenorphine treatment, operant responding for food
increased significantly above control levels (P < .01). In contrast, heroin-induced
disruption of food-maintained responding recovered only slightly and remained
significantly reduced (P < .01) throughout the 25-day treatment period.
Regression analysis of the linear portion of the time-effect curve revealed
significant differences in both the rate and the degree of tolerance development to
these three opioids. The buprenorphine and diprenorphine recovery curves were
parallel while the slope of the heroin recovery curve was not significantly different
from zero. Saline substitution for all three drugs resulted in a gradual return to
control levels of food pellets earned (i.e., increased responding after heroin and
decreased responding after buprenorphine and diprenorphine). These differences
in tolerance development may reflect pharmacokinetic differences between the
relatively short-acting heroin and the longer-acting diprenorphine and
buprenorphine.
AFFILIATION
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Comparison Study of Oral Pentazocine,
Pentazocine + Naloxone and Placebo in
Postepisiotomy and Postoperative Pain
A. Sunshine, N. Olson, R. Axtmayer, I. Ramos and E. Laska
Our objective was to study the effect of the addi-
tion of 0.5mg naloxone (NX) to Pentazocine 50mg on
the analgesic efficacy of pentazocine 50mg. A
single oral dose of either p e n t a z o c i n e ,
pentazocine-NX or placebo was given to 48 patients
with moderate pain and 76 patients with severe pain
resulting from episiotomy, cesarean section or
gynecological surgery in a randomized double-blind
parallel groups study. Patients were evualted over
a I-hour period. An analysis of the entire popula-
tion showed both pentazocine and pentazocine-NX to
be significantly more effective than placebo for
all measures. In addition, pentazocine-NX was sig-
nificantly less efficacious than pentazocine for
%SPID and for relief and PID at the fourth hour.
Because there was a significant interaction between
drug and baseline pain intensity for the variable
SPID, comparisons were made between pentazocine and
pentazocine-NX within each baseline pain intensity
group. For patients with moderate baseline pain,
pentazocine-NX produced significantly less pain
relief than pentazocine for SPID and for relief and
PID at hours 3 and 4. In patients with severe
baseline pain, there was no significant difference
between pentazocine and pentazocine-NX.
Four patients complained of adverse effects; 3
received pentazocine and 1 patient received
pentazocine-NX as the treatment.
AFFILIATIONS:
NYU-Medical Center1, 907 Fifth Avenue, NY, NY
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Psychiatric Research3 , Orangeburg, NY 10962
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Buprenorphine: Pilot Trials in Borderline
Patients and Opiate Dependence - Treatment
of a Common Disorder?
R. Resnick and F. Falk
Buprenorphine (BUP), a morphine-type mixed agonist/antagonist, has
low dependence liability and toxicity, with a pharmacological
profile determined primarily by partial agonism and slow kinetics
at u-receptors. These features, plus clinical reports indicating
acceptance by heroin addicts and antidepressant activity, suggest
it be evaluated for use in treating psychiatric disorders. Two
groups were studied.
In Group A, 15 symptomatic patients in ongoing psychotherapy,
received a sublingual test dose BUP 0.2 mg. Positive responders
(N=9) all met DSM-III criteria for borderline personality disorder
(BPD), while negative responders (N=6) all had other diagnoses.
Symptom severity scores, BUP vs. placebo (PL), were reduced by a
mean of 43% and 50% respectively, in 5 ss who received,
single-blind, BUP (0.3-1.2mg IM) or PL daily for 9-14 days in an
ABA design (A=PL; B=BUP) and 4 ss who received, in 2 sessions, BUP
and PL administered 1-2 hours apart, in counterbalanced order.
Hamilton depression scores were reduced by 30-50% (mean 13.9 to
5.7). after 1 month on daily self-administered BUP. Subjects
reported a profound sense of feeling better, but upon discon-
tinuing BUP, symptoms returned immediately and most subjects asked
to continue treatment.
In Group B, 20 opiate dependent subjects, in various stages of
withdrawal, received IM BUP (0.3-1.2mg) and, after 1-2 hours, mean
abstinent severity scores were reduced by 65%. Eight ss completed
detoxification (14 days BUP + 7 days PL). Except for 4 ss who
started naltrexone, all others met DSM-III criteria for BPD.
Twelve subjects received maintenance BUP (0.6-3.0mg/day); 5 were
terminated for illicit drug use, 7 were drug-free at 6-9 months.
Diagnostic comparisons between negative and positive responders to
BUP and the favorable clinical results, support the idea of using
BUP to identify and treat a homogeneous subgroup within the
borderline personality disorder category. Guidelines need to be
developed for using BPN in clinical psychiatry.
AFFILIATION
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Serologic Investigations in Parenteral
Drug Abusers
L. Brown, B. Primm and D. Murphy
The prevalence of the acquired immunodeficiency syn-
drome (AIDS) and related infections has been associat-
ed with exposure to the human immunodeficiency virus
(HIV). Previously, we have shown that intravenous
drug abusers (IVDAs), the second largest risk group
for the development of AIDS, exhibit derangements in
immunologic function that are associated with various
patterns of drug abuse. However, the relationship of
underlying immunologic function to subsequent HIV in-
fection remains unclear. We examined the seropreva-
lence of infection by pathogens often associated with
HIV infection and other immunologic markers in 384
newly enrolled patients in methadone maintenance
clinics in New York City and 59 healthy volunteers.
Chi-Square analyses were conducted for the presence of
antinuclear antibody (ANA) and rheumatoid factors and
for abnormal levels of titers of antibody to
Toxoplasma gondii (TG), cytomegalovirus (IgG and IgM),
and herpes simplex virus (type 1 & 2) in enrollees as
compared to controls and in relationship to HIV seropo-
sitivity.
The results demonstrated that the prevalence of ab-
normal antibody titers was greater in the enrollees,
reaching statistical significance in ANA (p<0.001),
and TG (p<0.001). These abnormal serological results
were not associated with HIV seropositivity in the en-
rollees. These findings suggest that intravenous drug
users incur a greater prevalence of alterations in
these serological markers, suggestive of immunologic
dysfunction yet unrelated to previous HIV exposure.
AFFILIATIONS: Addiction Research and Treatment Corpora-
tion, Brooklyn, NY and Department of Medicine, Harlem
Hospital Medical Center, College of Physicians and
Surgeons and Division of Sociomedical Sciences, School
of Public Health, Columbia University, New York, NY
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Clonidine and Naltrexone: Rapid Treatment of
Opioid Withdrawal in the Outpatient Setting
E. Vining, T. Kosten and H. Kleber
Clonidine hydrochloride (an alpha-2 adrenergic agonist) and
naltrexone hydrochloride (an opioid antagonist), given in
combination, provide a safe and effective treatment of abrupt
opioid withdrawal over four or five days in an outpatient
setting. Following a naloxone challenge test to verify and
quantify opioid dependence, 14 of 17 (82%) heroin users suc-
cessfully withdrew from opioids and attained maintenance levels
of naltrexone. Eight of nine (89%) successfully completed the
five day study in which naltrexone therapy was begun on day two.
Six of eight (75%) successfully completed the four day study in
which naltrexone therapy was begun on day one. Three to five
days of clonidine hydrochloride treatment with a peak mean dose
of 0.6 mg/day on day two for the patients in the five day study,
and 0.5 mg on days one and two for patients in the four day
study, attenuated the withdrawal-inducing effects of naltrexone.
Both groups received naltrexone in single morning doses which
were rapidly increased from 12.5 mg on the first day of nal-
trexone therapy to 50 mg on the third day. Significant cor-
relations were observed between naloxone challenge test score
and observer-rated symptomdtology during treatment. Clonidine
significantly decreased blood pressure in both groups without
producing clinical problems. This study has improved the avail-
ability of the clonidine- naltrexone combination by developing a
single dose per day naltrexone regimen with naltrexone doses
generally available to any opioid treatment facility.
AFFILIATION: Yale University Department of Psychiatry, School of
Medicine, 34 Park Street New Haven, CT 06519
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Doxepin Treatment of Depressed Opiate
Addicts Undergoing Methadone Detoxification
S. Batki, S. Wheeler, R. Jones, J. Sorensen and K. Brennan
Eighty-one opiate addicts with DSM-III Major Depressive Disorder
underwent 21-day outpatient methadone detoxification and were
concurrently treated with a seven-week course of doxepin or placebo in a
double-blind randomized clinical trial.
Preliminary analysis of the full sample showed differences in treatment
outcome between the doxepin and placebo groups. Addicts treated with
doxepin improved more than those receiving placebo. Improvement was
consistently greater in the doxepin group in depression, opiate use, opiate
withdrawal symptoms, and craving for opiates. These outcome differences
approached statistical significance for most of the measures. Improvement
in the doxepin group began to reach statistically significant differences over
placebo at Week 3, when methadone detoxification was completed. This
pattern of improvement is consistent with the expected onset of
antidepressant treatment effectiveness. Attrition posed problems for both
the doxepin and control groups, yet about half of subjects succeeded in
completing the seven weeks of treatment and reached the final 12-week
follow-up. While serum doxepin levels were low in the subsample of
subjects in whom this measure was obtained, medication compliance was
judged to be satisfactory as measured by the consistently higher levels of
antidepressant side effects reported by the doxepin group.
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From Methadone Maintenance to Abstinence:
Evaluation of an Outpatient Tapering Network
J. Sorensen, S. Brummett, M. Gold, S. Batki, M. Trier
and L. Wermuth
This is the first outcome report of a study that investigated the
impact of providing tapering and aftercare assistance heroin
addicts enrolled in methadone maintenance. In an earlier effort
our group had demonstrated the efficacy and limitations of
providing such assistance through concurrent treatment in a
therapeutic community (Sorensen, et al., 1984); the current effort
extended this approach to outpatients. A pre-post, matched
comparison group design assessed the program's impact on patients'
ability to achieve detoxification from methadone, their drug and
alcohol usage, treatment progress, treatment satisfaction,
severity of problems associated with addiction, and assimilation
into the non-drug-using community. Fifty-eight patients in three
Experimental group received and enriched taping and after-
care program, while 56 patients in three matched Comparison
clinics received written materials only. Of the 114 subjects, 101
were reached for a follow-up interview three months after study
termination (89%).
Repeated measure analyses of variance generally did not reveal
differences between the Experimental and Comparison conditions.
The Experimental group had been more dysfunctional at study entry,
but results showed few differences between the two groups on the
outcome measures. Twenty-nine percent of the Experimental subjects
and 20% of the Comparison subjects tapered off methadone during
the study. The study results underscore the difficulties that
heroin addicts nave in tapering off methadone to a drug-free
lifestyle.
REFERENCE
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LAAM Maintenance for Opioid Addicts Who
Cannot Maintain with Methadone
F. Tennant. Jr.
Ten heroin addicts who could not adequately maintain
on a high daily dosage of methadone were studied.
They demonstrated continuous drug and/or alcohol
abuse and showed low or non-detectable plasma
concentrations (mean 38.9 ± 63.3 S.D. ng/ml) 24
hours after a 100 mg oral dose. Urine testing of
these individuals revealed that 66.4% of the
samples showed use of cocaine, heroin, or
benzodiazepines. Nine of the ten (90%) were able
to maintain with LAAM as evidenced by lack of
drug/alcohol abuse and adequate plasma
concentrations of LAAM metabolites. The mean
plasma concentrations of NOR-LAAM and DI-NOR-LAAM
were 201.6 ± 255.0 S.D. ng/ml and 160.2 ± 62.3 S.D.
ng/ml respectively. Opioid addicts who cannot
successfully maintain with high dosages of
methadone should attempt LAAM maintenance due to
LAAM's different metabolism.
AFFILIATION:
Community Health Projects, Inc., Research and
Education Division, 336½ So. Glendora Ave.,
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Differences Among Treatment Clinic Types
in Attitudes Toward Narcotic Addiction
D. Nurco, T. Hanlon, J. Shaffer, T. Kinlock, K. Duszynski
and P. Stephenson
The present study examined treatment related attitudes and expect-
ations across drug abuse clinics classified according to the
number and types of treatment modalities offered. Assessment of
the attitudes and expectations of respondents concerning narcotic
addiction and its treatment was accomplished by the use of a 142-
item questionnaire whose content areas included four major domains:
the nature of addiction; the origins of addiction; ways of dealing
with addiction, including treatment; and the personalities and
characteristics of addicts in general. Data were collected on 783
clients and 230 agency personnel in 24 drug treatment clinics in
five states. A components-type factor analysis of the entire set
of items for an original sample of 1137 respondents (clients and
staff) was performed to determine the major content dimensions of
the questionnaire. Of the ten factors identified, three were
measures of attitudes and perceptions more directly relating to
the treatment process: ExAddict Counselor Good/Methadone Bad;
Addicts Can Change; and Group Treatment Good. Two additional
factors, Drugs OK and Addicts Need Control, also appeared likely
to have treatment implications that would be reflected in drug
abuse intervention strategies. For these dimensions, differences
were determined among clients and staff according to type of treat-
ment clinic (three types involving the provision of methadone
maintenance in various combinations with other treatments and one
involving the use of abstinence only). The most pronounced
differences were between the methadone clinics and those offering
abstinence only. Both the clients and staff of abstinence clinics
were more skeptical concerning treatment effectiveness, were more
negative regarding the use of narcotic drugs, and were more dis-
posed to the use of ex-addict counselors and group procedures in
treatment.
AFFILIATION
Department of Psychiatry, University of Maryland Medical School
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Treatment of the Dually Diagnosed Substance
Abuser
H. Weiner and M. Wallen
Definition: Patient who is addicted and also has a clinically
significant psychiatric disorder.
Major Considerations:
1.
2.
3.
4.
5.
6.
Psychopathology is a definite risk factor for
addiction.
Psychopathology may precede addiction or may develop
as a result of addiction.
Some portion of substance abuse in almost all addicts
is an attempt to self-medicate discomfort associated
with life stress or psychological problems.
The degree of psychiatric impairment will affect
treatment outcome and post-treatment success. In
general, the higher the level of impairment, the
less favorable is the treatment outcome.
Untreated psychopathology greatly increases the
probability of relapse.
Accurate diagnosis and effective treatment of
psychopathology might prevent the behavioral problems
which commonly result in patients being discharged
for "treatment resistance".
Eagleville's Treatment Model
1. Comprehensive Assessment - evaluations by a physician,
nurse, psychologist, social worker, adjunctive
therapist and psychiatrist.
2. Individual Treatment Plan, utilizing results 'of
assessments and patient's own goals. Components
of treatment are individually prescribed based on
the patient's abilities and limitations.
3. Psychiatrist, as clinical leader of the team, provides
guidance and direction in treating the addiction
and the psychiatric impairment.
4. Components of treatment include group therapy (major
modality), individual and family therapy, art and
horticulture therapy, assertiveness and relaxation
296
training, vocational and educational guidance, social
skills development, leisure time education, arts
and crafts, physical activities, AA/NA/CA meetings,
and educational seminars.
5. Aftercare planning - as with any chronic disease,
this is the critical component. Continued treatment
for both substance abuse and psychiatric problems
must be implemented, as well as AA, NA, or CA.
AFFILIATION
Eagleville Hospital, 100 Eagleville Road, Eagleville, PA
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Contingency Management with a Poly-Drug
Abuse Methadone Maintenance Population:
Take-Home and Dose Incentives
M. Iguchi, M. Stitzer, G. Bigelow and I. Liebson
Previous studies have shown that take-home (TH) incentive programs
based on urinalysis (UA) results can reduce illicit drug use among
methadone maintenance (MM) clients. This study sought to determine
whether additional therapeutic benefit could be obtained by adding a
negative incentive dose reduction procedure to a TH incentive program.
Sixteen polydrug abusing MM clients were randomly assigned to 1 of 2
treatment (TX) conditions. In both TXs, TH doses were available for drug-
free urines while in one TX methadone dose was also reduced as a
consequence of multiple drug-positive UA results. The number of TH’s
available each week to study subjects was increased by 1 for each 2
consecutive weeks (x3 weekly testing; broad-spectrum TLC) of drug-free
results, up to 3 TH’s per week. The number of TH’s was reduced by 1 for
each urine sample that tested positive for any illicit substances. The dose
change and TH cont ingencies operated independent ly .  Al l  dose
alterations were in increments of 10% of the original dose. Two or three
drug-positive samples resulted in a dose reduction, 1 drug-positive
sample had no effect on dose and 0 drug-positive samples resulted in a
dose increase. Dose decreases continued until a 0 mg dose was
reached (clients could remain in TX at 0 mg methadone) while dose
increases could not exceed the original dose. A significant TX effect was
noted (F=11.11; p<.005). Only 8% of the UA results were drug-free during
a 12-week baseline period for all subjects while 42% of the UA results
were drug-free during the 20 weeks of TX intervention (missing data from
study dropouts replaced by average % drug-free during the 6 weeks prior
to dropout). No group or group by time effect was noted. While there were
an equal number of successful and failed cases in the two study
conditions, a significant difference was noted in the final disposition of
the TX failures from each group. Three of five TX failures in the TH only
condition remained at the clinic using drugs, while all 5 TX failures in the
dose incentive condition were no longer in TX (z=3.53; p < .001). TX
outcome results are consistent with previous work from this laboratory
showing that positive reinforcement interventions as compared to
aversive control procedures can produce an equivalent number of TX
successes while avoiding dropout among clients who fail to respond to
TX.
AFFILIATION: Department of Psychiatry and Behavioral Sciences, BPRU,
D-5-W, Johns Hopkins/Key Medical Center, Baltimore, Maryland, 21224.
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Identification of Personality Disorder
Subtypes Among Drug Abusers Using the
Million Clinical Multiaxial Inventory
D. Calsyn and A. Saxon
The high prevalence rates of DSM-III Axis II disorders in drug
abusing individuals have previously been established. The Millon
Clinical Multiaxial Inventory (MCMI) , a relatively new
personality assessment tool, purports to assess Axis II as well
as Axis I disorders. This research investigated the frequency of
MCMI Axis II subtypes among drug abusers. The MCMI was
administered to 45 opioid addicts and 31 polydrug abusers at the
VA Drug Dependency Treatment Program, Seattle. The mean age of
patients was 36.8 (SD=7.6); the racial make up, 78% White, 19%
Black and 3% Hispanic. The MCMI profiles were sorted four times
identifying profiles indicating: 1) the most severe Axis I
psychopathology, 2) some affective/somatic disturbance, 3) more
serious personality disturbance and, 4) as one of 5 categories
based on 3 high point codes for the 8 basic personality scales.
Categories based on authors’ clinical experience and cluster
analysis reported previously were: (a) narcissistic/antisocial,
(b) negativism/anxiety/social withdrawal, (c) dependent, (d) no
disorder, (e) unclassified. Of the sample 12% exhibited severe
psychopathology often associated with psychotic processes. These
elevations were more common for polydrug abusers (19%) than
opioid addicts (7%, =2.8, p <.10). Fifty-five percent
exhibited affective disturbance (polydrug abusers 71% vs. opioid
addicts 44%, =5.2, p <.05). Severe personality disorder was
exhibited in 28% of the cases with no significant difference
between polydrug abusers and opioid addicts. Eighty-six percent
of all profiles can be placed into one of the first four subtype
groups based on the 8 basic personality scales. A contingency
table analysis ( =8.1, p <.05) indicates the polydrug abusers
(45%) were most likely to obtain the highest elevations on the
schizoid, avoidant, and passive-aggressive scales. These
individuals are seen as being socially isolated; pessimistic and
negative. Others view them as withdrawn complainers. Opioid
addicts (38%) were more likely to obtain the highest elevations
on the narcissistic and antisocial scales. These people are seen
as self centered, with little empathy for others. They often
have strong feelings of entitlement and aggressive feelings
toward others. These first two subtypes accounted for 61% of all
profiles. Another 17% were classified as dependent profiles
(opioid addicts 22% vs. polydrug abusers 10%). Eight percent of
profiles had no elevations on the basic personality scales.
AFFILIATION
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lntrathecal Injections: Ca++ Causes Anal-
gesia, Morphine Produces Hypoglycemia
F. Lux, D. Brase and W. Dewey
The acute percutaneous intrathecal (i.t.) administration of cal-
cium (0.24 umole) to ICR mice produced an increased latency in the
tail-flick test that was blocked by naloxone (1-2 mg/kg, s.c.).
A dose-dependent potentiation of the analgesic effects of i.p mor-
phine or i.t. leu- or met-enkephalin was observed after i.t: cal-
cium. EGTA and verapamil, given i.t., antagonized the analgesic
effect of i.p. morphine, These results contrast with previous
work showing antagonism of morphine by i.c.v. calcium. Calcium,
injected i.c.v., prevented the analgesic effect of i.t. calcium,
when equal doses were given by both routes.
The i.t. administration of morphine (12.5-50 ug) caused a dose-
dependent hypoglycemia, whereas the s.c. injection of morphine
(2.5-80 mg/kg) produced a dose-dependent hyperglycemia. Both ef-
fects on blood glucose were antagonized by s.c. naloxone. Nalox-
one also blocked the lethality, but did not prevent scratching
behavior and tonic seizures. caused by high-dose i.t. morphine.
Only the lethal effect of high-dose i.t. morphine was partially
blocked by loading mice with glucose i.p. Although delayed, the
hypoglycemic effect of i.t. morphine was still seen after-glucose
loading, after induction of diabetes with streptozocin, and after
administration to genetically diabetic C57BL/KsJ (db/db) mice.
All of these effects of i.t. morphine were blocked by acute spinal
transection at T10-T11, but were not mimicked by morphine injected
i.c.v. (6.25-50 ug), which showed a bell-shaped dose-response
curve for hyperglycemia, without producing any hypoglycemia.
These results indicate a supraspinal/infraspinal dichotomy regard-
ing modulation of analgesia by calcium and modulation of glucose
by morphine. It is concluded that 1) the modulation of morphine-
induced analgesia by centrally-administered calcium depends upon
the route of calcium administration, and 2) the modulation of
blood glucose by morphine also depends upon the route of morphine
administration.
AFFILIATION
Department of Pharmacology and Toxicology, Medical College of
Virginia/Virginia Commonwealth University, Richmond, VA 23298-0613
300
Number of Risk Factors Predicts Three-Year
Probabilities of Heavy Drug and Alcohol Use
in Adolescents
B. Bry, M. Pedraza and R. Pandina
Three year probabilities of heavy drug and alcohol use in
adolescents can be predicted by applying a nonlinear, multiple
risk factors methodology to current knowledge about precursors.
In 1979, 446 adolescents recruited through a random household
survey were classified according to the number of 10 established
psychosocial risk factors they each displayed. A second
assessment in 1982 revealed that 100% of the youth who had
displayed 5 or 6 risk factors and 75% of those who had displayed
4 risk ractors in 1979 reported heavy drug or alcohol use by 1982,
yielding 90% predictive accuracy. Conversely, 93% of the youth
with no risk factors in 1979 reported no heavy use by 1982. The
findings support a multiple pathways model of substance abuse in
that many disparate combinations of risk factors were associated
with heightened risk of heavy use.
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Ethanol Self-Administration in Alcoholic
Methadone Patients: Analysis of Drinking
Patterns and Evaluation of Behavioral-
Pharmacological Treatment
W. Bickel, W. Knight, P. Pangiosonlis, E. Mernit,
J. Klobas, R. Zieloney, L. Handelsman, I. Marion,
P. Rizzuto and J. Lowinson
Alcoholism is a problem frequently encountered in the
methadone treatment of narcotic addicts. The methadone clinic
is a unique setting for the study of alcohol consumption by
virtue of its requirement of frequent patient attendance which
permits the intensive assessment of alcohol consumption as
indicated by breath-analysis. In this study we report on the
assessment of the drinking patterns of alcoholic methadone
patients and on a combined behavioral-pharmacological treatment
of excessive alcohol consumption. We have intensively assessed
the drinking patterns of over twenty alcoholic methadone
patients for periods of up to a hundred consecutive clinic
visits in some cases. An analysis of those patterns of alcohol
consumption shows that the temporal distribution of blood
alcohol levels obtained from alcoholic methadone patients is
very similar to that reported in studies of alcohol consumption
of alcoholics living on research wards; that is, several days
with large quantities of alcohol consumption alternating with
several days with small quantities consumed. These results
indicate that the findings from laboratory inpatient studies are
representative of naturalistic alcohol consumption. Moreover,
these results provide evidence that the methadone clinic can
serve as a naturalistic laboratory for the study of ethanol
self-administration and for the treatment of excessive alcohol
consumption. After the assessment of alcohol consumption. we
provided treatment of alcoholism consisting of reinforcing
disulfiram consumption with methadone clinic privileges.
Disulfiram is an effective treatment, but often patients elect
to discontinue disulfiram maintenance. By reinforcing
disulfiram consumption the problem of patient compliance can be
resolved. The results of our study indicate that relative to
baseline data the reinforcement of disulfiram consumption
results in significant decreases in the number of days drinking.
the amount consumed and improved laboratory measures of liver
function. Thus, combined-behavioral pharmacological treatment
is effective for alcoholic methadone patients.
Address: Division of Substance Abuse, Albert Einstein College of
Medicine, 1500 Waters Place, Bronx, NY 10461
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Methodological Problems in Psychopharmaco-
logical Studies with Alcoholism and
Drug Addiction
B. Mason and J. Kocsis
Results from early psychopharmacological studies with alcoholism
and other addictions are difficult to interpret because they often
lacked control groups and standardized instruments for establish-
ing diagnosis and efficacy. This paper addresses issues relating
to research design, patient selection, and treatment adequacy and
safety in psychopharmacological studies involving alcoholism and
the addictions. Use of placebo controls, management of side
effects, preservation of the double blind, control of potential
confounding variables, compliance with medications, treatment
duration, ethical issues, and concomitant therapies are among the
topics discussed.
AFFILIATION
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Opioids’ Modulation of Alcohol Intake
L. Reid and C. Hubbell
Results of various procedures designed to assess the effects
of administration of opioids on voluntary intake of alcoholic
beverages among rats leads to a number of conclusions. Across a
wide variety of experimental arrangements including sex, age,
housing conditions and nutrient deprivation of rats and including
different alcoholic beverages and schedules of presenting bever-
ages (night or day, flavored or unflavored beverage), it is
consistently found that injections of small doses of morphine
increase rats' intakes of ethanol. Other agonists at opioceptors,
such as methadone and fentanyl at small doses, also increment
intake of alcoholic beverages. Naloxone, as well as other anta-
gonists at opioceptors, decrease intakes of ethanol. Doses of
morphine as low as 0.4 mg/kg, subcutaneously given, reliably
increase intakes of sweetened ethanol solutions. Doses of
naloxone at 2.5 mg/kg produce as much decrease as larger doses,
except very high doses. So, it is clear that opioids modulate
intake of alcoholic beverages.
Opioids also modulate intake of other ingesta such as
sweet and salty water. Although opioids' modulation is not
specific to ethanol solutions, the effects on alcohol-intake can
be quite dramatic. Rats fixed with osmotic pumps for delivery of
chronic infusion of morphine were given daily opportunities to
take, after water-deprivation, either water or a sweetened
alcoholic beverage for 1.5 hrlday. These rats, after 3 days of
the daily regimen, were taking more ethanol solution than
controls. When these same rats were given an injection of
morphine after 8 days on the regimen, they took on the average,
over 5.0 g of pure ethanol/kg of body weight during 1.5 hr and
did so across 8 consecutive days. Other data confirm that
morphine's appetitional effects are unrelated. to morphine's
capability to produce analgesic or narcotic effects. Also, the
small-dose-morphine-effect of incrementing intake of alcoholic
beverages does not show tolerance. Our results lead to the
suggestion that surfeits of opiodergic functioning (as achieved
by morphine administration) may be a salient variable with
respect to instances of excessive intake of alcoholic beverages.
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Ethanol Withdrawal Anxiety: Characterization
in an Animal Model
H. Lal, D. Benjamin, C. Harris, S. Bhadra and
M. Emmett-Oglesby
Ethanol given acutely exhibits a mild anxiolytic action, but
chronic ingestation of ethanol produces dependence that is charac-
terized by withdrawal consisting of anxiety-like subjective
symptoms. Typically, the subjective effects of withdrawal occur
earlier and last longer than overt signs of withdrawal. While the
anxiolytfc effects of ethanol may contribute to occasional drink-
ing, ethanol-withdrawal anxiety may be critical in the genesis and
maintenance of ethanol abuse. Because of their subjective nature,
anxiety-like effects have been difficult to study in animal exper-
iments. Our experiments used an interoceptive discriminative
stimulus (IDS) produced by an anxiogenic drug, pentylenetetrazol
(PTZ) as an index of subjective effects in animals. We proposed
that a comparison of the IDS produced by test treatments with the
IDS produced by PTZ would serve as a suitable animal model to
bioassay subjective effects related to ethanol use or ethanol
withdrawal. We measured the efficacy of ethanol in blocking two
different levels of PTZ stimulus. Also, we investigated the
degree to which withdrawal from ethanol produces an IDS which
mimicks that of PTZ in rats previously trained to discriminate
PTZ. To date we have observed that ethanol fully blocks only the
weaker of two stimuli produced by PTZ. Also, withdrawal in rats
given chronically intoxicating doses of ethanol produced a PTZ-
like IDS. This stimulus was speciffically associated with ethanol
withdrawal and was not a result of stress or handling associated
with ethanol administration or its intoxication. The PTZ-like
withdrawal stimulus began when ethanol blood levels declined, and
disappeared within 2-3 days. The intensity of this stimulus was
related to the dose and duration of ethanol administration as well
as the duration of abstinence. The withdrawal stimulus was
blocked by ethanol or diazepam. Thus, these experiments provide
an animal model for objective evaluation of a subjective symptom
related to ethanol abuse. Characterization of ethanol withdrawal
with respect to its subjective effects offers a new tool to
investigate behavioral and neurobiological factors in ethanol
dependence and abuse. (Supported by Grant AA06890)
AFFILIATION
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Effects of Ethanol Self-Administration and
Withdrawal in Rats Responding for Food and
Water
P. Beardsley, H. Kalant, A. Stiglick and I. Woodworth
Four, adult male Long-Evans rats were trained to lever-press for water, ethanol
(8, 16 or 32% w/v) and food-pellet deliveries in a three-lever operant
conditioning chamber. Periods of ethanol availability both preceded and followed
periods of response-contingent food availability. In Experiment 1, the rats were
exposed to seven, 3.5-hr blocks each day, each block sequentially consisted of
30 min of ethanol alone, 1 hr of food, 30 min of ethanol and water, and 1.5 hr
of water alone. In Experiment 2, the same schedule was employed but a 7-day
ethanol withdrawal period (only water and food were available) followed tests at
each concentration. In Experiment 3, both water and an ethanol solution were
available in each drinking period; during each day there were 16, 0.5-hr periods
of fluid availability separated by 15, 1-hr periods of food availability.
Often more daily ethanol than water deliveries occurred. The number of ethanol
deliveries decreased with increases in concentration but the amount of ethanol
consumed (g/kg body wt.) increased and reached values as high as 11.5
g/kg/day. Blood ethanol concentrations determined during the final hour of
availability of each ethanol concentration across the three experiments ranged
from trace amounts to 114 mg/dl, and were observed as high as 135 mg/dl
shortly after (i.e., 30 min after) the end of drinking bouts during Experiment 3.
The ingestion of small amounts of ethanol tended to increase. response rates for
food whereas ingestion of progressively larger amounts of ethanol significantly
and progressively decreased food response rates. Ethanol self-administration was
greater when it followed food sessions than when it preceded food sessions.
When ethanol availability was withdrawn, food response rates increased.
Tolerance tests administered at the end of Experiment 3 demonstrated that the
rats’ ethanol self-administration histories had produced tolerance to the
hypothermic and the motor incoordination effects of an ethanol test dose (2.5
g/kg i.p.) and that this tolerance was lost after two weeks of abstinence.
The conditions of these experiments satisfy many of the requirements of an
animal model of alcoholism and could provide baselines for which to assess
specific effects of pharmacological agents on rates of self-administered ethanol.
Affiliation
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Free Choice Consumption of Ethanol by AA
and ANA Rats in an Operant Model
H. Kalant
Rats genetically selected for high and low voluntary
consumption of ethanol (Alko AA and ANA respectively, kindly
provided by Dr. K. Kiianmaa) were trained to lever-press for
fluid in the paradigm described by Beardsley et al. (this
conference). In a 3-lever operant chamber they learned to press
one lever for access to ethanol solution, a second for water,
and a third for food. A daily 23-hr schedule consisted of
sixteen 30-min sessions in which both fluids were available on a
CRF schedule, separated by fifteen 1-hr sessions of pressing a
third lever for food pellets [chained FI40' (FR5:S) FR1(20)
schedule, maximum of 20 pellets per session or 300 per day].
Each rat was carried through 3 complete cycles, a cycle
consisting of at least 6 days of stable responding at each of 3
ethanol concentrations: 8%, 16% and 32% w/v.
AA rats preferred ethanol over water at all 3 concentrations
in all 3 cycles, except for the 32% in the first cycle. ANA
rats preferred water throughout. However, the absolute amount
of ethanol consumed rose with increasing ethanol concentration
in both groups, and both showed increasing preference and
consumption with 8% ethanol over the 3 successive cycles. The
difference between strains remained constant: e.g., at 32%
ethanol, AA rats took 10.4 ± 1.4 g/kg/day vs. 5.4 ± 1.0
ANA rats. Tail blood ethanol levels, 30 min after a burst of
drinking at 32% ethanol in cycle 3, were 145-270 mg/dL in AA and
0-112 in ANA rats. On completion of the third cycle,
hypothermia and tilting plane tests on each rat after IP
injection of ethanol 2.5 g/kg showed no tolerance in ANA rats,
but the AA rats had clear functional tolerance that was lost
after 25 days' abstinence.
Over the next 105 days the AA rats were gradually brought
back to free-feeding weight by increasing the number of pellets
available. Ethanol consumption gradually fell and that of water
rose. This was not due to altered volume of distribution.
Thus, AA rats met most of the criteria for an animal model of
alcoholism, but the caloric value of ethanol perhaps contributed
to its reinforcing properties. ANA rats drank less than they could
metabolize, and aversive effects may have set the upper limit.
AFFILIATION
Department of Pharmacology, University of Toronto, and Addiction
Research Foundation of Ontario, Toronto, Canada M5S 1A8
307
The Effect of DL-Propranolol and its
Enantiomers on Ethanol Induced Cardiac
Hypertrophy in the Rat
D. King and M. Hirst
Severe subacute intoxication with ethanol causes cardiac hyper-
trophy in the rat and myocardial disruption is evident on histo-
logical examination. The relative weight of hearts (heart
weight/body weight) increases by some 10% after 48 hours and by
20% after 96 hours of treatment. Both dry heart weight and
cardiac tissue protein increase equivalently. In parallel with
the cardiac hypertrophy there is a marked rise in excreted
norepinephrine and epinephrine. As beta-adrenoceptor agonists
have a trophic influence on the heart it was postulated that the
effect of ethanol is caused indirectly through an increased
peripheral sympathetic tone. To test this hypothesis rats were
given ethanol (10% w/v), with Liquidiet (Bio-Serv), intra-
gastrically, at 8 hour intervals over 48 hours. Pair matched
control animals received isocaloric maltose-dextrin and Liqui-
diet. Other groups of animals (n=6) received dl-propranolol
(10, 20 mg/kg), 1-propranolol (5, 10, 20 mg/kg), or d-
propranolol (10, 20 mg/kg) in saline (1 mL/kg), or saline (1
mL/kg), subcutaneously, at the times of the intubations. The
1- and d-propranolols were included to distinguish effects of
beta-adrenoceptor blockade from stabilization of cardiac
membranes. Following anesthesia with pentobarbital, rats were
decapitated, their hearts removed and rinsed with cold water.
They were blotted dry after trimming off fat, the aorta and
pericardium, and weighed. Data of relative heart weights in the
different treatment groups were analysed by ANOVA, with post hoc
comparisons of means, with p < .01 being considered significant.
Both doses of dl-propranolol suppressed ethanol-induced cardio-
megaly, whereas neither dose of d-propranolol was effective. 1-
Propranolol (10, 20 mg/kg) attenuated the cardiac hypertrophy,
whereas the lowest dose was ineffective. It is concluded that
the rapid development of cardiac hypertrophy in rats severely
intoxicated with ethanol occurs, at least in part, through
responses mediated by cardiac beta-adrenoceptors.
AFFILIATION
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Naturalistic Monkey Environment for Study-
ing Social Influences on Alcohol Self-
Administration and Alcohol Effects on Social
Behavior
T. Crowley and A. Goebel
We have developed techniques for studying high-dose, alcoholic-
like drinking among group-living monkeys (Psychoharmacology 92:196,
1987). The preliminary data suggest that high ranking animals assume
priority of access to alcohol drinking spouts, causing low ranking
animals to avoid the spouts; it appears that low ranking animals
thus are "protected" from developing high-dose drinking habits. To
more systematically test this hypothesis we wanted several widely
separated spouts; this is difficult to arrange indoors. We now are
conducting such studies outdoors year-round in a northern climate
using a large, naturalistic, outdoor corral. This poster describes
our rather inexpensive, but very functional facility, the design of
which may make it easier for other investigators to begin using
primate social groups in alcohol studies. The Japanese Snow Monkey
(Macaca fuscata) ranges further north then any primate except man,
adapting to snowy coniferous forests of Northern Japan, where
temperatures reach about -5 C. In this species existing laboratory
drug studies are complemented by an extensive literature on
ethological field studies. M. fuscata adapts well to North American
winters, and with some shelter colonies live outdoors in Oregon,
Minnesota, Quebec, Michigan, and (unsheltered) in Texas. After
consulting Peggy O'Neill at the NIH Poolesville facility, we enclosed
a rough ellipse, approximately 32 x 40 m, with a 1 m high chain link
fence, surmounted by a 3 m wall of electrically-conductive nylon
net. High-voltage brief-pulse charges prevent climbing on or over
this net. Materials for this fence cost less than $14.50 per running
meter. Weeds and grass grow freely within the ellipse, and seven
dead trees, interconnected with ropes, permit climbing and swinging.
A hut with post-supported roof but no walls provides sun and rain
shelter. A small kennel run, approximately 2.2 x 4.6 m and 1.7 m
high, fully roofed over with chain-link fencing, connects the yard
with a small, partially-heated building; the monkeys usually have
free access between yard and building via the kennel-run, but they
may be locked into yard, run, or building. Inside the building are
three pens, each approximately 2.8 x 1.5 x 2.2 m. The monkeys usually
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pass freely among these pens, but we can close doors to separate
them. A raceway through this pen area can be divided into separate
compartments to isolate animals briefly; the raceway incorporates a
squeeze cage, used for administering medications, drawing blood, or
weighing animals. Water is continually available in the building.
Monkey-chow biscuit rations are given outdoors. Three mouth-
activated drinkometer spouts, located about 18.5 m apart in the yard,
supply alcohol test solutions for self-administration studies. An
observation hut atop the building provides a full view of the yard
and houses counters displaying cumulative numbers of 2 ml doses taken
at each drinkometer. Using ethologic techniques, one observer
records the frequency of occurrence of various social behaviors
(e.g., groom, mount, attack, flee). Another observer records self-
administration of alcohol doses, by animal and time. In this facility
we hope to clarify how pre-existing social relationships influence
alcohol consumption, and how alcohol drinking modifies subsequent
social behavior. The facility uniquely and unexpensively supports
the "psychological well-being of research primates," which now is
legally required.
AUTHORS
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Symptoms of Intoxication and Hangovers
Perceived to Modify Subsequent Alcoholic
Beverage Consumption
C. Smith
The observations that alcoholic patients are
significantly less likely than moderate drinkers to
have had severe hangovers (Pristach et al., 1983;
Harburg et al., 1981; Whitfield et al., 1986) prompted
the development of a structured survey of the reasons
individuals perceive for drinking and for modifying
their drinking practices, including signs and symptoms
during and following intoxication. The pilot text of
the instrument included anonymous responses from 83
faculty, staff, and medical student volunteers, almost
evenly divided as to sex (38 female, 40 male). Ages
ranged from 22 to 64 years with most in the 20-30 age
group. The signs and symptoms were scaled for
intensity or severity. The questions were found to be
easy to answer with the extensive pilot version
requiring 15 to 60 minutes to complete. The items had
face validity and internal cross-checks were answered
consistently.
The results of analyses of these pilot data were
consistent with preliminary observations and prior
studies. More than three fourths (47, 78%) of the
drinkers reported decreases in their alcohol
consumption over the years, 13 increased, and 10
reported no change. A large variety of influences
associated with the decreases were ranked and rated
with concerns about driving, increased personal
responsibility, nausea, hangovers, and headache cited
most frequently.
Hangovers were reported and described by 76%: of
these, 75 to 90% reported being influenced to moderate
how much or how often they drank an alcoholic beverage
for periods of time ranging from months to many years.
Thus, the results of the pilot test establishes the
feasibility and utility of the instrument.
Acknowledgement: Supported in part by a grant from the
Alcoholic Beverage Medical Research Foundation.
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Acute Tolerance to Cocaine: Steady State
Experiments
J. Ambre, R. Smith-Coggins, S. Belknap, T. Ruo,
A. Atkinson, and J. Nelson
The euphoric and cardiovascular effects of cocaine
have been reported to decline more rapidly than the
drug leaves the plasma after a single dose. This and
other observations suggest that cocaine exhibits acute
tolerance development. We reported previously an
analysis of single dose cocaine pharmacokinetics and
dynamics that modeled apparent tolerance development
as an exponential process, describable by a rate
constant (and halftime). We have now done steady
state experiments to demonstrate tolerance directly
and to determine the rate and extent of its
development.
Six healthy intravenous cocaine users were studied.
They were given an intravenous cocaine regimen
consisting of an injection dose followed by a cocaine
infusion that exponentially decreased to a constant
rate, designed to immediately produce and then
maintain a constant cocaine concentration of 750 ng/mL
over four hours. Heart rate was measured by
computerized continuous electrocardiographic monitor.
Subjective effects were evaluated every five minutes
by visual analogue scales marking.
Cocaine administration produced a 32±13 BPM
(mean±SD) increase in heart rate which reached its
peak within 3-5 minutes and began to decline
immediately toward a plateau at a level 32±23 percent
of the peak response. Approach to the plateau was
exponential with a halftime of 38±16 minutes, similar
to the value of the tolerance factor we calculated in
our single dose studies.
The level of intensity of subjective effects (high,
anxiety, and stimulation) had similar contours,
developed more slowly, reached a peak after an hour
and then declined to baseline at the end of four
hours. The halftime for decline in "high" rating was
30±9 minutes.
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The Cocaine Receptor: Reinforcing Potency
Correlates with Dopamine Uptake Inhibition
M. Ritz and M. Kuhar
While several binding sites for cocaine have been identified, the
biochemical mechanisms mediating cocaine-reinforced behavior in
animals and cocaine abuse in humans is unknown. In an attempt to
identify the relevant receptors associated with the addictive
properties of cocaine, we have compared the published potencies
of cocaine and several pharmacologically related compounds in
studies of drug reinforced behavior with their binding potencies
at both presynaptic uptake sites and postsynaptic monoamine
receptor sites.
The affinities of cocaine and related drugs at dopamine and
choline uptake sites in striatum, norepinephrine uptake sites in
frontal cortex and serotonin uptake sites in the medulla were
examined using standard in vitro binding techniques. Inhibition
of ligand binding to these sites was determined by analysis of
competition curves and calculation of Ki values. Similar values
were also determined for dopaminergic, adrenergic and
serotonergic postsynaptic sites.
The results of these experiments indicate that drugs which were
most potent in drug reinforcement studies were also potent
inhibitors of ligand binding at the dopamine, norepinephrine and
serotonin uptake sites, but showed little inhibition at the other
receptor sites tested. Statistical analyses of the data indicate
that inhibition of 3H-mazindol binding to the dopamine uptake
site is significantly positively correlated with the reinforcing
effects of cocaine-related drugs. Thus, we have shown for the
first time that dopamine uptake inhibition is the primary
mechanism associated with the reinforcing or addictive properties
of cocaine.
AFFILIATION
Molecular Pharmacology Laboratory, Neuroscience Branch, NIDA
Addiction Research Center, Baltimore, Maryland 21224.
313
Genetic Factors in Behavioral and Lethal
Responses to Cocaine in Rats
F. George, L. Porrino and S. Goldberg
Although the pharmacology and biochemistry of cocaine
have been widely studied, little is known about the
contribution of genotype in determining response to
this increasingly abused drug. The present study was
conducted to establish a data base of cocaine-related
behavior and to use genetic correlations in examining
the biological substrates which mediate behavioral and
physiological responses to cocaine. The following rat
stocks were used: NBR/NIH, ACI/HSD, F344/CR1BR,
LEW/CR1BR and S-D/HSD. Several-fold differences in the
efficacy of cocaine in producing locomotor stimulant
effects were found, with NBR rats displaying the
greatest maximum response, and F344 rats showing the
lowest peak locomotor response. Large potency
differences were also found, with NBR rats being the
most sensitive, while rats from the LEW and F344
strains were the least sensitive. Large differences in
lethality in response to cocaine were also seen: 50%
of NBR rats tested at 40 mg/kg, and 100% of NBR rats
tested at 60 mg/kg died shortly after injection, while
no LEW or S-D rats died even at 60 mg/kg. These data
should be useful to researchers interested in exploring
the mechanisms of behavioral and physiological
responses to cocaine.
AFFILIATION: Preclinical Pharmacology Branch, National
Institute on Drug Abuse, Addiction Research Center,
Baltimore, MD 21224
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Effect of Cocaine on Hippocampal Acetyl-
choline, Norepinephrine and Serotonin
S. Robinson, K. Hambrecht and E. Pennell
The stimulant amphetamine has been found to increase the activity
of cholinergic neurons in the hippocampus by an indirect effect
involving noradrenergic neurons (Robinson et al, Naunyn-
Schmiedeberg's Arch. Pharmacol. 304:263-269, 1978, and Robinson,
Brain Research 397:181-184, 1986). Because cocaine and ampheta-
mine share many behavioral and neurochemical actions, it was
decided to study the effect of cocaine on cholinergic neurons, as
well as on noradrenergic and serotonergic neurons in the hippo-
campus. The turnover rate of acetylcholine (TRACH) was used as a
measure of activity of cholinergic neurons and was determined as a
quantitating the relative incorporation of deuterium label into
hippocampal ACh and choline using a mass fragmentographic tech-
nique. The activity of noradrenergic and serotonergic neurons
was estimated by determining the ratio of metabolites (MOPEG,
5HIAA) to neurotransmitter (NE, 5HT) using HPLC with electrochem-
ical detection. Male Sprague Dawley rats (160 g) were injected
with physiological saline or cocaine (30 mg/kg, i.p.). Thirty
min after injection and immediately after infusion with phos-
phoryl [2H9] choline (15 µmol/kg/min, 9 min, i.v.), rats were
killed by focussed microwave radiation (8.5 KW, 1.6 sec). This
treatment resulted in a greater than threefold increase in TRACh
(P< 0.05) with no significant effect on ACh or choline content
Hippocampal MOPEG content and the ratio MOPEG/NE were
significantly increased by cocaine treatment (P< 0.01), whereas
5HT and 5HIAA were not significantly affected (P> 0.05).
These results suggest that acute cocaine administration increases
the activity of cholinergic and noradrenergic neurons projecting
to the hippocampus. Additional experiments must be performed to
determine if the action of cocaine on cholinergic neurons results
from noradrenergic activation. Although hippocampal 5HT neurons
are not significantly affected 30 min following i.p. cocaine, it
cannot be ruled out that they are affected at other times follow-
ing such treatment.
AUTHOR'S AFFILIATION: Medical College of Virginia
Virginia Commonwealth University
Department of Pharmacology and Toxicology,
Richmond, Virginia 23298
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Amantadine Treatment of Cocaine Abuse
L. Handelsman, W. Bickel, T. Quesada, P. Chordia, I. Marion,
I. Escovar and J. Lowinson
Behavioral pharmacology studies of cocaine suggest that dopamine
(DA) agonists attenuate cocaine craving and self-administration.
Based on this evidence, an open trial of the indirect DA agonist
amantadine was initiated to attenuate cocaine abuse in methadone-
maintained patients. Inclusion criteria were male or non-pregnant
infertile female methadone-maintained patients, age 21-50, who
met DSM-III criteria for cocaine abuse for at least 3 months,
confirmed by urine reports. Exclusion criteria were schizophrenia,
bipolar disorder, epilepsy or current medical illness requiring
chronic medication. Amantadine 200 mg po daily was administered
for 3 weeks, then the dose was increased to 200 mg po BID for 3
weeks more; ingestion of 200 mg was observed 5 days per week by
a nurse. Methadone dosage was unchanged throughout. Self-reports
of cocaine craving and use and the Beck Depression Index were
obtained before and during treatment once per week; urine drug
tests were obtained twice weekly. Twelve patients completed 6
weeks of amantadine treatment: 11 males, 1 female; mean age, 33
(range 23-40); mean duration of cocaine use meeting DSM-III cri-
teria for cocaine abuse, 4.6 yrs (range 1-23). Both cocaine
craving and self-reported use declined significantly during
amantadine treatment (Wilcoxon matched pairs signed ranks test,
p<.OO3 and p<.004, respectively). Self-reports of cumulative
cocaine use was correlated with urine drug tests positive for
cocaine (Spearman R=.77, p<.011). Initial pretreatment Beck
score was related to the degree of decrease in cocaine craving
during amantadine treatment (R= .69, p<.022). Three patients
attained and maintained abstinence from cocaine use up to 2
months after treatment. These findings support the need for
blind, controlled studies to test the efficacy of amantadine
for treatment of cocaine abuse.
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Step-Wise Withdrawal from Cocaine Depen-
dence Outcome of 106 Consecutive Cases
F. Tennant, Jr., and A. Tarver
A step-wise withdrawal procedure utilizing amino
acids, amantadine hydrocloride (AH), levodopa (LD),
bromocriptine mesylate (BM), and desipramine (DES)
was investigated in 106 consecutive subjects who
sought medical withdrawal from cocaine dependence.
Initial medications given to the 77 subjects in
Group I consisted of AH, 100 mg, and tyrosine, 400
mg, given twice per day, and tryptophan, 500 mg,
given at bedtime. If, after one week of treatment,
the subject reported cocaine craving, continued use,
cocaine dreams or the withdrawal symptoms of
agitation and depression, BM 2.5 mg or LD 250 mg,
given twice per day, was added to the regimen.
During the third week of treatment, subjects who
could not refrain from cocaine use were administered
DES, 25 mg, given three times per day. Group II was
comprised of 29 subjects, and they received a higher
dosage regimen which consisted of AH, 100 mg, and
tyrosine, 400 mg, given four times per day and
tryptophan, 1500 mg, at bedtime.. When administered,
the dosage of LD, was 250 mg, three times per day,
BM was 2.5 mg, given two times per day, and DES, 25
mg given three times per day. Group II subjects
demonstrated superior outcomes in that more subjects
in Group I (20 of 77; 20.6%) than Group II ( 2 of
29; 6.9%) dropped out of treatment in the first week
(x2=5.039; P<.05), and a higher percentage of Group
II (25 of 29; 86.2%) than Group I (43 of 77; 61.0%)
reported cessation of cocaine use (x2=6.350; P<.05).
Although not statistically significant, Group II
subjects had slightly longer retention in treatment.
and demonstrated more urine conversions from cocaine
in urine on admission to absent during treatment. The
superior performance of Group II suggests that the
dosages and regimen utilized in these subjects should
be further studied for medical treatment of cocaine
dependence.
AFFILIATION:
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A Comparison of the Effects of Repeated
Doses of MDMA (Ecstasy) on Biogenic Amine
Levels in Adult and Neonate Rats
J. Rosecrans, S. Robinson, G. Patrick and D. Mokler
MDMA was administered to adult rats as a single 40 mg/kg in-
jection or 40 mg/kg (s.c.) every other day for 4 injections.
Sixteen days after the last injection rats were killed rapidly
and brain area biogenic amine and metabolite levels determined
using HPLC techniques. MDMA produced significant depletions of
5-HT and its metabolite, 5-HIAA, in the hippocampus (Hp) and
frontal cortex (FC). 5-HT was depleted to 30% of control values
in the Hp following single doses. 5-HT levels were unaffected by
MDMA in the hypothalamus, suggesting a differential effect on
5-HT containing neurons. DA levels were significantly increased
in the hypothalamus, while frontal cortex NE levels were de-
creased to 73% of control values following 4 doses of MDMA. These
data suggest that MDMA is neurotoxic to 5-HT neurons in the rat.
In a separate study neonate rats were administered MDMA in doses
of 10, 20 and 40 mg/kg (s.c.) on days 4,6,8 and 10. An analysis of
biogenic amine turnover (metabolite/amine ratios) indicated that
DA turnover was significantly increased 18 days after the last of
4 doses of either 10 or 20 mg/kg (+18-27% brain), while 40 mg/kg
of MDMA induced a decrease in turnover. A similar increase in
5-HT turnover was observed at lower doses (10 and 20 mg/kg); 5-HT
levels were also reduced by at least 25% in all MDMA treated
rats. In addition there appeared to be a dose-dependent decline
in 5-HIAA levels suggestive of an MDMA-neurotoxic effect similar
to that observed in the adult.
EFFECTS OF MDMA ON DOPAC AND 5-HIAA LEVELS
This research was supported by a VCU-Faculty-Grant-in-Aid to JAR.
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MDMA (3,4-Methylenedioxymethamphetamine):
Selective Neurotoxic Effects and Inter-
actions with Brain Serotonin Systems
G. Battaglia, S. Yeh and E. De Souza
MDMA, a ring-substituted derivative of methamphetamine, has
recently received a great deal of attention due to its increasing
abuse among certain segments of the population and due to the
controversy surrounding its proposed benefits as an adjunct in
psychotherapy. MDMA has been reported to possess stimulant
properties similar to the amphetamines and psychotomimetic
properties somewhat like those of the hallucinogens. Since 5-HT2
serotonin receptors have been postulated to play a role in
mediating the hallucinogenic activity of amphetamine derivatives,
we examined the relative affinities of MDMA on pre- and post-
synaptic brain serotonin recognition sites using radioligand
binding techniques. An in vitro pharmacological profile of MDMA
at a number of brain recognition sites revealed that MDMA exhibit-
ed relatively high affinity (Ki=5µM) for serotonin uptake sites,
5-HT2 and 5-HT1A serotonin receptors. MDMA demonstrated a stereo-
specificity at serotonin uptake sites (i.e. S(+) more potent than
R(-)) consistent with its reported stereospecisiicity in blocking
the active uptake of serotonin and in causing H-5-HT release. In
contrast, the stereospecificity of MDMA at 5-HT2 serotonin
receptors was the opposite of that observed at serotonin uptake
sites but consistent with that observed for other hallucinogenic
amphetamines. Furthermore, MDMA demonstrated radioligand binding
characteristics at 5-HT2 serotonin receptors consistent with
those observed for serotonin agonists and similar to those
previously reported for other substituted hallucinogenic de-
rivatives of amphetamine. Thus, MDMA may produce some of its mood
altering actions by indirect effects at presynaptic serotonin
terminals as well as by direct agonist effects at postsynaptic
5-HT2 serotonin receptors. We examined the potential neurotoxic
effects of MDMA on monoamine neurons in brain. Short-term (4 day
treatment) subcutaneous administration of MDMA in rats produced
long-term and widespread neurodegeneration of serotonin axons and
terminals in a number of brain regions including the cerebral
cortex, striatum, hippocampus and hypothalamus up to 14 days
following treatment. Marked, dose-dependent decreases in the
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content of brain serotonin and 5-hydroxyindoleacetic acid as well
as in the density of serotonin uptake sites were observed follow-
ing MDMA treatment. The neurotoxic effects of MDMA appear to be
preferentially localized to serotonergic neurons as there were
only minor and inconsistent changes observed in some of the
markers for catecholamines. Administration of the selective
serotonin uptake blocker citalopram prior to administration of
MDMA protected against the neurodegenerative effects of MDMA on
brain serotonin in neurons. In vitro autoradiographic visualiz-
ation of changes in the density of serotonin uptake sites in-
dicated that there may be some morphological selectivity to the
neurodegenerative effects of MDMA as little change was observed
in regions such as dorsal and median raphe nuclei which contain
primarily serotonin cell bodies. We are presently investigating
in more detail whether some serotonergic pathways in brain may be
more vulnerable than others to the neurotoxic effects of MDMA. In
summary, MDMA may exert some of its psychotomimetic effects by
both direct and indirect actions on serotonin neurons and short-
term administration of MDMA causes profound, widespread and
long-lasting neurodegeneration of brain serotonin axons and
terminals.
AFFILIATION: Neuroscience Branch, Addiction Research Center,
National Institute on Drug Abuse, Baltimore, Maryland 21224.
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Identification of 3,4 Methylenedioxyamphet-
amine (MDA) as a Major Urinary Metabolite
of 3,4 Methylenedioxymethamphetamine (MDMA)
R. Fitzgerald, R. Blanke, N. Narasimhachari, R. Glennon
and J. Rosecrans
MDMA ("ecstasy") is a substituted phenylisopropylamine which
produces a unique state of enhanced emotional and sensory aware-
ness. The effects of its N-demethylated analog MDA on humans has
been characterized as being both LSD-like and amphetamine-like.
Both MDMA and MDA have been shown to be fairly selective at
destroying serotonin nerve terminals. As a preliminary study to
investigate the metabolism of MDMA, male Sprague-Oawley rats were
housed in metabolism cages and received a single subcutaneous
injection of 40 mg/kg of (+/-) MDMA every other day for eight
days. Urine and feces were collected at 24 hour intervals. Plasma
was collected on the eighth day four hours after the final dose
of MDMA. Initial identification of MDA as a metabolite was
suggested by thin layer chromatography of rat urine. MDA and MDMA
had the same Rf values as their respective standards when visua-
lized with four different developing solutions. To confirm this
observation alkaline urine and plasma extracts were derivatized
with trifluoroacetic anhydride (TFAA) and chromatographed using a
mass spectrometer as a detector. The mass spectra obtained from
the two major peaks of derivatized urine and plasma extracts were
identical to authentic TFAA derivatives of MDMA and MDA.
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The Effect of MDA and MDMA (“Ecstasy”)
Isomers in Combination with Pirenperone on
Operant Responding in Mice
J. Rosecrans, P. Little, M. Yousif and R. Glennon
The optical isomers of MDA and MDMA were evaluated as to their
ability to disrupt operant behavior (FR-20) in the mouse. These
compounds were prepared by acylation of 1-(3,4,-methylenedioxy-
phenyl)-2- aminopropane with ethyl chloroformate followed by
reduction with lithium aluminum hydride and treatment of an
etheral solution of the product with HCl gas. The melting points
determined after recrystallization agreed with those values
obtain by others studying these compounds. All agonists were
administered (i.p.) 15 min prior to behavioral testing; animals
received daily injections of saline except on test days which
were conducted every 3rd day. Results were expressed as ® of
vehicle rates of operant responding' vehicle response rates from
the day prior to the test session served as control. These
compounds as well as S(t)-amphetamine (AMPH) and DOM disrupted
behavior in a dose-related manner. ED-50 values indicated the
order of potency amongst isomers to be as follows: S(+)-MDA
>R(-)MOA>S(+)MDMA >R(-)-MDMA. Both AMPH and DOM were several
times more potent than these isomers and disrupted behavior at
<1mg/kg. The preadministration of the 5-HT-2 receptor antagonist,
pirenperone (PIR), significantly antagonized DOM responding (0.1
mg/kg, s.c., 60 min. prior to 1 mg/kg DOM) supporting previous
data obtained in rat drug discrimination studies. In the present
studies, pirenperone was observed to antagonize only R(-)-MDA in
the mouse operant. The results of this study are in accord with
other research conducted in these laboratories. That is, the
5-HT-2 antagonist, PIR, is able to antagonize the effects of
R(-)-MDA at a dose comparable to that which blocks the disruptive
effects of DOM. On the other hand, this dose of PIR was unable to
antagonize the effects of S(+)-MDA or of either optical isomer of
MDMA. Apparently, the disruption of behavior produced by the
isomers of MDA is via a different mechanism. In addition, the
disruptive effects produced by the R(-)-isomer of MDMA appear to
be via a mechanism that differs from that implicated for R-(-)-
MDA (i.e., a 5-HT-2 mechanism).
This research was supported by a NIDA (DA-01642) grant to RAG and
a VCU-Grant-In-Aid to JAR.
322
Survey of Medical Advice about Caffeine
J. Hughes, G. Amori, J. Lewis, F. Lavigne and
D. Hatsukami
Scientific reviews differ in whether the use of
caffeine is harmful. To determine consensus on the
harmful effects of caffeine we asked 784 medical
specialists when they advised reduction or abstinence
from caffeine. Specialists in private practice,
academia, or in both were surveyed. 388 (56%) of
physicians responded.
For most conditions, responses were similar across
specialties and types of practice. More than 75% of
the specialists recommended reduction in caffeine
with the following conditions: anxiety, arrhythmias,
esophagitis/hiatal hernia, fibrocystic disease,
insomnia, palpitations and tachycardia. 50 to 75% of
the specialists recommended reduction with
hyperactivity, depression, polyuria, and ulcers.
Less than 50% recommended reduction with acne,
akathesia, depression, dermatitis, diabetes,
diarrhea, eczema, glaucoma, headaches,
hypothyroidism, irritable bowel syndrome, nocturnal
enuresis, pancreatic cancer, post-myocardial
infarction, psoriasis, psychosis, restless legs
syndrome, scotoma, tinnitus and ulcerative colitis.
Our results indicate a consensus that caffeine is
harmful in several common medical disorders. If
caffeine is shown to produce behavioral or physical
dependence, then our results indicate that caffeine
cannot be dismissed as a drug of dependence because
it is not harmful.
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Effects of Nicotine and Nicotinic Agonists
on Calcium Influx into Brain Synaptosomes
C. Hillard
The CNS nicotinic cholinergic receptor has been shown to modulate the release of
norepinephrine. dopamine and acetylcholine. It is hypothesized that neuro-
transmitter release results from increased intracellular calcium levels. The
experiments carried out in this study demonstrate that nicotinic agonists
modulate calcium entry into synaptosomes and characterize this effect. Synap-
tosomes were prepared from rat forebrain and aliquots (approximately 0.5-0.7
mg of protein) were preincubated in incubation buffer (136 mM NaCI, 5 mM
KCI, 0.01 mM CaCl2, 1.3 mM MgCI2, 10 mM glucose and 20 mM Tris, pH 7.65)
for 10 min at 30°C. Agonists were added in buffer that also contained 1.0 x 106
dpm of 45Ca and the incubation was continued for 5 sec. Basal influx was
typically between 1.75 and 3.75 pmol 45Ca/mg protein and was diminished in
the presence of unlabelled calcium. Influx in the presence of 35 mM potassium
was increased by 300-400%. Nicotine produced a concentration-related change
in 45Ca influx into synaptosomes, increasing influx at concentrations between 1
and 300 µM. Nicotine did not increase 4 5Ca influx when the incubation
temperature was 4°C or in incubation buffer lacking sodium. The stimulation
produced by n icot ine was b locked by the n icot in ic  receptor  antagonist
mecamylamine and did not occur in the presence of cobalt. The effects of three
other nicotinic agonists on 4 5Ca influx were determined. 1,1-Dimethyl-4-
phenylpiperazinium iodide (DMPP) was the most potent and the most efficacious
of the agonists investigated, producing a maximal increase at a concentration of 1
µM. Cytisine was also an effective agonist, maximally increasing 45Ca influx at
10 µM. Carbachol was very similar to nicotine, both of which increased 45Ca
entry by 20% over control levels at concentrations of 100 and 300 µM. All of
the agonists had biphasic concentration response relationships in that the amount
of stimulation decreased at high concentrations. These studies offer direct
evidence that the result of nicotinic receptor stimulation in the CNS is an
increase in the influx of calcium into nerve terminals and support the hypothesis
that nicotinic receptor induced release of neurotransmitters results from an
increase in the intrasynaptosomal calcium concentration.
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Role of Opioid Mechanisms in the Behavioral
Effects of Nicotine
S. Herling and W. Corrigall
The effects of nicotine, heroin, mecamylamine, and naltrexone,
administered alone or in combination, were studied in rats
trained to respond under a fixed-interval 3-minute schedule of
food presentation. Dose-response curves were determined for
each drug by administering cumulative subcutaneous doses of a
drug 20 minutes prior to the start of a fixed-interval com-
ponent which consisted of five consecutive fixed-intervals.
Daily sessions consisted of three or four separate fixed-
interval components, each preceded by a 20 minute time-out.
Increasing doses of nicotine (0.1 - 3.0 mg/kg) first increased,
then decreased response rates. In contrast to nicotine,
heroin (0.03 - 0.6 mg/kg) produced only dose-related response
rate decreases. Mecamylamine (0.1 - 3.0 mg/kg) and naltrexone
(0.3 - 10.0 mg/kg), when administered alone, had little effect
on response rates. However, when administered in combination
with increasing doses of nicotine, mecamylamine (1.0 mg/kg)
blocked the response rate-increasing effects of 0.3 and 1.0
mg/kg nicotine and partially reversed the rate-decreasing
effects of 3.0 mg/kg nicotine. In contrast, the combination
of naltrexone and nicotine, at doses of each that alone had
no effect on or increased response rates, severely decreased
responding. In addition, these combinations of naltrexone
and nicotine produced profuse salivation in all rats, an
effect not observed when either drug was administered alone.
These latter observations may be related to previous results
which have suggested a role for endogenous opioids in
mediating certain of the behavioral effects of nicotine.
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Effect of Tobacco Withdrawal on Neuro-
hormonal Function
J. Hughes, G. Amori, F. Stewart, G. Arana and R. Workman
Ten smokers first underwent a dexamethasone
suppression test (DST) during ad-lib smoking.
Cortisols were drawn and dexamethasone (1 mg) given
at 2300 on day 1. On day 2, cortisol and
dexamethasone levels were drawn at 0800 and 2300.
Two weeks later, subjects quit smoking and the DST
was repeated as before on the second day of
abstinence. Abstinence from tobacco was verified
biochemically in nine subjects.
Abstinence increased pre-dexamethasone cortisol
levels (drawn at 2300) in all nine subjects, mean =
4.1 and 6.9 ug/dl (p<.05). Abstinence did not change
the cortisol response to dexamethasone nor the
metabolism of dexamethasone.
These results suggest abstinence from tobacco
produces a nonspecific increase in cortisol but does
not influence the responsivity of the neurohormonal
axis. They also suggest that temporary abstinence
from smoking does not cause false positive DST
results.
AUTHORS
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Replacement of Cigarette Smoking with
Nicotine Gum: Effects on Information
Processing
F. Synder, F. Davis and J. Henningfield
Results from a cigarette abstinence study conducted in our
laboratory indicated that conventional measures of cognitive
performance declined within 24 hours of tobacco deprivation and
remained below baseline levels for the entire 10-day abstinence
period. These findings confirm clinical observations that
performance impairment may be a determinant of relapse to
cigarette smoking. In particular, measures of attention, "working"
memory, and arithmetic were disrupted during tobacco withdrawal.
The present study examined the efficacy of nicotine gum in reducing
the deleterious effects of cigarette abstinence on our computer-
ized Performance Assessment Battery (PAB).
Eight male smokers, who smoked at least one pack of cigarettes per
day, participated in the study. Subjects were trained on a varia-
tion of the PAB, an approximately 20 minute battery which measures
memory, attention and logical reasoning, until stable baseline
levels of performance were reached (M = 13 sessions). The study
design consisted of 3 consecutive days during which subjects were
not permitted to smoke but were given a piece of gum to chew every
hour for 12 hours each day. The gum contained either 0, 2 or 4 mg
of nicotine but was constant for the 3-day block. Each subject
was tested in 3 such blocks at each dose condition. Blocks were
separated by 4 days of free smoking.
Irrespective of dose of nicotine gum, PAB performance was best
under the cigarette smoking condition. However, PAB performance
during the 4 mg dose condition closely approximated the cigarette
smoking condition, while the performance data from the 3 days of
placebo gum indicated a nicotine withdrawal. Performance during
the 2 mg nicotine gum condition was better than that at placebo
and worse than that at 4 mg.
These results confirm the viability of nicotine replacement in
blocking the performance impairing effects which may be produced
by tobacco withdrawal. They also suggest that, at least for
heavier smokers, higher maintenance doses of nicotine gum may be
required than those readily available with the 2 mg preparation
which is available in the United States.
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After Chronic Nicotine or Diazepam, the
Intensity of the Anxiogenic Effect of a
GABA Depleter is Increased
C. Harris and H. Lal
Dependence upon various drugs causes anxiety as a withdrawal
symptom. Pentylenetetrazol (PTZ) discrimination, an animal model
of anxiety (Lal and Emmett-Oglesby, Neuropharmacology 22:1423-
1444, 1983), has been utilized as a behavioral assay for this
subjective effect of withdrawal fran nicotine (Harris et al.,
Psychopharmacology 90:85-89, 1986) and from diazepam (Emmett-
Oglesby et al., Eur. J. Pharmacology 92:127-130, 1983). The
purpose of this study was to determine the effect of chronic
treatment with nicotine or diazepam upon the subjective response
to perturbations of the GABA system. Isoniazid was utilized to
deplete brain GABA, and diazepam to facilitate GABA activity.
Rats were first trained to press levers for food reward in a two-
lever operant task. To train the discrimination, they were
reinforced for presses on one lever after PTZ (20 m/kg) and on
the other lever after saline. Training was then suspended, and
rats were assigned to one of three groups. One group received
nicotine, 1.9 q/kg the first day and 3.75 mg/kg/day thereafter
for 15 to 21 days. A second group received diazepam, 20 to 160
mg/kg/day, for 16 to 24 days. The third group received no chron-
ic treatment. After the end of chronic treatment, the rats were
tested for the occurrence of a PTZ-like withdrawal stimulus.
When this withdrawal effect became minimal, the rats were further
tested for response to isoniazid and to diazepam. Isoniazid, 100
and 200 mg/kg,produced a dose-dependent PTZ-like stimulus of low
intensity in the control group, and of high intensity in the
groups which been given chronic nicotine or diazepm. Diazepam
reduced the percentage of rats selecting the PTZ-lever after PTZ,
after isoniazid and during withdrawal from nicotine or diazepam.
These data indicate that chronic treatment with agents from two
diverse classes of dependence-producing drugs increased sensitiv-
ity to a drug which lowers brain GABA function. We suggest that
this change in sensitivity may be caused by decreased GABA trans-
mission (due to alteration of the GAPA-benzodiazepine-receptor/-
chloride-ionophore-complex) or increased activity of ah anxiogen-
ic endocoid during withdrawal. (Supported by NIDA Grant DA03521)
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Diazepam Effects on the Spontaneous Electro-
encephalogram (EEG), Evoked Potentials, and
Performance in Humans
W. Pickworth and R. Herning
Diazepam is a commonly used drug with abuse potential. The
purpose of this study was to quantify EEG changes in humans
given diazepam in a wide range of doses. Nine male residential
volunteers with a mean age of 28.4 yrs (22-40) and a mean weight
of 78.0 kg (63.6-100.0) were given (0, 2.5, 5.0, 10, 20, and 40
mg) of diazepam by mouth in a randomly assigned order of a
double blind crossover study. Study days were separated by at
least 72 hours. Prior to the drug and at 2, 6 and 24 hrs
following the drug, the subjects were comfortably seated in a
dimly-lit sound attenuated recording chamber. Two min of
spontaneous EEG was recorded while the subject relaxed with eyes
closed (EC) and eyes open (EO). Cognitive evoked potentials
were illicited by means of the auditory oddball task.
Diazepam had significant effects on several measures of the
spontaneous EEG. Diazepam increased power in the beta (14-25
Hz) frequency band and decreased power in the alpha (8-13 Hz)
band. Only the diazepam 40 mg increased power in the delta
(0.5-4 Hz) band. The mean frequency in the beta band decreased
over dose; whereas, alpha frequency increased. The 40 mg dose
decreased the delta frequency. The effects occurred in subjects
with EC or EO and were orderly across the time periods.
Regardless of the dose, the spontaneous EEG in all measures
returned to control leads after 24 hrs. Error rate increased in
the cognitive task where there were concomitant dose-related
decreases in P300 amplitude and time related increases in
latency. These results indicate that diazepam has effects on
several neuroanatomically and functionally distinct systems.
The decrease in attention suggested by changes in the
spontaneous EEG and decrements in processing indicated by
changes in evoked potentials point to several mechanisms to
account for the diazepam-induced performance disruption we
observed.
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Differentiation of High Versus Low Dose
Chronic Benzodiazepine Dependence in the Rat
J. Guarino, N. Boisse and M. Gay
It has long been known that termination of chronic supra-therapeu-
tic dose benzodiazepine (BNZ) treatment can induce dependence
manifest as a severe withdrawal (WD) syndrome (Hollisteratal,
Psychopharm 2:63, 1961). More recent evidence reveals that BNZ
dependence can also be induced by long-term therapeutic exposures,
The WD signs following chronic high or low therapeutic dose expo-
sure are similar. However, meaningful comparisons between high
and therapeutic dose dependencies are lacking. Accordingly, we
compared spontaneous WD syndromes obtained following chronic high
(HD) versus low dose (LD) chlordiazepoxide (CDP) treatments in the
rat. Male S-D rats (300-500 gm) were dosed p.o. bid for 5 wks
with fixed doses of 0, 5, 10, 20, 40, 75 or 150 mg/kg CDP or by
chronically equivalent maximally tolerable dosing (JPET 226, 100,
1983). At the end of treatment, 20 motor, autonomic and behav-
ioral WD signs were observed daily by experienced raters. The sum
of all individual WD sign intensities for each animal at any time
point, termed the WD SCORE, was calculated. Chronic steady state
blood levels of CDP, norCDP and demoxepam were measured by HPLC
(Fed. Proc. 40: 2350, 1981) 4 hours after the last dose in separ-
ate groups. All chronic doses gave statistically significant WD
compared to controls. The LDR curves for WD Score and the maximum
weight loss during WD were both bfphasic: the HD component (40,
75, 150, CEMT) was steeper than the LD component (5, 10, 20, 40).
To increase the sensitivity for detecting differences between HD
and LD dependencies the sign data from the LD groups was pooled
and compared to pooled data from HD groups. Ten WD signs were
common to HD and LD groups. Of these, 7 were statistically
significantly more intense in the HD group than in the LD group.
Two WD signs were only seen in the HD group. Chronic blood levels
for all components increased linearly with increasing dose in a
monophasic fashion. These results differentiate LD versus HD
chronic BNZ dependence in an animal model. The biphasicfty of the
LDR curves for spontaneous WD Score and weight loss suggest of two
mechanisms. The absence of biphasicity in the final steady state
blood level curves implies it is pharmacodynamic (CNS specific)
rather than pharmacokinetic (not CNS specific). The two neural
mechanisms of chronic BNZ dependence might be due to different
receptor subtypes, conformations of the receptor or receptor
coupled counter-adaptive changes.
AFFILIATION: Section of Pharmacology, College of Pharmacy and
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Discriminative Stimulus Produced by
Diazepam Withdrawal is Increased by GABA
Antagonists
S. ldemudia and H. Lal
Withdrawal from diazepam produces anxiety (Petursson
and Lader, Br. Med. J., 283:643, 1981). This subjec-
tive effect can be experimentally investigated by
comparing it with the interoceptive discriminative
stimulus produced by the anxiogenic drug pentylene-
tetrazol (Lal and Emmett-Oglesby, Neuropharmacol.,
22:1422, 1983). The present experiments were
conducted to determine whether the pentylenetetrazol-
like interoceptive stimulus produced by diazepam
withdrawal (Emmett-Oglesby, et al., Eur. J. Pharmacol,
92:127-130, 1983) would be altered by drugs acting at
the GABA-BZ-picrotoxin modulated chloride ionophore
receptor complex. Rats were trained in a two-choice
operant task to obtain food reward by selectin one
lever after an injection of pentylenetetrazol (PTZ; 20
mg/kg) or the other lever after saline (1 ml/kg).
After rats had learned to discriminate PTZ from
saline, all of them selected the saline-appropriate
lever following saline, Ro 15-1788, or diazepam,
whereas some of them selected the PTZ-appropriate
lever following bicuculline, yohimbine, picrotoxinin,
or ED50 of PTZ. Diazepam (120 mg/kg) was then
administered to the rats in a liquid diet twice daily
for 3 days so that during spontaneous withdrawal, only
30% of the rats selected the PTZ-appropriate lever
following saline. In contrast, all of them selected
the PTZ-appropriate lever following Ro 15-1788,
bicuculline, yohimbine, picrotoxinin, or the ED50 of
PTZ. These data show that chronic diazepam produces a
PTZ-like stimulus which is enhanced by antiGABA drugs.
Therefore, these data support the hypothesis that the
PTZ-like IDS produced by withdrawal from chronic
diazepam may be due to a decrease in GABAergic
neurotransmission.
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The Effects of Yohimbine on Triazolam Self-
Administration in Subjects with Histories
of Sedative Abuse
J. Roache, R. Meisch, J. Henningfield and J. Jaffe
The effects of yohimbine (YOH) pretreatment on triazolam (TZ) self-
administration were examined in 3 single-blind paid male volunteers
with sedative abuse histories who ware living on a research ward
and were not dependent at the tine of the study. Five days each
week and over a 3 hr pariod beginning at O900 hr, subjects could
self-administer a maximum of 18 color-coded placebo or TZ capsules
on a signaled concurrent choice 1O min T.O. schedule of reinforce-
ment; with this schedule, a desk lamp was turned onto signal
capsule availability and was turned off for 10 min after subjects'
verbally requested and ingested their preferred capsule color.
All subjects showed a consistent preference for TZ capsules and
showed a general stability in the number of TZ capsules self-admin-
istered (at 0.125 mg/capsule), over a 10 day baseline period; the
number of capsules self-administered was inversely related to the
subjects' initial sensitivity to the psychomotor impairment pro-
duced by test doses of TZ administered in an initial phase of the
experiment. In two subjects, varying doses of TZ (0.0312-0.25 mg/
capsule) were tested and the number of capsules self-administered
was inversely related to TZ dose. After varying doses of TZ were
tested, all subjects received varying doses of YOH pretreatment
(20-40 mg) or placebo in 5 white capsules at 0815 hr. In all 3
subjects, YOH increased blood pressure and heart rate and in two
subjects, YOH increased subject ratings of tension/anxiety and
decreased ratings of calm/relaxed. With all three subjects, YOH
increasedthe number of TZ capsules self-administered although
this effectwas not consistently related to YOH dose.
Although preliminary, the current results suggest this self-admin-
istration paradigm can show relatively stable dose-related TZ self-
administration behavior in subjects with histories of sedative
abuse. Also preliminary are the findings that YOH produced a
cardiovascular acceleration and increased TZ self-administration
and in some subjects produced anxiety-like subjective effects.
Further research in this area may provide insights relating to the
"self-medication" or "need" hypotheses of drug dependence and my
lead to better laboratory analogs of drug-taking behavior.
AFFILIATION: NIDA/Addiction Research Center, Baltimore, MD. 21224
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The Abuse Potential of Adinazolam:
A Comparison with Diazepam, Lorazepam and
Placebo
M. Bird, D. Katz, M. Orzack, L. Friedman, E. Dessain,
B. Beake, J. McEachern and J. Cole
The subjective effects of adinazolam (ADZ 30 and 50 mg), a
triazolobenzodiazepine with clinical specificity thought to be
similar to alprazolam, were compared to lorazepam (LZ 2 and 4 mg)
and diazepam (DZ 20 mg) in a double-blind placebo-con-
trolled study in recreational sedative drug users. The dependent
measures were the Addiction Research Criteria Inventory (ARCI),
analog "street value", "use again", "physical high", and "mental
high" ratings.
A six treatment cross-over design was used to assess drug effects
in groups of five subjects each. Each session was run in a
setting intended to create a living room like atmosphere. The
ARCI was administered every hour starting at baseline and ending
at six hours post dosing. Analog ratings were collected at one
and two hours post treatment. All data was statistically analyzed
using analysis of variance covarying for baseline ratings
(ANCOVA) and Newman-Keuls post hoc multiple comparisons.
The ANCOVA/Newman Keuls analyses of time of onset and magnitude
of peak effect discriminated between the mood effects of each
active treatment. Using our revised scoring procedure for the
ARCI, significant main drug effects were obtained for measures of
"mental" and "physical sedation"; each treatment had a mean
magnitude of effect significantly greater than placebo on at
least one time point. Interestingly, in examining the maximum
sedating effects of each treatment ADZ 50 mg produced more
"mental" and "physical sedation" than all other treatments.
Lorazepam 2 and 4 mg, on the other hand, were the least sedating
of all treatments and, in fact, were more "physically stimulat-
ing" than diazepam or placebo.
The "mental unpleasantness" measure provided useful data re-
garding the abuse liability of ADZ. At three hours post dosing
(the time of peak onset), ADZ 30 mg produced significantly
greater "mental unpleasantness" than placebo. The results of ADZ
50 mg are even more striking. At all times except 4 hours post,
ADZ 50 mg produced significantly more "mental unpleasantness"
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than placebo. However, it should be noted that ADZ 30 mg and ADZ
50 mg, as with all active treatments, resulted in ratings of
"physical" and "mental highness" which were significantly higher
than placebo, and ADZ 50 mg received ratings of "street value"
significantly greater than all treatments except for DZ.
Taken together, these data suggest that DZ has the greatest abuse
liability. While LZ and ADZ produces pleasurable effects, sub-
jects' rating of sedation and negative subjective effects
indicate that the overall potential for abuse of these drugs may
be relatively limited.
AFFILIATION: McLean Hospital Psychopharmacology Program; Harvard
Medical School Belmont, MA 02178 (Supported in part by NIDA Grant
DA 02349)
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Stereoselectivity of 11-OH-Delta-8-
Dimethylheptyl Tetrahydrocannabinol
in the Mouse and Dog
P. Little, D. Compton, R. Mechoulam and B. Martin
(-)- 9-THC, the major psychoactive constituent of marijuana, produces a variety
of effects in animals and in man, however, the mechanism(s) involved in
mediating these actions have not been elucidated. The pharmacological effects of
9-THC may be due to membrane perturbation and evidence for this focuses on
the lipophilicity of the cannabinoids. On the other hand, there is evidence which
suggests the existence of specific sites of action for the cannabinoids. These
interactions may involve specific neurotransmitter receptors, enzymes, plasma
membrane constituents or a specific cannabinoid receptor. Evidence for a
specific cannabinoid receptor is based on the structure-activity relationship
establ ished for  numerous cannabinoid analogs  (Razdan,  1986) ,  the
demonstration of stereoselectivity (Dewey et al., 1981) and the demonstration of
specific, saturable binding in brain homogenates (Nye et al., 1985). The degree
of stereoselectivity demonstrated with the cannabinoids is modest. The synthetic
(+)-isomer of 9 and 8-THC have been reported to be 5-100 times less potent
than the (-)- isomers (Dewey et  a l . ,  1981) . The s tereoisomers  of
11-OH- 8-dimethylheptyl-THC (11-OH-DMH) have been synthesized and tested
for their analgesic, anti-convulsant and discriminative properties (Mechoulam et
al. in press). These isomers were examined for their effects on spontaneous
activity, rectal temperature, tail-flick, catalepsy, and the dog static-ataxia model.
The (-)-isomer decreased spontaneous activity [4 µg/kg (1-14); ED50(confidence
limits)], lowered rectal temperature by 3°C at 21 µg/kg, was analgetic [9 µg/kg
(2-39)], and cataleptogenic [19 µg/kg (3-111) following iv administration. In
contrast, no ED50 values could be obtained with the (+)- isomer in mice up to
doses of 30 mg/kg iv. Similarly, in the dog static-ataxia model the (-)-isomer
produced signs of static ataxia between 3-10 µg/kg iv, while the (+)-isomer was
inactive at 1 mg/kg iv. Therefore the (-)-isomer of 11-OH-DMH was at least 300
times more potent than the (+)-isomer in all tests. This is in contrast to the degree
of stereoselectivity reported with 9- or 8-THC. The stereoselectivity seen in
the mouse and dog with the isomers of 11-OH-DMH is indicative of what would
be expected if a specific receptor interaction was responsible for mediating the
action of the cannabinoids. The stereoisomers of 11-OH-DMH may be useful
tools in further elucidation of the mechanism(s) of action of the cannabinoids.
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Serum Cannabinoids in Pregnant Rat and
Fetus Following Acute and Chronic Adminis-
tration of Tetrahydrocannabinol (THC)
M. Subramanian, D. Waselewsky, C. Zajac and E. Abel
Measurement of THC and its metabolite, 11-nor-9-carboxy THC (THC
-COOH) in sera of pregnant rats (Long-Evans) and fetuses were
carried out following administration of THC (50 mg/kg) by
intubation, on gestation day 20 or on day 20 after daily
intubation on gestation days 16 to 20 (n = 8/group). Tail tip
blood samples were obtained at 1, 2, 4 and 6 hr. after
intubation in the acute study and at 1 hr. after intubation on
day 20 in the chronic study. Chronically treated rats were
sacrificed after sampling. Fetuses were then removed and blood
samples obtained. THC and THC-COOH were measured by radio-
immunoassay (RIA) utilizing kits provided by the Research
Triangle Institute. Since the concentration of these
cannabinoids was high, serum samples were diluted with normal
rat serum. In the acute study serum cannabinoid levels were as
follows:
Time (hr) After Administration
1 2 4 6
THC (ng/ml) 1687 ± 448 1612 ± 410 1420 ± 360 1424 ± 297
THC-COOH* 275 ± 40 544 ± 98
(ng/ml)
821 ± 122 1266 ± 225
*Serum THC-COOH levels were significantly different over time
(P < .01). Trend analysis showed a linear trend between serum
THC-COOH and time (P < 0.01).
In the chronic study, no significant differences were seen
between maternal and fetal serum THC (2270 ± 930 vs 1467 ± 370
ng/ml) and THC-COOH (1056 ± 317 vs 1004 ± 236 ng/ml). Absence
of significant differences in maternal and fetal serum
cannabinoids is in contrast to previously published studies.
Difference in dosages and routes of administration and method of
analysis might account for these discrepancies.
Summary: 1. High serum levels (-1500 ng/ml) were achieved 1 hr.
following a single intubation of 50 mg/kg of THC to rats on day
20 of pregnancy. This high level was maintained for the 6 hr.
studied. THC-COOH showed a linear increase during the same 6
hr. period. 2. Following daily intubation of 50 mg/kg of THC
from day 16 to 20 of pregnancy, high levels of THC and THC-COOH
were observed in maternal and fetal serum and no differences
were seen between the maternal and fetal serum levels for these
cannabinoids. Supported by NIDA Grant 604148.
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High Concentrations of Naloxone Lower
Natural Killer (NK) Activity
M. Ochshorn, D. Novick, M. J. Kreek and E. Hahn
Several studies performed by other workers have provided some
evidence that T lymphocytes may possess opiate receptors (or
specific binding sites).
We have hypothesized that naloxone, a specific opioid antagonist,
may alter natural killer cell (NK) cytotoxicity activity in normal
healthy control subjects, heroin abusers, and methadone
maintained patients (MMP) . In this study we have incubated
peripheral blood mononuclear cells with a wide concentration
range (10-12 - 10-3 M) of naloxone (-), the active enantiomer of
naloxone, (which displaces opioids from opiate receptors) and
naloxone (+) the inactive enantiomer, (which does not displace
opioids from opiate receptor binding sites), in paired experi-
ments, and then have determined NK activity using a standard
chromium release assay [1,2].
Our results suggest that both naloxone (-) and naloxone (+)
have the same effect on the NK cytotoxicity activity. A
reduction of NK cytotoxicity activity is observed when either
enantiomer of naloxone is present in concentrations equal to or
greater than 1x10-4 M. This reduction of NK activity is
significant (p 0.05) at naloxone (-) concentrations of 7x10-4M
and above, and essentially zero NK activity observed with
concentrations of 1x10-3 and above. No alterations in NK
activity n were observed when naloxone (+) or (-) were present in
lower concentrations (10-12 - 10-5M).
We conclude that naloxone alters NK activity when present in
high concentrations, and that the concentrations of naloxone (-)
and naloxone (+) required to effect this reduction in NK activity
are similar. This action of naloxone on NK activity does not
seem to be mediated through binding to specific opiate receptors
on NK cells, because the opiate receptor inactive naloxone is as
effective as is the opiate receptor active form of naloxone in this
effect.
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Heterosexual Partners of IV Drug Abusers:
Implications for the Next Spread of the
AIDS Epidemic
D. Murphy, L. Brown and B. Primm
Intravenous drug abusers (IVDAs) represent the group
which is at second highest risk for the contraction
of AIDS and are predicted as being the major mechanism
by which the HIV virus may be spread to the general
heterosexual community. Although much has been
reported with regards to the at-risk for AIDS needle
sharing practices of IVDAs, knowledge about the sexual
behavior patterns and practices of the IVDA is
scarce. The purpose of this study was to examine the
risk of exposure of the HIV virus to non-IVDA males
and females posed by sexual contact with IVDAs.
The participants consisted of 107 randomly selected
clients who consented to be anonymously interviewed
with regards to drug use and sexual behavior patterns
and practices. The sample was 58% male, 42% female,
54% black, 35% Hispanic, and 11% white and was
statistically indistinct from the total A.R.T.C.
population of 2100.
Results indicated that males in comparison with
females were significantly more likely to report
sexual contacts which were non-IVDAs than IVDAs.
Similarly, among those most likely to have been
exposed to the HIV virus (either by reported needle
sharing and/or sexual contact with other intravenous
drug abusers), gender was significantly associated
with the number of non-IVDA heterosexual contacts.
These findings are supportive of other studies which
suggest that the route by which the virus may most
likely be spread to the general heterosexual community
will be via IVDA males with non-IVDA sex partners.
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Treatment of Heroin Addicts with Buprenor-
phine: Evaluation Over a Three-year Period
M. Reisinger and I. Pelc
Buprenorphine is a semi-synthetic opioid with agonist/antagonist
properties. Its pharmacological properties soon led some to suggest
that it could be used in the treatment of heroin addicts (Mello and
Mendelson, Science 207:657-659, 1980). We have already published a
report on this use of buprenorphine (Reisinger, Drug Alcoh Depend
16: 257-262, 1985).
Between 1983 and 1986 we proposed a treatment with buprenorphine
sublingual tablets to 200 heroin addicts . 116 (58%) discontinued
the treatment after three appointments or less. 84 (42%) followed
the treatment : 3 were excluded from the treatment for various
reasons; 28 patients out of 84 (33%) followed the treatment regularly
without interrupting for a period longer than one month; 56 patients
out of 84 (66%) followed the treatment irregularly, interrupting
one or more times for longer than one month at a time, during which
they resumed taking heroin; 21 patients out of 84 (25%) recovered.
The duration of the treatment was between 2 and 24 months. Follow-
up ranged from 6 to 24 months. Dosage of buprenorphine was 2 to
4 mg/day at outset and was gradually decreased. First dose was admi-
nistered no less than 12 hours after last heroin intake.
This clinical experiment permitted us to draw the following conclu-
sions : (a) Physical withdrawal from heroin with buprenorphine is
almost asymptomatic; (b) Buprenorphine's antidepressant effects
prevent the secondary depressive syndrome following the cessation
of heroin use; (c) Buprenorphine does not induce any euphoric
effects; (d) Increasing the dosage of buprenorphine above a ceiling-
dose does not increase the agonist effects; (e) All of the patients
progressively decreased their dosage of buprenorphine without diffi-
culty during treatment; (f) Buprenorphine's antagonist action reduces
the effects of subsequent intake of heroin; (g) Buprenorphine can
induce withdrawal symptoms when it is taken immediately after heroin;
(h) Withdrawal symptoms at the end of the treatment are negligeable.
As the use of buprenorphine has increased, many cases have been
observed of drug addicts injecting themselves with crushed tablets.
We have been trying to cope with this problem recently by means of
a buprenorphine pill in a new form.
AUTHORS: Marc Reisinger and Isidore Pelc, M.D., Department of
Psychiatry, Hopital Universitaire Brugmann, 4 Place Van Gehuchten,
1020 Brussels, Belgium, Europe.
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Benzodiazepine Dependence in Mice: Effect
of Dose and Duration of Treatment
E. Gallaher, S. Henauer, C. Jacques and L. Hollister
The benzodiazepines (Librium, Valium et al.,) are widely used for
their sedative-hypnotic, anti-anxiety, anti-convulsant, and
muscle-relaxant properties. In high doses, these drugs can
clearly cause physical dependence, although dependence laibility
following long-term exposure to low therapeutic doses is not well-
established.
We recently described a method for producing and quantifying
benzodiazepine physical dependence in mice using high
concentrations (up to 0.75% by weight incorporated in chow) for
eight weeks (J. Pharmacol. Exp. Ther., 237:462-467, 1986). In the
current study, we administered diazepam (DZ) in a lower
concentration (0.1%) over two, four, or 16 weeks. Following
cessation of drug, the two-week group exhibited mild withdrawal
signs for two days, but no convulsions were observed. The four-
week group also exhibited withdrawal signs for two days, including
convulsions in 73% of the animals. The 16-week group exhibited
withdrawal signs for 11 days; 100% exhibited convulsions. We
conclude that a clear time relationship exists with respect to DZ
physical dependence. In a second set of studies, four groups of
mice were fed DZ in chow (O.1%, 0.03%, O.O1%, 0%) for four weeks.
A dose-dependent withdrawal syndrome was observed, with mice in
the low treatment group showing minimal withdrawal signs on only
one day. This method therefore, appears to be suitable for future
studies in which thresholddoses will be administered for several
months to determine if significant withdrawal signs are observed.
AUTHORS
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Opioid and Adrenergic Spinal Receptor
Systems and Pain Control
C. Stevens and T. Yaksh
INTRODUCTION
Pain, evoked by somatic or visceral stimulation, reflects the
activation of afferent systems which make synaptic contact with
second order neurons in the spinal cord and subsequently project
to the brain. Pharmacologically, it can be demonstrated that
transmission through this pathway is subject to modulation at the
spinal cord level by local receptors which are associated with the
substrates through which this nociceptive information is
transmitted. By virtue of this association, direct activation of
several of these receptor systems, with receptor selective
agonists, can be demonstrated to produce a powerful and selective
analgesia. In the following sections, we will consider: 1) the
effect of opioid and adrenergic agonists on spinal function
particularly as the effects relate to the processing of nocicep-
tive information; 2) the pharmacology of these spinal systems; and
3) recent studies characterizing changes in drug action when these
agents are chronically administered to the spinal cord. It should
be stressed that while many systems may modulate nociceptive
processing, the “analgesic” action of a particular spinal receptor
system can only be established in the in vivo bioassay where drugs
are given into the spinal space off the anesthetized animal.
Here the effects of the agents on the behavioral response of the
animal to a noxious stimulus can be assessed. Such studies are
accomplished in man by intrathecal and epidural drug administra-
tion and were facilitated in animals by the development of a
simple model in which the spinal intrathecal space is catheterized
(Yaksh and Rudy 1976).
EFFECTS OF RECEPTOR SELECTIVE AGENTS ON SPINAL NOCICEPTIVE
PROCESSING
Opioids
In spinally transected animals at relatively low doses, systemi-
cally administered opiates reduce: 1) the polysynaptic ventral
root reflex (Wikler 1950); 2) the response of dorsal horn neurons
otherwise evoked by activity in A /C, but not Aß fiber primary
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afferents; and 3) the size of the cutaneous receptive field of
dorsal horn neurons induced by a variety of somatic and visceral
stimuli which evoke pain behavior (Le Bars et al., 1975; Yaksh
1978a; Einsphar and Piercey 1980). Systemic morphine at analgesic
doses in paraplegic man will attenuate the polysynaptic reflex of
the tibialis anterior muscle evoked by sural nerve stimulation
with no effect on the monosynaptic H reflex (Willer and Bussel
1980). Importantly, in animal studies this inhibitory effect can
be demonstrated on spinal populations of nociceptive neurons which
project to supraspinal centers (Jurna and Grossman 1976; Jurna and
Heinz 1979). By other criteria, the effects of systemically admi-
nistered opiates on the activity of nociceptive neurons in spinal
transected animals are mediated by an opioid receptor: a)
ordering of the structure-activity relationship (i.e. the ability
of different opioids to suppress nociception in vivo is in accord
with their efficacy on in vitro opiate receptor bioassay systems
(Iwata and Sakai 1971; Yaksh 1978a; Piercey et al., 1982); and b)
the effects are dose-dependently antagonized by opioid antagonists
(Yaksh 1978b).
With regard to mechanism of action, focal application of opiates
within the substantia gelatinosa in the vicinity of the substantia
gelatinosa (Zieglgansberger and Bayerl 1976; Ouggan et al., 1981)
will suppress the spinal nociceptive neuron activity otherwise
evoked by stimuli which emit escape behavior in the unanesthetized
animal. Opioid ligand binding studies have demonstrated that
following dorsal root lesions, either produced by section or by
the afferent neurotoxin, capsaicin, major but subtotal reductions
in ooioid bindina occur in the dorsal horn (LaMotte et al., 1976:
Gamse et al., 1979), suggesting a significant proportion of opioid
binding sites in the dorsal horn exist on the terminals of small
primary afferents. These results suggesting a presynaptic action
of opiates are consistent with the ability of opioids to inhibit
the release of substance P from small primary afferents in a
naloxone reversible fashion (Jessell and Iversen 1977; Yaksh et
al., 1980). The incomplete depletion of dorsal horn opiate binding
and the ability of opioids to suppress excitatory postsynaptic
potentials evoked in dorsal horn neurons by excitatory amino acids
(Zieglgansberger and Bayerl 1976), however, suggest an additional
action directly on the second order neuron.
Intrathecally or epidurally injected opioids have been shown
to result in a powerful analgesia as assessed in a variety of
experimental pain models in man and animal and in the clinical
models of postoperative and chronic pain (see Yaksh and Noueihed
1985). All nociceptive input may not be equally altered by spinal
opiates. Thus, consideration of the types of clinical pain
affected, has indicated that following epidural morphine, the
characteristic sensation most readily relieved by epidural
morphine is that described as continuous and originating from deep
somatic and visceral structures. Less predictably managed are
intermittent somatic and visceral (intestinal obstruction) pain.
Cutaneous (incisional) pain is poorly modified by spinal morphine
at "analgesic" concentrations. Neurogenic pain such as associated
with deafferentation, is often little modified by even high doses
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of spinal opiates (Cousins and Mather 1984). This differential
effectiveness of spinal opiates against different types of pain
demonstrated in man and animals reflects upon the spinal substra-
tes whereby the information from these stimulus modalities are
coded and with which the opiate receptor is associated.
In vitro pharmacological and biochemical analysis suggest the
existence of several potentially distinct classes of opioid
receptors: µ (µ1/µ2), (see Yaksh 1984). The ini-
tial evidence of a functionally selective modulation of spinal
nociceptive processing emphasized the role of µ referring ago-
nists (e.g. morphine). Animal studies have now demonstrated that
both spinal receptor systems are also functionally able to
alter nociceptive processing (Wood et al., 1981; Yaksh 1983).
Several lines of evidence support the contention that these
several classes of ligands act upon discriminable receptors:
a) differential structure-activity relationships for µ-, and
agonists on different nociceptive measures (Schmauss and Yaksh
1984); b) distinguishable pA2 values of naloxone for the receptors
acted upon by putative µ, and receptor agonists (Tung and
Yaksh 1982); and c) differential cross-tolerance (Yaksh 1983;
Tseng 1982). With regard to the latter point, it has been shown
that animals rendered tolerant to a µ agonist (such as morphine)
show little loss of response to a receptor preferring ligand
(e.g. DADL) (Yaksh 1983). It should be stressed that this lack of
cross-tolerance is dependent upon the magnitude of morphine expo-
sure. Reductions in the response to other ligands will also occur
at higher concentrations (Stevens and Yaksh 1986; Russel et al.,
1987, see below).
The principal agents employed in man (such as morphine or
meperidine) are µ agents. The b-preferring peptide, DADL, has
also been shown to be a powerful analgesic in man after intrathe-
cal administration (Onofrio and Yaksh 1983; Moulin et al., 1985;
Krames et al., 1986) , though the selective agonist,
D-Pen2-D-Pen5-enkephalin, has not been examined. -Endorphin in
man produces a powerful analgesia when given spinally (Oyama et
al., 1980). Though it may act on several sites, one of which is
designated as the receptor, systematic animal studies have
suggested its effects are mediated by a site similar to that acted
upon by morphine (Tung and Yaksh 1982; Yaksh et al.,1982).
Considering the site, a number of traditional “partial”
agonists, such as nalbuphine or butorphanol, are thought to act in
part at the site. Both agents in man have been shown to be
mildly effective as analgesics following epidural administration
(Weintraub and Naulty 1985; Wang et al., 1985). In general,
receptors in animal models are weakly effective (Schmauss and
Yaksh 1984; but see Wood et al., 1981). Whether these agents will
be useful under different clinica1 conditions to produce adequate
analgesia remains to be seen. This limited effect appears to
occur not necessarily because these agents are "partial agonists",
but because the receptor with which they interact ( ) may be less
efficiently coupled to spinal systems relevant to pain
processing.
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Adrenergic receptors
Considerable data indicated that bulbospinal noradrenergic systems
would alter spinal nociceptive processing (Anden et al., 1966).
Such pathways were shown to be activated by brainstem microinjec-
tions of morphine (Yaksh and Rudy 1978). Local iontophoretic
administration of -adrenergic agonists into spinal cord will pro-
duce a powerful suppression of spinal nociceptive processing
(Headley et al., 1978; Fleetwood-Walker et al., 1985). These obser-
vations suggested that spinal adrenergic agonists should produce a
comparable modulation. Spinal administration of adrenergic ago-
nists in several species has indeed been shown to yield a powerful
analgesia (see Yaksh 1985). The pharmacology of this effect
revealed that the phenomenon reflects an action mediated by an
2-receptor. Thus, the relative activity of spinally administered
agonists is: ST-91 (a clonidine analogue) > norepinephrine >
methoxamine >> isoproterenol = 0. The effects of clonidine, ST-91
and norepinephrine were antagonized by the selective 2-antagonist
yohimbine (Howe et al., 1983). In man, clonidine, an 2-agonist,
has been usefully administered epidurally in cancer patients for
the treatment of pain (Coombs et al 1984; Tamsen and Gordh 1984).
Drug interactions
The antinociceptive effects of morphine following intracerebral
administration will synergize with the effects of spinal morphine
(Yeung and Rudy 1980). The apparent synergy is thought to result
from the property of the inhibitors. Thus, electrophysiological
studies have demonstrated that bulbospinal pathways and spinal
opiates (Yaksh 1978a; Gebhart et al., 1984) both serve to decrease
the slope of the stimulus intensify-response curve. For spinal
neurons, such a decrease in slope constitutes a reduction in the
gain of the system. The interaction between two such systems
would have a net outcome which might be expressed as the product
of the gain reductions and not the sum. Given the role of
bulbospinal adrenergic pathways in mediating a portion of the
opiate effect at the level of the brainstem, it is reasonable to
conclude that intrathecal a agonists might potentiate the effects
of intrathecal morphine. Such a synergy has indeed been
demonstrated (Monasky and Yaksh 1986; Wilcox et al., 1987). In
brief, a near maximum analgesic effect may be generated by com-
binations of a agonists and morphine at doses which alone produce
only minimal effects.
TOLERANCE AND CHRONIC SPINAL DRUG EXPOSURE
As outlined above, it is clear that the selective alteration of
the animals' organized response to a noxious somatic or visceral
stimulus can be achieved by the spinal administration of opioid
and -adrenergic agents. As indicated, in several instances,
these agents have been shown to produce a useful change in the
humans response to acute and chronic pain. The use of spinal
receptor selective agents for long term administration, however,
has the same caveat as the chronic use of opiates given
systemically; repeated or continuous dosing will frequently result
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in the progressive elevation of the concentration of drug required
to produce a given effect, i.e. tolerance. Thus, in man with the
chronic spinal administration of morphine, a highly variable
increase in drug utilization has been noted with 1 to 30-fold
increases being repeated in cancer patients over a 24-week period
(Yaksh and Onofrio 1987). Similar results have been reported in
more systematic, single center studies (Krames et al., 1985;
Shetter et al., 1986).
To assess the effects of long-term spinal administration, several
issues immediately pose themselves regarding the phenomenon of
tolerance. First, following chronic spinal administration of
receptor selective ligands, is the rate of loss related to the
chronic treatment concentrations? Second, are there differences
in the rate of tolerance development between different classes of
spinal receptors which produce analgesia? Third, within a given
class of agents, is the rate of tolerance development altered by
the potency of the agent?
We have recently utilized an osmotic minipump coupled to an
indwelling lumbar intrathecal catheter to deliver different
concentrations of several antinociceptive agents in the
unanesthetized rat (Yaksh and Stevens 1986). With this schedule
of administration, an equilibrium is reached at the receptor
biophase and concentration of drug remains constant throughout the
infusion period. This is a marked improvement over bolus injec-
tions where peak and trough drug concentrations occur and where
different concentrations yield different times of drug-receptor
exposure (e.g. increasing dose yields not only a higher agonist
concentration but a greater time of receptor exposure). Drug is
continuously administered at the rate of 1 µl/h, for 7 days, and
the antinociceptive effect is measured by the hot plate test.
Testing on day 0 before the implantation of the minipump i.t.
catheter assembly and daily thereafter allows an assessment of the
time course of tolerance development. Chronic spinal administra-
tion of three log-spaced concentrations each of morphine, sufen-
tanil, or DAGO (µ-opioid specific agents), DADL ( -opioid
preferring), or ST-91 (an analog of clonidine, 2-adrenergic
agonist) yields a dose-dependent increase in hot plate latency
after 1 day of infusion (Stevens and Yaksh 1987). These hot plate
values then decline over time, until by three to five days, they
are not different from saline-infused controls, i.e. tolerance has
developed. Standardization of the raw hot plate latency to maxi-
mum percent effect values and calculation of the area under the
time course curve (AUC) yields a quantification of the time needed
to return to baseline values for each dose in each treatment
group. An index of the rate of tolerance development is obtained
by plotting the maximum effect of each infusion dose (obtained on
day 1) against the area under the time course curve. These
points, for any drug, fall on a straight line. This analysis
shows that within each treatment group the rate of tolerance deve-
lopment is independent of the dose infused. Furthermore, com-
parison across treatment groups show that the same rate of
tolerance development is obtained for µ, and 2 antinociceptive
agents in the spinal infusion model (i.e., the slope of the MPE
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vs. AUC curves do not differ, see Table 1). This similarity of
rate constants suggests the involvement of common mechanisms of
tolerance to these several drugs. Given the lack of a symmetrical
tolerance between these agents (see below), the tolerance
mechanism(s), though common, may be independent. Finally, based
on the ED50 values observed on the hot plate after intrathecal
injections in the rat, the relative potency of the three µ ago-
nists is sufentanil DAGO > morphine. As indicated in Table 1,
there is no difference in the rate of tolerance development bet-
ween these agents when administered by chronic infusion. Thus,
simple potency differences do not alter the time course of
tolerance development.
TABLE 1. Slope of MPE vs. AUC Curves for the Effect of Agents
Chronically Infused in the Rat Spinal Space on the
Hot Plate Response
Infusion Drug Infusion Dosesa Slope of MPE vs. AUC Curve
Morphine 2, 6 or 20 0.32 (0.25 - 0.40)b
DAGO 0.1, 0.3 or 1.0 0.48 (0.37 - 0.58)
Sufentanil 0.06, 0.2 or 0.6 0.42 (0.34 - 0.51)
DADL 2, 6 or 20 0.43 (0.29 - 0.57)
ST-91 3, 10 or 30 0.37 (0.23 - 0.50)
aIn nmol/h; each dose infused in 4-6 animals.
bSlope (95% confidence interval).
CROSS-TOLERANCE
An important issue relates to cross-tolerance between the several
classes of agents. Using the above paradigm, animals were infused
for seven days with one of three concentrations of morphine or
saline, and then each received a single bolus dose of a “probe”
drug to allow construction of dose response curves. Table 2 pre-
sents the ED50 values at different morphine infusion con-
centrations for morphine, DADL and ST-91 given as the probe drug.
TABLE 2. IT ED50 Values
a for Morphine, DAM and ST-91 Assessed
in Rats after 7 Days of Intrathecal Morphine Infusion
Probe Drug Morphine Infusion Concentration (nmol/µl/hr)
0 (Saline) 2 6 20
Morphine 0.7 (0.3-1.9)b 3.1 (0.4-24) 39 (20-73) 83 (49-142)
DADL 0.2 (0.1-3) 0.7 (0.2-2) 0.5 (0.1-2) 5.9 (4-8.6)
ST-91 3.0 (0.9-9.4) 27 (16-47) 39 (19-83) 81 (35-188)
aEach dose response curve is constructed from results measured in
12 to 18 animals.
bED50 value (95% confidence interval).
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These results indicate only minimal signs of cross-tolerance.
Thus at the high concentration of morphine (20 nmol/µl/hr), the
ED50 for morphine increased by a factor of 120. The ratio
increase for DADL and ST-91 was 30 and 20, respectively.
Given the above results, we consider that rational strategies to
produce longer term utilization of receptor selective drugs may
thus theoretically involve several approaches: 1) Given the lack
of a symmetrical cross-tolerance between several classes of recep-
tor selective agents, alternating agents such as µ, and 2 might
be considered. 2) Employing combinations of agents which have
shown synergistic interactions (e.g. opioid and 2-agonists). As
these combinations are able to produce full antinociceptive effect
with a minimal degree of receptor occupancy, a less pronounced
tolerance may be produced or have a slower time course. 3) Recent
studies have suggested that it is possible to manipulate opioid
receptor number with antagonists. Thus, the chronic systemic
administration of an opiate antagonist, naltrexone, has been shown
to double the number of opiate binding sites in rat brain (Zukin
and Tempel 1986). These animals are then more sensitive to
morphine administration as compared to controls, suggesting that
the increased opiate receptors measured are indeed functionally
coupled. This approach might theoretically be employed to upregu-
late opiate receptors in tolerant patients by intermittent opiate
antagonist infusions with supplemental analgesia provided by
2-agonists or local anesthetics.
In conclusion, consideration of opioid and adrenergic agents able
to alter the pain message at the spinal level reveals potential
therapeutic approaches to pain control. Animal studies must
demonstrate basic mechanisms, pharmacokinetics and non-toxicity
before a rational and safe clinical trial can be implemented.
Finally, tolerance and cross-tolerance studies are important to
optimize drug regimen in patients requiring repeated or continuous
administration of analgesics for chronic pain states.
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Multiple Opioid Receptors
T. Burks
Abuse of opioids continues to represent a major medical and social
problem. Improved understanding of existing opioid drugs and
development of novel agents with reduced dependence potential
requires appreciation that the diversity of opioid effects in the
human or animal body results from complex actions at multiple
types of opioid receptors located at multiple sites in the central
nervous system and in the periphery.
A CPDD symposium, chaired by T.F. Burks and A.E. Takemori,
explored current concepts and data relating to the functional
implications of multiple opioid receptors. Several important new
concepts were brought out during the symposium. It is now evident
that research attention in a number of laboratories focuses on a
restricted number of opioid ligands that are proving their value
as probes of functions associated with specific types of opioid
receptors. Morphine, the classical prototype opioid that exhibits
preference for the mu opioid receptor, is included in many studies
as a useful standard of reference. The peptides [D-Ala2,NMePhe4,
Gly-ol]enkephalin (DAGO) and [MePhe3,DPro4]morphiceptin (PL017)
are more frequently included in investigations as highly selective
mu agonist ligands, cyclic [D-Pen2,D-Pen5]enkephalin (DPDPE) or
cyclic [D-Pen2,L-Pen5]enkephalin (DPLPE) as highly selective delta
ayonists, and U-50,488H as the nonpeptide kappa agonist.
Selective antagonists, recently available, are used with
increasing frequency. The selective antagonists include
-funaltrexamine ( -FNA) and cyclic D-Phe-Cys-Tyr-D-Trp-Lys-Thr-
Pen-Thr-NH2 (CTP) for mu receptors, N,N-diallyl-Tyr-Aib-Aib-Phe-
Leu-OH (ICI 174,864) for delta receptors, and the very recently
introduced nor-binaltorphimine (nor-BNI) for kappa opioid
receptors.
It is now possible to begin gaininy a coherent picture of
functions associated with distinct types of opioid receptors as
different investigators, using different techniques and endpoints,
present data obtained in individual systems with the same highly
selective opioid receptor agonists and antagonists. When
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different investigators use the same ligands, the similarity of
results is striking and confounding variables, such as species
differences, are much more readily identified than when totally
different, and often nonspecific, ligands are employed by
different investigators.
The drugs and peptides employed originally to allow proposals for
classification of opioid receptors show distinct preferences for
specific types of opioid receptors: morphine for the mu type,
ketocyclazocine for the kappa type, N-allylnormetazocine
10,047) for the sigma type, [D-Ala2, D-Leu5]enkephalin for the
(SKF
delta type, and, in some tissues, -endorphin for the epsilon
type. However, these ligands are not sufficiently selective in
most cases to allow identification of functions associated with a
single type of receptor.
Dr. Brian Cox, Department of Pharmacology, Uniformed Services
University of the Health Sciences, Bethesda, MD, described
radioligand binding conditions that allow identification of
binding to the three major types of opioid receptors, mu, delta
and kappa, by nonselective ligands. For example, complex
Scatchard plots obtained from binding of ethylketazocine (EKC)
alone can be simplified by the addition of selective ligands to
the binding assay with the aim of reducing EKC binding to specific
types of receptors. Addition of DAGO eliminates, by competition,
binding of EKC to mu receptors, and addition of U-50,488H
eliminates kappa binding. Addition of either selective ligand
eliminates binding to one type of receptor and results in a more
linear Scatchard plot reflecting binding primarily to the
unoccupied mu or kappa receptor. DAGO, DPDPE and U-50,488H are of
value as selective ligands in radioligand binding studies. Among
antagonists, naloxone is useful, displaying a KD of 1-2 nM at mu
receptors, but is only about 10-fold selective. Nor-BNI is
selective for kappa receptors, with a KD of approximately 1 nM.
ICI 174,864 has a high KD of about 200-400 nM, indicating low
potency, but is highly selective. Natural ligands tend to be
relatively nonselective. The longer dynorphin peptides, such as
dynorphin-(1-13), dynorphin-(1-17) and a-neo-endorphin, act mainly
at kappa opioid receptors but possess mu activity as well.
Shorter dynorphin peptides, such as dynorphin-(1-8), are
relatively nonselective. The natural enkephalins possess both
delta and mu activity. Similarly, -endorphin is not selective in
binding assays.
An important feature of opioid receptors is their uneven
distribution in different tissues. For example, estimates based
on Bmax values indicate that the cortex of guinea pig brain
contains approximately 23% mu, 12% delta and 65% kappa receptors.
In contrast, rat whole brain contains approximately 47% mu, 34%
delta and 19% kappa receptors. Regional differences also occur
even within the same species.
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There have been recent advances in understanding the regulation of
opioid receptors by sodium and by guanine nucleotides. Sodium
(IC50 10-20 mM) inhibits agonist binding at mu and delta
receptors, with less effect at kappa receptors. The apparent
effect of sodium at delta receptors is to decrease the apparent
number of opioid agonist binding sites. This effect has been
observed at delta receptors in NG108-15 neuroblastoma-glioma
hybrid cells and in guinea pig brain membranes. In 7315c
pituitary tumor cells, which possess mu opioid receptors, the
major effect of sodium seems to be a shift to lower affinity
states of mu receptors, with an overall apparent decrease in mu
receptor affinity. As relatively low concentrations of sodium can
alter agonist binding, an effect in the low-sodium intracellular
environment is suggested. Exposure of 7315c or NG108-15 cells to
the sodium ionophore, monensin, increased intracellular levels of
sodium and decreased mu and delta receptor agonist binding,
respectively. These data suggest that sodium acts at
intracellular regulatory sites to decrease opioid receptor binding
at both mu and delta receptors.
Guanosine triphosphate (GTP) also affects binding of agonists, but
not antagonists, in guinea pig cortical membranes and in 7315c
cells. Binding of mu and delta agonists is reduced by addition of
0.1 nM of GTP, probably because of a shift to low affinity states
of the receptors. Kappa receptor binding is affected less than mu
or delta binding by GTP.
In vitro studies designed to examine agonist potencies in
initiating opioid receptor-mediated events in brain have revealed
striking species differences. Release of norepinephrine evoked by
potassium depolarization was measured in slices of guinea pig and
rat cerebral cortex. In guinea pig cortical slices, mu, delta and
kappa opioid agonists produced concentration-dependent inhibition
of potassium-stimulated release of norepinephrine, apparently by
actions at presynaptic opioid receptors on terminals of
projections from the locus ceruleus. In guinea pig cortical
slices, actions of DAGO were blocked by naloxone, U-50,488H was
blocked by nor-BNI. Rat cortex, by contrast, is known to contain
few kappa opioid receptors. In slices of rat cortex, only mu
opioid agonists, not delta or kappa, produced inhibition of
potassium-stimulated release of norepinephrine. The same
species difference in response to opioids was observed in guinea
pig and rat cerebellum.
An interesting aspect of the studies of opioid inhibition of
potassium-stimulated release of norepinephrine from guinea pig
brain slices was the demonstration of selective opioid tolerance.
Guinea pigs were made tolerant to either morphine (mainly a mu
agonist) or U-50,488H (kappa agonist) by continuous infusion for 6
days by means of implanted osmotic minipumps. In brain slices
from animals infused with morphine, there was a decreased effect
with DAGO, whereas U-50,488H was fully active. In brain slices
from animals infused with U50,488H, there was reduced
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responsiveness to U-50,488H, whereas DAGO was fully active. The
tolerance induced by opioid infusion was thus specific for either
mu or kappa receptors. These studies have provided evidence for
biochemical and functional distinctions between types of opioid
receptors.
Dr. A.E. Takemori, Department of Pharmacology, Medical School,
University of Minnesota, Minneapolis, discussed use of antagonists
to provide pharmacological characterization of different types of
opioid receptors. Naloxone pA2 values can be used to classify
different actions of opioid agonists. For example, mixed opioid
agonist-antagonist drugs displayed lower naloxone pA2 values than
those obtained with pure agonists. Interestingly, different
centrally-mediated opioid endpoints in some cases had different
naloxone pA2 values: analgesia, respiratory effects and body
temperature effects.
However, the inferences to be made by use of naloxone to
discriminate between types of opioid receptors were limited.
Receptor selective antagonists would be expected to provide much
more precise information. Portoghese and Takemori theorized that
a complementary molecule possessing an electrophile would interact
with opioid receptor nucleophilic sites to generate covalent
binding if the electrophilic substitution were adequately
chemically reactive. After 12 years of effort, -chlornaltrex-
amine (-CNA) was developed. -CNA interacts irreversibly with
opioid receptors as an opioid-selective affinity label, but does
not differentiate between types of opioid receptors. They went on
to develop -FNA, a derivative of naltrexone, which has high
affinity for mu opioid receptors. Many other analogs have been
prepared and examined, but none is more selective than -FNA for
mu antagonism, implying strict spacial requirements of the
antagonist receptors.
In in vitro preparations of guinea pig ileum, which contain mu and
kappa opioid receptors, morphine and EKC display different
naloxone pA2 values. After treatment with -FNA, the naloxone pA2
value for EKC is not altered, but morphine acquires the same
naloxone pA2 value as EKC, implying that morphine acts at the EKC
(kappa) receptor after blockade of the mu receptor by -FNA. In
in vitro preparations of mouse vas deferens, which contain mu,
kappa and delta receptors, treatment with -FNA eliminates mu
receptors without altering the naloxone pA2 for EKC or
[Leu]enkephalin, which act primarily at kappa and delta receptors,
respectively. In membrane radioligand binding studies, naltrexone
and morphine binding are inhibited by -FNA, whereas enkephalin
binding is not significantly altered.
When administered to intact animals, -FNA behaves as a reversible
kappa agonist (as shown in the abdominal stretch test of
analgesia) and an irreversible mu antagonist. Even 48 hr after
administration of -FNA, morphine analgesia can be persistently
inhibited. -FNA can block development of morphine dependence in
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animals if given before morphine and can block ability of morphine
to alleviate the withdrawal response if given after development of
morphine dependence.
A more recent approach to development of selective opioid
antagonists has been the creation of bivalent antagonist ligands
with two pharmacophores at the ends of chemical spacer groups. An
early compound, TENA, had affinity for the kappa receptor and
displayed a kappa/mu ratio of approximately 5. A more recent
compound, BNI, is much more selective as an antagonist at kappa
opioid receptors and displays a kappa/mu ratio of 137.5. As
expected of a kappa antagonist, BNI and nor-BNI block actions of
kappa agonists in preparations of rabbit vas deferens, primarily a
kappa receptor tissue. In vivo, BNI and nor-BNI block actions of
kappa, but not mu or delta, opioid agonists. Nor-BNI has high
binding affinity for kappa opioid receptors in radioligand binding
assays.
The development of selective receptor antagonists has provided
useful pharmacological tool for studies of opioid receptors and
has allowed further differentiation of receptor types.
Dr. Thomas F. Burks, Department of Pharmacology, College of
Medicine, University of Arizona Health Sciences Center, Tucson,
Arizona, described differentiation of receptor specific central
and peripheral opioid actions by the use of highly selective
opioid agonists and antagonists. In unanesthetized mice, mu
agonists such as DAGO and morphine given intracerebroventricularly
(i.c.v.) are more potent in inducing analgesia than delta or kappa
agonists. To ascertain that mu and delta effects are in fact
mediated by pharmacologically distinct receptors, selective
receptor antagonists were employed for selective antagonism of mu
or delta effects. Prior administration of -FNA, a mu opioid
antagonist, produced a large rightward shift in the dose-response
curve for i.c.v. morphine, but did not alter analgesic responses
to i.c.v. DPDPE, a delta agonist. -FNA thus discriminated
between mu and delta opioid receptor mediated events. Prior
administration of the delta antagonist, ICI 174,864, produced
dose-dependent inhibition of analgesic responses to i.c.v. DPDPE,
but did not alter responses to i.c.v. morphine. The mu antagonist
thus selectively blocked the mu agonist and the delta antagonist
selectively blocked the delta agonist. These data indicate that
mu and delta agonists act at distinct recognition sites in the
brain to induce analgesia.
When given intrathecally (i.t.) and evaluated in the hot plate
test of analgesia, the delta opioids were relatively more potent
than after i.c.v. administration and were, in fact, close to
morphine in analgesic potency.
Morphine and other opioids can act at multiple sites to inhibit
gastrointestinal transit. Brain sites responsible for opioid
antitransit effects were evaluated in rats and mice by i.c.v.
administration of the receptor selective agonists, DAGO, DPDPE,
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and U-50,488H. Given i.c.v., DAGO (and other mu agonists)
produced dose-related inhibition of gastrointestinal transit, but
delta and kappa agonists were inactive. However, when given i.t.
in mice, both mu and delta agonists produced antitransit effects,
but kappa agonists did not. Thus, brain mu receptors, but not
delta or kappa, receptors inhibit transit, but in the spinal cord
both mu and delta receptors inhibit transit.
Opioid peptides, because they do not readily cross biological
membranes, can be of utility in studies to determine sites of
opioid actions. Systemic (s.c.) administration of the mu opioid
peptide, PL017, produces antitransit effects in mice at doses less
than those required to induce analgesia, thus indicating a
peripheral mu opioid antitransit site. The peripheral antitransit
effects of s.c. given PLO17 are blocked by the peptidic selective
mu opioid antagonist, CTP, also given s,c. Thus, present data
obtained in mice indicate that mu opioid receptors in the brain,
spinal cord and periphery are involved in opioid antitransit
effects. Delta receptors in the spinal cord, but not brain or
periphery, inhibit transit. Kappa receptors appear not to be
linked with antitransit activity of opioids.
In most mammalian species, including man and dogs, conventional
morphine-like opioids increase contractions of intestinal circular
smooth muscle.
small intestine,
In ex vivo vascularly perfused segments of dog
morphine-like opioids given intraarterially
(i.a.) induce dose-related, naloxone-sensitive phasic contractions
of circular smooth muscle. Both mu and delta selective opioid
agonists induce contractions, with DAGO and DPDPE approximately
equipotent, but DAGO more efficacious. By contrast to the mu and
delta agonists, kappa agonists such as U-50,488H caused little or
no contractile activity in the intestinal segments. The
contractions induced by mu agonists were relatively more sensitive
to blockade by the neurotoxin, tetrodotoxin, than delta
agonist-induced contractions, thus indicating that the mu
receptors in the wall of the dog intestine are associated mainly
with neurons, whereas delta receptors may be associated mainly
with smooth muscle.
Experiments with agonist and antagonist opioid drugs that act
selectively at only one type of opioid receptor in brain, spinal
cord, or periphery, can effectively separate functional aspects of
central and peripheral opioid receptors associated with sensory
perception, behavior, or visceral regulation.
Dr. Jeffrey Vaught, Janssen Research Foundation/McNeil
Pharmaceutical, Spring House, PA, described the use of mice with
special genetic traits to explore different types of opioid
receptors. This line of research grew out of an interest in
determining whether brain delta opioid receptors are inseparably
coupled somehow with mu receptors. It had been postulated that
thermal analgesia is predominantly a mu event, and that delta
opioid receptors might serve mainly to modulate mu receptor
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between mu and delta receptors. However, ICI 174,864 has been
found to block DPDPE (delta) analgesia without blocking mu
analgesia. Moreover, mu-delta cross-tolerance was not observed at
supraspinal levels. To provide additional evidence for or against
separation of mu and delta receptors, an animal model deficient in
mu receptors was sought.
mediated analgesia. Several laboratories have found comparable
naloxone pA2 values for mu and delta agonists, therefore, naloxone
pA2 values provide, in themselves, no evidence for differences
The B6CBAW-J/A-Tajp strain of "jimpy" mouse, deficient in brain
cerebroside sulfate, possibly required for mu opioid receptor
binding, was investigated with B6CBA-AW-J littermates as controls.
The jimpy mice were found to be less responsive than controls in
tail-flick tests of analgesia to morphine and DAGO, whereas the
jimpy and control animals were equally responsive to DPLPE, a
delta agonist. Two conclusions were suggested by this study:
delta opioid receptors can mediate analgesia in the tail-flick
assay in mice, and cerebroside sulfate is not an essential
component of the delta opioid receptor.
Another strain of mouse, the CXBK/By strain, is deficient in brain
and spinal cord mu opioid receptors. As observed with jimpy mice,
the CXBK/By mice showed diminished responses to morphine and DAGO,
but full responses to DPLPE in comparison with normal progenitor
control strains of mice. In normal mice, there is no
cross-tolerance between mu and delta selective agonists in the
brain, but in the spinal cord there is cross-tolerance between
DAGO (mu) and DPLPE (delta). Significantly, CXBK/By mice respond
normally to spinally injected morphine and DPLPE. The data in
CXBK/By mice suggest (1) that supraspinal delta opioid receptors
can mediate analgesia and (2) there is a difference between brain
and spinal opioid receptors.
A third strain of mouse, the C57BL/6JbgJ beige mouse, is
hyporesponsive to morphine but responds normally to the delta
ayonist, DPLPE. The beige mice thus are deficient in mu opioid
receptors and were used in experiments to explore molecular
mechanisms responsible for the deficient mu receptor-mediated
responses. Beige mice were given the cholineryic receptor
agonist, carbachol, in their drinking water for 3 weeks.
Carbachol treatment improved responsiveness to mu agonists to
normal levels. When two groups of mice treated with carbachol for
3 weeks were treated for an additional 3 weeks with either
continued carbachol or plain water, both groups lost the
responsiveness to mu agonists that the initial treatment with
carbachol had provided. These results suggested that beige mice
do not suffer from diminished ability to synthesize brain mu
receptors, but are not able to maintain functional mu receptors
after synthesis. Further experiments revealed that removal of the
spleen caused return toward normal mu opioid sensitivity in beige
mice. Further, spleen cells removed from beige mice caused
decreased mu opioid sensitivity when administered to normal mice.
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It therefore appears that the spleen of beige mice may produce a
substance, possibly of an immunological nature, capable of
reducing mu opioid receptor function in mice. The postulated
endogenous factor thus would decrease responses of beige mice to
morphine.
Studies by Dr. Vaught and colleagues show that genetically mutant
mice can serve as valuable tools in opioid research to separate mu
and delta mediated events and to stimulate research into a
possible immunological component responsible for diminished
responses to mu opioid agonists.
Dr. James Woods, Department of Pharmacology, University of
Michigan School of Medicine, Ann Arbor, MI, described an approach
to opioid receptors using techniques of behavioral pharmacology in
rhesus monkeys. The data obtained in monkeys are generally in
agreement with data obtained in other systems. For example,
behavioral experiments in monkeys are capable of clearly
classifying complex opioid drug effects as morphine-like
(including some mixed agonists/antagonists, such as
buprenorphine), EKC-like (cyclazocine and certain other mixed
agonists/antagonists), or as "pure" antagonists (such as
naltrexone).
Dpioid receptor antagonists, such as naltrexone, -FNA, and the
more novel mu plus kappa opioid antagonist, quadazocine (WIN
44,441-3), are useful for identification of the types of opioid
receptors responsible for, or involved in, opioid drug responses
in the monkey. In addition, kappa and mu agonists can be
differentiated frequently by their respective patterns of
analgesia, discriminative effects, fluid balance, reinforcing
properties, development of tolerance, and dependence profiles.
Analgesia is reliably measured by tail-flick and morphine produces
dose-related increases in tail withdrawal latency. Kappa opioid
receptor agonists, including bremazocine, EKC, MR2033, tifluadom
and U-50,488H, are potent and efficacious analgesics in rhesus
monkeys. Kappa opioids exhibit stereoselectivity; for example,
(+) and (-) tifluadom show different activity. Selective
antagonists can tease out different types of opioid receptors.
For example, -FNA does not alter responses to EKC (kappa), but
blocks analgesic responses to morphine (mu). Quadazocine, by
contrast, can cause dose-related riyhtward shifts of responses to
kappa agonists.
The basic pharmacological concept of multiple opioid receptors and
the actions of specific receptor agonists and antagonists are of
special importance in assessing the abuse liability of opioids in
monkeys. When given an opportunity to self-administer opioids
intravenously by pressing a control lever, monkeys readily
self-administer many opioids. Many opioids can also suppress
signs of abstinence caused by withholding morphine from morphine-
dependent monkeys. Careful studies show a direct correlation
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between potency of different opioids in self-administration tests
with their relative ability to suppress abstinence from morphine.
Along the same lines, there is also a positive correlation between
the subjective discriminative stimulus properties of opioids and
potency in self-administration tests. Studies such as these,
indicate a common receptor may be involved in analgesia,
discriminative stimulus (drug cue) properties, and reinforcement.
As monkeys sometimes terminate self-administration of kappa ago-
nists, drugs acting at the kappa receptor may be somewhat aversive
in this species. Monkeys may react to subjective effects of
opioids similar to the way humans react.
Tolerance and selective dependence can occur in monkeys with kappa
agonists, such as U-50,488H. Even after essentially complete
tolerance develops to certain effects of U-50,488H, the
sensitivity to morphine with the same endpoints is unchanged,
indicating highly selective kappa opioid tolerance.
Abrupt withdrawal of U-50,488H after 3 months of chronic
administration leads to a definite abstinence syndrome
characterized by hyperactivity, scratching, grooming, yawning,
picking at fingers and toes, and other behaviors. The abstinence
syndrome is different from that associated with withdrawal from
morphine and is not as pronounced. The U-50,488H withdrawal
syndrome is precipitated by kappa antayonists, but not by mu
antagonists, therefore seems associated with the kappa opioid
receptor. The U-50,488H withdrawal syndrome is suppressed by
kappa, not by mu, agonists.
These studies in monkeys obviously are of great value in
understanding the roles of major types of opioid receptors in
behavioral responses to opioids and their possible roles in opioid
abuse.
The CPDD symposium on "Multiple Opioid Receptors" brought out
several important and interesting features of opioid action.
Perhaps the most striking is the ability to identify and classify
the major types of opioid receptors, mu, delta and kappa, in an
immense variety of preparations ranging from the biochemical level
to physiological and behavioral levels. The general agreement
concerning receptor identity in a large variety of preparations
studied in different laboratories attests to the relative
selectivity of the key opioid agonist and antagonist drugs
described in this symposium. As the natural opioid liyands are
essentially nonselective, it is important that investigators
examininy opioid receptors use the most selective liyands
available.
Evidence for the existence of multiple types of receptors has come
primarily from pharmacological studies with receptor selective
agonists and antagonists. Other evidence for distinctions between
types has come from studies of fundamental regulatory mechanisms,
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such as effects of sodium and GTP, from species differences,
differential anatomical distributions, selective tolerance,
genetic differences, from different patterns of dependence and
withdrawal, and from different subjective cues in animals. It was
evident to all attending the symposium that a great amount of
progress has occurred in the past few years of study of opioid
receptors. We also anticipate many exciting new discoveries in
the years to come.
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FAS: The Need for an Interface
L. Weiner
It is an honor for me to pay tribute to the memory of Dr. Henry
L. Rosett, just as it was an honor and privilege to be his friend
and colleague for many years. From 1974 until his untimely death
in June, 1986, Hank had a sustained and effective commitment to
the prevention of alcohol-related birth defects. Hank was a true
physician-scientist. As a clinician, he was interested in
developing treatment strategies for women who were problem drink-
ers. As a scientist, he was concerned with gaining an under-
standing of the mechanisms which underlie alcohol's actions on
fetal development. He will long be remembered for the contri-
butions he made.
Hank was a familiar figure at scientific meetings, presenting
new findings and evaluating all reports with a view to their
clinical relevance. His inquiring mind helped to forge new
understandings of the relationships between alcohol and preg-
nancy. His creativity and ability to synthesize information
stimulated new research directions. Hank's integrity and strong
sense of caring committed him to focus on the needs of problem
drinking pregnant women and their children.
Hank's education and professional experience supplemented his
personal qualities. He graduated from Columbia College of
Physicians and Surgeons and the New York Psychoanalytic Society.
He maintained a private psychiatric and psychoanalytic practice
until his death. His research skills were honed on studies of
the relationships between cognitive style and career choice.
Receipt of the Career Teacher in the Addictions Award provided
him with the opportunity to explore the then uncharted field of
alcohol and pregnancy.
Hank's greatest contribution may well have been his recognition
of the importance of communication and cooperation between
researchers, clinicians, and those who make health policy. It
is only through an interface that solutions will be found to the
complex problems of alcohol abuse in general and problem drinking
by pregnant women in particular. But, people working to resolve
alcohol problems do not function automatically as an effective
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network. People operate within the laws of human nature. Each
person brings both individual dispositions and training in dis-
tinct professional specialities. Scientific progress requires
dialogue between these multiple specialities and their unique
perspectives with the acknowledgment that each is needed to con-
tribute to successful solutions.
The study of alcohol's effects on pregnancy is no exception to
this rule. An historical review of the effects of alcohol on the
fetus, which was Hank's first paper in this field, demonstrated
the need for interdisciplinary cooperation. The paper traced the
scientific community's awareness of the problem of alcohol use
during pregnancy and cited conflicts between people with diverse
viewpoints over 250 years (Warner and Rosett 1975).
Medical concern about alcohol use during pregnancy began in
England when traditional restrictions on distillation were lifted
and the country was flooded with cheap gin. In 1726, the Royal
College of Physicians and Surgeons petitioned Parliament for
control of distilling, calling gin "a cause of weak, feeble and
distempered children" (George 1965). Numerous clinical and
experimental research reports appeared in both the British and
American medical and biological literature throughout the 19th
century. By the middle of the 19th century religious and medical
temperance efforts had become closely intertwined. Medical
writers were influenced by moral attitudes and moral leaders
called upon physiologic evidence to strengthen their arguments.
Both groups stressed the idea that the sins of intemperate fathers
could be visited on their children for several generations.
Reports continued to be published in the U.S. into the beginning
of the 20th century. When the 18th amendment was ratified and
Prohibition went into effect in 1920, a dramatic drop in medical
writing on alcohol and pregnancy occurred. Medical researchers,
like many others, believed that alcohol was now a dead issue.
With the exception of a few animal experiments, studies on
alcohol's effects on offspring virtually disappeared until 1940.
When interest in this topic was revived, scientists discounted
and ridiculed the pre-Prohibition literature: the early epidemio-
logic research had "an axe to grind" and the animal experiments
were crude and uncontrolled. Although this criticism was valid
to a degree, researchers tended to overlook valuable ideas in the
medical temperance literature because of the moralistic and unsci-
entific language.
The effects of alcohol on offspring gained renewed scientific
attention in the U.S. in 1973 when Jones and associates reported
a pattern of malformation in children of chronic alcoholic mothers
which they termed fetal alcohol syndrome (FAS) (Jones et al., 1973).
Description of the fetal alcohol syndrome was consistent with the
many clinical observations made over the past 250 years. The
detrimental effects of heavy drinking on fetal development, once
widely accepted and subsequently rejected, regained scientific
recognition. To avoid repetition of the historical cycle of
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acceptance and rejection, scientists must work together to define
the interacting metabolic, environmental and social variables.
The Medical-Scientific Conference of the National Council on
Alcoholism in April, 1975, began the dialogue with the first
national workshop on the effects of maternal drinking on child
development. Presentations included clinical reports from Seattle
and Boston and experimental studies which underscored the complex-
ity of investigating these issues in both animals and humans. To
help facilitate the exchange of ideas between the several disci-
plines conducting research in the area, the Fetal Alcohol Study
Group was organized. Members, including practicing physicians,
clinical psychologists, and experimentalists trained in basic
research, began to meet annually: today's session marks the 13th
consecutive year. Hank was responsible for formally initiating
this group and was chairman for the first eight years.
The early years saw a re-awakening of scientific interest in the
effects of alcohol on pregnancy. There was an enthusiasm about
research findings and solutions to methodologic problems that was
contagious and all inclusive. Members of the Fetal Alcohol Study
Group shared ideas and provided one another with new areas of
exploration - with Hank often facilitating the process in late
night telephone calls. Investigators with similar interests were
linked and new investigators encouraged to join the discussions.
Diagnostic criteria for FAS were recommended (Rosett 1980).
Skepticism about the existence of FAS lessened as the hardy band
of pioneer researchers disseminated their findings.
Hank integrated the literature on the effects of alcohol consump-
tion during pregnancy into a review which served as a background
to a 1977 NIAAA conference. This meeting resulted in the first
Federal 'warnings on the adverse effects of alcohol on the fetus.
His review was included in the third NIAAA Special Report to
Congress on Alcohol and Health (1978).
From this synthesis of the literature, Hank developed a more com-
plex model of the biochemical and pharmacological actions of
ethanol than had been considered. He postulated that the fetal
alcohol syndrome represents the cumulative results of multiple
effects of alcohol consumption on the maternal-placental-fetal
system throughout gestation. Alcohol in high concentrations mod-
ifies cell functions throughout the body, affecting all organ
systems. Effects on fetal development can be both direct and
indirect. Biochemical and pathophysiologic effects of ethanol
and its metabolites can alter fetal srowth and development direct-
ly. In vivo and in vitro studies indicate direct effects of both
alcohol and acetaldehvde on cell differentiation and growth.
Multiple alcohol induced alterations in maternal physiology and
in intermediate metabolism of carbohydrates, proteins and fats
can alter the environment in which the fetus develops. Retarded
growth can be caused by chronic fetal hypoxia, hypoglycemia, or
hypothermia, all of which have been experimentally produced by
alcohol. Chronic exposure to high doses of alcohol can interfere
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with the passage of amino acids across the placenta and with the
incorporation of amino acids into proteins.
Susceptibility of particular organ systems may be greatest at the
time of their most rapid cell division. During the first trimester
effects of high concentrations of alcohol on cell membrane and cell
migrations can disturb embryonic organization of tissue. Through-
out pregnancy, disturbances in the metabolism of carbohydrates,
lipids, and proteins, and synthesis of RNA and DNA can retard cell
growth and division. Large quantities of alcohol can interfere
with active transport of amino acids across the placenta reducing
availability of essential nutrients. The third trimester is the
time of the most rapid brain growth and neurophysiologic organiza-
tion. High blood alcohol concentrations during this period may
impair central nervous system growth and development and limit
future intellectual and behavioral capacities. While structural
malformations persist, delays in growth and development may be
reversible. Some effects will be avoided. This model acknowledged
the influence of mediating factors in addition to dose and gesta-
tional stage at time of exposure, such as malnutrition, other drug
use, stress and parity.
Hank will also be remembered for his pioneering clinical program
for heavily drinking pregnant women. Between 1974 and 1979, we
conducted a prospective study interviewing more than 1700 women
at the time of registration for prenatal care at Boston City
Hospital (Rosett et al., 1983b). Women who reported drinking heavily
(about 10% of the population) were offered innovative, supportive
counseling focused on abstention and integrated with routine pre-
natal care. Two-thirds of the women who were counseled stopped
drinking heavily before the third trimester. Babies born to women
who continued to drink were growth retarded and suffered an in-
creased incidence of abnormalities. Benefits were observed in
the infants of women who stopped drinking heavily.
The findings at Boston City Hospital suggested the need to motivate
primary prenatal care providers to intervene with problem drinking
(Weiner et al., 1985). We developed professional educational mater-
ials which included basic information on the pharmacology of alco-
hol and alcohol's effects on fetal development, as well as strate-
gies for obtaining a systematic drinking history and initiating
supportive counseling.
Many of Hank's original hypotheses are now routinely accepted and
have provided a foundation for later studies. The Fetal Alcohol
Education Program at Boston University School of Medicine which
Hank and I developed has achieved world-wide recognition and
replication. We publish widely, seeking a diverse and broad
audience. Alcohol and the Fetus: A Clinical Perspective, published
in 1984, provides a unique synthesis of clinical and experimental
research with a focus on clinical relevance (Rosett and Weiner
1984). Hank was most proud of the award he received from the
Research Society on Alcoholism in 1985 for his overall contribution
to the advancement of knowledge about the effects of alcohol on
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the unborn.
Hank knew that continued progress in research on prevention and
treatment of alcohol-related birth defects depends on contributions
from and collaboration of many disciplines. We have seen in recent
years a proliferation of clinical and experimental reports, leading
to a more sophisticated understanding of alcohol's effects. There
is still much to be learned in this complex area. We need more
knowledge about the mechanisms which cause adverse fetal outcome
as well as a better understanding of the pregnant woman who drinks
heavily. We must keep our minds open to the multiple factors
involved and different strategies proposed. Long term benefits
will result from open and objective evaluation.
In this tribute to Henry Rosett, I have focused on his professional
contributions. In a short space, it is not possible to fully des-
cribe a life as full of accomplishments as his. Nor is it possible
to convey what his unique and sensitive personality gave to so
many - his colleagues, his patients, his myriad friends and, most
especially, his family - his wife, Atholie, and daughters, Amy and
Jane.
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Growing Up with Fetal Alcohol
Syndrome
M. Russell
I deeply appreciate the honor of being selected as the first to
give a lecture in memory of Henry Rosett. As Lynn Weiner (this
volume) has so eloquently reminded us, Hank played a major role
in establishing the Fetal Alcohol Syndrome (FAS) Study Group and
in initiating significant clinical studies on FAS and its
prevention. We shall continue to miss him and deeply regret the
loss of a productive researcher, a stimulating critic, and a
friend.
The title of my talk, "Growing up with FAS," was chosen because
it tied together the two main themes that came to mind when I
began to think about the current state of the art. One is the
degree to which, as the subjects of our prospective studies are
growing up, we are able to begin to assess the long-term effects
of prenatal alcohol exposure in children as they are developing.
Second is the degree to which our field is growing up-that is,
our efforts to refine our research questions and methodologies.
The adequacy of our measurements and research designs is basic to
the state of the art.
Obviously, there is not sufficient time in the next half hour or
so to do justice to all the researchers who have contributed to
clinical FAS research, let alone to summarize their work. My
aim, then, is to discuss in a rather general way the areas of
consensus and divergence in the field.
FETAL ALCOHOL EFFECTS IN CHILDREN BORN TO ALCOHOLIC MOTHERS WHO
DRINK HEAVILY THROUGHOUT PREGNANCY
For some time it has been well accepted that women in the latter
stages of alcoholism who drink heavily during pregnancy give
birth to infants who are at risk for fetal alcohol syndrome,
defined as having: prenatal and postnatal growth retardation,
central nervous system deficits, and distinctive facial features
(Rosett, 1980). Many other anomalies, often affecting the
cardiovascular, skeletal, and urogenital systems, have also been
associated with FAS (Clarren and Smith, 1978; Abel, 1984).
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The label 'fetal alcohol syndrome' for the above constellation of
birth defects has been challenged on the grounds that it is not
unique to alcohol. The fetus can respond to an insult in a
limited number of ways. Accordingly, there are other teratogens
and conditions, such as phenylhydantoin (Hill, 1976) and
phenylketonuria (Lipson et al., 1981), that can produce effects
similar to the fetal alcohol syndrome if they are present at
critical periods in development. This makes it necessary to rule
out these factors and to confirm a history of maternal alcohol
abuse during pregnancy to make a definite diagnosis of FAS. At
the same time, alcohol is the most commonly used teratogen, and
the occurrence of the syndrome can lead to a diagnosis of
maternal alcoholism in unsuspected cases (Clarren, 1981).
Infants of alcoholic mothers without the full syndrome have an
excess incidence of these alcohol-related birth defects and are
characterized as having fetal alcohol effects (Rosett and Weiner,
1984). Alcoholic mothers also have a high incidence of
spontaneous abortion (Sokol, 1980).
FETAL ALCOHOL EFFECTS IN CHILDREN HORN TO NONALCOHOLIC MOTHERS
The question of how infants of non-alcoholic mothers are affected
by drinking during pregnancy is more controversial (Stein and
Kline, 1983; Zuckerman and Hingson, 1986). A number of
prospective studies of heavy drinking in representative obstetric
populations have found an increased incidence of abortions
(Harlap and Shiono, 1980; Kline et al., 1980); stillbirths
(Kaminski et al., 1981); retarded intrauterine growth (Little,
1977; Little et al., 1986a; Streissguth et al., 1981; Mills et
al ., 1984); and deficits in cognitive, behavioral, and motor-
development among infants (Ernhart et al., 1985; Coles et al.,
1985; Streissguth et al., 1983a; Richardson et al., 1986; Smith
et al., 1986a) and older children (Gusella and Fried, 1984;
Streissguth et al., 1980; 1984a; 1984b; Landesman-Dwyer, et al.,
1981; Tlucak-Morrow and Ernhart, 1987). However, these findings
have not been consistent. Some of the more recent large-scale
prospective studies have failed to find a relationship between
heavier drinking and such hallmarks of the fetal alcohol syndrome
as birthweight (Ernhart et al., 1985; Hingson et al., 1982; Day,
et al., 1987). Since consistency is critical to establishing a
causal relationship, it will be useful to examine possible
sources of these variable findings.
One source of variability undoubtedly stems from difficulties
inherent in the measurement of alcohol intake during pregnancy.
Since almost all clinical research on drinking during pregnancy
is based on self-reported measures of maternal alcohol-intake,
the reliability and validity of these measures are critical to
the interpretation of findings from studies of drinking during
pregnancy and adverse effects on the fetus.
A major factor is underestimation. Surveys indicate that self-
report data underestimate alcohol consumed in the U.S. by about
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40 to 60 percent (Midanik, 1982). There is some evidence to
indicate that women report their alcohol consumption more
reliably than men (Thompson et al., 1987). If so, this may be
because women tend to drink less than men, and infrequent and
light drinkers tend to report their alcohol consumption more
reliably than heavier drinkers (Armor et al., 1976). On the
other hand, women who do drink heavily may be more likely to
conceal their high intakes because heavy drinking is less
socially acceptable for women than for men.
A second factor influencing the accuracy of self-reports is the
time during pregnancy women are questioned. It has been reported
consistently that pregnant women tend to deny current alcohol
use, such that women asked after the fourth month of pregnancy
about their drinking in the first trimester report higher intakes
than when asked during the first trimester itself (Little et al.,
1977; Robles et al., 1986).
Women interviewed postpartum underestimate their alcohol intakes
during pregnancy. Comparison of alcohol intakes reported by
women during pregnancy and after delivery in a study at Boston
City Hospital found that lower intakes were reported after
delivery (Hingson et al., 1982). Factors which are likely to
account for the report of higher intakes during pregnancy are
better recall, concern for a healthy baby, and greater
opportunity for prenatal staff to establish rapport. After
delivery the context of the questions about behavior during
pregnancy is quite different. They have the aura of "What have
you done that might have affected your babies' health," rather
than, "How can we help you have a healthier baby." Mothers of
infants with problems may consciously or unconsciously minimize
their intakes out of guilt about having drunk during pregnancy.
Heavy drinkers may fear their babies will be taken from them if
they are candid about their alcohol consumption, and memory may
be poor or influenced by lowered intakes later in pregnancy.
A final point about the validity of self-reports has to do with
the possibility that public health messages on alcohol-related
birth defects may deter mothers from admitting heavy drinking
during pregnancy. This tendency was documented in a pilot for
the Detroit prospective study in which women inadvertently were
cautioned about fetal alcohol effects before their alcohol
intakes were determined (Nadler et al., 1987). These women
reported lower intakes than a comparable group who were
questioned about their drinking before hearing about fetal
alcohol effects. This clearly demonstrates an effect of
intervention on reporting. As ethical researchers it is
important to inform study participants of the potential danger of
drinking as early in pregnancy as possible. However, real
reductions in alcohol consumption reported later in pregnancy,
after these warnings, may be confounded by denial. Denial is
always a problem, and anything that increases the negative
aspects of drinking has the potential to make it worse.
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There is a relevant literature on attempts to increase the
validity of alcohol measures. Cahalan (1981), the dean of
measuring alcohol consumption, advises that people tend to report
higher intakes in response to lengthy, open-ended questions that
use descriptions of drinking familiar to the respondent. This is
in contrast to questions most often found on health inventories,
which he characterizes as “nasty, brutish, and short.”
Accordingly, data from health inventories, such as those used by
the Kaiser-Permanente health maintenance organization, may
underestimate actual alcohol intakes more than studies focussed
on alcohol that have implemented some of the above suggestions.
The Kaiser-Permanente data are frequently cited as providing
evidence that abortion (Harlap and Shiono, 1980) and lower
birthweight (Mills et al., 1984) are associated with having one
or two drinks a day, and the above considerations suggest that
alcohol consumption may actually be higher than reported.
Indeed, only two to three percent of the population reported
drinking an average of one or more drinks per day, indicating
that these relatively low levels include the heaviest drinkers in
the population (Mills et al., 1984).
It is a truism that the more questions you ask about alcohol
intake, the higher the intake--the amount goes up for every extra
“yes.” At least two current approaches to measurement take
advantage of this principle. Day’s study in Pittsburgh gets
quantity-frequency data, not only on the usual amount drunk, but
also for amounts more than usual and less than usual. Studies of
Sokol, et al. (1985) in Cleveland and Detroit utilize a 14-day
recall. Although I have colleagues who argue this point, some
studies assume that since alcohol consumption tends to be
underestimated, the higher the quantity reported, the more likely
it is to be valid (Midanik, 1982). To the extent that this is
so, it seems reasonable to suppose that these approaches increase
the validity of reported consumption.
Lowe (1986) recommends using a “bogus pipeline” approach to
improve validity. In his study from Birmingham, Alabama,
pregnant women who thought their self-reports of alcohol
consumption would be checked by an objective, physiologic test,
reported drinking almost twice as often as those who didn’t, 27%
compared to 14%. This technique has been implemented in the
Pittsburgh prospective study.
Ruth Little et al., (1986) have examined the usefulness of
laboratory tests in measuring alcohol and other substance use in
women postpartum. They confirm the prevailing opinion that
currently available laboratory tests for ‘alcohol consumption are
not sufficiently specific or sensitive to replace self-report
data, although they may be useful in supplementing it. For
example, a positive laboratory finding might help break down
denial in some women. However, failure to confirm self-report of
heavy drinking with laboratory tests is more likely to reflect
the lack of sensitivity of the laboratory test, rather than
overestimation of her drinking by the respondent.
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Pregnancy itself affects drinking. The effect of pregnancy on
the validity of reported alcohol consumption is confounded by its
effects on the actual intake. There is a spontaneous tendency
for women to reduce their alcohol intake when they become
pregnant (Hook, 1976; Little et al., 1976), and reductions are
also made consciously, out of concern for a healthy baby. These
tendencies are influenced by mothers' original drinking levels
and by whether or not she is alcoholic (Little and Streissguth,
1978).
Reductions in drinking during pregnancy tend to be proportional
(Little et al., 1976). That is to say, women who drank heavily
prior to pregnancy are likely to continue drinking more during
pregnancy than women who drank infrequently or lightly prior to
pregnancy, even though both may reduce their alcohol
consumptions. Alcoholic women also tend to reduce their intakes
during pregnancy, but they may increase binge drinking, (Little
and Streissguth, 1978), and studies in animal models suggest that
binge drinking during critical periods of development can be
harmful to the fetus (Sulik et al., 1981).
What about validity? Can we believe women who say they reduced
their drinking during pregnancy? The tendency for women to
reduce their alcohol intake during pregnancy was well documented
before there was any widespread report of alcohol-related birth
defects. Therefore, it is probably safe to assume that in the
majority of cases, the reductions reported are real. Women who
are highly motivated to continue drinking, pre-alcoholic or
alcoholic drinkers, who are most likely to continue drinking
heavily or binge drinking, may be unwilling to report this
behavior to health professionals who have indicated that heavy
drinking is dangerous to their babies. However, reductions have
been validated by collateral reports in the Atlanta prospective
studies, and others have noted improvements in maternal
appearances, weight gains, and blood chemistries associated with
reported reductions.
Although denial tends to reduce the sensitivity of self-reports
in identifying women who drink heavily during pregnancy, self-
report tends to be highly specific. There is little reason for
pregnant women to exaggerate their alcohol intakes, and it seems
reasonable to believe that women who report heavy drinking drank
at least as much as they say they did. Even so, for all but
intakes that approach lethal limits, there is room for
underestimation.
How does the issue of validity influence our interpretation of
the clinical research on FAS? It suggests that one must keep in
mind, not only the amount of alcohol reported, but also the
following: time during pregnancy of the-alcohol intake, time
during pregnancy the alcohol intake is reported, whether the
woman is alcoholic or has indications of problem drinking,
whether the woman has been sensitized to the relevancy of her
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drinking regarding possible harm to the fetus, and whether intake
data are gathered in a way that promotes accurate reporting.
Variability in the available studies regarding these factors
could account for some of the lack of consistency in their
findings.
The timing of measurements as they relate to critical periods
during pregnancy may also contribute to variability in study
findings. This is an issue of great importance since it
determines the efficacy of intervention at various points during
pregnancy. The first trimester is the period of organogenesis,
during which alcohol exposure produces an increased incidence of
congenital malformations, distinctive facial features, hearing
abnormalities, and abnormalities in early CNS development (Rosett
and Weiner, 1984). Growth in body size takes place, for the most
part, during the second and third trimesters, and drinking during
these periods would influence birth weight and length. The brain
is smooth at four months gestation, and rapid growth during the
latter half of pregnancy results in the development of normal
corrugations in the surface and is characterized by active
dendritic branching, synapse formation, and myelination--all
critical to later function.
The differentiation of fetal alcohol effects by period of
exposure is a very active field of research using animal models.
Clinical studies that have measured alcohol intakes in every
trimester have found, however, that in human populations, much of
the variability in drinking during pregnancy is accounted for by
drinking prior to pregnancy, or embryonic drinking. Thus, some
researchers have found drinking prior to pregnancy relates more
strongly to adverse pregnancy outcomes than drinking during
pregnancy itself (Hanson et al., 1978; Little, 1977; Wright et
al., 1983).
A major factor in accounting for these findings is the fact that
drinking patterns prior to pregnancy generally persist up until
pregnancy is recognized, from six to eight weeks after
conception, overlapping with much of the period during which
embryonic development takes place (Moron et al., 1985). In
heavier drinkers whose alcohol intake interferes with regular
menstrual periods, pregnancy recognition may be delayed even
more, prolonging this early period of exposure (Russell and
Czarnecki, 1985). Women usually come in for prenatal care toward
the end of the first trimester. Their drinking at this time
tends to be more like drinking during the second trimester. This
factor, together with women’s reluctance to report current
drinking during pregnancy, may also contribute to failure in some
studies to observe associations between first trimester drinking
and poor pregnancy outcome.
In Atlanta, Coles et et al., (1985) have been able to match women
who continued drinking throughout pregnancy with a comparable
group which stopped drinking in the second trimester. Compared
to unexposed infants, infants exposed to alcohol at any time
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during pregnancy had alterations in reflexive behavior, less
mature motor behavior, and increased activity level, as measured
by the Brazelton Neonatal Behavior Scale. In addition to effects
seen in infants exposed through the second trimester, infants
exposed throughout pregnancy were inferior in observed state
control, need for stimulation, motor tone, tremulousness, and
asymmetries in reflexive behavior.
This is consistent with what might be expected based on the
animal research; however, alcohol exposure during the third
trimester is associated with other factors that may increase the
vulnerability of the fetus to alcohol effects. Smith et al.,
(1986) found in the Atlanta population studied above that
continuing to drink throughout pregnancy was also associated with
a history of alcohol withdrawal and/or abstinence syndrome,
length of drinking history, reported tolerance to alcohol,
drinking by siblings, and drinking most often with other family
members. This suggests that drinking during the third trimester
may be symptomatic of prealcoholic problem drinking or
alcoholism.
Sokol et al., (1981) included the Michigan Alcohol Screening Test,
more popularly known as the MAST, in their Cleveland prospective
study. As expected, they found that fetal alcohol syndrome was
most strongly associated with persistent exposure of the fetus
throughout pregnancy (Sokol et al., 1986). In addition, positive
MAST scores also accounted for a significant portion of the
variability in Fetal Alcohol Syndrome. In our Buffalo data, we
measured alcohol intake prior to pregnancy using a self-
administered questionnaire and found an increased risk of
spontaneous abortion associated with heavy drinking, but no
effect on intrauterine growth or Apgar scores in the newborn,
(Russell, 1985) or physical, cognitive, or behavioral development
at age six years (Russell et al., 1987). By contrast, we do see
deficits in head circumference at birth and in cognitive
development at six that are related to maternal indications of
problem drinking.
These observations are consistent with European studies by
Majewski (Majewski, 1981) and Olegard (Olegard et al., 1979) that
indicate that the effect on the fetus of a given alcohol
consumption is greater if a woman is in the chronic stage of
alcoholism than if she is in the prodromal state. They have
hypothesized that women in the chronic stage of alcoholism may
pattern their drinking to maximize blood alcohol levels and
enhance its intoxicating effect, for example, by not eating when
they drink. Also, women in the latter stages of alcoholism may
metabolize alcohol less well, which could produce higher blood
alcohol levels and extend the period of exposure to these higher
levels. If acetaldehyde metabolism were also affected, this
could produce greater fetal injury since acetaldehyde is much
more toxic than alcohol.
It is not clear from these studies whether third trimester
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effects in humans are related solely to alcohol exposure during
this critical period of development or if maternal alcoholism
increases fetal vulnerability. To the extent that only alcoholic
or prealcoholic women continue to drink throughout pregnancy, it
may be difficult, if not impossible, to disaggregate these
effects in humans. Even in studies of alcoholic women who do and
do not drink throughout pregnancy, there could be unmeasured
differences that determine whether or not they continue to drink
and also affect fetal well-being.
OTHER FACTORS INFLUENCING THE EFFECT ON THE FETUS OF A GIVEN
ALCOHOL EXPOSURE
Maternal alcoholism is not the only factor that may influence
fetal susceptibility to alcohol exposure. Differential
vulnerability is a very "hot" area of research at the moment, and
it may account for some of the lack of consistency in our
clinical studies and help us understand why only some children of
heavy drinking alcoholics are affected.
Sokol et al., (1986) hypothesize that blacks are more vulnerable
to alcohol-related birth defects than whites and have published
data showing that infants born to heavy drinking black women are
more likely to be small for gestational age and seven times more
likely to have the full fetal alcohol syndrome than similarly
exposed infants born to whites. In their Cleveland data, they
have also found a lower threshold for alcohol-related anatomic
abnormalities among blacks, for whom incidence increases above
four or more drinks per day, compared to a threshold of six or
more drinks per day for whites (Sokol et al., 1987). Results for
craniofacial and other anomalies were similar. This may have
implications for alcohol exposure thresholds as they relate to
child development as well, since Ernhart et al., (1987) found a
relationship between facial anomalies associated with embryonic
alcohol exposure and deficits in cognitive, psychomotor, and
language development up through age three years.
Abel's (1984) reviews of FAS case reports found that women giving
birth to FAS babies tended to be older and of higher parity. He
designed animal experiments to differentiate between these two
possibilities, and concluded that pregnancies among older mothers
were at higher risk for alcohol-related birth defects (Abel and
Dintcheff, 1984; Abel and Dintcheff, 1985). More recently, a
study of alcohol use in primiparous women over age 30 reported
significantly lower scores on the Bayley Mental Development Index
and more physical anomalies associated with heavy drinking prior
to pregnancy (O'Connor et al., 1986).
Genetic differences in vulnerability to a given alcohol dose have
been demonstrated in inbred strains of mice and rats (Chernoff,
1980; Gilliam et al., 1987). Differences between dizygotic twins
in the fetal effects of alcohol exposure suggest that there are
also genetic differences in vulnerability in humans (Christoffel
and Salafsky, 1975). There have been few, if any, clinical
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studies to investigate genetic factors in FAS. However, Brien et
al., (1983) have demonstrated substantial individual differences-
in the disposition of alcohol among six healthy women, 16 to 18
weeks pregnant. These differences could play a major role in
determining the level and length of fetal exposure to alcohol and
acetaldehyde, and there is evidence to suggest that the
disposition of alcohol is at least partly under genetic control.
There is also renewed interest in the role of paternal drinking
and how it may relate to some of the outcomes that are being
examined with respect to maternal drinking during pregnancy. It
is unusual for a woman to drink more than her mate. Therefore,
fathers of children born to women who drink heavily during
pregnancy are also likely to drink heavily. Little and Sing
(1986) recently reported an association between fathers' drinking
and lowered birthweight; however, a second group was unable to
replicate this finding. Several investigators have found a
negative correlation between children's IQs and their fathers'
drinking (Gabrielli and Mednick, 1983; Werner, 1986; Ervin et
al., 1984). Although recent animal studies suggests that this
influence may be mediated via a direct effect on the sperm (Lee
et al., 1987; Moore et al., 1987; Tan, et al., 1987), it is
generally thought to be a genetic effect. In either case, it
represents an additional factor to be taken into consideration
when evaluating the effect of maternal drinking on child
development.
Clearly, there may be other factors that may affect fetal
vulnerability to alcohol exposure, but I want to save some time
to mention a few significant studies of fetal alcohol exposure
and child development that I have not already discussed.
Spohr and Steinhausen (1987) have extended their follow-up of FAS
children. Their subjects now have a mean age of eight years.
They have a fairly large sample of 54 children, including some
less severely affected cases, which they feel complements earlier
work (Darby et al., 1981). They found a general trend of
improvement in physical symptoms and psychiatric findings. IQs
stayed about the same for those below 70 or above 115, but tended
to increase between 70 and 115. However, the children still had
higher abnormality scores and a number of relevant psychiatric
symptoms showing no significant change, especially hyperactivity.
Persisting handicaps were most obvious in looking at educational
status; only six children, 17% of those school age, attended
"normal" school, and two of these attended normal schools
specializing in hearing defects and speech disorders. 51%
attended schools for the educationally subnormal, and 20%
attended a training center only. At least 4% were severely
subnormal and without any education. Severity of the morphologic
damage at the initial exam correlated with educational status,
with less severely affected children tending to be in the normal
schools.
There are fewer follow-up studies in children of nonalcoholic
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mothers; however, the Seattle Longitudinal Study is unique in
having the longest follow-up of a prospectively identified group
of children. AM Streissguth et al., (1986) reported that,
between seven and eight years of age, early prenatal alcohol
exposure was most significantly related to continuous performance
test errors of commission, reaction time, and the vigilance
errors summary score. These results are consistent with earlier
reports of alcohol-related attention deficits in this population
at one day of life and at four years, and they are also
consistent with findings from animal models. By way of contrast,
Morrow-Tlucak and Ernhart (1987) found that maternal alcohol and
marijuana use during pregnancy was associated with reductions in
activity, emotional reactivity, irritability and dependence, and
increased rigidity and unusual task absorption--counter to what
would be expected. Clearly, more studies are needed! No state-
of-the-art lecture would be complete without that phrase!
This has been a brief overview of some of the measurement issues
and research questions that influence the current state of the
art in clinical FAS research. It suggests that we should not be
lulled into a possibly false sense of complacency by surveys
which find low levels of drinking among pregnant women. While
the evidence indicates that women are reducing their alcohol
intakes early in pregnancy (Smith et al., 1986c; Fried et al.,
1984; Streissguth et al., 1983b), it is not clear that this is
true for women at highest risk. Women in the chronic stages of
alcoholism who have lost control over their drinking and are
dependent on alcohol may be less likely to spontaneously reduce
their alcohol intakes to “safe” levels during pregnancy and less
responsive to intervention efforts. Even intelligent, well-
educated women, who are very health conscious during pregnancy,
may drink heavily prior to pregnancy, and current data suggest
that this may represent a risk to fetal well-being.
The methodological issues discussed suggest that control groups
of abstinent and light, infrequent drinkers may be contaminated
by heavy drinkers who underreport their intakes. This has the
potential to make it more difficult to detect real differences
related to alcohol consumption and may make tests of significance
more conservative. Balanced against this is the tendency for
levels of alcohol consumption in the exposed group to be
underestimated. This leads the unwary to conclude that alcohol-
related birth defects are associated with lower levels of alcohol
intake than, in fact, they are. Alcohol classifications that
lump all the heaviest drinkers into a single group with a rather
low cut point may also suggest to the naive reader that defects
are associated with lower alcohol exposures than are typical of
the affected cases.
In designing studies of alcohol-related birth defects, one must
strike a balance between what is perfect and what is possible.
It is impossible to conduct the “perfect study” of alcohol-
related birth defects in humans. Such a study would require the
accurate measurement of all the factors that could potentially
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influence pregnancy outcome. Any such effort would not only be
prohibitively expensive, but also so intrusive that it could not
fail to modify some of the behaviors/exposures under study.
Finally, if potentially harmful behaviors were not spontaneously
modified, there would be an ethical imperative to intervene in
all but the most benign circumstances. Indeed, we are already
intervening to the best of our ability by cautioning the public
regarding the dangers of drinking during pregnancy.
My intention, in mentioning these limitations, is not to end this
state-of-the-art lecture on a negative note, but to put it into
perspective. Findings from studies of alcohol-related birth
defects in nonalcoholic populations are inconsistent and must be
interpreted cautiously. However, fetal alcohol effects have been
reported from a number of carefully conducted studies, and the
public health significance of these findings is such that it is
very important to continue our efforts to achieve a better
understanding of the factors that influence them. FAS
researchers have done much to refine their measures, their
analyses, and their research questions, and these efforts are
continuing.
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The Dilemma of Cocaine Exposure
in the Perinatal Period
L. Finnegan
Cocaine's pharmacological action including decrease in
uterine blood flow, increase in uterine vascular
resistance, and reduction in fetal oxygen levels
contraindicate its use in pregnancy. The
vasoconstriction, tachycardia, and increased blood
pressure found to be associated with perinatal cocaine
use increase the chance for intermittent intrauterine
hypoxia, preterm labor, precipitous labor, and
abruptio placenta. In spite of some animal data and
limited human studies, more research is essential to
further evaluate cocaine's effect upon the perinatal
period, the infant and the child. The following
summarizes these issues: 1) Maternal medical and
obstetrical complications need further delineation
with reference to nutrition, disease entities and
appropriate treatment regimens. 2) There is a need to
develop epidemiological studies in order to determine
if cocaine exposure in-utero influences formation of
congenital malformations and the incidence of Sudden
Infant Death Syndrome. 3) By clinical and ultrasound
measures, the effects of cocaine upon brain growth and
brain pathology must be evaluated. 4) The
neurobehavioral outcome of neonates exposed to cocaine
in-utero via clinical measurement scales such as
abstinence scoring and the Brazelton Neurobehavioral
Scale need more precise definition. 5) The potential
long-term developmental effects upon the infant and
child must be further delineated. 6) Psychosocial
situations with regard to parenting abilities and
child protection in cocaine abusing families must be
evaluated.
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Department of Pediatrics, Jefferson Medical College of
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Fetal Alcohol Effects: Central
Nervous System Differentiation
and Development
J. West
There is evidence indicating that in spite of considerable pub-
licity regarding the risk to the fetus from heavy maternal drink-
ing (Surgeon General, 1981; Rosett and Weiner, 1984; Little et
al., 1984), alcohol-induced birth defects (ARBD) remain a serious
problem. Mental retardation is the most devastating feature of
the fetal alcohol syndrome (FAS), and it is now known that it can
occur in the absence of other FAS features (Majewski et al. ,
1976). A recent paper by Abel and Sokol (1987) indicates that
maternal alcoholism is now the leading known cause of environ-
mentally-induced mental retardation in the Western world, sur-
passing even Down's syndrome and cerebral palsy as a cause of
CNS-related birth defects. Therefore, the study of CNS fetal
alcohol effects remains an important area on which to focus
research. This paper will review some of the relevant neuro-
morphological findings demonstrating the effects of alcohol
exposure on the developing brain.
The human literature focused on structural damage to the brain
resulting from prenatal exposure to alcohol is sketchy. Only a
few brains from fetuses and infants diagnosed as exhibiting FAS
have been examined (Clarren et al., 1978; Clarren, 1981, 1986;
Majewski et al., 1978; Peiffer et al., 1979; Wisniewski et al.,
1983). Fetal brain tissue is often damaged at delivery so that
it is inadequate for neuropathological evaluation of fetal alco-
hol effects (Clarren, 1986). Furthermore, because death in these
children was often due to severe cardiac problems, there is a
concern that these brains represent a skewed sample. Neverthe-
less, some interesting findings have been reported and they may
give us some clues as to the type and location of deficits in FAS
animal studies.
Many of the human FAS brains were smaller and some of them had
neuroglial heterotopias with viable ectopic cell clusters
(Clarren, 1986), suggesting that alcohol may not only be neurally
toxic, but may also specifically interrupt the migration of
neurons after they are generated. Other brains exhibited en-
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larged ventricles and small or nonexistent commissures,
indicating either underdeveloped commissural systems or white
matter lesions (Clarren, 1986). The exact amount of alcohol
required to produce such damage and the timing of the insult for
causing specific defects are questions that remain unanswered.
Since many women who consume large amounts of alcohol during
pregnancy also abuse other drugs, may suffer from nutritional
deficits, and may not accurately report how much alcohol they had
consumed during pregnancy, animal studies have been used to
answer important questions associated with CNS-related fetal
alcohol effects. Although data derived from some of the human FAS
autopsy material suggesting that alcohol could affect the
generation and migration of neurons have been available for
nearly a decade, it has been only during the past year that
experimental evidence has been forthcoming to support such a
hypothesis. Miller (1986, 1987) found that the "birth" of
corticospinal neurons was delayed and that they sometimes
migrated to the wrong cell layer. Interestingly, there also were
more of the cells, suggesting that the normal process of paring
down the number of neurons (normally occurring cell death) was
impaired.
Parenthetically, this latter conclusion is consistent with a
report of a significant lag in the rate at which non-myelinated
axons of the optic nerve of animals exposed to alcohol during
gestation were lost in association with the overproduction of
neurons (Samorajski, Landcaster and Wiggins, 1986). In most
brain regions during development there is a normal overproduction
of neurons followed by a loss of those cells that do not make
appropriate contacts, which appears to be a mechanism to permit
an optimal number of neurons while avoiding errors in connec-
tivity. This ability may be impaired as a consequence of fetal
alcohol exposure.
It has been hypothesized that alcohol's main effect on develop-
ment is primarily a function of interfering with cell division
(Pennington et al., 1983). However, the limited cell count data
available do not corroborate that idea very well. Cell count
studies in the hippocampus have revealed alcohol-induced deficits
in field CA1 following exposure to alcohol during days 10-21 of
gestation (Barnes and Walker, 1981), and in field CA4 following
early postnatal exposure (West et al., 1986). Interestingly, in
both cases the population of granule cells in the dentate gyrus,
which undergoes most of its neurogenesis during the first three
weeks of postnatal life (Bayer, 1980), was either unaffected or
increased. In the cerebellum, it also appears that the pop-
ulation of large Purkinje cells that were generated prior to
early postnatal alcohol exposure was more vulnerable to alcohol
than the population of granule cells which was in the process of
division at the time of the alcohol insult (Phillips and Cragg,
1982).
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One of the most common effects of alcohol exposure during devel-
opment appears to be a general delay in growth and maturation.
Restrictions in overall brain growth are quite common in response
to alcohol in both humans and animals (Samson, 1986). One of the
clinical signs of FAS is microcephaly (a small head for body
size); its corollary, microencephaly (a small brain for body
size), is an indicator of mental retardation. Microencephaly
also has often been reported as a fetal alcohol effect (FAR) in
animals, although there is evidence that it may be associated
only with alcohol exposure during the third trimester unless
accompanied by undernutrition (Samson, 1986).
Not surprisingly, neurons in these developing brains tend to be
smaller and have poorly developed processes. Pyramidal cells in
the cortex (Hammer, 1986) and hippocampus (Davies and Smith,
1981) exhibit smaller somas and stunted dendritic growth with
fewer dendritic branches and spines. Importantly, evidence of
delayed neuronal development other than simply stunted growth has
been reported. Volk (1984) demonstrated that perisomatic pro-
cesses, which normally protrude abundantly from the somas of
cerebellar Purkinje cells in eight-day-old rats, but are absent
by postnatal day 12, are still present at that time in rats that
were exposed pre- and postnatally to alcohol.
Alcohol exposure during development not only produces neurons
with stunted dendritic arbors and fewer dendritic spines, but
some of the surviving spines are aberrantly shaped (Hammer,
1986). Dendritic spines are perhaps the most dynamic and
variable element of dendritic structure. Spines were originally
thought to be a simple mechanism for increasing dendritic surface
area. More recently, it has been shown that spines are much more
involved functionally and that they can provide a means for ad-
justing synaptic potency (Rall, 1978). Long thin spines have
larger stem resistance values matched to higher input resis-
tances. Longer, thinner spines can cause greater attenuation of
incoming signals (Wilson, 1984). Therefore, in addition to
simple measures such as the number of spines present, the
diameter and length of the spine shaft are key morphological
factors in determining the consequences of alcohol exposure on
developing neurons (Hammer, 1986).
Few studies have investigated the effects of alcohol on neuronal
development at the ultrastructural level. However, the cytoplasm
of Purkinje cells in 12-day-old rats exhibits fragmented rough
endoplasmic reticulum with large quantities of free ribosomes
(Spohr and Stoltenburg-Didinger, 1985). Furthermore, photomicro-
graphs of the cerebellar molecular layer, stained with ethanolic-
phosphotungstic acid, showed a reduced number of stained synapses
(Volk, 1984). Other reports, however, indicate that synapse
formation may be delayed less by alcohol than other developmental
processes (Hoff et al., 1984; Jones and Colangelo, 1985). Con-
sidering the paucity of data available, it is not known whether
the reported difference is a function of regional vulnerability,
regimen of alcohol treatment or the ages of the animals when
examined.
It is essential to realize that when conducting studies directed
toward detecting the effects of alcohol on the developing brain,
there are key points that must be kept in mind. While it is
important to address the questions of when alcohol affects the
brain during development, it is not appropriate simply to divide
the gestation period of the species being examined into three
equal periods and expose the fetus to alcohol during one or more
of these three so-called "trimesters." In order to extrapolate
the results from animal studies to humans, it is necessary to
consider equivalent periods of brain development of the two
species. Although all mammals pass through the same stages of
brain development, the timing of those stages, relative to birth,
can be quite different (Dobbing, 1981; Dobbing and Sands, 1973,
1979). When the timing of the alcohol exposure is considered,
different effects may occur as a consequence of alcohol exposure
during different "trimesters equivalent" (West, 1987). Further-
more, there is evidence that the third trimester equivalent may
be a period when the brain is especially vulnerable to alcohol
(Phillips and Cragg, 1982; West and Hamre, 1985).
Another key question is whether there are regional differences in
susceptibility of the brain to the deleterious effects of alcohol
exposure. Although there is surprisingly little information
available on the subject, the data that are available indicate
that various regions of the brain are affected differentially by
alcohol exposure (Sulik et al., 1984; Pierce and West, 1987).
In spite of the already extensive fetal alcohol literature, we
still have many questions concerning the permanency of fetal
alcohol effects. Most of the FAS patients that were identified
in the 1970s are just now teenagers. Although it appears that
the mental retardation in these patients is persisting
(Streissguth et al., 1985), we know almost nothing about the long
term consequences of exposure to alcohol during development.
The morphological data derived from adult animals exposed to
alcohol during different stages of development are meager and
they give a conflicting message. Abel and his associates (1983)
found a decrease in the number of dendritic spines and a shift in
the type of spines on pyramidal cells in field CA1 of the hippo-
campus of adult rats treated with alcohol in utero. On the other
hand, Pentney et al. (1984) did not find alterations in dendritic
branching of cerebellar Purkinje cells. That finding is quite
remarkable considering the number of studies that have found
extensive damage to the cerebellum in younger animals that were
exposed to alcohol during development (Bauer-Moffett and Altman,
1977; Phillips and Cragg, 1982; Volk, 1984; Pierce and West,
1987).
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A thorough understanding of the relationship between the struc-
tural and functional changes associated with fetal alcohol ex-
posure will provide the foundation for understanding the mech-
anisms that produce fetal brain damage, and ultimately for pro-
viding treatment regimens for preventing or reversing fetal
alcohol effects. Such research begs our attention.
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Genetics and the Specific
Dimensions of Risk for Alcoholism
M. Schuckit
INTRODUCTION
Alcoholism is a genetically influenced disorder. Detailed reviews
published on almost an annual basis have documented the familial
pattern of this problem, the probable increased concordance among
identical twins, and the four-fold increased risk for alcoholism
in children of alcoholics, even when they were adopted out at
birth and raised without knowledge of their biological parents'
problems (Goodwin 1985; Schuckit 1985a; Schuckit 1986a). Despite
this evidence, it is important to remind ourselves that the
genetic factors are likely to be complex, and that there is at
least one twin and one adoption study that do not support the
other results (Roe and Burks 1945; Murray et al., 1983). It is
also essential to recognize that genetic influences only explain
part of the risk for alcoholism, and that environmental events
must also play a role (Peele 1986; Cadoret et al., 1987;
Beardslee et al., 1986).
The preponderance of positive results in genetic studies has
spawned further work attempting to identify what might be in-
herited to increase the alcoholism risk. Most of these investi-
gations have studied young individuals with enhanced vulnerabi-
lity for alcoholism, characterizing them before alcohol-related
life problems and associated treatments obscured any pre-existing
clinical picture. Like the genetic studies themselves, these
approaches have also been reviewed in depth in recent years, and
their liabilities as well as their assets must be kept in mind
(Schuckit 1985b; Schuckit 1985c). The high potential cost and the
probability that only 1 out of 3 sons of alcoholics will actually
develop alcoholism are balanced by the ready availability of such
populations for study and the hope that these efforts might
eventually improve prevention and treatment approaches.
The present manuscript is not a simple repetition of the recent
reviews, but places an emphasis on a limited number of topics
relevant to both studies of populations at high risk for alcohol-
ism and a discussion of psychiatric aspects of alcohol and drug
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abuse. The following sections review some aspects of the relation-
ship between alcoholism and other psychiatric illnesses and the
possible importance of alcoholic subtypes, present recent de-
velopments emanating from protocols evaluating individuals at
high risk for alcoholism, and outline a number of issues for the
future.
SOME CONCEPTUAL ISSUES
Establishing accurate diagnoses in most areas of health care
requires the use of both historical data and relevant laboratory
tests to indicate a probable prognosis and optimal treatment
(Goodwin and Guze 1984). Psychiatry, unfortunately, has few (if
any) relevant biological diagnostic tests, and thus places almost
total emphasis on the past and present clinical pictures. How-
ever, our field is handicapped by the observation that similar
behavior is often seen in the context of multiple disorders.
Thus, severe and relatively persistent psychotic symptoms re-
sembling schizophrenia are likely to be seen in the context of
ongoing abuse of stimulants, and anxiety syndromes resembling
panic disorder or generalized anxiety disorder can frequently be
observed during withdrawal from brain depressants (Schuckit
1984a; Schuckit 1983b). Such "dual diagnosis" patients raise the
question of whether two or more independent disorders are
present, or if one picture represents a symptom cluster inherent
in the other disorder. In the latter case, it is logical that
successful treatment of the primary problem could result in the
disappearance of the second symptom pattern. This is a key issue
in genetic research because the inclusion of multiple hereditary
problems in the same clinical sample can make it difficult, if
not impossible, to isolate any genetic influences for either
disorder. The philosophy used in our laboratory has been to limit
study to the individuals with the more straight-forward diag-
noses, e.g., the 70% or so of alcoholics who have no obvious
pre-existing psychiatric disorder and thus can be said to have
primary alcoholism (Schuckit 1984a; Schuckit 1986b). For at least
two psychiatric disorders this becomes a potentially important
consideration in the study of the genetics of alcoholism.
The relationship between affective disorders and alcoholism is
too complex to generate a sure answer or to produce a general
rule that is correct 100% of the time. However, it can be clin-
ically and scientifically useful to establish a heirachy where,
until proven otherwise, it is assumed that even major depressive
episodes occurring only in the context of substance abuse should
be considered secondary and are likely to disappear with time
alone (Schuckit 1986b). Similarly, patients with major depres-
sions antedating the severe alcohol problems should be considered
to have primary affective disorder, not primary alcoholism. As
discussed in a recent review, this is relevant because approxi-
mately 90% of alcoholics in treatment give a history of severe
sadness at some time in the past (a rate perhaps no higher than
other patients coming to treatment with major life problems); one
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in three alcoholic men have experienced a severe and persistent
depression fulfilling criteria for major depressive disorders at
some time in the past (but most of these were temporary and only
occurred in the context of heavy drinking); but in all likelihood
only about 5 percent of alcoholic men and perhaps 15 percent of
alcoholic women demonstrate major depressive episodes independent
of their heavy drinking (Schuckit 1986b; Schuckit and Winokur
1972; Powell et al., 1987). Thus, it is probable that the rate of
independent major depressive disorders is no higher among
alcoholics than the general population. Family studies are also
consistent with the probability that in most families alcoholism
and bipolar affective disorders are not related (Dunner et al.,
1979), and evaluations of adult children of alcoholics adopted
out close to birth have failed to document an increased rate of
major depressive disorder or mania (Schuckit et al., 1972;
Goodwin et al., 1974; Cloninger et al., 1984; Cadoret 1980). Also
supporting the probable distinction between alcoholism and
depressive disorder are follow-up studies of alcoholics that
demonstrate that those who have been diagnosed as having primary
affective disorder with secondary alcoholism appear to run a
course that is different from primary alcoholics (Schuckit and
Winokur 1972; Schuckit 1986b; Powell et al., 1987), and the
finding that the major predictor of depressive symptoms in
alcoholics, other than an independent family history of depres-
sion, is the quantity and frequency of drinking (Brown 1987).
Thus, Angst (1966) and Cloninger et al., (1983) each concluded
that alcohol and depressive disorder appear to congregate in
different families and show little evidence of genetic linkage.
As a result, it is important in genetic studies to focus only on
primary alcoholics and to consider separately men and women with
primary affective disorder antedating the secondary alcoholism.
A second conceptually important diagnosis is the antisocial
personality disorder (ASPD). A potentially confusing clinical
picture occurs when an alcoholic demonstrates periods of violence
and criminal behavior, raising the possibility of the presence of
an ASPD. Contributing to the dilemma is the observation that
perhaps 70 percent or more of men fulfilling criteria for ASPD
develop severe enough alcohol-related problems to be labelled as
secondary alcoholic during their teenage and early adulthood
years (Schuckit 1973; Vaillant 1982; Vaillant 1984). Carefully
defined ASPD also appears to be genetically influenced (Crowe
1972; Cloninger et al., 1975; Cloninger et al., 1983; Cloninger
and Reich 1981). However, while antisocial problems can be seen
among practicing alcoholics and while ASPD patients are likely to
have secondary alcoholism, there are a number of indications that
primary ASPD and primary alcoholism are two independent dis-
orders. First, there is little evidence of increased rates of
primary alcoholism in the families of men with bonafide ASPD
(Hesselbrock et al., 1985; Vaillant 1982). Second, the adoption
studies of chirdren of alcoholics do not demonstrate an increased
risk for ASPD (Cloninger et al., 1983; Goodwin et al., 1974;
Bohman 1978), and there is evidence that children of ASPD
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subjects who are adopted out demonstrate high rates of ASPD, not
primary alcoholism (Cadoret et al., 1985; Cadoret et al., 1987).
Finally, on follow-up, individuals with primary ASPD and secon-
dary alcoholism appear to have a clinical course distinct from
primary alcoholics (Schuckit 1985d; Hesselbrock et al., 1986;
Vaillant 1982). Thus, Cloninger and colleagues (1981) as well as
others, have concluded that family and adoption data indicate a
surprising degree of independence between genetic factors that
predispose to alcoholism and those that predispose to ASPD.
Similar conclusions can probably be drawn regarding the indepen-
dence of primary alcoholism and other genetically influenced
disorders, including several of the major anxiety diagnoses
outlined in DSM III (American Psychiatric Association 1980;
Schuckit 1984a). The point of this methodological review is not
to prove that alcoholism, ASPD, and depressive disorders are
definitely separate illnesses. The emphasis is on the possibility
that in most families they are independent genetic disorders,
although symptoms observed in one illness are also likely to be
seen in the others. Because of this possibility and as a re-
flection of the rather primitive tools available for studying
genetic factors in alcoholism, it makes sense to limit most
genetic investigations to relatives of alcoholics who developed
their alcohol-related symptom complex before the onset of any
other major psychiatric disorder: (i.e., primary alcoholics).
An additional factor that needs to be considered in developing
studies of populations at high risk is that there are probably
subtypes among alcoholics with different patterns of interactions
between genetic and environmental influences. One such possible
subgrouping has been presented by Cloninger and colleagues
(Cloninger et al., 1984; Cloninger 1987). They outline an early
onset male predominant type with high levels of genetic in-
fluences, a severe clinical course and relatively weak sensiti-
vity to environment, as well as a second type with a compli-
mentary pattern of characteristics. It is also possible that
there are other subtypes differentiated by gender, patterns of
brain waves, responses to alcohol, and so on (Pollock 1986). More
data will be required however, before these potential groupings
can be optimally used.
The data presented in the next sections must be considered in
light of all of the methodological issues discussed above.
Indeed, considering the difficulties inherent in using a history
to accurately diagnose the alcoholic parent, the possible hetero-
geneity within samples regarding the presence of multiple psychi-
atric disorders within the families, and the almost certain
existence of alcoholic subtypes, it is impressive that the
studies of populations at high risk for alcoholism have produced
such consistent results.
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AN UPDATE OF STUDIES OF POPULATIONS AT HIGH ALCOHOLISM RISK
Reviews of investigations of children of alcoholics published up
to 1986 have highlighted several potentially important findings
associated with a family history of alcoholism. The following
comments are organized around the major findings; first, giving a
summary of prior results, then expanding with information pre-
sented over the last two years.
Our laboratory first documented a decreased intensity of reaction
to three to five drinks of ethanol in sons of alcoholics in 1976.
a finding which was corroborated by additional studies in the
United States and Scandinavia (Schuckit 1985a; O'Malley and
Maisto 1985; Mednick 1982). This decreased intensity of subjec-
tive feelings after drinking has recently been replicated among
sons of alcoholics, and a trend in the same direction has also
been observed in a study of a small sample of daughters (Erwin
1987; Lex and Mendelson 1987; Pollock et al., 1986). The findings
regarding subjective feelings were bolstered by the original
reports of a decreased amount of change in body sway or static
ataxia following drinking in our own and other laboratories
(Schuckit 1985e; O'Malley and Maisto 1985), and these in turn
have recently been corroborated among newer samples of both male
and female children of alcoholic fathers (Lex and Mendelson 1987;
Erwin 1977). In an effort to measure reactions to alcohol in more
biological systems, earlier studies in our laboratory had docu-
mented lower intensities of change for prolactin and cortisol
following drinking in FHPs (Schuckit et al., 1983; Schuckit
1984b), findings which have been replicated more recently in a
more demanding three session research paradigm (Schuckit et al.,
in press a; Schuckit et al., in press b). Thus, research present-
ed over the last year continues to support a decreased intensity
of reaction to alcohol in children of alcoholics as measured by
subjective feelings, a motor performance test, and changes in
hormones sensitive to ethanol. It is hypothesized that a de-
creased sensitivity to lower doses of alcohol might make it more
difficult for some individuals at high risk for alcoholism to
train themselves to stop drinking during an evening before they
become too intoxicated to modify their behavior.
A second series of studies published prior to 1986 documented
electrophysiological differences between FHPs and FHNs, including
a decreased amplitude of the P3 wave of event-related potentials
(ERPs) in alcoholics and in their sons (Begleiter et al., 1984).
Additional recent studies from the same laboratory (Begleiter
1987) and work using a similar research paradigm with college men
have corroborated these results (Tasman et al., 1986; O'Connor
1985), although Polich and colleagues have failed to replicate a
decreased amplitude of P3's among sons of alcoholics using either
an auditory or a visual ERP approach (Polich and Bloom in press;
Polich et al., in press). A second neurophysiological measure has
involved the documentation in FHPs of a decreased amount of alpha
power on background cortical electroencephalograms (EEGs) or a
significantly enhanced increase in this wave following low doses
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of ethanol (Volavka et al., 1982; Pollock et al., 1983). Recent
findings consistent with these results have been generated in
those same laboratories (Pollock 1986), as well as through a
collaboration between our group and Cindy Ehlers in a pilot study
with 7 FHP/FHN pairs.
In a third area of research, sons of alcoholics have been report-
ed to demonstrate higher levels of impairment on neurocognitive
testing when compared to controls in studies generate both in
the United States and Denmark (Schaeffer et al., 1984; Knop et
al., 1985; Tarter et al. , 1984). While one recent investigation
corroborated the earlier findings in 8 to 12 year old sons of
alcoholics (Noble et al., 1986), two large scale studies were
unable to document any consistent cognitive deficiency in student
and employed groups of men in their late teens to early 20's
(Workman-Daniels and Hesselbrock 1987; Schuckit et al., in press
c). Thus, the question of the importance of neurocognitive
differences between FHPs and FHNs is still unanswered.
A fourth area of research highlighted in reviews in 1985 is based
on the observation that the personality profile of alcoholics may
be unique, at least in the first months following detoxification.
However, retrospective evaluation of personality test scores
measured before the alcoholism developed did not reveal unusual
characteristics (Kammeier et al., 1973; Vaillant 1983; Vaillant
1984), and tests of men at high risk for alcoholism had revealed
no significant differences from FHNs on anxiety, locus of con-
trol, the Eysenck Personalit Inventory, the rod and frame test,
nor on subtests of the MMPI (Saunders and Schuckit 1981; Schuckit
1982; Schuckit 1983 a; Tarter et al., 1986; Schuckit and Penn
1985). More recent leads on personality variables include the
possible importance of a scale from the MMPI modified specifical-
ly for adolescents, and an additional scale evaluating novelty-
seeking, harm avoidance and reward-dependence (Cloninger 1987;
MacAndrew 1986; DeWit et al., 1987). The current studies however,
have found no evidence that FHPs have an increased tendency
toward sensation seeking or type A personalities, and tend to
question the importance of any major personality variable
(Beardslee et al., 1986; Manning 1986). Similar to neurocognitive
results, more work will be required before the role of person-
ality profiles in the alcoholism risk can be understood.
Several additional laboratories have recently evaluated other
possible markers. Regarding the intensity of reaction to alcohol,
Erwin and colleagues have raised the question of a possible
greater drop in beta-endorphin in the plasma following alcohol in
sons of alcoholics (Erwin 1987), while Linnoila and colleagues
have reported differences between sons of alcoholics and controls
in their thyroid stimulating hormone (TSH) response to thyrotro-
pin releasing hormone (TRH) infusions (George et al., 1986;
Linnoila 1985). An additional recent electrophysiological measure
of relevance is Linnoila's observation of less change in saccadic
eye movement after a benzodiazepine for sons of alcoholics
(Linnoila 1985), as well as the documentation by Newlin and
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Aldrich (1986) of differences between 9 FHP and 9 FNH men on the
autonomic response observed in their second ethanol challenge and
on the intensity of reaction to placebo.
An additional current development centers on the simultaneous
evaluation of multiple attributes of FHPs and FHNs. Until recent-
ly, most studies have focused on only one type of finding at a
time, rarely including a large enough sample to evaluate inter-
actions between subjective feelings, cognitive test performance
and hormonal changes. Our laboratory has just completed a series
of baseline and post-challenge evaluations following placebo,
0.75 ml/kg of ethanol, and 1.1 ml/kg of ethanol in 30 sons of
alcoholics and 30 controls (60 men) (Schuckit and Gold, in press).
Using a discriminant function analysis, four items (the maximum
terrible subjective feelings after high dose, cortisol values at
two time points after high dose, and a prolactin result after low
dose) combined to correctly identify 83% of the controls and 70%
of the sons of alcoholics. This included approximately 40% of
each group whose discriminant scores were +1 or -1 and who were
considered to be solid classifications. These results were
relatively robust on a jackknife validation procedure. A search
for clusters of factors of test scores after ethanol using a
principal components analysis was also consistent with the
discriminant analysis. The PCA indicated the possibility of three
overlapping domains of the ethanol response including subjective
feelings after the high dose ethanol challenge (explaining 46% of
the variance); hormonal changes after low dose ethanol as well as
body sway items (14 percent of the variance); and prolactin
changes after low dose ethanol (9% of the variance).
SOME CONCLUSIONS
Impressive progress has been made in the last decade regarding
our knowledge of genetic factors relevant to alcoholism. Studies
have progressed from questioning whether alcoholism is genetical-
ly influenced to attempting to increase our understanding of
biological and genetically mediated factors that might contribute
to the alcoholism risk. Recognizing that a number of recent
reviews have throughly discussed the importance of genetic
factors and have presented a number of methodological issues
relevant to studying populations at high risk for this disorder,
this paper has focussed on several additional methodological
questions and reviewed some very recent results.
Reflecting our lack of sophisticated measures of genetic influ-
ences and difficulties in accurately diagnosing alcoholics, it is
important to keep studies of populations at high risk as narrowly
focused as possible. Thus, while there is crossover in symptomato-
logy between alcoholism, depressive disorders, and antisocial
personality disorder, most studies have centered on children of
carefully defined primary alcoholics. Evaluations of such indi-
viduals from preteen years to early adulthood have documented
numerous leads for potential FHP/FHN differences that might
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relate to the alcoholism risk, although no specific, sensitive,
and reliable marker (e.g., a protein) has yet been identified.
The most important and consistent leads include a decreased
intensity of reaction to alcohol (a behavioral observation), a
decreased amplitude of the P3 brain wave of the event-related
potential, and a decreased amount of alpha power or a greater
increase in the amount of this wave after ethanol for sons of
alcoholics. Additional investigations are beginning to evaluate
the generalizability of the major findings, and an effort is
being made to simultaneously evaluate multiple aspects of
baseline and post-ethanol responses.
A number of additional steps are required to allow for optimal
progress. First, it is hoped that the various laboratories
evaluating populations at high risk for alcoholism will begin to
standardize their definitions and methods for dealing with the
relationship between alcoholism and other genetically influenced
disorders. Second, it is hoped that laboratories can begin to
standardize the baseline and post-beverage challenge procedures
so that greater understanding of the variability and generaliz-
ability of test results will ensue. Finally, recognizing the
great expense involved in identifying, testing, and following
populations at high risk, it is hoped that major funding agencies
will be able to generate additional long-term commitments to
these studies.
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Progress in Understanding the
Conditioning Aspects of Drug
Dependence
C. O’Brien, A. Childress, A. McLellan,
R. Ehrman and J. Ternes
INTRODUCTION
The puzzle of addiction has confounded clinicians and researchers for
decades. Many theories have been invoked to explain the initiation of drug
use and the continuation of drug use, but the problem of relapse has
remained difficult to explain. Why is it that after months or even years of
abstinence, a former addict may again lose control and resume drug use
when exposed to certain situations? Is there some retained susceptibility to
addiction in a drug-free former addict who feels physically well and
expresses strong commitment to refrain from future use?
One of the first theorists to address this question was Abraham Wikler
(1948). At the Addiction Research Center in Lexington, Kentucky, in the
1940’s he began to consider the possibility that relapse in recovering
addicts might be influenced by classically conditioned responses. Wikler
was aware of work by Pavlov and colleagues (1927) demonstrating that
repeated injections of morphine could produce a form of learning in dogs.
Subsequently the mere sight of the investigator preparing to give the
injection could produce a response in the animal which resembled
morphine effects (e.g. salivation, vomiting and sedation).
Wikler suggested that some of the behaviors observed in addicts might also
be examples of Pavlovian conditioning. He observed that during group
therapy sessions, the discussion would often turn to the details of drug
procurement and usage. During such times when the topic of drugs was
being discussed, the drug-free recovering addicts showed yawning and
tearing as though they might be going through mild withdrawal.
A similar behavior which Wikler noted was the report of withdrawal
symptoms in drug-free recovering addicts upon their return home. Typically
the former addict felt well just after leaving the hospital, however, on
returning to his home neighborhood, symptoms similar to withdrawal
sickness began to occur. Sometimes there would be actual nausea and
vomiting as well as the strong urge to inject heroin during this period just
after leaving the hospital. The recovering addict would often give in to this
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craving and quickly become re-addicted.
These clinical observations led Wikler to begin a series of laboratory
studies with animals confirming that withdrawal symptoms could be
classically conditioned (Wikler and Pescor, 1967). He showed that a
distinctive environment repeatedly paired with morphine withdrawal in rats
could eventually acquire the ability to evoke signs of withdrawal after the
rats were healthy and drug-free. This work was confirmed by other
investigators over the years in other species and analogous results were
obtained using other drugs including alcohol, stimulants and haloperidol.
This literature has been extensively reviewed (e.g. Grabowski and O’Brien
1981).
On the basis of his clinical observations and animal studies, Wikler
postulated that repeated drug self-administration produces a new disease
suis generis (of its own kind). This new disease consists of the
conditioned responses produced by pairing the effects of drugs (or
withdrawal) with environmental or internal stimuli. In recent years our group
has attempted to test and expand this hypothesis using an experimental
approach in several different clinical populations.
CATEGORIES OF CONDITIONED RESPONSES
Studies in human subjects show that both drug-like and drug-opposite
responses can be produced in human subjects as conditioned responses
(CR’s) depending on the circumstances (For reviews, see O’Brien et al. ,
1986; O’Brien et al., 1987). We have attempted to classify these responses
according to the proposed mechanism of their origin and the conditions
under which they can be demonstrated.
Drug-opposite CR’s
a. Conditioned withdrawal
b. Conditioned tolerance
Drug-like CR’s
a. Conditioned euphoria (“Needle-Freak” phenomena)
b. ? Placebo effects
DRUG-OPPOSITE CONDITIONED RESPONSES
Drug-opposite conditioned responses are those responses which are
elicited by previously neutral stimuli (CS’s) following a series of pairings
with a drug (Unconditioned Stimulus, US), but which are opposite to the
responses produced by the drug itself. For example, opiate injections
produce elevations in skin temperature, but stimuli which have preceded
opiate injections will reliably produce reductions in skin temperature.
There are many other examples of “drug-opposite” CR’s which can be
measured by polygraphic measurement of physiological changes, ratings
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by patients of subjective changes or observer ratings of patient behavior.
Conditioned withdrawal was the first type of conditioning considered by
Wikler and it still is the phenomenon most closely associated with his name.
Actually, Wikler studied other types of conditioning phenomena and he did
not view dependence as simply avoidance of withdrawal. The presumed
mechanism for the development of conditioned withdrawal is shown in
Figure 1. Since some withdrawal symptoms may occur at least once per
day in most opioid addicts, there may be thousands of pairings of
environmental stimuli with these withdrawal symptoms during the
FIGURE 1
Conditioned Withdrawal (Dependent Subject)
Unconditioned Stimulus ------>
Opioid metabolized
Receptors evacuated
Unconditioned Response
Rebound activity; adrenergic,
cholinergic, etc. (tearing,
rhinorrhea, tachycardia, nausea,
diarrhea, etc.) Drug-opposite effects
Conditioning Stimulus ----->
Drug -procuring or -using
environment: sights, sounds,
smells, situations, fantasies
Conditioned Response
mild version of above symptoms,
drug-opposite effects
life of a patient before he seeks treatment. We have shown that after as few
as seven pairings of mild withdrawal symptoms and a novel conditioning
stimulus (CS), humans begin to show signs of withdrawal (Conditioned
Response) when exposed to the CS alone (O’Brien et al 1977). These
CR’s have been found to be long-lasting (Goldberg and Schuster 1970)
and they have been found to occur when the subject is exposed to the CS
long after detoxification from drugs. This mechanism could, therefore,
explain the stories reported by Wikler (1965) and others (O’Brien 1975)
concerning onset of withdrawal symptoms when a drug-free patient returns
to an area where withdrawal symptoms had occurred in the past.
Conditioned tolerance is a term applied to another mechanism whereby
drug-opposite responses might be conditioned. Siegel, in a series of
experiments utilizing morphine, alcohol and insulin (see Siegel 1978, 1979,
1987), presented evidence that drug tolerance could be considered, at
least in part, to be a classically-conditioned phenomenon. As shown in
Figure 2, the drug disturbs homeostatic equilibrium resulting in a reflex
response against the drug as the organism attempts to regain equilibrium.
This reflex response (Unconditioned Response) tends to reduce the effects
of the drug. The environmental cues (sights, smells, situations) repeatedly
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associated with drug procurement or injection provide a signal (CS) which,
after some repetition, can by themselves trigger homeostatic responses
(tolerance) which are opposite to drug effects. The conditioning of tolerance
was termed “counter-adaptation” by Wikler (1953, p. 44).
FIGURE 2
Conditioned Tolerance (Dependent or Non-Dependent Subject)
Unconditioned Stimulus -----> Unconditioned Response
Drug injection, Drug effects, Homeostatic response counter to
Disturbances in homeostasis drug effect so as to return to status
produced by the drug before the drug (TOLERANCE)
Conditioning Stimulus ----->
Sights, sounds, smells which
signal that drug is about to appear
Conditioned Response
Homeostatic responses counter to
drug effects which in the absence
of drug can be perceived as
WITHDRAWAL or ?CRAVlNG
These conditioned drug-opposite or tolerance responses can occur in a
drug user who has never been dependent on drugs, but has only used
intermittently. Also, repeated episodes of withdrawal sickness in a specific
environment would not be necessary for the development of drug-opposite
responses according to this theoretical mechanism. However, the CR is
physiologically similar to a withdrawal response and therefore the
symptoms may be perceived as “withdrawal-like.” Those drug users who
have had repeated episodes of withdrawal in a specific environment will
thus have two mechanisms for producing conditioned withdrawal-like
symptoms: the first by the “conditioned withdrawal” paradigm described in
Figure 1 and the second by the “conditioned tolerance” mechanism
described in Figure 2.
DRUG-LIKE CONDITIONED RESPONSES
Pavlov’s original report (1927) of morphine conditioning described a CR
which resembled the unconditioned effects of morphine itself. Similar
findings of “drug-like” conditioning have been reported by others in dogs
(Collins & Tatum 1925; Lynch et al.,1976; Rush et al., 1970) and in rats
(Eikelboom & Stewart, 1979; Miksic et al., 1975; Numan et al., 1975).
Drug-like effects are found clinically in patients known as “needle freaks”
(Levine 1974). Typically these are individuals who may formerly have
been physically dependent on opioids, but are currently using drugs
intermittently or using low potency drug supplies. These “needle freaks”
report euphoria from the act of self-injection and they have also been
observed to show physiological signs such as pupillary constriction after
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injecting saline (O’Brien 1975). A similar finding was reported by Myer
and Mirin’s (1979). Some of these “needle freaks” have been detected
among applicants applying for methadone treatment. Federal regulations
limit the use of methadone maintenance (except in certain special cases)
to individuals who are physically dependent on opioids. If there are no
signs of withdrawal in an applicant, the opioid antagonist naloxone may be
given as a diagnostic test for the presence of dependence (Blachly 1973).
Even a very small dose of naloxone will precipitate withdrawal symptoms
in a person physically dependent on opioids. Occasionally we have
observed the naloxone injection to produce mild euphoria instead of
withdrawal in applicants for methadone who claim to be addicts and who
show the scars of chronic drug injections. Subsequently we observed
sedation and reports of euphoria when these subjects self-injected saline;
thus the euphoria observed after naloxone was not a pharmacological
effect of naloxone but likely a conditioned response to the injection
procedure which served as a conditioned stimulus (O’Brien 1975).
There have been few direct observations using physiological and
psychological monitoring of human addicts in the act of self-injecting
addicting drugs. Our group reported a series of such studies (O’Brien
1975; O’Brien et al., 1974; O’Brien et al., 1980) that described self-injections
in detoxified opioid addicts being treated with the opioid antagonists
cyclazocine or naltrexone. Several experimental protocols were used with
these antagonists which block the pharmacological effects of opioids. In
one series of experiments, the patients were randomly assigned to
self-injections with either saline or opioid; in others the patients were
tested with both saline and opioid on different occasions. These
experiments began with “credibility” trials in which the subject was allowed
to self-inject opioid or saline (double-blind, unblocked) prior to beginning
antagonist maintenance. Subsequently we conducted “extinction trials” in
which the subject repeatedly self-injected opioid or saline while being
maintained on the opioid antagonist for up to 6 months. The findings were
that saline self-injections were usually reported as pleasurable and
identified as a low dose of opioid. This reaction to saline was assumed to
be a drug-like conditioned response. The effect was greatest when the
subjects injected themselves under naturalistic conditions resembling the
patient’s “shooting gallery” with the patient expecting to get “high.” The
drug-like effect was diminished but still present when the patient was
placed alone in a more artificial setting, such as a recording chamber,
with various electrodes and strain gauges attached.
We found that these drug-like effects in most patients were not long-lasting
when compared to the drug-opposite effects described above. After
several un-reinforced trials consisting of either saline injections or opioid
injections in patients pre-treated with a narcotic antagonist, the drug-like
effects disappeared. The drug-opposite effects persisted in these patients,
however.
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Meyer and Mirin (1979) used a different design and also observed
conditioned opioid-like autonomic effects in human subjects. Their
subjects were all recently detoxified inpatients who were given either
naltrexone or naltrexone placebo under double-blind conditions. The
subjects were then permitted to self-inject known amounts of heroin that
they had earned by performing a simple operant task. The subjects who
received naltrexone placebo in effect had the opportunity to inject ”free”
heroin unimpeded by naltrexone, and they injected it nearly the maximum
number of times permitted by the protocol. However, the 22 subjects who
received naltrexone had the rewarding effects of heroin blocked by this
antagonist. Eleven of these subjects stopped injecting heroin after fewer
than five trials, but the other 11 subjects took an average of 16 doses of
heroin despite the presence of naltrexone. These 11 subjects were found
to be different from those who stopped quickly in that they showed distinct
autonomic changes resembling opioid effects after the first three
presumably blocked injections. The authors interpreted these autonomic
changes (pupil, heart rate, and blood pressure) as conditioned opioid-like
effects and they found that these autonomic changes had disappeared
(extinguished) by the time the subjects decided to stop injecting. Unlike
the outpatient studies described above, the Meyer and Mirin protocol did
not require the subjects to continue to inject unless they wished to do so.
Since they did not continue injecting past the point at which the patient’s
response to the procedure changed from positive to neutral, this probably
explains why unpleasant or withdrawal-like symptoms were not reported.
Thus, the evidence for conditioned opioid-like effects in humans is based
on clinical anecdotes and the self-injection studies described above.
These CR’s are elicited by the complex CS of pre-injection rituals and the
act of self-injection. In most subjects the opioid-like CR is extinguished
quickly and then withdrawal-like CRs are elicited by the same CSs that
previously produced opioid-like effects.
CLINICAL RELEVANCE OF CONDITIONING PHENOMENA
Now that there is laboratory evidence that opioid drugs can produce
conditioned responses in humans as well as animals, it is proper to ask
whether there is any clinical relevance to these phenomena. We
developed a set of standard drug-related stimuli consisting of video tapes
and paraphernalia associated with the procurement and injection of
opioids. When we presented these drug-related stimuli to patients while
measuring their behavioral, subjective and physiological responses
(Childress et al 1986) the most common responses were increases in
feelings of drug “craving” with or without evidence of conditioned
withdrawal. Reports of drug-like effects were less common. Presumably,
the patients would have reacted even more strongly to stimuli from their
own environment as contrasted to the standard set.
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Additional research in this area indicates that these conditioned responses
are long-lasting and remain robust even after the completion of 30 days of
drug-free addiction treatment (Childress et al 1987). In these studies,
formerly dependent opiate addicts were tested with our standard stimuli
following completion of a 30-day therapeutic community treatment
program. Thirty-six per-cent of these patients showed pronounced
drug-opposite changes in their physiological responses (usually skin
temperature and skin resistance) and 90 % reported subjective increases
in feelings of withdrawal and craving. The majority of these patients were
surprised and upset by their responses. Several suggested that “...it’s as
though I was never in treatment...”
While the majority of work in this laboratory has focussed on opioid
addiction, we have recently completed a similar series of studies with
cocaine-dependent subjects, showing very similar results. In our
laboratory, sets of cocaine-related video tapes, audio tapes and
paraphernalia reliably elicit physiological arousal and strong subjective
reports of craving and withdrawal. Again, these responses were seen in
patients even after 30 days of therapeutic community treatment (Childress
et al 1987, in preparation). These findings support Wikler’s original
concept of a “new disease,” suis generis and suggest that treatments
which focus exclusively on the physiological aspect of addiction and
ignore the learned or conditioned aspects may not be providing adequate
care.
Wikler’s description of conditioned abstinence or withdrawal caused
clinicians to begin looking for such phenomena in their patients. Relapse
occurs in the vast majority of detoxified patients and when asked about
reasons for relapse, most patients report very little insight into their own
behavior. The first drug use after a detoxification usually appears to be an
impulsive act. The impulsivity can be so marked that the individual often
really does not know why he performed a given action. When questioned
about the reasons for a particular drug administration, the typical response
is, “I wanted to get high.” Addicts usually do not talk spontaneously about
relieving withdrawal or discomfort. However, tolerance tends to diminish
drug pharmacological effects and street drugs are notoriously low in purity;
therefore, the injection of opioids often simply relieves withdrawal and
does not produce the desired euphoria.
McAuliffe (1982) interviewed 40 street heroin addicts in an attempt to
assess the role of conditioned withdrawal in relapse. All of these subjects
had experienced a period of abstinence on the street. While 27.5%
reported being aware of conditioned withdrawal, only two (5%) gave this
as a reason for resuming drug use. The author concluded that
conditionied withdrawal was unlikely to be a major cause of relapse. Of
course, it is difficult to extrapolate self-report data from active street addicts
and apply them to the problem of relapse after treatment.
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Our group also conducted interview studies with former addicts trying to
remain drug-free and found varied reasons for relapse. A third to a half of
the subjects were able to identify places or situations that made them feel
unexplainably ill, anxious, or in need of a fix (Childress et al 1986c;
O’Brien, 1975). Of particular interest was that certain moods (e.g.,
depression or anger) were found to trigger drug craving or sickness
(Childress et al 1987). In these reports, negative feelings, affects, or even
withdrawal sickness (sniffing, tearing) were commonly mentioned, but
euphoria was rarely experienced as a possible conditioned effect. Our
patients were able to recall situations or places where they began to feel a
desire (craving) or need for an injection, but they rarely reported the
opposite feelings, that is, situations that made them feel euphoric in the
absence of a drug.
Surveys which rely on patients’ memories of past experiences are subject
to many sources of potential error. In order to improve our source of
information, we conducted an eight week prospective study which
involved weekly structured interviews concerning situations which
provoked desires to use drugs. Seventeen methadone patients have
been studied in this manner and interviews of abstinent, former opioid
abusers are now in progress. The structured interviews enabled us to
obtain a clearer picture of the occurrence of drug-related responses over
time. Sixteen of the seventeen methadone patients (94%) reported
episodes of drug craving in real-life situations (e.g. sight of a drug-using
friend) which occurred during the period of study. Sixteen of seventeen
patients (94%) also experienced episodes of withdrawal-like feelings.
Though patients often attributed these withdrawal-like episodes to physical
discomfort or “methadone-dose- -not-holding,” some of these episodes
may have been conditioned in origin: their occurrence was unrelated to
the time since the last dose of methadone. Spontaneous high-like feelings
were less commonly reported, but 76% of the methadone patients reported
at least one such episode (Childress et al 1986a).
Among the abstinent patients who have been followed for eight weeks, all
(8 of 8 thus far) have reported episodes of opioid craving, averaging 11
episodes per patient over the eight week period. In contrast to the
frequency of craving episodes, reports of withdrawal and high-like
episodes were relatively rare (totalling 3 and 2 episodes respectively).
These results are still being analyzed and are being used to develop a
database on the sequence of events in relapse. We are in the process of
collecting the same type of “natural incidence” data from abstinent cocaine
abusers as they proceed through outpatient follow-up. Our longitudinal
work in this area thus far, indicates that the concurrent collection of data
from outpatients is feasible. By this longitudinal method, we hope to obtain
a clearer and perhaps more valid picture of the role of conditioning in
relapse to drug dependence.
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POSSIBLE INTERVENTIONS BASED ON CONDITIONING
The most important benefit of a theory of drug dependence is the potential
practical value. Does the theory lead to a new form of prevention or
treatment for this enormous public health problem? Relapse to drug abuse
is such a complex problem that changing a single factor may not
significantly influence the outcome. We have attempted to reduce or
eliminate the conditioned responses found in drug abusers by a process
called extinction. This involves repeatedly showing the patient the
drug-related stimuli which produce symptoms, usually craving or
withdrawal symptoms. Our first attempt at extinction involved having the
drug-free recovering heroin addict perform un-reinforced self-injections
(either saline or opioid blocked by antagonist) (O’Brien et al 1979). This
procedure was impractical because it produced such severe conditioned
responses. We now expose the patient to drug-related stimuli in a more
gradual way beginning with stimuli remote from the act of drug
administration. We also combine the extinction with a comprehensive
rehabilitation program which involves attention to psychiatric disorders,
family problems, employment problems-- in short, attention to conditioned
responses becomes just one more aspect in a multi-modality approach to
treatment.
Using this multi-modal approach, recent work (Childress et al 1986, 1987)
shows that in both former cocaine-dependent and former opioid-
dependent patients, the extinction procedure produces a marked
diminution of the conditioned responses over 15 to 30 sessions. There is
also a significant improvement in the majority of cases, but few remain
drug-free. Several important questions remain:
a. ls the extinction procedure truly effective in reducing conditioned
responses? We see decreases in the patient’s responses while in the
laboratory, but is there any generalization to the patients “real world?”
Perhaps we need more personalized stimuli for extinction; perhaps we
must deal with the difficult problem of going into the patients environment
and continuing the extinction where relapse is most likely to be
precipitated.
b. Even if we are able to successfully extinguish the conditioned
responses, will this have any effect on relapse? All of the conditions which
caused the patient to use drugs the first time are probably still present after
treatment. Obviously some relapses have nothing to do with conditioning.
Only prospective studies with random assignment and adequate sample
size will show whether there is a subset of patients who want to avoid
resumption of drug use and whose chances will be improved by
eliminating the conditioning factor.
c. Are conditioned responses simply epiphenomena which occur in
association with drug use, but have no role in determining resumption of
drug use? Clearly this is a logical possibility which can be addressed by
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appropriate controlled studies of treatment outcome.
Finally, one must consider the problem of reinstatement of conditioned
responses. If during the drug-free period, the patient “slips” for any reason
and uses drugs again, the conditioning responses are likely to be rapidly
reinstated. Thus a long and difficult period of extinction could be quickly
neutralized. These thoughts are sobering, but realistic. We have
progressed a great deal in understanding what conditioned responses are
likey to occur under which conditions. This understanding of conditioning
is interwoven in many of the current approaches to the prevention of
relapse in all types of substance abusers. But we still lack evidence that
either conditioning factors or any other element of modern treatment
programs are actually effective in preventing relapse.
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Psychiatric Diagnoses and
Substance Abuse in the General
Population: The ECA Data
J. Helzer
The ECA Survey
The Epidemiologic Catchment Area (ECA) survey (Regier et
al., 1984) is a multicenter study of the population
prevalence and incidence of psychiatric disorder and
associated health utilization in the United States. During
the course of this investigation, approximately 20,000
persons were personally interviewed to obtain baseline
information on the lifetime and recent occurrence of
psychiatric symptoms and disorders. The baseline
examination was then followed by at least one telephone
interview several months later and at least one follow-up
personal interview one year later, to ascertain more recent
use of services, and new occurrences of illness in order to
estimate annual incidence of psychiatric disorder.
In addition to information about the prevalence and
incidence of psychiatric illness, the ECA also ascertained
data on associated risk factors, treatment seeking, barriers
to treatment, and other issues related to psychiatric
impairment. Furthermore, the survey will provide baseline
samples which can be followed over time in order to help
fill our tremendous gaps in knowledge about the natural
history of mental illness and substance abuse in the general
population.
The ECA is neither a random sample of the entire United
States, samples were drawn from 5 cities only, nor does the
Diagnostic Interview Schedule (DIS) (Robins et al., 1981),
the interview instrument used, cover the entire range of
DSM-III disorders (American Psychiatric Association 1980).
But the major disorders are covered and the data presented
in this report have been combined from the five ECA sites
and weighted to match the age/sex/race distribution of the
total U.S. population.
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For the interpretation of the findings reported here, it is
important to understand that the DIS is based on lifetime
rather than cross-sectional ascertainment of symptoms and
illnesses. The interview ascertains whether each symptom in
a particular diagnostic set has ever occurred and the ages
of first and most recent symptoms, representing ages of
onset and recency, respectively. For some disorders, like
the affective disorders, the diagnosis is based on the
occurrence of a simultaneous cluster of symptoms, because
that's what DSM-III specifies. But for others, like the
substance abuse disorders, there is no clustering
requirement. Thus the minimum of two alcohol symptoms
specified by the DSM-III may be separated by a period of
several years and there is no guarantee there was ever a
cluster of symptoms or alcohol problems occurring
together.
Prevalence Findings
Table 1 shows the lifetime prevalence estimates for the
major psychiatric disorders as ascertained in the ECA survey
(Eaton and Kessler 1985). We have collapsed individual
diagnoses (specific drugs of abuse, for example) into single
categories (i.e., drug abuse and/or dependence). Since the
disorders are presented here nonhierarchically, a given
individual may fall into more than one category.
TABLE 1. Lifetime prevalence of major DSM-III disorders in
five cities (ECA 5-site data, weighted to the U.S.
population) (Unweighted N = 19,357)
Disorder Lifetime Prevalence
Alcohol abuse and/or dependence
Phobic disorder
Drug abuse and/or dependence
Major depression
Antisocial personality
Obsessive compulsive disorder
Dysthymia
Panic disorder
Cognitive dysfunction
Schizophrenia
Mania
Somatization disorder
Anorexia
13.7
12.6
5.9
5.1
2.5
2.5
1.5
1.5
1.1
1.0
0.4
0.1
0.1
lifetime occurrence of symptoms, the diagnosis here may be
closer to what some might consider alcohol problems rather
According to these findings, alcohol abuse and/or dependence
(also for convenience called alcoholism) is the most
prevalent of the psychiatric disorders we examined. It is
important to recognize that since the data are based on
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than alcoholism. DSM-III requires one or more alcohol
related problems in each of two symptom categories for the
diagnosis of abuse. For alcohol dependence, the requirement
is a minimum of one alcohol problem and evidence of
tolerance to alcohol or withdrawal symptoms.
Examining the rest of the table, the substance use disorders
are seen to figure very prominently; drug abuse and/or
dependence is the third most prevalent disorder. Only
phobic disorder rivals alcoholism in terms of prevalence,
and drug abuse/dependence is slightly more prevalent than
major depression. Antisocial personality disorder, another
diagnosis that will figure prominently in this report, is
about half the lifetime prevalence of major depression.
Data in Table 1 are aggregated across the five ECA sites
and, as mentioned above, the sample has been adjusted to the
age/sex/race distribution of the U.S. population as of the
1980 census. Figure 1 shows that drinking patterns are not
uniform across the five sites. The first category shown in
Figure 1 is those who have never taken a drink of alcohol,
i.e. lifelong, total abstention. Social drinkers are those
who deny total abstention and also deny either a period of
heavy alcohol consumption and or any of the alcohol-related
problems we asked about. Heavy drinkers also deny lifetime
problems but report consumption of seven or more drinks at
least one evening a week for a period of several weeks or
more at some time in their lives. Problem drinkers report
one or more lifetime drinking problems, but fail to meet the
full criteria for abuse or dependence. Heavy and problem
drinkers are aggregated in the figure. The final category
is those who do meet the full DSM-III criteria for
alcoholism.
In terms of heavy/problem drinking and alcoholism rates, the
sites fall into two groups: St. Louis, Baltimore, and Los
Angeles, where the rates are relatively high, and Durham and
New Haven, where they are relatively lower. Apart from this
similarity, the drinking patterns at the latter two sites
are very different. New Haven has the lowest rate of
abstinence, and the highest rate of social drinking. For
Durham, a more rural region lying in the Bible Belt, the
opposite is the case.
Comorbidity
Next we examine the comorbidity of alcoholism with other
psychiatric disorders, including the abuse of other
substances. Thirty four percent of the total ECA sample met
lifetime criteria for at least one of the diagnoses shown in
Table 1. Of those 34%, about an equal proportion (32%) had
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a second core diagnosis. As we saw above, about 13% of the
total sample had a diagnosis of alcohol abuse or dependence,
but the odds of having a second diagnosis in this group is
almost half (47%). Thus alcoholics are very much more
likely than the total ill sample to have met criteria for at
least one other psychiatric disorder. Figure 2 shows that a
good bit of this comorbidity is accounted for by drug abuse
and dependence, including both canabinoids and harder
drugs. Among those with no diagnosis of alcohol abuse or
dependence, 3.5% have a lifetime history of any illicit drug
use sufficient to get a diagnosis of drug abuse or
dependence, and most of this reported drug use is marijuana
or some other canabinoid (Figure 2). Among those with an
alcohol diagnosis, the lifetime prevalence of drug abuse or
dependence is much greater and half of this drug abuse is of
harder drugs, compared to a much smaller proportion of hard
drug use in the nonalcoholics.
Figure 2 can be contrasted with Table 2, the latter showing
the lifetime history of alcohol abuse or dependence among
those abusing drugs. Recall (from Table 1) that the
population rate of alcoholism is over 13%. As shown in
Table 2, this lifetime prevalence is only 11% among those
who have never abused drugs. This rate is considerably
higher (36%) in those who have a history of marijuana abuse
but no other drugs. Among those who have abused or been
dependent on harder drugs, the lifetime prevalence of
alcoholism is over half (55%).
TABLE 2. The association of alcohol and drug abuse or
dependence (5-site ECA data weighted to U.S.
population)
Group
Lifetime Prevalence
of Alcoholism
(%)
Total sample 13.7
Respondents with lifetime
history of:
No drugs 11
THC only 36
Sedatives, hypnotics, or opiates 55
Although this association is striking, comorbidity with
alcoholism is not confined to other substances of abuse, as
is illustrated in Figure 3. This shows the weighted
lifetime prevalence of the major, nonalcohol diagnoses in
the total ECA population, by sex, on the left side of the
graph. On the right side, these same lifetime prevalences
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are shown for respondents with alcohol abuse and/or
dependence. First it can be seen that the prevalence rates
rise for both sexes for every diagnosis.
There are some other noteworthy findings as well. First,
for none of the diagnoses is the change in prevalence from
the total to the alcohol sample trivial. Major depression
is not greatly increased in alcoholic men compared to all
men, but the prevalence does almost double (3% to 5%).
Among women this prevalence almost trebles (7% to 19%).
These differences are even greater for other diagnoses. For
example, antisocial personality disorder is almost 4 times
greater than the population rate among alcoholic men, and
almost 10 times greater in alcoholic women.
Another noteworthy finding in Figure 3 is that while some
disorders are male predominant in the total population, all
are female predominant in the alcoholic population. Even
the male:female ratio for drug abuse/dependence, which is
1.4/1 in the general population, is 1/1.6 among
alcoholics. Since it is so much more deviant for women to
be alcoholic than for men, it is not surprising that the
association of alcoholism with other diagnoses is stronger
in women.
Conclusion
This has been a brief examination of the comorbidity between
alcohol abuse/dependence and other substance and
nonsubstance psychiatric diagnoses. Other aspects of these
associations in the ECA data have also been examined in a
recent article in the periodical literature (Helzer and
Przybeck in press), and the interested reader is referred
there for more detail. It is clear, however, from this
brief report that alcoholism is associated with all of the
other major psychiatric disorders, even in a general
population sample in which one might expect less
comorbidity. The strongest associations were with
antisocial personality disorder and, not surprisingly, other
substances of abuse. There was a weaker association between
alcoholism and depression, which, in fact, tends to be
contrary to reports from clinical samples (Hesselbrock et
al., 1985).
in samples.
However, this is probably due to the difference
It is logical to assume that one of the factors
which might motivate alcoholics to seek treatment would be
the occurrence of major depression. If that is the case,
the comorbidity between these two would indeed appear
greater in subjects drawn from a treatment setting compared
to a population sample unselected for treatment seeking.
Furthermore, as we showed in Figure 3, the association
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between alcoholism and major depression is a good bit
stronger for women than it is for men.
These results have important implications for the
recognition and the treatment of alcoholism. First, it seems
clear that clinicians are underattentive to the existence of
alcohol problems. In our own review of over 1200 inpatient
and outpatient records, we frequently found records in which
an occasional symptom was mentioned, but no evidence of a
systematic review of alcohol problems could be found (Helzer
et al., 1985). Others have provided evidence that
alcoholism is underrecognized in clinical settings (Coulehan
et al., 1987). By increasing the likelihood that alcoholics
will come to treatment, comorbidity with other disorders
increases our opportunities to detect alcoholism and thus to
offer appropriate care to those who might not otherwise be
receiving it. On the other hand, the potential opportunity
for increased recognition that comorbidity provides might be
lost if attention is focused exclusively on the comorbid
diagnosis, or if the overlapping of two disorders produces a
confusing clinical picture. This argues strongly for
further attention to physician education, both in terms of
increasing the provider's alertness to the possibility of
alcoholism in the context of other illness and of accurate
recognition when such "double diagnosis" occurs (Moen and
Batey 1986).
There are also important implications of the findings here
for the appropriate treatment of alcoholism. The high
degree of comorbidity between alcoholism and other disorders
in the community argues for increased research attention to
the natural history and the treatment of comorbid
disorders. Research on the natural history of alcoholism
per se in the general population is badly needed (Polich and
Kaelber 1985). But if, as the findings here suggest, half
of the alcoholics in the general community have a second
psychiatric diagnosis, our research agenda for this most
prevalent of psychiatric disorders is even further behind
than we suspected.
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LIFETIME DRINKING PATTERNS
BY-ECA SITE
(Data Weighted to Si te)
ASSOCIATION OF DRUG ABUSE
WITH ALCOHOLISM
Combined 5—Site ECA Data
(Weighted to U.S. Population)
PREVALENCE OF KEY DIAGNOSES
RESPONDENTS WITH ALCOHOL ABUSE/DEPENDENCE
COMPARED TO TOTAL ECA POPULATION
C o m b i n e d  5 — S i t e  E C A  D a t a  ( W t d .  t o  U . S . )
The Symptomatic and Prognostic
Implications of Psychiatric Diag-
noses in Treated Substance Abusers
T. Kosten
INTRODUCTION
Despite theoretical propositions and empirical findings
suggesting that psychopathology is common in opiate addicts,
treatment has traditionally focused on social rehabilitation and
control of substance abuse, while placing little emphasis on
treatment of psychiatric disorders. This lack of focus on
psychopathology has been addressed in more recent studies, and
the importance of systematic, categorical psychiatric diagnosis
has been underlined by recent developments in biological
psychiatry. Advances in psychiatric genetics and
psychopharmacology have tenatively suggested specific treatments
and biological abnormalities associated with the major
psychiatric disorders. Particularly for affective disorders
pharmacotherapy has been demonstrated to have specific efficacy
with lithium treatment for bipolar disorders and with tricyclics
and other antidepressants for unipolar depressions. Detecting
these treatable conditions within clinical populations is clearly
important, and this detection might rely on an initial screening
using symptom scales followed by the more resource intensive
application of categorical diagnoses to selected patients.
This paper will focus on depression, because it is the most
prevalent disorder among addicts, but the paper will also address
antisocial personality disorder and more general psychopathology.
The treatment implications of three questions will be addressed.
First, what are the rates of major psychiatric disorders in
substance abusers, particularly alcoholics, opiate addicts and
cocaine abusers? Second, what is the course of depression among
substance abusers? Third, what are the prognostic implications
of psychiatric comorbidity? To address this question substance
abusers with and without comorbid diagnoses such as depression
will be compared using several follow-up studies in which
substance abusers were first diagnostically assessed on entrance
to treatment and then reevaluated six months, one year and 2.5
years later. While treatment outcome in substance abusers has
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most commonly focused on two relatively limited definitions of
success - retention in treatment or remaining drug-free, this
paper will use a multi-dimensional approach. This approach
includes medical, psychological, employment, legal, family and
social problems as important and relatively independent outcome
measures that may not necessarily improve with sustained
abstinence or program participation or which may improve without
abstinence or program retention.
WHAT ARE THE RATES OF PSYCHIATRIC DISORDERS IN SUBSTANCE ABUSERS?
The most common disorders among substance abusers are depression,
antisocial personality disorder and concurrent abuse of a
secondary drug (e.g. alcohol for opiate addicts). Among
alcoholics secondary drug abuse has the highest rate (43%),
followed by antisocial personality (41%) and major depression
(38%). Phobias are also common (27%). Having any lifetime
disorder is quite common at 77%. Among opiate addicts major
depression is most common (54%), followed by alcoholism (35%) and
antisocial personality (26.5%). Phobias are less common (16%),
and having any lifetime disorder (87%) is even higher than among
alcoholics. Among cocaine abusers major and minor depressions
are the most common disorders (about 30%), but the next most
common disorder is bipolar disorder (10-20%). Concurrent
alcoholism is commonly encountered clinically, but antisocial
personality has been relatively uncommon in studies over the last
few years. Thus, depressive disorders, which are amenable to a
number of treatment approaches appear to be quite common among
substance abusers.
WHAT IS THE COURSE OF DEPRESSION AMONG SUBSTANCE ABUSERS?
Recent drug use may have an effect on the presentation of a
substance abuser in a current depressive episode. Opiate abusers
with more severe drug abuse are more likely to be depressed.
Opiate addicts first entering treatment are more likely to be
depressed than those on methadone maintenance (29% vs 20%). At
higher methadone doses depression is more likely, particularly
comparing under 30 mg to over 60 mg daily. For these two patient
groups the rates of depression were 8% and 39%, respectively.
Concurrent alcoholism also increases the risk of depression in
opiate addicts from 22% to 34%.
Major depression appears to clear up during long term follow-up.
During a 2.5 year follow-up of opiate addicts, only 5.4% were
depressed at both the initial and follow-up evaluations, and
20.5% had recovered. New cases of depression had occurred in 7%
of the patients, but 67% were not depressed at either evaluation.
About half of these 67% had been depressed some time in the past,
while not being in a current episode of depression at either
evaluation. Thus, as indicated earlier the lifetime rate of
depression was 54% overall among these patients.
417
WHAT ARE THE PROGNOSTIC IMPLICATIONS OF PSYCHIATRIC COMORBIDITY?
In examining outcome this paper takes a multidimensional approach
rather than focusing on the more traditional unidimensional
outcomes of drug abstinence and treatment retention. Among the
various supports for a multidimensional approach, the most
graphic indication of the relative independence of outcome areas
is the intercorrelation among an array of outcomes. In a six
month follow-up of opiate addicts only five of 21 possible
intercorrelations among 7 outcomes were significant, and the
largest amount of shared variance was only 25%. The outcomes
included weeks of treatment, weeks of illicit opiate use, weeks
of alcohol use, number of arrests, weeks worked, social
adjustment and psychological symptoms. The intercorrelated areas
were between social and psychological adjustment, and the drug
abuse and treatment retention outcomes were unrelated to these
psychosocial outcomes. Similarly, at a 2.5 year follow-up, the
shared variance among outcomes was generally quite low with the
most significant intercorrelations between psychological and
social problems which were also associated with medical problems.
Drug abuse was only associated with legal problems and no other
outcome. Thus, a multidimensional approach to outcome seems
justified.
The prognostic significance of comorbid psychiatric disorders
appears to vary for the different disorders. Among opiate
addicts, major depression at intake predicted more severe
occupational, drug use and psychological problems at a 6 month
follow-up, while antisocial personality disorder predicted more
severe legal problems. Diagnosis at entrance to treatment also
predicted more severe problems at a 2.5 year follow-up. For
major depression, current functioning and psychosocial adjustment
during the 2.5 years were worse than for non-depressed patients.
For anxiety disorders, current functioning was also worse than
for non-anxious patients. For antisocial personality,
psychosocial adjustment was worse, but interestingly legal
problems were not worse than for non-antisocial patients. For
opiate abusers with concurrent alcoholism, no differences in
outcome were found compared to the non-alcoholics. No
differences were found in substance use and medical disability
outcomes among abusers with psychiatric comorbidity. Using the
psychological problems scale of the Addiction Severity Index as a
measure, general psychopathology can also be shown to predict
worse long term outcome among opiate addicts. On all five
outcome measures from our 2.5 year follow-up - current
functioning, psychosocial adjustment, substance use, legal
problems and medical disability - those patients with medium to
high severity of psychological problems at intake had worse
outcomes at follow-up than the low severity patients. The
highest severity patients did particularly poorly in current
functioning, psychosocial adjustment and substance use suggesting
some relationship between continued drug abuse and impairment in
other areas, a unidimensional view of outcome.
418
Depressive disorders may also predict subsequent abstinence or
relapse to drug abuse. In our 2.5 year follow-up, we examined
recent life events as precipitants of relapse to drug abuse in
opiate addicts who either dropped out or remained in treatment.
We found that former addicts who remained in treatment were more
likely to remain abstinent (43% vs 58%), while those who were
depressed at intake or who reported recent life events within 6
months of the follow-up evaluation were less likely to be
abstinent (39% vs 50% for depression) (35% vs 54% for recent life
events). Exit events, such as a divorce or death of a family
member, were particularly associated with less abstinence (39% vs
64%). These three factors - treatment, recent life events and
depression - also had an additive effect on abstinence or
relapse. Patients who had no exit events, were not depressed at
intake and remained in treatment had the highest rate of
abstinence (75%), while patients who experienced exit events,
were depressed at intake and had dropped out of treatment had
three times lower rate of abstinence (24%). For every
combination of treatment status and exit events (except the no
treatment patients without exits), the depressed were less likely
than the non-depressed patients to be abstinent. Thus, the long
term prognostic significance of depressive disorders for relapse
to drug abuse may be related to a patient's ability to cope with
life stresses, particularly losses.
Among alcoholics, psychopathology was associated with more severe
psychosocial problems and alcohol dependence. Patients with
primary major depressive disorders had more impaired control,
psychological problems and alcohol dependence than those without
these disorders at a 6 month follow-up. Patients with antisocial
personality disorder also had more impaired control and social
problems than those without this disorder. Alcoholic patients
with concurrent drug abuse had more impaired control, social and
psychological problems than "pure" alcoholics. At a one year
follow-up, similar results were obtained for depressed men who
more frequently had pathological patterns of alcohol use, social
impairment, withdrawal symptoms from alcohol, physical conditions
due to alcohol, more intense drinking, and more psychopathology
on the MMPI than those without depression. However, in most of
these areas major depression showed the opposite prognostic
pattern for women alcoholics. Only on the MMPI measure of
psychopathology did depressed men and women both have higher
levels than non-depressives; otherwise, at follow-up depression
in women appeared to be associated with fewer problems in these
alcohol related areas. Similarly, the men with antisocial
personality had more alcohol related problems and MMPI
psychopathology than the non-antisocial men, but the antisocial
women appeared to have fewer problems than the non-antisocial
women in every area except MMPI assessed psychopathology. These
findings for women alcoholics are quite different from the
majority of studies, but most research samples have been
dominated by the more common male substance abusers. Using a
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more global assessment of psychopathology for one year outcome,
differences are still evident between men and women alcoholics,
but in general the direction of the associations are more
consistent with other studies. For women in particular, more
severe psychiatric severity at intake was correlated with more
severe alcohol and psychosocial problems including pathological
pattern of use (r=0.27), social impairment (r=0.26), withdrawal
symptoms (r=0.25), poorer social adjustment (r=0.30), total
drinking days (r=0.22), intensity of drinking (r=0.32), MMPI
psychopathology (r=0.64) and the Cornell Medical Index (r=0.34).
WHAT ARE THE IMPLICATIONS FOR TREATMENT PROGRAMS?
Since comorbid psychiatric disorders appear to have prognostic
significance, it is important to detect these disorders in
substance abusers and provide appropriate treatment. A two step
process may be useful for this purpose. Step 1 is to screen
patients for these disorders, since the resources needed for a
full diagnostic evaluation are not available for every patient in
most community programs. A reasonable screening battery might
include the Addiction Severity Index and Beck Depression
Inventory and for programs that do not specialize in alcohol
treatment, the Michigan Alcoholism Screening Test (MAST). These
tests are very useful, because they are either self reports or
can be administered by non-professional staff with relatively
little training. Step 2 is to establish diagnoses in patients
who are identified as being psychologically impaired on the
screening instruments. These instruments such as the Diagnostic
Interview Schedule (DIS), Schedule for Affective Disorders and
Schizophrenia (SADS), and Structured Clinical Interview for
DSM-III-R are much more labor intensive and usually require
extensively trained personnel or professionals for proper
administration. Their importance lies in their identifying
specific disorders for which pharmacological and
psychotherapeutic interventions have been developed. Review of
these interventions is beyond the purpose of this paper, but
particularly for depressive disorders a number of interventions
now have demonstrated efficacy among substance abusers and should
be applied in order to improve treatment outcome.
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Behavioral Concomitants of Ethanol
and Drug Reinforcement
S. Lukas and J. Mendelson
Both ethyl alcohol and marihuana are two of the oldest used and abused
substances, yet the neural mechanisms underlying intoxication and resultant
reinforcing properties of these drugs are unknown. In fact, the abuse of ethanol
is quite paradoxical since relaxation and pleasurable effects after moderate
consumption rapidly changes to dysphoria and anxiety as drinking progresses.
The chronic ethanol abuser is also plagued by bouts with anxiety, depression (cf.
Mendelson, 1964, Mello, 1972; Nathan et al., 1970) as well as a deterioration of
vital organ function. Similarly, the first few experiences with marihuana may
evoke anxiety which is perhaps due to delta-9-tetrahydrocannibinol ( 9-THC)-
induced tachycardia.
The present study measured a number of behavioral, electrophysiological and
endocrine events immediately after exposure to various doses of ethanol or
marihuana in an attempt to determine which measures co-vary with the
pleasurable components of the drug effect.
METHODS
Subjects: Adult male and female volunteers between the ages of 21 and 35 years
were recruited via newspaper advertisements and provided informed consent for
participation in this study. Subjects were examined by a specialist in internal
medicine and only those with normal physical examinations, medical and mental
health histories and blood hemogram and chemistry studies were admitted to the
study. Urine specimens were screened for psychoactive drugs and all results
were negative. No subject had a history of drug or ethanol abuse, but all subjects
described themselves as social drinkers who, on the average, consumed the
equivalent of 3 beers per week.
Experimental Design and Setting: Effects of two doses of ethanol or marihuana
were compared with placebo in a group design (n=6 per group) under randomized
double-blind conditions. The studies were conducted within the context of a
multidisciplinary program designed to assess EEG, physiologic, endocrine and
behavioral responses following acute ethanol or marihuana administration.
Results obtained using the instrumental device were previously validated and
compared with verbal reports of subjective mood states (Lukas et al., 1986a,c,d).
Subjects were told that they could receive either “placebo, a low dose of alcohol
(about 1 shot) or a high dose of alcohol (about 3 shots).” Six subjects received
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placebo (350 ml of concentrated grapefruit juice plus 3 ml of ethanol “primer” as
described below), six subjects received 0.347 g/kg of ethanol (1.1 ml/kg of 80
proof vodka in 350 ml of fruit juice) and six subjects received 0.695 g/kg of
ethanol (2.2 ml/kg of 80 proof vodka in 350 ml of fruit juice). Similar
instructions were given to subjects in the marihuana study. All cigarettes weighed
about 950 mg. Placebo, low-dose, and high-dose marihuana cigarettes contained
0.004%, 1.26% and 2.53% 9-THC, respectively.
All studies were conducted in an electrically shielded, sound- and light-attenuated
double-walled chamber (IAC, Bronx, NY). The chamber was equipped with a
wired intercom and a one-way glass window for maintaining auditory and visual
contact with the subjects. Subjects sat in a comfortable reclining chair and were
instructed to relax and keep their eyes closed, but to remain awake.
Electrophysiologic Recording Procedures: Electroencephalographic and
physiologic activity were recorded on a Model 78D polygraph (Grass Instrument
Co., Quincy, MA). Scalp EEG electrodes (C3, C4, P3 and P4) were referenced
to linked earlobes and were applied using the International 10-20 System (Jasper,
1958). Temporalis muscle electrodes were used to record muscle tension, a
Grass TC-1 thermocouple electrode was attached to the subject’s nostril via a
plastic clip to record respiratory rate and a Grass PTTL-F photoelectric transducer
was attached to a finger to record the subject’s pulse. The EEG activity was also
recorded on FM magnetic tape for off-line power spectral analysis using a
Pathfinder Signal Averaging Microprocessor (Nicolet Instrument Co., Madison,
WI). A digital time-code was also recorded on one channel of the magnetic tape
to facilitate identification of specific epochs of EEG activity during off-line
computerized power spectral analysis.
Blood Sampling Procedures: Blood samples for analysis of integrative plasma
ethanol concentrations were withdrawn continuously during the entire study. A
183 cm Kowarski-Cormed Thromboresistant Blood Withdrawal Butterfly Needle
and Tubing Set (Conned Inc., Medina, NY) was used for blood sampling. The
extra long length was necessary so that blood could be drawn from outside the
chamber without disturbing the subject. The tubing was attached to a 10 ml
syringe mounted on a withdrawal syringe pump (Harvard Apparatus, Cambridge,
MA) and adjusted to withdraw blood at a rate of 1 ml/min; syringes were changed
every 5 min. Plasma samples were immediately prepared and frozen for
subsequent ethanol concentration analysis by the spectrophotometric method of
Leric et al. (1970); 9-THC levels were measured using a radioimmunoassay kit.
Behavioral Measures of Subjective Mood States: A custom-designed
manipulandum resembling a joystick device was placed next to the subject’s left
hand (Lukas et al. 1986a,c). Movement of the joystick produced a corresponding
deflection of a polygraph pen while pushing the button located on the top of the
joystick activated an event pen on the polygraph. A second button located below
the first activated a second event pen for indicating dysphoria. The joystick could
be moved either forward, backward, or to one side and was spring-loaded so that
it returned to the center position once it was released. Less than 1 Newton of
force was required to move the joystick to one of the three different positions.
All subjects were read the following instructions regarding the definition of
ethanol-related effects: “You may use any of the following terms to describe
alcohol effects or intoxication: giddy, light-headed, buzz-on, high, drunk, or
euphoria.” Subjects were then instructed to operate the joystick as follows:
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Forward--“when you feel intoxicated or under the influence of alcohol”; Side--
“when you feel that these effects are getting stronger”; Backward--“when the
alcohol effects disappear”; Button--“when you experience a feeling of intense
well-being or euphoria.” Self-reports of intoxication were obtained from the
subjects with both an instrumental response and a questionnaire. A previous
study comparing instrumental and verbal responses reported that dose-related
ethanol-induced changes in mood states were detected using an instrumental
response but not with the self-rating questionnaire (Lukas et al., 1986a).
Consequently, only data obtained with the instrumental device are presented here.
Ethanol Administration: Placebo and drug solutions were placed in an inverted IV
bottle and attached to a Masterflex peristaltic pump (Cole Partner Co., Chicago,
IL). Tubing from the pump entered through the wall of the experimental
chamber. A disposable mouthpiece was attached to the end of the tubing and was
supported by a flexible metal arm located near the subject’s mouth. For all three
treatments (two doses of ethanol and placebo) a 10 ml reservoir located between
the pump and the subject’s mouthpiece was filled with 3 ml of vodka (i.e.,
“primer”) and 7 ml of juice to provide a strong initial taste of ethanol. This
procedure for disguising the solution’s taste has proven useful as an effective
ethanol placebo control. The small amount of ethanol in the placebo solution does
not produce any measurable plasma ethanol levels (Mendelson et al., 1984; Lukas
et al., 1986a,c).
Marihuana Administration: Placebo and marihuana cigarettes were affixed to a
custom-designed trap bottle located outside of the experimental chamber. A
flexible plastic tube was attached to the vented side of the bottle and was passed
through the chamber wall A standard cigarette-holder mouthpiece was attached to
the distal end of the tubing and was supported by a flexible metal arm so that the
subject was free to leave one hand on the joystick device while smoking. The
smoke was cooled and filtered by routing it through cold water contained within
the trap bottle. In addition, a vacuum transducer was attached to the plastic tubing
which was connected to an event pen to provide a direct record of individual puffs
on the polygraph. Specific instructions for smoking the cigarette were recorded
on magnetic tape and played for the subject as follows: “inhale” for 3 sec, “hold”
your breath for 5 sec and then “exhale”. This sequence was repeated every 30 sec
until 10 mm of the cigarette remained unsmoked. All subjects finished smoking
within 10 - 13 mm.
Procedure: Baseline EEG, physiologic and behavioral data were recorded during
the first 30 min of the study. During this control period subjects were asked to
move the joystick and press the button while the EEG was observed for
movement-related artifacts. The EEG during these responses was analyzed as
described below. After the 30 min baseline period, the subject was instructed to
place either the drinking or smoking tube mouthpiece comfortably into his mouth
and the peristaltic pump was activated to deliver 350 ml of solution over a 15 min
time period (ethanol) or the cigarette was lit. Continuous measures of EEG,
physiologic and behavioral responses and blood samples were obtained for the
next 2 hours.
Data Analysis: Pulse rate, muscle tension and respiratory rate were measured
each mm during the first 60 min after drinking or smoking and at 5-min intervals
for the subsequent 60 mm. Movements of the joystick indicating drug detection
and episodes of euphoria were directly recorded on the polygraph. Discrete, 2
min artifact-free epochs of EEG activity were selected every 15 min for power
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spectral analysis using Frequency Analysis Software developed by Nicolet
Instrument Co. The process digitized the analog waves at a rate of 256 Hz,
performed a Fast Fourier Transformation on the sample and then generated a
compressed spectral array representing EEG power as a function of frequency.
The corresponding power (µV2/Hz) and peak frequency (Hz) in the 0.25-4 Hz, 4-
8 Hz, 8-13 Hz and 13-30 Hz bands were quantified and printed for 20 sec
epoches of EEG activity.
In addition, topographic mapping of brain electrical activity was conducted in six
female subjects after placebo and 0.7 g/kg ethanol. EEG activity from 25 scalp
electrodes were processed using Brain Electrical Activity Mapping (BEAMTM)
technology (Duffy et al., 1979). Details of the recording, artifact rejections, and
display procedures are available from the authors.
Statistical analysis was performed on an Apple IIe microcomputer using software
developed by Human Systems Dynamics (Northridge, CA). Analysis of variance
with repeated measures followed by Dunnett’s significant difference text, linear
regression, and correlation and covariance tests were utilized as necessary. Tests
for parallelism were conducted using the method of Tallarida and Murray (1981).
RESULTS
Subjective reports of intoxication, as indicated by joystick responding, were
evident after both ethanol and marihuana administration. Subjects clearly
discriminated between simple detection of ethanol or marihuana effects (joystick
position) and a qualitative measure of intense pleasure or euphoria (button
pressing). Subjects typically detected drug effects 10-20 minutes after initiation
of drinking or smoking and reported a decrease in response 60-90 minutes later.
An unexpected finding was that subjective reports of euphoria were paroxysmal
in nature, averaging 2-8 minutes in duration and occurred about 3-5 times during
the first 40 minutes after drug administration. Plasma ACTH levels peaked at this
time. Subjects also provided verbal confirmation of the fleeting nature of the
response during post-session debriefing. Responding after placebo ethanol was
characterized by a longer delay to detect, shorter overall duration, and no
euphoria All subjects were able to discriminate placebo marihuana from active.
Quantitative measures of brain electrical activity using power spectral analysis
revealed that EEG alpha activity increased abruptly during these brief reports of
euphoria. This was observed after both ethanol and marihuana, but was absent in
subjects who received placebo. Furthermore, these alterations occurred as plasma
ethanol and THC levels were rapidly rising. Concomitant measures of P300
auditory evoked potentials revealed that disruption of selective attention did not
parallel reports of euphoria, but instead reflected the intensity and duration of
intoxication.
Topographic mapping of brain electrical activity during ethanol-induced
intoxication revealed that increases in EEG alpha power were widely distributed
over the scalp and encompassed parietal and frontal scalp electrodes. These areas
are usually devoid of prominent alpha activity during control recordings.
Furthermore, this distribution of brain electrical activity was not observed in any
subject after placebo ethanol administration. However, one female subject who
reported a positive family history of alcoholism, also failed to exhibit either
behavioral or electrophysiological signs of intoxication in spite of relatively high
plasma ethanol levels.
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DISCUSSION
The present study demonstrated that acute administration of both ethanol and
marihuana results in pronounced behavioral effects that were temporally related to
alterations in brain electrical activity. Such a relationship might reflect the nature
of reinforcement processes. Abrupt increases in EEG alpha activity are associated
with a pleasurable, free-floating and extremely relaxed state (Lindsley, 1952;
Brown, 1970; Matejcek, 1982) similar to that induced by transcendental
meditation (Wallace, 1970). The finding that both ethanol and marihuana produce
increased alpha EEG activity suggests that this neurophysiologic index may be
intimately associated with the processes that control feelings of we&being.
The results presented here suggest that pleasurable drug-related experiences are
reported during a time of rapid transition between a sober and intoxicated
behavioral state. For example, the paroxysmal episodes of subjective reports of
intense pleasure or euphoria after either ethanol or marihuana suggest that under
the present laboratory conditions, the reinforcing mechanism is intense, but
fleeting in nature. Furthermore, the temporal correlation among EEG, behavioral
and endocrine effects of ethanol and marihuana suggest that these processes may
be related. Such rapid intense sensations of intoxication are comparable to the
heroin rush and the cocaine high that persist for seconds or minutes and then
rapidly disappear.
Throughout this report a distinction has been made between detection or
identification of drug effect, and intense pleasure or euphoria. Without a
continuous probe of behavioral states, such rapid transitions cannot be detected.
During debriefing after a study, subjects who received active drug are universally
surprised that the pleasurable effects of the drug were so brief and episodic in
nature. The precise mechanism of these transient episodes of drug-induced
euphoria remain an enigma. The precise mechanism underlying these transient
behavioral and EEG changes remain unknown. However, the concomitant pulse
of ACTH during ethanol-induced euphoria suggests that the mechanism may very
well involve the hypothalamic-pituitary axis.
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Opiate-Ethanol Interactions:
lmplications for the Biological
Basis and Treatment of
Combined Addictive Diseases
M. J. Kreek
Co-existence of narcotic abuse and ethanol abuse, and combined
narcotic and alcoholic addictive disease, are common
[8,11,12,14,27,28]. Both require specialized clinical
management. Relations between these two clinical problems may
or may not bear any direct relationship to the undefined
mechanisms underlying each separate addictive disease entity,
and to the production and maintenance of the tolerant and
dependent state. Drug interactions may occur between opiates
and ethanol which alter pharmacological properties and the
various effects caused by each, and in turn may contribute to
the addictive diseases. Types of opiate-ethanol interactions
include two theoretical possibilities: 1) dispositional
interactions, which include changes in absorption, distribution,
metabolism and excretion, resulting in alterations in
pharmacokinetics; and 2) pharmacodynamic interactions, either
of a general non-specific type, or at a specific site of drug
actions such as a receptor site. The results of opiate-ethanol
interactions could include additive, synergistic, diminished or
antagonistic effects of pharmacological, physiological,
pathological or toxicological types [5,6,8,10-15,16,18-21,24,
29-311.
In the United States it is estimated that there are now at least
2 million persons who have used heroin at some time, and at
least 500,000 long-term heroin addicts. It is estimated that
there are 164 million persons who have ever used ethanol with
11,500,000 problem drinkers, and 5,750,000 alcoholics. In the
1985 DAWN survey report, alcohol in combination with other
drugs was the leading cause (20%) mentioned by emergency
rooms, of acute medical problems related to drug abuse [28].
Heroin was the second most commonly mentioned drug in acute
medical emergency problems (13.9%). Over 40% of the heroin
cases were medical emergencies where alcohol was also present.
Alcohol in combination with other drugs accounted for 31.6% of
medical examiner reports of deaths related to or caused by drug
abuse; heroin, often in combination with alcohol, accounted for
27.4% of the deaths. Thus it is evident that alcohol in
combination with heroin, is a very common cause of major
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medical problems leading to medical emergencies severe enough
to require emergency room visits, in many cases resulting in
death. With respect to possible drug interactions between the
heroin and ethanol, it is of interest to consider what are the
patterns of the combined use. Heroin used concomitantly with
ethanol apparently results in the desired effect of enhancement
of the heroin “high” or euphoria, whereas, heroin use followed
several hours later by the use of alcohol apparently has the
desired side effect of self medication of narcotic withdrawal
symptoms. These patterns of drug abuse may provide some
insights into the actual drug interactions of a pharmacokinetic
and pharmacodynamic type which may occur. Similar patterns
of alcohol abuse may occur in some patients during chronic
methadone maintenance treatment for narcotic addiction.
Since drug interactions may result in altered toxicity,
physiological or pharmacological effects, it is necessary to
consider the toxicities and effects of each drug when used
alone. Alcohol is an intrinsic hepatotoxin, neurotoxin and
cardiotoxin, and is also directly toxic to the gastrointestinal
tract and pancreas. Of especial importance with regard to drug
interactions, ethanol is a powerful enhancer of specific hepatic
microsomal P450 dependent drug metabolizing enzyme activities.
Therefore, when alcohol has been used on a chronic basis, the
hepatic drug metabolizing enzyme capacity is enhanced.
Conversely, when alcohol is acutely administered in high doses,
either to a naive subject or a chronic user of alcohol, alcohol
may inhibit drug metabolism by certain hepatic P450 dependent
microsomal enzymes. This is related to the fact that when
present in high doses, 25-30% of ethanol is itself metabolized by
a hepatic P450 dependent microsomal enzyme system in addition
to its major pathway by cytosolic alcohol dehydrogenase.
Therefore, alcohol has two very distinct and opposite effects on
drug metabolism: inhibition of drug metabolism when present in
large amounts, and enhancement of oxidative drug metabolism
when alcohol has been used on a chronic basis and is then
withdrawn. This dual effect by alcohol on metabolism of
another drug has been documented for many different drugs.
Alcohol is also a modifier of several physiological functions,
with resulting abnormalities of endocrine, reproductive,
gastrointestinal, and immune functions.
Heroin, on the other hand, is not intrinsically toxic to any
organ system. There is no evidence that heroin, or any other
opiate such as morphine or methadone, has any effect on
hepatic P450 drug metabolizing enzyme activities in humans,
although such effects may occur in other species. Heroin, and
other narcotics, when given in very large doses may result in
respiratory depression with resultant hypoxia which can cause
toxic changes in all tissues and organs. Frequently in animal
model studies, such changes are incorrectly ascribed to direct
toxic effects of the narcotic, rather that correctly ascribed to
the results of severe hypoxia. Like ethanol, heroin may be a
potent modifier of physiological functions.
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When research on the possible long-term pharmacological
treatment of narcotic addiction was initiated by Dole and
colleagues in 1964, a long-acting orally effective opioid,
methadone, was chosen for use [3]. It was shown that steady
daily dose administration of methadone provided several needed
effects, including prevention of abstinence symptoms over a
dosing interval of 24 hours, prevention of drug hunger and
drug seeking behavior, and normalization of overall status, In
other attempts to treat narcotic addiction pharmacologically,
when short-acting narcotics such as heroin or morphine were
used, it had been repeatedly demonstrated that repeated
parenteral doses of narcotic, usually in increasing doses, were
required to prevent narcotic withdrawal and drug hunger.
Such frequent dosing with a short-acting narcotic, leads to
high peak plasma levels followed by rapid decline in plasma
levels and results in intermittent periods of narcotic effects
followed by a very short period of relatively normal functional
status and then by a period of narcotic withdrawal,
Subsequently, when pharmacokinetic studies could be carried out
using both standard techniques, and stable isotope labeled
tracer techniques, it was shown that methadone is essentially
completely systemically bioavailable after oral administration,
with an apparent plasma terminal half-life of 16-28 hours for the
dl racemic compound used in therapeutics, and up to 48 hours
for the active 1-enantiomer [4,9,21,22,27]. This was to be
sharply contrasted with the pharmacokinetics of heroin which
has a plasma terminal half-life of approximately 4-6 hours, and
very limited systemic bioavailability after oral administration
(less than 30%)) thus requiring parenteral administration.
Methadone is metabolized primarily by the hepatic microsomal’
P-450 drug metabolizing enzymes, undergoing oxidative
metabolism with N-demethylation followed by cyclization as the
major route of biotransformation in humans [9,19]. Conversely,
heroin is metabolized primarily by deacetylation followed by
glucuronidation of the resultant morphine in humans.
In clinical pharmacodynamic and pharmacokinetic studies, when
methadone is given in an adequate dose orally once a day, a
steady state plasma level of methadone is sustained over a 24
hour dosing interval. Peak plasma levels of methadone occur
2-4 hours after the oral dosing, and represent barely a
doubling of the nadir of steady state background levels. Thus,
in addition to clinical observations of normalization of behavior
and general physical functioning, it was demonstrated
pharmacologically that a steady state of plasma levels of
methadone is achieved, and presumably a steady state of opioid
is available at specific opiate receptor sites. It is this steady
state of plasma and receptor levels of this long-acting opioid
that probably allows normalization of many physiological
functions which are disrupted by acute use of any opioid and
remain disrupted during chronic use (such as in cycles of
addiction) of short-acting narcotics, of which heroin is the most
commonly abused drug.
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To date, over 150,000 former heroin addicts have been treated
with methadone maintenance treatment, and approximately
100,000 are currently in treatment. The voluntary retention in
methadone maintenance treatment for more than 2 years ranges
from 55-80%, with retention higher in clinics well structured to
provide general medical and behavioral services, along with
counseling and rehabilitation services. As shown by many
studies, less than 10% of long-term methadone maintained
patients continue to show illicit narcotic abuse. However,
several studies have now documented the early observations
that relapse rates after cessation of methadone maintenance
treatment are very high. From 70-80% of former well
rehabilitated methadone maintained patients will ultimately return
to narcotic use, with increased prevalence of ethanol abuse
often preceding the return to illicit narcotics. These data
suggest that for a large proportion of methadone maintained
patients, chronic long-term treatment is essential.
The actions of methadone treatment include three important
separate effects: 1) prevention of withdrawal symptoms over a
24 hour dosing interval; 2) prevention of “drug-hunger”
(whatever ultimately turns out to be the physiological and/or
behavioral basis of this well-documented entity): and 3)
blockade of the euphoric effects of any illicitly self-administered
narcotics, by the well studied phenomena of opiate-cross-
tolerance [3], The mechanism of action of methadone in
maintenance treatment is probably related to the fact that the
long-acting opioid provides steady levels of opioid at receptor
sites, thus allowing normalization of functions disrupted by
intermittent receptor occupancy.
It has become quite clear from both early and more recent
studies that alcohol abuse, a very common problem in street
heroin addicts, also remains a problem of patients in methadone
maintenance treatment [1,5,6,8,10-15,20,21,29-31]. Between
20% and 50% of heroin addicts are abusers of alcohol or are
alcoholics by definition; several studies have also shown that
between 25-50% of patients in methadone maintenance treatment
continue to use alcohol to excess or are alcoholics. Contrary
to earlier predictions, it has been shown that alcohol abusing,
or alcoholic methadone maintained patients do benefit from
methadone maintenance treatment with respect to cessation of
heroin addiction but continue to have the second alcohol
addictive disease process [1,5], Therefore, in the current
setting of an increasing AIDS epidemic in which parenteral drug
abusers are the second highest risk group, it is important to
address the second addictive disease of alcoholism in methadone
maintained patients, rather than discharging alcohol abusing or
alcoholic methadone maintained patients from methadone
treatment. However, there are many indications, both from
laboratory and clinical studies, that concomitant alcohol abuse,
through dispositional interactions with the opioid methadone,
may disrupt the steady state which otherwise may be achieved
during chronic methadone maintenance treatment. By altering
the disposition and pharmacokinetics of methadone, normalization
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of various functions of potential importance, including
neuroendocrine functions, may be prevented or impaired.
Along with other workers, we have carried out studies in rat
models to determine what may be the interactions between
methadone and ethanol. In one such study, rats were treated
with methadone (25mg per kg per day po), or water daily by
gavage for two weeks. Rats were then treated concomitantly
with methadone and either ethanol (2g per kg per day po), or
isocaloric sucrose for two weeks. On the day following the last
dose of ethanol administration, rats were sacrificed at sequential
time points following the last oral dose of methadone and plasma
levels of methadone were determined by gas chromatographic
methods developed in our laboratory. In these studies it was
shown that plasma levels of methadone at one and two hours
after the last oral dose of methadone was administered, and 24
hours after the last dose of ethanol, were significantly lower in
animals which had been treated with ethanol as contrasted with
the animals which had received isocaloric sucrose. These
studies therefore demonstrated the capacity of chronic ethanol
treatment to accelerate or enhance methadone metabolism
[10,12,15].
Studies have also been performed in an animal to, determine
whether or not the impairment of methadone metabolism, which
is postulated to occur when high levels of ethanol are
administered concomitantly with opioid, are due to acute effects
of ethanol on hepatic uptake and distribution. A series of
studies were carried out using an isolated perfused rabbit liver
preparation [24]. We had earlier shown that morphine, which
has very limited systemic bioavailablity after oral administration,
was extracted by the liver to a much lesser extent (a
paradoxical finding) than both methadone and
1-alpha-acetylmethadol, two opioids which are long-acting in man
and which have very high systemic bioavailability after oral
administration. This paradox was explained by demonstrating
that, whereas morphine undergoes rapid biotransformation
(N-demethylation in most animals and glucuronidation in
humans) in its “first pass” through the liver, substantial
amounts of unchanged methadone and LAAM were initially
nonspecifically bound to hepatic plasma membrane fractions and
subsequently slowly released. Therefore, both in the isolated
perfused rabbit liver preparation, and in whole animal (rodent)
preparations, as well as in compartmental pharmacokinetic
analyses of methadone disposition in human subjects after the
administration of stable isotope labeled enantiomers of methadone,
it has been shown that the liver is an important reservoir for
the storage and subsequent release in unchanged form of these
long-acting opioids [4,22,27,30,31]. In studies carried out to
determine the effects of ethanol preperfusion on the acute
hepatic uptake and distribution of narcotics in the isolated
perfused rabbit liver, isolated rabbit livers were perfused with
rabbit blood, both with and without ethanol added to maintain
ethanol levels around 200mg/dl. After a 75 minute of
pre-perfusion, a pulse injection of 14C labeled narcotic (1.5mg)
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was made into the portal vein cannula followed by a two minute,
open, non-recirculating perfusion. At the end of the two
minute perfusion, the entire liver was homogenized, sub-cellular
fractionation performed, aliquots of whole liver homogenate and
sub-cellular fractions oxidized and radioactivity content
determined. In these studies, it was shown that alcohol
pre-perfusion and co-perfusion had no observable effects on the
hepatic uptake of either. of the short-acting narcotics studied,
morphine and meperidine. nor on the hepatic uptake of the
long-acting narcotics, methadone and I-alpha-acetylmethadol
[24]. Similarly ethanol pre-perfusion and co-perfusion had no
effects on the sub-cellular distribution of these opioids in the
liver in this acute perfusion system [24]. Therefore, it would
seem that when ethanol is present in large amounts, it acutely
inhibits narcotic metabolism; this effect is probably exerted at
the level of the hepatic microsomal P-450 drug metabolizing
enzymes.
Studies were then carried out to determine what may be the
extent and nature of interactions between this long-acting
opioid, methadone, and ethanol in human subjects in methadone
maintenance treatment. First, a study was carried out in
chronic methadone maintained patients who had no history of
alcohol abuse, polydrug abuse, or significant liver disease [2].
Five subjects were studied both while receiving methadone alone
in steady-state treatment doses (30-100mg/day orally), and then
on a special study day when ethanol (90ml of a 50% solution)
was co-administered with a morning daily dose of methadone.
In this study the ethanol dose administered, equivalent to 45 ml
of ethanol, did not cause any significant alteration in methadone
disposition [2].
A study is currently in progress to determine the interactions
between ethanol and methadone in alcoholic methadone
maintained patients [23]. In this study methadone maintained
patients with identified alcoholism and who have been
voluntarily admitted for detoxification treatment for alcoholism,
and to participate in this pharmacokinetic study, are admitted
to a clinical care unit where research studies may also be
performed [23]. The patients are stabilized for 2-3 days on
the minimum doses of ethanol required to prevent alcohol
withdrawal symptoms. On the third or fourth day of
hospitalization, a study is performed in which the stabilizing
dose of ethanol is administered at the beginning of the day
along with the daily oral dose of methadone used in maintenance
treatment. Preliminary data analyses suggest that in those
“subjects receiving an initial ethanol dose equal to or greater
than 75ml equivalent of ethanol on the study day”, the
methadone dose adjusted area under the plasma concentration
time curve (AUC0-24) is significantly higher during the ethanol
study, than when those same subjects are studied two weeks
following cessation of ethanol treatment. Therefore, these
studies may provide quantitative evidence for the first time
which supports the clinical evidence that there is a dispositional
interaction between ethanol and methadone in man following
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acute large doses of ethanol, resulting in elevation in plasma
levels of methadone during the time course when ethanol was
present in the body [23]. However, these preliminary studies,
as well as the animal model studies, may show that following
withdrawal of ethanol, plasma levels of methadone may be lower
than anticipated for the dose of methadone received.
Chronic liver disease resulting in part from chronic alcohol use
may also alter methadone disposition. It has been shown in
several studies that from 50-70% of all heroin addicts and
methadone maintained patients have laboratory evidence of
chronic liver disease [8,20]. A history of clinically evident
hepatitis is present in only 20-30% of patients. It has been
shown that chronic hepatitis B antigenemia is present in 5-15%
of heroin addicts and also patients in chronic methadone
maintenance treatment. Other serological markers of hepatitis B
infection (including HBsAb and HBcAb), may be found in
50-75% of patients. More recently, there is evidence of an
increasing prevalence of hepatitis delta infection with serological
markers found in 15-30% of heroin addicts and ‘methadone
maintained patients studied. As stated above, a history of
chronic heavy usage of ethanol (greater than the equivalent of
4oz of whiskey per day), may be elicited in 20-50% of both
heroin addicts and methadone maintained patients. It has been
shown that liver disease due both to alcohol abuse and viral
liver disease may progress more rapidly than disease due to
viral infection alone [1,5,8,20,29].
We have carried out two sets of studies of methadone disposition
in patients with alcoholic cirrhosis, at a time when there has
been no alcohol ingested for at least 2 weeks prior to study
130,311. In the first of these studies of compensated alcoholic
cirrhotics, all of whom were able to undergo liver biopsy, the
one pharmacokinetic index of methadone disposition which was
significantly altered was the apparent terminal half-life of
methadone, with the control group in this study having a
half-life of 18.8 hours for the racemic methadone and the group
of subjects with alcohol cirrhosis having a half-life of 35.5
hours [31]. In a second study of patients with more severe
alcoholic cirrhosis, some of whom had liver function too impaired
to allow liver biopsy, prolongation of apparent terminal half-life
of methadone was again documented. However, in this group,
the mean plasma level of methadone was found to be
significantly lower than the mean plasma level in the control
group [30]. In most studies of disposition of other drugs in
patients with cirrhosis, in whom biotransformation of the study
drug may be compromised because of hepatic dysfunction with
resultant prolongation of plasma apparent terminal half-life,
accumulation of drug and therefore increased plasma levels are
seen. It is postulated that the significantly reduced plasma
levels observed in our study of methadone disposition in
cirrhotic patients was due to the fact that methadone requires
an intact liver for storage and subsequent release. In the
setting of severe cirrhosis, with decreased functional hepatic
mass, it is probable that the storage capacity for methadone
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was markedly reduced and that therefore methadone was more
extensively, though more slowly, biotransformed in its first
passage through the liver, thus resulting in lowered plasma
levels over a 24 hour dosing interval. Other studies were
carried out to examine the urinary and fecal excretion of
methadone and its major metabolites in maintenance patients with
and without severe liver disease [18,19]. In these studies it
was shown that in a setting of severe liver disease, the urinary
excretion of methadone and its metabolites is significantly
decreased, reflecting the decreased total plasma load of
methadone, whereas, the fecal excretion of methadone and its
metabolites is increased, reflecting a probable increased “first
pass” effect with biotransformation and hepatobiliary secretion
to feces of methadone, rather than storage and subsequent
release of methadone in unchanged form into the plasma.
Several workers have recently shown that ethanol may interfere
with binding of the specific endogenous opioids to their opiate
receptors, and may possibly interfere with the binding of opiate
drugs to opiate receptors. Any such disruption of normal
binding and release from binding of the endogenous opiates
from their receptors, or disruption of binding of narcotic drugs
could alter functions modulated or affected by endogenous or
exogenous opioids such as neuroendocrine function. Acute
administration of either a short- or long-acting narcotic and
also chronic administration of a short-acting narcotic will cause
inhibition of release of ACTH and beta-endorphin in humans,
along with abnormal release and subsequent lowered levels or
altered diurnal circadian rhythm of levels of cortisol. During
withdrawal from narcotics, there is increased release of ACTH
with increased levels of cortisol. Similarly acute bolus
administration of a specific opioid antagonist, naloxone and
chronic treatment with the antagonist naltrexone has been
shown by our group to result in increased release of
beta-endorphin and also increased levels of cortisol [7].
We have hypothesized that during acute and chronic use of
short-acting narcotics in humans, with 3 or 4 doses
administered each day, and with intermittent periods of narcotic
effect followed by relative narcotic withdrawal, alterations in
neuroendocrine function may occur. Conversely, during
chronic use of the long-acting opioid, methadone, normalization
of most indices of neuroendocrine function may result because
of the long-acting properties of this drug in humans and the
steady-state opiate receptor perfusion which may be achieved
during treatment. In the controlled environment of the General
Clinical Research Center, we have studied patients who have
been in long-term chronic methadone maintenance treatment for
2 years or more who have no significant liver disease, no
alcohol abuse and no other polydrug abuse [25,26]. In these
studies we have shown that plasma levels and the circadian
release of levels of ACTH. beta-endorphin, and cortisol are all
normal. This is to be sharply contrasted with our findings in
patients their first 1 to 2 months of methadone treatment during
which time dose of methadone is being ascended and tolerance
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to other narcotic effects developing. In that setting ACTH and
beta-endorphin release is reduced and cortisol levels are
altered, along with disruption of the normal circadian
rhythmicity. The effects of alcohol on disrupting methadone
disposition, with probable initial reduction of methadone
metabolism followed by acceleration of metabolism and resultant
disruption of the steady-state plasma levels, and presumably
receptor levels of drug, may also disrupt neuroendocrine and
endocrine function. Although we do not know the relationships
of the disruption of endocrine function to addictive disease,
with its major feature of drug seeking behavior, there may be
some direct or indirect relationship between the two.
Normalized behavior is found in chronic methadone maintained
patients around the same time that normalization of endocrine
and neuroendocrine function is achieved. It is known that the
narcotic abstinence symptoms experienced by, alcohol abusing
methadone maintained patients at the end of their methadone
dosing interval may be directly related to the accelerated
metabolism of methadone in that setting. It is not known
whether or not any of these effects may also be related to
induced alterations in neuroendocrine function.
It has been shown by other workers in normal control subjects
and in alcoholic patients that acute high levels of alcohol result
in release of cortisol. A so-called “pseudo-Gushing’s syndrome”
has been observed in chronic alcoholics, and has been related
to this hypercortisolemia. However, studies in humans have not
yet clarified whether or not alcohol causes an increased release
of the controlling peptide, ACTH, and also beta-endorphin
released from the same peptide precursor, or whether the
alcohol effect is directly on the adrenal cortex, with either a
normal negative loop which would result in decreased levels of
ACTH and also beta-endorphin, or a disrupted loop which could
result in no change in ACTH and beta-endorphin levels. In
our ongoing studies in alcoholic methadone maintained patients,
we have observed that acute alcohol administration at moderate
levels or above results in elevation in levels of serum cortisol
[23]. Further studies are in progress to determine the effects
of alcohol, when used on acute and chronic basis, on the
peptide hormones of the hypothalamic-pituitary-adrenal axis
which could have implications both for the biological basis of
combined addictive diseases and for the treatment of these
disorders.
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The Reinforcing Functions of
Drugs and Assessment of Abuse
Liability
J. Brady
Among the many perplexing aspects of the substance abuse domain,
self administration models appear to present some of the more
challenging methodological and conceptual problems. For at least
several decades, this field of inquiry has been cultivated
assiduously, and the current lively interest in alcohol and drug
self-administration is generously generously reflected in the combined
program of this joint research meeting as well as in an expand-
ing literature of multidisciplinary origins (Brady and Lukas,
1984; Goldberg and Stolerman, 1986; Balster and Lukas, 1985;
Ator and Griffiths, 1987). It is unfortunately true however,
that dedication and industry, even of the most intense sort, do
not guarantee authentic scientific achievement. In biology and
particularly the social sciences, wide gaps frequently separate
experimental operations and interpretive formulations. Progress
in developing systematic and coherent conceptualizations that
serve to integrate and unify interactive levels of discourse can
be painfully slow. At the most basic level, for example, there
appear to be no generally acceptable formulations that bring
conceptual order to the rapidly expanding frontiers of inquiry
and application in the extended domain of substance abuse. It
seems clear, nonetheless, that the development of a unifying
framework for conceptualizing the commonalities in alcohol and
drug abuse must encompass the data base that focuses upon those
behavioral interactions characterized in the title of this
symposium as self-administration.
Traditional views of this process as exemplified in alcohol and
drug abuse, emphasized its reactive futures -- attention
focused heavily upon the antecedent conditions that appear to
"drive" or at least provoke substance use and abuse. But almost
three decades have passed since the discovery that animals
implanted with intravenous catheters would repeatedly self-
inject drugs (Clark, Schuster, and Brady, 1961; Weeks, 1962).
And there is now convincing evidence of concordance between the
range of chemical substances self-administered by animals and
those abused by humans (Brady, Griffiths, and Winger, 1975;
Johanson and Balster, 1978; Griffiths and Balster, 1979).
Moreover, the variables of which such drug self-administration
are a function (e.g., dose, response cost, schedule of avail-
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ability, environmental conditions, past history) have been found
to exert their influence in a similar fashion independently of
the type of substance maintaining the performance or the species
of organism involved (Griffiths, Bigelow, and Henningfield,
1980; Johanson and Schuster, 1981). The recognition of these
cross-species and cross-drug generalities has radically changed
conceptualizations of substance abuse from a reactive to a more
active process, and has encouraged the kind of functional
analysis of drug-seeking and drug-taking that has proven produc-
tive and useful in other behavioral interactions (Brady, 1981).
This emphasis upon substance abuse commonalities makes contact
with an expanding body of research knowledge based upon the
analysis of behavior and is advantaged by the strong empirical
influence of the experimental laboratory. The most important
point of contact between the experimental analysis of behavior
and substance abuse is the demonstrated relationship between the
pharmacological properties of drugs and their stimulus functions
in behavioral interactions. The aspect of this relationship that
dominates investigative attention has continued to focus upon
the reinforcing functions of drugs and the conditions under
which drug seeking and drug taking behaviors are influenced by
their pharmacological properties. As a result, experimental
procedures for the generation and maintenance of drug self-
administration performances have become the hallmark of abuse
liability assessment in both animal and human laboratory
settings (Brady and Lukas, 1984). The procedures used most
commonly to assess the reinforcing functions of unknown pharma-
cologic agents involve either direct access to the test compound
(via instrumental lever pressing, intragastric catheters, or
automatic oral drinking systems) without prior drug self-
injection experience (Deneau, et. al., 1969; Altshuler, et.
al., 1975; Meisch and Henningfield, 1977), or substitution of
the test compound on a drug self-administration baseline
previously established with standard reinforcing agents (Brady,
et. al., 1975; Brady and Griffiths, 1976). One variant of the
latter procedure described by Griffiths, et. al. (1976) for
example, has been used to systematically evaluate the reinforc-
ing efficacy and compare a range of doses of some 15 stimulant
anorectics and more than 20 sedative anxiolytics substituted
after several consecutive days of multiple cocaine injections
per day. Access to each dose of each of the test compounds was
permitted for at least 12 days, and Figures 1 and 2 illustrate
the resulting comparative analysis of reinforcing efficacy based
upon drug self-administration trial freguency with a series of
prototypical stimulants (Figure 1), and upon drug self-ad-
ministration lever pressing response rate with a series of
prototypical sedatives (Figure 2), both as a function of dose.
Comparisons between self-administration drugs with respect to
their reinforcing functions however, have continued to present
methodological challenges to the extent that effects upon
response topography (e.g., disruption of motor control) may
compromise instrumental performance measures (e.g., lever
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Figure 1. Average number of injections per day with 14
phenylethylamines. Intravenous
completion of 160 lever presses: a 3 hour time-out followed each
injections were delivered upon
injection permitting a maximum of eight injections per day. C
indicates mean of all the 3-day periods with cocaine which
immediately preceded every substitution of a phenylethylamine or
saline. S indicates mean of day 8-12 after substitution of
saline (two saline substitutions in each of 15 animals).
Brackets indicate ranges of individual animal's means. Drug data
points indicate mean of days 8-12 after substitution of a drug
for individual animals. Lines connect means at indicated doses
of drug.
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Figure 2. Mean response rates maintained by drug. Y-axis:
responses per second, log scale. X-axis: dose (mg/kg/injection),
log scale. For each animal exposed to a drug dose or vehicle
(V), the overall response rate was calculated for the last 5
days of the condition by dividing the total responses (excluding
those emitted during time-out) by the total time in seconds
(excluding time-out periods). The mean and range of these
overall response rates are presented. Control cocaine data (C)
were calculated identically from the 3-day control periods which
immediately preceded substitution of vehicle or the drug doses.
pressing), per se. A range of investigative approaches to the
solution of this problem has been reported including the use of
concurrent schedule procedures (Iglauer, et. al., 1975), choice
precedures (Griffiths, et. al., 1976; Johanson and Schuster,
1977), response rate analysis (Balster and Schuster, 19735
Griffiths, et al., 1981), and progressive ratio procedures
(Yanagita, 1973; Brady, et al., 1975; Brady and Griffiths,
1976). The most extensively documented results have involved the
use of progressive ratio methods for measuring the relative
reinforcing strength of a drug by determining the maximum amount
of responding (i.e., work) that can be maintained by the
compound (Brady, et. al., 1982). The response requirement is
systematically increased until the number of completed injection
trials falls below a criterion level. Such "breaking point"
determinations, for example, have been made over a range of
doses with fenfluramine, chlorphentermine diethylpropion, and
cocaine (Griffiths, et. al., 1978a). Within-animal comparison of
the maximum breaking points maintained by the different drugs
are illustrated in Figure 3 which shows that cocaine generally
maintained by the highest breaking points, followed in order by
diethylpropion, chlorphentermine, and fenfluramine.
A useful procedure for ranking  the abuse liability of anorectic
drugs has also been described (Griffiths, et. al., 1978b) based
upon an ordering of compounds in terms of a ratio between two
doses: a dose that produced a specified anorectic effect and a
dose that produced a specified reinforcing effect. Clearly, the
most desirable anorectic drug would have potent anorectic pro-
perties but minimal reinforcing functions. An undesirable
anorectic would be a weak appetite suppressant but a potent
reinforcer. A number of substituted phenylethylamines and
cocaine have been evaluated using this anorectic/reinforcement
ratio (akin to the "therapeutic ratio", for example) and Figure
4 illustrates the results of such comparisons based upon both
animal and human anorectic dose determinations.
Significantly, the generality of these results reported with
animal self-injection models of abuse liability has been well
documented in controlled laboratory drug self-administration
studies with human volunteers. A broad range of phamacologic
agents including heroin (Mello, et. al., 1981), methadone
(McLeod, et. al., 1982; Stitzer, et. al., 1983), ethanol
(Griffiths, et. al., 1974; Mello, et. al., 1971). pentobarbital
(Griffiths, et. al., 1979), diazepam (Griffiths, et. al., 1983),
cocaine (Fischman and Schuster, 1982), amphetamine (Johanson and
Uhlenhuth, 1980 a,b), nicotine (Griffiths, et. al., 1982), and
marijuana Mendelson, et. al., 1976), among others (Chart, et.
al., 1984), has been shown to maintain drug self-administration
by humans independently of whether the participant volunteers
were occasional or casual drug users (Johanson and Uhlenhuth,
1980 a), had substantial and varied drug use histories (Fischm-
an, 1976), or were physically dependent on drugs (Mello, et.
al., 1981; Stitzer, et. al., 1983).
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Figure 3. Breaking point values for doses of fenfluramine,
chlorphentermine, diethylpropion, and cocaine in five baboons.
Ordinates: Breaking points; Abscissae: Dose (mg/kg/inj.) Each
point represents a single breaking point observation. Lines
connect the means of the breaking point observations at dif-
ferent doses of drug. Filled circles indicate data obtained
during the first exposure to a drug dose. Unfilled circles
indicate data obtained during a second exposure to a drug dose.
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Figure 4. Anorectic-Reinforcment Ratios for cocaine and eight
anorectic drugs. Filled bars show data derived entirely from
baboon experiments. Striped bars show data derived from both
human clinical information and baboon experiments. Compounds
with high ratio values are more potent reinforcers (relative to
their anorectic potency) than compounds with lower ratio values.
In other respects as well, the human data from drug self-admini-
stration studies in experimental settings tend to confirm the
functional relations described in laboratory animal invest-
igations (Bigelow, et. al., 1976). When "response cost" was
manipulated, for example, with human inpatient volunteers self-
administering their maintenance dose of methadone contingent
upon an operant performance, introduction of a progressive ratio
requirement for methadone decreased response rates and increased
the likelihood that the subjects would detoxify (McLeod, et.
al., 1983). Similarly, response cost studies with humans have
shown that alcohol consumption levels varied inversely with the
amount of work required to maintain drug access (Mello, et. al. ,
1968). And the reported data from experiments using choice
procedures with human volunteers to assess the relative rein-
forcing strength of drugs has been generally consistent with the
animal laboratory findings: pentobarbital is preferred to
diazepam (Griffiths, et. al., 1980); high doses of cocaine are
chosen, over lower doses (Fischman and Schuster, 1979); and
cocaine is preferred to procaine (Fischman, 1982).
While reinforcing functions as reflected by self-administration
have provided a dominant focus for procedural approaches to the
assessment of abuse liability over most of the last two decades,
recent refinements in the analysis of discriminative stimulus
functions have provided a more comprehensive basis for char-
acterizing a drug's spectrum of action and evaluating its abuse
liability (e.g., Schuster and Balster, 1977 a,b: Brady and
Fischman, 1985). In addition, assessment procedures have been
further enhanced by analysis of the behavioral effects, both
acute and chronic, that follow as a direct consequence of drug
administration, these eliciting stimulus functions have long
provided a major focus for evaluating the biochemical and
physiological dependence producing properties (i.e., tolerance
and withdrawal effects) of drugs (Deneau, 1956; Jasinski, 1977:
Seevers, 1936; Wikler, 1976). But the measurement  of such direct
behavioral effects has added an important dimension to the
assessment of abuse liability as well. Substances with only
minimal if any, disruptive behavioral effects are generally not
regarded as drugs of abuse (e.g., caffeine in tea, coffee, or
.coca cola). In contrast, compounds self-administered even
sparingly that are associated with behavioral decrements are
considered to be highly abusable (e.g., lysergic acid diethyl-
amide, LSD). Drugs may fall anywhere on the continua defined by
these interacting parameters and a comprehensive  evaluation of
such behavioral toxicity can contribute importantly to the
assessment of abuse liability. Procedures are now available
(Brady, et. al., 1979; Heinz and Brady, 1980; Hienz, et. al. ,
1981), for example, to operationalize and quantify these re-
lationships and provide a comparative analysis of the inter-
actions between the disruptive eliciting effects of abused drug-s
upon sensory/motor functions, on the one hand, and their rein-
forcing functions in maintaining self-administration, on the
other. This reinforcement/toxicity ratio (Brady, et. al., 1983;
Brady, et. al., 1984) compares the relative potency of a drug as
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a reinforcer with its relative potency in eliciting sensory/-
motor decrements and provides a quantitative comparative
assessment of the relationship between drug self-administration
and behavioral disruption. Figure 5 illustrates the results of
such a relational analysis with a range of sedatives, stimu-
lants, and dissociative anesthetics.
All of which is by was of emphasizing that there are now several
converging lines of evidence-convergent operations, if you
will-that testify to the reliability and broad generality of
observations confirming the reinforcing functions of drugs.
Morever, the orderliness of the data relating these reinforcing
functions to independently derived measures of pharmacological
activity (e.g., the anorectic/reinforcement ratio, the rein-
forcement/toxicity ratio, etc.) speaks directly to the issue of
construct validity in evaluating the contribution of drug self-
administration methods for the assessment of abuse liability.
The issue of predictive validity on the other hand, continues to
plague our most conscientious efforts largely because it remains
unclear as to just how the purported phenomena to be predicted-
drug abuse - is appropriately identified, defined, and measured
in the natural ecology. Despite somewhat differing opinions in
these regards, however, self-administration performances are
clearly recognized to be prominently common feature of both
alcohol and drug abuse.
The validity of laboratory self-administration assessment pro-
cedures however, is not to be judged on the basis of predicting
"drug dependence" (i.e., tolerance and abstinence) nor even
"drug abuse" (i.e., drug seeking and drug taking plus behavioral
toxicity). Rather, their predictive validity resides in the
evaluation of "abuse liability" (i.e., the likelihood that a
given physiologically or behaviorally toxic substance  will
maintain drug seeking and drug taking under at least some
conditions). An extensive array of chemical substances have
abuse liability under some conditions within the framework of
this definition, and an evaluation of the reinforcing functions
of drugs provides information about at least this one prominent
aspect of abuse liability assessment. To this extent, laboratory
drug self-administration procedures can be seen to have "face
validity", at the very least. They not only tell you that there
are at least some conditions under which a drug can be self-
administered (i.e., evidence of "inherent" reinforcing func-
tions, if you will), but they can as well define the range of
those conditions to a significant extent (i.e., different
species of organism, dose dependence, etc.) and the influence of
circumstances  (i.e., environmental contingencies, deprivation,
etc.) in potentiating or attenuating such reinforcing functions.
Finally, to provide a fitting "Come-to-Jesus" conclusion to this
all-too-familiar "three-little-bears" story, let me add my
equally tiresome "broken-record" commentary on the deplorable
state of the nomenclature in this muddled arena of drug and
alcohol "addiction", "dependence", "abuse" or whatever! The
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Figure 5. Relationship between criterion sensory and motor
toxicity doses and criterion self-administration doses for three
barbiturates, two benzodiazepines, two dissociative anesthetics,
and a stimiiant. The broken diagonal line represents equality
between reinforcing and toxic doses.
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interchangeable, quasi-technical use of these terms as referents
for a bewildering range of phenomena and experimental pseudo-
phenomena continues to produce a degree of semantic and taxo-
nomic confusion that is perpetuated in even the most current and
authoriative treatments of the subject by friends and relatives
alike (Johanson, et. al., 1987). The terms themselves, persis-
tently reified as substantive noun "things" that enter into
subject-predicate relationships with other "things" (and affect,
as well as are in turn affected by these other "things"), are
seldom accorded appropriate conceptual status as constructs
emerging from observed relationships between specifiable antece-
dents (biological and social) and definable consequences (bio-
chemical, physiological, and behavioral). Within this relational
context, the analysis of interacting biological and behavioral
events would seem to provide a basis for defining these con-
structs more operationally and specifying the conditions under
which a unifying conceptual framework can be developed for this
prominent aspect of substance use and misuse.
At least some definitional clarity can be attained by dividing
the vast array of events that characterize this domain into two
reasonably exclusive categories based upon explicity operational
criteria. Such a division is possible, for example, by distin-
guishing between events that occur before and events that occur
after actual substance intake. As a first approximation, the
defining operations of the "before" class, on the one hand,
would include (but are not necessarily limited to) proactive
drug-seeking and drug-discrimination behaviors. The defining
operations of the "after" class, on the other hand, would focus
upon the reactive biochemical, physiological, and behavioral
changes associated with tolerance and an abstinence syndrome
when drug is withdrawn. Figure 6 illustrates schematically
(courtesy of my fellow iconoclast, Scott Lukas) this charact-
erization of the drug dependence and abuse universe.
The temporal ordering of biochemical, physiological, and
behavioral changes in relationship to the drug intake event can
thus provide an operational basis for characterizing the range
of a pharmacologic agents functional properties and for iden-
tifying distinguishable features of its spectrum of action. The
relevance and importance of this distinction between proactive
"abuse liability" and reactive "physiological dependence
potential" resides in the fact that, from the perspective of
drug assesment - the topic to which this essay is addressed-
their defining properties are not coextensive, they do not
invariably occur together, and the methods by which they are
evaluated differ. Proactive drug-seeking and drug self-ad-
ministration performances as cardinal signs in the assessment of
abuse liability for example, can be maintained in strength by
use patterns and doses of compounds (e.g., cocaine) that produce
no significant tolerance or withdrawal - the reactive changes
traditionally associated with physiological dependence. On the
other hand, there are tolerance and abstinence-producing
compounds (e.g., propranolol) that neither generate not maintain
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Figure 6. Schematic Characterization of Abuse and Dependence
Processes.
drug self-administration.
Interactions between these proactive and reactive features of
the drug and alcohol scene are of course, commonplace. Changes
in drug-seeking and drug-taking often occur as sequelae to both
the acute effects of a pharmacologic agent and to the tolerance
and withdrawal effects that follow more chronic drug exposure.
Conversely, the chemical and biological changes that define
physiological dependence can as well be sequelae to the repeated
self-administration of abused drugs. But the relative contribu-
tions of these distinguishable processes to drug and alcohol-
related problems can vary with different pharmacological agents
as a function of dose, environmental circumstances, and previous
drug history (Mendelson and Mello, 1982).
Despite these interactive features however, it is important in
confronting the validity questions at issue in this discussion
to recognize that the methods used in both laboratory animals
and humans to assess these distinguishable pharmacological
properties are quite different. Not surprisingly, the predictive
validity of self-administration as a drug evaluation procedure
may be quite poor if the objective is to assess a compound's
physiological dependence potential. But if the abuse liability
of a substance as defined by the likelihood of it supporting
drug-seeking and drug-taking, is to be evaluated, an assessment
of its reinforcing functions by self-administration is clearly
the method of choice.
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A Critique of Drug Self-Adminis-
tration as a Method for Predict-
ing Abuse Potential of Drugs
E. lwamoto and W. Martin
The Committee on Problems of Drug Dependence has participated in
an effort to assist federal regulatory and enforcement agencies
in their effort to minimize problems of drug abuse by precluding
the introduction of drugs with a high potential for abuse into
extensive medical usage and illicit drug traffic. Drugs of high
abuse potentiality are identified and their availability is
delimitated. This endeavor has required the close cooperation
between the scientific community and the regulatory agencies.
Some of the major factors in these interactions has been the
rapid development of the pharmaceutical industry. the rapid
evolution of new drugs which act on the CNS, and the growing
understanding of brain function. Despite the rapid development
of the neurosciences and the understanding of psychopathology,
the views of drug abuse have remained much the same over the last
five or six decades. These views consist of the following
propositions:
(1) A drug which
similar potential for abuse.
of face validity even though it is not readily reconciled with a
large body of epidemiologic data concerning the relative abuse of
a number of narcotic analgesics, sedative-hypnotics, antianxiety
shares a pharmacology with an abused drug has a
This proposition has a great deal
drugs, and stimulants. There has been the view that these
discrepancies can be explained by nonpharmacologic factors such
as prevailing attitudes, the disposition of the drug culture, and
drug availability.
(2) In 1931, Tatum and Seevers introduced the concept of
drug-induced dependency as an important dimension of drug
addiction based on the demonstration of physical dependence on
narcotic analgesics in animals. The concept of physical
dependence obtained vogue as an explanation for continued and
compulsive use of drugs because the discomforting signs,
symptoms, and feeling states of both acute and protracted
abstinence could be relieved by drugs of abuse. However, we were
soon reminded that the production of physical dependence was not
a necessary condition for the abuse of many drugs. Thus,
LSD-like drugs, and marijuana, when used chronically in moderate
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but abused doses, do not produce a readily measurable abstinence
syndrome. Furthermore, the chronic administration of certain
opioid antagonists, notably nalorphine and cyclazocine, induce
physical dependence; however, their abstinence syndromes are not
associated with drug-seeking behavior.
(3) A third pharmacologic framework from which drug abuse has
been viewed is that drugs of abuse produce subjective effects
which are pleasant and reinforcing. The remainder of this
chapter will be concerned with the validity of this proposition
and with methods used to measure these subjective states.
The abuse potential of a drug has been assessed by showing it to
be pharmacologically equivalent to a standard drug that is known
to be abused. Techniques for establishing pharmacologic
equivalence included studies. in both animals and man, which
utilized tolerance, dependence, cross-tolerance, suppression, and
direct addiction methodologies. Other estimates of abuse
liability of drugs have been made using drug self-administration
substitution procedures in animals. Relative reinforcing
efficacy can also be determined by comparison with standard drugs
of abuse using progressive ratio and choice procedures. Although
drug discrimination paradigms provide valuable data they will not
be discussed in this chapter.
The mechanisms underlying self-administration behavior in animals
are not well-understood. It is believed that self-administration
behavior is a particular case of operant behavior, that is,
behavior controlled by its consequences, and that certain drugs
are positive reinforcers. It is believed that drugs of abuse are
self-administered because they produce pleasant subjective
effects which increases the future occurrence of their self-
administration. It is usually assumed that humans
self-administer drugs because they "like" the effects of the
drugs. Fraser et al., (1961). Martin et al., (1971). and McClane
and Martin (1976), have reported that addicts show a dose-related
increase in the degree of liking of opiates, amphetamines, and
barbiturates. With respect to subject's liking in a study of
five amphetamines, the order of potency (highest to lowest) was
methamphetamine, amphetamine, methylphenidate, phenmetrazine, and
ephedrine (Martin et al.. 1971). This order of potency
corresponds well with the animal literature; however, it should
be noted that while ephedrine is capable of producing positive
subjective effects in humans of the same magnitude as
amphetamine, the incidence of ephedrine abuse currently is
probably very small.
The agreement between self-administration data in several species
and liking-data obtained in several patient populations is
excellent for some classes of drugs but is poor for other classes
of drugs. Probably very nearly 100 percent of animals tested
with cocaine will intravenously self-administer the drug. Rats.
cats, dogs, squirrel monkeys, rhesus monkeys, and baboons all
intravenously self-administer d-amphetamine as summarized by
Griffiths et al., (1980). In addition, the results with
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amphetamine correspond well with the effects of amphetamine in
humans with no prior chronic drug experience. In Lasagna's 1955
study. "amphetamine was outstanding in its ability to create a
pleasant state" in normal individuals not in pain.
There is also a human/animal concordance with respect to the
relative potencies of d- and l-amphetamine. In a comparative
study in humans on maximum mood responses, the potency of
d-amphetamine versus l-amphetamine was on the order of 1.5 to 1
and 3 to 1 (Smith and-Davis 1977). These data correspond to
amphetamine self-administration data in rats and in the rhesus
monkey (Yokel and Pickens 1973; Balster and Schuster 1973).
There are many examples in the self-administration literature
which support the contention that many drugs which are abused by
humans are self-administered by animals: alcohol, nicotine,
opiates, benzodiazepines, cocaine, sedative-hypnotics,
amphetamines, and phencyclidine (Balster and Lukas 1985;
Griffiths et al., 1985; Griffiths and Balster 1979). There is
no doubt that self- administration techniques are powerful
methods for measuring the central CNS effects of certain types of
drugs. There are drugs, however, which are abused by humans that
are not self-administered by animals and include LSD. mescaline,
DOM and THC.
In one study using rhesus monkeys, Hoffmeister (1975) gave
evidence that LSD, had negative reinforcing properties in
drug-naive animals. Deneau et al., (1969) found that none of four
monkeys initiated self-administration of mescaline either
spontaneously or after programmed administrations. In contrast
to the phenylalkylamine MDMA which is in fact self-administered
(Lamb and Griffiths. 1987). the phenylpropylamine DOM (Griffiths
et al., 1979). is not (Griffiths et al., 1979). In addition to
DOM, various indolealkylamines such as psilocybin, psilocin and
N,N-DMT appear to involve serotonin type 2 receptors or possibly
tryptamine receptors: this difference from MDMA may be a basis
why these latter compounds are not self-administered by animals.
Finally, in contrast to reports that humans will work for
marijuana and THC doses, rats and rhesus monkeys will only
self-administer THC at very low levels. van Ree et al., (1978)
observed self- administration of THC, 300 µg/kg/injection, in
only 2 of 5 rats. Kaymakcalan (1973) found that programmed THC
injections promoted THC self-administration in only 2 of 6
monkeys; however, Harris et al., (1974) did not find this maneuver
to be successful in a total of 10 monkeys.
In another category, there are drugs which are not abused by
humans that are self-administered by animals and include the
following agents: ketocyclazocine, ethylketocyclazocine,
apomorphine, piribedil, clonidine, procaine,
N-allylnormetazocine, metazocine and phenylethanolamine.
Ketocyclazocine or ethylketocyclazocine were self-administered by
both morphine-dependent or drug-naive rats, but not by rhesus
monkeys (Young and Khazan 1983; Collins et al., 1984; Tang and
Collins 1985; Woods et al., 1979). This species difference raises
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important issues concerning the selectivity and specificity of
the self-administration method, an issue which will be discussed
subsequently. The DA 1 and DA 2 agonist apomorphine was
self-administered by rats; the DA 2 agonist piribedil was
self-administered by both rats and the rhesus monkey (Yokel and
Wise. 1978; Woolverton 1986). The alpha 2 adrenergic agonist
clonidine is self-administered (Woolverton et al., 1982) but the
alpha 1 agonist methoxamine is not in dogs (Risner 1975). The
esteratic local anesthetic procaine is self-administered by rats
and monkeys in the same pattern as cocaine self-administration
(Collins et al., 1984; Ford and Balster 1977; Hammerbeck and
Mitchell 1978). Three other short-acting esteratic local
anesthetics, chloroprocaine, dimethylprocaine, and dimethocaine,
also supported self-administration behavior in the rhesus monkey
(de la Garza and Johanson 1982; Woolverton and Balster 1982).
It is interesting to note that three human subjects identified
large, (48 and 96 mg) doses of i.v. procaine as cocaine (Fischman
et al., 1983). However, lower doses of procaine were like placebo
on the ARCI and POMS scales. (+)-NANM and both (+) and
(-)-metazocine supported self-administration behavior in rhesus
monkeys, and these data bear on PCP self-administration (Slifer
and Balster 1983; Slifer et al., 1986). In the dog, the
endogenous compound beta-phenylethanolamine was self-administered
(Shannon and Thompson 1984). Thus, self-administration studies
in animals have shown a good ability to predict abuse potential
for some drug classes but not for others. A number of factors
can be identified which may contribute to the diversity of these
results.
One complicating variable that relates to selectivity is species
differences which has been alluded to and exemplified. Other
examples are the differences between man, monkeys, dogs, rats,
and mice in their responses to normorphine, benzomorphans and
meperidine. In studies of maximally abstinent morphine-dependent
dogs Martin et al., (1978) found that meperidine and normorphine
did not suppress morphine withdrawal. It is also well known that
there are marked differences in drug metabolism between species
and that there may be active metabolites which may enhance or
antagonize the reinforcing properties of the parent drug (e.g.
ethanol and acetaldehyde; diazepam and nordiazepam). New
knowledge about the nicotinic cholinergic receptor reveals
species differences in the amino acid sequences of the receptor
protein. How do these differences impinge upon the
self-administration of nicotine across species and on the
specificity of the receptor? The same questions may be asked of
other drug receptors. And finally, the "wiring" of brain
reinforcing systems and their neurotransmitter constituency may
differ from species to species.
Between difference's in individual and species pharmacologic and
physiologic responses to drugs is paralleled by differences in
behavioral measures. Although the monkey and the rat can be
trained to self-administer opiates, it is much more difficult to
do so in the dog. Jones and Prada (1973) found that 18 of 22
dogs decreased their rates of responding for morphine in doses
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ranging between 0.01 and 0.25 mg/kg/injection. Subsequently,
only 1 dog in 10 was able to be trained to self-administer
morphine. These data compare with the 1955 human study by
Lasagna et al., showing the low incidence of "pleasant" reactions
to the administration of morphine or heroin in a normal
population. Although 7 of 14 addicts reported that 4 mg of
heroin was "pleasant", 7 of 11 normal subjects reported that this
dose of heroin was unpleasant. Likewise, 12 of 14 post-addicts
reported that 15 mg of morphine was pleasant, while 8 of 11
normal subjects reported that this dose of morphine was "the most
unpleasant medication". Thus, although morphine-like drugs
appear to be reinforcing in opiate addicts, many normal subjects
not In pain do not like the effects of opiates. These data raise
an important issue: What is the relevant population for human
studies? Drug-experienced? or drug-naive?
It Is important In attempting to formulate general theories of
drug abuse to relate animal and human behavior. In the United
States estimates would suggest that no more than 15% of the
population uses alcohol compulsively. A somewhat greater
percentage, 30%, but nevertheless, a relatively small percent,
smoke cigarettes. A smaller percent use cocaine, amphetamines
and marijuana regularly, and the number of people in the U.S.
that abuse opiates probably does not exceed 750,000, or about
0.3% of the population. These data compare with 30-day
prevalence data from high school seniors of the class of 1985
(Johnston et al., 1986). Hence, the overall conclusion that one
must draw is that in humans only a relatively small portion will
use socially approved or socially disapproved euphoriants on a
regular basis. A prudent conclusion from these sorts of
considerations would be that the largest portion of human beings
use euphoriants only occasionally, or not at all.
Because of the variability of subjective states produced by drugs
In humans, the problem of validating methods for assessing the
abuse potentiality of drugs in animals Is a difficult one. How
can the self-administration model be validated? First, as
outlined by Martin (1977), there must be concordance between
animal and clinical results. In order to define the limitations
of methodologies, more effort should be placed on determining the
reasons for discordant results. Secondly, there also must be
some sort of concordance between both the incidence and
perniciousness of street abuse on the one hand, and the results
of both animal and clinical studies on the other. Because fads
and trends play a major role in drug abuse patterns, a good
concordance can be expected only for those drugs whose street
abuse is well established. The following is an attempt at
finding such concordances.
One quantitative estimate of the relative reinforcing strengths
of drugs has been made by determining the highest number of
responses that can be performed by the animal before
self-administration performance diminishes to baseline control
levels. This "progressive ratio" test entails the systematic
increase of the response requirement until the subject fails to
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Table 1. Breakpoints of Drug Self-Administration Derived from
Progressive Ratio Tests in Various Species
Author
Yanagita
1976
Species
rhesus
Griffiths
et al., 1978
Hoffmeister
1979
Griffiths
et al., 1975
Moreton
et al., 1977
Risner and
Silcox 1977
Risner and
Goldberg 1983
baboon
rhesus
baboon
rhesus
dog
Drug
Cocaine
Morphine
Amphetamine
Ethanol
Pentobarbital
Caffeine
Cocaine 3840 (4800)
Diethylpropion 3120 (3600)
Chlorphentermine 1820 (3600)
Fenfluramine 0
Mean Breakpoint
2850 (6400)
1608 (4800)
1383 (3200)
1050 (2400)
967 (1600)
458 (1600)
Heroin 10667 (12800)
Codeine 6400 (6400)
Dextropropoxyphene 3733 (6400)
Pentazocine 2267 (3200)
Secobarbital 4800 (4800)
Cocaine 4320 (4800)
Pentazocine 1653 (2400)
Ketamine 192 (256)
Cocaine 1435 (3750)
Amphetamine 652 (1350)
Mazindol 650 (1350)
Fenfluramine 15 (30)
Cocaine 2430 (3750)
Nicotine 390 (510)
dog
The data depicted are the mean break points for each drug used in
each study. The numbers in parentheses are the highest ratios
attained for that drug in the study.
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Table 2. Correlations of Breakpoint Data from Drug
Self-Administration Studies with DAWN Mentions from 1985.
Drug
Normalized Mentions 1985
Breakpoint ER ME
Secobarbital
Cocaine
Diethylpropion
Heroin/Morphine
Amphetamine
Chlorphentermine
Mazindol
Methylphenidate
Ethanol
Pentobarbital
Codeine
Dextropropoxyphene
Caffeine
Nicotine
Pentazocine
Fenfluramine
Spearman Rank
111
100
81
56
49
47
45
38
37
34
34
20
16
16
12
0.5
508 107
13501 643
16696
1118
1315
77
377 3 0
21090 1288 161
178 44 10
1014 351 33
1876 234 45
617
Correlation Coefficient 0.28
10
0.35
Deaths
21
152
0
353
8
0
0.41
Breakpoint data for the drugs have been normalized, cocaine =
100. Emergency room (ER) and medical examiner (ME) mentions and
deaths are from the 1985 DAWN data system. None of the
correlations are significant; critical (rs) 0.05 (2), 14=0.54
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complete a ratio, i.e. until the "break-point" of the performance
is reached. Breakpoints have been used to compare the relative
reinforcement efficacies of drugs. Table 1 summarizes the
available break-point data in animals for certain abused drugs.
As can be seen in Table 2, there is a poor correlation between
the breakpoint data from drug self-administration studies in
animals, and the data from the DAWN system. The numbers of
emergency room and medical examiner mentions as well as the
number of deaths reported for the drugs listed were not
significantly correlated with the order of drugs determined from
progressive ratio tests. Thus. it would appear that the relative
reinforcing efficacy of drugs as determined in animals is a poor
predictor of drug use in humans. Although there are many caveats
in this interpretation, the basic tenet of this conclusion is
probably true.
We will turn now to the issue of whether drugs are especially
reinforcing to certain populations. During the development of
the ARCI and the validation of its subscales, it was observed
that a certain constellation of items were associated in a
dose-related manner with certain abused drugs. These items were
designated as the Morphine-Benzedrine Group scale which measures
feelings of popularity, efficiency, pleasantness, satisfaction,
and ease in talking. Morphine-like drugs (Fraser et al., 1961),
amphetamines (Martin et al., 1971). and barbiturates (Fraser et
al., 1961) produced dose-related increases of MBG scores. These
subjective effects of morphine which were reported by abstinent
heroin addicts contrasted with those reported by Smith and
Beecher (1962) in non-addict subjects. A list of somatic and
physical activities characterizing morphine and heroin includes:
itchy, nauseated, dizzy, blurry-eyed, drowsy, tired, sleepy,
sluggish, weak, heavy-lidded, fuzzy-headed, mentally cloudy,
mentally slow, groggy, dreamy and irritable. Furthermore, Hill
et al., (1962) as well as other investigators had observed that
abstinent heroin addicts had elevations on the depression (D)
scale of the MMPI. Although the prisoner addicts, who were
experimental subjects on the wards of the ARC, reported a number
of depressive symptoms, none had a depressive psychosis. That
is, they did not feel worthless, they had a good sense of humor,
were not impotent, did not have diminished libidos, had good
appetites, and had few sleep problems. The negative feeling
states that they reported seemed to be polarly opposite to many
of the euphoric symptoms reported after the administration of
morphine, amphetamine, and barbiturates. These negative feeling
states were designated by Martin et al., (1977) as hypophoria and
include feelings of unpopularity, ineptness and inefficiency, a
negative perception of life, and of being unappreciated. These
negative feelings are decreased by single doses of opiates,
amphetamines and barbiturates (Hill et al., 1963; Haertzen 1966;
Martin et al., 1971; Martin et al., 1974). A questionnaire was
devised which not only measured feelings of hypophoria but also
feelings related to egocentricity, impulsivity, need, and
sociopathy. The combined score of these subscales was called the
ARC Maturation Scale and measures immaturity. The first study
employing this scale examined groups of prisoner addicts,
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alcoholics who had sought treatment, and a group of students and
faculty of a theologic seminary (Martin et al., 1977; Hewitt and
Martin 1979; Martin et al., 1978). These data show that there is
a highly positive correlation between alcoholism, narcotic abuse,
and other antisocial behavior, and scores on the ARC Maturation
Scale and its subscales.
Thus, the reinforcing properties of drugs of abuse may be
especially strong in subjects who have a high degree of
hypophoric feelings. Whether there are animal models of
hypophoria, or whether animal models can be developed, is not
known at the present time. It may be that affective state (e.g.
hypophoria and depression) is a critical dimension which
predisposes individuals to drug abuse. It is important to
realize that the ability of a drug to transform feelings of
hypophoria into feelings of well being is not necessarily a
pernicious property; rather, it may have practical therapeutic
value. Early studies by Martin suggested that hypophoria was
negatively related to age. More recent studies support these
findings. The high vulnerability of adolescents to the use and
abuse of drugs probably subsides with age in most people.
Although identifying the positive reinforcing properties of drugs
may serve a useful exercise in preventive medicine, it has not
provided an adequate solution to the pernicious and toxic
properties of drugs of abuse. It is our opinion that the results
of screening methods for identifying reinforcing properties of
drugs should not be overinterpreted, and that these properties
may provide valuable clues for identifying drugs of therapeutic
value.
A complete reference list is available from the authors.
Edgar T. Iwamoto, Ph.D., Associate Professor of Pharmacology,
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Biological Evaluation of Compounds for Their
Physical Dependence Potential and Abuse
Liability. Xl. Drug Testing Program of
the Committee on Problems of
Drug Dependence, Inc. (1987)
A. Jacobson
The analgesic testing program of the Committee on Problems of Drug
Dependence (CPDD) has been concerned with the biological evaluation
of compounds for their physical dependence potential and abuse
liability for more than 37 years. Although the name of the
Committee was modified from the “Committee on Drug Addiction and
Narcotics” (of the National Research Council, in the National
Academy of Sciences), at least one of the Committee’s main purposes
has remained constant over almost four decades - to provide
scientific information about a drug’s potential for abuse, as a
public service. For the past several years the CPDD has attempted
to find procedures and laboratories which would be adequate to
provide information about two other drug classes, the stimulants
and depressants. This year, the groups involved with the
stimulant/depressant program examined a number of compounds at the
request of the World Health Organization, and provided the obtained
information to that organization under the auspices of the CPDD.
Unlike the analgesic testing program, however, the
stimulant/depressant program has not, as yet, been opened for
examination of compounds submitted from the two other groups which
have been noted to be part of our constituency (Jacobson, 1987),
the universities and the pharmaceutical industry.
ANALGESIC AND STIMULANT/DEPRESSANT LABORATORIES
Three groups are concerned with the evaluation of compounds as
analgesics: the Medical College of Virginia (MCV) (Drs. M. Aceto,
L. Harris, E. May, and E. Bowman), the University of Michigan (UM)
(Drs. J. Woods, F. Medzihradsky, C. Smith, G. Winger, and D.
Gmerek), and NIDDK; NIH (Dr. A. Jacobson and M. Mattson). The
complete work of the MCV and UM groups is published in this
monograph (Aceto et al. 1988; Woods et al. 1988), and should be
consulted for detailed information on the evaluated compounds.
Five groups have been involved with the evaluation of the stimulant
and depressant classes of compounds: the University of Chicago
(Drs. C. Johanson, S. Evans, and K. Grant), the Medical College of
Virginia (Drs. G. Patrick, L. Powell, and L. Harris), the Johns
Hopkins University (Drs. R. Griffiths, N. Ator, and J. Brady),
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NIDDK, NIH (Dr. A. Jacobson, M. Mattson), and NIDA (Dr. E. Cone).
The report from the stimulant/depressant laboratories has been
submitted to the CPDD and the World Health Organization. It was
prepared by a subcommittee (Drs. C. Johanson, G. Patrick, L. Harris
and A. Jacobson), and it is included in this paper.
DRUG TESTING PROGRAM STATISTICS
The number of compounds sent to MCV and UM has varied considerably
over the past nine years. This year (5/1/86 to 4/30/87) the number
of compounds which were sent to MCV and UM was 49 and 40,
respectively, within the standard deviation of the mean for the
previous eight years. There has been a change in the procedures of
the two groups. MCV has undertaken all of the single dose
suppression and precipitated withdrawal studies in the rhesus
monkey for new compounds, and has continued to examine compounds by
rat infusion and in their antinociceptive assays (tail flick and
PPQ), and the assay for narcotic antagonist activity (TFA) in mice.
UM has continued their study of the effect of the new compounds in
vitro (rat brain membrane binding studies, and in the electrically
stimulated mouse vas deferens) and, when desired, in drug
discrimination and self administration in the rhesus monkey. Both
groups will continue to study compounds in primary physical
dependence in the monkey. My group at NIH, NIDDK, studies the
antinociceptive properties of the compounds in the hot plate assay
in mice, as well as some in vitro assays when indicated. The
number of reports. which will be included in this year’s Annual
Report from MCV and UM are either slightly above the mean, or very
near the mean, respectively, of the number included in their
reports in the past 8 years.
We have seen a continued diminution of the number of compounds
submitted from industrial sources in the US (3% of the total number
of compounds received for evaluation from 5/1/86 to 4/30/87);
however, submissions from foreign industry (12%) has remained at
about the mean of the percentage determined for them over the
previous 8 years (10%). We have also seen a slight decline in the
number of compounds submitted by US universities (27% - the mean is
33% ± 9%), and a decided increase in the number of compounds
submitted by foreign universities (32% - mean of 14% ± 11%). The
NIDA/DEA series of fentanyl-like compounds which were examined this
year was extensive (22% of the total number), well over the mean of
the number usually received from that source (2%). The total
number of compounds we have examined this year increased
considerably (by ca. 26%) over the mean of the number submitted
during the previous three years. Thus far, as one source declines,
another increases. Overall, 59% of the examined compounds
originated in university laboratories, 15% were from industrial
sources, and 25% were from US governmental agencies. It should be
mentioned that the standard deviations of the mean of all of these
sources are very large; the percentage from any one source has
undergone considerable fluctuation over the last several years.
Nevertheless, it is obvious that there has been a statistically
significant decline in US industry interest in narcotic analgesics
over the past decade, but not of foreign industry interest.
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CLASSES OF OPIOID-LIKE COMPOUNDS, AND SPECIFIC COMPOUNDS OF
INTEREST AMONG THE EXAMINED OPIOIDS
The 72 compounds which have been evaluated as analgesics in the
reports from MCV (Aceto et al., 1988) and UM (Woods et al., 1988)
have been distributed, according to their structural similarity,
among nine tables appended to this report. The compounds are
conveniently classified as the 4,5-epoxymorphinans (tables 1 and
2), the morphinans and 6,7-benzomorphans (table 3), and methadone-
like and pethidine-like compounds (table 4). The pethidine-like
compounds are continued in table 5, with the considerable number of
fentanyl-like compounds in tables 6 and 7. Compounds which are not
as easily labelled by a conventional class are shown as the
miscellaneous compounds in tables 8 and 9. Structure-activity
relationships are, perhaps, more easily seen when compounds are
grouped in this way, and the evolution of the structural types can
be discerned by comparison with those shown in my previous reports
(Jacobson, 1987).
The CPDD has been examining 4,5-epoxymorphinans for the past four
decades. Heroin, morphine, codeine, nalorphine, naloxone and
naltrexone are classified as 4,5-epoxymorphinans. This year we
have a remarkable group of six new compounds in that class (NIH
10420, 10426, 10427, 10443 - 10445 in table 1), submitted by our
pharmaceutical industry constituency. Some of these compounds have
a very long duration of action as narcotic antagonists, others show
potent agonist and antagonist activity. The activity of some or
all of these compounds may be due to their interaction with various
opioid receptors in an irreversible manner. That is, they may be
acting as affinity ligands which, unlike most other affinity
ligands, easily access the brain on parenteral introduction. For
example, pretreatment of a non-dependent rhesus monkey with 0.35
mg/kg of NIH 10445 blocked the acute effects of morphine for two
weeks (Aceto et al., 1988). NIH 10420 clearly substituted for
morphine in the SDS assay and had morphine-like potency in the PPQ
assay, it showed weak antagonist properties in precipitated
withdrawal studies - two monkeys were in withdrawal for 3 days,
even after morphine was given to them (Aceto et al., 1988). NIH
10426 was a mixed agonist-antagonist on the mouse vas deferens. It
displayed fairly potent antagonist actions to U50,488, suggesting
selectivity for kappa opioid receptors (Woods et al., 1988). Two
of these compounds appeared to be fairly “pure” antagonists, NIH
10443 and 10444. All of the six compounds have a cyclopropylmethyl
group on the nitrogen atom and a 6-keto moiety, as in naltrexone.
Half of the six had a phenolic hydroxyl, the other half a methoxy
group on the aromatic ring, as in codeine. The difference between
these compounds and former 4,5-epoxymorphinans lies in the C-14
position. Naltrexone has a C-14 hydroxyl group, but these
compounds have para-substituted cinnamoylamino moieties at C-14,
the para substituent being either bromine, chlorine or a methyl
group. An amide at the C-14 position is a little unusual.
However, Dr. S. Archer’s group (Archer et al., 1985) prepared
chloroacryloyl amides (NH-CO-CH=CH-Cl) at the C-6 position in
structurally similar compounds and found them to be good Michael
acceptors (i.e., potential affinity ligands).
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The industrial constituency has also provided us with a potent
compound which was classified among the miscellaneous compounds
(NIH 10412, table 8), although it somewhat resembles to 4,5-
epoxymorphinans. It is a potent agonist-antagonist. It clearly
indicates the evolution of that class of analgesic.
A structurally interesting group of compounds is being prepared by
the second of our constituencies, the university group. NIH 10500,
shown in table 3, is based on the morpbinans. It is reminiscent of
the Diels-Alder products which gave us etorphine and diprenorphine.
However, the new ring formed beta, rather than alpha, between C-6
and C-14, providing a beta C-7 side-chain, rather than the usual
alpha as in etorphine. These compounds should, in the future,
provide us with information about the conformational requirements
of the opioid receptors for those rings. At the moment, such
compounds pose complex problems in nomenclature. We should have
further biological information about that series next year. The
university constituency has also given us compounds resembling PCP
structurally (NIH 10531, table 5), but which seem to have
pethidine-like, rather than PCP-like, activity (see, also, NIH
10012-10014 in table 4). These compounds do not bind appreciably
to the PCP receptor. A re-examination of pethidine itself (NIH
10522 or 5221, table 4) exemplifies our ability to replicate
experiments, and provides base-line information for comparison with
the pethidine-like bicycle compounds, NIH 10479, 10480, 10481,
10529 and 10530 (table 9), some of which had agonist activity
comparable to, or greater than, pethidine in our mouse
antinociceptive assays.
Two university compounds examined this year, NIH 10399 and 10400
(table 2), are quite similar to the aforementioned Archer et al.
(1985) series of compounds. They are potent narcotic antagonists.
The data provided to the university groups, most of which are
supported by NIDA grants, will eventually be published by these
groups with acknowledgement to either MCV or UM and the CPDD for
the provision of data.
Lastly, a governmental unit submitted a considerable number of
fentanyl-like compounds. Our data enabled them to proceed with the
scheduling of the compounds. The structures of the compounds are
shown in tables 6 and 7 (NIH 10468, 10482-10491, 10493, 10505-
10506, and 10538). Some of the compounds are 50 to 100 times as
potent as morphine in the SDS assay in monkeys, and in the mouse
antinociceptive assays. It should be noted that the university
constituency is also submitting fentanyl-like compounds (NIH 10476-
10478, in table 6) which are fairly potent in the mouse
antinociceptive assays.
STIMULANT/DEPRESSANT EVALUATION
At the request. of the World Health Organization (WHO) the Committee
on Problems of Drug Dependence (CPDD) agreed to undertake the
evaluation of the dependence potential of six compounds proposed
469
for review of possible control under the 1971 Convention on
Psychotropic Drugs. The drugs were supplied to the CPDD by the
International Federation of Pharmaceutical Manufacturers
Associations (IFPMA). Of the six original drugs, one was
unavailable and a second was provided both as a free alcohol and as
a carbamate.
The compounds were assigned for evaluation to the CPDD
Stimulant/Depressant Testing Group. I served as the coordinator at
NIDDK, NIH, and the laboratories at the University of Chicago,
Johns Hopkins University and Virginia Commonwealth University
served as the biological testing sites. All compounds were tested
by code number and the laboratories were blind as to the structures
until the report was prepared. Due to pressures of time, all tests
on the drugs were not completed at the time of the initial report.
Subsequent data were provided for the report to the Expert
Committee (not included herein). One drug proved to be so unstable
in aqueous solution as to preclude many tests (stability studies
were carried out in a NIDA laboratory).
A summary of the data obtained for the six compounds can be found
in table 10 along with a number of control drugs. The test
procedures were designed to give some information concerning the
pharmacological resemblance to known drugs, their physical
dependence potential and the reinforcing effects of the compounds.
The results will be presented in this order for all of the drugs
tested.
CPDD 0011, 3-Methyl-1-pentyn-3-ol (Methyloentynol, meparfynol)
Methylpentynol, like the barbiturates and benzodiazepines, is
active in the inverted screen tests and depresses spontaneous
activity. In drug discrimination procedures, the drug was
generally recognized as a barbiturate. In physical dependence
studies, the drug partially substituted for pentobarbital in
dependent rats and exhibited barbiturate-like abstinence signs on
withdrawal. The fact that the drug may produce physical dependence
was confirmed in one monkey in the self-administration study.
Methylpentynol is readily self-administered indicating that it has
positive reinforcing properties. In all of these tests, the drug
has between 1/5 and 1/8 the potency of pentobarbital.
CPDD 0011A. 3-Methyl-1-pentyn-3-ol-carbamate (Methylpentynol
carbamate, Meparfynol carbamate, etc.)
This carbamate analog of methylpentynol is active in the inverted
screen test. Its effect on spontaneous activity is one of slight
stimulation. This is often seen with low doses of barbiturates.
Higher doses of this compound were precluded by toxicity. Drug
discrimination studies are in progress but have been impeded by
toxicity. Like the parent compound, the drug partially substituted
for pentobarbital in dependent rats and exhibited barbiturate-like
abstinence signs on withdrawal. The reinforcing properties of this
drug have not been tested due to limited supply of the compound.
In the tests completed, this drug is about twice as potent as the
parent compound.
470
CPDD 0017, 2-Methyl-4-(2,2,2-trichloro-1-hydroxyethoxy)-2-pentanol
(Chloralodol, chlorhexadol).
This prodrug for trichloroethanol is active in the inverted screen
test and in depressing locomotor activity, when administered in
sesame oil. In drug discrimination studies, it was not identified
as diazepam-like by rats trained on diazepam, when given in aqueous
solution immediately upon dissolution. Due to the chemical
instability of this compound on standing in aqueous solution, it
has not been tested in the other test procedures. The compound
appears relatively impotent, approximately 1/15 the potency of
pentobarbital.
CPDD 0013, N-(Aminocarbonyl)-2-bromo-2-ethylbutanamide (Carbromal)
This drug may be metabolized to a barbiturate-like compound or to a
bromide carrier. It is active in the inverted screen test, and
produced mild stimulant effects on spontaneous activity in the same
dose range. In drug discrimination studies it was identified as
pentobarbital-like by the pigeon, and there was partial
generalization in the pentobarbital-trained rhesus monkey. It has
not been tested in diazepam-trained rats or baboons. Studies of
physical dependence liability in the rat are in progress; the
compound has not been tested in drug self-administration. The
potency of compound CPDD 0013 appears to be in the range of 1/3 to
1/5 that of pentobarbital.
CPDD 0014, 5-(2-Chloroethyl)-4-methylthiazole ethanedisulfonate
(Clomethiazole edisilate, heminevrin)
This compound exhibited activity in both the inverted screen test
and depression of spontaneous locomotor activity. In drug
discrimination studies, it was identified as pentobarbital-like by
the pigeon, but it did not generalize in pentobarbital-trained
rhesus monkeys, diazepamtrained rats or lorazepam-trained baboons.
In physical dependence studies in the rat, the compound exhibited
only slight substitution in pentobarbital-dependent animals. Signs
of abstinence were not seen following discontinuation of the drug.
The drug appears to be reinforcing in that it was self-administered
by rhesus monkeys. Compound CPDD 0014 is approximately 1/3 to 1/5
as potent as pentobarbital.
CPDD 0016, 2,2,2-Trichloroethanol dihydrogen phosphate (Triclofos)
This trichloroethanol prodrug was active in both the inverted
screen test and in depression of spontaneous activity. It was
identified as diazepam-like by the rat in discrimination studies,
but did not generalize in lorazepam or pentobarbital-trained
baboons. Drug discrimination studies in pentobarbital-trained
pigeons and rhesus monkeys are in progress. In physical dependence
studies in the rat, the high dose substituted for pentobarbital,
and a mild abstinence syndrome was observed following withdrawal.
The compound has not been tested in self-administration procedures.
CPDD 0016 is rather weak, with potency in the range of 1/15 to 1/20
that of pentobarbital.
Standard Compounds
The laboratories also have evaluated additional compounds generally
under blind conditions that could be considered standards for the
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test compounds. These data are included in this report for
purposes of comparison.
Mearobamate (CPDD 0018)
Meprobamate is active in the inverted screen test and in depressing
locomotor activity. In drug discrimination studies, it substitutes
for diazepam in the rat and for pentobarbital in the baboon, but
does not substitute for pentobarbital in the pigeon or rhesus
monkey nor for lorazepam in the baboon. Physical dependence
liability has not been investigated in our study, but historical
data suggest that it does substitute for barbiturates in dependent
animals and can produce primary physical dependence. Self-
administration studies in the rhesus monkey are in progress.
Methaqualone (CPDD 0007)
Methaqualone is active in the inverted screen test and in
depression of locomotor activity. Drug discrimination studies
reveal that it substitutes for pentobarbital in the rhesus monkey
and diazepam in the rat, but not for pentobarbital in the pigeon or
baboon nor for lorazepam in the baboon. In physical dependence
studies, it substituted for pentobarbital in dependent rats, and
signs of abstinence occurred upon withdrawal. Methaqualone was
self-administered by rhesus monkeys. The potency of methaqualone
was similar to that of pentobarbital in most studies.
Ethchlorovvnol (CPDD 0015)
Ethchlorovynol was active in both the inverted screen test and
suppression of locomotor activity. In drug discrimination studies
it was identified as pentobarbital-like by both pigeons and rhesus
monkeys, but has not yet been tested in benzodiazepine-trained
animals. Studies on physical dependence liability in the rat are
in progress. The compound is self-administered by rhesus monkeys.
It appears to be approximately 1/2 to 3/4 as potent as
pentobarbital.
Chloral Hydrate
In drug discrimination studies, chloral hvdrate did not substitute
for pentobarbital nor for lorazepam in the baboon. However, with
intravenous self-injection in the baboon, reliable self-
administration was maintained.
ABBREVIATIONS USED IN TABLES 1 - 9.
ED50 OR AD50: Antinociceptive assay (ED50, sc injection except
where noted, mice) [Confidence limits are listed in the MCV and UM
reports (Aceto et al. 1988; Woods et al. 1988)]: HP = hot plate; N
= Nilsen; PPQ = phenylquinone; TF = tail flick; TFA = tail flick
antagonism vs. morphine. These assays are performed at MCV, except
for the HP and N (carried out at NIDDK, NIH).
I = inactive, without a reasonable dose-response relationship,
or insufficiently active for statistical analysis.
EC50 Determinations:
These assays are done at UM. RBH = binding affinity, in the
presence of 150mM NaCl, to rat cerebrum membrane preparations, in
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nM (parenthesized number is the +sodium/-sodium [+Na/-Na] ratio).
EC50 was determined by displacement of 0.5nM [3H]etorphine. T h e
EC50 of morphine, for comparison = 23.6 (1.69). NE = no effect.
NOTE: The present EC50 data cannot be directly compared with those
from previous reports (Jacobson 1984, and preceding years) in which
-Na values were quoted. However, the former numbers can be
recalculated for comparison with those which are currently utilized
through the use of the +Na/-Na ratio.
VD = electrically stimulated mouse vas deferens EC50 values,
rounded to one significant figure. Agonist activity is stated
using "E" followed by a negative number: E = 10-x M, where x = the
negative number, thus: 1E-3 = 0.001 M (1 mM), 1E-6 = 1 uM, and 1E-9
= 1 nM (parenthesized numbers are maximum percent inhibition at
EC50); [bracketed letters: A = antagonized by 10-7 M naltrexone;
NA = not antagonized by naltrexone; NE = no effect on inhibition of
twitch; SA = slight antagonism by naltrexone]. Compounds which
suppress the twitch and are not antagonized by naltrexone or UM 979
[NIH 8859, (-)-5,9-alpha dimethyl-2-(3-furylmethyl)-2'-hydroxy-6,7-
benzomorphanl are said to be non-opioid agonists (e.g. clonidine
can suppress the twitch, but is not antagonized by naltrexone. It
is a non-opioid agonist). (The effect of UM 979 is not noted in
this report, but see the UM report (Woods et al. 1988) for these
data). Compounds which bind with reasonable affinity in the rat
brain homogenate assay, suppress the twitch in the VD, but are not
blocked by narcotic antagonists may have antagonist properties,
also. This is experimentally determinable by observing their
antagonism to morphine’s suppression of the twitch in the VD
preparation (for these data see Woods et al. 1988).
Data From Monkey Colonies:
These data are from either MCV or UM. SDS = single dose
supression: NS = no suppression; CS = complete suppression; PS =
partial suppression. (Parenthesized numbers = dose range studied,
in mg/kg; if CS, then dose at which CS was observed’is noted in the
parentheses). Potency comparison with morphine [Ml may be stated,
in brackets.
.NW = studies in non-withdrawn monkeys: PW = precipitated
withdrawal at dose levels, in mg/kg, indicated in parentheses &/or
comparison with naloxone [N], in brackets; NP = no precipitation;
SP = slight precipitation.
Other Studies (OTHER):
RI = rat continuous infusion (from MCV): SM = substitution for
morphine procedure [NS = no substitution for morphine; CM =
complete substitution; PS = partial substitution], and PPD =
primary physical dependence.
ND = non-dependent monkeys: M-like = morphine-like effect.
PPD = primary physical dependence (in the rhesus monkey).
SA = self-administration (from UM): NE = no effect; High =
codeine-like; IN = intermediate between saline and codeine; SE =
slight effect.
DD = drug discrimination (from UM).
Previous Reports (PR):
Previous work on a compound is noted by year, the year listed in
473
the monograph title (e.g. Problems of Drug Dependence 1986). Note
that the date of publication of the monograph generally occurs one
year after the titled year of the monograph. The data which have
been published in previous reports are shown by a "PR" in the
appropriate column (e.g., a PR (1983) in the SDS column would
indicate that the SDS work was cited in "Problems of Drug
Dependence 1983", which was published in 1984).
N O T E : The numbers used in the tables may be rounded. For precise
values, and details of the procedures, see the MCV and UM reports
in these Proceedings (Aceto et al. 1988; Woods et al. 1988).
Abbreviations for structural formulae:
C B M =cyclobutylmethyl; ME=methyl;
. C P M=cyclopropylmethyl;
Et=ethyl; n-Pr=propyl; i-Pr-
isopropyl; n-Bu=butyl.
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TABLE 1 - 4.5-EPOXYMORPHINANSa
a) See text for explanation of column headings. b) Resembles irreversible agonists. Does not antagonize
morphine. Effect partially on delta receptors. c) Long duration of action. d) Weak antagonist, but very
long acting (3 days). e) Prolonged effect - slow return to codeine baseline. f) Antagonized morphine and
U50,488. Also has kappa actions. g) Savere withdrawal, not relieved by morphine. h) Antagonized
sufentanil. i) Antagonized sufentanil - "puren antagonist. j) Pretreatment (0.3mg/kg) blocked acute
effects of morphine for 2 weeks. k) Blocked weight loss associated with morphine.
TABLE 2 - 4,5-EPOXYMORPHINANS (CONTINUED)a
a) See text for explanation of column headings.
TABLE 3 - MORPHINANS AND 6,7-BENZOMORPHANSa
a) See text for explanation of column headings. b) 1982. c) Mild withdrawal (unlike morphine or (-)-
metazocine. d) SA - 1984, ND - 1969.
TABLE 4 - METHADONE-LIKE AND PETHIDINE-LIKE COMPOUNDSa
a) Sea text for explanation of column headings.
TABLE 5 - PETHIDINE-LIKE COMPOUNDS (CONTINUED)a
a) See text for explanation of column headings. b) Displacement assay using [3H]DAGO, where morphine =
4 nM.
TABLE 6 - FENTANYL-LIKE COMPOUNDSa
a) See text for explanation of column headings.
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TABLE 7 - FENTANYL-LIKE COMPOUNDS (CONTINUED)a
a) See text for explanation of column headings.
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TABLE 8 - MISCELLANEOUSa
a) See text for explanation of column headings. b) Cumulative doses. c) Behavioral effects, no weight
loss.
TABLE 9 - MISCELLANEOUS (CONTINUED)a
a) See text for explanation of column headings.
TABLE 10. SUMMARY OF RESULTS FROM THE REPORT OF THE STIMULANT/DEPRESSANT TESTING GROUP OF THE COMMITTEE ON PROBLEMS OF DRUG DEPENDENCE
a) ONE MONKEY THAT TOOK THE GREATEST AMOUNT SHOWED WITHDRAWAL SIGNS. b) SLIGHT STIMULATION AT DOSES EFFECTIVE IN INVERTED SCREEN.
c) COMPOUND UNSTABLE IN WATER. d) RESULTS TO DATE INDICATE WILL AT LEAST BE PARTIAL BUT HIGHER DOSES NEED TO BE TESTED.
e) SIDE EFFECTS NOTED AT LOW DOSES BUT NOT AT HIGHER f) HIGHEST DOSE WAS 56 MG/KG PO IN PENTOBARBITAL ANIMALS. HIGHER DOSES WERE NOT
TESTED DUE TO LACE OF COMPOUND. g) HAS BEEN FOUND POSITIVE BY OTHER LABORATORIES. h) ONLY TESTED IN MIDAZOLAM TRAINED PIGEONS.
i) WITH IV SELF-INJECTION, RELIABLE SELF-ADMINISTRATION WAS MAINTAINED.
Dependence Studies of Mew
Compounds in the Rhesus Monkey,
Rat, and Mouse, 1987
M. Aceto, E. Bowman, L. Harris, and E. May
All the drugs except cocaine, (+)- and (-)-metazocine, -butyrolactone, cotinine
and 4-(3-pyridyl)-4-methylaminobutyric acid were supplied by Dr. Arthur
Jacobson, Medicinal Chemistry Section, NIADDK, NIH under the auspices of
the Committee on Problems of Drug Dependence, Inc. The chemical
structures of the test compounds were unknown to us when they were
originally submitted.
For the most part, the procedures described by Seevers and his colleagues
(1936, 1963) and Deneau (1956) regarding the facilities and training of the
monkeys were used and a brief description follows. The monkeys were
injected with 3.0 mg/kg s.c. of morphine sulfate every 6 hr for at least 90 days
before being used. This dose schedule was reported by Seevers and Deneau
(1963) to produce maximal physical dependence.
Modified procedures for the precipitated withdrawal (PPt-W) and single-dose
suppression (SDS) tests were reported by Aceto and co-workers (1977 and
1978). The PPt-W test was initiated by the injection of a test drug 2 1/2 hr
after an injection of morphine and the animals were observed for signs of
withdrawal. The SDS test was started approximately 15 hr after the last dose
of morphine at which time the animals were showing withdrawal signs. The
onset and duration of action of the test drug were noted. In both tests, a
vehicle control and an appropriate positive control (naloxone•hydrochloride,
0.05 mg/kg or morphine sulfate, 3.0 mg/kg) along with 2 or 3 different
treatments (doses) of a test compound were randomly allocated to the 4 or 5
monkeys of a group. Usually, 3 or 4 groups per compound were used. All
drugs were given subcutaneously (1 ml/kg) and the vehicle was water except
where indicated. The observer was “blind” with regard to the treatment given.
A minimal 2-week washout and recuperation period between tests was
allowed. In the primary physical dependence (PPD) tests, the animals of a
group received the drug every 4-6 hr for 30-50 days. They were placed in
abrupt withdrawal and challenged with naloxone periodically, then observed
for signs of physical dependence. All potency estimates are rough
approximations only.
The rat-infusion method was reported by Teiger (1974) and certain
modifications are indicated as follows. Semi-restrained, male, Sprague-
Dawley rats were medicated by continuous infusion through indwelling
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intraperitoneal cannulas for 6 days with a drug. Rats were anesthetized after
which each was fitted with a specially prepared cannula which was passed
subcutaneously from the nape of the neck to the lateral side of the lower
abdomen and then inserted into the peritoneal cavity. The cannula was
anchored at both ends with silk sutures and attached to a flow-through, swivel
mechanism which allowed the animal to move about in the cage and eat and
drink normally. The swivel was connected to a syringe which was attached to
a syringe pump. The animals received 7-10 ml of solution every 24 hr.
In the substitution for morphine (SM) test, the animals first received morphine
(50 mg/kg/24 hr on the first day, 100 mg/kg/24 hr on the second day, and 200
mg/kg/24 hr from days 3-6). Then, a test drug was substituted for 2 days.
The morphine controls received an infusion of water. The animals were
observed for changes in body weight and for behavioral-withdrawal signs for
1/2 hr at 24, 48, 72 and/or 96 hr after stopping the infusion of morphine.
In the primary physical dependence (PPD) study, the rats received test
compound for 6 days and then were placed in abrupt withdrawal and observed
as above. Occasionally a drug was given with morphine.
Three mouse tests were used in our laboratory to provide a preliminary
estimate of the potency and profile of activity of each test compound. The tests
were the tail-flick agonist (TF) and the morphine antagonist (TV vs M) tests
and the phenylquinone (PPQ) test (Dewey et al., 1970; Dewey and Harris,
1971). Reference-standard data for these tests are shown in Table 1. In
addition, Dr. Jacobson sometimes provided us with estimated starting doses.
These doses were based on results obtained from the mouse-hot plate (HP)
(Eddy and Leimbach, 1953; Jacobson and May, 1965; Atwell and Jacobson,
1978) and Nilsen (N) (Penine et al., 1972) tests from this laboratory.
Reference data for these tests are shown in Table 2.
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Table 1
Comparative Data-ED50 mg/kg s.c. (95% C.L.) of Selected Standards in 3
Mouse Agonist-Antagonist Tests
Drug Tail-Flick Tail-Flick Phenylquinone
T e s t Antagonist Test Test
Pentazocine 15% at 10.0 18 (12-26) 1.7 (1.0-2.5)
Cyclazocine 17% at 1.0a 0.03 (0.020-0.78) 0.01 (0.005-0.03)
Nalorphine•HCl None at 10.0 2.6 (0.7-10.0) 0.6 (0.03-1.44)
NaIoxone•HCl None at 10.0 0.04 (0.01-0.09) No Activity
Naltrexone•HCl None at 10.0 0.007 (.002-0.02) No Activity
Morphine Sulfate 5.8 (5.7-5.9) ----- 0.23 (0.20-0.25)
aMice were ataxic at 3.0 and 10.0 mg/kg but there was no further increase in
reaction time.
Table 2
Comparative Data (ED50 mg/kg) [95% C.L.] from the Hot Plate and Nilsen
Assays
Hot Plate Nilsen
s.c./p.o, s.c./p.o,
Morphine Sulfate
Codeine Phosphate
Levorphanol Tartrate
0.98 (0.83-1.1) 13 (1.0-1.7)
6.3  (4.7-8.3) 8.3 (6.0-11.4)
5.8 (4.5-10.2) 7.4 (4.9-11.0)
13.5 (9.7-18.7) 14.7 (9.2-23.3)
0.2 (0.1-0.3) 0.2 (0.16-0.3)
- 2.5 (1.7-3.7)
5.3 (4.0-7.1) -
- -
Meperidine·HCl
(-)-Metazocine·HBr 0.6 (0.5-0.9) 0.5 (0.3-0.7)
10.6 (8.0-14.1) 26.0 (21.0-33.0)
Dihydromorphinone·HCl 0.19 (0.15-0.25) 0.2 (0.15-0.3)
0.9 (0.7-1.2) 1.8 (1.5-2.1)
Nalorphine·HCl
Cyclazocine
Pentazocine
Chlorpromazine·HCl
9.9 (5.7-2.1) 23.0 (16.2-32.7)
- -
1.5 (1.1-2.1) 0.1(0.0-7-0.16)
9.3 (6.7-12.8) 6.5 (4.4-8.8)
- -
1.1 (0.9-1.5) -
No dose response for naloxone and naltrexone.
Phenobarbital, amobarbital, oxazepam, flurazepam, meprobamate and
mescaline are inactive on the hot plate test.
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NIH 7569, (-)-2’-Hydroxy-2,5,9 -trimethyl-6,7-benzomorphan hydro-
chloride, (-)-Metazocine
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 0.81 (0.33-
1.98)
2) TF vs. M - Inactive
at 1.0 and
30.0
3) PPQ - 0.3 (0.1 - 0.9)
4) HP - 0.62 (0.45 -
0.85)
5) N - 0.46 (0.32 -
0.67)
MONKEY DATA
S D S
NIH 7659 did not substitute for morphine in the dose range of 1.0 - 4.0
mg/kg. There was a non-dose related reduction in withdrawal signs,
designated wet-dog shakes and rigid abdominal muscles (see fig.). In
addition, at the high dose, the signs salivation, drowsiness and slowing were
noted.
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NIH 7571, (+-Metazocine)
SEE OPTICAL ISOMER
NIH 7569 (ABOVE)
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg./s.c.)
1) TF - Inactive at 1.0,
10.0 and 30.0
2) TF vs. M - not done
3) PPQ - 14% at 3.0, 63%
a t 1.0 and 43% at
20.0
4) HP - Inactive at 20.0
5) N - Inactive at 20.0
RAT INFUSION
A .  S M
As shown in the figure, substitution of H2O or (+)- metazocine at 50 and
200.0 mg/kg/day for 2 days did not prevent loss of body weight or the
emergence of withdrawal signs (table) in abruptly withdrawn morphine-
dependent rats. (+)-Metazocine did not substitute for morphine.
B .  P P D
When (+)-metazocine given for 6 days at a dose regimen 1/2 that of morphine,
no loss of body weight was observed (see figure). However, 48 h after abrupt
withdrawal, the rats showed certain overt signs designated (wet-dog shakes,
rubbing and chewing but not squeaking and aggressiveness). Apparently, (+)-
metazocine produces a mild withdrawal syndrome different from that produced
by (-)-metazocine or morphine.
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NIH 7571 Table
Substitution for morphine and primary physical dependence studies
in the rat with (+)-metazocine
Treatment Hours after abrupt withdrawal and or substitutiona
2 4 4 8 72 96
H2O Controls
b 0.8 1.0 1.6 0
N=5
Morphine Infusionc 12.2d 6.0 d 5.0 d 0.4
N=5
(+)-Metazocine Infusione,f 1.2 6 . 0 d , g 4.6 0.2
N=5
Morphinec + (+)-Metazocineh 9.3 d 4.0 d 4.7 0.7
N=4, 1 died on day 9
Morphinec + (+)-Metazocinei 6.9d 5.2d 0.6 1.5
N=5,1 died on day 9
aMean number of withdrawal signs (hypersensitivity, squeaking, aggression,
wet-dog shakes, rubbing and chewing) noted during 12 hr observation periods
as specific intervals, b8 ml 24 hr, days 1-10, c50 mg/kg on day 1; 100 mg/kg
on day 2; 200 mg/kg on days 3-6 and H2O on days 7-10, 
dp = 0.05 or less
(one-tailed Mann Whitney U-Test), e25 mg/kg on day 1; 50 mg/kg on day 2;
100 mg/kg on days 3-6 and H2O on days 7-10, 
fall the rats in this groups
showed swollen features in the head and neck region, gonly signs noted were
wet dog shakes, rubbing and chewing, h200 mg/kg on days 7-8, i50 mg/kg
on days 7-8.
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MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
NIH 8211, (Cocaine•HC1)
1 ) TF - 1% at 1.0, 9% at
10.0 and 11% at
30.0
2 ) TF vs M - 0% at 1.0,
10.0 and 30.0
3 ) PPQ - 2.83 (0.97 - 8.28)
NIH 10017, (-)-N-Cyclopropylmetyl-3,4-dimethoxymorphinan-6-one
hydrobromide
MOUSE DATA-ED OR AD
50 95% C.L.) (mg/kg/s.c.)
1) T F -
2) TF vs. M - Inactive at
1.0 and 30.0
3) PPQ - 3.7 (1.6-8.8)
4) HP - 0.14 3.9 (2.8-5.5)
5) N - 11.1 (6.2-19.6)
NIH 10018, (-)-3,4-Dimethoxy-N-(2-phenylethyl)morphinan-6-one hydro-
bromide
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 0.1 (0.04-0.24)
2) TF vs. M - Inactive at
1.0 and 30.0
3) PPQ - 0.05 (0.02 - 0.12)
4) HP - 0.14 (0.01 - 0.18)
5) N - 0.02 (0.017 - 0.035)
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NIH 10261, m-Fluoronormethadone hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0,
and 30.0
2) TF vs. M - 22.5 (11.9 -
42.4)
3) PPQ - 3.1 (1.4 - 6.8)
4) HP - 22.8 (20.5 - 25.2)
NIH 10319, 10455, N-Propargyl-N’-(3-trifluoromethylphenyl)piperazine
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) T F vs. M - 1.0, 10.0 and
30.0
3) PPQ - 1. 5.8 (1.5 - 22.0)
2. 3.3 (0.34 -
32.54)
4) HP - 50% at 15% and
20.0, 60% at 100
Special TF vs M - (Naloxone Antagonism of ED80 of
NIH 10319 in PPQ Test)
Naloxone
Dose (mg/kg s.c.)
% Antagonism
40.0
20.0
11
14
10.0 25
1.0 11
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RAT INFUSION
A .  S M
AS can be seen in the first figure and table, NIH 10319 did not substitute for
morphine. Twenty-four hr after drug was substituted for morphine, the
animals were vocalizing and aggressive but displayed few wet-dog shakes and
little rubbing and chewing. However, severe tremors and eyelid ptosis, tail
jerks associated with clonic convulsions, rigidity and arched backs were
evident. This latter group of signs has never been seen in morphine-
withdrawn rats. At 48 hours, vocalization and some aggression and a few
wet-dog shakes were seen but the animals were still convulsing and dyspnea
and ptosis were also observed. At 72 hr, additional morphine withdrawal signs
emerged but the dominant feature was convulsions which developed when the
animals attempted to move about. One animal was found dead. By 96 hr, 2
animals were showing more wet-dog shakes than all the morphine control
animals. Another appeared moribund and died. At 120 hr, the two other
animals still showed morphine-like withdrawal signs. On day 11, (data not
shown) the survivors showed some weight gain. This observation may be
related to the fact that the animals receiving NIH 10319 drank little H2O during
the substitution period compared with the morphine controls.
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TABLE 1. Substitution of NIH 10319 for morphine in rat infusion test
HR IN WITHDRAWALa
24 48 72 96
H2O Control 0.6 0.4 0 0
(N=5)
Morphine Infusion
H2O Substitution 9.2
b
(N=5)
Morphine Infusion
NIH 10319 Substitution 5.8
(N=5)
8.6 1.8 2.5 b
3.6 5.5 5.4
aMean number of opioid-like withdrawal signs noted during 1/2 hr observation
bStatistically
period, at specified intervals.
significant differences (p<0.05 or less)b and H2O controls (8
ml/24 hr) or NIH 10319 substitution (200 mg/kg/24 hr. days 7-8).
Withdrawal signs evaluated were hypersensitivity, squealing, aggression, wet-
dog shakes, rubbing and chewing. Other overt signs observed are noted in the
report. One-tail test (Mann-Whitney U-test).
B .  P P D
In both groups of animals receiving different dose regimens of NIH 10319,
some morphine-like behavioral withdrawal signs but no body weight loss were
seen when drug was abruptly withdrawn (see Table 2). In addition, 2 animals
showed protruding eyeballs and deep red pupils 24 hr after the drug was
withdrawn. Regarding body weight, the animals gained during abrupt
withdrawal (see fig. PPD-body weight). This was in sharp contrast with the
weight loss observed in the NIH 10319- and morphine-treated rats in the
substitution test. However, the animals lost weight during the infusion and
this may be related to the sharp curtailment of water consumption (see fig.
PPD-water consumption) especially during the first 24 hr and on days 4-6.
On days 2 and 3, it seemed that some compensating mechanisms were
triggered and the animals drank. During abrupt withdrawal of NIH 10319,
water consumption increased.
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TABLE 2. Primary physical dependence rat infusion study (NIH 10319)
HR IN WITHDRAWALa
H2O Control
(N=5)
Morphine Infusion
H2O Substitution
(N=5)
NIH 10319 Infusionc
H2O Substitution
(N=5)
NIH 10319 Infusiond
H2O Substitution
(N=5)
24 48 7 2
0.6 0.9 0
9.2 b 8.6 b 1.8
9 .8 b 1.0 1.3
5 .8 b 1.6” 2.4 b
96
0
2.5
1.3
0.4 b
aMean number of opioid-like withdrawal signs noted during 1/2 hr observatic
period, at specified intervals. Hypersensitivity, squealing, aggression, we
dog shakes, rubbing and chewing. bStatistically significant differences
0.05 or less) between H2O controls and NIH 10319c (100 mg/kg/24 hr,
1-4; and 200 mg/kg/24 hr, days 5-6) or NIH 10319d (50 mg/kg/24, da
100 mg/kg/24 hr, day 4 and 200 mg/kg/24 hr, days 5 and 6) or m
controls. One-tailed test (Mann-Whitney U-test).
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Conclusion
NIH 10319 appears to have unique properties. It produces some morphine-
like behavioral withdrawal signs but no weight loss when given per se, yet,
when given to abruptly withdrawn morphine addicts, it produces a different
syndrome. One of the factors that can be associated with this curious profile
of activity is the fact that H2O consumption or regulation appears to be
drastically affected.
N I H  1 0 3 4 4 ,  4 - (m -Hydroxyphenyl)methylamino-1-(2-phenylethyl)piperidine
hydrochloride
MONKEY DATA
A. S D S
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 14% at .0, 13% at
10.0 and 8% at 30.0
2) TF vs. M - 5.8 (1.7 -
20.0)
3) PPQ - 0.2 (0.1 - 0.6)
4) HP - 0% at 20.0
This drug did not substitute for morphine. At the highest dose, it appeared to
exacerbate withdrawal.
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B. PPt-W
The drug elicited dose-related withdrawal signs. The syndrome did not appear
to be as severe as that produced by naloxone. Onset of action was prompt and
duration was about 1 hr. A potency estimate is about 1/100 that of naloxone.
NIH 10399 , 6 -Naltrexol- -methylacrylate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0,
10.0 and 30.0
2) TF vs. M - 0.008 (0.004
- 0.02)
3) PPQ - Inactive at 1.0 and
10.0, 11% at 30.0
4) HP - Inactive at 20.0
MONKEY DATA (Vehicle - HCl + H2O)
A. SDS
This drug did not substitute for morphine. Instead, it exacerbated withdrawal
(see SDS fig.).
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B. PPt-W
As shown in the figure, NIH 10399 precipitated withdrawal in nonwithdrawn
addicts. Onset of action is rapid. The duration of action is longer than that of
the reference standard naloxone. Potency is about 5 times that of naloxone.
NIH 10400, 6 -Naltrexol- -methylacrylate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 0.02 (0.009 -
0.07)
3) PPQ - Inactive at 1.0 and
10.0, 11% at 30.0
4) HP - Inactive
MONKEY DATA
A. SDS (Vehicle - HCl and H2O)
As shown in the figure, NIH 10400 did not substitute for morphine in the dose
range 0.002 - 0.05 mg/kg. The drug exacerbated withdrawal at the 2 higher
doses.
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B.  PPt-W
In nonwithdrawn morphine-dependent monkeys, NIH 10400 precipitated
withdrawal. The drug had a slower onset and longer duration of action than
naloxone and is approximately equipotent with it. The 0.002 mg/kg dose was
not plotted because N=1.
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NIH 10412, (±)-3-Cyclopropylmethyl-1,2,3,4,5,6,7,7a-octahydro-9-
hydroxy-4aH-4a,7-ethanobenzofuro(3,2-e)isoquinoline-5-methanol
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 3% at 0.001, 37% at
0.01, 35% at 0.1,
39% at 1.0, 41% at
10.0
2) TF vs. M - 2.7 (0.9-7.9)
3) PPQ - 0.03 (0.01 - 0.11)
4) HP - Inactive at 20.0
MONKEY DATA (Vehicle - lactic acid + H2O)
PPt-W
NIH 10412 promptly precipitated withdrawal in a dose-related manner (see
figure). The drug has a longer duration of action (longer than 2 1/2 hr) as
opposed to naloxone (90 min).
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NIH 10420, 14 - (p -Chlorocinnamoylamino)-7,8-dihydro-N-cyclopropyl-
methylnorcodeinone mesylate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg.kg/s.c.)
1) TF - Inactive at 1.0,
10.0 and 30.0a
2) TF vs. M - 6.0 (2.1 -
17.4)
3) PPQ - 0.2 (0.05 - 0.6)a
4) HP - Inactive at 20.0
aVehicle - Tween 80 + H2O.
MONKEY DATA (Vehicle Tween 80 + H2O)
A.  S D S
As shown in the fig., NIH 10420 produced a dose-related attenuation of
withdrawal signs. The onset of action was delayed by 30 min but the duration
was at least 2 1/2 hr.
B. PPt-W
During the period when naloxone was active, NIH 10420 showed very weak
antagonist properties (see figure). However, after 3-4 hr, the animals showed
signs of withdrawal which persisted for a long period in spite of the fact that
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morphine was given. These withdrawal signs were: fighting, contact
avoidance, slowing, wet-dog shakes, vocalization when abdomens palpated
even though their abdominal muscles were relaxed. The animals were in
obvious distress when handled. Two monkeys were in this state of
withdrawal for 3 days even though morphine was given.
NIH 10420 is an unusual compound. It nearly substituted for morphine in
withdrawn addicts but produced a delayed but long term withdrawal state
when given to nonwithdrawn addicts. This drug action in monkeys is
reminiscent of that of buprenorphine except that buprenorphine would
precipitate a full withdrawal syndrome without delay.
NIH 104326, 14 (p-Bromocinnamoylamino)-7,8-dihydro-N-cyclopropyl-
methylnorcodeinone mesylate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 7% at 0.1, 45% at
1.0, 25% at 10.0
and 19% at 30.0
2) TF vs. M - 2.3 (0.6 -
8.5)
3) PPQ -0.11 (0.03 - 0.4)
4) HP - Inactive at 5.0 to
20.0
Vehicle - Tween 80 + H2O.
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MONKEY DATA
A .  S D S
NIH 10426 nearly completely substituted for morphine. The drug acted
promptly and had a long duration of action. In fact, most of the animals did
not require morphine at noon and 2 of the monkeys at the highest dose did not
require it until the 6 p.m. injection period.
B.  PPt-W
This compound did not precipitate a withdrawal syndrome in the dose range
tested (see fig.). At the highest dose, the only signs noted during the entire 2
1/2 hr observation period were fighting, contact avoidance, restlessness,
drowsiness, tremors, wet-dog shakes and masturbation. The 0.1 mg/kg dose
was not plotted because N<3.
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NIH 10427, 14 -(p-Methylcinnamoylamino)-7,8-dihydro-N-cyclopropyl-
methylnorcodeinone mesylate
MONKEY DATA
A. S D S
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1)
2)
3)
4)
TF - 19% at 1.0, 21% at
10.0 and 46% at
30.0
TF vs. M - 5.7 (2.4 -
13.7)
PPQ - 0.1 (0.01 - 1.3)
HP - Inactive at 20.0
As shown in the figure, NIH 10427 nearly substituted completely for
morphine. The onset of action was prompt; however, the duration of action
was shorter than that of morphine.
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B. PPt-W
Although NIH 10427 showed only weak actions regarding precipitated
withdrawal during the usual 150 min of the assay (see fig.), some of the
animals showed signs of withdrawal through the next day. In the monkey
receiving the highest dose, morphine at twice the normal dose did not relieve
withdrawal. The 10.0 mg/kg dose was not plotted.
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NIH 10430, 2,2-Dimethyl-3-(dimethylamino)-7-hydroxy-1-tetralol
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0,
10.0 and 30.0
2) TF vs. M - 6% at 1.0,
10% at 3.0,
37% at 10.0
and 43% at
30.0
3) PPQ - 21.9 (6.8 - 70.8)
NIH 10438. 3-Cyclohexyl-1-N,N-dimethylamino-3-phenylpropane
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 7% at 1.0, 23% at
10.0, and 34% at
30.0
4) HP - Inactive at 5.0 and
20.0
NIH 10443, 14 -(p-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopropyl-
methylnormorphinone mesylate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 0.12 (0.07 -
0.23)
3) PPQ - 23% at 3, 34% at
10.0, 69% at 30.0
and 54% at 60.0
4) HP - Inactive at 20.0
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TF vs M - Special Time Course (ED50 of NIH 10443 of Morphine)
Pretreatment Time (hr) % Antagonism
2 73
24 86
MONKEY DATA
A .  S D S
Withdrawal was exacerbated and very frequent masturbation was seen.
Morphine promptly attenuated the withdrawal syndrome (see graph).
B. PRELIM, PPt-W
Another monkey received a cumulative dose of 0.4 mg/kg in 1 hr. By the third
15 min interval, the animal developed a severe withdrawal syndrome which
was not relieved by a double dose of morphine.
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NIH 10444, 14 (p-Methylcinnamoylamino)-7,8-dihydro-N-cyclopropyl-
methylnormorphinone mesylate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0a
2) T F vs. M - 0.2 (0.09 -
0 .6 ) a , b
3) PPQ - 3% at 0.5, 19% at
1.0, 17% at 10.0
and 0% at 30.0a
4) HP - Inactive at 20.0
aVehicle - Tween 80 + H2O.
MONKEY DATA (Vehicle - Tween 80 + H2O)
SDS
As shown in the fig., NIH 10444, exacerbated withdrawal. At the highest
dose, severe tremors and retching were noted in one animal. Morphine was
given 30 min after drug to terminate withdrawal. However, this animal was
still retching and/or vomiting 1 1/2 hr later. Another monkey receiving the
highest dose also showed severe retching and was given morphine. This
monkey stopped retching and had relaxed abdominal muscles 30 min later.
The third monkey receiving the highest dose did not show severe tremors or
retching. However, this animal still had rigid abdominal muscles and
vocalized when palpated 24 hr after drug. In addition, it moved about very
slowly. At the low dose, all the animals showed more withdrawal signs than
vehicle-treated animals but responded promptly to morphine. The drug
appears to be either a long acting or irreversible antagonist. Needless to say,
in this dose range NIH 10444 does not substitute for morphine.
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NIH 10445, 14 (p-Bromocinnamoylamino)-7,8dihydrocyclopropylmethyl-
normorphinone mesylate
MOUSE DATA-ED OR AD50
(95% C.L.) (mgkg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 0.8 (0.6 - 1.0)
3) PPQ - 7.1 (3.1 - 16.4)
4) HP - Inactive at 20.0
TF vs M - Special Time Course (ED50 of NIH 10443 vs ED80 of Morphine]
Pretreatment Time (hr) % Antagonism
24 93
48 39
72 45
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MONKEY DATA (Vehicle lactic acid + H2O)
A. PPt-W
After a 1-hr delay, NIH 10445 precipitated withdrawal. However, the data
shown in the figure do not begin to express the results because it illustrates
only the first 150 min of the experiment. The drug had a long duration of
action and its action could not be terminated with multiple double injections of
morphine. One animal receiving the low dose remained in withdrawal for 4
days in spite of the extra doses of morphine. Another monkey receiving a
dose of 0.085 mg/kg also remained on withdrawal despite efforts to reverse
the syndrome with morphine. This latter animal was finally anesthetized.
Recovery was slow. The monkey receiving the highest dose died after 4 days.
Of the 7 monkeys receiving NIH 10445 (including 1 tested in the preliminary
experiment) 3 died, and 2 showed attenuated abrupt and precipitated
withdrawal syndromes during a 4-6 week period after receiving drug.
In another study involving a non-addicted monkey, pretreatment with NIH
10445 (0.35 mg/kg) blocked the acute effects of morphine for 2 weeks.
Obviously, NIH 10445 is an unusual drug that merits much more study.
B. RAT INFUSION
Special Combination Study
As shown in the fig., at a dose of 10 mg/kg/day in combination with
morphine, NIH 10445 nearly blocked the weight loss commonly associated
with morphine withdrawal in addicted rats. In addition, per se the drug did not
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significantly affect body weight. No overt withdrawal in addicted rats. In
addition, per se the drug did not significantly affect body weight- No overt
withdrawal signs were seen during abrupt withdrawal either in combination
with morphine or by itself (see table).
TABLE (NIH 10445)
Means of Withdrawal Signs of Morphine-Treated, NIH 10445-Treated
and NIH 10445 + Morphine-Treated Rats Compared With H2O Controls
HR IN WITHDRAWALa
Treatment 0 2 4 4 8 7 2 9 6
H2O Controls
c 0.5 0 0 0.5 0
Morphine Controlsd 1.2 5.3 b 13.3b 13.7b 14.01b
Morphine + NIH 10445e 0.3 3.3 2.3 2.3 2.0
NIH 10445f 1.0 3.0 0.3 1.0 0.3
aMean number of withdrawal signs, bSignificant at p< 0.05. One-tailed test
(Mann-Whitney U-test), Hypersensitivity, squeaking, aggression, wet-dog
shakes, rubbing and chewing,c N=4,7ml/24 hr. Note - H2O controls are not
vehicle controls, d N=3,50 mg/kg 1st day, 100 mg/kg 2nd day, 200 mg/kg
days 3-6; H2O days 7-10, 
e N=3, morphine as above + 10 mg/kg NIH 10445
(suspended in Tween 80 + H2O,
f N=3, NIH 10445 = 10 mg/kg/24 hr
(suspended in Tween 80 + H2O).
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NIH 10453, N-(3-Carbethoxypropyl)-N-norketobemidone oxalate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 11% at 1.0,
2% at 10.0
and 0% at
30.0
3) PPQ - Inactive at 1.0,
10.0 and 30.0
4) HP - Inactive at 5.0 and
20.0
MONKEY DATA
S D S
NIH 10453 did not substitute for morphine at doses of 2.5 and 10.0 mg/kg.
However, the drug may have exacerbated withdrawal (see graph).
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NIH 10454, N-Carbethoxymetbyl)-N-norketobemidone oxalate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1 ) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 17% at 0.1, 20% at
1.0, 43% at 10.0
and 46% at 30.0
4) HP - Inactive at 5.0 and
20.0
MONKEY DATA
SDS
As shown in the fig., NIH 10454 did not substitute for morphine at doses of
2.5 and 10.0 mg/kg. One monkey receiving the highest dose retched more
frequently than controls.
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NIH 10462, Heroin methiodide
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ- 6% at 1.0, 11% at
10.0 and 19% at
30.0
4) HP - Inactive at 5.0 and
20.0
NIH 10463, Heroin ethiodide
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - Inactive at 1.0, 10.0
and 30.0
4) HP - Inactive at 5.0 and
20.0
NIH 10464, Heroin propiodide
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 14% at 1.0, 6% at 10.0
and 13% at 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 13% at 0.1, 45% at
1.0, 39% at 10.0
and 60.0 at 30.0
4) HP - Inactive at 5.0 and
20.0
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NIH 10465, Heroin allobromide
NIH 10466, Heroin benzobromide
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF- 1% at 1.0, 9% at
10.0 and 12% at
30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 9% at 1.0, 14% at
10.0 and 26% at
30.0
4) HP - Inactive at 5.0 and
20.0
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 20% at 1.0, 31% at
10.0 and 4% at 30.0
4) HP - Inactive at 5.0 and
20.0
NIH 10467, N-(2-Carboxyethyl)-N-norketobemidone hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 9% at 1.0, 17% at
10.0 and 37% at
30.0
4) HP - Inactive at 5.0 and
20.0
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NIH 10468 (or 10492), N-(1-Benzyl-4-piperidyl)-N-phenylpropanamide
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 6.9 (2.9 - 16.7)
4) HP - Inactive at 5.0 and
20.0
MONKEY DATA
SDS
NIH 10468 did not substitute for morphine at doses of 0.3 - 18.0 mg/kg. At
the highest dose, one animal convulsed and was given pentobarbital. In
addition, all showed severe tremors at this dose. The 0.3 and 3.0 mg/kg doses
were not plotted because N < 3 (see fig.).
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NIH 10472, N-Carboxymethyl-N-norketobemidone hydrobromide
MONKEY DATA
SDS
At doses of 3.0 and 12.0 mg/kg, NIH
nor exacerbated withdrawal (see fig.).
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - Inactive at 1.0,
10.0 and 30.0
4) HP - Inactive at 5.0 and
20.0
10473 neither substituted for morphine
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NIH 10475, N-(3-Carboxypropyl)-N-norketobemidone
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0,
10.0 and 30.0
2) TF vs. M - Inactive at
1.0, 10.0 and
30.0
3) PPQ - 6% at 1.0, 20%
at 10.0 and 40%
at 30.0
4) HP - Inactive at 5.0 and
20.0
NIH 10476, 1-Phenethyl-4-(4-nitrophenyl)aminopiperidine dihydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 5.7 (2.98 - 10.91)a
2) TF vs. M -
3) P P Q -
4) HP - Inactive at 20.0
aDrug supply exhausted
NIH 10477, 1-Phenethyl-4-(N-phenyl-p-methoxyphenylacetyl)amino-
piperidine hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 0.05 (0.02 - 0.7)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.2 (0.07 - 0.4)
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NIH 10478, 1-Phenethyl-4-(N-benzyl,N-propionyl)aminopiperidine
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 1.7 (0.9 - 3.0)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.2 (0.1 - 0.4)
NIH 10479, Ethyl 3 -(3-methoxyphenyl)-N-methyl-8-azabicyclo[3.2.1]-
octane carboxylate hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1)
2 )
3 )
4 )
TF - 9.8 (6.0 - 16.0)
TF vs. M - Inactive at 1.0,
10.0 and 30.0
PPQ - 1.1 (0.2 - 5.1)
HP - Inactive at 5.0, 50% at
20.0
NIH 10480, Ethyl 3 -(3-hydroxyphenyl)-N-methyl-8-azabicyclo[3.2.1]-
octane carboxylate hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 0% at 1.0, 4% at 10.0
and 11% at 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 4.5 (1.0 - 19.3)
4) HP - Inactive at 20.0
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NIH 10481, Ethyl N-methyl-3 -phenyl-8-azabicyclo[3.2.l]octane
carboxylate hydrochloride
MOUSE DATA-ED OR AD50
(95% CL.) (mg/kg/s.c.)
1) TF - 4.0 (3.6 - 4.3)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.5 (0.2 - 1.7)
NIH 10482, 1-Benzyl-4-phenyl-4-propionoxypiperidine hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 11.5 (6.4 - 20.6)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.4 (0.1 - 1.3)
4) HP - Inactive at 5.0, 33% at
20.0
MONKEY DATA
SDS
As shown in the fig., NIH 10482 substituted completely for morphine at 4.0
mg/kg. Onset of action was rapid and duration of action equal to morphine.
At the highest dose, the signs scratching, ataxia and body sag were noted.
Scratching was also observed at the lower dose.
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NIH 10483, N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylthiopropanamide
hydrochloride
(95% C.L.) (mg/kg/s.c.)
1 ) TF - 0.3 (0.2 - 0.6)a
2) TF vs. M - Inactive at 1.0,
1.0 and 30.0
3 ) PPQ - 0.06 (0.03 - 0.1)
a
Vehicle - Tween 80 + H2O
MOUSE DATA-ED OR AD50
MONKEY DATA
SDS
NIH 10483 substitutes completely and promptly for morphine at 0.15 and
0.0375 mg/kg). However, at the lowest dose, the duration of action is brief
(approximately 60 min). At both doses, some scratching was noted. In
addition, one monkey receiving the highest dose moved about slowly. The
drug is approximately 20 x more potent than morphine (see graph).
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NIH 10484, N-[1-(3-Phenylpropyl)-4-piperidyl]-N-phenylpropanamide
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 0.85 (0.6 - 1.2)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.009 (0.03 -
0.27)
MONKEY DATA
SDS
As shown in the figure. NIH 10484 substituted completely for morphine at 1.0
mg/kg. Its potency is 3 x that of morphine and appears to have similar onset
and duration of action. At the highest dose, scratching, ataxia, slowing, body
and jaw sags were noted. One animals receiving the highest dose and another
in the preliminary study receiving a 1.5 mg/kg cummulative dose was seen to
be “staring” and “tracking”.
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NIH 10485, N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylacetamide
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1 ) TF - 0.3 (0.2 - 0.5)
2 ) TF vs M - Inactive at 1.0,
10.0 and 30.0
3 ) PPQ - 0.05 (0.03 - 0.1)
MONKEY DATA
SDS
NIH 10485 rapidly but briefly (90 min), substituted completely for morphine
at 0.5 mg/kg (see figure). At peak effect, the drug is considered to be 6 times
as potent as the reference standard morphine.
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NIH 10486, N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylbutyramide
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 0.2 (0.1 - 0.5)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0a
3) PPQ - 0.04 (0.02 - 0.08)
aParalysis and Straub tail.
Two mice died at 10.0 and
30.0.
MONKEY DATA
SDS
NIH 10486 substituted completely for morphine (see fig.). The drug had a
quick onset of action. Duration of action was at least 2 1/2 hr. At peak effect,
the drug was 10-20X more potent than the reference standard morphine. At
the highest dose, the signs jaw sag, ataxia, slowing, scratching and severe
body sag were noted.
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NIH 10487, N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylisobutyramide
hydrochloride
MONKEY DATA
SDS
NIH 10487 substituted completely for morphine (see graph). Potency estimate
is 30 times morphine. Rapid onset and 2 1/2 hr duration of action were
observed. Sagging, ataxia, slowing and scratching were noted at the highest
dose during the first hr.
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NIH 10488, N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylvaleramide
hydrochloride.
TF vs. M - Inactive at 1.0,
MONKEY DATA
SDS
NIH 10488 substituted completely for morphine (see graph). The drug acted
promptly and at peak effect it was approximately equipotent with morphine.
Its duration of action was 2 1/2 hr. One animal convulsed an hr after receiving
the highest dose. The animal was given 60 mg of pentobarbital. Jaw sag and
ataxia were also noted during the first 1/2 hr.
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NIH 10490, N-[1-(2-Phenylethyl)-4-piperidyl]-N-(p-methoxyphenyl) pro-
panamide hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
2) TF vs. M.- Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.10 (0.05 - 0.17)
1) TF - 0.5 (0.2 - 1.5)
MONKEY DATA
SDS
NIH 10490 rapidly but briefly (90 min) substituted completely for morphine
(see fig.). At peak effect, the drug was about 6 x or active as morphine.
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NIH 10491, N-[1-(2-Phenylethyl)-4-piperidyl]-N-(p-fluorophenyl)pro-
panamide hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 0.07 (0.04 - 0.11)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0a
3) PPQ - 0.01 (0.004 - 0.025
aOne mouse died at 30.0
MONKEY DATA
S D S
NIH 10491 substituted completely for morphine in a dose-related manner (see
fig.). The drug acted promptly but its duration of action was about 2 hr. At
peak effect, this drug was 50-75 x as potent as morphine. Two animals
receiving the high dose scratched frequently.
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NIH 10493, N-[1-(2-Thienyl)methyl-4-piperidyl]-N-phenylpropanamide
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
MONKEY DATA
S D S
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 9% at 1.0, 14% at
10.0 and 53% at
30.0
4) HP - Inactive at 20.0
NIH 10493 neither substituted for morphine nor exacerbated withdrawal at
doses of 3.0 and 12.0 mg/kg. The drug produced effects similar to those of
vehicle controls (see fig.).
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NlH 10496, (E)-3-Chloro-6-[4-(3-phenyl-2-propenyl)-l-piperazinyl]
pyridazine hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 8% at 1.0, 17% at
10.0 and 30.5 at 30.0a
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 3.1 (0.8 - 12.4)
4) HP - Inactive at 20.0
a30% probably due to 1
mouse that went to 10.0 sec
cutoff.
MONKEY DATA
S D S
As shown in the accompanying figure, NIH 10496 did not substitute for
morphine. Note that dilute solutions of Tween 80 or DMSO were used as
vehicles.
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NIH 10498, 1-Methyl-5-(3-pyridyl)-2-pyrrolidinone (Cotinine)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 17.3 (5.6 -
53.6)
3) PPQ- 11% at 0.1, 40% at
1.0, 37% at 10.0
and 54% at 20.0
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
MONKEY DATA
SDS
Cotinine neither attenuates nor exacerbates withdrawal in withdrawn
morphine-addicted monkeys at doses of 16.0 and 48.0 mg/kg (see graph).
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NIH 10499, 4-(3-Pyridyl)-4-methylaminobutyric acid
NO MOUSE DATA
MONKEY DATA
SDS
As shown in the fig., NIH 10499 neither substituted for morphine nor
exacerbated withdrawal at doses of 12.0 and 48.0 mg/kg.
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NIH 10500, 3-Hydroxy- N-trimethyl-6,14-ethenomorphinan-7
methanol
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 22% at 1.0, 9%
at 10.0 and
45% at 30.0
3) PPQ - 0.2 (0.1 - 0.6)
4) HP - Inactive at 5.0
NIH 10502, (±)-2-Carboxymethyl-5,9 -dimethyl-2’-hydroxy-6,7-benzo-
morphan hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at
1.0, 10.0 and
30.0
3) PPQ - 22% at 1.0, 36% at
5.0, 28% at 10.0
and 28% at 30.0
4) HP - Inactive at 20.0
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NIH 10503, (±)-2-Carbethoxymethyl-5,9 -dimethyl-2’-hydoxy-6,7-
benzomorphan oxalate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ- 23% at 1.0, 11%
at 10.0, and 29%
at 30.0
4) HP - Inactive at 20.0 and
50.0
NIH 10505, N-[1-[2-(2-Thienyl)ethyl]-4-piperidyl]-N-phenylpropanamide
hydrochloride
MONKEY DATA
SDS
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 0.03 (0.02 - 0.05)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.02 (0.01 - 0.03)
NIH 10505 substituted completely for morphine (see fig.). Onset of action
was rapid but the duration of action was 90-120 min. The drug is estimated to
be 60 x as potent as morphine at peak effect.
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NIH 10506, N-[1-(2-Hydroxy-2-phenylethyl)-4-piperidyl]-N-phenylpro-
panamide hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 0.06 (0.05 - 0.09)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.01 (0.007 - 0.03)
MONKEY DATA
SDS
As shown in the fig., NIH 10506 substituted completely for morphine. The
drug acts promptly and its duration of action (120 - 150 min) is shorter than
that of morphine. The potency estimate is 50 x morphine at peak effect dose.
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NIH 10515, (±)-2-(2-Carbethoxyethyl-5,9 -dimethyl-2’-hydroxy-6,7-
benzomorphan hydrochloride
MOUSE DATA ED OR AD50
(95% C.L.) (mg/kg/s.c.)
NIH 10516, Oxycodone-6-spirohydantoin
1) TF - Inactive at 0.1, 1.0,
10.0 and 30.0
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 29% at 0.01, 34% at
0.1, 46% at 1.0,
20% at 3.0 and 49%
at 30.0
4) HP - Inactive at 50.0
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0
and 30.0
2) TF vs. M - 0% at 1.0, 9%
at 10.0 and
47% at 30.0
3) PPQ - 6.1 (2.2 - 17.0)
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NIH 10519, Naltrexone-6-spirohydantoin succinate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 7% at 1.0, 18% at
10.0 and 16% at
30.0
2) TF vs. M - 9.7% at 1.0,
25% at 10.0
and 33% at
30.0
3) PPQ - 22% at 1.0, 19% at
10.0 and 22% at
30.0
NIH 10522, 4-Carbethoxy-1-methyl-4-phenylpiperidine hydrochloride
(pethidine hydrochloride)
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 7.8 (3.0 - 20.6)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 0.8 (0.3 - 2.2)
MONKEY DATA
SDS
NIH 10522 substituted completely for morphine in dose-related manner (see
graph). Onset of action was prompt but duration of action was about two
hours. Jaw and body sag, scratching and some “staring” were noted. At peak
effect, the drug is slightly less potent than morphine.
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NIH 10529, Ethyl N-allyl-3 -(3-hydroxyphenyl)-8-azabicyclo[3,2.l]octane
carboxylate hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 1.0, 10.0a
and 30.0
2) TF vs. M - Inactive at
1.0, 10.0 and
30.0
3) PPQ - 7.7 (2.3 - 26.2)
aDrug supply exhausted
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NIH 10530, Ethyl 3 -(3-hydroxyphenyl)-N-phenethyl-8-azabicy clo-
[3.2.1.]octane carboxylate
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 2.5 (1.2 - 5.2)a
2) TF vs. M- Inactive at
1.0, 10.0
and 30.0
3) PPQ - 1.0 (0.5 - 2.0)
aVehicle - Tween 80 - H2O.
NIH 10531, 4-Hydroxy-3-methyl-4-phenyl-l-(1-phenylcyclohexyl)piperi-
dine hydrochloride (trans 3-methyl, reference 4-phenyl)
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 15.3 (5.7 - 41.1)a,b
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 1.2 (0.5 - 3.0)
aVehicle - Tween 80 + H2O.
b1 of 6 mice died.
NIH 10538, N-[1-[1-Methyl-2-(2-thienyl)ethyl]-4-piperidyl]-N-phenyl
propanamide hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 0.02 (0.01 - 0.05)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0a
3) PPQ - 0.005 (0.002 -
0.011)
a 3 of  6  mice died at  the
highest dose and 1 of 6 died
at the low dose.
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MONKEY DATA
SDS
Dose-related reduction of withdrawal signs and complete substitution for
morphine were observed with NIH 10538 (see figure). Onset of action was
rapid and duration was brief (about 2 hr). The drug is about 100 x more
potent than morphine.
NIH 10540, -Butyrolactone
MONKEY DATA
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - Inactive at 96
2) TF vs. M -
3) PPQ - 7.9 ( 3.2 - 19.4)a
aED80 not antagonized by 0.1,
1.0 and 10.0 mg/kg naloxone.
SDS
As shown in the figure, NIH 10450 neither substituted for morphine nor
exacerbated withdrawal.
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NIH 10542, (+)- -4-Acetoxy-1,2 -dimethyl-4-phenylpiperidine
hydrochloride
MOUSE DATA-ED OR AD50
(95% C.L.) (mg/kg/s.c.)
1) TF - 7.5 (4.2 - 13.7)
2) TF vs. M - Inactive at 1.0,
10.0 and 30.0
3) PPQ - 4.4 (2.1 - 9.4)
4) HP - 33% at 50.0
M.D. Aceto, E.R. Bowman, L.S. Harris and E.L. May
Department of Pharmacology and Toxicology
Medical College of Virginia
Virginia Commonwealth University
Richmond, VA 23298-0613
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Evaluation of New Compounds for
Opioid Activity: 1987 Annual Report
J. Woods, F. Medzihradsky, C. Smith, G. Winger
and D. Gmerek
The evaluation of new compounds by the programs at the
University of Michigan and the Medical College of Virginia is
coordinated by Dr. Arthur E. Jacobson, Medicinal Chemistry
Section, NIAMDD, National Institutes of Health, Bethesda, MD.
The drugs, which come originally from pharmaceutical companies,
universites, government laboratories, and international organi-
zations are submitted to Dr. Jacobson, who performs the MOUSE
ANALGESIA tests. Values obtained in these tests for some
representative opioid drugs are given in Table I.
At the UM and MCV laboratories, drug samples arrive from Dr.
Jacobson with only the following information: (1) an identifying
NIH number, (2) molecular weight, (3) solubility information and
(4) a recommended starting dose. After the evaluation is
complete and the report submitted to Dr. Jacobson, the
mouse-analgesia data are released to the evaluating laboratory,
and the submitter is requested to release the chemical structure
within three years.
DRUG DISCRIMINATION IN RHESUS MONKEYS
We currently use two groups of monkeys to test the discrimina-
tive effects of submitted drugs. One of these groups is trained
to discriminate the administration of the kappa agonist ethylke-
tazocine (EKC). The other group is trained to discriminate the
mu agonist, codeine.
The procedures used with the EKC-trained monkeys have been
described by Bertalmio et al., (1982). The monkeys are removed
from their home cages each day and seated in primate restraining
chairs: These chairs are placed in isolation chambers equipped
with two response levers, several stimulus lights and a cup to
receive Noyes, banana-flavored pellets. These monkeys are
required to make 100 consecutive responses on the correct one of
the two levers and receive ten 300-mg food pellets. The right
lever is correct if they were given a subcutaneous injection of
0.0032 mg/kg EKC immediately prior to the start of the trial.
The left lever is designated correct if they were given a sham
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injection before the start of the trial. Each trial lasts
15 min and consists of an initial 10-min, black out period
followed by a period of as long as 5 min, during which a blue
light is illuminated in the chamber and the monkey can respond
for food. If the food pellets are earned before the 5 min
period is completed, the lights are extinguished for the re-
mainder of this time. Typically, a daily session consists of
several 15-min trials. During a training session, if EKC is
given, it is given on the penultimate trial of that session.
Responding on the drug-appropriate lever is reinforced during
that trial and on the subsequent, final trial of the day. These
last two trials may be preceded by from zero to four sham trials
on a training day. A training session of six sham trials is
also scheduled from time to time.
With this type of multiple, discrete-trial training, the animals
can be tested with a cumulative dosing procedure. On a test
session, the first trial is preceded by an injection of saline,
and prior to subsequent trials, increasing, cumulative doses of
the test drug are administered. One hundred consecutive re-
sponses on either lever are reinforced throughout the test
session. The test drug is administered in increasing doses
until the monkey either responds on the drug-appropriate lever,
the response rate falls to less than half of the saline-control
rate, or six trials are given. In the last situation, it is
assumed that the selected dose range is too low, and the test is
continued at higher doses on the next test session. Each test
session is preceded and followed by a training session. The
criterion for satisfactory performance must be met on each
training session that is followed by a test session. This
criterion is that at least 90% of the responses during each
trial of a training session must be on the injection-appropriate
lever, either sham or EKC.
The procedure for the codeine-trained monkeys is similar, but
not identical. These animals are also trained and tested in a
discrete, multiple-trial paradigm. The main difference between
the codeine procedure and the EKC procedure is that the codeine
monkeys are required to make 20 rather than 100 responses, and
they receive a single pellet for correct responses. They can
earn as many as 10 pellets during the five-minute,
food-availability period of each trial, but each pellet is
earned by making 20 responses. Because in this procedure,
monkeys can switch from one lever to another following the
delivery of food, an additional criterion is added for satisfac-
tory performance. In addition to making 90% or more of their
responses on the correct lever, the monkeys must make fewer than
40 total responses prior to earning the first food pellet of
each trial. Tests of the discriminative effects of submitted
drugs in the codeine-trained monkeys are also done using a
cumulative-dosing procedure with dosing criteria identical to
those used in the EKC-trained monkeys.
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DEPENDENCE EVALUATION IN RHESUS MONKEYS
The single-dose suppression (SDS) test determines the ability of
a drug to suppress the signs of withdrawal in monkeys which have
been made dependent by the chronic administration of morphine (3
mg/kg every six hours). Compounds suspected of having morphine-
antagonist properties are tested for their ability to precipi-
tate the withdrawal syndrome in nonwithdrawn (NW), morphine-
dependent monkeys. Nondependent monkeys (Normals) are used to
determine whether the acute effects of the test drug are rever-
sible by nalorphine or naloxone. In a primary dependence (PDS)
study, non-dependent monkeys receive the test drug every six
hours for 30 days to determine whether withdrawal signs will
appear when the animals are challenged with an antagonist or
when drug administration is discontinued.
Details of these techniques have been presented in the ANNUAL
REPORT to the Committee in 1963 (Minutes of the 25th Meeting) by
Deneau and Seevers (1963) and by Villarreal (1973).
SELF-ADMINISTRATION BY MONKEYS
Tests of self-administration determine the ability of the drug
to maintain responding in monkeys trained to self-inject co-
deine. Each of at least three monkeys is studied with saline as
a negative control and a number of doses of the test compound
until a maximum rate of responding is obtained or until, in the
absence of evidence of a reinforcing effect, observable changes
in behavior are produced by the compound.
The schedule of intravenous drug delivery is a fixed-ratio 30;
when a light above a lever is illuminated, the 30th response
produces a five-sec, intravenous drug injection accompanied by
another light that is illuminated during drug delivery. After
each injection, a ten-min timeout condition is in effect, during
which responses have no scheduled consequence and neither light
is illuminated. Each of the two daily sessions consist of 13
injections or 130 min, whichever occurs first. Other details of
the procedure and initial findings with a variety of narcotics
are given in previous reports (Woods, 1977; 1980).
Doses of the drugs are typically described in terms of mg/kg/
injection (inj). Duplicate observations of codeine (0.32
mg/kg/inj) and of saline are obtained for each monkey. A saline
substitution is conducted before and after the series of
observations on a test drug; the control rates of codeine-rein-
forced responding are obtained by a random sampling of two
sessions interpolated between the drug-substitution sessions.
These data are represented in the following graphs with indivi-
dual symbols for each of the monkeys; each symbol is the mean of
duplicate observations for a given dose in each monkey. The
closed circles indicate the averaged data for observations on
the subset of monkeys used to study each drug under each of the
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experimental conditions. In all cases, the rates of responding
given are those calculated during only the fixed-ratio portion
of each session.
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
Details of the binding assay have been described previously
(Woods et al., 1979; Medzihradsky et al., 1984). Briefly,
aliquots of a membrane preparation from rat cerebrum are incu-
bated with 3H-etorphine in the presence of 150 mM NaCl, and in
the presence of different concentrations of the drug under
investigation. Specific, i.e., opioid-receptor-related inter-
action of 3H-etorphine is determined as the difference in
binding obtained in the absence and presence of an appropriate
excess of unlabeled etorphine. The potency of the drugs in
displacing the specific binding of 3H-etorphine is determined
from log-probit plots of the data. It should be noted that since
April 1982 the concentration of 3H-etorphine in the binding
assay was reduced from 3.0 nM to 0.5 nM, a concentration ap-
proaching the KD of the radiolabeled opioid. This change was
implemented in order to let the determined EC50 approximate the
true Ki of a given drug. However, due to the different concen-
trations of the radiolabeled ligand, the EC50 determined since
April, 1982 are lower than those obtained previously. For the
purpose of reference, Table II contains EC50 values of represen-
tative opioids determined in binding assays using 0.5 nM 3H-
etorphine.
As part of our goal to develop advanced procedures to assess the
interaction of newly synthesized compounds with opioid receptors
(Medzihradsky, 1987), this laboratory is now in the position to
determine the selectivity of ligands in binding to the mu,
delta, and kappa opioid receptor. We can provide EC50 values of
tested compounds in displacing the following radiolabeled opioid
ligands:
etorphine (nonselective)
sufentanil (my selective)
[D-Pen2-D-Pen5]enkephalin (delta selective)
U-69,593 (kappa selective)
Using these binding assays, we have described the selectivity of
various established opioids in membranes from rat and monkey
brain (manuscript submitted for publication).
INHIBITION OF TWITCH IN ELECTRICALLY-DRIVEN MOUSE VAS DEFERENS
PREPARATIONS.
The development of new, highly selective antagonists such as the
irreversible mu receptor antagonist beta-funaltrexamine (beta-
FNA) and the reversible delta receptor antagonist ICI-174864
have made possible the evaluation of selectivity of opioid
agonists and antagonists by use of the mouse vas deferens
preparation.
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Male, albino ICR mice, weighing between 25 and 30 g, are used.
The mice are decapitated, the vasa deferentia removed, and 1.5
cm segments are suspended in organ baths which contain 30 ml of
a modified Kreb's physiological buffer. The buffer contains the
following (mM): NaCl, 118; KCl, 4.75; CaCl2, 2.54; MgSO4, 1.19;
KH2PO4 1.19; glucose, 11; NaHCO3, 25; pargyline HCl, 0.3,
tyrosine, 0.2; ascorbic acid, 0.1; and disodium edetate, 0.03.
The buffer is saturated with 95% O2 - 5% CO2 and kept at 37° C.
The segments are attached to strain gauge transducers and
suspended between two platinum electrodes. After a 30-min
equilibration period, the segments are stimulated once every 10
sec with pairs of pulses of 2 msec duration, 1 msec apart and at
supramaximal voltage.
The following antagonists are studied: naltrexone HCl, ICI-
174864 [N,N-diallyl-Tyr-Aib-Aib-Phe-Leu-OH] and beta-FNA.
Naltrexone and ICI-174864 are added to the organ baths 15
minutes before the determination of cumulative concentration-
effect relationships for the various agonists. Beta-FNA is
added to the organ baths after the initial equilibration period.
Thirty min later, the beta-FNA is removed from the organ baths
by repeated washings with fresh buffer. The tissues are washed
three times every 5 min for 15 min. Cumulative concentration-
effect relationships for the various agonists are then deter-
mined 20 min after the last wash (i.e., 30 min after the beta-
FNA was removed from the organ baths). EC50's are calculated by
probit analysis, and pA2 values are determined to assess rela-
tive potencies of antagonists. All drugs which are submitted
for evaluation are studied in the following manner: 1) the
submitted drug is tested on the vas deferens preparation in the
absence and in the presence of naltrexone. The concentration of
the unknown drug is varied from the lowest with activity to that
which is maximally effective. 2) If the submitted drug inhi-
bits the twitch, the ability of naltrexone to reverse the
inhibition is determined. 3) The submitted drug is assessed
for its ability to antagonize the actions of morphine on the vas
deferens. 4) The drug is assessed for its ability to reverse
the inhibition produced by a maximally effective concentration
of morphine. 5) Finally, if the drug has opioid agonistic
activity, studies are conducted to determine the receptor type
upon which it acts. If it has antagonistic activity upon the
vas deferens or upon any of the other preparations used in the
Drug Evaluation Unit, the type of antagonism (competitive,
noncompetitive) and the receptor selectivity is determined. For
further details of the procedure see Smith (1986).
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TABLE I
MOUSE ANALGESIA. Before submission to The University of Michigan, all compounds are evaluated for
analgesic activity by Dr. Arthur E. Jacobson. Shown below are comparative data (ED50, mg/kg)
(95% Confidence Interval) from Hot Platea-c and Nilsend assays. umol/kg
TABLE I Continued
TABLE II
EC50 of representative opioids in displacing
the specific binding of 0.5 nM 3H-etorphine
in a membrane preparation from rat cerebrum
Compound -NaCl
UM 911* 14.6
EC50 (nM)
+NaCl
28.3
+Na/-Na
1.94
Morphine 14.0 23.6 1.69
Dextrorphan 6180 9820 1.59
UM 1071R** 1.14 1.55 1.36
Ketazocine 10.7 14.1 1.32
Ethylketazocine 5.22 6.60 1.26
(-)SKF 10047 4.09 3.93 0.96
Etorphine 0.47 0.37 0.79
(-)Cyclazocine 0.85 0.53 0.63
Naltrexone 1.43 0.63 0.44
NOTE: Binding data for these and other compounds, determined in
binding assays using 3.0 nM 3H-etorphine, are included in the
1978 and 1981 ANNUAL REPORTS.
*2-(3-methylfurfuryl)-2'-hydroxy-5,9 -dimethyl-6,7-benzomorphan
methane sulfanate.
** IR-5R-9R-2"R-5,9-dimethyl-2'-hydroxy-2-tetrahydrofurfuryl-
6,7-benzomorphan hydrochloride
SUMMARY OF TESTS PERFORMED
The compounds which were evaluated at the University of Michigan
during the past year, and the individual tests which were per-
formed are shown in Table III. Also shown are dates of Annual
Reports in which results are reported of earlier tests on those
compounds conducted at Michigan.
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TABLE III
SUMMARY OF TESTS PERFORMED
NIH MCV
9834 - - - -
10012 - - - - - +
10013 - - - - - +
10014 - - - - -  +
10167 - - - - + + - -
10318 - - -
10322 - - - -
10324 - - - - -
10399 - - - - - -
10400 - - - - - -
10412 - - - - - -
10420 - - - -  +
10426 - - - -  +
10427 - - - -  +
10444 - - - - - -
10445 - - - - - -
10462 - - - - - -
10463 - - - - - -
10464 - - - - - -
10465 - - - - - -
10466 - - - - - -
10467 - - - - - -
10468 - - - - - -
10473 - - - - - -
10482 - - - - - -
10483 - - - - - -
10484 - - - - - -
10485
4359
4399
4404
4408
4468
4469
4479
4478
4489
4490
4507
4506
4529
4530
4531
4532
4533
4534
4535
4436
4545
4546
4547
4848
CHEMICAL CLASS AND/OR
GENERIC NAME SDS
morphine-peptide hybrid -
aryicyclohexylamine
arylcyclohexylamine
arylcyclohexylamine
benzomorphan
imidazolidine
oxymorphone
oxymorphone
oxymorphone
oxymorphone
benzofuroisoquinoline
oxymorphone
oxymorphone
oxymorphone
oxymorphone
oxymorphone
morphine
morphine
morphine
morphine
morphine
phenylpiperidine
phenylpiperidine
phenylpiperidine
phenylpiperidine
phenylpiperidine
phenylpiperidine
phenylpiperidine
+
+
+
NW
+
N SA
+
+
+
+
MVD BIND
+  +
- -
- -
- -
1985 1985
-  +
-  +
+  +
+  +
+ +
+  +
+  +
+  +
+ +
+  +
+  +
+  +
+  +
+  +
+  +
+ +
+  +
+  +
+ +
+  +
+  +
- - - + +
PDS
+  -
DD REPORT*
05/16/86
05/16/86
05/16/86
05/16/86
06/10/86
10/09/86
09/17/86
09/17/86
06/01/85
27/01/85
19/11/85
19/11/85
27/01/86
02/02/86
16/05/86
02/05/86
04/03/86
04/03/86
05/02/86
05/02/86
05/02/86
02/05/86
16/05/86
07/01/87
28/10/86
28/10/86
03/02/87
- - - 03/02/87
Table III (continued)
NIH MCV
10486
10487
10489
10490
10491
10492
10493
10496
10505
10506
10516
10519
4849
4550
4552
4553
4554
4535
4556
4557
4567
4568
CHEMICAL CLASS AND/OR
GENERIC NAME
phenylpiperidine
phenylpiperidine
phenylpiperidine
phenylpiperidine
phenylpiperidine
phenylpiperidine
thienylpiperidine
piperazinylpiperazine
thienylpiperidine
phenylpiperidine
oxymorphone
oxymorphone
SDS NW N SA MVD BIND PDS DD
- - - - + = - -- 03/02/87
- - - - + + - -- 03/02/87
- - - - + + - -- 04/ 1 l/86
- - - - + + - -- 07/01/87
- - - - + + - -- 07/01/87
- - - - + + - -- 03/02/87
- - - - + + - -- 03/02/87
- - - - + + - -- 03/02/87
- - - - + + - -- 03/02/87
- - - - + + - -- 03/02/87
- - - - + + - -- 03/02/87
- - - - -I- + - -- 03/02/87
REPORT*
* Date report was submitted to CPDD Biological Coordinator.
NIH 9834 N-(6,14-endoethano-7,8-Dihydromorphine-7µ-carbonyl)-
L-phenylalanyl-L-leucinol
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 5.0 (3.6 - 6.9)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 0.30 nM in the presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Drug alone
After naltrexone
With equimolar concentration
of naltrexone
Equimolar concentration
with morphine
SUMMARY
Inhibitory
EC50 (M) Maximum Response
4.24 x 10-10 93.7%
2.61 x 10-10 92.7%
Reversal
No antagonism
NIH 9834 had potent opioid properties in both in vitro assays.
(See related compounds in previous Annual Reports)
NIH 10012 1-Methyl-4-phenyl-4-(1-piperidinyl)piperidine dihy-
drochloride
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 40% at 100
DRUG DISCRIMINATION TEST
This compound was administered to three rhesus monkeys that had
been trained to discriminate the stimulus effects of 1.8 mg/kg
ketamine. The procedure used to train and test the monkeys has
been described by Solomon et al., 1982. Doses of 0.03, 0.1,
0.32 and 1.0 mg/kg were given subcutaneously to each monkey
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NIH 10012 1-Methyl-4-phenyl-4-(1-piperidinyl)piperidine dihy-
drochloride
(continued...)
during a test session. NIH 10012 did not produce either
drug-appropriate responding or response suppression in any
monkey at any dose. NIH 10012, at these doses, appears to be
inactive in this test of ketamine-like effects.
NIH 10013 1,3-Dimethyl-4-phenyl-4-(l-piperidinyl)piperidine
dihydrochloride
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 56.3 (48.8-65.1)
DRUG DISCRIMINATION TEST
This compound was administered to three rhesus monkeys that had
been trained to discriminate the stimulus effects of 1.8 mg/kg
ketamine. The procedure used to train and test the monkeys has
been described by Solomon et al., 1982. Doses of 0.03, 0.1,
0.32 and 1.0 mg/kg were given subcutaneously to each monkey
during a test session. NIH 10013 did not produce either
drug-appropriate responding or response suppression in any
monkey at any dose. NIH 10013, at these doses, appears to be
inactive in this test of ketamine-like effects.
NIH 10014 1-Phenethyl-4-phenyl-4-(1-piperidinyl)piperidine
dihydrochloride
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 50% at 50
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NIH 10014 1-Phenethyl-4-phenyl-4-(1-piperidinyl)piperidine
dihydrochloride
DRUG DISCRIMINATION TEST
This compound was administered to three rhesus monkeys that had
been trained to discriminate the stimulus effects of 1.8 mg/kg
ketamine. The procedure used to train and test the monkeys has
been described by Solomon et al., 1982. Doses of 0.03, 0.1,
0.32 and 1.0 mg/kg were given subcutaneously to each monkey
during a test session. NIH 10014 did not produce either
drug-appropriate responding or response suppression in any
monkey at any dose. NIH 10014, at these doses, appears to be
inactive in this test of ketamine-like effects.
NIH 10167 (+)-N-cis-3-Chloroallyl-N-normetazocine hydrobromide
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 30% at 50
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 1.7 nM in presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone
After naltrexone
With equimolar concentration
of naltrexone
Equimolar concentration
with morphine
5.59 x 10-7 93.0 ± 5.5%
1.51 x 10-6 100%
No Reversal
Marked reversal
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NIH 10167 (+)-N-cis-3-Chloroallyl-N-normetazocine hydrobromide
...(continued)
SUMMARY
NIH 10167 was a moderately potent opioid substance in both in
vitro preparations. It appeared to have agonist-antagonist
activity in the mouse, vas deferens preparation.
NIH 10318 1-Acetonyl-2-(2,4-dichlorophenyl)iminoimidazolidine.
HCl
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 40% at 50
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 1050 nM in presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone
After naltrexone
With equimolar concentration
of naltrexone
Equimolar concentration
with morphine
MORPHINE-DEPENDENT MONKEYS
3.76 x 10-5 98.5 ± 7.7%
4.87 x 10-5 97.7 ± 12.5%
No Reversal
No reversal
NIH 10318 was given cumulatively to 14-hr withdrawn morphine-
dependent rhesus monkeys (n=6) at the following doses: 1.0,
3.2, 10.0 and 32.0 mg/kg. There were no apparent effects of NIH
10318 on withdrawal or otherwise.
SUMMARY
NIH 10318 inhibited the twitch of the mouse vas deferens but
through a non-opioid action. It displaced etorphine with a low
potency. It was inactive in the SDS evaluation up to 32 mg/kg.
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NIH 10322 6 -(2-Carboxy-1-propenyl)-naltrex-6 -ol -lactone
MOUSE ANALGESIA, ED50,
Hot Plate: 50% at 50
(mg/kg)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 24.8 nM in presence of 150 mM NaCl.
MORPHINE-DEPENDENT MONKEYS
NIH 10322 was given cumulatively to 14-hr withdrawn
morphine-dependent rhesus monkeys (n=6) at the following doses:
0.1, 0.3, and 1.0 mg/kg. Withdrawal was not suppressed; it was
exacerbated. Therefore, NIH 10322 was given cumulatively to
non-withdrawn morphine-dependent monkeys (n=6) at the following
doses: 0.1, 0.3, 1.0 and 3.2 mg/kg. NIH 10322 precipitated
withdrawal in a dose-related manner. It was approximately 30
times less potent than naloxone.
SUMMARY
NIH 10322 appeared to be a less potent, naloxone-like compound.
NIH 10324 6 -(2-Carboxy-1-propenyl)-oxymorph-6 -ol -lactone
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: 3.5 (2.4-5.3)
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NIH 10324 6 -(2-Carboxy-1-propenyl)-oxymorph-6 -ol -lactone
...(continued)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 361 nM in presence of 150 mM NaCl.
MORPHINE-DEPENDENT MONKEYS
NIH 10324 was given cumulatively to 14-hr withdrawn morphine-
dependent rhesus monkeys (n=6) at the following doses: 1.0, 3.2
and 10.0 mg/kg. Two monkeys also received 32 mg/kg. Following
the 3.2 mg/kg dose, the monkeys were eating and there was a
slight decrease in abdominal muscle rigidity upon palpation.
However, overall, there was no decrease in withdrawal. Two
monkeys had muscle tremors after 10.0 mg/kg.
SUMMARY
There was an apparent discrepancy among findings with this
compound. NIH 10324 needs further evaluation.
NIH 10399 6 -Naltrexol- -methylacrylate
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive (to 20)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 0.63 nM in presence of 150 mM NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 1.09 x 10-5 57.6 ± 16.8%
After naltrexone 1.22 x 10-5 46.1 ± 3.3%
With an equimolar
concentration of naltrexone No reversal
With an equimolar
concentration of morphine Marked reversal
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NIH 10399 6 -Naltrexol- -methylacrylate
...(continued)
SUMMARY
NIH 10399 was an opioid antagonist upon the mouse vas deferens
preparation. It was quite potent in the binding assay. It also
had naltrexone-insensitive inhibitory actions in the mouse vas
deferens.
NIH 10400 6 -Naltrexol- -methylacrylate
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 10.5 nM in
MOUSE VAS DEFERENS
Drug alone
After naltrexone
With equimolar
concentration of naltrexone
With equimolar
concentration of morphine
presence of 150 mM NaCl.
PREPARATION
Inhibitory
EC50 (M) Maximum Response
1.03 x 10-6
3.13 x 10-6
100%
100%
No reversal
Slight reversal
SUMMARY
NIH 10400 appeared to be a mixed agonist-antagonist upon the
isolated mouse vas deferens preparation. The estimates of
potency in the two preparations were discrepant, but it should
be noted that the antagonistic potency of NIH 10400 was not
assessed in the mouse vas deferens. It should be noted that the
compound is of quite high potency.
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NIH 10412 (±)-3-Cyclopropylmethyl-1,2,3,4,5,6,7,7a-octahydro-
9-hydroxy-4aH-4a,7-ethanobenzofuro(3,2-e)isoquinoline-5-methanol
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive (to 20)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 0.55 nM in presence of 150 mM NaCl
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone
After naltrexone
1.5 x 10-9 68.9 ± 5.9%
3.2 x 10-8 65.6 ± 8.0%
With equimolar
concentration of naltrexone Reversal
SUMMARY
NIH 10412 appeared to be an opioid agonist upon the mouse vas
deferens preparation equally efficacious to but more potent than
morphine. The data on rat-brain binding were consistent with
the findings from the smooth muscle preparation.
NIH 10420 14 -(p-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopro-
pylmethylnorcodeinone mesylate
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive (to 20)
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NIH 10420 14 -(p-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopro-
pylmethylnorcodelnone mesylate
. . . (continued)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 1 nM in presence of 150 mM NaCl
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 5.1 x 10-9 95.1 ± 3.2%
After naltrexone
After ICI-174864
1.4 x 10-8 100%
2.7 x 10-8 100%
With equimolar
concentration of naltrexone Slight reversal
With equimolar
concentration of morphine No reversal
SELF-ADMINISTRATION IN RHESUS MONKEYS
The reinforcing effects of NIH 10420 were evaluated in three
rhesus monkeys trained to respond for 0.32 mg/kg/inj codeine
(Woods, 1980). Doses of NIH 10420 were substituted for codeine
in single, 130 min test sessions. Each dose was tested twice in
each of the three monkeys. Rates maintained by NIH 10420 were
only very slightly above those maintained by saline at the two
lowest doses tested, 0.0003 and 0.001 mg/kg/inj, and at the
highest dose tested, 0.01 mg/kg/inj.
Figure 1 gives details of the results of this study: 81, 1497
and 1699 are the identification numbers of the individual
monkeys. Average refers to the mean of data from these three
animals, while Grand Average is a historical control value for
20 monkeys under the codeine and saline conditions. The two
topmost slashed horizontal lines indicate ± 3 SEM for the
codeine grand average. The bottom most slashed horizontal line
is ± 3 SEM for the saline grand average. NIH 10420 had more
prolonged effects on codeine-reinforced responding than most
drugs tested in this paradigm. It required several sessions for
monkeys to return to their baseline rates of codeine-reinforced
responding.
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NIH 10420 14 -(p-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopro-
pylmethylnorcodeinone mesylate
...(continued)
FIGURE 1
DRUG-DISCRIMINATION IN RHESUS MONKEYS
Cumulative doses of from 0.0001 to 0.1 mg/kg of NIH 10420 were
evaluated in monkeys trained to discriminate 1.0 or 1.8 mg/kg
codeine from sham injections in a drug-discrimination paradigm
(Bertalmio et al., 1982). All animals responded on the codeine-
appropriate lever at the highest dose tested. One of the
monkeys responded on the sham-appropriate lever on a second
occasion. Thus, its average percent codeine-appropriate res-
ponse was 50% (top panel, Figure 2). NIH 10420 did not produce
response rate decrements at any of the doses tested (not shown).
SUMMARY
NIH 10420 has a greater relative potency to morphine in the in
vitro preparations than in the drug discrimination assays. This
consistent with its low potency in precipitating withdrawal
(MCV report). Compounds (e.g., beta-FNA and Superfit) that have
"irreversible" agonist or antagonist activity have this property
in common.
NIH 10420 is unusual in producing morphine-like discriminative
effects without significant reinforcing effects. Compounds,
e.g., 1-alpha-acetyl-methadol) that have a very slow onset of
behavioral action are the only compounds noted in the drug
evaluation program so far that illustrate this type of dissoci-
ation.
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NIH 10420 14 -(p-Chlorocinnarnoylanlino)-7,C-dihydro-N-cyclopro-
pylmethylnorcodeinone mesylate
FIGURE 2
A further novel characteristic of NIH 10420 is the absence of
antagonist activity in the vas deferens, but the compound
precipitates abstinence in the morphine-dependent monkey. A
possible explanation, of course, is the metabolic conversion of
the compound to an antagonist in vivo. This could be assessed
in the drug discrimination assay by driving NIH 10420 and asses-
sing antagonistic activity following the cessation of agonist
action.
NIH 10426 14 -(p-Bromocinnamoylamino)-7,8-dihydro-N-cyclopro-
pylmethylnorcodeinone mesylate
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive (to 20)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 1.1 nM in presence of 150 mM NaCl
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NIH 10426 14 -(p-Bromocinnamoylamino)-7,8-dihydro-N-cyclopro-
pylmethylnorcodeinone mesylate
...(continued)
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 3.44 x 10-9 53.6 ± 11.3%
After naltrexone 3.37 x 10-8 73.4 ± 5.5%
With equimolar
concentration of naltrexone Slight reversal
With equimolar
concentration of morphine Reversal
SELF-ADMINISTRATION IN RHESUS MONKEYS
The reinforcing effects of NIH 10426 were evaluated in three
rhesus monkeys trained to respond for 0.32 mg/kg/injection
codeine (Woods, J.H., 1980). Doses of NIH 10426 were substi-
tuted for codeine in single, 130 min test sessions; each test
session was separated by at least three sessions with the
baseline codeine dose. Each dose was tested twice in each of
the three monkeys. Rates maintained by NIH 10426 were quite
variable among the three monkeys. Each monkey showed rates of
NIH 10426-maintained responding that were above those maintained
by saline. In one monkey (1497) the rates maintained by 0.01
and 0.10 mg/kg/injection were above those maintained by codeine.
In a second monkey (906) the rates maintained by 0.01 and 0.03
mg/kg/injection were as high as those maintained by codeine, and
in the third monkey (1719), 0.03 and 1.0 mg/kg/injection main-
tained the highest rates, and these were considerably below the
rates maintained by codeine. (This monkey had lower codeine-
reinforced rates than did the other monkeys).
Figure 1 gives details of the results of this study. The data
from the individual monkeys are indicated by each animal's
identification numbers (1497, 1719, and 906). Average refers to
the mean of data from these three animals, while Grand Average
refers to a historical control value for 20 monkeys under the
codeine and saline conditions. The two topmost slashed horizon-
tal lines indicate ± 3 SEM for the codeine grand average. The
bottom most slashed horizontal line is ± 3 SEM for the saline
grand average.
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NIH 10426 14 -(p-Bromocinnamoylamino)-7,8-dihydro-N-cyclopro-
pylmethylnorcodeinone mesylate
...(continued)
FIGURE 1
NIH 10426 had more prolonged effects on codeine-reinforced
responding than most drugs tested in this paradigm. It required
several sessions for two of the monkeys to return to their
baseline rates of codeine-reinforced responding.
DRUG-DISCRIMINATION IN RHESUS MONKEYS
Cumulative doses of from 0.01 to 0.10 mg/kg NIH 10426 were
evaluated in the monkeys trained to discriminate 1.0 or 1.8
mg/kg codeine from sham injections in a drug-discrimination
paradigm (Bertalmio et al., 1982). All three monkeys responded
on the codeine-appropriate lever at a cumulative dose of 0.10
mg/kg (Figure 2). NIH 10426 did not produce any response
decrements at any of the doses tested (not shown).
SUMMARY
NIH 10426 was a potent opiate agonist upon both the in vitro
assays. A novel finding was that the compound might have
significant kappa antagonist activity. The antagonist activity
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NIH 10426 14 -(p -Bromocinnamoylamino)-7,8-dihydro-N-cyclopro-
pylmethylnorcodeinone mesylate
...(continued)
FIGURE 2
of NIH 10426 may be difficult to study in vivo since the concen-
trations that exert this action also exert agonist activity. It
had morphine-like activity in the drug-discrimination and
drug-reinforcement studies.
NIH 10427 14 -(p-Methylcinnamoylamino)-7,8-dihydro-N-cyclopro-
pylmethylnorcodeinone mesylate
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive (to 20)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 4.5 nM in presence of 150 nM NaCl
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NIH 10427 14 -(p-Methylcinnamoylamino)-7,8-dihydro-N-cyclopro-
pylmethylnorcodeinone mesylate
...(continued)
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 2.60 x 10-8
After naltrexone 1.04 x 10-7
62.4 ± 13.7%
69.0 ± 6.7%
With equimolar
concentration of naltrexone Reversal
With equimolar
concentration of morphine No reversal
SELF-ADMINISTRATION IN RHESUS MONKEYS
The reinforcing effects of NIH 10427 were evaluated in three
rhesus monkeys trained to respond for 0.32 mg/kg/injection
codeine (Woods, J.H., 1980). Doses of NIH 10427 were substi-
tuted for codeine in single, 130 min test sessions. Each dose
was tested twice in each of the three monkeys. Rates maintained
by NIH 10427 were below those maintained by codeine, but above
those maintained by saline. The highest average rate of res-
ponding was approximately half way between these points and
occurred at a dose of 0.01 mg/kg/inj.
FIGURE 1
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NIH 10427 14 -(p-Methylcinnamoylamino)-7,8-dihydro-N-cyclopro-
pylmethylnorcodeinone mesylate
...(continued)
Figure 1 gives details of the results of this study: 1497, 906
and 7730 are identification numbers of individual monkeys.
Average refers to the mean of data from these three animals,
while Grand Average refers to a historical control value for 20
monkeys under the codeine and saline conditions. The two
topmost slashed horizontal lines indicate ± 3 SEM for the
codeine grand average. The bottom most slashed horizontal line
is ± 3 SEM for the saline grand average.
There was more variability than usual in the rates of responding
maintained by the three monkeys at each dose. There was also a
large amount of variability within each monkey at each dose.
This is not shown on the attached figure, but was much larger
than we typically see with drugs that act as reinforcers in this
paradigm. NIH 10427 also had more prolonged effects on codeine-
reinforced responding than most other drugs evaluated. It
required several sessions for monkeys to return to their base-
line rates of codeine-reinforced responding. On occasion, 0.32
mg/kg cocaine was substituted for the baseline dose of 0.32
mg/kg codeine when, following administration of NIH 10427, the
opiate was not maintaining high rates of responding. The
cocaine invariably' was able to maintain high rates of responding
even when codeine was not.
DRUG-DISCRIMINATION STUDIES
Cumulative doses of from 0.03 to 3.2 mg/kg of NIH 10427 were
evaluated in monkeys trained to discriminate 1.0 or 1.8 mg/kg
codeine from sham injections in a drug-discrimination paradigm
(Bertalmio et al., 1982). All animals responded on the codeine-
appropriate lever at a dose of 0.3 mg/kg (Figure 2). NIH 10427
did not produce any response decrements at any of the doses
tested (not shown).
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NIH 10427 14 -(p -Methylcinnamoylamino)-7,8-dihydro-N-cyclo-
propylmethylnorcodeinone mesylate
FIGURE 2
SUMMARY
NIH 10427 was a morphine-like agonist in behavioral assays; it
was 10 times as potent. It was different from morphine in that
it suppressed self-injection responding for an extended period
after its administration. In both in vitro assays it had potent
opioid activity. It was also an agonist in the mouse vas
deferens preparation.
NIH 10444 14 -(p-Methylcinnamoylamino)-7,8-dihydro-N-cyclo-
propylmethylnormorphinone mesylate
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive (to 20)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 0.79 nM in presence of 150 mM NaCl
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NIH 10444 14 -(p-Methylcinnamoylamino)-7,8-dihydro-N-cyclo-
propylmethylnormorphinone mesylate
. . . (continued)
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
At no concentration did NIH 10444 cause a significant inhibition
of the twitch. It markedly antagonized the inhibitory actions
of sufentanil, a potent mu receptor agonist. At a concentration
of 10 M, NIH 10444 caused a shift to the right in the sufenta-
nil concentration-effect curve and reduced the maximum response
to 15% of control value.
SUMMARY
NIH 10444 was a highly potent compound in the binding assay, and
to be a pure antagonist in the mouse vas deferens.
NIH 10445 14 -(p-Bromocinnamoylamino)-7,8-dihydro-N-cyclopropyl
-methylnormorphinone mesylate
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive (to 20)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 0.79 nM in presence of 150 mM NaCl
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
At no concentration did NIH 10445 cause a significant inhibition
of the twitch. It markedly antagonized the inhibitory actions
of sufentanil, a potent mu receptor agonist. At a concentration
of 10-7 M, NIH 10445 abolished all responses to sufentanil when
studied in concentrations up to 10-4 M.
SUMMARY
NIH 10445 was a highly potent opioid in the binding assay and a
quite "pure" antagonist in the mouse vas deferens.
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NIH 10462 Heroin methiodide
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive at 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 > 10 µM (23.6% inhibition at 10 µM).
INHIBITION OF TWITCH OF ELECTRICALLY DRIVEN MOUSE VAS DEFERENS
Inhibitory
EC50 (M) Maximum Response
Drug alone
After naltrexone
1.31 x 10-7 32.2% ± 6.6
5.97 x 10-8 26.5% ± 3.6
With equimolar concentration
of naltrexone Slight reversal
With equimolar concentration
of sufentanil No reversal
SUMMARY
NIH 10462 failed to significantly displace etorphine, but may
have some weak opioid activity in the mouse vas deferens.
NIH 10463 Heroin ethiodide
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive at 20
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NIH 10463 Heroin ethiodide
...(continued)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of > 10 µM in the presence of NaCl (15.2% inhibition at 10
µM).
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M)
Maximum
Response
Drug alone 2.82 x 1O-8 48.2% ± 7.4
After naltrexone 7.48 x 10-8 26.2% ± 3.47
With equimolar concentration
of naltrexone Slight reversal
Equimolar concentration
of sufentanil No reversal
SUMMARY
NIH 10463 probably has insignificant opioid agonist activity in
view of the results of both assay systems. Standards of refe-
rence (e.g., morphine, U-50,488, or enkephalin analogues)
suppress the twitch of the vas deferens to a greater extent than
NIH 10463.
NIH 10464 Heroin propiodide
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive at 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 > 10 µM in the presence of NaCl (20% inhibition at 6 µM).
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NIH 10464 Heroin propiodide
...(continued)
MOUSE VAS DEFERENS PREPARATION
No concentration of this drug significantly inhibited the
contractions of the vas deferens. In the presence of NIH 10464,
100 nM, the sufentanil concentration-effect curve was not
altered.
SUMMARY
NIH 10464 was without significant opioid activity in either
assay.
NIH 10465 Heroin allobromide
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive at 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of > 10 µM in the presence of NaCl (20% inhibition at 6
µM).
MOUSE VAS DEFERENS PREPARATION
NIH 10465 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation in concentrations which ranged
from 10-10 M to 10-4 M. No concentration of this drug signifi-
cantly inhibited the contractions of the vas deferens. In the
presence of NIH 10465, 100 nM, the sufentanil concentration-
effect curve was not altered.
SUMMARY
NIH 10465 was without significant opioid activity in either
assay.
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NIH 10466 Heroin benzobromide
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive at 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of > 10 µM in the presence of NaCl (18% inhibition at 6
µM).
MOUSE VAS DEFERENS PREPARATION
NIH 10466 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation in concentrations which ranged
from 10-10 M to 10-4 M. No concentration of this drug signifi-
cantly inhibited the contractions of the vas deferens. In the
presence of NIH 10466, 100 nM, the sufentanil concentration-
effect curve was not altered.
SUMMARY
NIH 10466 was without significant opioid activity in either
assay.
NIH 10467 N-2-(Carboxyethyl)-N-norketobemidone hydrochloride
MOUSE ANALGESIA, ED50, (mg/kg)
Hot Plate: Inactive at 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of > 10 µM in the presence of NaCl (36% inhibition at 6
µM).
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NIH 10467 N-2-(Carboxyethyl)-N-norketobemidone hydrochloride
...(continued)
MOUSE VAS DEFERENS PREPARATION
NIH 10467 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation in concentrations which ranged
from 10-10 M to 10-4. No concentration of this drug signifi-
cantly inhibited the contractions of the vas deferens. In the
presence of NIH 10467, 100 nM, the sufentanil concentration-
effect curve was not altered.
SUMMARY
NIH 10467 was without significant opioid activity in either
assay.
NIH 10468 N-(1-Benzyl-4-piperidyl)-N-phenylpropanamide hydro-
chloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive at 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE
EC50 of 2200 nM in presence of 150 mM
MOUSE VAS DEFERENS PREPARATION
BINDING
NaCl.
NIH 10468 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation in concentrations which ranged
from 10-10 M to 10-4 M. No concentration of this drug signifi-
cantly inhibited the concentration of the vas deferens.
SUMMARY
NIH 10468 failed to have significant opioid activity in either
preparation; there was a suggestion of slight antagonist acti-
vity in the vas deferens, but the compound had very low potency
in the binding assay.
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NIH 10473 -Carboxymethyl-N-norketobemidone hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Inactive at 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of > 10 µM in the presence of NaCl (32.8% inhibition at 6
µM).
MOUSE VAS DEFERENS PREPARATION
NIH 10473 was studied upon the isolated, electrically stimulated
mouse vas deferens preparation in concentrations which ranged
from 10-10 M to 10-4 M. No concentration of this drug signifi-
cantly inhibited the contractions of the vas deferens. In the
presence of NIH 10473, 100 nM, the sufentanil concentration-
effect curve was not altered.
SUMMARY
NIH 10473 was devoid of activity upon opioid
preparations.
receptors in both
NIH 10482 1-Benzyl-4-phenyl-4-propionoxypiperidine hydrochlo-
ride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot plate: 33% at 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 472 nM in presence of NaCl.
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NIH 10482 1-Benzyl-4-phenyl-4-propionoxypiperidine hydrochlo-
ride
...(continued)
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 1.09 x 10-6 86.7 ± 7.4%
After naltrexone
After ICI-174864
Complete blockade (0)
4.85 x 10-7 68.7 ± 29.3%
After beta-funaltrexamine Complete blockade (0)
With equimolar concentration
of naltrexone Reversal
Equimolar concentration
with sufentanil Did not alter response
SUMMARY
NIH 10482 appeared to be a less potent mu receptor agonist
compared to morphine upon the mouse vas deferens preparation.
This was consistent with its potency in the binding assay.
NIH 10483 N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylthiopropa-
namide hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot Plate: Insoluble
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 13.1 nM in presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 1.76 x 10-7 100%
After naltrexone
After ICI-174864
1.45 x 10-8 94.2 ± 5.8%
2.52 x 1O-8 100%
After beta-funaltrexamine 9.19 x 10-8 63.3 ± 24%
With equimolar concentration
of naltrexone Reversal
Equimolar concentration
with sufentanil Did not alter response
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NIH 10483 N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylthiopropa-
namide hydrochloride
...(continued).
SUMMARY
NIH 10483 appeared to be a mu receptor agonist similar to
morphine upon the mouse vas deferens preparation. It was more
potent in the binding assay than morphine.
NIH 10484 N-[1-(3-Phenylpropyl)-4-piperidyl]-N-phenylpropa-
namide hydrochloride
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 78.2 nM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 1.30 x 10-7 49.9 ± 11%
After naltrexone Complete blockade (0)
After ICI-174864 9.82 x 10-8 35.6 ± 11.2%
After beta-funaltrexamine Complete blockade (0)
With equimolar concentration
of naltrexone Reversal
Equimolar concentration
with sufentanil Did not alter response
SUMMARY
NIH 10484 appeared to be a mu receptor agonist similar to
morphine upon the mouse vas deferens preparation. It is some-
what less potent in the binding assay than morphine.
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NIH 10485 N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylacetamide
hydrochloride
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 676 nM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 4.42 x 1O-7 100%
After naltrexone 4.70 x 10-6 33.7 ± 3.3%
After ICI-174864 5.17 x 10-7
After beta-funaltrexamine 4.80 x 10-7
100%
29.3 ± 2.1%
With equimolar concentration
of naltrexone Reversal
Equimolar concentration
with sufentanil Did not alter response
SUMMARY
NIH 10485 appeared to be a mu receptor agonist similar to
morphine upon the mouse vas deferens preparation; it was much
less potent than morphine in both assays.
NIH 10486 N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylbutyramide
hydrochloride
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NIH 10486 N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylbutyramide
hydrochloride
...(continued)
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 58.7 nM in
MOUSE VAS DEFERENS
Drug alone
After naltrexone
After ICI-174864
1.11 x 10-7 71.5 ± 11.7%
2.11 x 10-6
1.88 x 10-7
82.7 ± 17.3%
45.1 ± 21.8%
After beta-funaltrexamine 2.19 x 10-7 46.9 ± 9.6%
With equimolar concentration
of naltrexone Reversal
Equimolar concentration
with sufentanil Did not alter response
the presence of NaCl.
PREPARATION
Inhibitory
EC50 (M) Maximum Response
SUMMARY
NIH 10486 appeared to be a mu receptor agonist similar to
morphine upon the mouse vas deferens preparation. The binding
and smooth muscle assessments of NIH 10486 was congruent.
NIH 10487 N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylisobutyra-
mide hydrochloride
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 85.1 nM in the presence of NaCl.
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NIH 10487 N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylisobutyra-
mide hydrochloride
...(continued)
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 5.89 x 10
-8 99.35 ± 0.3%
After naltrexone 4.84 x 10
-6 100%
After ICI-174864 1.64 x 10-8 95.0 ± 3.1%
After beta-funaltrexamine 2.98 x 10-7 44.8 ± 12.8%
With equimolar concentration
of naltrexone Reversal
Equimolar concentration
with sufentanil Did not alter response
SUMMARY
NIH 10487 appeared to be a mu receptor agonist similar
morphine upon the mouse vas deferens preparation; its potency
the binding assay was similar to that of morphine as well.
to
in
NIH 10489 N-[1-(2-Phenylethyl)-4-piperidyl]-N-( p-methylphenyl)
propanamide hydrochloride
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 85.1 nM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone
After naltrexone
After ICI-174864
After beta-funaltrexamine
With equimolar concentration
of naltrexone
Equimolar concentration
with sufentanil
4.30 x 10-7 99.6 ± 4.0%
39.0 ± 3.1%8.96 x 10-6
8.66 x 10-7 100%
4.27 x 10-5 96.5 ± 1.8%
No reversal
Did not alter response
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NIH 10489 N-[1-(2-Phenylethyl)-4-piperidyl]-N-( p-methylphenyl)
propanamide hydrochloride
...(continued)
SUMMARY
NIH 10489 appeared to be a mu receptor agonist upon the mouse
vas deferens preparation. It was close to morphine in potency
in the binding assay, and somewhat less potent than morphine in
the mouse vas deferens. The observation that beta-funaltrexa-
mine did not diminish the maximum response to NIH 10489 sugges-
ted that a component of the action of NIH 10489 upon the vas
deferens was mediated either by kappa receptors or by a non-
opiate mechanisms.
NIH 10490 N-[1-(2-Phenylethyl)-4-piperidyl]-N-( p-methoxyphenyl)
-propanamide hydrochloride
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 90.7 nM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 2.09 x 10-7 98.9 ± 0.8%
After naltrexone 2.40 x 10-5 97.4 ± 1.3%
With ICI 174,864 2.79 x 10-7 99.4 ± 0.6%
With beta-funaltrexamine 9.99 x 10-7 43.7 ± 7.3%
With equimolar concentration
of naltrexone Did not alter response
Equimolar concentration
of sufentanil No reversal
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NIH 10490 N-[1-(2-Phenylethyl)-4-piperidyl]-N-( p-methoxyphenyl)
-propanamide hydrochloride
...(continued)
SUMMARY
NIH 10490 appeared to be a relatively selective mu receptor
agonist upon the mouse vas deferens preparation. Its potency in
both preparations was somewhat less than that of morphine.
NIH 10491 N-[1-(2-Phenylethyl)-4-piperidyl]-N-( p-fluorophenyl)
propanamide hydrochloride
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 16.4 nM in
MCUSE VAS DEFERENS
the presence of NaCl.
PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone
After naltrexone
2.20 x 10-8 95.3 ± 1.5%
1.01 x 10-6 100%
After ICI 174864
After beta-funaltrexamine
5.95 x 10-8 83.1 ± 7.8%
1.14 x 10-7 81.3 ± 7.3%
With equimolar concentration
of naltrexone Did not alter response
Equimolar concentration
of sufentanil No reversal
SUMMARY
NIH 10491 appeared to act primarily as a mu receptor agonist
upon the mouse vas deferens preparation although actions upon
the kappa and delta receptors cannot be ruled out. NIH 10491
was as potent as morphine in both preparations.
583
NIH 10492 see NIH 10468
MOUSE ANALGESIA, ED50 (mg/kg)
Hot plate: Inactive at 30
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 2310 nM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10492 had no significant opiate activity on the mouse vas
deferens preparation.
SUMMARY
NIH 10492 was without significant opioid activity in both in
vivo preparations.
NIH 10493 N-[1-(2-Thienyl)methyl-4-piperidyl]-N-phenylpropana-
mide hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot plate: Inactive at 30
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 2460 nM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10493 had no significant activity upon the mouse vas defe-
rens preparation.
NIH 10493 was without significant opioid activity in both in
vivo preparations.
SUMMARY
584
NIH 10496 (E)-3-Chloro-6-[4-(3-phenyl-2-propenyl)-1-piperazi-
nyl]pyridazine hydrochloride
MOUSE ANALGESIA, ED50 (mg/kg)
Hot plate: Inactive at 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 1800 nM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10496 was inactive upon the isolated, electrically stimu-
lated mouse vas deferens preparation. It neither altered
responses to sufentanil, nor reversed the inhibitory effects of
sufentanil.
SUMMARY
NIH 10496 did not have significant opiate activity in both in
vivo preparations.
NIH 10505 N-[1-[2-(2-Thienyl)ethyl]-4-piperidyl]-N-phenylpropa-
namide hydrochloride
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 45.8 nM in the presence of NaCl.
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NIH 10505 N-[1-[2-(2-Thienyl)ethyl]-4-piperidyl]-N-phenylpropa-
namide hydrochloride
...(continued)
MOUSE VAS DEFERENS PREPARATION
Inhibitory
EC50 (M) Maximum Response
Drug alone 1.60 x 10-8 98.4 ± 1.62%
After naltrexone 1.65 x 10-6 93.6 ± 3.86%
After ICI 174864 1.27 x 10-8 99.3 ± 0.7%
After beta-funaltrexamine 4.57 x 10-7 49.5 ± 6.92%
With equimolar concentration
of sufentanil No reversal
SUMMARY
NIH 10505 appeared to be a relatively selective mu receptor
agonist upon the mouse vas deferens preparation. The binding
assay suggested NIH 10505 to be less potent than morphine; while
the reverse was true with the mouse vas deferens.
NIH 10506 N-[1-(2-Hydroxy-2-phenylethyl)-4-piperidyl]-N-phenyl-
propanamide hydrochloride
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 80.0 nM in the presence of NaCl.
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NIH 10506 N-[1-(2-Hydroxy-2-phenylethyl)-4-piperidyl]-N-phenyl-
propanamide hydrochloride
...(continued)
MOUSE VAS DEFERENS PREPARATION
Drug alone
After naltrexone
After ICI 174864
After beta-funaltrexamine
Inhibitory
EC50 (M) Maximum Response
2.71 x 10-8
3.31 x 10-6
100%
97.4 ± 1.29%
2.31 x 10-8 100%
1.34 x 10-6 87.6 ± 7. 53%
With equimolar concentration
of sufentanil
SUMMARY
No reversal
NIH 10506 appeared to be a relatively selective mu receptor
agonist upon the mouse vas deferens preparation. In binding to
opiate receptor in brain membranes, its EC50 was approximately
3-fold higher than that of morphine.
NIH 10516 Oxycodone-6-spirohydantoin
MOUSE ANALGESIA, ED50 (mg/kg)
Hot plate: Inactive at 20
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of > 6000 nM (3.1% inhibition at 5 µM) in the presence of
NaCl.
MOUSE VAS DEFERENS PREPARATION
NIH 10516 was inactive upon the mouse vas deferens preparation
in concentrations which ranged from 10-9 M to 3 x 10-5 M. It
neither altered responses to sufentanil nor reversed the inhibi-
tory effects of sufentanil.
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NIH 10516 Oxycodone-6-spirohydantoin
...(continued)
SUMMARY
NIH 10516 did not have opiate activity upon the mouse vas
deferens preparation. Both assays' results suggested that NIH
10516 had no significant opioid activity.
NIH 10519 Naltrexone-6-spirohydantoin succinate
DISPLACEMENT OF SPECIFIC 3H-ETORPHINE BINDING
EC50 of 55.2 nM in the presence of NaCl.
MOUSE VAS DEFERENS PREPARATION
Drug alone
After naltrexone
After ICI 174864
4.79 x 10-6
Inhibitory
54.2 ± 3.75%
EC50 (M) Maximum Response
2.75 x 10-6 75.2 ± 3.63%
1.69 x 10-5 55.2 ± 8.73%
4.96 x 10-5 76.5 ± 2.05%
After beta-funaltrexamine
With equimolar concentration
of sufentanil
SUMMARY
No reversal
NIH 10519 had delta receptor agonistic activity upon the mouse
vas deferens preparation. In the membrane binding assay, it was
approximately 2-fold less potent than morphine.
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Abstinence syndrome
occurrence and treatment of neonates exposed to drugs in utero, 274
Abuse liability
comparison with reinforcing properties, 440-456
prediction by drug self-administration procedures, 457-465
1-Acetonyl-2-(2,4-dichlorophenyl)iminoimidazolidine hydrochloride (NIH 10318)
biological evaluation of dependence liability, 482
dependence studies in monkeys, 556
depression of smooth-muscle twitch, 556
displacement of stereospecific 3H-etorphine binding, 556
mouse analgesia, 556
(+)- -4-Acetoxy-1,2 -dimethyl-4-phenylpiperidine hydrochloride (NIH 10542)
biological evaluation of dependence liability, 479
mouse analgesia, 542
Acetylcholine
effects of cocaine on turnover rate in hippocampus, 315
Acquired immunodeficiency syndrome
See AIDS
Addiction
attitudes of clinic types toward treatment of narcotic addiction, 295
conditioned craving and arousal in cocaine addiction, 74-80
contingency management with a poly-drug abuse, methadone-maintenance
population, 298
methodological problems in psychopharmacological studies, 303
quantification of morphine abstinence syndrome in humans, 8-18
treatment of the addict with a psychiatric disorder, 296-297
Adinazolam
abuse potential in humans, 333-334
Adolescents
risk factors predict probability of drug and alcohol use, 301
Adrenocorticotropic hormone (ACTH)
plasma levels following either alcohol or marijuana in humans, 422-427
regulation of adrenal biosynthesis of enkephalins, 129-135
AIDS
abnormal antibody titers in methadone maintenance patients, 290
prevalence among infants of i.v. drug using mothers, 273
prevalence of infection in association with drug use and ethnicity, 188-194
risk of HIV exposure by sexual contact with intravenous drug abuser, 339
Aggression
in human males, effects of secobarbital on, 60-66
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Alcohol
behavioral, electrophysiological and endocrine effects in humans, 422-427
characterization of withdrawal anxiety in an animal model, 305
CNS defects in fetal alcohol syndrome, 251
co-abuse with opiates, 428-439
cognitive and motor development following prenatal alcohol exposure, 252
concurrent use with tobacco by women, 26-32
dependence syndrome, 33-39
effects of intoxication and hangovers on consumption, 311
effects on fetal CNS differentiation and development, 380-386
effects on LH and FSH in ovariectomized monkeys, 122-128
frequency of use during methadone-maintenance treatment, 224-230
genetically selected rats as a model for alcoholism, 307
induced cardiac hypertrophy in the rat, effect of dl-propranolol and its
enantiomers, 308
inpatient medical detoxification, 19-25
intake modulated by opioids in rats, 304
neonatal effects associated with maternal drug use, 264
reinforcing efficacy measured by progressive ratio methods, 462-463
risk factors predict probability of use in adolescents, 301
self-administration and withdrawal in rats, 306
self-administration in alcoholic methadone patients and treatment, 302
social influences on self-administration and behavior in monkeys, 309-310
Alcoholics
conditioned responding to alcohol compared to placebo, 40-46
Alcoholism
methodological problems in psychopharmacological studies on, 303
prevalence in the general population, 405-415
review of genetic factors relevant to alcoholism, 387-394
(-)-N-Allylnormetazocine [(-)-SKF-10047]
displacement of stereospecific 3H-etorphine binding, 550
(+)-N-Allylnotmetazocine [(+)-SKF-10047]
characterization of binding sites in mouse brain, 282
Alprazolam
discriminative-stimulus properties in midazolam-trained pigeons, 115-121
Amantadine
treatment for cocaine abuse, 316
treatment for cocaine withdrawal, 81-85
utilized in step-wise withdrawal from cocaine dependence, 317
Amfonelic acid
effect on brain-stimulation reward alone and with morphine, 283
N-(Aminocarbonyl)-2-bromo-2-ethylbutanamide (Carbromal, CPDD 0013)
evaluation of dependence potential, 471, 484
Amitriptyline
evaluation in mouse, narcotic-dependence tests, 284
Amobarbital
reinforcing efficacy based upon self-administration response rate, 443
relationship between self-administration and behavioral disruption, 449
Amphetamine
anorectic/reinforcement ratio, 446
frequency of use during methadone-maintenance treatment, 224-230
reinforcing efficacy based upon self-administration frequency, 442
reinforcing efficacy measured by progressive ratio methods, 462-463
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Apnea
correlation with ß-endorphin levels and treatment with naltrexone, 181-187
incidence in infants born to drug-dependent mothers, 263
Barbiturates
frequency of use during methadone-maintenance treatment, 224-230
Benzodiazepine
dependence in mice, effect of dose and duration of treatment, 341
differentiation of high- and low-dose dependence in the rat, 330
See also Individual benzodiazepines
Benzodiazepine receptors
modification by repeated cocaine administration, 101-108
Benzphetamine
reinforcing efficacy based upon self-administration frequency, 442
1-Benzyl-4-phenyl-4-propionoxypiperidine hydrochloride (NIH 10482)
biological evaluation of dependence liability, 480
dependence studies in monkeys, 521-522
depression of smooth-muscle twitch, 577
displacement of stereospecific 3H-etorphine binding, 576
mouse analgesia, 521, 576
N-(1-Benzyl-4-piperidyl)-N-phenylpropanamide hydrochloride (NIH 10468; NIH
10492)
biological evaluation of dependence liability, 481
dependence studies in monkeys, 517
depression of smooth-muscle twitch, 575,584
displacement of stereospecific 3H-etorphine binding, 575, 584
mouse analgesia, 517,575,584
nor -Binaltorphimine (nor-BNI)
selective kappa antagonist, 353-362
14 - (p -Bromocinnamoylamino)-7,8-dihydro-N-cyclopropylmethylnorcodeinone
mesylate (NIH 10426)
biological evaluation of dependence liability, 475
dependence studies in monkeys, 504-505
depression of smooth-muscle twitch, 564
displacement of stereospecitic 3H-etorphine binding, 563
drug discrimination in codeine-trained monkeys, 565-566
mouse analgesia, 503,563
self-administration in codeine-trained monkeys, 564-565
14 -(p-Bromocinnamoylamino)-7,8-dihydrocyclopropylmethylnormorphinone
mesylate (NIH 10445)
biological evaluation of dependence liability, 475
dependence studies in rats, 511-512
dependence studies in monkeys, 511
depression of smooth-muscle twitch, 570
displacement of stereospecific 3H-etorphine binding, 570
mouse analgesia, 510, 570
time course of antagonism of morphine in tail flick, 510
Bromocriptine
utilized in step-wise withdrawal from cocaine dependence, 317
Buprenorphine
drug discrimination in human post-addicts, 209-215
precipitated syndrome in U50,488H- and trifluadom-treated rats, 136-142
tolerance to disruption of conditioned responding in monkeys, 287
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treatment of heroin addicts, 340
trials in borderline patients and opiate dependence, 289
Buspirone
discriminative-stimulus properties in midazolam-trained pigeons. 115-121
Butorphanol
drug discrimination in human post-addicts, 209-215
-Butyrolactone (NIH 10540)
biological evaluation of dependence liability, 482
dependence studies in monkeys, 541-542
mouse analgesia, 541
Caffeine
medical advice regarding consumption, 323
reinforcing efficacy measured by progressive ratio methods, 462-463
Calcium
alterations in influx into brain synaptosomes by nicotine, 324
analgesic effects following intrathecal injections, 300
Cannabinoids
serum concentrations in pregnant rat and fetus following acute and chronic
administration of 9-THC
stereoselectivity in the mouse and dog, 325-326
Cannabis
See Marijuana
(±)-2-(2-Carbethoxyethyl)-5,9 -dimethyl-2'-hydroxy-6,7-benzomorphan
hydrochloride (NIH 105 15)
biological evaluation of dependence liability, 477
mouse analgesia, 537
(±)-2-Carbethoxymethyl-5,9 -dimethyl-2’-hydroxy-6,7-benzomorphan oxalate
(NIH 10503)
biological evaluation of dependence liability, 477
mouse analgesia, 535
N-Carbethoxymethyl-N-norketobemidone oxalate (NIH 10454)
biological evaluation of dependence liability, 479
dependence studies in monkeys, 514
mouse analgesia, 514
4-Carbethoxy-1-methyl-4-phenylpiperidine hydrochloride (NIH 10522)
See Pethidine hydrochloride
N-(3-Carbethoxypropyl)-N-norketobemidone oxalate (NIH 10453)
biological evaluation of dependence liability, 479
dependence studies in monkeys, 513
mouse analgesia, 513
N-(2-Carboxyethyl)N-norketobemidone hydrochloride (NIH 10467)
biological evaluation of dependence liability, 479
depression of smooth-muscle twitch, 575
displacement of stereospecific 3H-etorphine binding, 574
mouse analgesia, 516, 574
(±)-2-Carboxymethyl-5,9 -dimethyl-2’-hydroxy-6,7-benzomorphan hydrochloride
(NM 10502)
biological evaluation of dependence liability, 477
mouse analgesia, 534
N-Carboxymethyl-N-norketobemidone hydrobromide (NIH 10473)
biological evaluation of dependence liability, 479
594
dependence studies in monkeys, 518
depression of smooth-muscle twitch, 576
displacement of stereospecific 3H-etorphine binding, 576
mouse analgesia, 518, 576
6 -(2-Carboxy-1-propenyl)-naltrex-6 -ol -lactone (NIH 10322)
biological evaluation of dependence liability, 475
dependence studies in monkeys, 557
displacement of stereospecific 3H-etorphine binding, 557
mouse analgesia, 557
6 -(2-Carboxy-1-propenyl)-oxymorph-6 -o l -lactone (NIH 10324)
biological evaluation of dependence liability, 475
dependence studies in monkeys, 558
displacement of stereospecific 3H-etorphine binding, 558
mouse analgesia, 557
N-(3-Carboxypropyl)-N-norketobemidone (NIH 10475)
biological evaluation of dependence liability, 479
mouse analgesia, 519
Carbromal [N-(Aminocarbonyl)-2-bromo-2-ethylbutanamide, CPDD 0013]
evaluation of dependence potential, 471, 484
Chloral hydrate
evaluation of dependence potential, 472, 484
Chloralodol [2-Methyl-4-(2,2,2-trichloro-1-hydroxyethoxy)-2-pentanol,
chlorhexadol, CPDD 0012]
evaluation of dependence potential, 471, 484
Chlordiazepoxide
differentiation of high- and low-dose dependence in the rat, 330
flurothyl seizure thresholds associated with acute and chronic dependence
and withdrawal, 109-114
Chlorhexadol [2-Methyl-4-(2,2,2-trichloro-1-hydroxyethoxy)-2-pentanol,
chloralodol, CPDD 0012]
evaluation of dependence potential, 471, 484
(+)-N-cis-3-Chloroallyl-N-normetazocine hydrobromide (NIH 10167)
biological evaluation of dependence liability, 477
depression of smooth-muscle twitch, 555
displacement of stereospecific 3H-etorphine binding, 555
mouse analgesia, 555
14 -(p-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopropylmethylnorcodeinone
mesylate (NIH 10420)
biological evaluation of dependence liability, 475
dependence studies in monkeys, 502-503, 561-562
depression of smooth-muscle twitch, 561
displacement of stereospecific 3H-etorphine binding, 561
drug discrimination in codeine-trained monkeys, 562-563
mouse analgesia, 502, 560
14 -(p-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopropylmethylnormorphinone
mesylate (NIH 10443)
biological evaluation of dependence liability, 475
dependence studies in monkeys, 508
mouse analgesia, 507
time course of antagonism of morphine in tail flick, 508
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5-(2-Chloroethyl)-4-methyhhiazole ethanedisulfonate (Clomethiazole edisilate,
heminevrin, CPDD 0014)
evaluation of dependence potential, 471,484
(E)-3-Chloro-6-[4-(3-phenyl-2-propenyl)-1-piperazinyl]pyridazine hydrochloride
(NIH 10496)
biological evaluation of dependence liability, 482
dependence studies in monkeys, 531-532
depression of smooth-muscle twitch, 585
displacement of stereospecific 3H-etorphine binding, 585
mouse analgesia, 531, 585
Chlorphentermine
anorectic/reinforcement ratio, 446
reinforcing efficacy based upon self-administration frequency, 442
reinforcing efficacy measured by progressive ratio methods, 445, 462-463
Chlorpromazine
discriminative-stimulus properties in midazolam-trained pigeons, 115-121
evaluation in mouse, narcotic-dependence tests, 284
mouse analgesia, 487, 549
Cigarette
See Tobacco
CL 218,872
discriminative-stimulus properties in midazolam-trained pigeons, 115-121
Clomethiazole edisilate [5-(2-Chloroethyl)-4-methylthiazole ethanedisulfonate,
heminevrin, CPDD 0014]
evaluation of dependence potential, 471, 484
Clonazepam
reinforcing efficacy based upon self-administration-response rate, 443
Clonidine
treatment of opioid withdrawal in outpatients, 291
Clorazepate
reinforcing efficacy based upon self-administration-response rate, 443
Clortermine
anorectic/reinforcement ratio, 446
reinforcing efficacy based upon self-administration frequency, 442
Cocaine hydrochloride (NIH 8211)
biological evaluation of dependence liability, 483
mouse analgesia, 492
Cocaine
abstinence and relapse to cocaine abuse in opioid addicts, 231-236
adverse perinatal outcome following use during pregnancy, 265
amantadine treatment for abuse, 316
amantadine treatment for ambulatory withdrawal in humans, 81-85
anorectic/reinforcement ratio, 446
chronic administration modifies rat brain benzodiazepine receptors, 101-108
conditioned craving and arousal in human addiction, 74-80
continuous exposure to monkeys and rats, behavioral and neurochemical
effects 86-93
correlation of receptor binding with reinforcing potency, 313
desipramine treatment of cocaine-abusing, methadone-maintenance patients,
237-241
detection in stools of infants of drug-dependent mothers, 262
development of tolerance during chronic infusion in humans, 312
dilemma of exposure in the perinatal period, 379
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effects of repeated exposure on benzodiazepine receptors in rat brain, 101-108
effects on hippocampal acetylcholine, norepinephrine and serotonin, 315
frequency of use during methadone-maintenance treatment, 224-230
genetic factors in behavioral and lethal effects in rats, 314
hyperprolactinemia during withdrawal in humans, 67-73
neonatal effects associated with maternal drug use, 264
neurochemical basis for interactions with methamphetamine in rats, 94-100
reinforcing efficacy measured by progressive ratio methods, 445, 462-463
step-wise withdrawal procedure utilizing amino acids, amantadine, levodopa,
bromocriptine and desipramine, 317
Codeine
administration to chronic pain patients, 174-180
reinforcing efficacy measured by progressive ratio methods, 462-463
Codeine phosphate
mouse analgesia, 487, 548
Computers
system for inventory of controlled drug substances, 163-166
Controlled drug substances
development of a computerized system for inventory of, 163-166
Corticosterone
mu and kappa receptor control of secretion in perinatal rats, 280
tolerance and abstinence to mu and kappa receptor stimulated release, 278
Cortisol
levels in smokers following withdrawal from tobacco, 326
secretion in methadone-dependent and abstinent patients, 216-223
Cotinine (NIH 10498; 1-Methyl-5-(3-pyridyl)-2-pyrrolidinone)
biological evaluation of dependence liability, 483
dependence studies in monkeys, 532-533
mouse analgesia, 532
Counseling
differences in counselors in methadone treatment, 242-250
CPDD 0007 (Methaqualone)
evaluation of dependence potential, 472, 484
CPDD 0011 (Meparfynol, 3-methyl-1-pentyn-3-01, methylpentynol)
evaluation of dependence potential, 470, 484
CPDD 0011A (Meparfynol carbamate, 3-methyl-1-pentyn-3-ol carbamate,
methylpentynol carbamate)
evaluation of dependence potential, 470, 484
CPDD 0012 [2-Methyl-4-(2,2,2-trichloro-1-hydroxyethoxy)-2-pentanol,
Chloralodol, chlorhexadol]
evaluation of dependence potential, 471, 484
CPDD 0013 [N-(Arninocarbonyl)-2-bromo2-ethylbutanamide, Carbromal]
evaluation of dependence potential, 471, 484
CPDD 0014 [5-(2-Chloroethyl)-4methylthiazole ethanedisulfonate, Clomethiazole
edisilate, heminevrin]
evaluation of dependence potential, 471, 484
CPDD 0015 (Ethchlorovynol)
evaluation of dependence potential, 472, 484
CPDD 0016 (2,2,2-Trichloroethanol dihydrogen phosphate, Triclofos)
evaluation of dependence potential, 471, 484
CPDD 0018 (Meprobamate)
evaluation of dependence potential, 472, 484
Crime
reduction during methadone maintenance, 224-230
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CTP (D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NHZ)
intrathecal administration in morphine-dependent mice, 143-148
selective mu antagonist, 353-362
Cyclazocine
mouse analgesia, 487, 549
(-)-Cyclazocine
displacement of stereospecific 3H-etorphine binding, 550
3-Cyclohexyl-1-N,N-dimethylamino-3-phenylpropane hydrochloride (NIH 10438)
biological evaluation of dependence liability, 478
mouse analgesia, 507
(-)-N-Cyclopropymethyl-3,4-dimethoxymorphinan-6-one hydrobromide (NIH
10017)
biological evaluation of dependence liability, 477
mouse analgesia, 492
(+)-3-Cyclopropylmethyl-1,2,3,4,5,6,7,7a-octahydro-9-hydroxy-4aH-4a,7-
ethanobenzofuro(3,2-e)isoquinoline-5-methanol (NIH 10412)
biological evaluation of dependence liability, 482
dependence studies in monkeys, 501
mouse analgesia, 501
DADL
development of tolerance after chronic intrathecal infusion in rats, 343-352
DADLE ([D-Ala2-D-Leu5]enkephalin)
separation of receptor blockade from functional supersensitivity, 275
DAGO ([D-Ala2,NMePhe4,Gly-ol]enkephalin)
development of tolerance after chronic intrathecal infusion in rats, 343-352
lack of antagonism by U-50,488H in the rat, 277
selective mu agonist, 353-362
Desipramine
treatment of cocaine-abusing, methadone-maintenance patients, 237-241
utilized in step-wise withdrawal from cocaine dependence,  17
Detoxification
alcohol, 19-25
Dexamethasone
effect on adrenal biosynthesis of enkephalins, 129-135
Dextrorphan
displacement of stereospecific 3H-etorphine binding, 550
Diazepam
dependence in mice, effect of dose and duration of treatment, 341
discriminative-stimulus properties in midazolam-trained pigeons, 115-121
effect of chronic treatment on perturbation of the GABA system, 328
effects on EEG, evoked potentials and performance by humans, 329
influence of GABA antagonists on withdrawal discriminative stimulus, 331
reinforcing efficacy based upon self-administration response rate, 443
relationship between self-administration and behavioral disruption, 449
treatment of the opiate and non-opiate abstinence syndrome in neonates, 274
Diethylpropion
anorectic/reinforcement ratio, 446
reinforcing efficacy based upon self-administration frequency, 442
reinforcing efficacy measured by progressive ratio methods, 445, 462-463
Dihydromorphinone hydrochloride
mouse analgesia, 487, 549
5,7-Dihydroxytryptamine
effect on food, water and morphine self-administration in rats, 149-155
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2,5-Dimethoxy-4-ethylamphetamine (DOET)
reinforcing efficacy based upon self-administration frequency, 442
2,5-Dimethoxy-4-methylamphetamine (DOM)
reinforcing efficacy based upon self-administration frequency, 442
(-)-3,4-Dimethoxy-N-(2-phenylethyl)morphinan-6-one hydrobromide (NIH 10018)
biological evaluation of dependence liability, 477
mouse analgesia, 492
2,2-Dimethyl-3-(dimethylamino)-7-hydroxy-1-tetralol (NIH 10430)
biological evaluation of dependence liability, 482
mouse analgesia, 507
1R-5R-9R-2”R-5,9-Dimethyl-2’-hydroxy-2-tetrahydrofurfuryl-6,7-benzomorphan
hydrochloride (UM 1071R)
displacement of stereospecific 3H-etorphine binding, 550
1,3-Dimethyl-4-phenyl-4-(1-piperidinyl)piperidine dihydrochloride (NIH 10013)
biological evaluation of dependence liability, 478
drug discrimination in ketamine-trained monkeys, 554
mouse analgesia, 554
Diprenorphine
tolerance to disruption of conditioned responding in monkeys, 287
l I-Dopa
utilized in step-wise withdrawal from cocaine dependence, 317
Dopamine
effects of MDMA on levels in neonate and adult rat brain areas, 318
rat-brain levels following continuous infusion of cocaine, 86-93
rat-brain levels following exposure to cocaine and methamphetamine, 94-100
Doxepin
treatment of depressed opioid addicts undergoing methadone treatment, 292
DPDPE (cyclic [D-Pen2,D-Pen5]enkephalin)
endocrine response following administration to perinatal rats, 280
selective delta agonist, 353-362
DPLPE (cyclic [D-Pen2,L-Pen5]enkephalin)
selective delta agonist, 353-362
Drug abuse
identification of personality disorder subtypes among drug abusers, 299
risk factors in the etiology of drug abuse, 254-261
Drug dependence
acute physical dependence to opioids in humans, 195-201, 202-208
alcohol- and opiate-dependence syndrome, 33-39
flurothyl seizure thresholds associated with acute and chronic
chlordiazepoxide dependence, 109-114
hormone secretion in methadone-dependent and abstinent patients, 216-223
in vitro assessment of opiate dependence, 167-173
paradoxes of experimental opiate dependence, 156-162
prevalence in the general population, 405-415
role of conditioning aspects, 395-404
Dynorphin
endocrine response following administration to perinatal rats, 280
Ecstasy
See MDMA
Electroencephalography
effects following either alcohol or marijuana in humans, 422-427
N-(6,14-Endoethano-7,8-dihydromorphine- -carbonyl)-L-phenylalanyl-L-leucinol
(NIH 9834)
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biological evaluation of dependence liability, 475
depression of smooth-muscle twitch, 553
displacement of stereospecific 3H-etorphine binding, 553
mouse analgesia, 553
ß-Endorphin
endocrine response following administration to perinatal rats, 280
role in respiratory disorders in humans, 181-187
Enkephalin
glucocorticoid regulation of adrenal biosynthesis, 129-135
l -Ephedrine
reinforcing efficacy based upon self-administration frequency, 442
Ethanol
See Alcohol
Ethchlorovynol (CPDD 0015)
evaluation of dependence potential, 472, 484
Ethyl N-allyl-3 -(3-hydroxyphenyl)-8-azabicyclo[3.2.1]octane carboxylate
hydrochloride (NIH 10529)
biological evaluation of dependence liability, 483
mouse analgesia, 539
Ethyl 3 -(3-hydroxyphenyl)-N-methyl-8-azabicyclo[3.2.1]octane carboxylate
hydrochloride (NIH 10480)
biological evaluation of dependence liability, 483
mouse analgesia, 520
Ethyl 3 -(3-hydroxyphenyl)-N-phenethyl-8-azabo[3.2.1.]octane carboxylate
(NIH 10530)
biological evaluation of dependence liability, 483
mouse analgesia, 540
Ethylketazocine
displacement of stereospecific 3H-etorphine binding, 550
Ethyl 3 -(3-methoxyphenyl)-N-methyl-8-azabicyclo[3.2.1]octane carboxylate
hydrochloride (NIH 10479)
biological evaluation of dependence liability, 483
mouse analgesia, 520
Ethyl N-methyl-3 -phenyl-8-azabicyclo[3.2.1]octane carboxylate hydrochloride
(NIH 10481)
biological evaluation of dependence liability, 483
mouse analgesia, 521
Etorphine
antagonism by U-50,488H in the rat, 277
displacement of stereospecific 3H-etorphine binding, 550
receptor changes in guinea-pig colon with age, 276
Fentanyl
tolerance and cross-tolerance with morphine in drug discrimination, 286
Fenfluramine
anorectic/reinforcement ratio, 446
reinforcing efficacy based upon self-administration frequency, 442
reinforcing efficacy measured by progressive ratio methods, 445, 462-463
Fetal alcohol syndrome
central nervous system defects in, 251
review of the literature, 363-367
m -Fluoronormethadone hydrochloride (NIH 10261)
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biological evaluation of dependence liability, 478
mouse analgesia, 493
Flurazepam
discriminative-stimulus properties in midazolam-trained pigeons, 115-121
reinforcing efficacy based upon self-administration response rate, 443
Flurothyl
seizure thresholds associated with acute and chronic chlordiazepoxide
dependence and withdrawal, 109-114
ß-FNA (ß-Funaltrexamine)
selective mu antagonist, 353-362
Follicle-stimulating hormone
levels in ovariectomized monkeys following alcohol administration, 122-128
GABA
alterations by chronic treatment with nicotine and diazepam, 328
influence of antagonists on diazepam withdrawal discriminative stimulus, 331
Glucocorticoid
regulation of adrenal biosynthesis of enkephalins, 129-135
Growth hormone
mu and kappa receptor control of secretion in perinatal rats, 280
Hallucinogens
frequency of use during methadone-maintenance treatment, 224-230
Haloperidol
evaluation in mouse, narcotic-dependence tests, 284
Heminevrin [5-(2-Chloroethyl)-4methylthiazole ethanedisulfonate, Clomethiazole
edisilate, CPDD 0014]
evaluation of dependence potential, 471, 484
Henry L.Rosett
contribution to fetal alcohol syndrome research, 363-367
Henry L.Rosett Memorial Lecture
“Growing Up with Fetal Alcohol Syndrome”, 368-378
Heroin
addicts maintained with LAAM, 294
detection in stools of infants of drug-dependent mothers, 262
neonatal effects associated with maternal drug use, 264
reduced use during methadone maintenance, 224-230
reinforcing efficacy measured by progressive ratio methods, 462-463
tapering methadone treatment in addicts, 293
tolerance to disruption of conditioned responding in monkeys, 287
treatment of addiction with buprenorphine, 340
Heroin allobromide (NIH 10465)
biological evaluation of dependence Liability, 476
depression of smooth-muscle twitch, 573
displacement of stereospecific 3H-etorphine binding, 573
mouse analgesia, 516, 573
Heroin benzobromide (NIH 10466)
biological evaluation of dependence liability, 476
depression of smooth-muscle twitch, 574
displacement of stereospecific 3H-etorphine binding, 574
mouse analgesia, 516, 574
Heroin ethiodide (NIH 10463)
biological evaluation of dependence liability, 476
depression of smooth-muscle twitch, 572
displacement of stereospecific 3H-etorphine binding, 572
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mouse analgesia, 515, 571
Heroin methiodide (NIH 10462)
biological evaluation of dependence liability, 476
depression of smooth-muscle twitch, 571
displacement of stereospecific 3H-etorphine binding, 571
mouse analgesia, 515, 571
Heroin propiodide (NIH 10464)
biological evaluation of dependence liability, 476
depression of smooth-muscle twitch, 573
displacement of stereospecific 3H-etorphine binding, 572
mouse analgesia, 515, 572
HIV
See AIDS
Hydrocodone
administration to chronic pain patients, 174-180
Hydromorphone
administration to chronic-pain patients, 174-180
drug discrimination in human post-addicts, 209-215
11-Hydroxy- 8-dimethylhepylytetrahydrocannabinol
stereoselectivity in the mouse and dog, 325-326
4-Hydroxy-3-methyl-4-phenyl-1-(1-phenylcyclohexyl)piperidine hydrochloride
(trans 3-methyl, reference 4-phenyl) (NIH 10531)
biological evaluation of dependence liability, 479
mouse analgesia, 540
N-[1-(2-Hydroxy-2-phenylethyl)-4-piperidyl]-N-phenylpropanamide hydrochloride
(NIH 10506)
biological evaluation of dependence liability, 481
dependence studies in monkeys, 536-537
depression of smooth-muscle twitch, 587
displacement of stereospecific 3H-etorphine binding, 586
mouse analgesia, 536
4-(m -Hydroxyphenyl)methyhtmino-1-(2-phenylethyl)piperidine hydrochloride (NIH
10344)
biological evaluation of dependence liability, 478
dependence studies in monkeys, 497-498
mouse analgesia, 497
(-)-2’-Hydroxy-2,5,9 -trimethyl-6,7-benzomorphan hydrochloride (NIH 7569)
See (-)-Metazocine
(+)-2’-Hydroxy-2,5,9 -trimethyl-6,7-benzomorphan hydrochloride (NIH 7571)
See (+)-Metazocine
3-Hydroxy- N-trimethyl-6.14-ethenomorphinan-7 -methanol (NIH 10500)
biological evaluation of dependence liability, 477
mouse analgesia, 534
Hyperprolactinemia
during cocaine withdrawal, 67-73
Hypothalamo-pituitary-adrenal axis
tolerance and abstinence to mu and kappa receptor stimulation, 278
ICI 174,864 (N,N-Diallyl-Tyr-Aib-Aib-Phe-Leu-OH)
selective delta antagonist, 353-362
Inhalants
frequency of use during methadone-maintenance treatment, 224-230
Ketamine
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reinforcing efficacy measured by progressive ratio methods, 462-463
relationship between self-administration and behavioral disruption, 449
Ketazocine
displacement of stereospecific 3H-etorphine binding, 550
LAAM
maintenance in heroin addicts, 294
Levodopa
utilized in step-wise withdrawal from cocaine dependence, 317
Levorphanol tartrate
mouse analgesia, 487, 548
Lorazepam
discriminative-stimulus properties in midazolam-trained pigeons, 115-121
Luteinizing hormone
development of tolerance to naloxone-induced release in neonatal rats, 279
levels in ovariectomized monkeys following alcohol administration, 122-128
secretion in methadone-dependent and abstinent patients, 216-223
Marijuana
behavioral, electrophysiological and endocrine effects in humans, 422-427
frequency of use during methadone-maintenance treatment, 224-230
interactions between social behavior and smoking, 47-52
Mazindol
affinity of cocaine and analogs for binding site, correlation with reinforcing
potency, 313
discriminative-stimulus properties in midazolam-trained pigeons, 115-121
reinforcing efficacy measured by progressive ratio methods, 462-463
MDA (3,4-Methylenedioxyamphetamine)
effect of isomers in combination with pirenperone in operant responding in
mice, 322
identification as a metabolite of MDMA in the rat, 321
MDMA (3,4-Methylenedioxymethamphetamine)
effect of isomers in combination with pirenperone in operant responding in
mice, 322
effects on biogenic amine levels in adult and neonate rats, 318
metabolic conversion to MDA in the rat, 321
selective neurotoxicity and interactions with brain-serotonin systems, 319-320
Mecamylamine
blockade of nicotine’s effects on conditioned responding in rats, 325
Medazepam
reinforcing efficacy based upon self-administration response rate, 443
Meparfynol(3-Methyl-1-pentyn-3-ol, methylpentynol, CPDD 0011)
evaluation of dependence potential, 470, 484
Meparfynol carbamate (3-Methyl-1-pentyn-3-ol carbamate, methylpentynol
carbamate, CPDD 0011A)
evaluation of dependence potential, 470, 484
Meperidine
administration to chronic-pain patients, 174-180
mouse analgesia, 487, 548
Meprobamate (CPDD 0018)
evaluation of dependence potential, 472, 484
(-)-Metazocine [NIH 7569; (-)-2’-Hydroxy-2,5,9 -trimethyl-6,7-benzomorphan
hydrochloride]
biological evaluation of dependence liability, 477
dependence studies in monkeys, 489
603
dependence studies in monkeys, 489
mouse analgesia, 489
(-)-Metazocine hydrobromide
mouse analgesia, 487, 548
(+)-Metazocine [NIH 7571; (+)-2’-Hydroxy-2,5,9 -trimethyl-6,7-benzomorphan
hydrochloride]
biological evaluation of dependence liability, 477
dependence studies in rats, 490-491
mouse analgesia, 490
Methadone
administration to chronic-pain patients, 174-180
cognitive ability of children exposed to methadone in utero, 253
contingency management with a poly-drug abuse population, 298
counselor differences in maintenance treatment, 242-250
desipramine treatment of cocaine-abusing, methadone-maintenance patients,
237-241
doxepin treatment of depressed opioid addicts in methadone treatment, 292
endocrine response following administration to perinatal rats, 280
ethanol self-administration in alcoholic, methadone patients and treatment, 302
in utero exposure of tricyclic antidepressants to infants born to methadone-
maintained women, 266-272
hormone secretion in dependent and abstinent patients, 216-223
LAAM maintenance for opiate addicts refractory to methadone, 294
neonatal effects associated with maternal drug use, 264
reduced heroin and non-opiate use and crime during maintenance, 224-230
tapering treatment in heroin addicts, 293
Methamphetamine
neurochemical basis for interactions with cocaine in rats, 94-100
relationship between self-administration and behavioral disruption, 449
Methaqualone (CPDD 0007)
evaluation of dependence potential, 472, 484
4-Methoxyamphetamine (PMA)
reinforcing efficacy based upon self-administration frequency, 442
14 -(p-Methylcinnamoylamino)-7,8-dihydro-N-cyclopropylmethylnorcodeinone
mesylate (NIH 10427)
biological evaluation of dependence liability, 475
dependence studies in monkeys, 505-506
depression of smooth-muscle twitch, 567
displacement of stereospecific 3H-etorphine binding, 566
drug discrimination in codeine-trained monkeys, 568-569
mouse analgesia, 505,566
self-administration in codeine-trained monkeys, 567
14 - (p-Methylcinnamoylamino)-7,8-dihydro-N-cyclopropylmethylnormorphinone
mesylate (NIH 10444)
biological evaluation of dependence liability, 475
dependence studies in monkeys, 509-510
depression of smooth-muscle twitch, 570
displacement of stereospecific 3H-etorphine binding, 569
mouse analgesia, 509, 569
3,4-Methylenedioxyamphetamine
See MDA
3,4-Methylenedioxymethamphetamine
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See MDMA
2-(3-Methylfurfuryl)-2’-hydroxy-5,9 -dimethyl-6,7-benzomorphan methane
sulfonate (UM 911)
displacement of stereospecific 3H-etorphine binding, 550
3-Methyl-1-pentyn-3-ol (Meparfynol, methylpentynol, CPDD 0011)
evaluation of dependence potential, 470,484
3-Methyl-1-pentyn-3-ol carbamite (Meparfynol carbamate, methylpentynol
carbamate, CPDD 0011A)
evaluation of dependence potential, 470,484
Methylpentynol (Meparfynol, 3-methyl-1-pentyn-3-ol, CPDD 0011)
evaluation of dependence potential, 470,484
Methylpentynol carbamate (Meparfynol carbarnate, 3-methyl-1-pentyn-3-ol
carbamate, CPDD 0011A)
evaluation of dependence potential, 470,484
Methylphenidate
reinforcing efficacy measured by progressive ratio methods, 463
1-Methyl-4-phenyl-4-(1-piperidinyl)piperidine dihydrochloride (NIH 10012)
biological evaluation of dependence liability, 478
drug discrimination in ketamine-trained monkeys, 553-554
mouse analgesia, 553
1-Methyl-5-(3-pyridyl)-2-pyrrolidinone (NIH 10498)
See Cotinine
N-[1-[1-Methyl-2-(2-thienyl)ethyl]-4-piperidyl]-N-phenylpropanamide
hvdrochloride (NIH 10538)
biological evaluation of dependence liability, 481
dependence studies in monkeys, 541
mouse analgesia, 540
2-Methyl-4-(2,2,2-trichloro-1-hydroxyethoxy)-2-pentanol (Chloralodol,
chlorhexadol, CPDD 0012)
evaluation of dependence potential, 471, 484
Methylxanthines
treatment of apnea in infants born to drug-dependent mothers, 263
Midazolam
discriminative-stimulus properties in pigeons, 115-121
reinforcing efficacy based upon self-administration response rate, 443
Morphiceptin
endocrine response following administration to perinatal rats, 280
Morphine
administration to chronic pain patients, 174-180
alcohol intake modulated by opioids in rats, 304
calorimetric analysis following ICV administration in rats, 285
cross-tolerance with fentanyl in a drug discrimination procedure, 286
development of tolerance after chronic intrathecal infusion in rats, 343-352
discriminative-stimulus properties in midazolam-trained pigeons, 115-121
displacement of stereospecitic 3H-etorphine binding, 550
effect of 5,7-dihydroxytryptamine on self-administration of, 149-155
effect on brain-stimulation reward alone and with amfonelic acid, 283
endocrine response following administration to perinatal rats, 280
hypogylcemia following intrathecal injections in mice, 300
influence of tolerance and abstinence on corticosterone release, 278
intrathecal administration of naloxone and D-Phe-Cys-Tyr-D-Trp-Lys-Thr-
Pen-Thr-NH2 in dependent mice, 143-148
mouse analgesia, 487, 548
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quantification of abstinence syndrome/addiction liability in humans, 8-18
reinforcing efficacy measured by progressive ratio methods, 462-463
separation of receptor blockade from functional supersensitivity, 275
MR2266
endocrine response following administration to perinatal rats, 280
Nalbuphine
drug discrimination in human post-addicts, 209-215
Nalotphine hydrochloride
mouse analgesia, 487, 549
induced LH release, development of tolerance, 279
Naloxone
effect on natural killer cell activity, 338
effect on pentazocine analgesic efficacy in patients, 288
endocrine response following administration to perinatal rats, 280
intrathecal administration in morphine-dependent mice, 143-148
mouse analgesia, 487,549
precipitated syndrome in U50,488H- and trifluadom-treated rats, 136-142
precipitated withdrawal in humans following single opioid exposure, 195-
201,202-208
receptor changes in guinea-pig colon with age, 276
6 -Naltrexol- -methylacrylate (NIH 10400)
biological evaluation of dependence liability, 476
dependence studies in monkeys, 499-500
depression of smooth-muscle twitch, 559
displacement of stereospecific 3H-etorphine binding, 559
mouse analgesia, 499, 559
6 -Naltrexol- -methylacrylate (NIH 10399)
biological evaluation of dependence liability, 476
dependence studies in monkeys, 498-499
depression of smooth-muscle twitch, 558
displacement of stereospecitic 3H-etorphine biding, 558
mouse analgesia, 498, 558
Naltrexone
alteration of nicotine’s effects on conditioned responding in rats, 325
displacement of stereospecific 3H-etorphine binding, 550
mouse analgesia, 487, 549
separation of receptor blockade from functional supersensitivity, 275
treatment of opioid withdrawal in outpatients, 291
treatment of sudden-infant-death and Rett’s syndrome, 181-187
Naltrexone-6-spirohydantoin succinate (NIH 10519)
biological evaluation of dependence liability, 476
depression of smooth-muscle twitch, 588
displacement of stereospecific 3H-etorphine binding, 588
mouse analgesia, 538
Nathan B. Eddy Memorial Award
introduction of recipient, 6-7
Nathan B. Eddy Memorial Award Lecture, 8-18
Natural killer cell
effect of naloxone on, 338
Neonates
occurrence and treatment of abstinence syndrome, 274
Nicorette
606
See Nicotine gum
Nicotine
behavioral effects, role of opioid mechanisms in, 325
effect of chronic treatment on perturbation of the GABA system, 328
effects on calcium influx into brain synaptosomes, 324
reinforcing efficacy measured by progressive ratio methods, 462-463
Nicotine gum
efficacy in suppressing smoking, 59
replacement effects on nicotine-withdrawal symptoms and weight gain, 53-58
replacement of cigarette smoking, 327
NIH 7569 [(-)-2’-Hydroxy-2,5,9 -trimethyl-6,7-benzomorphan hydrochloride]
See (-)-Metazocine, 477, 489
NIH 757 1
See (+)-Metazocine, 477, 490-491
NIH 8211
See Cocaine hydrochloride, 483, 492
NIH 9834
See N-(6,14-Endoethano-7,8-dihydromorphine-7 -carbonyl)-L-
phenylalanyl-L-leucinol, 475, 553
NIH 10012
See 1-Methyl-4-phenyl-4-(1-piperidinyl)piperidine dihydrochloride, 478,
553-554
NIH 10013
See 1,3-Dimethyl-4-phenyl-4-(1-piperidinyl)piperidine dihydrochloride, 478,
554
NIH 10014
See 1-Phenethyl-4-phenyl-4-(1-piperidinyl)piperidine dihydrochloride, 478,
554-555
NIH 10017
S e e (-)-N-Cyclopropylmethyl-3,4-dimethoxymor-6-one
hydrobromide, 477, 492
NIH 10018
See (-)-3,4-Dimethoxy-N-(2-phenylethyl)morphinan-6-one hydrobromide,
477, 492
NIH 10167
See (+)-N-cis-3-Chloroallyl-N-normetazocine hydrobromide, 477, 555
NIH 10261
See m-Fluoronormethadone hydrochloride, 478, 493
NIH 10318
See 1-Acetonyl-2-(2,4-dichlorophenyl)iminoimidazolidine hydrochloride,
482, 556
NIH 10319 (NIH 10455)
See N-Propargyl-N’-(3-nifluoromethylphenyl)piperazine hydrochloride,
482, 494-497
NIH 10322
See 6 -(2-Carboxy-1-propenyl)-naltrex-6 -o l -lactone, 475, 557
NIH 10324
See 6 -(2-Carboxy-1-propenyl)-oxymorph-6 -ol -lactone, 475, 557-558
NIH 10344
See 4-(m -Hydroxyphenyl)methylamino-l-(2-phenylethyl)piperidine
hydrochloride, 478, 497-498
NIH 10399
607
See 6 -Naltrexol- -methylacrylate, 476, 498-499, 558
NIH 10400
See 6 -Naltrexol- -methylacrylate, 476, 499-500, 559
NIH 10412
S e e (±)-3-Cyclopropylmethyl-1,2,3,4,5,6,7,7a-octahydro-9-hydroxy-4aH-
4a,7-ethanobenzofuro(3,2-e)isoquinoline-5-methanol, 482, 501
NIH 10420
See 14 - (p -Chlorocinnamoylamino)-7.8-dihydro-N-cyclopropyl-
methylnorcodeinone mesylate, 475,502-503,560-563
NIH 10426
NIH 10427
NIH 10430
NIH 10438
NIH 10443
NIH 10454
NIH 10455 (NIH 10319)
NIH 10462
See Heroin methiodide, 476, 515, 571
NIH 10466
NIH 10467
NIH 10468 (NIH 10492)
See 14 -(p-Bromocinnamoylamino)-7,8-dihydro-N-cyclopropyl-
methylnorcodeinone mesylate, 475, 503-504, 563-566
See 14 - (p -Methylcinnamoylamino)-7.8-dihydro-N-cyclopropyl-
methylnorcodeinone mesylate, 475, 505-506, 567-569
See 2,2-Dimethyl-3-(dimethylamino)-7-hydroxy-1-tetralol, 482, 507
See 3-Cyclohexyl-1-N,N-dimethylamino-3-phenylpropane hydrochloride,
478,507
See 14 -(p-Chlorocinnamoylamino)-7,8-dihydro-N-cyclopropyl-
methylnormorphinone mesylate, 475, 507-508
NIH 10444
See 14 -(p-Methylcinnamoylamino)-7,8-dihydro-N-cycloptopyl-
methylnormorphinone mesylate, 475, 509-510, 569-570
NIH 10445
See 14 - (p -Bromocinnamoylamino)-7,8-dihydrocyclopropylmethyl-
normorphinone mesylate, 475, 510-512, 570
NIH 10453
See N-(3-Carbethoxypropyl)-N-norketobemidone oxalate, 479, 513
See N-Carbethoxymethyl)-N-norketobemidone oxalate, 479, 514
See N-Propargyl-N’-(3-uifluoromethylphenyl)piperazine hydrochloride,
482,494-497
NIH 10463
See Heroin ethiodide, 476, 515, 571-572
NIH 10464
See Heroin propiodide, 476, 515, 572-573
NIH 10465
See Heroin allobromide, 476, 516, 573
See Heroin benzobromide, 476, 516, 574
See N-(2-Carboxyethyl)-N-norketobemidone hydrochloride, 479, 516, 574-
575
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NIH 10473
NIH 10475
NIH 10476
NIH
NIH 10478
NIH 10479
NIH 10480
NIH 10481
NIH 10482
NIH 10483
NIH 10484
NIH 10485
NIH 10486
NIH
NIH 10488
NIH 10489
See N-(1-Benzyl-4-piperidyl)-N-phenylpropanamide hydrochloride, 481,
517, 575,584
See N-Carboxymethyl-N-norketobemidone hydrobromide, 479, 518, 576
See N-(3-Carboxypropyl)-N-norketobemidone, 479, 519
See 1-Phenethyl-4-(4-nitrophenyl)aminopiperidine dihydrochloride, 480,
519
10477
See 1-Phenethyl-4-(N-phenyl-p -methoxyphenylacetyl)aminopiperidine
hydrochloride, 480, 519
See 1-Phenethyl-4-(N-benzyl-N-propionyl)aminopiperidine hydrochloride,
480, 520
See Ethyl 3 -(3-methoxyphenyl)-N-methyl-8-azabicyclo[3.2.1]octane
carboxylate hydrochloride, 483, 520
See Ethyl 3 -(3-hydroxyphenyl)-N-methyl-8-azabicyclo[3.2.1]octane
carboxylate hydrochloride, 483, 520
See Ethyl N-methyl-3 -phenyl-8-azabicyclo[3.2.1]octane carboxylate
hydrochloride, 483, 521
See 1-Benzyl-4-phenyl-4-propionoxypiperidine hydrochloride, 480, 521-
522, 576, 577
See N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylthiopropanamide
hydrochloride, 480, 522-523, 577
See N-[1-(3-Phenylpropyl)-4-piperidyl]-N-phenylpropanamide
hydrochloride, 481, 523, 578
See N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylacetamide hydrochloride,
480, 524-525, 579
See N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylbutyramide hydrochloride,
480, 525-526, 580
10487
See N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylsobutyramide
hydrochloride, 480, 526-527, 580-581
See N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylvaleramide hydrochloride,
480, 527-528
See N-[1-(2-Phenylethyl)-4-piperidyl]-N-( p -methylphenyl)propanamde
hydrochloride, 481, 581
NIH 10490
See N-[1-(2-Phenylethyl)-4-piperidyl]-N-( p -methoxyphenyl)propanamide
hydrochloride, 481, 528-529, 582
NIH 10491
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See N-[1-(2-Phenylethyl)-4-piperidyl]-N-( p -fluorophenyl)propanamide
hydrochloride, 481, 529-530, 583
NIH 10492 (NIH 10468)
See N-(1-Benzyl-4-piperidyl)-N-phenylpropanamide hydrochloride, 481,
517, 575, 584
NIH 10493
NIH 16496
NIH 10498 (1-Methyl-5-(3-pyridyl)-2-pyrrolidinone)
NIH 10499
NIH 10500
NIH 10502
NIH 10503
NIH 10505
NIH 10506
NIH 10515
NIH 10516
NIH 10519
NIH 10522 (4-Carbethoxy-1-methyl-4-phenylpiperidine hydrochloride)
NIH 10529
NIH 10530
NIH 10531
NIH 10538
See N-[1-(2-Thienyl)methyl-4-piperidyl]-N-phenylpropanamide
hydrochloride, 481, 530-531, 584
See (E)-3-Chloro-6-[4-(3-phenyl-2-propenyl)-1-piperazinyl]pyridazine
hydrochloride, 482, 531-532, 585
See Cotinine, 483, 532-533
See 4-(3-Pyridyl)-4-methylaminobutyric acid, 482, 533-534
See 3-Hydroxy- N-trimethyl-6,14-ethenomorphinan-7 -methanol, 477,
534
S e e (±)-2-Carboxymethyl-5,9 -dimethyl-2’-hydroxy-6,7-benzomorphan
hydrochloride, 477, 534
See (±)-2-Carbethoxymethyl-5,9 -dimethyl-2’-hydroxy-6,7-benzomorphan
oxalate, 477, 535
See N-[1-[2-(2-Thienyl)ethyl]-4-piperidyl]-N-phenylpropanamide
hydrochloride, 481, 535-536, 585-586
See N-[1-(2-Hydroxy-2-phenylethyl)-4-piperidyl]-N-phenylpropanamide
hydrochloride, 481, 536-537, 586
See (±)-2-(2-Carbethoxyethyl)-5,9 -dimethyl-2’-hydroxy-6,7-
benzomorphan hydrochloride, 477, 537
See Oxycodone-6-spirohydantoin, 476, 537, 587
See Naltrexone-6-spirohydantoin succinate, 476, 538, 588
See Pethidine hydrochloride, 478, 538-539
See Ethyl N-allyl-3 -(3-hydroxyphenyl)-8-azabicyclo[3.2.1]octane
carboxylate hydrochloride, 483, 539
See Ethyl 3 -(3-hydroxyphenyl)-N-phenethyl-8-azabicyclo[3.2.1.]octane
carboxylate, 483, 540
See 4-Hydroxy-3-methyl-4-phenyl-l-(1-phenylcyclohexyl)piperidine
hydrochloride (trans-3-methyl, reference 4-phenyl), 479, 540
See N-[1-[1-Methyl-2-(2-thienyl)ethyl]-4-piperidyl]-N-phenylpropanamide
hydrochloride, 481, 540-541
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NIH 10540
See -Butyrolactone, 482, 541-542
NIH 10542
See (+)- -4-Acetoxy-1,2 -dimethyl-4-phenylpiperidine hydrochloride, 479,
542
Nitrazepam
discriminative-stimulus properties in midazolam-trained pigeons, 115-121
Nomifensine
evaluation in mouse narcotic-dependence tests, 284
Norepinephrine
effects of cocaine on metabolite/neurotransmitter ratio in hippocampus, 315
Nordiazepam
discriminative-stimulus properties in midazolam-trained pigeons, 115-121
Opiate
acute physical dependence to opioids in humans, 195-201, 202-208
co-abuse with alcohol, 428-439
dependence syndrome, 33-39
in vitro assessment of opiate tolerance and dependence, 167-173
paradoxes of experimental opiate dependence, 156-162
receptor changes in guinea pig colon with age, 276
Opioid addicts
abstinence and relapse to cocaine abuse, 231-236
Oxycodone
administration to chronic-pain patients, 174-180
Oxycodone-6-spirohydantoin (NIH 10516)
biological evaluation of dependence liability, 476
depression of smooth-muscle twitch, 587
displacement of stereospecific 3H-etorphine binding, 587
mouse analgesia, 537, 587
Pain
chronic opioid treatment of intractable, non-malignant pain, 174-180
Paregoric
treatment of the opiate and non-opiate abstinence syndrome in neonates, 274
D-Pen2-Pen5-enkephalin
See DPDPE
Pentazocine
drug discrimination in human post-addicts, 209-215
effect of naloxone on analgesic efficacy in patients, 288
mouse analgesia, 487,549
reinforcing efficacy measured by progressive ratio methods, 462-463
Pentobarbital
disctiminative-stimulus properties in midazolam-trained pigeons, 115-121
reinforcing efficacy based upon self-administration-response rate, 443
relationship between self-administration and behavioral disruption, 449
reinforcing efficacy measured by progressive ratio methods, 462-463
Pentylenetetrazol
interoceptive discriminative stimulus for measuring alcohol-withdrawal
anxiety, 305
Personality disorder
identification of subtypes among drug abusers using the MCMI, 299
Pethidine hydrochloride (NIH 10522; 4-Carbethoxy-1-methyl-4-phenylpiperidine
hydrochloride)
611
biological evaluation of dependence liability, 478
dependence studies in monkeys, 538-539
mouse analgesia, 538
Phencyclidine
binding to (+)-N-allylnormetazocine sites in mouse brain, 282
relationship between self-administration and behavioral disruption, 449
stereospecific binding of opiates to the receptor, 281
Phendimetrazine
reinforcing efficacy based upon self-administration frequency, 442
1-Phenethyl-4-(N-benzyl,N-propionyl)aminopiperidine hydrochloride (NIH 10478)
biological evaluation of dependence liability, 480
mouse analgesia, 520
1-Phenethyl-4-(4-nitrophenyl)aminopiperidine dihydrochloride (NIH 10476)
biological evaluation of dependence liability, 480
mouse analgesia, 519
1-Phenethyl-4-(N-phenyl- p-methoxyphenylacetyl)aminopiperidine hydrochloride
(NIH 10477)
biological evaluation of dependence liability, 480
mouse analgesia, 519
1-Phenethyl-4-phenyl-4-(1-piperidinyl)piperidine dihydrochloride (NIH 10014)
biological evaluation of dependence liability, 478
drug discrimination in ketamine-trained monkeys, 555
mouse analgesia, 554
Phenmetrazine
reinforcing efficacy based upon self-administration frequency, 442
anorectic/reinforcement ratio, 446
Phenobarbital
discriminative-stimulus properties in midazolam-trained pigeons, 115-121
treatment of the opiate and non-opiate abstinence syndrome in neonates, 274
Phentennine
anorectic/reinforcement ratio, 446
N-[1-(2-Phenylethyl)-4-piperidyl]-N-( p -fluorophenyl)propanamide hydrochloride
(NIH 10491)
biological evaluation of dependence liability, 481
dependence studies in monkeys, 529-530
depression of smooth-muscle twitch, 583
displacement of stereospecific 3H-etorphine binding, 583
mouse analgesia, 529
N-[1-(2-Phenylethyl)-4-piperidyl]-N-( p-methoxyphenyl)propanamide hydrochloride
(NIH 10490)
biological evaluation of dependence liability, 481
dependence studies in monkeys, 528-529
depression of smooth-muscle twitch, 582
displacement of stereospecific 3H-etorphine binding, 582
mouse analgesia, 528
N-[1-(2-Phenylethyl)-4-piperidyl]-N-( p-methylphenyl)propanamide hydrochloride
(NIH 10489)
biological evaluation of dependence liability, 481
depression of smooth-muscle twitch, 581
displacement of stereospecific 3H-etorphine binding, 581
N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylacetamide hydrochloride (NIH 10485)
biological evaluation of dependence liability, 480
dependence studies in monkeys, 524-525
612
depression of smooth-muscle twitch, 579
displacement of stereospecific 3H-etorphine binding, 579
mouse analgesia, 524
N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylbutyramide hydrochloride (NIH 10486)
biological evaluation of dependence liability, 480
dependence studies in monkeys, 525-526
depression of smooth-muscle twitch, 580
displacement of stereospecific 3H-etorphine binding, 580
mouse analgesia, 525
N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylisobutyramide hydrochloride (NIH
10487)
biological evaluation of dependence liability, 480
dependence studies in monkeys, 526-527
depression of smooth-muscle twitch, 581
displacement of stereospecific 3H-etorphine binding, 580
mouse analgesia, 526
N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylthiopropanamide hydrochloride (NIH
10483)
biological evaluation of dependence liability, 480
dependence studies in monkeys, 522-523
depression of smooth-muscle twitch, 577
displacement of stereospecific 3H-etorphine binding, 577
mouse analgesia, 522, 577
N-[1-(2-Phenylethyl)-4-piperidyl]-N-phenylvaleramide hydrochloride (NIH 10488)
biological evaluation of dependence liability, 480
dependence studies in monkeys, 527-528
mouse analgesia, 527
Phenylpropanolamine
anorectic/reinforcement ratio, 446
N-[1-(3-Phenylpropyl)-4-piperidyl]-N-phenylpropanamide hydrochloride (NIH
10484)
biological evaluation of dependence liability, 481
dependence studies in monkeys, 523
depression of smooth-muscle twitch, 578
displacement of stereospecific 3H-etorphine binding, 578
mouse analgesia, 523, 578
Physical dependence
morphine in humans, 8-18
Pirenperone
effect on changes in operant responding in mice induced by isomers of MDA
and MDMA, 322
Placebo challenge
effects compared to those after alcohol administration in alcoholics, 40-46
PLO17 ([MePhe3,D-Pro4]morphiceptin)
selective mu agonist, 353-362
Prolactin
mu and kappa receptor control of secretion in perinatal rats, 280
plasma levels during cocaine withdrawal, 67-73
secretion in methadone-dependent and abstinent patients, 216-223
N-Propargyl-N’-(3-trifluoromethylphenyl)piperazine  hydrochloride (NIH 10319;
NIH 10455)
biological evaluation for dependence liability, 482
dependence studies in rats, 494-497
613
mouse analgesia, 493
naloxone antagonism of tail-tlick activity, 493
Propoxyphene
administration to chronic-pain patients, 174-180
reinforcing efficacy measured by progressive ratio methods, 462-463
Propranolol
effects on alcohol-induced cardiac hypertrophy in the rat, 308
Psychiatric illness
diagnoses in treated substance abusers, 416-421
4-(3-Pyridyl)-4-methylaminobutyric acid (NIH 10499)
biological evaluation of dependence liability, 482
dependence studies in monkeys, 533-534
mouse analgesia, 533
Rett’s syndrome
role of ß-endorphin in, treatment with naltrexone, 181-187
Ro 15-1788
effects on diazepam-withdrawal-discriminative stimulus, 331
Secobarbital
effects on agressive and non-aggressive responding in male subjects, 60-66
relationship between self-administration and behavioral disruption, 449
reinforcing efficacy measured by progressive ratio methods, 462-463
Serotonin
effects of cocaine on metabolite/neurotransmitter ratio in hippocampus, 315
effects of MDMA on levels in neonate and adult rat brain areas, 318
effects of MDMA on receptor subpopulations and neurotoxicity, 319-320
innervations of the nucleus accumbens, involvement in morphine self-
administration in rats, 149-155
rat-brain levels following continuous infusion of cocaine, 86-93
rat-brain levels following exposure to cocaine and methamphetamine, 94-100
SKF- 10047
See N-Allylnormetazocine
ST-91
development of tolerance after chronic intrathecal infusion in rats, 343-352
Substance abusers
psychiatric diagnoses in, 416-421
treatment of the addict with a psychiatric disorder, 296-297
Sudden-infant-death syndrome
role of ß-endorphin in, treatment with naltrexone, 181-187
Sufentanil
development of tolerance after chronic, intrathecal infusion in rats, 343-352
Testosterone
secretion in methadone-dependent and abstinent patients, 216-223
9-Tetrahydrocannabinol
serum concentrations in pregnant rat and fetus following acute and chronic
administration of 9-THC
N-[l-[2-(2-Thienyl)ethyl]-4-piperidyl]-N-phenylpropanamide hydrochloride (NIH
10505)
biological evaluation of dependence liability, 481
dependence studies in monkeys, 535-536
depression of smooth-muscle twitch, 586
displacement of stereospecific 3H-etorphine binding, 585
mouse analgesia, 535
614
N-[1-(2-Thienyl)methyl-4-piperidyl]-N-phenylpropanamide hydrochloride (NIH
10493)
biological evaluation of dependence liability, 481
dependence studies in monkeys, 530-531
depression of smooth-muscle twitch, 584
displacement of stereospecific 3H-etorphine binding, 584
mouse analgesia, 530, 584
Tifluadom
neuroadaptation of rats to, 136-142
Thyroid stimulating hormone
mu and kappa receptor control of secretion in perinatal rats, 280
Tobacco
concurrent use with alcohol by women, 26-32
effect of withdrawal on cortisol levels in smokers. 326
replacement of cigarette smoking with nicotine gum, 327
See also nicotine gum
Tolerance
in vitro assessment of opiate tolerance, 167-173
Trazodone
evaluation in mouse narcotic-dependence tests, 284
Triazolam
discriminative-stimulus properties in midazolam-trained pigeons, 115-121
effects of yohimbine on self-administration in humans, 332
relationship between self-administration and behavioral disruption, 449
2,2,2-Trichloroethanol dihydrogen phosphate (Triclofos, CPDD 0016)
evaluation of dependence potential, 471,484
Triclofos (2,2,2-Trichloroethanol dihydrogen phosphate, CPDD 0016)
evaluation of dependence potential, 471,484
Tricyclic antidepressants
effects of in utero exposure to infants born to methadone-maintained women,
266-272
Tryptophan
utilized in step-wise withdrawal from cocaine dependence, 317
Tyrosine
utilized in step-wise withdrawal from cocaine dependence, 317
U-50,488
differential blockade of mu agonists in the rat, 277
endocrine response following administration to perinatal rats, 280
influence of tolerance and abstinence on corticosterone release, 278
neuroadaptation of rats to, 136-142
selective kappa agonist, 353-362
UM911
See 2-(3-Methylfurfuryl)-2’-hydroxy-5,9 -dimethyl-6,7-benzomorphan
methane sulfanate
UM 1071R
See 1R-5R-9R-2”R-5,9-Dimethyl-2’-hydroxy-2-tetrahydrofurfury-6,7-
benzomorphan hydrochloride
Withdrawal
amantadine for ambulatory withdrawal for cocaine dependence, 81-85
associated conditioned responses in cocaine users, 74-80
flurothyl seizure thresholds associated with acute and chronic
chlordiazepoxide withdrawal, 109-114
615
precipitated in morphine-dependent mice by intrathecal injection of naloxone
and D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2, 143-148
treatment of opioid withdrawal with clonidine and naltrexone, 291
Yohimbine
effects on triazolam self-administration in humans, 332
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